[
    {
        "model": "Source",
        "documents": [
            {
                "_id": "Tissue",
                "description": ""
            },
            {
                "_id": "Blood",
                "description": ""
            },
            {
                "_id": "Glioma Stem Cells",
                "description": ""
            },
            {
                "_id": "Serum",
                "description": ""
            },
            {
                "_id": "Imaging",
                "description": ""
            },
            {
                "_id": "TIssue",
                "description": ""
            },
            {
                "_id": "Cell lines",
                "description": ""
            },
            {
                "_id": "Cell line",
                "description": ""
            },
            {
                "_id": "Fluid",
                "description": ""
            },
            {
                "_id": "Sera",
                "description": ""
            }
        ]
    },
    {
        "model": "Category",
        "documents": [
            {
                "_id": "Others",
                "description": ""
            },
            {
                "_id": "Cytokine",
                "description": ""
            },
            {
                "_id": "RNA",
                "description": ""
            },
            {
                "_id": "Aminopeptidase",
                "description": ""
            },
            {
                "_id": "Lipid",
                "description": ""
            },
            {
                "_id": "Stem cells",
                "description": ""
            },
            {
                "_id": "Enzyme",
                "description": ""
            },
            {
                "_id": "Labelling index",
                "description": ""
            },
            {
                "_id": "Protein",
                "description": ""
            },
            {
                "_id": "Other",
                "description": ""
            },
            {
                "_id": "Metabolite",
                "description": ""
            },
            {
                "_id": "DNA",
                "description": ""
            }
        ]
    },
    {
        "model": "Entity",
        "documents": [
            {
                "_id": "E000000",
                "name": "Primate specific miR-663",
                "abreviations": [
                    "1F3B"
                ],
                "categoryId": "Metabolite",
                "description": "Amet velit numquam non etincidunt quiquia labore eius. Quaerat aliquam eius dolor numquam ut. Dolor velit quiquia labore dolore. Velit numquam sed tempora sed neque quisquam aliquam. Consectetur modi dolorem eius est velit numquam. Quisquam quaerat amet quiquia est numquam."
            },
            {
                "_id": "E000001",
                "name": "Proneural molecular signature",
                "abreviations": [],
                "categoryId": "Aminopeptidase",
                "description": "Neque eius quaerat quiquia quisquam quisquam tempora quaerat. Aliquam labore etincidunt quaerat dolor numquam quiquia porro. Etincidunt quisquam dolorem labore est. Ut velit ipsum voluptatem dolore ut est. Consectetur velit consectetur eius. Neque sed dolore non quiquia eius etincidunt. Dolorem etincidunt ipsum porro velit quiquia numquam labore. Dolor aliquam magnam sed dolor. Quisquam amet modi etincidunt dolor numquam."
            },
            {
                "_id": "E000002",
                "name": "let-7g-5p",
                "abreviations": [
                    "FA",
                    "99A",
                    "24F8",
                    "1B33"
                ],
                "categoryId": "Lipid",
                "description": "Dolore ipsum ut est adipisci consectetur dolore labore. Sit labore velit aliquam non. Quaerat aliquam dolor non dolore. Dolorem etincidunt magnam dolore etincidunt. Dolorem ipsum sit quisquam amet. Ipsum sit velit non modi quisquam ut. Dolor adipisci porro tempora sit magnam."
            },
            {
                "_id": "E000003",
                "name": "lncRNA H19",
                "abreviations": [
                    "73",
                    "363",
                    "24A3",
                    "448",
                    "15CF"
                ],
                "categoryId": "Stem cells",
                "description": "Sed quaerat numquam neque quaerat quaerat sed dolor. Etincidunt porro modi ipsum quaerat. Ipsum quiquia dolore porro. Tempora consectetur labore eius eius numquam dolor neque. Dolore voluptatem aliquam voluptatem non dolorem eius non. Ut amet magnam quaerat tempora sed dolor non. Sit quisquam dolorem quisquam tempora. Quiquia non sit neque. Quaerat quaerat velit porro amet. Ipsum voluptatem labore dolore est velit velit."
            },
            {
                "_id": "E000004",
                "name": "ILF2",
                "abreviations": [],
                "categoryId": "Others",
                "description": "Sit neque neque est. Neque numquam quisquam adipisci. Labore modi quiquia quiquia sed etincidunt. Dolore dolorem sed tempora. Sit modi neque consectetur est non velit. Dolorem quiquia tempora consectetur dolore. Aliquam amet neque velit quaerat ipsum labore. Etincidunt est consectetur sed velit."
            },
            {
                "_id": "E000005",
                "name": "PTEN-COL17A1 fusion gene",
                "abreviations": [],
                "categoryId": "Lipid",
                "description": "Adipisci tempora dolorem non amet etincidunt aliquam. Magnam quiquia tempora dolore. Voluptatem tempora voluptatem labore quaerat. Labore quisquam labore quaerat adipisci aliquam. Numquam adipisci etincidunt etincidunt quiquia tempora. Dolor magnam quiquia dolorem magnam ut eius."
            },
            {
                "_id": "E000006",
                "name": "Phosphorylated ribosomal protein S6",
                "abreviations": [
                    "1595",
                    "1947"
                ],
                "categoryId": "Others",
                "description": "Quaerat eius amet est non etincidunt amet sit. Ut tempora neque non dolore est. Modi quiquia voluptatem voluptatem quisquam. Quisquam eius velit aliquam numquam etincidunt eius ut. Numquam ut non est sed non. Etincidunt neque quiquia dolore sit. Tempora aliquam magnam porro etincidunt. Tempora sit sed neque dolore voluptatem modi modi. Dolorem ut porro ipsum est tempora neque. Dolore quiquia sit magnam."
            },
            {
                "_id": "E000007",
                "name": "microRNA-7",
                "abreviations": [],
                "categoryId": "Others",
                "description": "Numquam modi consectetur amet quiquia adipisci adipisci consectetur. Aliquam numquam dolor dolorem eius numquam quiquia. Non est ipsum dolore magnam quisquam dolorem. Voluptatem magnam ut aliquam modi eius non. Quaerat dolor porro tempora est."
            },
            {
                "_id": "E000008",
                "name": "Cancer stem cells",
                "abreviations": [
                    "1957",
                    "758",
                    "12BB",
                    "45C"
                ],
                "categoryId": "RNA",
                "description": "Ut quiquia modi est quaerat. Neque voluptatem quaerat amet dolorem. Amet dolore ipsum aliquam dolore tempora magnam tempora. Quisquam est dolor etincidunt. Neque quiquia eius non eius consectetur ipsum. Adipisci dolorem etincidunt tempora velit amet porro. Porro voluptatem sit quiquia sit non adipisci."
            },
            {
                "_id": "E000009",
                "name": "Cyclin E",
                "abreviations": [
                    "1F4B",
                    "765",
                    "5EF",
                    "CA3"
                ],
                "categoryId": "RNA",
                "description": "Amet est ut adipisci ipsum sit tempora. Ipsum sit aliquam dolor dolore. Quaerat aliquam velit adipisci modi sed. Magnam quaerat amet ipsum quaerat tempora dolor. Dolore sit non ut neque. Dolore dolor aliquam porro non. Sed consectetur dolore ut dolorem. Est ipsum ipsum neque. Etincidunt quaerat sed amet modi."
            },
            {
                "_id": "E00000A",
                "name": "s-100",
                "abreviations": [
                    "8CE",
                    "1B75",
                    "548"
                ],
                "categoryId": "Enzyme",
                "description": "Neque dolore tempora voluptatem consectetur voluptatem. Tempora consectetur velit aliquam labore porro. Etincidunt quiquia tempora eius dolorem sed quaerat ut. Modi voluptatem ipsum eius amet labore. Dolorem dolore ut eius magnam. Dolore amet neque magnam. Ut quiquia amet aliquam consectetur."
            },
            {
                "_id": "E00000B",
                "name": "Protein tyrosine kinase 7",
                "abreviations": [
                    "9B8",
                    "944",
                    "7AD"
                ],
                "categoryId": "Stem cells",
                "description": "Etincidunt amet sit porro numquam quisquam voluptatem. Porro adipisci quisquam ut est etincidunt numquam non. Ut sit quiquia dolore sit magnam. Magnam ipsum dolorem tempora non aliquam ut. Etincidunt aliquam modi ut sed consectetur amet porro. Eius quisquam labore dolorem quisquam ut. Magnam quiquia quaerat labore tempora dolorem."
            },
            {
                "_id": "E00000C",
                "name": "Gender",
                "abreviations": [
                    "25B7",
                    "5D",
                    "34C",
                    "1031",
                    "156A"
                ],
                "categoryId": "Aminopeptidase",
                "description": "Amet dolor sit quiquia dolor. Numquam modi aliquam dolor dolore dolor non dolorem. Quiquia ut voluptatem non labore adipisci dolorem. Non adipisci dolore eius magnam modi. Sit magnam consectetur eius sit. Etincidunt ut modi etincidunt. Quiquia numquam tempora quisquam ipsum quaerat numquam etincidunt. Non neque sit dolore. Dolorem aliquam sed consectetur. Non modi etincidunt numquam quaerat magnam est."
            },
            {
                "_id": "E00000D",
                "name": "Podocalyxin",
                "abreviations": [
                    "15B6",
                    "1DA8"
                ],
                "categoryId": "Cytokine",
                "description": "Non magnam labore dolore quaerat. Porro aliquam adipisci quiquia quaerat non eius. Est tempora ipsum quaerat voluptatem dolore quiquia. Magnam quaerat voluptatem dolor consectetur. Sit tempora porro numquam tempora dolor dolorem consectetur. Etincidunt voluptatem ut dolor. Est sed quisquam ut dolore. Dolorem tempora neque numquam."
            },
            {
                "_id": "E00000E",
                "name": "Annexin VII",
                "abreviations": [
                    "1440",
                    "1411",
                    "14F8",
                    "1784"
                ],
                "categoryId": "Metabolite",
                "description": "Dolorem neque quiquia sit aliquam neque est. Sed sed neque voluptatem tempora non dolore dolore. Ut quiquia eius voluptatem consectetur dolorem tempora porro. Numquam quisquam quiquia amet. Velit sed modi quiquia adipisci. Sit non adipisci labore. Consectetur dolor ut amet labore. Modi velit dolorem etincidunt. Quiquia porro labore adipisci dolorem dolorem."
            },
            {
                "_id": "E00000F",
                "name": "Genetic losses from chromosomes 9p",
                "abreviations": [
                    "58F",
                    "1CA5",
                    "22F8",
                    "4EE",
                    "6E3"
                ],
                "categoryId": "Cytokine",
                "description": "Non ut consectetur aliquam quiquia sed tempora. Sit velit quaerat ipsum sed etincidunt. Tempora adipisci dolore dolorem dolore ut amet. Etincidunt quisquam numquam labore numquam dolore voluptatem labore. Quiquia sed labore ipsum neque. Est tempora voluptatem dolor. Magnam sit velit adipisci modi. Tempora neque dolor neque neque quaerat. Porro dolorem dolor quaerat quaerat tempora. Velit porro numquam quiquia quiquia ipsum."
            },
            {
                "_id": "E000010",
                "name": "Chemokine CC-motif receptor-like 2 expression",
                "abreviations": [
                    "2311",
                    "20B5",
                    "24C4"
                ],
                "categoryId": "Aminopeptidase",
                "description": "Amet tempora amet tempora numquam. Quisquam velit sed dolore numquam dolorem aliquam. Modi ipsum quisquam quaerat amet amet. Ipsum dolor labore consectetur tempora dolor tempora. Non sit numquam aliquam quisquam eius modi ut. Magnam aliquam consectetur velit non aliquam tempora. Tempora modi dolor dolor non voluptatem. Amet eius adipisci modi. Porro quaerat velit voluptatem est quisquam ipsum. Est aliquam modi dolorem neque numquam numquam."
            },
            {
                "_id": "E000011",
                "name": "Semaphorin 3C",
                "abreviations": [
                    "19AA",
                    "71C",
                    "13DF",
                    "85F"
                ],
                "categoryId": "Stem cells",
                "description": "Adipisci eius ut dolorem. Porro etincidunt eius dolore ipsum voluptatem. Ut sit labore non quiquia. Modi numquam sit velit sit sit adipisci. Ut consectetur dolorem eius ut."
            },
            {
                "_id": "E000012",
                "name": "Fibroblast growth factor receptor 1",
                "abreviations": [
                    "93C",
                    "518",
                    "7DF"
                ],
                "categoryId": "Aminopeptidase",
                "description": "Tempora consectetur ipsum non dolorem. Porro etincidunt velit velit voluptatem dolor dolore labore. Ipsum quisquam porro neque magnam dolore. Quaerat velit neque sit etincidunt consectetur. Aliquam voluptatem porro consectetur. Dolorem non sed voluptatem numquam porro quaerat amet. Dolorem voluptatem non amet. Adipisci dolor adipisci quisquam adipisci."
            },
            {
                "_id": "E000013",
                "name": "TNFR-associated factor 2",
                "abreviations": [
                    "1284",
                    "20E2",
                    "89F",
                    "1518",
                    "376"
                ],
                "categoryId": "Others",
                "description": "Porro numquam est tempora voluptatem tempora ipsum. Sed sed numquam quisquam ipsum. Amet non quaerat etincidunt dolore dolorem quisquam dolor. Quiquia eius velit ut porro dolorem modi. Sit quaerat velit ut etincidunt labore ut."
            },
            {
                "_id": "E000014",
                "name": "DNA topoisomerase II\u03b1 labeling index",
                "abreviations": [
                    "594",
                    "A2B",
                    "1636",
                    "1E1F"
                ],
                "categoryId": "Protein",
                "description": "Magnam dolore amet dolorem consectetur non labore consectetur. Eius numquam amet dolorem velit sed. Voluptatem adipisci sed labore velit modi aliquam. Etincidunt eius dolorem neque sed aliquam etincidunt. Neque sit modi porro. Dolor quisquam quaerat quaerat tempora numquam quiquia quisquam."
            },
            {
                "_id": "E000015",
                "name": "hTERT MNS16A (study has been revoked later)",
                "abreviations": [
                    "752"
                ],
                "categoryId": "Metabolite",
                "description": "Modi quisquam labore numquam. Consectetur dolore amet magnam adipisci quisquam. Sed velit dolore ipsum quisquam ut quaerat neque. Est eius velit est dolor. Etincidunt aliquam quisquam voluptatem."
            },
            {
                "_id": "E000016",
                "name": "miR-328 expression",
                "abreviations": [
                    "1460",
                    "26BC",
                    "ADD",
                    "ECD"
                ],
                "categoryId": "RNA",
                "description": "Voluptatem aliquam sed etincidunt. Dolorem ut modi dolor. Neque ipsum amet consectetur numquam voluptatem dolor. Velit ut numquam modi sit magnam. Dolore adipisci numquam consectetur velit dolore. Sit voluptatem voluptatem amet dolorem voluptatem. Sed ut consectetur tempora. Neque eius dolore consectetur dolor quiquia ut quaerat. Ipsum modi amet quiquia voluptatem."
            },
            {
                "_id": "E000017",
                "name": "Notch 1",
                "abreviations": [
                    "3C8",
                    "21F5",
                    "FA2"
                ],
                "categoryId": "Lipid",
                "description": "Quaerat modi est quisquam. Eius dolore quisquam eius quisquam ut. Voluptatem etincidunt voluptatem eius dolorem neque aliquam amet. Ipsum sit dolor dolorem ut magnam. Voluptatem eius consectetur magnam consectetur dolore aliquam. Etincidunt consectetur quisquam numquam ut. Ut labore quisquam numquam sit tempora magnam."
            },
            {
                "_id": "E000018",
                "name": "SNAT3",
                "abreviations": [
                    "F95",
                    "1CBB",
                    "81E"
                ],
                "categoryId": "Other",
                "description": "Quiquia sed dolor etincidunt magnam. Modi adipisci velit neque numquam quisquam magnam. Adipisci velit eius est sed velit. Eius ut consectetur ut numquam aliquam. Quaerat numquam dolor consectetur. Ipsum etincidunt ut porro. Adipisci neque porro labore dolor dolor. Dolore etincidunt ut est non etincidunt sed eius. Magnam consectetur tempora dolor voluptatem."
            },
            {
                "_id": "E000019",
                "name": "PlGF",
                "abreviations": [
                    "26E3"
                ],
                "categoryId": "Stem cells",
                "description": "Consectetur sed quiquia modi dolore. Dolorem dolor quisquam voluptatem dolor dolore magnam ipsum. Ut magnam amet magnam consectetur ut porro neque. Est non non quaerat. Velit sed amet aliquam dolorem dolore. Adipisci labore sit dolore amet. Neque eius eius etincidunt neque modi quiquia adipisci. Quiquia eius tempora labore. Quiquia etincidunt tempora velit."
            },
            {
                "_id": "E00001A",
                "name": "IDH1 R132H mutation",
                "abreviations": [],
                "categoryId": "Protein",
                "description": "Magnam est consectetur velit magnam quisquam ipsum sit. Tempora porro ut etincidunt dolor ut. Voluptatem tempora non amet consectetur ut. Voluptatem tempora est sed ipsum modi. Quaerat sit magnam dolor. Numquam etincidunt sit tempora consectetur non sed velit. Sed dolor dolor aliquam ipsum. Est quisquam aliquam sit modi dolor dolorem numquam. Amet voluptatem adipisci tempora ut numquam."
            },
            {
                "_id": "E00001B",
                "name": "14-3-3\u03b6 positive expression",
                "abreviations": [
                    "1B4C",
                    "166C",
                    "1641"
                ],
                "categoryId": "Other",
                "description": "Tempora non ipsum magnam voluptatem ut quisquam. Non quiquia quisquam quisquam sit dolor porro. Est neque dolorem dolore quaerat quisquam. Sed labore dolor quiquia tempora numquam non dolorem. Ipsum neque quaerat quiquia numquam quaerat. Labore ipsum est dolor dolorem quiquia labore. Dolorem voluptatem labore etincidunt tempora dolor. Tempora adipisci magnam labore."
            },
            {
                "_id": "E00001C",
                "name": "O6-Methyl-guanyl-methyl-transferase promoter status",
                "abreviations": [
                    "78A",
                    "1058",
                    "806",
                    "1E2",
                    "CFD"
                ],
                "categoryId": "Enzyme",
                "description": "Velit est etincidunt consectetur ipsum porro est est. Velit eius dolor ipsum magnam. Amet velit sit quaerat consectetur. Consectetur sit velit voluptatem porro dolorem etincidunt. Eius etincidunt est sit sit. Magnam neque dolorem tempora porro aliquam sit. Quaerat sit est neque magnam. Dolorem est neque amet quisquam."
            },
            {
                "_id": "E00001D",
                "name": "hsa-miR-107_st",
                "abreviations": [
                    "156E",
                    "1D06"
                ],
                "categoryId": "RNA",
                "description": "Magnam sed dolorem dolore ut. Labore non velit quiquia dolor quiquia. Modi sed tempora aliquam ut. Ipsum voluptatem labore voluptatem quiquia. Est ut amet dolor numquam quiquia aliquam. Etincidunt neque non magnam labore magnam aliquam. Numquam est sed etincidunt sed. Porro numquam magnam dolor adipisci adipisci sed neque."
            },
            {
                "_id": "E00001E",
                "name": "CR613436",
                "abreviations": [
                    "B50"
                ],
                "categoryId": "Lipid",
                "description": "Adipisci quaerat quisquam non dolore. Labore porro labore dolore. Aliquam dolorem tempora labore ipsum ipsum tempora. Aliquam eius consectetur est numquam non. Dolorem ut tempora quisquam. Dolore numquam dolorem est magnam numquam quiquia voluptatem. Modi dolorem neque non etincidunt."
            },
            {
                "_id": "E00001F",
                "name": "Glycoprotein transmembrane nmb",
                "abreviations": [
                    "1D6B",
                    "1C92",
                    "1CFB"
                ],
                "categoryId": "Enzyme",
                "description": "Porro voluptatem amet non modi ut magnam sit. Quisquam neque ut porro adipisci dolor sed quisquam. Modi quaerat ut dolorem modi velit ut. Adipisci dolore dolor quaerat. Numquam consectetur neque dolorem sit voluptatem. Aliquam sed ipsum consectetur labore amet. Quisquam sit ipsum labore quaerat ipsum. Dolore velit consectetur neque ipsum quiquia labore consectetur."
            },
            {
                "_id": "E000020",
                "name": "Nuclear factor-kappa-B inhibitor interactingras-lke protein 1",
                "abreviations": [
                    "3E8",
                    "54A",
                    "13EF",
                    "A8E",
                    "1C56"
                ],
                "categoryId": "DNA",
                "description": "Etincidunt dolor modi sit neque quaerat. Est sed dolore dolorem adipisci sed. Sit quaerat quiquia modi aliquam porro etincidunt. Tempora sit quaerat aliquam porro adipisci aliquam. Numquam quiquia quiquia dolor etincidunt. Voluptatem eius sit sed porro. Aliquam magnam eius dolore amet."
            },
            {
                "_id": "E000021",
                "name": "PTEN  index",
                "abreviations": [
                    "2351"
                ],
                "categoryId": "RNA",
                "description": "Quisquam velit quisquam quiquia. Ut labore quisquam velit ut etincidunt non quisquam. Consectetur etincidunt est est eius amet dolore. Ut porro labore velit quisquam. Dolorem consectetur labore sit neque. Ut numquam sed etincidunt porro ut dolorem. Aliquam dolorem eius quaerat dolorem adipisci. Porro etincidunt quaerat neque etincidunt labore magnam voluptatem. Quisquam tempora etincidunt quaerat. Neque porro adipisci labore ut."
            },
            {
                "_id": "E000022",
                "name": "CHEK1",
                "abreviations": [
                    "EEF",
                    "2287",
                    "AE0",
                    "1E38",
                    "84A"
                ],
                "categoryId": "DNA",
                "description": "Dolor tempora etincidunt amet aliquam. Ut adipisci sit ipsum ipsum. Ipsum eius labore aliquam. Etincidunt amet quisquam numquam neque tempora dolor. Quisquam quisquam numquam sed porro porro. Magnam consectetur labore magnam. Non eius numquam adipisci quiquia. Dolorem est ut non. Sed numquam sit velit dolorem quisquam porro quisquam. Neque est quaerat dolore tempora quaerat."
            },
            {
                "_id": "E000023",
                "name": "Endosialin",
                "abreviations": [
                    "23D0",
                    "5EE"
                ],
                "categoryId": "Cytokine",
                "description": "Modi dolorem adipisci tempora dolorem aliquam est consectetur. Consectetur quiquia amet modi labore amet numquam. Tempora non velit eius eius dolore sit. Dolore velit non ut amet. Velit quisquam adipisci voluptatem labore magnam. Sit voluptatem ipsum adipisci quiquia aliquam labore. Etincidunt modi labore dolorem ipsum quisquam. Non non ipsum etincidunt. Magnam sed velit non velit eius dolore quaerat. Adipisci adipisci quiquia labore ipsum voluptatem velit."
            },
            {
                "_id": "E000024",
                "name": "Glut-1",
                "abreviations": [
                    "186B",
                    "636",
                    "1F0A",
                    "1D4B",
                    "1CD2"
                ],
                "categoryId": "Metabolite",
                "description": "Aliquam dolore tempora numquam ipsum. Tempora dolorem magnam dolorem modi magnam tempora. Numquam etincidunt velit quaerat modi porro. Quiquia magnam sit dolore labore tempora dolor. Non dolore tempora modi tempora voluptatem quiquia magnam. Ipsum sed modi eius velit quaerat. Magnam velit dolor dolorem labore labore adipisci. Etincidunt dolorem numquam amet ipsum. Ut modi est sit. Magnam labore dolorem magnam."
            },
            {
                "_id": "E000025",
                "name": "Guanosine triphosphatase-activating protein RLIP76",
                "abreviations": [
                    "106C",
                    "1252"
                ],
                "categoryId": "Metabolite",
                "description": "Quiquia ipsum quisquam voluptatem quisquam porro. Non modi dolor neque magnam non porro non. Magnam est dolorem neque adipisci. Est tempora labore labore quaerat porro etincidunt amet. Tempora numquam neque numquam non."
            },
            {
                "_id": "E000026",
                "name": "Superoxide dismutase 2",
                "abreviations": [
                    "E39",
                    "1CDC",
                    "16B3",
                    "166F",
                    "208E"
                ],
                "categoryId": "Protein",
                "description": "Neque dolore modi quisquam consectetur quisquam. Numquam neque modi voluptatem amet quisquam. Neque ut est neque consectetur. Non modi tempora modi. Dolore amet tempora sed neque est sed. Magnam sit consectetur dolor."
            },
            {
                "_id": "E000027",
                "name": "O6-methylguanine DNA methyltransferase",
                "abreviations": [
                    "1038"
                ],
                "categoryId": "Enzyme",
                "description": "Magnam neque voluptatem est etincidunt modi eius. Modi modi velit ipsum eius. Non modi dolorem non neque dolor quiquia non. Consectetur velit numquam voluptatem neque. Sed velit porro numquam consectetur. Etincidunt ut adipisci dolore consectetur sit adipisci. Adipisci aliquam quaerat dolorem etincidunt quiquia. Adipisci ut amet modi numquam quiquia sit. Velit eius numquam eius voluptatem velit consectetur quiquia. Quisquam dolore labore aliquam."
            },
            {
                "_id": "E000028",
                "name": "TFRC",
                "abreviations": [
                    "852",
                    "1889"
                ],
                "categoryId": "Cytokine",
                "description": "Consectetur adipisci modi voluptatem dolor consectetur sit quisquam. Magnam porro voluptatem non neque sed quiquia etincidunt. Labore labore eius tempora amet amet. Labore sit sit quaerat. Consectetur voluptatem magnam etincidunt est est est voluptatem."
            },
            {
                "_id": "E000029",
                "name": "J1-31",
                "abreviations": [
                    "252",
                    "DCE",
                    "268F",
                    "175F"
                ],
                "categoryId": "Labelling index",
                "description": "Quisquam eius labore modi. Eius quiquia magnam non ut neque. Porro sit porro neque ut eius modi magnam. Consectetur ipsum consectetur magnam non neque quisquam consectetur. Ut ut numquam quiquia dolorem quiquia neque amet. Quiquia eius porro quiquia ipsum non voluptatem. Sit sed eius dolor labore."
            },
            {
                "_id": "E00002A",
                "name": "Anticalin N7A",
                "abreviations": [
                    "113C"
                ],
                "categoryId": "Aminopeptidase",
                "description": "Aliquam consectetur voluptatem dolor. Eius tempora dolorem non magnam. Eius labore numquam dolor magnam neque. Ipsum est neque quaerat voluptatem magnam. Adipisci ut numquam magnam quisquam modi velit porro."
            },
            {
                "_id": "E00002B",
                "name": "AREG",
                "abreviations": [
                    "7BC",
                    "21B9",
                    "1379"
                ],
                "categoryId": "Metabolite",
                "description": "Est sit est ut eius amet. Adipisci eius voluptatem aliquam non est modi adipisci. Sit amet etincidunt consectetur neque dolorem. Tempora ut quisquam est. Tempora porro sit voluptatem eius porro ipsum. Modi non est modi. Dolorem quiquia quaerat non. Dolorem adipisci sit non sit magnam. Dolorem tempora ipsum modi."
            },
            {
                "_id": "E00002C",
                "name": "MIAT",
                "abreviations": [
                    "DAA",
                    "1326",
                    "23EC",
                    "1650"
                ],
                "categoryId": "Metabolite",
                "description": "Quisquam adipisci labore dolore. Quaerat tempora numquam quaerat. Ipsum quisquam quiquia modi non. Ipsum aliquam tempora sit dolore. Quaerat tempora magnam dolor etincidunt voluptatem quaerat. Aliquam ut numquam porro dolore quaerat. Non sit quisquam est voluptatem. Quaerat non dolorem dolorem sed est."
            },
            {
                "_id": "E00002D",
                "name": "Fatty acid binding protein 7",
                "abreviations": [
                    "1366"
                ],
                "categoryId": "Metabolite",
                "description": "Voluptatem voluptatem neque amet dolor dolor. Magnam porro dolorem ut eius sed. Labore quaerat modi dolor. Etincidunt magnam amet dolore adipisci sit modi. Consectetur etincidunt quisquam porro neque quisquam quiquia. Dolorem dolore dolor quisquam eius voluptatem modi quiquia. Labore ipsum modi labore modi velit sit eius."
            },
            {
                "_id": "E00002E",
                "name": "LOH at chromosomes 1p, 4q, 6p, 9p, 11p, 11q, 13q, 14q, 15p, 17p, 17q, and 19q",
                "abreviations": [
                    "10F1",
                    "1CD2",
                    "25F5"
                ],
                "categoryId": "Stem cells",
                "description": "Dolorem amet porro modi ut quaerat ut. Labore numquam numquam neque sed. Quaerat sed voluptatem numquam. Voluptatem adipisci est quiquia eius numquam amet quisquam. Tempora est quiquia sit amet ipsum dolorem. Consectetur consectetur dolor consectetur dolorem dolore ut. Consectetur est adipisci non. Aliquam voluptatem voluptatem aliquam adipisci voluptatem numquam. Magnam numquam quiquia neque amet labore tempora dolore."
            },
            {
                "_id": "E00002F",
                "name": "1p19q LOH",
                "abreviations": [
                    "AA6",
                    "14A6",
                    "1457",
                    "20C3"
                ],
                "categoryId": "Enzyme",
                "description": "Etincidunt quisquam etincidunt sit. Porro adipisci numquam quiquia aliquam porro. Quisquam non consectetur dolorem. Dolorem porro ipsum sed. Non etincidunt ipsum ut voluptatem dolorem. Quiquia quaerat numquam dolore est neque adipisci dolore. Modi voluptatem modi est ut modi velit quisquam."
            },
            {
                "_id": "E000030",
                "name": "High level PDGFRA amplification",
                "abreviations": [
                    "10D5"
                ],
                "categoryId": "Aminopeptidase",
                "description": "Est labore quiquia ipsum velit. Aliquam porro amet dolor numquam porro porro. Quiquia voluptatem etincidunt neque. Quaerat sed dolor ipsum porro velit neque ipsum. Quisquam ut eius non eius."
            },
            {
                "_id": "E000031",
                "name": "Chemokine receptor CXCR7",
                "abreviations": [
                    "255A",
                    "9BE",
                    "4E3",
                    "485"
                ],
                "categoryId": "Cytokine",
                "description": "Sit magnam tempora porro numquam amet numquam. Numquam ut labore eius etincidunt. Dolor sit porro consectetur adipisci non. Dolorem tempora quisquam dolorem etincidunt. Adipisci ipsum eius dolore. Magnam est est etincidunt non porro dolor. Adipisci consectetur ut sit aliquam numquam quiquia. Sit quaerat magnam quaerat ipsum. Quiquia dolorem sed quaerat porro aliquam. Voluptatem velit ut amet numquam quisquam modi numquam."
            },
            {
                "_id": "E000032",
                "name": "Transforming growth factor beta",
                "abreviations": [
                    "2290",
                    "270A"
                ],
                "categoryId": "Metabolite",
                "description": "Dolor consectetur dolor porro modi non ipsum. Eius labore ut eius eius voluptatem porro adipisci. Consectetur porro non adipisci voluptatem. Ipsum voluptatem quiquia non non eius etincidunt velit. Sed sit magnam dolor amet velit aliquam. Quisquam sed adipisci tempora labore dolor. Voluptatem sed tempora est amet non etincidunt. Modi dolorem dolorem voluptatem aliquam neque."
            },
            {
                "_id": "E000033",
                "name": "RAB38 expression",
                "abreviations": [
                    "843",
                    "AE",
                    "21EB",
                    "126B"
                ],
                "categoryId": "Lipid",
                "description": "Quaerat non numquam eius quiquia. Voluptatem magnam quaerat dolorem. Tempora labore velit adipisci quaerat porro quiquia. Quaerat magnam sed quisquam magnam aliquam voluptatem dolor. Ipsum porro aliquam quaerat porro ut adipisci ut."
            },
            {
                "_id": "E000034",
                "name": "p4E-BP1",
                "abreviations": [
                    "1AF7"
                ],
                "categoryId": "Cytokine",
                "description": "Quiquia dolor labore quiquia. Est dolor neque voluptatem sed dolore quaerat. Ipsum voluptatem sed quiquia neque. Magnam aliquam ut velit etincidunt. Consectetur dolorem magnam numquam velit amet modi porro. Sit consectetur ut quiquia consectetur quiquia eius porro. Porro non ipsum tempora voluptatem velit velit tempora. Sit quiquia ipsum sit."
            },
            {
                "_id": "E000035",
                "name": "TGF-\ud835\udec3",
                "abreviations": [
                    "D17"
                ],
                "categoryId": "RNA",
                "description": "Magnam aliquam ipsum ipsum sit aliquam. Modi velit ipsum amet est voluptatem est est. Neque quiquia ipsum ipsum numquam modi labore. Sit numquam quaerat non. Etincidunt ipsum est tempora labore consectetur sed ipsum. Consectetur non etincidunt neque. Consectetur velit sed quaerat dolorem tempora dolorem. Porro quiquia quaerat ut velit adipisci tempora. Tempora numquam non sit non dolorem non. Non adipisci consectetur quisquam amet amet voluptatem aliquam."
            },
            {
                "_id": "E000036",
                "name": "Transforming growth factor-beta",
                "abreviations": [
                    "1FED",
                    "1510",
                    "23E2"
                ],
                "categoryId": "Protein",
                "description": "Modi quaerat sed aliquam. Quaerat aliquam velit aliquam. Dolor quisquam porro neque dolor est neque. Velit non quaerat aliquam. Magnam quiquia quiquia ut neque."
            },
            {
                "_id": "E000037",
                "name": "Glycolysis-based ten-gene signature",
                "abreviations": [
                    "14D3",
                    "1ED0",
                    "958",
                    "68"
                ],
                "categoryId": "Others",
                "description": "Aliquam eius adipisci consectetur. Quisquam etincidunt adipisci sed. Sed dolorem est quiquia voluptatem modi quisquam non. Non dolore adipisci consectetur eius adipisci ipsum. Dolore ut aliquam porro modi. Magnam porro sed eius dolor ut voluptatem."
            },
            {
                "_id": "E000038",
                "name": "miR-1280",
                "abreviations": [
                    "1907",
                    "C34"
                ],
                "categoryId": "Cytokine",
                "description": "Quisquam modi voluptatem sit voluptatem. Neque porro consectetur modi. Tempora non quisquam porro adipisci non. Numquam labore adipisci tempora amet non. Magnam sit sit dolore amet."
            },
            {
                "_id": "E000039",
                "name": "CCT7",
                "abreviations": [
                    "23CF",
                    "15E2",
                    "1B7E",
                    "2310"
                ],
                "categoryId": "Others",
                "description": "Ut quiquia amet sit ut. Adipisci modi aliquam ut dolore etincidunt quiquia quiquia. Dolor etincidunt consectetur sed ipsum amet. Sit numquam non dolorem velit. Dolorem dolor neque magnam neque quisquam eius. Dolore magnam amet sed numquam etincidunt. Dolor adipisci eius consectetur etincidunt. Ut eius adipisci velit sit consectetur dolor quaerat."
            },
            {
                "_id": "E00003A",
                "name": "Heat shock protein 70",
                "abreviations": [
                    "503",
                    "D76"
                ],
                "categoryId": "Protein",
                "description": "Sed adipisci quiquia quaerat porro etincidunt. Est aliquam numquam etincidunt etincidunt voluptatem voluptatem. Neque quaerat neque labore voluptatem quisquam. Dolorem sit ut amet labore ut. Ut non dolorem tempora. Sed magnam ut quiquia modi. Ipsum modi ut aliquam aliquam magnam etincidunt."
            },
            {
                "_id": "E00003B",
                "name": "ZEB1",
                "abreviations": [],
                "categoryId": "Cytokine",
                "description": "Eius adipisci ut voluptatem. Non ut quaerat dolore ipsum modi adipisci. Numquam consectetur tempora dolorem. Consectetur neque tempora numquam neque velit. Dolorem modi dolor eius aliquam consectetur dolor. Porro neque quisquam ipsum voluptatem quisquam quaerat voluptatem. Aliquam porro consectetur voluptatem voluptatem quisquam ut. Amet numquam dolore ut numquam amet. Adipisci dolorem quiquia porro dolorem sed. Eius modi sit quisquam."
            },
            {
                "_id": "E00003C",
                "name": "Histone deacetylase 1",
                "abreviations": [
                    "1A1E",
                    "F21",
                    "D27"
                ],
                "categoryId": "RNA",
                "description": "Adipisci etincidunt quaerat non tempora modi dolor. Velit dolor dolorem eius. Quisquam eius quiquia etincidunt ut dolor consectetur. Velit est modi quaerat ut eius sit. Numquam sit aliquam voluptatem adipisci sit dolorem."
            },
            {
                "_id": "E00003D",
                "name": "miRNA-504",
                "abreviations": [
                    "1C58",
                    "8C2"
                ],
                "categoryId": "Others",
                "description": "Magnam ut velit quisquam modi. Sit etincidunt dolore tempora sit. Est quaerat amet porro dolore quiquia velit ut. Non tempora porro quaerat consectetur modi. Amet aliquam ut ut. Sit non etincidunt ut etincidunt. Neque dolor numquam sed. Magnam dolor non eius."
            },
            {
                "_id": "E00003E",
                "name": "SOX11",
                "abreviations": [
                    "205B"
                ],
                "categoryId": "Aminopeptidase",
                "description": "Ut labore numquam labore. Quaerat sit velit aliquam etincidunt. Consectetur porro quiquia magnam dolore. Ut sed velit quisquam. Sit dolorem sed dolor numquam. Etincidunt ut dolorem ipsum dolor. Dolor quiquia porro non voluptatem etincidunt."
            },
            {
                "_id": "E00003F",
                "name": "miR-340",
                "abreviations": [
                    "62D",
                    "14F5",
                    "4FF",
                    "1C92"
                ],
                "categoryId": "Stem cells",
                "description": "Etincidunt dolorem est quisquam voluptatem adipisci labore dolor. Ipsum dolorem adipisci labore labore dolore sit. Velit dolor dolore quiquia est dolore velit. Adipisci ut ipsum quisquam. Voluptatem velit eius dolor velit modi quisquam adipisci. Quiquia dolor magnam numquam etincidunt. Etincidunt dolorem ipsum numquam adipisci."
            },
            {
                "_id": "E000040",
                "name": "Indoleamine 2,3-dioxygenase",
                "abreviations": [
                    "148F",
                    "1AB4",
                    "1A41",
                    "1FAF"
                ],
                "categoryId": "Protein",
                "description": "Est dolor numquam quaerat modi. Modi aliquam modi non. Labore amet est sit modi labore. Etincidunt porro modi modi tempora tempora. Quiquia quisquam sed dolore non eius dolorem non."
            },
            {
                "_id": "E000041",
                "name": "c-Met",
                "abreviations": [
                    "2050"
                ],
                "categoryId": "Lipid",
                "description": "Dolor sit consectetur etincidunt sit. Sed non velit amet magnam. Ipsum velit labore consectetur non magnam. Etincidunt amet etincidunt ut quisquam. Dolorem ut tempora ipsum quisquam labore neque tempora. Etincidunt velit non est quaerat adipisci labore. Neque dolor eius eius quisquam quiquia neque."
            },
            {
                "_id": "E000042",
                "name": "SH3RF1",
                "abreviations": [
                    "1E48",
                    "248A",
                    "1BB9"
                ],
                "categoryId": "RNA",
                "description": "Non modi quiquia neque dolorem adipisci adipisci adipisci. Eius ut neque quaerat sit aliquam dolore. Adipisci adipisci dolore quaerat velit quaerat. Quiquia dolore aliquam voluptatem neque. Dolor amet dolorem tempora ut sit amet numquam."
            },
            {
                "_id": "E000043",
                "name": "PSA-NCAM",
                "abreviations": [
                    "18C5"
                ],
                "categoryId": "Metabolite",
                "description": "Porro labore magnam porro etincidunt dolore numquam est. Etincidunt sed eius quiquia adipisci amet. Porro porro sed magnam porro. Dolore ut dolor dolor voluptatem. Consectetur etincidunt magnam sed labore numquam. Dolor quiquia ut voluptatem. Consectetur velit numquam voluptatem adipisci dolore voluptatem dolorem."
            },
            {
                "_id": "E000044",
                "name": "DTX1",
                "abreviations": [
                    "1713",
                    "229C",
                    "20B6"
                ],
                "categoryId": "DNA",
                "description": "Dolore dolorem eius aliquam. Non numquam quaerat voluptatem etincidunt est magnam. Non est dolor dolore. Amet aliquam numquam tempora. Amet eius quiquia magnam modi aliquam. Non dolorem non neque tempora porro neque. Etincidunt dolorem magnam ut non ipsum adipisci. Quiquia modi neque amet est quaerat. Porro adipisci ipsum dolor adipisci magnam quaerat."
            },
            {
                "_id": "E000045",
                "name": "SMAD1",
                "abreviations": [
                    "1002"
                ],
                "categoryId": "Enzyme",
                "description": "Est dolor aliquam etincidunt dolor. Modi amet dolore sed dolore est modi. Etincidunt dolor quiquia voluptatem neque. Labore velit numquam neque. Est est dolor dolor tempora sed voluptatem labore."
            },
            {
                "_id": "E000046",
                "name": "miR-181d",
                "abreviations": [
                    "63A"
                ],
                "categoryId": "Labelling index",
                "description": "Voluptatem tempora ipsum eius velit. Quaerat dolorem quisquam eius quiquia amet. Modi etincidunt ut non sed. Velit consectetur adipisci tempora porro porro non. Dolore dolor quaerat porro dolor neque eius non. Est magnam consectetur ut eius. Etincidunt adipisci labore quisquam non eius quiquia. Adipisci etincidunt dolorem dolore etincidunt. Quiquia etincidunt dolor tempora non dolor."
            },
            {
                "_id": "E000047",
                "name": "PTEN promoter methylation",
                "abreviations": [
                    "1B18",
                    "17DA"
                ],
                "categoryId": "Other",
                "description": "Tempora labore magnam amet dolorem ut consectetur ut. Etincidunt modi labore dolor est est magnam. Velit ipsum ipsum quaerat ipsum etincidunt ipsum quiquia. Consectetur est quaerat amet porro quaerat dolorem ipsum. Quisquam labore ut ipsum non. Non sit amet dolor."
            },
            {
                "_id": "E000048",
                "name": "POFUT2",
                "abreviations": [
                    "DDC"
                ],
                "categoryId": "Enzyme",
                "description": "Numquam eius voluptatem sed. Dolore etincidunt voluptatem etincidunt aliquam tempora velit tempora. Eius ut quisquam tempora dolor. Sed labore sed ipsum. Quisquam non tempora voluptatem. Etincidunt ut neque voluptatem sit numquam modi. Dolor aliquam sit eius neque."
            },
            {
                "_id": "E000049",
                "name": "pSrc",
                "abreviations": [
                    "1AEE",
                    "C53"
                ],
                "categoryId": "DNA",
                "description": "Modi quisquam dolore quiquia dolorem. Dolor sit quaerat labore. Adipisci voluptatem consectetur amet. Consectetur neque numquam porro etincidunt. Consectetur ipsum magnam quiquia sit labore."
            },
            {
                "_id": "E00004A",
                "name": "High in normal-1",
                "abreviations": [
                    "268E",
                    "1D34",
                    "1C7",
                    "20A5",
                    "12D6"
                ],
                "categoryId": "Labelling index",
                "description": "Sit quaerat quiquia etincidunt porro consectetur. Modi dolor ut non numquam ut. Numquam amet tempora neque. Labore sit ipsum etincidunt ut velit modi modi. Dolore neque eius quiquia sed magnam numquam sit."
            },
            {
                "_id": "E00004B",
                "name": "Neuropilin-plexin-A1",
                "abreviations": [
                    "8AD",
                    "A19"
                ],
                "categoryId": "Protein",
                "description": "Tempora neque quisquam tempora. Adipisci labore ipsum amet tempora consectetur. Quaerat dolorem numquam etincidunt magnam porro. Dolor dolorem tempora tempora neque consectetur. Dolore labore adipisci sit quaerat adipisci eius. Sit labore ut adipisci aliquam magnam. Tempora numquam quaerat magnam quiquia eius est est."
            },
            {
                "_id": "E00004C",
                "name": "JUN",
                "abreviations": [
                    "26E3",
                    "BF4",
                    "1D22",
                    "9EB",
                    "6CE"
                ],
                "categoryId": "Other",
                "description": "Neque est dolor adipisci amet quaerat. Quisquam neque tempora etincidunt sit. Etincidunt labore magnam ipsum magnam adipisci magnam amet. Quaerat est dolorem eius est amet amet. Etincidunt voluptatem consectetur magnam porro. Non sed porro labore. Etincidunt magnam velit dolor. Magnam non amet magnam aliquam sit sed non."
            },
            {
                "_id": "E00004D",
                "name": "Wnt receptor Frizzled-7",
                "abreviations": [
                    "2070"
                ],
                "categoryId": "Stem cells",
                "description": "Adipisci dolorem amet neque dolore dolore adipisci eius. Non sit dolor ut est ut. Porro numquam velit velit. Dolore dolore modi dolore non eius. Etincidunt dolorem sed quaerat ipsum eius quisquam. Velit labore velit neque. Ut aliquam non sed neque consectetur. Dolore voluptatem quaerat voluptatem non porro modi. Dolor modi non non sed dolore quiquia. Dolor adipisci ipsum eius non magnam non."
            },
            {
                "_id": "E00004E",
                "name": "c-erbB-2",
                "abreviations": [
                    "17D3",
                    "1EF1",
                    "1401",
                    "1904",
                    "1B0C"
                ],
                "categoryId": "Stem cells",
                "description": "Dolor tempora quaerat quisquam quaerat quiquia. Aliquam dolorem dolore quiquia aliquam etincidunt. Sed consectetur aliquam porro quisquam. Modi adipisci porro labore. Adipisci dolore aliquam porro ipsum. Porro velit quiquia dolore quaerat velit. Modi est dolorem ipsum sed. Voluptatem labore adipisci consectetur. Dolorem consectetur consectetur etincidunt modi amet numquam quiquia. Voluptatem aliquam eius sed est non etincidunt consectetur."
            },
            {
                "_id": "E00004F",
                "name": "lncRNA Fer-1-like family member 4",
                "abreviations": [
                    "FBE",
                    "6DD"
                ],
                "categoryId": "Metabolite",
                "description": "Etincidunt ipsum labore dolor quaerat. Eius quiquia dolor magnam est quisquam adipisci aliquam. Quaerat dolore aliquam modi dolore. Est dolore modi dolore. Tempora quisquam dolore dolor dolorem. Aliquam amet est magnam est. Non sed sed dolorem est magnam. Adipisci amet porro tempora dolor. Amet numquam ut amet magnam etincidunt labore. Dolore neque dolor eius quisquam porro."
            },
            {
                "_id": "E000050",
                "name": "SND1",
                "abreviations": [
                    "1C54",
                    "1CDD",
                    "CF6",
                    "269B"
                ],
                "categoryId": "Enzyme",
                "description": "Magnam labore amet non. Velit ut aliquam quiquia magnam ipsum ipsum etincidunt. Aliquam dolorem dolorem quisquam dolor non numquam quiquia. Modi amet neque est. Modi ut magnam non non."
            },
            {
                "_id": "E000051",
                "name": "Cathepsin D",
                "abreviations": [
                    "1A0D"
                ],
                "categoryId": "Protein",
                "description": "Non quaerat porro non quisquam est. Voluptatem sit sit est dolore. Ut quisquam eius quiquia sed magnam sed. Tempora numquam est sed porro. Dolor sit dolor dolor labore."
            },
            {
                "_id": "E000052",
                "name": "NLRP2",
                "abreviations": [
                    "10F3",
                    "1561",
                    "A6E",
                    "A6E",
                    "207D"
                ],
                "categoryId": "Stem cells",
                "description": "Quisquam est non consectetur velit quaerat quisquam. Non amet aliquam quiquia. Sed quiquia dolor non. Etincidunt velit neque consectetur quisquam amet. Magnam modi ipsum est consectetur ipsum. Sit etincidunt amet ipsum magnam. Numquam etincidunt eius magnam. Neque tempora numquam neque neque ipsum. Porro dolor porro magnam neque ipsum sed velit. Quisquam numquam amet tempora non amet."
            },
            {
                "_id": "E000053",
                "name": "High-mobility group A1",
                "abreviations": [
                    "119A",
                    "2494",
                    "17F5"
                ],
                "categoryId": "Cytokine",
                "description": "Tempora voluptatem neque etincidunt amet. Porro amet non ut aliquam. Porro ut aliquam dolor. Dolore numquam adipisci sed dolorem ut dolor ipsum. Tempora quaerat est quaerat sed. Adipisci sit sed porro dolor dolore etincidunt ipsum. Ut labore eius ipsum tempora aliquam. Amet consectetur porro eius adipisci. Dolore sit sit quiquia eius sed labore quaerat."
            },
            {
                "_id": "E000054",
                "name": "Metallothionein expression",
                "abreviations": [
                    "26D2",
                    "171E",
                    "18DB",
                    "1619",
                    "14E8"
                ],
                "categoryId": "Others",
                "description": "Velit non etincidunt aliquam velit adipisci tempora. Amet quaerat tempora est. Neque aliquam amet eius dolorem non dolore. Adipisci tempora sit adipisci numquam velit. Voluptatem etincidunt tempora magnam tempora modi quisquam. Amet voluptatem sed porro adipisci sit magnam. Labore quisquam dolore etincidunt aliquam porro. Dolore labore consectetur consectetur dolore ipsum quiquia. Dolorem ut ipsum porro consectetur sed tempora. Non dolorem voluptatem modi."
            },
            {
                "_id": "E000055",
                "name": "p-VEGFR2/3",
                "abreviations": [
                    "1569",
                    "18F",
                    "622"
                ],
                "categoryId": "Protein",
                "description": "Dolore velit neque dolor. Dolorem quiquia magnam quaerat velit neque. Dolor quiquia sed amet voluptatem. Neque voluptatem sed quisquam porro ipsum sit. Consectetur quaerat tempora amet consectetur. Ut porro eius dolore. Quaerat quaerat numquam numquam quiquia adipisci. Sit adipisci dolor consectetur numquam est dolorem. Adipisci ut adipisci dolor."
            },
            {
                "_id": "E000056",
                "name": "miR-326",
                "abreviations": [
                    "8A",
                    "1701",
                    "EE",
                    "D2E"
                ],
                "categoryId": "Lipid",
                "description": "Quaerat sed sed labore ut. Labore tempora amet numquam. Voluptatem numquam voluptatem velit quaerat quisquam. Ipsum dolorem sed numquam tempora. Eius magnam sed eius adipisci quisquam adipisci porro."
            },
            {
                "_id": "E000057",
                "name": "FABP7 expression",
                "abreviations": [
                    "1FBA",
                    "12B5",
                    "588"
                ],
                "categoryId": "RNA",
                "description": "Dolorem tempora non adipisci. Tempora modi labore dolore. Adipisci amet non labore. Sed neque eius velit. Est ipsum magnam velit est modi dolor."
            },
            {
                "_id": "E000058",
                "name": "TOPO1 expression",
                "abreviations": [
                    "9CA",
                    "71A"
                ],
                "categoryId": "Stem cells",
                "description": "Amet tempora adipisci consectetur. Voluptatem quaerat etincidunt labore consectetur dolore velit quisquam. Est porro ipsum numquam etincidunt etincidunt. Magnam consectetur quisquam quaerat non aliquam quiquia sit. Dolor magnam porro neque neque. Quiquia amet porro velit magnam magnam aliquam modi."
            },
            {
                "_id": "E000059",
                "name": "CD31 expression",
                "abreviations": [],
                "categoryId": "Enzyme",
                "description": "Dolorem modi dolor dolor magnam aliquam velit voluptatem. Velit adipisci quisquam numquam ut labore est. Sit quiquia amet sed voluptatem magnam neque dolorem. Eius quiquia modi aliquam magnam magnam quisquam aliquam. Voluptatem adipisci labore modi consectetur non velit. Quaerat etincidunt adipisci velit labore. Consectetur aliquam magnam tempora dolore labore. Quiquia voluptatem modi amet aliquam dolorem quisquam velit. Voluptatem quisquam numquam labore sit. Dolor consectetur ut sed ipsum modi amet ut."
            },
            {
                "_id": "E00005A",
                "name": "eIF4E",
                "abreviations": [],
                "categoryId": "Other",
                "description": "Eius non numquam ipsum sit neque. Voluptatem est porro non numquam sed ut porro. Dolore porro quiquia sit eius aliquam adipisci. Sit etincidunt ipsum eius dolor sit ipsum. Quisquam consectetur quaerat amet labore. Neque numquam voluptatem non ut ipsum."
            },
            {
                "_id": "E00005B",
                "name": "miR\u2011500a\u20115p",
                "abreviations": [
                    "305"
                ],
                "categoryId": "Aminopeptidase",
                "description": "Porro ipsum magnam modi dolore amet non. Etincidunt neque est numquam non eius magnam aliquam. Tempora dolorem amet modi dolore tempora consectetur. Modi quisquam modi modi velit tempora. Sed quiquia non neque aliquam ipsum. Ipsum aliquam sit tempora neque dolorem neque quaerat. Dolor consectetur labore labore quiquia. Neque eius magnam aliquam dolorem. Dolor ipsum non quisquam dolore est est. Non magnam amet dolorem voluptatem ipsum consectetur dolorem."
            },
            {
                "_id": "E00005C",
                "name": "NF-E2-related factor 2",
                "abreviations": [
                    "2404",
                    "D4F",
                    "156B",
                    "19A5"
                ],
                "categoryId": "Other",
                "description": "Dolore quaerat quisquam quaerat voluptatem. Numquam ipsum etincidunt labore neque ipsum consectetur modi. Sed tempora sit quiquia sed dolorem. Magnam porro etincidunt aliquam dolore dolor numquam. Dolore amet sed ut quiquia."
            },
            {
                "_id": "E00005D",
                "name": "O6-methylguanine-DNA methyltransferase promoter methylation",
                "abreviations": [
                    "1FF9",
                    "EC9"
                ],
                "categoryId": "Stem cells",
                "description": "Neque neque tempora dolor quaerat consectetur tempora. Dolorem aliquam magnam dolor. Non ipsum quiquia quaerat. Aliquam est voluptatem tempora sed etincidunt non ut. Aliquam numquam sed est adipisci adipisci modi aliquam. Ipsum quiquia etincidunt quiquia magnam sed ipsum adipisci. Sit velit dolorem est quisquam porro. Dolor est ipsum dolor."
            },
            {
                "_id": "E00005E",
                "name": "Interferon-induced protein with tetratricopeptide repeat 1",
                "abreviations": [
                    "6FB",
                    "1E94"
                ],
                "categoryId": "Aminopeptidase",
                "description": "Quiquia quisquam consectetur eius. Aliquam velit dolor velit labore. Non voluptatem numquam amet dolor sed. Quiquia tempora quaerat tempora magnam labore magnam eius. Consectetur aliquam adipisci adipisci porro tempora quisquam. Non ut eius dolore amet amet."
            },
            {
                "_id": "E00005F",
                "name": "Adipocyte binding protein 1",
                "abreviations": [
                    "1E30",
                    "1335",
                    "1607"
                ],
                "categoryId": "Aminopeptidase",
                "description": "Aliquam quiquia ipsum consectetur quisquam. Dolore amet sit amet dolore. Dolor adipisci non eius quiquia quaerat quaerat etincidunt. Dolorem neque est tempora. Ipsum magnam tempora dolor. Adipisci quaerat sed neque aliquam labore. Aliquam sed dolorem amet quaerat dolor. Dolore eius ipsum sed sed aliquam etincidunt sed. Magnam tempora sed sed adipisci magnam."
            },
            {
                "_id": "E000060",
                "name": "Alkylpurine-DNA-N-glycosylase",
                "abreviations": [
                    "CD4",
                    "1856",
                    "1437"
                ],
                "categoryId": "Lipid",
                "description": "Porro etincidunt sit sit. Porro porro ut ut etincidunt. Etincidunt ipsum ut magnam. Dolore neque quiquia consectetur ipsum eius etincidunt aliquam. Numquam dolorem voluptatem numquam tempora voluptatem non magnam. Non voluptatem dolorem numquam sit. Dolore etincidunt etincidunt dolorem sit dolore."
            },
            {
                "_id": "E000061",
                "name": "Podocalyxin-like protein",
                "abreviations": [],
                "categoryId": "Lipid",
                "description": "Dolorem eius sit est dolor aliquam ut tempora. Quaerat sed quaerat adipisci voluptatem porro velit. Aliquam porro aliquam sit. Quiquia eius est sed eius dolore. Quiquia magnam voluptatem sit labore quisquam. Non eius ut quaerat dolore eius eius magnam. Modi aliquam amet etincidunt consectetur dolor ut dolore. Amet dolorem modi tempora. Est quisquam quisquam quaerat."
            },
            {
                "_id": "E000062",
                "name": "HOXA11",
                "abreviations": [
                    "1070",
                    "180E"
                ],
                "categoryId": "Aminopeptidase",
                "description": "Aliquam aliquam ut numquam labore labore dolore. Eius quaerat tempora consectetur sit consectetur quisquam. Aliquam porro dolore etincidunt. Labore sed adipisci consectetur tempora non porro. Consectetur dolore etincidunt velit neque tempora amet. Eius etincidunt est porro."
            },
            {
                "_id": "E000063",
                "name": "Nuclear karyopherin a2",
                "abreviations": [
                    "D04"
                ],
                "categoryId": "Metabolite",
                "description": "Sit ipsum labore numquam velit neque porro aliquam. Etincidunt tempora aliquam ipsum tempora. Voluptatem est non quiquia. Est ut dolor sit dolorem numquam tempora modi. Neque est magnam velit ipsum numquam dolorem. Amet eius dolorem est quisquam aliquam eius dolore."
            },
            {
                "_id": "E000064",
                "name": "IGFBP2",
                "abreviations": [
                    "1CA2",
                    "1351"
                ],
                "categoryId": "Aminopeptidase",
                "description": "Tempora adipisci amet quaerat ipsum neque amet amet. Dolor quisquam ipsum magnam velit dolor quisquam consectetur. Velit voluptatem consectetur dolore dolor magnam magnam. Consectetur numquam sit dolore labore non est. Non quisquam aliquam consectetur porro non. Eius tempora ut adipisci amet."
            },
            {
                "_id": "E000065",
                "name": "Twist",
                "abreviations": [
                    "1F72",
                    "D44",
                    "17E0",
                    "190B",
                    "680"
                ],
                "categoryId": "Aminopeptidase",
                "description": "Quiquia voluptatem etincidunt eius consectetur est ut eius. Dolor dolore amet ut. Quaerat aliquam magnam dolorem etincidunt dolor sit. Ut ut dolor voluptatem quaerat porro magnam. Aliquam magnam est labore neque quaerat non voluptatem. Porro ut etincidunt adipisci neque ipsum. Adipisci consectetur dolorem labore est dolorem. Voluptatem sit non sit amet modi."
            },
            {
                "_id": "E000066",
                "name": "lncRNA",
                "abreviations": [
                    "1D9C"
                ],
                "categoryId": "Cytokine",
                "description": "Numquam consectetur sed eius neque velit dolorem adipisci. Sed eius non sit sit. Consectetur quisquam quiquia eius non porro dolore. Voluptatem modi porro quiquia aliquam. Consectetur aliquam amet etincidunt eius amet non. Consectetur voluptatem modi labore. Non magnam amet sit. Ut dolore voluptatem numquam. Aliquam consectetur sit est."
            },
            {
                "_id": "E000067",
                "name": "Epidermal growth factor, latrophilin and 7 transmembrane domain-containing protein 1 on chromosome 1)",
                "abreviations": [
                    "1EAD",
                    "1213",
                    "14B1"
                ],
                "categoryId": "Protein",
                "description": "Numquam modi voluptatem numquam etincidunt quaerat. Dolor dolorem adipisci velit tempora sed tempora. Quiquia est non ipsum labore. Sed est tempora ipsum etincidunt velit. Aliquam numquam sed aliquam dolore quiquia voluptatem voluptatem."
            },
            {
                "_id": "E000068",
                "name": "microRNA-129",
                "abreviations": [
                    "7F4",
                    "11E0",
                    "888"
                ],
                "categoryId": "DNA",
                "description": "Etincidunt voluptatem modi dolorem ipsum labore labore. Eius consectetur modi est quaerat etincidunt ut quiquia. Magnam amet eius tempora adipisci non dolorem. Quisquam neque numquam ipsum voluptatem labore tempora. Ipsum sed magnam est dolor eius eius."
            },
            {
                "_id": "E000069",
                "name": "miR-21",
                "abreviations": [
                    "A6F",
                    "23BB",
                    "13B9",
                    "17BA"
                ],
                "categoryId": "Other",
                "description": "Quisquam consectetur neque ipsum labore adipisci. Tempora quaerat consectetur voluptatem eius. Dolorem dolore quiquia adipisci quiquia est sit. Tempora sed non eius aliquam sed. Quisquam dolore est dolorem velit numquam aliquam dolore. Dolore voluptatem consectetur ipsum quiquia etincidunt est. Quaerat dolorem amet consectetur quiquia modi neque tempora. Dolore numquam quaerat porro dolore. Eius magnam amet dolore."
            },
            {
                "_id": "E00006A",
                "name": "TP73-AS1",
                "abreviations": [
                    "1CA7",
                    "2215",
                    "1409"
                ],
                "categoryId": "Others",
                "description": "Aliquam modi ipsum non modi tempora sed. Modi labore magnam ut numquam labore. Voluptatem numquam adipisci dolor. Velit ut neque amet. Quiquia est neque tempora numquam labore porro ut. Amet aliquam consectetur tempora ut. Sed numquam neque quiquia. Neque sed velit porro numquam ipsum quiquia. Velit quiquia voluptatem numquam dolor sit. Numquam tempora adipisci ipsum consectetur adipisci."
            },
            {
                "_id": "E00006B",
                "name": "mi-151-3p",
                "abreviations": [
                    "829",
                    "1933",
                    "411",
                    "2358",
                    "19E6"
                ],
                "categoryId": "Others",
                "description": "Sed sed labore amet quisquam. Voluptatem est ipsum labore eius tempora adipisci. Est magnam modi ipsum magnam modi dolore. Porro dolor etincidunt modi dolor. Dolorem velit ut velit ipsum. Dolor etincidunt velit dolor labore dolore. Non sed tempora ipsum tempora eius voluptatem. Tempora sed tempora amet modi labore voluptatem ipsum. Magnam dolor voluptatem sed sed sed."
            },
            {
                "_id": "E00006C",
                "name": "MAPK",
                "abreviations": [],
                "categoryId": "Other",
                "description": "Porro quisquam magnam velit sed. Ut eius velit numquam. Velit ut ut porro tempora. Modi consectetur numquam dolor neque quiquia eius. Quiquia voluptatem quiquia neque est numquam eius. Magnam quiquia ipsum sed aliquam numquam sed dolore."
            },
            {
                "_id": "E00006D",
                "name": "HES1",
                "abreviations": [],
                "categoryId": "Metabolite",
                "description": "Magnam sed ipsum est consectetur numquam. Numquam sit adipisci labore modi. Est quaerat adipisci aliquam. Dolore porro voluptatem tempora quisquam dolore numquam. Velit consectetur tempora magnam amet quisquam sit. Neque quaerat aliquam labore. Dolorem amet ipsum velit. Eius modi magnam amet est amet. Sed labore aliquam eius sit aliquam sed."
            },
            {
                "_id": "E00006E",
                "name": "Mdm2",
                "abreviations": [
                    "8D"
                ],
                "categoryId": "Metabolite",
                "description": "Amet adipisci numquam est dolore tempora dolore. Quisquam quaerat aliquam est consectetur. Voluptatem amet non quiquia ipsum numquam ipsum. Quisquam labore est consectetur porro. Ut sed consectetur adipisci aliquam amet labore. Eius numquam voluptatem voluptatem neque consectetur. Sed neque ipsum ipsum eius. Sit aliquam numquam non quisquam. Amet dolore labore adipisci quisquam quiquia. Neque adipisci neque tempora consectetur ut voluptatem."
            },
            {
                "_id": "E00006F",
                "name": "GLUT-1",
                "abreviations": [
                    "2531",
                    "1757",
                    "1D99",
                    "22C9",
                    "13FE"
                ],
                "categoryId": "Others",
                "description": "Dolor modi adipisci quiquia. Velit dolorem sed velit aliquam amet modi neque. Porro eius ipsum dolor labore quaerat magnam velit. Velit adipisci sit labore magnam tempora. Sit magnam etincidunt eius adipisci modi est velit. Amet est ut dolor sed quiquia."
            },
            {
                "_id": "E000070",
                "name": "miR-191",
                "abreviations": [
                    "1CBF",
                    "CF8",
                    "A1B",
                    "16D1",
                    "7E0"
                ],
                "categoryId": "RNA",
                "description": "Adipisci modi dolor quiquia consectetur labore adipisci ipsum. Quisquam dolor magnam porro. Labore dolore est ipsum etincidunt neque quaerat. Consectetur quiquia numquam non amet consectetur velit amet. Consectetur adipisci aliquam porro magnam."
            },
            {
                "_id": "E000071",
                "name": "Phosphorylated PRAS40",
                "abreviations": [
                    "A44",
                    "1CDF",
                    "158E",
                    "EE5",
                    "41B"
                ],
                "categoryId": "Stem cells",
                "description": "Etincidunt magnam aliquam eius eius amet. Neque etincidunt tempora labore. Etincidunt porro voluptatem numquam sed. Numquam aliquam eius non quaerat consectetur. Ipsum magnam non tempora consectetur modi numquam est. Labore amet aliquam quaerat quisquam etincidunt eius. Ut ut voluptatem amet magnam sit sed. Eius modi aliquam quaerat quaerat. Consectetur dolor eius aliquam sed magnam ut ipsum. Porro tempora amet velit dolor tempora."
            },
            {
                "_id": "E000072",
                "name": "miR-524",
                "abreviations": [
                    "5B6",
                    "1763",
                    "9B0",
                    "1926",
                    "9D1"
                ],
                "categoryId": "Protein",
                "description": "Dolorem tempora velit ipsum. Non labore tempora quiquia voluptatem velit dolorem. Porro eius dolorem porro dolor. Tempora quisquam etincidunt ipsum quaerat tempora sit velit. Quisquam ipsum tempora dolor labore adipisci velit. Etincidunt labore eius labore ut. Ipsum voluptatem consectetur ut eius adipisci eius dolor. Quaerat dolore labore dolore tempora. Voluptatem velit labore modi non dolorem labore dolor. Quaerat dolore magnam ipsum dolorem aliquam eius non."
            },
            {
                "_id": "E000073",
                "name": "Genetic losses from chromosomes 10q",
                "abreviations": [
                    "2245"
                ],
                "categoryId": "Stem cells",
                "description": "Dolore quiquia consectetur adipisci dolorem. Amet dolor dolor aliquam. Dolorem dolor numquam quisquam neque porro. Aliquam neque quisquam ipsum etincidunt. Eius quiquia tempora dolor non ipsum. Voluptatem numquam etincidunt est. Tempora eius est amet numquam aliquam modi ipsum. Dolore numquam ut dolor."
            },
            {
                "_id": "E000074",
                "name": "Connexin 30 gene gap junction beta-6 expression",
                "abreviations": [
                    "203",
                    "2A2",
                    "233A"
                ],
                "categoryId": "Aminopeptidase",
                "description": "Labore modi dolorem tempora. Est adipisci adipisci neque. Adipisci sit eius etincidunt porro consectetur etincidunt. Dolor quaerat consectetur etincidunt sed. Quaerat voluptatem adipisci magnam. Modi velit sit est eius sit consectetur dolorem. Adipisci quiquia modi non dolor etincidunt."
            },
            {
                "_id": "E000075",
                "name": "PRDX1",
                "abreviations": [
                    "1C3A",
                    "1980",
                    "14DF"
                ],
                "categoryId": "Protein",
                "description": "Consectetur numquam neque ipsum dolore. Porro quaerat labore adipisci labore. Consectetur dolorem dolor consectetur ut consectetur ipsum amet. Ut sit est eius consectetur. Numquam velit magnam ut. Labore dolorem magnam sed numquam magnam. Dolorem dolorem eius voluptatem."
            },
            {
                "_id": "E000076",
                "name": "miRNA-210",
                "abreviations": [
                    "B6D",
                    "1BC8",
                    "15C4",
                    "3EC",
                    "9D9"
                ],
                "categoryId": "Others",
                "description": "Neque non adipisci ut ut eius non porro. Quaerat modi ut dolore est modi quisquam. Eius numquam numquam ut non voluptatem quaerat quaerat. Consectetur labore est etincidunt ut adipisci dolore modi. Dolorem dolorem quiquia consectetur velit dolorem labore quaerat. Eius quiquia modi amet dolor tempora. Dolorem dolor non sed quisquam quaerat eius magnam."
            },
            {
                "_id": "E000077",
                "name": "Interleukin-13 receptor alpha 2",
                "abreviations": [
                    "21C8",
                    "30B",
                    "3D9",
                    "AA5"
                ],
                "categoryId": "Enzyme",
                "description": "Quisquam quaerat modi adipisci. Labore ut porro adipisci sed. Quiquia ipsum modi neque modi quiquia etincidunt ipsum. Quaerat porro velit consectetur. Velit velit velit dolor ut quisquam aliquam modi. Ut modi neque dolorem. Dolor neque dolorem tempora."
            },
            {
                "_id": "E000078",
                "name": "AC104653.1",
                "abreviations": [
                    "1DE0",
                    "1E37",
                    "C28",
                    "1C27"
                ],
                "categoryId": "Enzyme",
                "description": "Aliquam labore voluptatem neque. Sit velit etincidunt sit velit sed dolore. Adipisci adipisci etincidunt velit. Sit quiquia consectetur aliquam tempora quiquia quiquia aliquam. Sit modi etincidunt quiquia quaerat quaerat dolor est."
            },
            {
                "_id": "E000079",
                "name": "IMP3",
                "abreviations": [
                    "193F",
                    "242A",
                    "F32",
                    "BD9"
                ],
                "categoryId": "Aminopeptidase",
                "description": "Magnam velit porro aliquam porro magnam quaerat. Aliquam magnam ut ipsum. Sed consectetur aliquam porro tempora sed quiquia. Sed quisquam magnam numquam. Modi sit quisquam quisquam aliquam. Sit porro porro ut velit neque velit. Adipisci velit quiquia sit sit etincidunt adipisci velit."
            },
            {
                "_id": "E00007A",
                "name": "p-EGFR",
                "abreviations": [
                    "20F7",
                    "BE3",
                    "AE2",
                    "C92"
                ],
                "categoryId": "Cytokine",
                "description": "Consectetur ut quiquia ut aliquam est. Magnam aliquam eius voluptatem ut. Quaerat adipisci neque adipisci. Voluptatem aliquam modi dolor porro dolore. Eius quisquam aliquam est est. Magnam quaerat dolor tempora quisquam. Amet eius voluptatem labore quaerat dolorem adipisci."
            },
            {
                "_id": "E00007B",
                "name": "MIR155 host gene 7miR-155 axis",
                "abreviations": [
                    "83F",
                    "22EC",
                    "111F",
                    "B98",
                    "25A3"
                ],
                "categoryId": "Labelling index",
                "description": "Velit ut dolorem ut numquam consectetur velit. Eius magnam eius dolor quaerat porro. Sed modi magnam eius magnam. Quiquia non dolore magnam. Eius amet ut quaerat amet non. Tempora modi modi voluptatem voluptatem porro. Sit voluptatem dolorem consectetur velit amet aliquam quisquam. Modi numquam magnam est. Non neque dolor tempora numquam modi."
            },
            {
                "_id": "E00007C",
                "name": "PEA-15",
                "abreviations": [
                    "D04",
                    "941",
                    "12B4",
                    "189C",
                    "1335"
                ],
                "categoryId": "RNA",
                "description": "Tempora neque ipsum etincidunt modi sit sit. Quaerat neque neque amet eius dolor neque. Quiquia dolore velit dolorem dolorem amet porro sed. Quiquia est etincidunt ipsum modi dolorem amet aliquam. Amet labore amet sit etincidunt quaerat ipsum. Dolor numquam ipsum voluptatem consectetur. Quaerat est numquam eius modi magnam velit modi. Ut velit etincidunt dolore non adipisci magnam."
            },
            {
                "_id": "E00007D",
                "name": "TS expression",
                "abreviations": [
                    "94E",
                    "9BE",
                    "1A02",
                    "1E7D",
                    "E35"
                ],
                "categoryId": "Labelling index",
                "description": "Modi est modi voluptatem dolorem amet. Quaerat etincidunt aliquam etincidunt. Ipsum ut ut ipsum est. Consectetur sed modi labore. Dolor ipsum dolore numquam etincidunt velit non sit. Tempora aliquam amet neque magnam numquam dolore sed."
            },
            {
                "_id": "E00007E",
                "name": "HK2",
                "abreviations": [],
                "categoryId": "Others",
                "description": "Quisquam sit dolorem neque velit amet etincidunt. Quisquam non adipisci sit adipisci. Non aliquam sed est dolor eius. Numquam porro eius dolorem dolore quiquia. Magnam ipsum sed velit amet quisquam. Numquam sed porro sed est adipisci. Amet quiquia eius adipisci quaerat dolor eius amet. Porro numquam velit magnam dolorem numquam neque aliquam. Neque dolor quiquia neque. Aliquam ut etincidunt sed eius consectetur sed dolore."
            },
            {
                "_id": "E00007F",
                "name": "pCHEK1",
                "abreviations": [],
                "categoryId": "Labelling index",
                "description": "Porro non voluptatem modi amet sed quaerat. Dolorem consectetur eius quaerat aliquam etincidunt porro modi. Porro aliquam amet voluptatem velit numquam quisquam quisquam. Voluptatem ipsum ut ut amet quaerat. Dolorem ipsum sit sit amet etincidunt sed quiquia."
            },
            {
                "_id": "E000080",
                "name": "Upregulation of human Distal-less Homeobox 2",
                "abreviations": [
                    "A5D",
                    "449"
                ],
                "categoryId": "Lipid",
                "description": "Consectetur voluptatem magnam dolor aliquam est. Est voluptatem magnam quaerat quaerat ipsum. Quisquam dolorem aliquam etincidunt. Dolore dolorem eius non. Ut ipsum magnam ut velit. Etincidunt dolor sit eius amet neque. Neque dolorem quiquia dolore labore modi. Numquam dolor est amet labore dolore sit."
            },
            {
                "_id": "E000081",
                "name": "leptin/ObR",
                "abreviations": [
                    "91B",
                    "1814",
                    "551",
                    "9C7",
                    "7D5"
                ],
                "categoryId": "DNA",
                "description": "Sed modi modi ut. Dolor magnam numquam sed voluptatem neque. Magnam adipisci est non voluptatem etincidunt quisquam. Quisquam aliquam aliquam ut consectetur porro neque adipisci. Aliquam tempora neque dolor ut aliquam adipisci."
            },
            {
                "_id": "E000082",
                "name": "IDH1 mutation",
                "abreviations": [
                    "26B1",
                    "161F"
                ],
                "categoryId": "Labelling index",
                "description": "Porro non quaerat voluptatem consectetur modi quiquia. Non porro dolor ut. Est modi aliquam ipsum. Quaerat velit consectetur numquam ut quiquia. Est eius voluptatem consectetur non aliquam modi amet. Dolorem voluptatem velit velit."
            },
            {
                "_id": "E000083",
                "name": "Cancer-testis antigen XAGE3",
                "abreviations": [
                    "1F78"
                ],
                "categoryId": "Metabolite",
                "description": "Sit ut non adipisci sed eius. Est dolor labore sit adipisci ut voluptatem. Porro sed est dolorem quiquia dolore numquam. Porro consectetur modi eius est neque consectetur magnam. Numquam consectetur eius quaerat amet."
            },
            {
                "_id": "E000084",
                "name": "NPTX2",
                "abreviations": [],
                "categoryId": "RNA",
                "description": "Ipsum dolor dolor dolore labore quaerat dolor. Labore adipisci eius neque est adipisci magnam. Quiquia modi magnam quaerat consectetur ut neque est. Neque quaerat aliquam porro velit eius magnam neque. Sed dolor labore voluptatem ipsum est. Adipisci est quisquam dolorem magnam. Sit ipsum quiquia quiquia ut dolor sit sit. Voluptatem non numquam velit non sit adipisci."
            },
            {
                "_id": "E000085",
                "name": "CD133 mRNA",
                "abreviations": [],
                "categoryId": "Aminopeptidase",
                "description": "Velit quaerat non labore ipsum dolorem. Sed eius dolorem non modi etincidunt consectetur. Adipisci quisquam sit dolore tempora. Dolore eius velit etincidunt sed. Quisquam est amet numquam dolor magnam. Adipisci velit adipisci dolore."
            },
            {
                "_id": "E000086",
                "name": "IDH 1/2 mutation",
                "abreviations": [],
                "categoryId": "Others",
                "description": "Voluptatem velit neque non adipisci amet. Eius non dolore aliquam est tempora. Porro modi dolor dolor numquam ut sit modi. Voluptatem adipisci tempora sed etincidunt modi. Sed dolorem neque magnam ut adipisci. Eius eius voluptatem voluptatem amet. Neque amet porro quisquam dolor."
            },
            {
                "_id": "E000087",
                "name": "CD99",
                "abreviations": [
                    "58E",
                    "1499",
                    "FC7"
                ],
                "categoryId": "Metabolite",
                "description": "Voluptatem amet neque amet dolorem modi. Non etincidunt quisquam dolore. Quaerat labore quisquam tempora quisquam modi. Aliquam dolor ipsum est ipsum. Ut dolore ipsum ut consectetur. Numquam ut velit est modi. Aliquam est aliquam etincidunt dolorem sit quisquam. Magnam sed etincidunt labore modi tempora."
            },
            {
                "_id": "E000088",
                "name": "Guanylate binding protein 1",
                "abreviations": [
                    "18FC",
                    "5F3",
                    "1CE5",
                    "13A2"
                ],
                "categoryId": "Enzyme",
                "description": "Adipisci porro neque non porro quiquia eius. Etincidunt labore sed eius. Amet dolore amet aliquam. Tempora velit dolore sit magnam tempora voluptatem tempora. Numquam dolorem quiquia dolore etincidunt neque quisquam. Non quiquia porro dolor quiquia ut neque quaerat."
            },
            {
                "_id": "E000089",
                "name": "YKL-40 protein expression",
                "abreviations": [],
                "categoryId": "Enzyme",
                "description": "Dolorem quisquam est quaerat etincidunt quaerat sit. Dolor magnam dolor numquam. Etincidunt dolore velit aliquam numquam est magnam aliquam. Aliquam quaerat consectetur voluptatem dolorem dolorem. Neque quiquia non consectetur porro."
            },
            {
                "_id": "E00008A",
                "name": "N\u2010Myc downstream\u2010regulated gene 2",
                "abreviations": [
                    "F1C",
                    "18F8",
                    "1EA4",
                    "1B6F"
                ],
                "categoryId": "Other",
                "description": "Sit eius adipisci est dolor. Aliquam dolore voluptatem magnam non ipsum. Non porro numquam ut porro non. Tempora ut eius dolor non est. Quisquam ipsum neque dolor dolor. Porro quisquam eius magnam labore ut tempora etincidunt. Sit tempora ipsum consectetur."
            },
            {
                "_id": "E00008B",
                "name": "Ki-67 proliferation index",
                "abreviations": [
                    "848"
                ],
                "categoryId": "Metabolite",
                "description": "Labore quisquam quisquam velit sit ut dolorem labore. Non quaerat consectetur etincidunt magnam adipisci non. Eius sed dolore dolorem quaerat modi numquam magnam. Dolor quiquia velit dolore quisquam consectetur. Etincidunt adipisci amet neque etincidunt consectetur aliquam. Sit ipsum ipsum voluptatem. Quiquia magnam magnam voluptatem dolorem sed."
            },
            {
                "_id": "E00008C",
                "name": "hsa-miR-628-5p",
                "abreviations": [
                    "47",
                    "20A3",
                    "EFD",
                    "26FA"
                ],
                "categoryId": "DNA",
                "description": "Etincidunt est ut amet quiquia. Dolorem tempora modi modi quisquam numquam quisquam. Quiquia non velit numquam tempora numquam. Porro ipsum ipsum voluptatem. Magnam sed ipsum labore modi consectetur ut. Dolore numquam est ut adipisci. Quiquia ut quisquam quisquam dolorem sit magnam. Sit neque non amet aliquam. Est eius dolore tempora tempora est ut neque. Labore quiquia amet amet."
            },
            {
                "_id": "E00008D",
                "name": "MCM3AP-AS",
                "abreviations": [
                    "8CE",
                    "1F9F",
                    "2688",
                    "1B32"
                ],
                "categoryId": "Others",
                "description": "Quiquia numquam adipisci numquam aliquam sed. Quisquam quiquia etincidunt porro neque labore. Non aliquam quisquam magnam quaerat quisquam. Adipisci sed dolor eius sit sit tempora amet. Numquam consectetur consectetur quiquia velit quaerat. Quisquam modi porro tempora adipisci. Quiquia dolor dolor quisquam aliquam numquam est quiquia."
            },
            {
                "_id": "E00008E",
                "name": "Cytoplasmic polyadenylation element binding protein 4",
                "abreviations": [],
                "categoryId": "Labelling index",
                "description": "Adipisci dolore tempora amet dolorem. Quisquam dolorem neque quaerat amet voluptatem ut consectetur. Etincidunt dolorem eius ipsum ipsum etincidunt quisquam. Modi magnam modi sit velit sed ipsum. Adipisci voluptatem est quisquam. Neque etincidunt aliquam eius neque ut eius quisquam. Tempora numquam neque porro tempora quiquia. Quiquia ipsum dolorem dolor. Amet dolor consectetur ut adipisci non."
            },
            {
                "_id": "E00008F",
                "name": "Forkhead-box A1",
                "abreviations": [
                    "1B71",
                    "1BE1",
                    "4EF",
                    "AFA"
                ],
                "categoryId": "Enzyme",
                "description": "Porro sit ipsum non etincidunt labore eius dolore. Amet non porro sed voluptatem ut eius voluptatem. Est labore adipisci etincidunt sit quisquam aliquam neque. Dolore ipsum consectetur eius quiquia modi porro consectetur. Aliquam modi adipisci dolorem. Aliquam labore modi non voluptatem neque."
            },
            {
                "_id": "E000090",
                "name": "31 gene signature",
                "abreviations": [
                    "1E28",
                    "1C49",
                    "44C",
                    "878",
                    "1152"
                ],
                "categoryId": "Aminopeptidase",
                "description": "Modi etincidunt dolorem porro. Quiquia eius dolore porro consectetur. Est quaerat tempora etincidunt dolore labore modi. Consectetur etincidunt quaerat velit. Quiquia quisquam quiquia neque ipsum non sed."
            },
            {
                "_id": "E000091",
                "name": "TERT promoter mutation",
                "abreviations": [
                    "1692",
                    "BCE"
                ],
                "categoryId": "Metabolite",
                "description": "Quiquia porro est quisquam eius sed. Magnam eius dolor numquam quaerat aliquam etincidunt. Etincidunt est eius labore adipisci voluptatem. Tempora neque voluptatem aliquam voluptatem. Consectetur adipisci ut tempora ipsum."
            },
            {
                "_id": "E000092",
                "name": "p60/CAF-1",
                "abreviations": [
                    "1FF",
                    "ADA",
                    "2E9",
                    "135D"
                ],
                "categoryId": "Labelling index",
                "description": "Non labore neque adipisci. Aliquam dolore amet porro etincidunt eius est magnam. Adipisci ipsum ut etincidunt sed dolor velit. Tempora dolore dolor ipsum sit velit quaerat porro. Dolor eius quaerat adipisci consectetur dolor. Labore voluptatem non labore modi consectetur amet. Dolor dolor etincidunt est eius. Adipisci sit etincidunt ipsum quaerat adipisci. Velit adipisci magnam numquam neque eius aliquam magnam. Eius aliquam etincidunt consectetur aliquam voluptatem."
            },
            {
                "_id": "E000093",
                "name": "Survivin",
                "abreviations": [
                    "1BB",
                    "163D",
                    "C50",
                    "1C40"
                ],
                "categoryId": "Other",
                "description": "Labore tempora quaerat dolor adipisci dolore. Eius sed aliquam consectetur eius. Adipisci velit eius amet eius adipisci. Labore quisquam consectetur quiquia amet eius etincidunt modi. Non neque eius consectetur dolor magnam. Quisquam labore ipsum etincidunt dolore ut magnam modi. Porro consectetur quisquam sed quisquam dolor dolor."
            },
            {
                "_id": "E000094",
                "name": "PLOD2",
                "abreviations": [
                    "A67",
                    "115E",
                    "100"
                ],
                "categoryId": "Aminopeptidase",
                "description": "Porro non amet ipsum neque quaerat sit etincidunt. Ut dolore labore velit. Porro dolor quiquia quiquia. Quiquia adipisci quisquam sit quiquia dolorem. Etincidunt amet aliquam voluptatem dolor modi voluptatem dolorem. Non sed etincidunt dolore quisquam eius. Sit ipsum labore non neque. Tempora dolor sed quaerat consectetur etincidunt."
            },
            {
                "_id": "E000095",
                "name": "\u03b2-catenin",
                "abreviations": [
                    "110D",
                    "2616",
                    "1589"
                ],
                "categoryId": "Enzyme",
                "description": "Ipsum quiquia consectetur magnam dolore etincidunt voluptatem numquam. Quisquam ipsum quaerat quisquam magnam consectetur quaerat. Non magnam aliquam aliquam sit sed consectetur. Adipisci neque modi eius ut. Ut est numquam sit eius. Quiquia neque eius magnam quiquia etincidunt sit sed. Adipisci consectetur non adipisci. Velit ipsum quiquia magnam aliquam adipisci. Quaerat neque porro dolor."
            },
            {
                "_id": "E000096",
                "name": "miR-142-5p",
                "abreviations": [
                    "1F9C",
                    "F7B"
                ],
                "categoryId": "Stem cells",
                "description": "Etincidunt dolor magnam labore. Dolor aliquam porro ut consectetur sit sed labore. Etincidunt magnam consectetur velit consectetur quisquam. Dolor amet quisquam etincidunt quaerat. Aliquam quaerat sit adipisci. Aliquam modi tempora est eius velit labore adipisci. Magnam amet sed numquam magnam modi. Modi adipisci neque quisquam."
            },
            {
                "_id": "E000097",
                "name": "miRNA-363",
                "abreviations": [
                    "1A4"
                ],
                "categoryId": "Cytokine",
                "description": "Quiquia dolore dolore ipsum labore magnam. Voluptatem amet aliquam numquam adipisci modi. Consectetur voluptatem dolorem aliquam ut quaerat labore. Dolore quiquia neque aliquam est etincidunt velit porro. Etincidunt voluptatem voluptatem ut non est. Sit velit dolor amet tempora voluptatem quaerat. Sit neque quisquam numquam labore."
            },
            {
                "_id": "E000098",
                "name": "Osteonectin",
                "abreviations": [
                    "25A1",
                    "2430"
                ],
                "categoryId": "Protein",
                "description": "Eius non amet quisquam. Dolorem quisquam dolor sed neque porro dolore consectetur. Velit ut dolore quaerat est dolorem voluptatem neque. Numquam quisquam etincidunt aliquam quisquam etincidunt est. Amet numquam quaerat consectetur sit quiquia dolorem. Etincidunt tempora neque non magnam magnam. Ut velit neque neque adipisci dolor amet. Ipsum quaerat sed sit porro numquam. Ipsum adipisci tempora est non consectetur adipisci ipsum."
            },
            {
                "_id": "E000099",
                "name": "CCL11/CCR3",
                "abreviations": [
                    "6A",
                    "209C",
                    "CA2"
                ],
                "categoryId": "Stem cells",
                "description": "Dolore non quaerat dolor ipsum. Quiquia voluptatem tempora ut quaerat est eius. Dolor magnam quisquam adipisci quisquam. Velit sit amet eius consectetur quiquia numquam tempora. Quiquia consectetur quaerat porro ut dolor quisquam. Porro est ipsum labore ut. Dolor dolorem ut modi quiquia. Aliquam porro amet ut. Ut numquam aliquam tempora amet."
            },
            {
                "_id": "E00009A",
                "name": "H3F3A K27M mutation",
                "abreviations": [
                    "789",
                    "7E1"
                ],
                "categoryId": "Cytokine",
                "description": "Dolore neque adipisci ipsum porro. Amet magnam quaerat voluptatem. Dolor aliquam numquam adipisci sed quiquia quaerat. Labore labore adipisci velit quisquam etincidunt. Consectetur ipsum consectetur tempora adipisci. Quaerat amet tempora quiquia sed neque amet tempora. Dolor labore modi dolore quaerat velit aliquam. Ipsum amet etincidunt velit. Amet modi neque consectetur tempora."
            },
            {
                "_id": "E00009B",
                "name": "MGMT methylation",
                "abreviations": [
                    "2176",
                    "24A3",
                    "1877",
                    "C0E",
                    "1926"
                ],
                "categoryId": "Other",
                "description": "Tempora aliquam porro non. Quaerat modi dolore quaerat sit eius. Modi quisquam tempora dolor. Dolor voluptatem sed porro neque dolorem. Adipisci porro magnam eius. Aliquam dolor quisquam dolore modi quaerat modi."
            },
            {
                "_id": "E00009C",
                "name": "GQ1b",
                "abreviations": [
                    "DCD",
                    "210C",
                    "1DFA",
                    "1727"
                ],
                "categoryId": "Cytokine",
                "description": "Amet non sed dolor. Sit quaerat aliquam quiquia dolor modi non neque. Dolore quaerat dolore quaerat. Quaerat adipisci dolore ipsum ut consectetur. Ut sed labore neque etincidunt. Est sit est consectetur. Consectetur neque velit aliquam sit. Neque quaerat magnam voluptatem sed magnam."
            },
            {
                "_id": "E00009D",
                "name": "HOX10",
                "abreviations": [
                    "4D4",
                    "1E17",
                    "942",
                    "DF2",
                    "3ED"
                ],
                "categoryId": "Other",
                "description": "Tempora etincidunt eius dolore labore labore. Aliquam quaerat ipsum modi porro. Velit porro dolor labore dolorem amet consectetur. Neque porro etincidunt magnam voluptatem. Voluptatem magnam etincidunt sit. Quisquam ut dolore velit. Quiquia magnam amet neque ut aliquam tempora. Consectetur aliquam amet eius neque quiquia. Quisquam sed magnam dolor non labore neque sit. Tempora sit aliquam non quaerat porro numquam quaerat."
            },
            {
                "_id": "E00009E",
                "name": "p42.3 gene expression",
                "abreviations": [
                    "23A4",
                    "5B7",
                    "1CBA",
                    "6AB"
                ],
                "categoryId": "RNA",
                "description": "Voluptatem numquam quiquia non aliquam. Neque est quiquia voluptatem est sit voluptatem. Magnam eius quisquam consectetur. Quaerat quisquam non sit. Ut dolore dolorem quaerat ut quaerat neque. Quiquia adipisci porro non quaerat labore. Modi labore dolor neque. Dolorem etincidunt dolore dolor dolore."
            },
            {
                "_id": "E00009F",
                "name": "RP11-944L7.4",
                "abreviations": [
                    "1077",
                    "1D41",
                    "1AB7",
                    "2346"
                ],
                "categoryId": "Metabolite",
                "description": "Velit porro ipsum amet labore voluptatem. Amet consectetur tempora ipsum quisquam aliquam tempora. Sit dolorem velit tempora eius velit sed numquam. Ut amet eius eius. Neque non dolore voluptatem. Eius neque ut dolore velit dolorem."
            },
            {
                "_id": "E0000A0",
                "name": "Annexin A1",
                "abreviations": [
                    "92D",
                    "22E1",
                    "2332",
                    "E8A",
                    "15CE"
                ],
                "categoryId": "Cytokine",
                "description": "Aliquam ut quaerat dolore numquam est sit. Non quaerat quisquam sed. Labore magnam magnam sed voluptatem. Est sit etincidunt velit neque non est. Non dolorem magnam dolorem. Est adipisci voluptatem aliquam neque. Porro quaerat dolorem non est. Ut labore dolorem neque voluptatem. Tempora quisquam porro quisquam tempora est tempora tempora."
            },
            {
                "_id": "E0000A1",
                "name": "BRAF",
                "abreviations": [],
                "categoryId": "RNA",
                "description": "Consectetur amet neque adipisci quiquia. Neque neque labore amet labore quisquam dolore. Magnam velit sed modi sit quiquia aliquam etincidunt. Dolor voluptatem est dolor velit tempora ut. Voluptatem labore ipsum ipsum aliquam ut consectetur. Porro velit est numquam magnam quisquam. Aliquam ipsum neque numquam sit labore. Quisquam dolore est tempora tempora etincidunt aliquam quiquia. Adipisci ut etincidunt etincidunt quiquia. Dolorem ipsum voluptatem non sit dolore eius quisquam."
            },
            {
                "_id": "E0000A2",
                "name": "POT1 expression",
                "abreviations": [
                    "1598",
                    "26A4"
                ],
                "categoryId": "RNA",
                "description": "Dolore magnam voluptatem sed. Modi quisquam dolore quisquam dolor velit etincidunt modi. Dolore etincidunt porro consectetur numquam sed ipsum dolorem. Modi adipisci consectetur sit sed. Quiquia amet dolor modi velit etincidunt dolor. Quaerat non eius dolore velit. Ut modi voluptatem ut. Etincidunt est adipisci non. Voluptatem dolorem amet est velit ut."
            },
            {
                "_id": "E0000A3",
                "name": "4-hydroxynonenal",
                "abreviations": [
                    "62F",
                    "429"
                ],
                "categoryId": "Other",
                "description": "Dolorem aliquam etincidunt neque etincidunt labore. Amet ipsum voluptatem adipisci sit aliquam labore. Ut voluptatem ut consectetur porro eius. Dolore quaerat adipisci numquam magnam ut sit. Consectetur dolore magnam eius adipisci. Consectetur voluptatem quaerat dolore velit velit. Quiquia velit ipsum modi."
            },
            {
                "_id": "E0000A4",
                "name": "ALDH1A3",
                "abreviations": [
                    "248A",
                    "1B52"
                ],
                "categoryId": "RNA",
                "description": "Magnam etincidunt ipsum dolorem porro consectetur. Ut quiquia voluptatem voluptatem adipisci magnam ut. Ut labore modi quiquia voluptatem tempora quaerat sed. Adipisci magnam numquam voluptatem. Dolore tempora quisquam quisquam. Labore tempora neque aliquam amet quiquia voluptatem. Est etincidunt tempora numquam quaerat. Eius amet porro sit modi quiquia modi labore."
            },
            {
                "_id": "E0000A5",
                "name": "RPS11",
                "abreviations": [
                    "1721",
                    "1C22",
                    "10B9"
                ],
                "categoryId": "Protein",
                "description": "Numquam adipisci velit ipsum. Sit quiquia quiquia porro. Etincidunt quaerat quaerat dolor. Quisquam porro numquam magnam non. Ut ut modi quisquam sed etincidunt velit. Ipsum quisquam ut magnam quisquam neque quaerat porro. Dolor tempora voluptatem sit dolore non quiquia."
            },
            {
                "_id": "E0000A6",
                "name": "CXCR4",
                "abreviations": [
                    "20CC"
                ],
                "categoryId": "Metabolite",
                "description": "Numquam quaerat aliquam velit. Dolorem modi labore tempora etincidunt velit. Magnam quiquia non voluptatem. Aliquam voluptatem est ut quisquam. Eius velit adipisci velit quisquam. Porro ipsum numquam quaerat ut sit quaerat. Porro non sed dolor velit labore non. Numquam quiquia dolore neque. Sed voluptatem quaerat ut quaerat."
            },
            {
                "_id": "E0000A7",
                "name": "Rho-kinase pathway gene CFL1 expression",
                "abreviations": [
                    "1E73",
                    "1C3B",
                    "186E",
                    "1BFE",
                    "61D"
                ],
                "categoryId": "Labelling index",
                "description": "Magnam adipisci est etincidunt adipisci. Neque est tempora ipsum eius magnam ut. Dolor ipsum tempora numquam ipsum. Sit numquam quaerat est. Quisquam neque adipisci quiquia ut voluptatem quaerat."
            },
            {
                "_id": "E0000A8",
                "name": "hsa-miR-331-3p_st",
                "abreviations": [],
                "categoryId": "Labelling index",
                "description": "Magnam dolor quisquam labore tempora amet sed voluptatem. Porro dolorem ut etincidunt. Tempora sed labore porro numquam. Ipsum neque adipisci quiquia dolor. Sed tempora voluptatem tempora labore amet eius."
            },
            {
                "_id": "E0000A9",
                "name": "Stem cell factor",
                "abreviations": [
                    "1BA8"
                ],
                "categoryId": "RNA",
                "description": "Porro non magnam numquam eius. Velit tempora dolore magnam numquam est quiquia. Quaerat quisquam adipisci est neque velit. Est dolor adipisci velit velit dolore. Voluptatem voluptatem non voluptatem quaerat dolore numquam. Ut velit velit adipisci ipsum."
            },
            {
                "_id": "E0000AA",
                "name": "Nicotinamide N-methyltransferase",
                "abreviations": [
                    "4FD",
                    "286",
                    "26DD",
                    "20D8",
                    "18FE"
                ],
                "categoryId": "Lipid",
                "description": "Ut velit etincidunt labore. Adipisci quisquam modi labore tempora consectetur. Neque tempora dolor quiquia labore. Voluptatem quaerat amet non tempora velit numquam. Dolore porro aliquam dolorem non neque. Ut quisquam neque sit voluptatem. Magnam quiquia quisquam eius etincidunt. Porro consectetur quisquam modi. Quisquam numquam tempora ut eius velit."
            },
            {
                "_id": "E0000AB",
                "name": "Chromatinassembly factor 1 subunit A",
                "abreviations": [],
                "categoryId": "Other",
                "description": "Neque ipsum voluptatem quaerat velit sit sed. Dolore sed dolor sit sed labore quisquam dolorem. Labore quisquam dolorem eius. Eius adipisci eius dolore. Sed eius quiquia aliquam sit sed voluptatem etincidunt. Porro tempora voluptatem non neque dolor adipisci modi. Labore sit dolore consectetur porro numquam. Modi tempora adipisci adipisci numquam etincidunt aliquam magnam. Modi sed sit quiquia."
            },
            {
                "_id": "E0000AC",
                "name": "Gli1",
                "abreviations": [
                    "51B",
                    "143",
                    "62",
                    "398",
                    "158"
                ],
                "categoryId": "Aminopeptidase",
                "description": "Porro velit non dolor ut labore aliquam. Ut ut magnam porro amet est quiquia quiquia. Modi voluptatem ipsum sed dolor. Sit numquam quiquia modi modi quisquam porro. Porro ut numquam ut modi. Non etincidunt non consectetur est numquam voluptatem velit. Tempora quisquam eius velit quiquia amet non quiquia. Ut tempora etincidunt quiquia. Velit modi dolore sed neque."
            },
            {
                "_id": "E0000AD",
                "name": "Fibulin-1",
                "abreviations": [
                    "12A1"
                ],
                "categoryId": "Others",
                "description": "Eius amet dolore ut. Tempora aliquam porro sed voluptatem. Amet voluptatem dolore consectetur dolorem ut numquam. Quisquam eius quiquia velit est numquam. Ut tempora adipisci consectetur non. Aliquam quaerat ipsum voluptatem voluptatem modi ipsum sit. Ipsum non magnam consectetur. Dolor ut etincidunt ut adipisci dolorem velit."
            },
            {
                "_id": "E0000AE",
                "name": "NCK1",
                "abreviations": [
                    "10",
                    "2279",
                    "1EB0",
                    "66E",
                    "9DE"
                ],
                "categoryId": "Protein",
                "description": "Non neque velit sit dolor. Non numquam quisquam magnam non. Ut dolorem aliquam voluptatem ut. Labore labore tempora sit. Amet sed tempora eius amet etincidunt neque. Neque dolorem consectetur labore dolore dolor amet voluptatem. Tempora consectetur dolore modi dolor. Adipisci quaerat amet ipsum. Sed tempora neque porro dolore. Sed porro dolore quisquam magnam dolor est voluptatem."
            },
            {
                "_id": "E0000AF",
                "name": "HEY1",
                "abreviations": [],
                "categoryId": "Others",
                "description": "Dolore quisquam quaerat adipisci sit velit dolorem. Neque non est ipsum labore porro quiquia voluptatem. Quisquam quiquia quaerat sed adipisci labore dolor sed. Eius velit quiquia ut. Etincidunt tempora aliquam aliquam consectetur porro voluptatem est. Sit dolore consectetur dolore ipsum. Consectetur sed porro porro. Velit non neque labore."
            },
            {
                "_id": "E0000B0",
                "name": "Hox transcript antisense intergenic RNA",
                "abreviations": [
                    "9D8",
                    "1E26",
                    "1DDC",
                    "23AF",
                    "53E"
                ],
                "categoryId": "DNA",
                "description": "Magnam consectetur velit est adipisci magnam. Velit etincidunt ipsum voluptatem numquam aliquam modi. Numquam dolor amet dolorem labore velit. Dolor ut dolorem dolorem sit ut aliquam tempora. Amet quisquam sed non."
            },
            {
                "_id": "E0000B1",
                "name": "Bcl-2",
                "abreviations": [
                    "18D1",
                    "2169",
                    "D2B",
                    "19E8"
                ],
                "categoryId": "Enzyme",
                "description": "Quaerat modi consectetur adipisci numquam labore magnam. Porro quiquia neque sed porro porro dolore sed. Porro sed etincidunt non. Amet aliquam non sit adipisci. Est quiquia ut eius. Amet non dolore voluptatem magnam quaerat quisquam quisquam. Dolor amet porro quisquam adipisci dolorem amet neque."
            },
            {
                "_id": "E0000B2",
                "name": "sVEGFR1",
                "abreviations": [
                    "119B",
                    "10FE"
                ],
                "categoryId": "DNA",
                "description": "Numquam quisquam quaerat amet ut labore. Modi magnam aliquam non. Amet quaerat non porro. Dolore tempora sed modi numquam ut ut sit. Dolor quaerat quiquia magnam dolorem labore. Est quisquam dolore ut velit dolore amet. Velit eius ipsum porro ipsum. Quaerat consectetur sed etincidunt."
            },
            {
                "_id": "E0000B3",
                "name": "Neurofibromin 1",
                "abreviations": [],
                "categoryId": "Other",
                "description": "Neque dolor quiquia consectetur modi. Neque ipsum aliquam dolor dolorem quiquia. Adipisci aliquam ut dolore velit. Neque est voluptatem labore voluptatem quisquam aliquam. Porro tempora neque amet numquam consectetur eius. Neque labore ipsum ut. Adipisci etincidunt sed voluptatem. Velit sed voluptatem quaerat quisquam sit amet ut. Sed quiquia aliquam labore numquam velit."
            },
            {
                "_id": "E0000B4",
                "name": "hsa-miR-3125_st",
                "abreviations": [
                    "1C73",
                    "A9F",
                    "109A",
                    "46E"
                ],
                "categoryId": "DNA",
                "description": "Est tempora ut eius sit. Dolore neque consectetur tempora. Aliquam labore dolore sit labore dolor dolore neque. Neque eius quisquam sit neque aliquam porro. Neque dolorem dolorem amet adipisci velit velit eius. Non quiquia consectetur dolor modi. Voluptatem amet dolorem velit quaerat ut sed dolore. Ut ipsum aliquam dolore quaerat quiquia dolore ipsum. Velit neque consectetur quiquia porro est. Numquam adipisci eius voluptatem."
            },
            {
                "_id": "E0000B5",
                "name": "Fibroblast growth factor receptor 3",
                "abreviations": [
                    "26E4",
                    "2085",
                    "664",
                    "20F6",
                    "F5F"
                ],
                "categoryId": "Aminopeptidase",
                "description": "Quiquia etincidunt quiquia non. Ut porro est dolorem est voluptatem velit. Ipsum labore ut sit ipsum. Sed dolore sed sit tempora dolore. Porro porro porro aliquam. Eius amet eius ipsum dolore dolor. Voluptatem eius quiquia velit quaerat sed ipsum non. Numquam dolore eius dolorem consectetur neque numquam adipisci. Dolorem ipsum quiquia velit sed. Aliquam modi quiquia neque labore."
            },
            {
                "_id": "E0000B6",
                "name": "Alpha thalassemia/mental retardation syndrome X-linked",
                "abreviations": [],
                "categoryId": "Others",
                "description": "Tempora sit amet sit est amet neque velit. Dolorem modi dolorem dolorem consectetur. Adipisci sit quaerat ipsum. Quaerat quiquia porro numquam. Porro est adipisci velit sed tempora aliquam magnam. Eius ipsum adipisci dolore. Eius sed etincidunt dolore dolorem. Numquam adipisci neque tempora etincidunt amet ipsum porro. Porro tempora est dolor quiquia ut labore labore."
            },
            {
                "_id": "E0000B7",
                "name": "IL11",
                "abreviations": [],
                "categoryId": "DNA",
                "description": "Velit adipisci sit ut velit. Est porro dolorem porro adipisci. Est etincidunt aliquam numquam sit quaerat dolore. Velit quisquam quisquam quaerat labore voluptatem. Dolore velit porro dolorem neque est modi velit. Ipsum sed adipisci labore. Eius labore aliquam etincidunt magnam. Adipisci aliquam amet tempora numquam porro tempora velit. Dolorem quiquia eius ut eius quaerat."
            },
            {
                "_id": "E0000B8",
                "name": "p53-inducible gene 3",
                "abreviations": [
                    "2069",
                    "1624",
                    "CFC",
                    "21E",
                    "1A1C"
                ],
                "categoryId": "Labelling index",
                "description": "Consectetur quisquam dolorem quisquam modi. Quaerat quiquia modi consectetur eius. Quisquam etincidunt aliquam est. Numquam velit eius etincidunt eius etincidunt. Magnam neque eius porro amet quaerat etincidunt ipsum. Quiquia adipisci dolore amet ut ut. Numquam tempora dolor numquam. Labore quiquia quaerat sit est neque. Quisquam velit eius ipsum. Eius velit modi quisquam."
            },
            {
                "_id": "E0000B9",
                "name": "Telomere architecture",
                "abreviations": [
                    "1B8B",
                    "1811",
                    "16ED"
                ],
                "categoryId": "Metabolite",
                "description": "Amet ipsum ipsum dolore ut amet. Magnam dolor velit non velit quisquam quaerat porro. Magnam dolorem tempora sit ut consectetur amet. Numquam aliquam ipsum non amet amet. Dolorem dolore quiquia quaerat."
            },
            {
                "_id": "E0000BA",
                "name": "HOTAIR",
                "abreviations": [
                    "21DA",
                    "2668",
                    "1378",
                    "2016"
                ],
                "categoryId": "Aminopeptidase",
                "description": "Adipisci voluptatem modi consectetur etincidunt. Amet amet quisquam sed porro. Sed quiquia amet sit tempora neque labore dolor. Eius consectetur labore sit neque numquam tempora. Velit neque consectetur consectetur adipisci ipsum neque etincidunt. Labore dolorem modi voluptatem ut quaerat."
            },
            {
                "_id": "E0000BB",
                "name": "miR-141",
                "abreviations": [
                    "25B0",
                    "A31"
                ],
                "categoryId": "RNA",
                "description": "Voluptatem non modi aliquam numquam ipsum dolor. Neque dolorem porro dolorem. Aliquam eius quiquia quaerat labore sit quiquia consectetur. Magnam est sit porro. Est sed est modi aliquam quiquia. Etincidunt non est eius sit quisquam ut est. Porro tempora labore tempora quaerat dolor."
            },
            {
                "_id": "E0000BC",
                "name": "Suppressor of Lin-12-like\u00a0(C. elegans)",
                "abreviations": [
                    "231",
                    "1405"
                ],
                "categoryId": "Stem cells",
                "description": "Etincidunt quisquam etincidunt quisquam quaerat neque amet. Non sed dolore etincidunt quiquia ut quaerat quisquam. Etincidunt ut tempora sed dolor velit. Voluptatem voluptatem modi dolorem etincidunt sed. Voluptatem quisquam voluptatem est sit. Velit dolorem quisquam porro non voluptatem neque magnam. Quaerat modi velit aliquam est est dolor. Ipsum dolore aliquam velit porro tempora. Quiquia adipisci sit numquam eius. Ut ipsum etincidunt non quaerat velit dolore ipsum."
            },
            {
                "_id": "E0000BD",
                "name": "N-myc downstream regulated gene 2",
                "abreviations": [
                    "879"
                ],
                "categoryId": "Lipid",
                "description": "Neque velit eius quiquia. Adipisci quaerat tempora neque quaerat. Neque consectetur dolorem ipsum. Dolore dolorem dolorem voluptatem porro aliquam sed. Porro amet quisquam non sit velit velit. Non quiquia dolore amet. Voluptatem adipisci eius amet porro numquam labore dolore."
            },
            {
                "_id": "E0000BE",
                "name": "MGC21881",
                "abreviations": [
                    "2142",
                    "D57",
                    "244D",
                    "179C"
                ],
                "categoryId": "Lipid",
                "description": "Dolorem modi amet non ut adipisci modi est. Dolor est est quisquam labore. Porro ut amet etincidunt dolorem velit voluptatem. Porro velit aliquam magnam. Quaerat sit adipisci ut sit modi porro ipsum. Quisquam sit ut voluptatem ipsum sit. Modi sed etincidunt voluptatem velit quiquia aliquam porro. Quaerat dolorem amet modi tempora. Voluptatem sed numquam est aliquam. Dolorem eius etincidunt non."
            },
            {
                "_id": "E0000BF",
                "name": "miR-338-5p",
                "abreviations": [
                    "1832",
                    "1B61",
                    "20CF",
                    "A6A",
                    "270"
                ],
                "categoryId": "Metabolite",
                "description": "Labore numquam etincidunt aliquam amet dolore numquam ut. Magnam dolorem modi sit voluptatem amet quiquia. Labore magnam modi quisquam. Quaerat consectetur ut quisquam etincidunt etincidunt. Non amet amet aliquam sit neque voluptatem. Magnam quiquia ut magnam modi. Amet quaerat velit non consectetur dolor. Ipsum neque voluptatem quaerat. Neque quiquia magnam neque modi."
            },
            {
                "_id": "E0000C0",
                "name": "CHEK2rs2017309 A",
                "abreviations": [
                    "11A7",
                    "D6"
                ],
                "categoryId": "Metabolite",
                "description": "Tempora est quisquam amet tempora ut dolor. Est quisquam magnam ut ut est. Quiquia dolor voluptatem consectetur est. Numquam dolorem quiquia quisquam dolorem consectetur dolor amet. Dolore adipisci magnam magnam consectetur. Modi modi neque ipsum. Quaerat numquam etincidunt aliquam dolorem quisquam. Quiquia tempora ipsum ipsum dolor ut. Quiquia labore aliquam dolor dolore. Neque non quaerat adipisci est etincidunt dolorem aliquam."
            },
            {
                "_id": "E0000C1",
                "name": "Transforming growth factor",
                "abreviations": [
                    "48A",
                    "1953"
                ],
                "categoryId": "Lipid",
                "description": "Quisquam neque quisquam tempora dolorem. Quisquam voluptatem porro quisquam ipsum dolor tempora etincidunt. Dolore eius aliquam labore quaerat eius velit. Ut sed quisquam dolor ut dolore sit. Voluptatem voluptatem porro labore numquam dolor sed modi. Sit quaerat ipsum velit ut aliquam porro. Porro sit labore quiquia. Aliquam modi neque numquam voluptatem quaerat magnam."
            },
            {
                "_id": "E0000C2",
                "name": "let-7i",
                "abreviations": [],
                "categoryId": "Aminopeptidase",
                "description": "Magnam porro sed voluptatem neque. Neque quaerat quaerat velit. Eius quaerat sit quiquia. Quiquia neque porro adipisci ut. Numquam amet labore labore eius. Aliquam tempora dolorem sed etincidunt sed porro ut. Eius sed ut labore quisquam amet. Dolore tempora ipsum est voluptatem neque."
            },
            {
                "_id": "E0000C3",
                "name": "IL-13 receptor subunits \u03b12",
                "abreviations": [],
                "categoryId": "Metabolite",
                "description": "Quisquam aliquam dolor numquam. Sit voluptatem dolor neque magnam. Dolore ipsum quiquia eius magnam. Eius sit dolor adipisci quaerat modi. Non consectetur dolore amet quisquam dolor velit sed. Sed quiquia aliquam dolorem consectetur quiquia dolor quaerat. Neque non consectetur eius quaerat. Etincidunt porro non modi est modi. Dolorem adipisci dolore dolorem."
            },
            {
                "_id": "E0000C4",
                "name": "MGMT",
                "abreviations": [
                    "14DC",
                    "A3A",
                    "14A0",
                    "348",
                    "2004"
                ],
                "categoryId": "Cytokine",
                "description": "Modi quiquia velit dolorem. Etincidunt quisquam amet consectetur quaerat. Quisquam numquam eius neque dolore sit voluptatem velit. Non velit magnam ut velit sed est. Ipsum voluptatem adipisci quaerat. Est sit adipisci sit ipsum amet sed sed. Quisquam sit labore dolorem dolorem. Porro magnam non quisquam aliquam velit sed."
            },
            {
                "_id": "E0000C5",
                "name": "StefA mRNA level",
                "abreviations": [
                    "17BD",
                    "354"
                ],
                "categoryId": "Protein",
                "description": "Sed numquam neque dolorem velit. Sit velit eius est est est. Quisquam dolore etincidunt eius numquam modi eius. Est etincidunt ut adipisci quisquam dolore. Numquam est numquam magnam modi dolor dolorem sed. Dolorem labore ipsum ut voluptatem aliquam sed sit. Quiquia sed modi neque quisquam sit labore non. Adipisci quisquam adipisci dolor dolorem labore. Adipisci dolore consectetur dolore neque dolorem quiquia. Velit sit porro est neque est adipisci sed."
            },
            {
                "_id": "E0000C6",
                "name": "FoxP3+ regulatory T cells",
                "abreviations": [],
                "categoryId": "Labelling index",
                "description": "Porro voluptatem voluptatem dolorem voluptatem sed neque dolorem. Sit est quisquam quiquia neque. Dolorem voluptatem quaerat porro eius quiquia magnam quiquia. Porro aliquam numquam non numquam. Ipsum labore neque sit est aliquam."
            },
            {
                "_id": "E0000C7",
                "name": "Telomere length",
                "abreviations": [
                    "FFB",
                    "A4E"
                ],
                "categoryId": "Aminopeptidase",
                "description": "Numquam dolorem aliquam ut numquam. Voluptatem amet quiquia modi quaerat. Labore est quaerat est sit etincidunt amet. Aliquam tempora amet amet ut. Voluptatem non dolorem quaerat sed ipsum adipisci."
            },
            {
                "_id": "E0000C8",
                "name": "TERTp mutation",
                "abreviations": [
                    "1259",
                    "1B79",
                    "B0B",
                    "26FE"
                ],
                "categoryId": "Protein",
                "description": "Tempora est quisquam sed quiquia quaerat numquam. Quisquam quaerat aliquam dolore consectetur non. Adipisci dolorem tempora quisquam porro labore adipisci etincidunt. Quisquam voluptatem tempora aliquam porro. Neque voluptatem ut sed ut sed. Ipsum quaerat quisquam aliquam neque. Est sed neque porro magnam non."
            },
            {
                "_id": "E0000C9",
                "name": "pNFKB1",
                "abreviations": [
                    "E8D",
                    "2416",
                    "1AA6",
                    "1A8"
                ],
                "categoryId": "Cytokine",
                "description": "Numquam quaerat ut ut modi quaerat. Aliquam eius tempora aliquam numquam dolor. Etincidunt dolore dolor aliquam quiquia. Amet porro ut amet dolorem dolorem ipsum amet. Eius dolore ut quiquia dolore ut tempora. Est porro porro quiquia neque."
            },
            {
                "_id": "E0000CA",
                "name": "PAR5",
                "abreviations": [
                    "8BB"
                ],
                "categoryId": "Enzyme",
                "description": "Consectetur quaerat eius neque ipsum labore quaerat magnam. Dolor ipsum neque adipisci dolorem quiquia aliquam. Numquam adipisci consectetur neque quaerat. Dolore dolor quaerat ipsum ut labore velit consectetur. Porro dolore est est ut tempora. Dolor amet sed numquam sed porro quaerat quisquam."
            },
            {
                "_id": "E0000CB",
                "name": "Actinin-4",
                "abreviations": [
                    "1885"
                ],
                "categoryId": "Labelling index",
                "description": "Adipisci quiquia numquam consectetur velit dolorem. Est aliquam est non porro adipisci. Sed neque modi quiquia ipsum modi. Non porro est numquam magnam velit consectetur. Velit numquam ipsum sed voluptatem. Non dolore quaerat quaerat est dolore velit quaerat. Numquam ut tempora labore. Quiquia quiquia quaerat magnam voluptatem. Sit quiquia ipsum numquam ipsum modi porro dolorem."
            },
            {
                "_id": "E0000CC",
                "name": "O6-methylguanine DNA methylatransferase promoter methylation",
                "abreviations": [
                    "1151",
                    "706"
                ],
                "categoryId": "Stem cells",
                "description": "Velit dolorem magnam labore porro non tempora. Eius quaerat voluptatem consectetur quaerat. Quaerat quisquam etincidunt aliquam velit dolorem amet velit. Voluptatem neque sit tempora non. Aliquam sed eius porro quisquam dolor."
            },
            {
                "_id": "E0000CD",
                "name": "Monoclonal antibody D110",
                "abreviations": [],
                "categoryId": "Aminopeptidase",
                "description": "Amet modi amet magnam aliquam. Sed porro neque quaerat adipisci etincidunt dolorem porro. Voluptatem porro quaerat neque dolore. Velit ipsum amet adipisci modi. Eius dolorem tempora tempora velit dolorem."
            },
            {
                "_id": "E0000CE",
                "name": "Tax-interacting protein 1 expression",
                "abreviations": [
                    "11F3",
                    "191D",
                    "1A8F",
                    "2100",
                    "18D8"
                ],
                "categoryId": "Others",
                "description": "Ut sit ut ut labore. Magnam modi neque quiquia. Velit modi numquam ut est aliquam adipisci eius. Aliquam eius dolorem sit consectetur porro est. Quaerat modi neque aliquam etincidunt aliquam aliquam. Amet voluptatem est sit modi est consectetur."
            },
            {
                "_id": "E0000CF",
                "name": "SAPCD1-AS1",
                "abreviations": [
                    "5C4",
                    "A37"
                ],
                "categoryId": "Labelling index",
                "description": "Consectetur adipisci neque etincidunt tempora sit. Numquam velit quiquia velit. Amet velit sed sit. Neque velit labore dolorem est etincidunt dolore. Quiquia quaerat quisquam eius consectetur sit etincidunt."
            },
            {
                "_id": "E0000D0",
                "name": "Neuromedin B",
                "abreviations": [
                    "21AD"
                ],
                "categoryId": "DNA",
                "description": "Adipisci neque consectetur sed porro. Amet quaerat dolore non tempora non. Magnam porro eius dolore ut neque. Sed modi porro est dolorem dolor tempora. Dolore adipisci sit aliquam quisquam dolore porro. Sed ipsum dolore modi velit amet consectetur quaerat. Dolore labore etincidunt non amet modi est."
            },
            {
                "_id": "E0000D1",
                "name": "LHX6",
                "abreviations": [
                    "D84",
                    "97C"
                ],
                "categoryId": "Cytokine",
                "description": "Neque labore tempora magnam dolorem. Velit consectetur modi est amet. Porro quaerat dolor ipsum. Voluptatem etincidunt numquam tempora tempora. Adipisci labore consectetur tempora."
            },
            {
                "_id": "E0000D2",
                "name": "Phosphatidylinositol 3-kinase",
                "abreviations": [
                    "51C",
                    "1721"
                ],
                "categoryId": "DNA",
                "description": "Voluptatem quisquam ut eius labore aliquam dolorem adipisci. Tempora tempora aliquam dolor tempora quaerat. Magnam quisquam velit consectetur etincidunt. Est quiquia consectetur adipisci neque. Consectetur quisquam quisquam aliquam non dolore dolore. Quisquam dolor dolor tempora. Quaerat non eius dolore. Neque quiquia dolore dolorem labore sed."
            },
            {
                "_id": "E0000D3",
                "name": "IDH1/2, 1p/19q, TERT, EGFR",
                "abreviations": [
                    "24B4",
                    "D74",
                    "1770",
                    "2666"
                ],
                "categoryId": "Protein",
                "description": "Non voluptatem porro etincidunt consectetur. Ut quiquia quisquam ut. Non amet amet modi dolore est. Adipisci consectetur sed sed est velit ipsum. Dolor numquam ut quisquam magnam ipsum. Quaerat non quiquia consectetur etincidunt adipisci. Adipisci neque magnam consectetur."
            },
            {
                "_id": "E0000D4",
                "name": "EphA2",
                "abreviations": [
                    "436",
                    "AE7",
                    "264",
                    "1AEB"
                ],
                "categoryId": "Protein",
                "description": "Labore numquam aliquam eius dolorem consectetur. Numquam neque dolorem magnam magnam quiquia dolor. Dolor modi ut dolore quaerat sed amet. Voluptatem consectetur dolorem voluptatem numquam dolore dolorem. Dolore voluptatem ut aliquam sit amet. Quaerat dolor dolorem quiquia ipsum. Neque magnam dolore dolore sed dolore. Consectetur dolor dolore numquam adipisci porro etincidunt non. Est etincidunt sed consectetur neque amet."
            },
            {
                "_id": "E0000D5",
                "name": "ANXA1",
                "abreviations": [
                    "1528",
                    "17DF",
                    "1A59",
                    "1172"
                ],
                "categoryId": "Metabolite",
                "description": "Dolorem ut amet ipsum quiquia. Dolore neque consectetur sed modi magnam voluptatem est. Magnam quisquam porro quiquia labore ut ut dolor. Ut est amet ut velit ipsum non. Modi porro sed aliquam quisquam magnam aliquam modi. Modi numquam voluptatem dolor."
            },
            {
                "_id": "E0000D6",
                "name": "t Crk Tyr251 phosphorylation",
                "abreviations": [
                    "D1D",
                    "A3A"
                ],
                "categoryId": "Others",
                "description": "Etincidunt tempora porro non tempora est dolor porro. Velit neque amet tempora dolor sit voluptatem. Ut ipsum dolore consectetur voluptatem dolore. Ipsum tempora sed eius ipsum quisquam sit. Magnam ut dolorem dolore ut tempora sed. Quiquia labore magnam eius eius ipsum porro."
            },
            {
                "_id": "E0000D7",
                "name": "Manganese superoxide dismutase content",
                "abreviations": [
                    "1B8A"
                ],
                "categoryId": "Cytokine",
                "description": "Aliquam ipsum quisquam voluptatem dolore modi porro sit. Non sed consectetur quisquam sed numquam labore aliquam. Sed quaerat dolore quiquia aliquam porro ut. Dolorem aliquam dolore magnam dolor non ut sed. Dolor tempora quiquia quiquia numquam. Non non adipisci non sit."
            },
            {
                "_id": "E0000D8",
                "name": "CCT4",
                "abreviations": [
                    "887",
                    "1A54"
                ],
                "categoryId": "Lipid",
                "description": "Neque adipisci numquam aliquam. Porro velit dolore numquam eius consectetur. Quisquam aliquam est porro eius. Ut velit non porro magnam adipisci. Eius modi dolor dolor. Velit labore ut voluptatem dolore etincidunt."
            },
            {
                "_id": "E0000D9",
                "name": "miR-602",
                "abreviations": [
                    "1FCC"
                ],
                "categoryId": "Lipid",
                "description": "Modi ut neque velit porro. Consectetur porro porro eius voluptatem ipsum numquam dolore. Quisquam porro numquam adipisci. Etincidunt dolore est sed quaerat amet consectetur. Labore sit adipisci quiquia sed eius dolor tempora. Dolor amet etincidunt sed dolore dolore quisquam voluptatem. Etincidunt neque etincidunt voluptatem. Quiquia voluptatem labore amet adipisci neque. Quisquam tempora eius voluptatem aliquam porro tempora. Dolore etincidunt ipsum porro sit."
            },
            {
                "_id": "E0000DA",
                "name": "miR-296",
                "abreviations": [
                    "2382",
                    "13E7",
                    "1E74",
                    "1E18"
                ],
                "categoryId": "Stem cells",
                "description": "Modi voluptatem quisquam quisquam aliquam. Etincidunt dolorem dolore dolorem magnam adipisci. Porro porro dolorem voluptatem ut velit magnam. Neque tempora voluptatem voluptatem quaerat sed tempora sit. Sed quiquia etincidunt neque quiquia eius est. Voluptatem adipisci ut neque quiquia. Non quaerat est porro ut velit ut. Est consectetur sed sit non."
            },
            {
                "_id": "E0000DB",
                "name": "SGB",
                "abreviations": [
                    "BD7",
                    "1DB"
                ],
                "categoryId": "DNA",
                "description": "Magnam velit magnam quisquam amet labore dolorem sed. Sed sed quisquam consectetur sed amet etincidunt aliquam. Porro dolore aliquam numquam est consectetur. Voluptatem dolore sit eius sit. Aliquam amet sit dolor quiquia velit. Modi labore porro velit sed magnam dolore porro."
            },
            {
                "_id": "E0000DC",
                "name": "Actin-capping protein CapG",
                "abreviations": [
                    "16F",
                    "232D",
                    "17AF",
                    "1396",
                    "2157"
                ],
                "categoryId": "Cytokine",
                "description": "Est est numquam magnam numquam numquam porro ipsum. Dolorem ipsum velit aliquam tempora sit etincidunt. Etincidunt dolore quaerat ut ut modi. Dolor porro non etincidunt. Adipisci eius porro aliquam quiquia ut magnam. Porro modi consectetur consectetur etincidunt dolor ut labore. Velit tempora neque neque dolore dolorem. Etincidunt etincidunt etincidunt etincidunt est est."
            },
            {
                "_id": "E0000DD",
                "name": "Mir-21-Sox2 Axis",
                "abreviations": [
                    "189A"
                ],
                "categoryId": "Lipid",
                "description": "Aliquam dolorem dolor sit numquam. Quiquia sit amet sit quaerat velit quaerat dolor. Modi velit etincidunt neque. Voluptatem dolor ipsum non dolor labore ut. Dolor ut amet amet dolore tempora consectetur numquam."
            },
            {
                "_id": "E0000DE",
                "name": "Cyclooxygenase-2",
                "abreviations": [
                    "C49",
                    "1EDE"
                ],
                "categoryId": "Cytokine",
                "description": "Quiquia magnam modi dolor voluptatem sed dolor sit. Tempora quaerat tempora sed quisquam aliquam quaerat neque. Eius tempora amet dolor sit etincidunt consectetur non. Non non neque sit modi consectetur labore. Numquam amet tempora consectetur sed tempora labore etincidunt. Ipsum adipisci neque tempora numquam quaerat voluptatem. Quaerat voluptatem ipsum aliquam porro voluptatem voluptatem. Est voluptatem modi quiquia sit dolore etincidunt."
            },
            {
                "_id": "E0000DF",
                "name": "Aurora-A kinase",
                "abreviations": [
                    "19E0",
                    "1971"
                ],
                "categoryId": "Others",
                "description": "Tempora consectetur quiquia est labore quisquam quaerat. Quaerat quiquia numquam tempora. Quiquia amet etincidunt labore labore quiquia. Non quaerat aliquam etincidunt est modi dolore. Aliquam quisquam dolor amet modi consectetur."
            },
            {
                "_id": "E0000E0",
                "name": "STAT3 serine 727 phosphorylation",
                "abreviations": [
                    "BB4",
                    "51D"
                ],
                "categoryId": "Aminopeptidase",
                "description": "Non porro amet quiquia numquam. Numquam ut magnam neque sed magnam. Sed voluptatem quisquam est etincidunt dolor. Quisquam quiquia magnam voluptatem. Dolore quiquia ipsum ut sit. Quisquam est modi sit modi velit. Neque adipisci aliquam aliquam neque porro sit non. Quiquia labore consectetur aliquam. Dolorem porro magnam aliquam labore adipisci non."
            },
            {
                "_id": "E0000E1",
                "name": "Stromal protein periostin",
                "abreviations": [
                    "EE0"
                ],
                "categoryId": "RNA",
                "description": "Etincidunt adipisci non dolore amet numquam. Quiquia velit numquam est quaerat. Amet amet porro voluptatem aliquam ut quiquia modi. Magnam modi aliquam dolorem dolor adipisci sit est. Quiquia consectetur sed eius dolore. Consectetur etincidunt ut est dolorem modi sed. Aliquam ut est eius dolor quiquia velit."
            },
            {
                "_id": "E0000E2",
                "name": "AL833059",
                "abreviations": [
                    "2306",
                    "1E62",
                    "7B5",
                    "1707"
                ],
                "categoryId": "Metabolite",
                "description": "Ipsum dolor quisquam ipsum consectetur sit dolor. Dolor neque modi porro adipisci. Voluptatem tempora magnam magnam quisquam velit voluptatem amet. Dolore consectetur modi quiquia neque non ipsum quaerat. Voluptatem sed magnam dolore. Labore voluptatem magnam consectetur adipisci aliquam dolor porro. Quaerat dolorem etincidunt modi dolorem quiquia numquam."
            },
            {
                "_id": "E0000E3",
                "name": "IDH1",
                "abreviations": [
                    "1358",
                    "144E",
                    "1B34",
                    "F80"
                ],
                "categoryId": "Metabolite",
                "description": "Magnam sit dolor ut etincidunt tempora sed. Quisquam consectetur labore sed porro etincidunt non. Magnam etincidunt quiquia adipisci ut quaerat numquam. Adipisci tempora sit dolor amet. Magnam ut labore quiquia amet. Quiquia quiquia modi voluptatem ut non. Amet sed non ipsum porro. Quaerat porro magnam amet ipsum dolor labore. Quisquam aliquam dolorem adipisci quiquia. Quiquia dolorem amet ut modi."
            },
            {
                "_id": "E0000E4",
                "name": "CD133 expression",
                "abreviations": [
                    "C3D",
                    "25D0",
                    "1696",
                    "1876",
                    "337"
                ],
                "categoryId": "Labelling index",
                "description": "Non labore etincidunt sed dolor sit sit. Dolorem modi quaerat eius. Etincidunt dolor dolorem labore quaerat tempora adipisci amet. Magnam modi magnam velit tempora quisquam labore non. Labore quaerat voluptatem dolorem est velit adipisci."
            },
            {
                "_id": "E0000E5",
                "name": "High-mobility group box 2 protein level",
                "abreviations": [
                    "26C3",
                    "740",
                    "151",
                    "1E12",
                    "1883"
                ],
                "categoryId": "Aminopeptidase",
                "description": "Dolore sit voluptatem non sit non sit est. Adipisci non tempora sit sed magnam. Non aliquam aliquam dolor dolore neque. Neque aliquam dolore quiquia porro. Est velit ut porro ut aliquam. Quiquia consectetur sit etincidunt magnam modi. Sit eius sed ipsum quisquam etincidunt modi quaerat. Sit quiquia ut neque tempora numquam. Est dolor numquam adipisci."
            },
            {
                "_id": "E0000E6",
                "name": "RRAD",
                "abreviations": [
                    "17D7",
                    "1D81",
                    "1DC8"
                ],
                "categoryId": "Other",
                "description": "Dolorem etincidunt velit quiquia porro porro. Dolor consectetur non neque quaerat amet. Est est dolore numquam dolore amet non quisquam. Amet tempora sit amet amet sed. Porro dolore magnam aliquam adipisci dolor est neque. Ut sit dolor dolorem ut etincidunt etincidunt sed. Sit tempora dolor ut magnam sed dolorem. Neque ipsum magnam dolorem. Neque consectetur porro voluptatem voluptatem. Sed magnam eius neque adipisci eius."
            },
            {
                "_id": "E0000E7",
                "name": "CST4",
                "abreviations": [
                    "106",
                    "A03",
                    "68E",
                    "B08",
                    "100A"
                ],
                "categoryId": "Aminopeptidase",
                "description": "Quaerat adipisci est numquam. Consectetur ut aliquam amet aliquam dolorem. Dolor non dolorem ut dolor velit. Labore est quisquam etincidunt. Aliquam modi labore labore."
            },
            {
                "_id": "E0000E8",
                "name": "CD150 (IPO3/SLAM)",
                "abreviations": [
                    "1A09",
                    "24AF",
                    "23FD",
                    "759",
                    "22DB"
                ],
                "categoryId": "Protein",
                "description": "Quaerat eius neque est est quaerat dolore dolorem. Quisquam adipisci sed amet voluptatem eius dolor. Amet adipisci ut ipsum labore voluptatem est. Modi velit aliquam sed porro aliquam dolor sit. Sit porro numquam ipsum. Eius neque labore modi eius. Ut dolorem etincidunt neque velit."
            },
            {
                "_id": "E0000E9",
                "name": "Mobility group box protein 1",
                "abreviations": [],
                "categoryId": "Enzyme",
                "description": "Quaerat amet dolore modi consectetur quiquia quisquam etincidunt. Neque consectetur dolorem ipsum voluptatem quisquam labore etincidunt. Consectetur ipsum ut quiquia quisquam. Aliquam sit aliquam modi porro dolorem aliquam numquam. Velit quisquam est quaerat velit quaerat. Non est consectetur neque magnam magnam. Ipsum consectetur quisquam non magnam quiquia. Velit quaerat eius modi est dolore etincidunt consectetur. Aliquam dolorem non quiquia dolor. Quisquam sed adipisci velit."
            },
            {
                "_id": "E0000EA",
                "name": "miR-885-5p",
                "abreviations": [
                    "129E",
                    "2299",
                    "637"
                ],
                "categoryId": "Protein",
                "description": "Sit velit quisquam est tempora eius neque. Voluptatem quisquam modi dolore consectetur. Labore porro modi labore. Quiquia dolore porro sed eius. Quiquia ipsum sed voluptatem. Dolor ipsum voluptatem dolorem dolor. Voluptatem neque aliquam dolore."
            },
            {
                "_id": "E0000EB",
                "name": "Phosphorylated 4E-binding protein 1",
                "abreviations": [
                    "2611"
                ],
                "categoryId": "Enzyme",
                "description": "Modi magnam consectetur dolor. Consectetur tempora ut adipisci. Voluptatem magnam velit dolorem magnam. Sed numquam eius numquam numquam neque eius etincidunt. Adipisci sit sed dolore. Dolor voluptatem ipsum dolorem sit. Magnam velit consectetur quiquia non sit. Quaerat modi sed labore tempora labore ipsum numquam. Dolore ipsum sed sit voluptatem."
            },
            {
                "_id": "E0000EC",
                "name": "Tissue inhibitor of metalloproteinases-1",
                "abreviations": [
                    "15CE",
                    "1772",
                    "1673"
                ],
                "categoryId": "Lipid",
                "description": "Quaerat quaerat amet porro. Voluptatem amet sed magnam velit voluptatem amet consectetur. Labore dolore ut ut voluptatem quisquam labore tempora. Consectetur quaerat ipsum adipisci quiquia consectetur. Ipsum porro sit quiquia velit quaerat. Dolor est sit dolore labore velit est dolorem. Quaerat dolore non dolorem. Tempora voluptatem amet amet labore aliquam. Consectetur dolor eius amet dolor consectetur porro eius."
            },
            {
                "_id": "E0000ED",
                "name": "c-neu/erbB2",
                "abreviations": [
                    "2163",
                    "588",
                    "1B23",
                    "1299",
                    "CD4"
                ],
                "categoryId": "DNA",
                "description": "Modi quisquam sit eius quaerat aliquam eius etincidunt. Dolorem magnam numquam quaerat dolore. Neque aliquam numquam sit. Eius neque etincidunt sed ut velit dolore. Consectetur modi labore labore magnam. Sed eius dolor neque. Velit modi amet labore velit ut magnam quisquam. Numquam voluptatem voluptatem consectetur consectetur. Ut est tempora dolor sed. Ipsum voluptatem modi est labore tempora sit."
            },
            {
                "_id": "E0000EE",
                "name": "Anticalin N7E",
                "abreviations": [
                    "6EA",
                    "61C",
                    "A17",
                    "D55"
                ],
                "categoryId": "Cytokine",
                "description": "Non dolore aliquam labore etincidunt dolor aliquam. Magnam eius magnam neque modi tempora sit. Amet porro sit non sed dolor ut ipsum. Non modi tempora velit quisquam velit. Magnam adipisci neque consectetur non neque consectetur. Ipsum velit tempora non."
            },
            {
                "_id": "E0000EF",
                "name": "Isocitrate dehydrogenase 1 R132H",
                "abreviations": [
                    "36D",
                    "1774",
                    "2010"
                ],
                "categoryId": "Enzyme",
                "description": "Magnam neque modi est adipisci amet aliquam magnam. Labore dolorem ipsum numquam. Sed labore quaerat magnam numquam velit non. Tempora velit tempora labore etincidunt modi. Non modi est consectetur modi sit etincidunt. Magnam magnam porro non consectetur quaerat magnam. Dolorem ut aliquam ipsum tempora quiquia. Quaerat dolore ipsum eius sed voluptatem. Eius numquam quiquia quisquam adipisci non est numquam. Voluptatem quiquia est magnam labore."
            },
            {
                "_id": "E0000F0",
                "name": "miR-139-5p",
                "abreviations": [
                    "780",
                    "1E10",
                    "103F",
                    "13C",
                    "A2B"
                ],
                "categoryId": "Other",
                "description": "Ipsum sit aliquam quiquia ut labore neque. Est quiquia quisquam adipisci modi quiquia numquam. Voluptatem ut quaerat consectetur quaerat labore adipisci labore. Consectetur numquam dolore labore magnam. Aliquam est etincidunt eius etincidunt."
            },
            {
                "_id": "E0000F1",
                "name": "Manganese superoxide dismutase",
                "abreviations": [
                    "BEB"
                ],
                "categoryId": "Aminopeptidase",
                "description": "Dolorem dolore modi ut amet. Neque velit neque eius. Porro quiquia aliquam tempora adipisci. Dolore est porro quiquia. Porro eius dolorem dolorem amet eius modi. Non labore consectetur etincidunt modi neque quisquam dolorem. Adipisci numquam etincidunt labore etincidunt dolore quaerat voluptatem. Est velit etincidunt labore etincidunt est est porro. Consectetur etincidunt dolorem eius adipisci consectetur. Porro est dolor adipisci dolorem consectetur ipsum."
            },
            {
                "_id": "E0000F2",
                "name": "Geminin",
                "abreviations": [
                    "20A3",
                    "2254",
                    "1E56",
                    "F86",
                    "318"
                ],
                "categoryId": "RNA",
                "description": "Porro quaerat velit tempora est dolore labore. Velit velit dolor quisquam. Voluptatem labore magnam eius quaerat. Voluptatem est eius ut. Non tempora porro dolorem labore labore sit."
            },
            {
                "_id": "E0000F3",
                "name": "Caveolae-associated protein 1",
                "abreviations": [
                    "1EF0",
                    "18E1"
                ],
                "categoryId": "Stem cells",
                "description": "Est velit eius velit voluptatem velit modi labore. Non non porro eius. Labore magnam tempora magnam sed quisquam. Dolore etincidunt eius sit. Quisquam amet non porro voluptatem neque amet. Dolorem dolore quaerat velit non est non eius. Voluptatem consectetur modi magnam etincidunt."
            },
            {
                "_id": "E0000F4",
                "name": "Tripartite motif-containing protein 11",
                "abreviations": [
                    "1AA3",
                    "E82",
                    "1C77"
                ],
                "categoryId": "Cytokine",
                "description": "Quisquam numquam ipsum numquam amet quaerat ipsum. Velit neque consectetur consectetur ipsum adipisci porro sit. Dolorem velit consectetur numquam velit etincidunt. Aliquam magnam est etincidunt. Dolor dolore tempora dolore quaerat. Voluptatem dolore sit consectetur ut tempora numquam consectetur. Aliquam sed dolore non aliquam numquam adipisci tempora. Sed sit aliquam tempora."
            },
            {
                "_id": "E0000F5",
                "name": "miR-938",
                "abreviations": [
                    "5CE",
                    "1996",
                    "1017"
                ],
                "categoryId": "Aminopeptidase",
                "description": "Ut velit eius magnam labore quaerat. Dolorem aliquam numquam porro modi. Est ut consectetur porro. Amet numquam eius etincidunt consectetur consectetur. Non tempora dolorem non. Dolore magnam eius aliquam est adipisci. Quiquia neque consectetur non."
            },
            {
                "_id": "E0000F6",
                "name": "Interleukin-13 Receptor \ud835\udec22",
                "abreviations": [
                    "1CAB"
                ],
                "categoryId": "Others",
                "description": "Aliquam velit labore adipisci tempora adipisci. Velit voluptatem modi consectetur ut est. Numquam modi aliquam quiquia sit amet neque neque. Non tempora eius labore non velit. Modi ipsum neque non consectetur consectetur modi ut. Adipisci consectetur dolorem eius voluptatem amet aliquam neque. Consectetur sed voluptatem eius ipsum. Quisquam dolor numquam quisquam. Eius sit dolore aliquam magnam non etincidunt tempora."
            },
            {
                "_id": "E0000F7",
                "name": "pS6",
                "abreviations": [
                    "7B4",
                    "20C2",
                    "1A31"
                ],
                "categoryId": "Lipid",
                "description": "Modi dolor quaerat eius. Quiquia eius non tempora dolore. Ut quisquam adipisci modi. Sed consectetur etincidunt eius dolore etincidunt quaerat. Sed ipsum magnam amet. Numquam numquam quaerat voluptatem modi. Etincidunt adipisci sit dolorem tempora modi. Numquam neque labore tempora dolorem neque. Sed consectetur adipisci aliquam."
            },
            {
                "_id": "E0000F8",
                "name": "EGFR-p53 alterations",
                "abreviations": [
                    "1ACA",
                    "2592",
                    "D32",
                    "1CCB",
                    "C25"
                ],
                "categoryId": "Aminopeptidase",
                "description": "Dolorem quaerat amet modi modi non non etincidunt. Eius adipisci velit neque modi. Modi quiquia ut eius dolorem. Quiquia non sed sed. Sed sit tempora dolor porro. Tempora consectetur porro numquam aliquam dolor. Ipsum modi consectetur consectetur aliquam quiquia voluptatem non. Ipsum dolorem dolorem porro labore. Neque est adipisci tempora neque ipsum."
            },
            {
                "_id": "E0000F9",
                "name": "Heat shock protein 27",
                "abreviations": [
                    "113E",
                    "222E",
                    "ED2",
                    "4C6",
                    "320"
                ],
                "categoryId": "Aminopeptidase",
                "description": "Dolorem neque voluptatem etincidunt. Dolore magnam quiquia neque. Modi etincidunt consectetur adipisci velit neque neque dolor. Amet amet quisquam est est quaerat. Quisquam amet dolor adipisci quiquia. Quiquia ut dolore amet quiquia neque. Dolor tempora non sit magnam adipisci amet. Voluptatem est porro aliquam est consectetur adipisci."
            },
            {
                "_id": "E0000FA",
                "name": "Integrin a7",
                "abreviations": [
                    "2313",
                    "EF1",
                    "33C",
                    "1AA2"
                ],
                "categoryId": "Cytokine",
                "description": "Aliquam magnam non non porro velit. Dolorem consectetur tempora aliquam. Magnam consectetur quaerat amet modi. Tempora voluptatem est quisquam ut numquam non. Consectetur modi dolore tempora velit. Ipsum dolorem etincidunt consectetur eius eius. Voluptatem adipisci dolore ipsum velit."
            },
            {
                "_id": "E0000FB",
                "name": "Neurofilament protein",
                "abreviations": [
                    "14EF"
                ],
                "categoryId": "Aminopeptidase",
                "description": "Amet labore amet neque aliquam. Velit aliquam quisquam non. Modi aliquam magnam magnam quaerat eius ut dolor. Porro dolor ut tempora quiquia. Velit etincidunt ipsum dolore. Labore ut dolore eius quisquam. Dolor modi numquam ipsum quaerat."
            },
            {
                "_id": "E0000FC",
                "name": "microRNA-139",
                "abreviations": [],
                "categoryId": "Lipid",
                "description": "Quisquam tempora eius consectetur velit etincidunt quaerat. Quaerat aliquam adipisci consectetur numquam amet. Etincidunt voluptatem voluptatem ut ut voluptatem quiquia. Sit est eius magnam sit aliquam ipsum. Magnam quisquam non quaerat velit etincidunt. Amet ipsum adipisci amet etincidunt. Consectetur adipisci eius ipsum quiquia velit modi neque. Dolor etincidunt ipsum non eius ut amet magnam. Tempora numquam consectetur quaerat porro dolorem adipisci. Aliquam quaerat ut amet non est sit dolor."
            },
            {
                "_id": "E0000FD",
                "name": "RE1 silencing transcription factor gene signature",
                "abreviations": [],
                "categoryId": "Cytokine",
                "description": "Dolore dolore numquam dolorem quaerat modi ipsum. Porro labore quisquam modi magnam. Eius consectetur velit eius est modi amet. Ipsum ipsum ipsum quisquam sed dolor neque. Dolore dolorem magnam dolor dolorem velit quaerat magnam. Consectetur eius sed quaerat ipsum modi. Amet numquam voluptatem etincidunt sed modi. Est amet ipsum adipisci sit labore. Voluptatem modi sed consectetur aliquam dolor dolor porro."
            },
            {
                "_id": "E0000FE",
                "name": "Rho-kinase pathway gene BCL2 expression",
                "abreviations": [
                    "1FB7"
                ],
                "categoryId": "Others",
                "description": "Tempora dolore dolorem dolorem numquam. Modi est numquam quaerat dolore voluptatem ipsum. Dolorem voluptatem neque amet adipisci sed etincidunt. Dolorem quisquam neque dolor ut tempora neque. Numquam eius numquam consectetur voluptatem. Etincidunt neque voluptatem amet voluptatem. Tempora porro ipsum adipisci aliquam ipsum modi. Ut ut quiquia neque dolore ut."
            },
            {
                "_id": "E0000FF",
                "name": "High-mobility group AT-hook protein 2",
                "abreviations": [
                    "6F8",
                    "116",
                    "F2F",
                    "25F"
                ],
                "categoryId": "Protein",
                "description": "Amet eius amet numquam adipisci quisquam. Quiquia sit velit consectetur. Porro dolor ipsum ut modi. Aliquam labore voluptatem quiquia amet magnam est eius. Tempora neque adipisci velit quisquam. Sed ut aliquam tempora sit porro modi. Non est quaerat dolorem ut porro dolor. Est amet quaerat consectetur aliquam."
            },
            {
                "_id": "E000100",
                "name": "miR-181c",
                "abreviations": [],
                "categoryId": "Metabolite",
                "description": "Dolore non sed ipsum voluptatem etincidunt dolore. Dolor sed quaerat non quisquam sed numquam. Sed etincidunt dolor porro. Quisquam neque adipisci tempora dolore amet. Modi aliquam dolorem etincidunt. Dolor est dolor quiquia. Neque porro eius sit aliquam eius modi. Ipsum adipisci eius ipsum. Ipsum adipisci numquam dolor."
            },
            {
                "_id": "E000101",
                "name": "CD97",
                "abreviations": [
                    "482",
                    "1BC2",
                    "128C"
                ],
                "categoryId": "Others",
                "description": "Velit numquam dolorem ut. Porro eius non dolore. Numquam modi modi quaerat. Tempora labore voluptatem non ut sed. Non ut est voluptatem aliquam ut quiquia. Tempora dolor ut quiquia modi. Modi labore eius voluptatem porro est. Eius quisquam sit numquam quisquam consectetur. Magnam sit sed voluptatem dolore quisquam."
            },
            {
                "_id": "E000102",
                "name": "O6-methylguanine-DNA methyltransferase protein expression",
                "abreviations": [
                    "58A"
                ],
                "categoryId": "Enzyme",
                "description": "Adipisci labore adipisci aliquam. Est etincidunt ipsum voluptatem amet. Numquam velit dolorem ipsum. Amet dolore neque porro. Adipisci ipsum tempora adipisci amet. Quaerat dolore velit est magnam. Tempora ipsum eius neque est eius consectetur. Ut dolor dolorem est labore eius quisquam numquam. Aliquam dolor dolor dolor. Modi eius modi ut labore eius."
            },
            {
                "_id": "E000103",
                "name": "Anticalin N9B",
                "abreviations": [
                    "C10",
                    "1B3B",
                    "86B",
                    "67E",
                    "2452"
                ],
                "categoryId": "Labelling index",
                "description": "Dolor modi adipisci eius quiquia ut est ipsum. Numquam etincidunt quaerat consectetur magnam eius quaerat. Voluptatem labore velit aliquam non eius neque. Sed numquam eius quiquia sed. Porro modi quaerat modi ipsum adipisci quisquam. Velit dolor ut quaerat est voluptatem numquam ipsum. Aliquam tempora quaerat numquam. Quisquam non consectetur dolor sit amet modi. Tempora modi est est neque quaerat sit."
            },
            {
                "_id": "E000104",
                "name": "Synaptosome associated protein 91",
                "abreviations": [
                    "53E",
                    "D3E"
                ],
                "categoryId": "Labelling index",
                "description": "Velit tempora eius sit amet tempora etincidunt numquam. Dolor sed consectetur porro non ipsum ipsum est. Adipisci non quaerat amet amet est est dolorem. Modi dolor non amet dolor magnam velit. Est numquam labore magnam. Amet numquam tempora etincidunt."
            },
            {
                "_id": "E000105",
                "name": "SLC7A7 expression",
                "abreviations": [
                    "1D8",
                    "21D9",
                    "242",
                    "42A",
                    "ACE"
                ],
                "categoryId": "RNA",
                "description": "Sed numquam quaerat sit dolorem non dolore ipsum. Sit neque labore ut quiquia. Sit ut eius magnam porro amet quiquia. Quaerat voluptatem consectetur adipisci etincidunt. Sed consectetur aliquam quiquia. Non sed quiquia ut. Voluptatem est consectetur eius quaerat voluptatem adipisci. Numquam neque labore dolor."
            },
            {
                "_id": "E000106",
                "name": "HOXA9",
                "abreviations": [
                    "F1B",
                    "20EF",
                    "2053",
                    "24ED"
                ],
                "categoryId": "DNA",
                "description": "Modi dolore tempora est. Modi labore modi ut. Dolore consectetur aliquam magnam dolore sed. Magnam neque quaerat quaerat velit velit labore. Etincidunt neque dolorem dolorem modi. Est velit est ut. Amet non adipisci dolorem dolore aliquam quaerat neque. Non est eius magnam. Voluptatem neque neque dolor sit dolor porro ut. Voluptatem sit quisquam adipisci sit quaerat numquam adipisci."
            },
            {
                "_id": "E000107",
                "name": "Doublecortex",
                "abreviations": [],
                "categoryId": "Protein",
                "description": "Voluptatem voluptatem quisquam aliquam. Non aliquam eius dolore. Tempora velit adipisci consectetur etincidunt consectetur adipisci. Modi aliquam neque quaerat porro. Dolore quaerat adipisci tempora voluptatem ipsum. Dolorem quisquam sit aliquam non consectetur amet labore. Consectetur labore etincidunt est numquam. Amet quisquam dolor eius sit. Dolor labore quiquia consectetur eius quisquam."
            },
            {
                "_id": "E000108",
                "name": "DCC",
                "abreviations": [
                    "1B6E",
                    "22F9",
                    "3F8",
                    "19B1",
                    "2080"
                ],
                "categoryId": "Enzyme",
                "description": "Est sit numquam non eius modi consectetur tempora. Dolor non quaerat dolor non adipisci. Voluptatem quaerat quiquia velit. Magnam dolore eius adipisci quaerat porro. Magnam amet magnam voluptatem quisquam ut. Magnam dolore dolor ipsum. Labore eius neque quisquam magnam tempora quaerat."
            },
            {
                "_id": "E000109",
                "name": "CD133 promoter methylation",
                "abreviations": [
                    "DFC",
                    "DD7",
                    "2588",
                    "19BE"
                ],
                "categoryId": "RNA",
                "description": "Quiquia est labore non sit aliquam dolorem. Amet dolor numquam non consectetur. Est sit velit porro velit sit etincidunt etincidunt. Sit dolore quaerat quiquia ipsum ipsum eius dolorem. Aliquam etincidunt est numquam non neque amet quisquam. Quiquia porro sit aliquam. Quisquam etincidunt labore dolor non voluptatem consectetur. Quaerat porro numquam etincidunt non sit etincidunt. Adipisci sed quisquam eius etincidunt neque consectetur dolor. Neque etincidunt neque sit labore ipsum."
            },
            {
                "_id": "E00010A",
                "name": "Rho-kinase pathway gene MAPK1 expression",
                "abreviations": [],
                "categoryId": "Other",
                "description": "Sit quaerat adipisci numquam sit. Etincidunt etincidunt porro porro numquam quiquia adipisci. Quisquam numquam labore est modi quiquia. Labore eius aliquam porro neque etincidunt adipisci eius. Non neque sit dolore dolore. Ipsum sed numquam modi amet sit eius. Dolorem quisquam quiquia adipisci. Magnam neque voluptatem labore velit. Dolore numquam sit modi tempora aliquam."
            },
            {
                "_id": "E00010B",
                "name": "HJURP",
                "abreviations": [
                    "279",
                    "B4D",
                    "5A9"
                ],
                "categoryId": "Lipid",
                "description": "Aliquam non ipsum non. Quiquia eius modi non est sit dolor. Numquam numquam sed amet non eius quiquia neque. Amet quisquam adipisci quisquam labore numquam consectetur est. Sit etincidunt non dolor dolor quiquia. Magnam adipisci etincidunt quisquam."
            },
            {
                "_id": "E00010C",
                "name": "Urokinase-type plasminogen activator",
                "abreviations": [
                    "1E47",
                    "21ED",
                    "1F30",
                    "2443"
                ],
                "categoryId": "Others",
                "description": "Voluptatem modi numquam ipsum dolore dolore. Sit amet dolorem consectetur non dolore. Tempora amet velit consectetur quiquia amet ipsum sed. Non quaerat numquam porro voluptatem tempora aliquam sed. Porro sed quiquia adipisci etincidunt voluptatem dolore. Modi etincidunt consectetur numquam magnam eius quiquia neque. Consectetur eius eius velit. Porro dolorem neque sit. Numquam neque neque etincidunt est."
            },
            {
                "_id": "E00010D",
                "name": "Epithelial membrane protein-2",
                "abreviations": [
                    "1276"
                ],
                "categoryId": "Cytokine",
                "description": "Non numquam magnam amet quiquia consectetur. Ut neque dolore non adipisci quiquia porro. Sed ut sit dolorem magnam. Ut aliquam ut amet modi velit amet dolorem. Aliquam porro ipsum numquam velit sed labore porro."
            },
            {
                "_id": "E00010E",
                "name": "Lysosomal-associated membrane protein 1",
                "abreviations": [
                    "1CF4",
                    "21D5",
                    "1AB9",
                    "6B7"
                ],
                "categoryId": "Others",
                "description": "Amet quiquia quisquam dolore etincidunt non dolor dolorem. Porro ut numquam aliquam tempora tempora ipsum. Labore magnam magnam porro ipsum. Dolore numquam etincidunt dolor velit quisquam neque. Sit voluptatem sed velit tempora. Eius labore etincidunt porro ipsum."
            },
            {
                "_id": "E00010F",
                "name": "LINGO1",
                "abreviations": [
                    "1FBB",
                    "EDF",
                    "CA0"
                ],
                "categoryId": "Others",
                "description": "Adipisci ipsum amet modi voluptatem. Magnam est sed dolorem voluptatem porro sit. Dolor labore modi ut neque neque. Aliquam modi sed non modi modi tempora. Quiquia quaerat eius dolor sed numquam consectetur modi. Quisquam amet est numquam dolorem magnam."
            },
            {
                "_id": "E000110",
                "name": "VEGF",
                "abreviations": [
                    "1FCE",
                    "F8E",
                    "1C95",
                    "1DDC"
                ],
                "categoryId": "Others",
                "description": "Non sed dolor est quiquia quaerat modi. Sed dolorem etincidunt numquam adipisci. Amet voluptatem aliquam sed quisquam sit. Quisquam dolorem modi dolorem. Porro tempora voluptatem quisquam dolor etincidunt sit. Consectetur adipisci neque numquam ut sit. Aliquam consectetur adipisci porro."
            },
            {
                "_id": "E000111",
                "name": "miRNA-203",
                "abreviations": [
                    "1BA5",
                    "22A0"
                ],
                "categoryId": "Others",
                "description": "Magnam labore adipisci numquam eius. Sit consectetur velit est. Adipisci voluptatem porro dolorem labore non est. Tempora magnam modi velit dolor modi porro. Numquam consectetur sit tempora magnam eius non ipsum."
            },
            {
                "_id": "E000112",
                "name": "AC078883.3",
                "abreviations": [],
                "categoryId": "DNA",
                "description": "Modi sed amet dolor tempora consectetur voluptatem. Dolorem magnam quaerat eius dolore ut dolor consectetur. Dolorem quisquam non neque dolorem. Quiquia non quisquam magnam tempora labore. Dolor aliquam voluptatem labore."
            },
            {
                "_id": "E000113",
                "name": "EZH2",
                "abreviations": [],
                "categoryId": "Lipid",
                "description": "Tempora etincidunt amet quisquam. Ut voluptatem etincidunt quaerat. Aliquam sed sed sed ipsum quisquam quisquam. Sit magnam voluptatem eius amet. Adipisci dolorem quaerat sed velit. Ut neque ut modi tempora adipisci sit voluptatem. Velit labore porro labore aliquam. Ut est quiquia neque tempora sed. Tempora labore consectetur eius quisquam quaerat. Modi neque sed sit aliquam dolore."
            },
            {
                "_id": "E000114",
                "name": "Sphingosine-1-phosphate receptor and enzyme expression",
                "abreviations": [
                    "1E69",
                    "17FE",
                    "1F58",
                    "1E2D"
                ],
                "categoryId": "Cytokine",
                "description": "Dolorem dolorem quaerat consectetur. Est ut eius sed ut dolore. Amet numquam non velit dolorem ipsum. Tempora ipsum magnam etincidunt labore. Quaerat magnam quisquam labore etincidunt dolor quisquam etincidunt."
            },
            {
                "_id": "E000115",
                "name": "Amino acid ADP-ribosyltransferase 1",
                "abreviations": [
                    "1BF0",
                    "2DF",
                    "C0C",
                    "229E"
                ],
                "categoryId": "DNA",
                "description": "Voluptatem dolorem etincidunt est non. Non neque eius aliquam dolore eius etincidunt. Sit voluptatem quaerat quisquam. Modi quiquia velit voluptatem numquam amet aliquam magnam. Non dolore numquam non modi. Magnam dolore dolorem etincidunt. Dolore dolorem non ipsum dolore quiquia tempora amet. Consectetur numquam aliquam ut labore quisquam non."
            },
            {
                "_id": "E000116",
                "name": "TGM2",
                "abreviations": [
                    "209B",
                    "1958"
                ],
                "categoryId": "DNA",
                "description": "Quaerat neque modi quiquia est aliquam voluptatem. Aliquam sed consectetur quaerat. Est dolor sit non dolor. Sed neque aliquam modi ipsum amet. Magnam dolore quiquia sed etincidunt. Neque magnam consectetur non labore porro. Quiquia tempora sed ut neque. Dolorem labore modi quisquam ut. Modi quiquia neque eius amet ipsum."
            },
            {
                "_id": "E000117",
                "name": "PI3K mutation",
                "abreviations": [],
                "categoryId": "Protein",
                "description": "Tempora non ut dolorem porro est amet. Dolore magnam adipisci dolorem labore etincidunt quisquam. Non adipisci labore neque adipisci numquam tempora non. Consectetur est neque sed sed sed velit. Neque magnam ut aliquam."
            },
            {
                "_id": "E000118",
                "name": "Circular RNAs",
                "abreviations": [
                    "9BA",
                    "E37",
                    "22F7"
                ],
                "categoryId": "Aminopeptidase",
                "description": "Velit velit tempora magnam velit est voluptatem. Dolore ipsum porro dolorem. Consectetur eius magnam modi adipisci numquam. Dolor non numquam modi aliquam tempora. Sit eius ipsum sit. Amet dolore quisquam etincidunt eius ipsum. Etincidunt labore est aliquam quiquia dolorem consectetur magnam. Neque numquam velit eius modi."
            },
            {
                "_id": "E000119",
                "name": "Epidermal growth factor module-containing mucin-like hormone receptor-3",
                "abreviations": [
                    "2433",
                    "346",
                    "41A",
                    "421",
                    "E81"
                ],
                "categoryId": "Metabolite",
                "description": "Consectetur velit etincidunt sit est velit eius quisquam. Quaerat quiquia neque dolor dolorem non. Labore adipisci neque tempora sit amet dolorem est. Magnam dolore sed quisquam aliquam tempora sit. Modi quisquam etincidunt modi velit dolore quisquam etincidunt. Quaerat dolorem ut voluptatem. Numquam quaerat quiquia dolore tempora adipisci quiquia. Sed modi ipsum ipsum. Amet labore neque consectetur."
            },
            {
                "_id": "E00011A",
                "name": "Hyaluronic acid receptor CD44",
                "abreviations": [
                    "2349",
                    "416",
                    "1A41"
                ],
                "categoryId": "DNA",
                "description": "Neque quaerat voluptatem eius adipisci numquam adipisci. Magnam tempora dolor etincidunt dolorem. Consectetur voluptatem porro sed labore dolore etincidunt ipsum. Dolorem velit quisquam aliquam velit quisquam. Magnam dolorem magnam modi modi adipisci tempora. Consectetur ipsum dolorem quisquam labore. Adipisci eius voluptatem etincidunt labore dolor adipisci est. Ut quiquia tempora labore. Neque ut non velit sit dolor. Velit quiquia dolorem tempora neque neque dolorem."
            },
            {
                "_id": "E00011B",
                "name": "Mouse double minute 2 homolog",
                "abreviations": [
                    "1C92"
                ],
                "categoryId": "Lipid",
                "description": "Amet numquam neque labore sed tempora numquam. Dolor neque tempora tempora dolor sed est aliquam. Sed non velit velit tempora dolorem consectetur. Aliquam ipsum quisquam est. Non quiquia dolor est numquam sed porro. Ipsum numquam ut porro est modi dolor. Dolore neque sit velit sit dolorem adipisci sed. Non ut quisquam est voluptatem magnam quaerat."
            },
            {
                "_id": "E00011C",
                "name": "lncRNA signature KIAA0495",
                "abreviations": [
                    "10D8"
                ],
                "categoryId": "DNA",
                "description": "Modi ipsum quiquia eius aliquam ut dolore. Voluptatem consectetur dolor dolor quaerat porro. Neque quaerat dolorem quiquia. Neque tempora tempora dolor consectetur. Etincidunt porro labore dolorem amet dolore neque. Sit porro velit eius. Velit modi quisquam aliquam."
            },
            {
                "_id": "E00011D",
                "name": "CD133 mRNA expression",
                "abreviations": [
                    "C8F"
                ],
                "categoryId": "Enzyme",
                "description": "Magnam numquam magnam modi ut neque aliquam tempora. Sed ipsum velit quaerat. Quisquam ipsum eius ut magnam voluptatem. Dolorem magnam non velit aliquam. Dolore dolorem tempora numquam modi. Numquam neque ipsum tempora."
            },
            {
                "_id": "E00011E",
                "name": "Tetraspanin CD151 expression",
                "abreviations": [
                    "1B",
                    "1832",
                    "1629",
                    "17A7",
                    "1A4D"
                ],
                "categoryId": "DNA",
                "description": "Porro dolor dolor quiquia. Magnam eius consectetur dolore. Tempora modi amet dolorem. Neque amet neque aliquam. Quisquam sed labore voluptatem dolor dolore dolorem. Voluptatem modi numquam magnam porro consectetur. Magnam sit consectetur modi sit velit dolore. Dolor consectetur neque voluptatem magnam. Ut magnam numquam etincidunt."
            },
            {
                "_id": "E00011F",
                "name": "H3F3A",
                "abreviations": [],
                "categoryId": "Metabolite",
                "description": "Velit dolore est quisquam non dolore. Sit voluptatem eius etincidunt adipisci tempora tempora numquam. Quaerat etincidunt labore quisquam tempora porro magnam. Est sit ut dolore dolor dolore numquam. Voluptatem dolor dolore ut numquam."
            },
            {
                "_id": "E000120",
                "name": "MIB-1 labeling index",
                "abreviations": [
                    "1B12",
                    "40",
                    "1AD3"
                ],
                "categoryId": "Lipid",
                "description": "Non tempora tempora dolorem consectetur labore numquam. Ut quisquam ut voluptatem porro quiquia. Adipisci ut dolorem modi. Non amet dolorem eius quiquia eius voluptatem. Porro numquam magnam ipsum. Aliquam ipsum dolore sit neque est labore tempora."
            },
            {
                "_id": "E000121",
                "name": "HOXA11-AS",
                "abreviations": [],
                "categoryId": "Protein",
                "description": "Ut dolor ipsum modi dolore sit est. Ut quisquam eius non numquam sit. Consectetur consectetur modi numquam ipsum velit non quiquia. Dolorem porro etincidunt quisquam. Adipisci voluptatem magnam magnam. Amet quisquam adipisci quisquam quisquam. Adipisci consectetur etincidunt ipsum porro. Dolore ut amet adipisci."
            },
            {
                "_id": "E000122",
                "name": "Proliferating cell nuclear antigen",
                "abreviations": [
                    "1703",
                    "147B",
                    "1F96",
                    "18BB"
                ],
                "categoryId": "Enzyme",
                "description": "Voluptatem quisquam dolore neque etincidunt quiquia tempora quisquam. Velit aliquam tempora consectetur. Est porro dolorem modi porro. Aliquam quiquia porro ipsum dolore aliquam. Ipsum dolorem ut dolore. Dolor voluptatem sed dolor velit non."
            },
            {
                "_id": "E000123",
                "name": "Rho-kinase pathway gene CFL2 expression",
                "abreviations": [
                    "8DA",
                    "4AF",
                    "B71",
                    "9BB"
                ],
                "categoryId": "Enzyme",
                "description": "Dolor quiquia labore consectetur quisquam quiquia. Etincidunt eius eius sed. Quiquia adipisci dolore porro numquam adipisci sed dolorem. Quisquam modi voluptatem neque amet modi quiquia sed. Modi quiquia consectetur dolore dolore. Dolore est aliquam etincidunt est. Eius eius numquam quiquia sit. Ut porro neque voluptatem voluptatem ipsum numquam. Non aliquam modi dolorem porro ut."
            },
            {
                "_id": "E000124",
                "name": "Subfamily C Member 3",
                "abreviations": [
                    "24E5",
                    "19B2",
                    "1250",
                    "CF8"
                ],
                "categoryId": "Others",
                "description": "Sed velit dolore labore quaerat porro quisquam etincidunt. Modi quisquam eius etincidunt magnam modi quisquam. Adipisci dolore aliquam consectetur aliquam labore. Aliquam quiquia aliquam non sit non magnam neque. Labore neque dolorem sit."
            },
            {
                "_id": "E000125",
                "name": "IL-17",
                "abreviations": [],
                "categoryId": "Stem cells",
                "description": "Consectetur magnam sed quiquia. Velit quiquia aliquam dolore. Quiquia porro consectetur sed. Quaerat labore neque magnam est voluptatem ipsum. Sit tempora quaerat amet quiquia numquam consectetur."
            },
            {
                "_id": "E000126",
                "name": "Isocitrate dehydrogenase",
                "abreviations": [
                    "87"
                ],
                "categoryId": "RNA",
                "description": "Aliquam amet consectetur numquam. Neque velit adipisci ut. Dolor eius dolor ut dolor aliquam dolor quiquia. Quiquia quaerat ut quiquia voluptatem sed eius. Etincidunt numquam etincidunt quisquam est. Modi porro dolore velit."
            },
            {
                "_id": "E000127",
                "name": "Annexin-1 (ANXA1, lipocortin-1)",
                "abreviations": [
                    "9B3",
                    "1515",
                    "1336",
                    "914",
                    "1B2E"
                ],
                "categoryId": "Labelling index",
                "description": "Quaerat amet adipisci tempora tempora. Consectetur quisquam etincidunt etincidunt. Porro ut quisquam sed. Sed modi ut est adipisci est. Neque voluptatem neque dolorem sit labore tempora consectetur. Etincidunt velit modi velit numquam dolorem adipisci. Quaerat est voluptatem sit. Porro dolore dolor sit aliquam magnam adipisci."
            },
            {
                "_id": "E000128",
                "name": "Autophagy marker LC3B",
                "abreviations": [
                    "746",
                    "13BA",
                    "570"
                ],
                "categoryId": "Stem cells",
                "description": "Voluptatem adipisci sit dolore. Neque etincidunt dolor eius. Etincidunt etincidunt dolorem velit. Quiquia modi est consectetur sed adipisci neque. Sit quiquia quisquam amet eius est labore."
            },
            {
                "_id": "E000129",
                "name": "miR-137",
                "abreviations": [
                    "165F",
                    "1681",
                    "1EE0",
                    "17B",
                    "10E9"
                ],
                "categoryId": "Cytokine",
                "description": "Dolore dolore non voluptatem quiquia adipisci non. Ipsum amet adipisci non sit amet. Ipsum est adipisci amet. Amet modi quisquam ipsum tempora dolore. Porro etincidunt eius sed neque dolorem est magnam. Sed quisquam non numquam sed ipsum."
            },
            {
                "_id": "E00012A",
                "name": "GRP78",
                "abreviations": [
                    "21E3",
                    "E12",
                    "E83",
                    "17CE",
                    "23E2"
                ],
                "categoryId": "Cytokine",
                "description": "Sit voluptatem tempora quisquam labore dolorem eius numquam. Dolorem velit sed ipsum eius consectetur quisquam labore. Eius non quisquam sed porro etincidunt. Dolor ut amet modi quisquam modi amet. Sed est velit eius sed."
            },
            {
                "_id": "E00012B",
                "name": "NDRG2",
                "abreviations": [
                    "1356",
                    "208D",
                    "1397",
                    "71D",
                    "1DC1"
                ],
                "categoryId": "Stem cells",
                "description": "Ut numquam numquam sit ipsum consectetur modi neque. Ipsum tempora quaerat sed quaerat velit voluptatem. Dolorem aliquam tempora quisquam numquam eius porro est. Dolore amet tempora aliquam quisquam. Sed neque eius velit amet amet tempora. Sed eius labore velit quiquia eius quiquia dolor. Adipisci modi est velit sed sed ipsum modi. Dolorem numquam sed eius."
            },
            {
                "_id": "E00012C",
                "name": "APEX1",
                "abreviations": [
                    "14B4",
                    "1C2E",
                    "415",
                    "1948",
                    "250F"
                ],
                "categoryId": "Other",
                "description": "Sit ut modi numquam etincidunt ipsum. Velit numquam porro numquam. Tempora ipsum magnam numquam amet. Numquam numquam quaerat etincidunt labore porro eius velit. Porro dolor aliquam aliquam ipsum etincidunt adipisci dolore. Non tempora velit porro dolore."
            },
            {
                "_id": "E00012D",
                "name": "STAT3 tyrosine 705 phosphorylation",
                "abreviations": [
                    "3F9",
                    "17EC",
                    "216C"
                ],
                "categoryId": "RNA",
                "description": "Velit non porro etincidunt. Numquam non eius porro tempora adipisci est. Modi magnam eius amet etincidunt non consectetur quaerat. Etincidunt magnam est neque numquam. Ut sit quiquia labore consectetur quiquia quiquia. Tempora eius quisquam ipsum numquam tempora."
            },
            {
                "_id": "E00012E",
                "name": "Adrenocortical dysplasia expression",
                "abreviations": [
                    "1762",
                    "25A1",
                    "2054",
                    "56D"
                ],
                "categoryId": "Other",
                "description": "Quaerat porro sed ut porro. Aliquam voluptatem labore amet. Amet adipisci numquam tempora etincidunt sed amet. Quaerat numquam quisquam quaerat quiquia quisquam. Etincidunt est sed quisquam eius. Dolorem sed consectetur voluptatem non est."
            },
            {
                "_id": "E00012F",
                "name": "Semaphorin3B",
                "abreviations": [
                    "1D12"
                ],
                "categoryId": "Protein",
                "description": "Aliquam porro eius etincidunt quiquia dolorem. Aliquam quaerat non quiquia. Dolor eius numquam eius tempora ut neque sed. Quisquam dolore velit sit. Consectetur ut voluptatem eius voluptatem. Labore velit voluptatem dolor magnam dolorem quisquam. Labore sed eius ipsum ipsum quisquam ipsum. Dolorem dolore tempora etincidunt magnam. Quaerat etincidunt neque voluptatem sit dolore labore."
            },
            {
                "_id": "E000130",
                "name": "Six-CpGs panel",
                "abreviations": [],
                "categoryId": "Labelling index",
                "description": "Ut porro dolorem aliquam ipsum est non tempora. Sit amet etincidunt etincidunt magnam dolore modi numquam. Quiquia neque non quiquia labore ipsum quaerat ut. Voluptatem ipsum labore non sed. Dolor numquam voluptatem consectetur quisquam quiquia labore."
            },
            {
                "_id": "E000131",
                "name": "Glucose-regulated protein 94",
                "abreviations": [
                    "2613",
                    "1F3B",
                    "97A",
                    "2386"
                ],
                "categoryId": "Metabolite",
                "description": "Quiquia dolorem consectetur amet ut adipisci. Non ut ut non. Quisquam tempora quaerat consectetur amet. Sed labore neque consectetur porro. Porro etincidunt eius quisquam numquam sit. Amet amet non etincidunt quiquia. Etincidunt labore non numquam. Numquam sed velit etincidunt est aliquam. Eius amet voluptatem labore dolor. Ipsum numquam velit consectetur."
            },
            {
                "_id": "E000132",
                "name": "CD34 mRNA",
                "abreviations": [
                    "277",
                    "24E5",
                    "1FE3",
                    "139D"
                ],
                "categoryId": "Protein",
                "description": "Tempora etincidunt quaerat modi aliquam ipsum ut. Labore aliquam ut magnam aliquam sed. Ut aliquam dolorem voluptatem tempora. Sed adipisci sit tempora. Etincidunt quaerat amet labore tempora. Quiquia dolore quiquia quisquam. Est quiquia porro numquam. Quiquia velit labore labore."
            },
            {
                "_id": "E000133",
                "name": "Subtelomeric DNA methylation",
                "abreviations": [],
                "categoryId": "Aminopeptidase",
                "description": "Aliquam ipsum sit quiquia quaerat ut labore. Sed velit sit porro adipisci quisquam. Etincidunt neque adipisci consectetur tempora voluptatem. Dolorem porro voluptatem etincidunt. Porro eius dolore aliquam etincidunt porro. Labore quaerat porro ipsum sit."
            },
            {
                "_id": "E000134",
                "name": "Glia maturation factor \ud835\udec3",
                "abreviations": [
                    "1693",
                    "19FA",
                    "954",
                    "BDB",
                    "154"
                ],
                "categoryId": "Metabolite",
                "description": "Dolore consectetur sed est labore adipisci non. Neque numquam consectetur ut non dolor dolorem velit. Eius quisquam dolor dolore aliquam ut. Amet dolorem aliquam neque. Dolor aliquam non quaerat magnam labore."
            },
            {
                "_id": "E000135",
                "name": "OLIG2",
                "abreviations": [
                    "13AE",
                    "2161",
                    "1A4F",
                    "128B"
                ],
                "categoryId": "Protein",
                "description": "Quisquam tempora non tempora voluptatem sit. Quiquia dolore quiquia non labore quiquia dolore. Tempora ut amet sit voluptatem quiquia. Etincidunt dolorem labore tempora. Labore modi consectetur dolore labore. Est quisquam sed dolor sed. Consectetur ipsum etincidunt adipisci quiquia dolore magnam magnam. Tempora sit quiquia voluptatem tempora numquam ut."
            },
            {
                "_id": "E000136",
                "name": "miR-206",
                "abreviations": [
                    "1675",
                    "1127",
                    "B1E"
                ],
                "categoryId": "Enzyme",
                "description": "Sed labore non neque aliquam modi. Quisquam quisquam consectetur ipsum consectetur ipsum dolor sed. Dolore consectetur adipisci quisquam tempora. Non modi amet modi neque tempora neque voluptatem. Est dolore ipsum sed velit non ipsum tempora. Voluptatem quaerat sed magnam adipisci amet dolore. Dolorem amet dolorem etincidunt. Aliquam voluptatem labore eius. Numquam porro porro amet est. Adipisci velit consectetur dolor quaerat etincidunt."
            },
            {
                "_id": "E000137",
                "name": "Activator protein 2\u03b1",
                "abreviations": [],
                "categoryId": "Labelling index",
                "description": "Labore consectetur quisquam tempora quiquia quaerat quiquia. Quaerat ut dolor dolorem. Eius aliquam tempora dolorem porro. Est velit sit tempora labore. Neque eius neque amet eius porro dolorem. Dolore quaerat dolore aliquam voluptatem non."
            },
            {
                "_id": "E000138",
                "name": "Isocitrate dehydrogenase 1",
                "abreviations": [
                    "B3D",
                    "CFC",
                    "1547",
                    "2479",
                    "291"
                ],
                "categoryId": "RNA",
                "description": "Labore labore dolore aliquam etincidunt quiquia. Modi porro numquam voluptatem sit aliquam ut. Neque quiquia sit labore dolor. Ipsum non non magnam quiquia ut est sit. Sit etincidunt quaerat adipisci velit amet amet. Adipisci tempora est quiquia modi ipsum. Dolore modi ipsum quaerat ipsum dolorem. Adipisci labore dolorem est. Sit adipisci magnam labore consectetur quisquam. Dolor dolore magnam velit dolore est."
            },
            {
                "_id": "E000139",
                "name": "CCDC81",
                "abreviations": [
                    "BE3"
                ],
                "categoryId": "DNA",
                "description": "Voluptatem aliquam labore dolorem sed labore tempora modi. Magnam tempora dolor modi. Etincidunt numquam velit quaerat quiquia. Est etincidunt velit eius neque numquam. Velit dolorem quaerat tempora sit quiquia velit non. Aliquam sed adipisci aliquam quiquia dolore. Dolore consectetur consectetur neque non eius quaerat neque. Est dolore neque dolore."
            },
            {
                "_id": "E00013A",
                "name": "CDC25B",
                "abreviations": [
                    "169F",
                    "1BC6"
                ],
                "categoryId": "Metabolite",
                "description": "Amet voluptatem tempora modi. Labore quisquam magnam consectetur quiquia consectetur. Numquam numquam numquam quisquam voluptatem consectetur. Quiquia porro ut est sit sed ipsum. Neque est velit ipsum ipsum eius quisquam ut. Voluptatem etincidunt amet dolore etincidunt amet. Consectetur labore quisquam adipisci. Aliquam non modi magnam modi sed. Neque dolore quaerat quisquam tempora voluptatem."
            },
            {
                "_id": "E00013B",
                "name": "SLIT3",
                "abreviations": [
                    "C70",
                    "133E",
                    "4D6"
                ],
                "categoryId": "Labelling index",
                "description": "Adipisci tempora quisquam adipisci dolor adipisci. Velit quisquam ut voluptatem ipsum ipsum. Dolorem voluptatem velit velit quiquia quaerat. Numquam numquam quaerat dolorem amet. Tempora modi ipsum aliquam. Quaerat consectetur voluptatem aliquam adipisci quaerat. Non voluptatem ipsum consectetur numquam consectetur dolorem amet."
            },
            {
                "_id": "E00013C",
                "name": "p16",
                "abreviations": [
                    "20D6",
                    "12F1"
                ],
                "categoryId": "Labelling index",
                "description": "Modi adipisci quiquia consectetur ut dolorem. Numquam voluptatem adipisci velit velit. Etincidunt quaerat est dolorem voluptatem modi ut eius. Sit modi quisquam adipisci quaerat. Non eius velit labore consectetur. Porro aliquam quisquam dolore eius adipisci. Voluptatem numquam modi sit dolor amet adipisci eius. Ut sit sed numquam aliquam. Voluptatem adipisci ipsum voluptatem etincidunt. Dolore ut dolor sit consectetur neque sed."
            },
            {
                "_id": "E00013D",
                "name": "Tes genes",
                "abreviations": [
                    "DCF",
                    "2404"
                ],
                "categoryId": "Others",
                "description": "Quiquia aliquam voluptatem aliquam magnam. Amet sit etincidunt voluptatem velit. Labore aliquam dolorem voluptatem sit. Velit dolore aliquam sed sed labore. Neque quisquam modi neque."
            },
            {
                "_id": "E00013E",
                "name": "Collagen type III alpha 1 chain",
                "abreviations": [],
                "categoryId": "DNA",
                "description": "Labore neque sit modi non magnam magnam modi. Modi eius ut etincidunt tempora consectetur. Tempora quaerat dolor dolore. Numquam quisquam consectetur aliquam numquam magnam. Quiquia modi sit magnam tempora magnam. Eius velit sit ipsum sed neque."
            },
            {
                "_id": "E00013F",
                "name": "KAZALD1 promoter methylation",
                "abreviations": [
                    "1FCD"
                ],
                "categoryId": "Enzyme",
                "description": "Consectetur ipsum quisquam numquam quisquam consectetur. Sit quaerat sit etincidunt. Sit est porro porro sit. Adipisci sed neque labore velit tempora. Tempora non quisquam adipisci dolor. Amet labore ut ipsum sed ipsum. Numquam sit quiquia aliquam quisquam voluptatem est. Adipisci sed dolorem est quisquam voluptatem etincidunt quiquia. Porro sit non est voluptatem quiquia amet."
            },
            {
                "_id": "E000140",
                "name": "Alpha-PIX",
                "abreviations": [
                    "14F1"
                ],
                "categoryId": "Aminopeptidase",
                "description": "Ut modi sit aliquam neque. Est dolor voluptatem velit est. Amet quisquam sit tempora dolorem modi dolor magnam. Quaerat ipsum adipisci tempora tempora amet voluptatem. Magnam dolore ipsum neque voluptatem."
            },
            {
                "_id": "E000141",
                "name": "Epidermal growth factor receptor gene amplification",
                "abreviations": [
                    "C19",
                    "1523"
                ],
                "categoryId": "DNA",
                "description": "Sit quaerat adipisci labore voluptatem consectetur. Consectetur sed sed quisquam quaerat. Quisquam aliquam est quaerat consectetur. Quaerat voluptatem dolore eius voluptatem quisquam. Velit numquam eius ipsum non magnam sed."
            },
            {
                "_id": "E000142",
                "name": "Cyclin-dependent kinase inhibitor p27",
                "abreviations": [],
                "categoryId": "Others",
                "description": "Magnam quiquia velit ipsum voluptatem labore amet quiquia. Labore voluptatem numquam est labore quiquia etincidunt. Amet adipisci neque modi est modi. Quaerat est dolorem est. Ut labore velit quaerat quisquam consectetur tempora. Porro neque consectetur magnam. Sit sed quiquia ipsum dolore. Consectetur quaerat adipisci etincidunt adipisci ipsum dolore neque. Numquam amet quisquam tempora numquam."
            },
            {
                "_id": "E000143",
                "name": "miR-455-3p",
                "abreviations": [
                    "E73"
                ],
                "categoryId": "DNA",
                "description": "Labore ut amet sed consectetur adipisci est. Dolorem labore consectetur consectetur labore labore. Etincidunt ut quisquam eius consectetur eius consectetur eius. Quisquam ipsum ut adipisci labore eius quaerat porro. Est ut numquam dolore dolore consectetur. Sit est consectetur numquam non adipisci. Numquam eius sed dolore velit adipisci dolor."
            },
            {
                "_id": "E000144",
                "name": "RAR\u03b2 methylation",
                "abreviations": [
                    "8E1",
                    "1BC6",
                    "211",
                    "1FE9",
                    "2551"
                ],
                "categoryId": "Others",
                "description": "Labore sit sit voluptatem. Non labore modi quaerat labore porro. Consectetur aliquam eius consectetur ut magnam ut dolorem. Adipisci dolore sit adipisci. Neque velit dolorem modi modi dolore eius amet."
            },
            {
                "_id": "E000145",
                "name": "miR-106a",
                "abreviations": [
                    "A3E",
                    "260",
                    "D9E",
                    "966"
                ],
                "categoryId": "Lipid",
                "description": "Non magnam adipisci dolorem. Tempora sit labore numquam adipisci dolore dolore magnam. Dolore modi etincidunt numquam adipisci aliquam dolore labore. Quiquia sed non modi voluptatem labore amet. Magnam porro ipsum neque voluptatem est adipisci. Sed dolor amet est. Modi est ipsum non. Consectetur modi porro sit non voluptatem dolore."
            },
            {
                "_id": "E000146",
                "name": "\ud835\udec2v\ud835\udec33 integrin",
                "abreviations": [
                    "170C"
                ],
                "categoryId": "Protein",
                "description": "Dolore adipisci etincidunt ipsum. Aliquam dolor voluptatem quaerat dolore etincidunt. Eius sed neque eius voluptatem dolor. Neque labore consectetur dolorem. Velit amet labore eius."
            },
            {
                "_id": "E000147",
                "name": "miR-132 expression",
                "abreviations": [
                    "16BB",
                    "1057",
                    "11F5",
                    "42B",
                    "245D"
                ],
                "categoryId": "Labelling index",
                "description": "Quiquia sed quiquia consectetur. Adipisci labore non dolorem magnam est aliquam quaerat. Neque aliquam voluptatem magnam dolorem magnam quiquia. Voluptatem non ipsum porro magnam. Non quisquam dolore quiquia adipisci numquam sed est. Tempora velit consectetur velit amet ut dolorem. Dolore numquam est tempora. Quisquam magnam etincidunt labore modi consectetur. Est labore labore numquam ipsum tempora aliquam magnam. Dolor sit dolorem modi velit modi."
            },
            {
                "_id": "E000148",
                "name": "Minichromosome maintenance protein 6 expression",
                "abreviations": [
                    "C3C",
                    "114D",
                    "256",
                    "385"
                ],
                "categoryId": "RNA",
                "description": "Est quisquam porro aliquam. Ut velit dolorem sit etincidunt. Sed numquam dolor voluptatem aliquam sed. Dolorem eius neque tempora. Voluptatem tempora eius porro dolore est numquam numquam."
            },
            {
                "_id": "E000149",
                "name": "Interleukin-6",
                "abreviations": [
                    "1D87",
                    "10AB",
                    "1CDE",
                    "212B"
                ],
                "categoryId": "Enzyme",
                "description": "Etincidunt dolor amet magnam tempora quaerat. Eius quaerat voluptatem aliquam ipsum. Magnam sit etincidunt numquam. Neque neque dolor eius modi eius sed. Est adipisci modi non quaerat est."
            },
            {
                "_id": "E00014A",
                "name": "miRNA-10b",
                "abreviations": [
                    "398",
                    "201D"
                ],
                "categoryId": "Enzyme",
                "description": "Porro sed ut aliquam velit sed quaerat. Velit aliquam etincidunt sed dolor. Etincidunt consectetur dolorem ipsum porro est tempora amet. Numquam est aliquam voluptatem dolor est. Amet consectetur quiquia sit quisquam labore velit. Quaerat quiquia consectetur dolor. Est ipsum consectetur est. Numquam sit eius est eius consectetur dolore dolore. Dolor quiquia tempora dolore eius numquam ipsum dolor."
            },
            {
                "_id": "E00014B",
                "name": "Poly(C)-binding protein 2",
                "abreviations": [],
                "categoryId": "Cytokine",
                "description": "Porro quaerat modi amet magnam eius non dolorem. Est labore numquam consectetur. Neque ipsum aliquam porro. Sit non velit amet. Quiquia neque est voluptatem voluptatem. Dolorem dolor adipisci eius numquam non dolor. Quisquam consectetur dolore non dolore eius. Quiquia adipisci sit quaerat adipisci. Tempora quiquia quaerat amet quiquia modi ut numquam."
            },
            {
                "_id": "E00014C",
                "name": "Epidermal growth factor receptor",
                "abreviations": [
                    "1282",
                    "212A"
                ],
                "categoryId": "Enzyme",
                "description": "Velit neque eius numquam neque. Dolor amet porro quaerat modi dolor dolor. Labore sit adipisci quiquia quaerat. Non eius sed consectetur porro. Labore etincidunt ipsum porro sit. Ut quaerat quaerat amet dolorem tempora. Sit magnam dolore voluptatem etincidunt numquam."
            },
            {
                "_id": "E00014D",
                "name": "mRNA expression signature KCNF1",
                "abreviations": [],
                "categoryId": "DNA",
                "description": "Sed magnam est est est. Non consectetur velit aliquam magnam numquam. Velit amet quisquam neque dolorem ipsum. Magnam quisquam quisquam dolor. Non dolor magnam neque non ut. Dolore dolor eius ut non. Tempora aliquam aliquam dolore est dolorem ut. Aliquam ut labore eius. Quiquia consectetur etincidunt dolor. Dolor dolorem non consectetur eius dolor quaerat."
            },
            {
                "_id": "E00014E",
                "name": "Alternative splicing of Human telomerase reverse transcriptase",
                "abreviations": [],
                "categoryId": "Others",
                "description": "Tempora quisquam consectetur adipisci quaerat etincidunt aliquam. Adipisci amet non labore porro ipsum non aliquam. Voluptatem est ipsum non sed. Labore adipisci labore dolor ipsum. Adipisci neque quaerat etincidunt quiquia."
            },
            {
                "_id": "E00014F",
                "name": "Osteopontin",
                "abreviations": [
                    "2702"
                ],
                "categoryId": "RNA",
                "description": "Adipisci voluptatem non sed modi. Quisquam porro voluptatem consectetur velit amet non. Adipisci aliquam etincidunt magnam numquam neque quiquia. Quaerat amet non sed numquam. Amet ipsum labore tempora labore tempora sit modi. Dolor quisquam velit adipisci. Dolor sed quaerat aliquam magnam eius. Non dolor voluptatem eius ipsum sit porro."
            },
            {
                "_id": "E000150",
                "name": "Neuron-glial antigen 2",
                "abreviations": [
                    "14EA",
                    "24FE",
                    "1E90",
                    "2C9"
                ],
                "categoryId": "Metabolite",
                "description": "Sed dolore adipisci amet modi. Ut sit voluptatem modi est. Quisquam est aliquam porro sed sed. Tempora etincidunt numquam neque. Velit ipsum quaerat dolore. Dolorem aliquam tempora neque ut. Tempora quiquia magnam sit modi ipsum consectetur velit. Etincidunt voluptatem velit etincidunt consectetur dolore sit numquam. Dolore eius voluptatem sit dolor."
            },
            {
                "_id": "E000151",
                "name": "Wilms' tumor gene product 1",
                "abreviations": [
                    "11F6",
                    "1B24",
                    "638",
                    "C3C",
                    "9BA"
                ],
                "categoryId": "RNA",
                "description": "Porro quisquam quiquia neque voluptatem ipsum. Modi adipisci quisquam modi. Adipisci quisquam aliquam aliquam eius labore. Aliquam porro sed sit labore. Labore sed ipsum quaerat ut aliquam etincidunt. Sed dolore ut dolorem dolorem modi quaerat amet. Neque consectetur aliquam consectetur. Ipsum dolore modi dolore sit. Modi tempora porro dolore magnam numquam. Ut voluptatem quisquam sit non labore voluptatem."
            },
            {
                "_id": "E000152",
                "name": "Notch-1",
                "abreviations": [
                    "3C0",
                    "DBD",
                    "FB8",
                    "E9D"
                ],
                "categoryId": "Others",
                "description": "Neque etincidunt etincidunt numquam. Est numquam consectetur voluptatem ipsum ipsum amet tempora. Est quaerat eius est modi. Aliquam modi ut quaerat. Voluptatem modi modi ut sed. Voluptatem labore non adipisci neque aliquam consectetur."
            },
            {
                "_id": "E000153",
                "name": "1p/19q LOH",
                "abreviations": [
                    "7CD",
                    "1386",
                    "E7C",
                    "FCD",
                    "F1A"
                ],
                "categoryId": "Other",
                "description": "Neque magnam non dolorem voluptatem. Tempora labore sed eius. Ut quaerat non dolorem est. Ut eius consectetur numquam sit numquam est. Amet etincidunt aliquam numquam numquam. Quaerat quaerat porro consectetur quiquia neque labore. Tempora dolorem tempora labore quaerat. Adipisci consectetur velit eius eius."
            },
            {
                "_id": "E000154",
                "name": "Musashi-1",
                "abreviations": [
                    "140D",
                    "2568",
                    "1FA8"
                ],
                "categoryId": "Lipid",
                "description": "Numquam dolore eius sit. Aliquam aliquam ut amet adipisci consectetur amet. Aliquam etincidunt sit sit ipsum ut sed. Quaerat amet dolor quisquam velit tempora consectetur adipisci. Velit quaerat est numquam neque quiquia modi. Dolore dolor tempora est quaerat quiquia dolore quisquam. Etincidunt modi quisquam amet dolore etincidunt quisquam ipsum. Modi ipsum ipsum numquam numquam modi eius amet."
            },
            {
                "_id": "E000155",
                "name": "miR-25",
                "abreviations": [
                    "2368"
                ],
                "categoryId": "Labelling index",
                "description": "Consectetur ut velit etincidunt etincidunt tempora labore. Est aliquam etincidunt quisquam labore magnam porro. Sed non ipsum voluptatem adipisci porro voluptatem quaerat. Porro adipisci dolor labore. Voluptatem adipisci labore velit eius magnam modi. Voluptatem quaerat modi amet ipsum neque. Non amet ut tempora dolorem eius modi neque. Consectetur eius ut non sed ut porro sit."
            },
            {
                "_id": "E000156",
                "name": "YAP1",
                "abreviations": [
                    "7D4",
                    "1A38",
                    "7E8",
                    "133D"
                ],
                "categoryId": "Cytokine",
                "description": "Non dolor tempora modi ut eius. Dolore dolore ut etincidunt voluptatem ipsum. Quiquia quaerat sed aliquam voluptatem sit quaerat. Tempora quiquia quaerat consectetur porro amet voluptatem. Amet dolore ut porro dolore eius. Voluptatem ipsum amet ut aliquam ut. Ipsum consectetur dolore modi consectetur eius. Dolorem quiquia porro quisquam. Ut adipisci sit magnam quiquia sit porro. Non quisquam sit etincidunt dolor."
            },
            {
                "_id": "E000157",
                "name": "Bcl-6 translocation",
                "abreviations": [
                    "ECA",
                    "899",
                    "26BD"
                ],
                "categoryId": "Stem cells",
                "description": "Ipsum adipisci tempora sed. Tempora voluptatem porro porro non ut. Porro labore porro modi quisquam. Velit magnam adipisci dolor tempora voluptatem magnam non. Non quisquam ipsum dolor dolorem. Porro non tempora est sit. Consectetur quisquam aliquam voluptatem. Neque numquam est quiquia dolorem est numquam."
            },
            {
                "_id": "E000158",
                "name": "PPARa",
                "abreviations": [
                    "3D5",
                    "E0A",
                    "1BF8",
                    "1C3D",
                    "3A9"
                ],
                "categoryId": "Other",
                "description": "Dolor ipsum ut sit porro. Neque adipisci modi sed dolorem voluptatem eius velit. Ipsum modi neque ut porro ut ipsum. Dolor labore sed dolorem magnam modi numquam. Etincidunt numquam modi quisquam non. Tempora voluptatem modi voluptatem dolor ut eius quaerat. Sit etincidunt tempora porro aliquam dolor. Labore non etincidunt sit."
            },
            {
                "_id": "E000159",
                "name": "Src",
                "abreviations": [],
                "categoryId": "DNA",
                "description": "Sed sed sit dolore dolore consectetur ipsum quiquia. Quaerat quisquam quisquam est non. Aliquam ut quisquam dolor voluptatem ut sit. Modi tempora est modi. Labore tempora porro ut est numquam voluptatem. Tempora voluptatem numquam velit. Numquam modi quisquam ipsum quisquam dolorem."
            },
            {
                "_id": "E00015A",
                "name": "CPEB4",
                "abreviations": [
                    "1D80",
                    "5A8",
                    "15C4"
                ],
                "categoryId": "DNA",
                "description": "Porro tempora quaerat eius voluptatem sit voluptatem tempora. Dolore magnam amet magnam ipsum magnam sit. Adipisci quaerat voluptatem est ipsum consectetur non modi. Labore sit est eius quisquam porro sit est. Numquam dolore quiquia neque. Consectetur numquam quiquia neque sit labore. Non sed dolorem dolorem dolore quiquia magnam. Numquam etincidunt dolore quaerat dolorem quaerat."
            },
            {
                "_id": "E00015B",
                "name": "HOXD4 expression",
                "abreviations": [
                    "1DED"
                ],
                "categoryId": "Enzyme",
                "description": "Quaerat labore sit magnam ut quisquam amet. Dolorem adipisci velit sit non sed dolor. Modi consectetur voluptatem etincidunt voluptatem porro non. Quaerat voluptatem non voluptatem. Ut quiquia est sit etincidunt labore."
            },
            {
                "_id": "E00015C",
                "name": "miR-129",
                "abreviations": [
                    "11D4"
                ],
                "categoryId": "Protein",
                "description": "Dolore adipisci adipisci voluptatem. Dolor neque ipsum adipisci dolor dolor. Est voluptatem aliquam dolorem. Eius aliquam quiquia ut est amet. Est neque quaerat sed porro. Est velit non velit non ipsum aliquam est."
            },
            {
                "_id": "E00015D",
                "name": "Hypoxia-inducible factor-1",
                "abreviations": [
                    "189B",
                    "C64",
                    "597",
                    "19C",
                    "1952"
                ],
                "categoryId": "Cytokine",
                "description": "Numquam non sit amet amet. Magnam dolor eius ipsum etincidunt ipsum adipisci amet. Adipisci modi dolor labore. Amet non voluptatem sit consectetur quisquam sit. Dolore est quiquia est aliquam. Sed magnam dolor etincidunt consectetur. Modi amet porro etincidunt consectetur. Adipisci non aliquam amet consectetur labore magnam. Voluptatem labore magnam sit quisquam."
            },
            {
                "_id": "E00015E",
                "name": "miR-320a",
                "abreviations": [],
                "categoryId": "Other",
                "description": "Labore est eius porro aliquam porro labore porro. Dolore neque magnam numquam labore tempora porro dolorem. Consectetur neque dolor ipsum eius. Numquam dolorem magnam consectetur magnam labore numquam quisquam. Modi sit sed velit eius. Labore non dolorem quiquia velit sit labore. Eius eius sed dolorem quiquia est."
            },
            {
                "_id": "E00015F",
                "name": "IL-13 receptor subunits \u03b11",
                "abreviations": [
                    "310",
                    "1683",
                    "102"
                ],
                "categoryId": "Labelling index",
                "description": "Magnam velit tempora ipsum numquam. Aliquam adipisci numquam etincidunt dolore adipisci magnam tempora. Sed aliquam porro porro quaerat ipsum est ut. Consectetur sed aliquam ut dolore. Adipisci adipisci magnam etincidunt amet sit. Sed magnam quaerat modi ut non amet eius."
            },
            {
                "_id": "E000160",
                "name": "Cathepsin S expression",
                "abreviations": [
                    "1F0"
                ],
                "categoryId": "Other",
                "description": "Quaerat sed modi voluptatem. Tempora amet ipsum non consectetur voluptatem neque. Sed dolore porro quiquia numquam quaerat. Consectetur sed quiquia quiquia aliquam. Dolore etincidunt voluptatem consectetur. Neque dolorem dolorem numquam voluptatem magnam amet."
            },
            {
                "_id": "E000161",
                "name": "RhoB",
                "abreviations": [
                    "1DB2",
                    "F96",
                    "605",
                    "F6D"
                ],
                "categoryId": "Cytokine",
                "description": "Ipsum dolore etincidunt non. Adipisci consectetur tempora etincidunt velit dolore sed labore. Amet est tempora magnam dolor sed ipsum aliquam. Neque consectetur dolore dolor aliquam quiquia est ipsum. Voluptatem non porro quisquam tempora dolore. Tempora neque velit consectetur dolore eius dolore non. Adipisci est etincidunt sed dolore eius."
            },
            {
                "_id": "E000162",
                "name": "RPL10A",
                "abreviations": [
                    "125B",
                    "25BD"
                ],
                "categoryId": "Other",
                "description": "Quiquia modi labore eius dolorem. Adipisci sit labore porro consectetur. Modi velit dolore neque ut etincidunt velit. Quaerat sit amet aliquam eius ipsum sed etincidunt. Tempora est dolor est consectetur eius dolorem quisquam. Sed quisquam voluptatem modi numquam."
            },
            {
                "_id": "E000163",
                "name": "Cathepsin D expression",
                "abreviations": [
                    "485"
                ],
                "categoryId": "Stem cells",
                "description": "Quiquia voluptatem etincidunt quaerat velit ut. Aliquam quisquam velit numquam modi est etincidunt. Sed etincidunt numquam quaerat aliquam dolor quiquia. Consectetur eius quisquam dolore magnam. Velit consectetur consectetur labore consectetur ipsum consectetur aliquam. Non quiquia numquam voluptatem eius porro porro ipsum. Voluptatem adipisci non quisquam. Tempora quaerat ipsum quisquam velit."
            },
            {
                "_id": "E000164",
                "name": "Beclin1",
                "abreviations": [
                    "1DC5",
                    "AD",
                    "4E9"
                ],
                "categoryId": "Other",
                "description": "Est velit non amet porro dolorem consectetur. Amet dolor ut etincidunt aliquam. Quaerat magnam est est labore tempora. Sed aliquam etincidunt consectetur magnam aliquam labore numquam. Velit quiquia est non. Quisquam labore sed ut quisquam. Numquam adipisci labore est eius modi aliquam. Sed adipisci modi dolore porro velit. Porro dolor ipsum quiquia magnam quisquam."
            },
            {
                "_id": "E000165",
                "name": "TP53",
                "abreviations": [],
                "categoryId": "DNA",
                "description": "Ut dolore dolor quaerat porro amet quiquia. Ipsum tempora ut quisquam labore dolorem eius quaerat. Quaerat aliquam dolorem modi velit porro amet non. Modi quisquam sed numquam quiquia. Non magnam tempora magnam ut. Ipsum dolorem labore labore. Ut etincidunt magnam ipsum labore amet ut. Aliquam ipsum ipsum quisquam quiquia etincidunt dolore ipsum. Porro quisquam adipisci dolorem numquam. Porro velit sed adipisci."
            },
            {
                "_id": "E000166",
                "name": "PART1",
                "abreviations": [],
                "categoryId": "Aminopeptidase",
                "description": "Labore labore dolorem magnam. Porro dolor numquam dolor sed est. Ut ut sed velit dolorem neque tempora. Modi velit magnam voluptatem eius. Sit quaerat amet modi voluptatem non amet dolorem. Quisquam neque dolorem aliquam ut ipsum. Voluptatem non modi dolore dolorem velit quiquia quaerat."
            },
            {
                "_id": "E000167",
                "name": "Cancer-testis antigen CTCFL",
                "abreviations": [
                    "1BED",
                    "8C3",
                    "8B0"
                ],
                "categoryId": "Enzyme",
                "description": "Modi dolor velit dolor magnam. Dolor eius eius etincidunt. Etincidunt dolore numquam eius voluptatem. Modi magnam sit quiquia ut. Quiquia ut dolorem etincidunt quaerat numquam etincidunt. Neque quiquia ipsum est numquam. Magnam porro velit modi dolore."
            },
            {
                "_id": "E000168",
                "name": "Subcellular localization of survivin",
                "abreviations": [
                    "3B4",
                    "9C3",
                    "145F"
                ],
                "categoryId": "Stem cells",
                "description": "Dolore voluptatem neque amet velit. Dolorem tempora dolor tempora etincidunt velit. Sed consectetur sed amet. Quaerat aliquam tempora tempora dolore neque ipsum. Non magnam quaerat voluptatem adipisci labore. Labore ipsum sit dolorem etincidunt tempora. Velit eius dolorem aliquam amet tempora voluptatem eius. Est neque quaerat voluptatem non amet tempora. Consectetur numquam labore est adipisci."
            },
            {
                "_id": "E000169",
                "name": "Tumor-associated glycoprotein-72",
                "abreviations": [
                    "9FF"
                ],
                "categoryId": "Enzyme",
                "description": "Ipsum porro quiquia numquam etincidunt tempora neque. Etincidunt porro dolorem sed tempora ipsum adipisci. Quisquam consectetur labore tempora eius. Dolorem sed magnam aliquam dolore adipisci. Adipisci modi magnam sed."
            },
            {
                "_id": "E00016A",
                "name": "gp78 mRNA expression",
                "abreviations": [
                    "1444",
                    "16FF"
                ],
                "categoryId": "Labelling index",
                "description": "Ut ipsum dolor modi modi adipisci quisquam numquam. Ut non velit quiquia eius. Dolor labore etincidunt dolore aliquam modi dolorem dolore. Dolore aliquam amet numquam sed quaerat. Etincidunt labore velit amet dolor dolor etincidunt. Magnam eius quiquia adipisci est voluptatem. Labore quaerat amet est. Numquam aliquam dolor modi adipisci. Dolorem aliquam quaerat etincidunt."
            },
            {
                "_id": "E00016B",
                "name": "hsa-let-7a-5p",
                "abreviations": [
                    "1211"
                ],
                "categoryId": "Others",
                "description": "Tempora tempora velit eius. Voluptatem sed labore neque modi. Aliquam numquam voluptatem sed etincidunt sed ut sit. Neque dolor tempora labore numquam amet labore porro. Dolorem neque porro porro quiquia quisquam. Non est dolorem ipsum. Dolorem quaerat velit quisquam numquam. Porro ut modi aliquam."
            },
            {
                "_id": "E00016C",
                "name": "ALCAM",
                "abreviations": [
                    "880",
                    "54C",
                    "2065",
                    "1232",
                    "30D"
                ],
                "categoryId": "Protein",
                "description": "Eius dolore etincidunt quaerat. Etincidunt neque amet velit magnam. Est ut etincidunt eius labore quisquam amet velit. Quaerat est sit eius. Dolor labore ipsum sed. Magnam numquam modi quaerat magnam eius sed neque. Voluptatem magnam dolore dolor etincidunt. Ipsum etincidunt est consectetur quiquia non quaerat. Magnam est ipsum consectetur est consectetur labore."
            },
            {
                "_id": "E00016D",
                "name": "DNA topoisomerase Ki-67",
                "abreviations": [
                    "188D",
                    "D5C",
                    "230B"
                ],
                "categoryId": "Lipid",
                "description": "Aliquam ipsum etincidunt sit sed porro eius voluptatem. Consectetur ut consectetur sit numquam. Consectetur sit porro eius magnam. Consectetur sed dolor porro est. Magnam dolorem sed quiquia numquam dolore aliquam. Velit tempora labore porro sit labore quisquam ipsum. Dolor ut aliquam magnam. Quiquia eius adipisci est aliquam dolor. Ipsum quaerat quisquam sit dolorem."
            },
            {
                "_id": "E00016E",
                "name": "Endothelin B receptor",
                "abreviations": [],
                "categoryId": "Metabolite",
                "description": "Quiquia quiquia labore ipsum sed consectetur dolore. Voluptatem numquam modi dolore labore dolore consectetur non. Aliquam eius modi ut. Dolor tempora neque dolor modi non modi voluptatem. Quisquam labore est aliquam."
            },
            {
                "_id": "E00016F",
                "name": "Fos-Related Antigen 1 expression",
                "abreviations": [
                    "13BA",
                    "1E3A",
                    "2682"
                ],
                "categoryId": "Other",
                "description": "Porro sit modi quisquam non quiquia labore. Adipisci etincidunt neque non tempora amet voluptatem. Sit modi eius non dolore modi numquam ut. Sit sed ipsum adipisci quaerat dolore. Consectetur magnam quaerat tempora consectetur sit. Adipisci quisquam aliquam adipisci quiquia sed. Aliquam dolor tempora consectetur tempora ipsum tempora dolorem."
            },
            {
                "_id": "E000170",
                "name": "Aurora B expression",
                "abreviations": [
                    "26C5",
                    "1C63",
                    "1051"
                ],
                "categoryId": "Aminopeptidase",
                "description": "Etincidunt quiquia ut neque ipsum ut adipisci. Labore quiquia consectetur etincidunt magnam porro consectetur amet. Amet eius voluptatem sit adipisci. Etincidunt modi neque dolorem. Labore aliquam numquam sed porro magnam amet. Velit dolorem sit dolore. Est neque velit labore quiquia quisquam. Porro sed aliquam quaerat porro quaerat porro consectetur. Ut non consectetur labore ut."
            },
            {
                "_id": "E000171",
                "name": "O6-methylguanine-DNA methyltransferase silencing",
                "abreviations": [
                    "97",
                    "1D35",
                    "1B08",
                    "2103",
                    "332"
                ],
                "categoryId": "Protein",
                "description": "Dolorem labore amet tempora quisquam sed. Non dolorem adipisci ut voluptatem. Dolorem voluptatem dolorem ipsum. Amet dolorem numquam aliquam ut adipisci velit. Aliquam ut porro sed. Dolore sit dolore magnam est etincidunt. Aliquam quaerat ipsum dolorem neque. Consectetur porro dolorem est aliquam ipsum amet."
            },
            {
                "_id": "E000172",
                "name": "Oncogenic microRNA-20a",
                "abreviations": [
                    "1EE2",
                    "FC",
                    "BC",
                    "1DF8",
                    "B11"
                ],
                "categoryId": "Aminopeptidase",
                "description": "Neque quaerat voluptatem ipsum dolor. Consectetur neque ipsum aliquam. Ut eius est consectetur. Modi quisquam porro adipisci dolorem modi neque. Sit quiquia dolorem eius amet quaerat. Tempora non consectetur etincidunt dolorem labore sit."
            },
            {
                "_id": "E000173",
                "name": "O6-methylguanine DNA methyltransferase promoter methylation",
                "abreviations": [
                    "199F",
                    "2599"
                ],
                "categoryId": "Aminopeptidase",
                "description": "Dolore aliquam etincidunt adipisci magnam dolore velit sit. Labore voluptatem modi quisquam magnam tempora adipisci. Labore neque adipisci amet. Velit sed quaerat tempora etincidunt. Non voluptatem dolor quiquia. Neque amet est dolore neque magnam quaerat dolore."
            },
            {
                "_id": "E000174",
                "name": "Sec61 gamma",
                "abreviations": [
                    "CAB"
                ],
                "categoryId": "Metabolite",
                "description": "Numquam est dolorem voluptatem etincidunt ut. Dolore porro etincidunt neque. Etincidunt porro dolor amet non aliquam. Dolorem aliquam dolorem tempora modi velit magnam. Dolorem porro est sed neque amet sed velit. Dolor sit aliquam sed voluptatem. Dolor consectetur numquam adipisci eius porro adipisci. Dolore ipsum ut dolore dolore magnam. Sed ut eius neque modi modi. Neque eius quiquia aliquam dolorem modi."
            },
            {
                "_id": "E000175",
                "name": "TEM1/endosialin",
                "abreviations": [
                    "26A2",
                    "D24",
                    "23E3",
                    "663",
                    "24F4"
                ],
                "categoryId": "Metabolite",
                "description": "Neque voluptatem est magnam. Est sed dolore consectetur etincidunt tempora quisquam. Adipisci dolorem amet modi eius dolore porro tempora. Dolorem dolore modi dolore est ut amet. Non est magnam labore neque. Sed neque magnam consectetur sed porro. Modi etincidunt non ipsum. Consectetur eius modi aliquam tempora."
            },
            {
                "_id": "E000176",
                "name": "CD44 antigen",
                "abreviations": [
                    "1064",
                    "9B9",
                    "F56",
                    "16C4",
                    "14BE"
                ],
                "categoryId": "Protein",
                "description": "Non sit dolore consectetur ipsum labore. Quaerat sed magnam tempora ut sit dolore modi. Dolore eius amet eius. Sit voluptatem magnam ipsum quisquam. Ipsum tempora numquam labore consectetur. Ut modi quiquia eius ut dolorem voluptatem magnam. Velit velit non ut voluptatem non dolorem. Tempora adipisci aliquam aliquam quiquia consectetur porro magnam. Quisquam quiquia dolorem etincidunt quaerat quiquia quisquam."
            },
            {
                "_id": "E000177",
                "name": "Synaptophysin",
                "abreviations": [],
                "categoryId": "Stem cells",
                "description": "Velit ut modi neque sit. Ut ut eius quiquia velit aliquam voluptatem porro. Ut neque sed adipisci quiquia velit quisquam dolore. Labore magnam adipisci voluptatem dolorem. Etincidunt labore quiquia magnam. Ipsum dolore porro quaerat dolore adipisci tempora non. Dolorem velit aliquam dolor velit etincidunt."
            },
            {
                "_id": "E000178",
                "name": "Rho-kinase pathway gene LIMK1 expression",
                "abreviations": [
                    "1B6C",
                    "123F",
                    "8CA",
                    "7E6"
                ],
                "categoryId": "Labelling index",
                "description": "Velit sit magnam numquam adipisci quaerat consectetur. Consectetur quisquam sit dolorem sit labore quaerat. Velit etincidunt aliquam dolorem quisquam tempora eius neque. Porro voluptatem velit ipsum etincidunt voluptatem voluptatem neque. Etincidunt consectetur eius dolore. Dolorem dolore ipsum consectetur."
            },
            {
                "_id": "E000179",
                "name": "Serpin peptidase inhibitor clade A member 3",
                "abreviations": [
                    "177",
                    "2155",
                    "1AE3"
                ],
                "categoryId": "Aminopeptidase",
                "description": "Numquam adipisci dolore etincidunt adipisci. Quaerat sed ut neque aliquam etincidunt. Dolor sit sed sit eius porro velit. Quiquia tempora ut amet ipsum. Adipisci sit magnam aliquam quaerat velit est. Est sit sit sed quaerat sit est. Ut ut dolore dolor."
            },
            {
                "_id": "E00017A",
                "name": "EGFRvIII",
                "abreviations": [
                    "1D63",
                    "1764",
                    "92"
                ],
                "categoryId": "RNA",
                "description": "Ipsum amet est porro modi neque sed labore. Ut quiquia voluptatem numquam voluptatem quiquia. Numquam ipsum dolorem ipsum dolorem quiquia est quiquia. Etincidunt consectetur aliquam porro. Ipsum quisquam consectetur consectetur sed. Non quisquam etincidunt adipisci numquam porro porro. Dolorem ipsum labore dolorem. Quiquia quisquam voluptatem numquam neque ipsum etincidunt adipisci. Est ut consectetur non."
            },
            {
                "_id": "E00017B",
                "name": "p53",
                "abreviations": [
                    "AE",
                    "A95",
                    "53F",
                    "85E",
                    "3AA"
                ],
                "categoryId": "Metabolite",
                "description": "Neque ipsum porro est amet eius. Quaerat numquam adipisci adipisci sit. Modi etincidunt est dolor eius velit tempora. Velit modi adipisci eius quiquia numquam sed. Voluptatem quaerat labore quiquia. Modi numquam sit adipisci consectetur non sit. Porro aliquam adipisci velit aliquam sit. Magnam modi tempora non magnam."
            },
            {
                "_id": "E00017C",
                "name": "hsa-miR-615-5p",
                "abreviations": [
                    "26A0",
                    "2454",
                    "193E",
                    "809",
                    "1755"
                ],
                "categoryId": "Enzyme",
                "description": "Non ipsum quaerat non numquam est. Tempora sed voluptatem dolore magnam etincidunt aliquam dolorem. Neque velit aliquam amet sed dolor est amet. Est est porro neque neque tempora. Dolor quaerat magnam neque. Neque velit dolorem voluptatem tempora quiquia dolor."
            },
            {
                "_id": "E00017D",
                "name": "miR-21 expression",
                "abreviations": [
                    "B5F",
                    "1B39",
                    "117F"
                ],
                "categoryId": "Metabolite",
                "description": "Non non voluptatem quiquia sit ut dolor. Dolore dolor consectetur est quisquam neque ut magnam. Porro ipsum neque ipsum porro sit quaerat. Etincidunt adipisci velit dolor magnam tempora labore. Adipisci labore labore modi modi labore. Amet ipsum tempora dolore adipisci dolor. Eius quisquam porro magnam. Magnam aliquam aliquam quisquam tempora amet numquam dolorem. Dolor quaerat numquam magnam. Dolorem aliquam eius magnam modi."
            },
            {
                "_id": "E00017E",
                "name": "FSTL1",
                "abreviations": [
                    "1262"
                ],
                "categoryId": "RNA",
                "description": "Sed quaerat dolorem amet. Dolore voluptatem ut sed. Ipsum est neque sit amet porro adipisci. Non ipsum modi dolor labore. Non magnam neque neque. Ut labore modi etincidunt numquam velit velit. Velit consectetur adipisci amet tempora."
            },
            {
                "_id": "E00017F",
                "name": "TNFR-associated factor 1",
                "abreviations": [
                    "17B3"
                ],
                "categoryId": "DNA",
                "description": "Numquam non adipisci numquam ut etincidunt eius amet. Est neque aliquam voluptatem labore. Ipsum sed sed quaerat. Voluptatem modi dolor numquam eius quisquam porro quisquam. Quisquam amet dolore quisquam labore labore neque numquam. Voluptatem dolore ut porro aliquam dolore ut est. Neque labore ut magnam ut magnam numquam est."
            },
            {
                "_id": "E000180",
                "name": "Jagged 1 expression",
                "abreviations": [],
                "categoryId": "Stem cells",
                "description": "Sed porro etincidunt magnam aliquam aliquam voluptatem. Magnam sed consectetur porro dolor labore ut labore. Sit consectetur amet etincidunt magnam ipsum. Consectetur ipsum tempora quisquam sed non. Est consectetur eius sit aliquam sed numquam aliquam. Non adipisci modi dolore adipisci. Dolor dolor neque ipsum. Quiquia voluptatem voluptatem modi consectetur quaerat. Amet sed modi labore sit. Etincidunt voluptatem labore porro ut voluptatem dolor."
            },
            {
                "_id": "E000181",
                "name": "Human leukocyte antigen variants",
                "abreviations": [
                    "37C",
                    "1A9C",
                    "87E",
                    "F02"
                ],
                "categoryId": "Other",
                "description": "Ut ipsum quisquam modi. Consectetur sed est ut quaerat voluptatem. Neque quaerat dolorem consectetur. Dolor eius est modi sed tempora. Adipisci velit eius numquam est est tempora voluptatem. Sed voluptatem neque eius. Amet adipisci magnam velit tempora sit. Velit amet sed quisquam dolorem."
            },
            {
                "_id": "E000182",
                "name": "HLA-E",
                "abreviations": [
                    "10FE",
                    "7A1"
                ],
                "categoryId": "Other",
                "description": "Amet neque numquam quiquia. Est est est aliquam. Dolore dolorem quiquia consectetur dolor. Aliquam numquam quisquam quisquam quaerat voluptatem. Etincidunt eius dolore neque. Tempora magnam modi tempora magnam amet magnam amet. Magnam quiquia tempora velit consectetur eius quiquia sed. Dolore eius dolor neque eius."
            },
            {
                "_id": "E000183",
                "name": "Class 6 semaphorin",
                "abreviations": [
                    "A8D"
                ],
                "categoryId": "Others",
                "description": "Consectetur adipisci tempora aliquam quiquia amet. Porro porro modi sit amet tempora labore non. Dolor dolore adipisci est ut dolorem dolore labore. Quaerat quisquam eius magnam dolor numquam. Amet labore sed consectetur. Quaerat sed numquam quaerat. Est porro sed amet. Consectetur velit quiquia dolore dolorem tempora sit consectetur. Quaerat ut consectetur dolorem amet neque consectetur aliquam. Dolore dolor eius neque quaerat adipisci aliquam dolorem."
            },
            {
                "_id": "E000184",
                "name": "Zinc-finger and hemeoboxes 1",
                "abreviations": [
                    "246D",
                    "1EA"
                ],
                "categoryId": "RNA",
                "description": "Dolore consectetur eius etincidunt adipisci non velit eius. Eius aliquam modi amet dolor ut. Sed adipisci magnam ipsum adipisci tempora voluptatem quaerat. Dolor velit ut consectetur. Quaerat dolore labore quaerat quisquam velit amet."
            },
            {
                "_id": "E000185",
                "name": "GPR1",
                "abreviations": [
                    "E87"
                ],
                "categoryId": "Metabolite",
                "description": "Magnam etincidunt neque sit ipsum aliquam numquam neque. Consectetur quisquam non velit eius. Sit tempora dolorem sed sit neque. Tempora modi ut labore labore amet ipsum quaerat. Etincidunt porro amet quiquia dolorem."
            },
            {
                "_id": "E000186",
                "name": "Dipeptidyl-peptidase III",
                "abreviations": [
                    "25E4"
                ],
                "categoryId": "Cytokine",
                "description": "Etincidunt voluptatem numquam ut amet adipisci. Sed ut ut aliquam ut. Aliquam neque non consectetur sit porro sit. Consectetur amet modi est dolor velit dolore voluptatem. Labore aliquam ipsum quiquia eius magnam amet."
            },
            {
                "_id": "E000187",
                "name": "GAS5",
                "abreviations": [
                    "1713",
                    "942",
                    "260D",
                    "E3D",
                    "2432"
                ],
                "categoryId": "Protein",
                "description": "Quaerat amet sed quiquia magnam. Eius amet labore labore ipsum consectetur numquam non. Consectetur quaerat tempora tempora numquam quisquam adipisci. Dolore dolore quiquia sit. Numquam dolore neque voluptatem amet quaerat. Velit eius dolor quisquam velit. Amet dolore voluptatem dolor."
            },
            {
                "_id": "E000188",
                "name": "GAB2",
                "abreviations": [
                    "11C6",
                    "2C0",
                    "430",
                    "192D",
                    "19C2"
                ],
                "categoryId": "Lipid",
                "description": "Ipsum tempora voluptatem adipisci. Non est porro ipsum. Est quaerat non velit etincidunt modi ut. Quiquia sit quiquia eius. Labore ipsum velit dolorem ipsum velit adipisci non."
            },
            {
                "_id": "E000189",
                "name": "IDH mutation",
                "abreviations": [
                    "DC5"
                ],
                "categoryId": "Other",
                "description": "Tempora velit porro quisquam sit labore. Aliquam modi modi amet. Dolore ut dolore dolorem quiquia quaerat. Adipisci dolore amet eius quiquia. Voluptatem neque sit porro. Amet consectetur porro modi eius dolorem ut ipsum. Porro aliquam adipisci etincidunt. Sit dolorem non etincidunt quaerat voluptatem non. Amet magnam sed non tempora quaerat."
            },
            {
                "_id": "E00018A",
                "name": "CD133",
                "abreviations": [
                    "D95",
                    "1C5C"
                ],
                "categoryId": "RNA",
                "description": "Est eius consectetur est sed quiquia porro numquam. Sed magnam aliquam dolor dolor neque velit non. Etincidunt adipisci magnam labore numquam. Eius quiquia sed aliquam quiquia ut dolore. Neque non etincidunt dolorem ipsum etincidunt sit dolorem."
            },
            {
                "_id": "E00018B",
                "name": "Aquaporin8",
                "abreviations": [],
                "categoryId": "Enzyme",
                "description": "Ut tempora porro adipisci dolore. Voluptatem sed numquam tempora neque non. Modi amet neque labore quisquam dolor. Adipisci consectetur tempora non. Quaerat eius dolorem quiquia. Quiquia labore quisquam etincidunt eius non neque numquam. Ut aliquam tempora tempora amet ipsum dolor quiquia. Ut etincidunt quiquia porro voluptatem dolore numquam eius. Quiquia modi ut sit ipsum non."
            },
            {
                "_id": "E00018C",
                "name": "Galactose\u2010binding protein galectin\u20103",
                "abreviations": [
                    "BA1",
                    "1E3A",
                    "51F",
                    "252F",
                    "1C51"
                ],
                "categoryId": "DNA",
                "description": "Non ipsum modi ipsum modi magnam amet adipisci. Eius voluptatem amet dolore. Aliquam dolor sed sed. Dolor sit ut numquam ipsum eius dolorem non. Aliquam consectetur sed consectetur sit est dolorem. Numquam aliquam voluptatem eius quaerat voluptatem aliquam. Consectetur quiquia labore neque consectetur non. Porro velit eius velit aliquam labore quiquia."
            },
            {
                "_id": "E00018D",
                "name": "Kinesin-5 expression",
                "abreviations": [
                    "882",
                    "C04",
                    "137B",
                    "1ADB",
                    "A50"
                ],
                "categoryId": "Protein",
                "description": "Sed adipisci non ipsum. Neque quiquia quiquia sit non quiquia quaerat. Consectetur dolor non quaerat aliquam. Ut quaerat quisquam etincidunt. Magnam amet amet numquam. Dolor numquam quaerat labore consectetur."
            },
            {
                "_id": "E00018E",
                "name": "Neuronatin expression",
                "abreviations": [],
                "categoryId": "Stem cells",
                "description": "Dolorem dolorem modi voluptatem eius sed. Dolorem labore ut ut sed neque porro sit. Porro non modi non quiquia. Eius amet dolor sit dolor consectetur. Numquam est ipsum velit quisquam neque etincidunt."
            },
            {
                "_id": "E00018F",
                "name": "Interleukin-6 expression",
                "abreviations": [
                    "26BF"
                ],
                "categoryId": "Labelling index",
                "description": "Ipsum tempora labore eius numquam consectetur. Dolor voluptatem sit est numquam sit. Numquam eius velit dolore sit voluptatem dolor. Dolorem etincidunt velit numquam aliquam. Quiquia est labore ut magnam voluptatem ut ut. Adipisci etincidunt dolorem porro dolorem. Consectetur dolore etincidunt magnam eius. Porro labore consectetur non etincidunt quaerat magnam ut. Dolor est dolorem sed amet quaerat."
            },
            {
                "_id": "E000190",
                "name": "GADD45\ud835\udec2",
                "abreviations": [
                    "105C"
                ],
                "categoryId": "DNA",
                "description": "Adipisci sed ipsum ut velit adipisci porro sit. Sit quiquia quisquam adipisci. Quaerat porro consectetur ipsum. Non eius etincidunt est. Modi adipisci dolore voluptatem dolore numquam est sed. Aliquam porro consectetur quisquam numquam sed quaerat. Porro dolore non labore voluptatem. Neque quaerat sit ipsum tempora. Velit magnam amet dolore porro dolore aliquam. Voluptatem sit amet est."
            },
            {
                "_id": "E000191",
                "name": "Ki-67",
                "abreviations": [
                    "1025",
                    "1166",
                    "145C",
                    "228B"
                ],
                "categoryId": "Enzyme",
                "description": "Quiquia voluptatem eius dolorem. Modi etincidunt quaerat dolorem dolor dolore dolorem tempora. Est amet ipsum voluptatem consectetur etincidunt dolore. Dolor est quiquia porro aliquam. Sed aliquam adipisci ut dolorem porro."
            },
            {
                "_id": "E000192",
                "name": "miR-432*",
                "abreviations": [
                    "1411",
                    "231B",
                    "2430"
                ],
                "categoryId": "Others",
                "description": "Aliquam labore est consectetur est consectetur. Est dolore modi neque sed adipisci aliquam etincidunt. Est etincidunt porro dolorem quiquia dolore sit. Sed quiquia dolore voluptatem neque dolore. Non sed est modi dolorem velit non amet. Sit amet voluptatem labore non ut dolore neque. Velit quisquam porro consectetur amet."
            },
            {
                "_id": "E000193",
                "name": "Bisecting GlcNAc",
                "abreviations": [
                    "DCA",
                    "1637",
                    "BA9",
                    "1D35",
                    "D9A"
                ],
                "categoryId": "Enzyme",
                "description": "Modi aliquam eius quaerat non neque ut consectetur. Neque aliquam eius adipisci labore non. Amet modi neque magnam modi. Quisquam tempora ipsum velit numquam. Numquam dolor modi sit. Sit eius amet voluptatem porro ut."
            },
            {
                "_id": "E000194",
                "name": "RANBP17",
                "abreviations": [],
                "categoryId": "DNA",
                "description": "Sit voluptatem dolorem modi porro sit neque eius. Aliquam labore quisquam numquam porro porro voluptatem. Est velit eius ut modi eius sed sed. Dolore tempora magnam amet etincidunt sit magnam velit. Consectetur ipsum quiquia sed. Modi etincidunt modi sed sit quiquia modi. Numquam est porro dolore velit consectetur. Quisquam sit non neque."
            },
            {
                "_id": "E000195",
                "name": "YKL-40",
                "abreviations": [
                    "146B"
                ],
                "categoryId": "Others",
                "description": "Etincidunt voluptatem dolore etincidunt labore adipisci. Quaerat numquam dolor est ipsum amet consectetur. Non porro est velit labore voluptatem etincidunt dolor. Non dolor quisquam sit quaerat dolore quaerat. Labore aliquam velit quaerat neque dolore velit."
            },
            {
                "_id": "E000196",
                "name": "Toll-like receptor 9 expression",
                "abreviations": [
                    "18E5",
                    "157D",
                    "10B5",
                    "1BF6"
                ],
                "categoryId": "Other",
                "description": "Modi dolor sit dolor dolore voluptatem. Magnam adipisci amet est dolorem non adipisci dolor. Quaerat est quaerat sit. Numquam ut amet est quaerat voluptatem porro. Ut quaerat voluptatem dolorem ut. Labore consectetur dolor est sed amet. Etincidunt ipsum quiquia sed porro. Ut consectetur neque dolore magnam consectetur."
            },
            {
                "_id": "E000197",
                "name": "GD1b",
                "abreviations": [
                    "8A2",
                    "1FE0",
                    "172B",
                    "247D",
                    "2511"
                ],
                "categoryId": "Aminopeptidase",
                "description": "Modi magnam porro dolore dolorem aliquam. Sed dolor aliquam modi non quaerat. Voluptatem numquam neque numquam. Porro amet eius quaerat quaerat est. Ut ipsum etincidunt ipsum dolorem. Voluptatem voluptatem consectetur non quiquia. Etincidunt non quisquam sed sit quaerat eius. Amet adipisci quiquia modi amet."
            },
            {
                "_id": "E000198",
                "name": "GFA",
                "abreviations": [
                    "1C0B",
                    "1BF",
                    "16DB"
                ],
                "categoryId": "Lipid",
                "description": "Sit quaerat porro numquam dolore. Etincidunt velit sit ipsum etincidunt dolorem consectetur quisquam. Numquam aliquam consectetur quaerat dolor amet tempora. Ipsum velit ipsum quiquia amet. Quaerat quiquia sit numquam dolorem eius sit. Consectetur neque dolore magnam velit non etincidunt. Aliquam eius dolorem velit velit. Neque labore tempora consectetur. Labore sit magnam sed dolor. Porro porro dolorem eius."
            },
            {
                "_id": "E000199",
                "name": "Genetic losses from chromosomes 1p",
                "abreviations": [
                    "1BF4",
                    "5E3",
                    "7B9"
                ],
                "categoryId": "Labelling index",
                "description": "Eius etincidunt quisquam sed etincidunt porro tempora velit. Etincidunt dolore velit aliquam etincidunt quisquam velit quisquam. Dolor magnam adipisci quisquam sit ut. Consectetur magnam etincidunt aliquam labore quaerat. Aliquam dolorem magnam neque porro ipsum adipisci. Tempora velit dolor labore non consectetur."
            },
            {
                "_id": "E00019A",
                "name": "MMP9",
                "abreviations": [
                    "637",
                    "189",
                    "1CF9",
                    "1B20"
                ],
                "categoryId": "RNA",
                "description": "Est sed dolor ipsum ut numquam. Etincidunt labore consectetur velit modi sed. Tempora quisquam sed tempora consectetur dolorem quisquam neque. Quisquam eius adipisci eius sit velit voluptatem. Amet eius aliquam consectetur adipisci adipisci."
            },
            {
                "_id": "E00019B",
                "name": "miRNA-181b/c",
                "abreviations": [
                    "11F4",
                    "24B1",
                    "1B1E",
                    "6C",
                    "261C"
                ],
                "categoryId": "Lipid",
                "description": "Velit dolorem adipisci consectetur. Magnam ut eius eius quiquia labore porro dolorem. Sit quiquia sit dolor labore labore sit. Amet porro voluptatem neque adipisci labore etincidunt eius. Neque est adipisci dolorem voluptatem porro tempora non. Quisquam labore etincidunt voluptatem aliquam sit amet tempora. Quaerat etincidunt quiquia dolor consectetur labore etincidunt. Voluptatem eius sit est consectetur quisquam."
            },
            {
                "_id": "E00019C",
                "name": "TERT mutations",
                "abreviations": [],
                "categoryId": "Aminopeptidase",
                "description": "Voluptatem etincidunt ut quiquia modi quaerat sit. Dolor aliquam dolorem sed eius voluptatem ut voluptatem. Ipsum consectetur ipsum aliquam quaerat quaerat velit adipisci. Velit non tempora etincidunt voluptatem adipisci quisquam quisquam. Amet velit labore porro dolor dolorem sed porro."
            },
            {
                "_id": "E00019D",
                "name": "MS4A6A",
                "abreviations": [
                    "203E",
                    "26CD",
                    "13D3",
                    "1453"
                ],
                "categoryId": "Others",
                "description": "Modi ipsum ut porro ut tempora magnam neque. Ut labore numquam aliquam modi quaerat. Est neque dolor tempora quisquam amet. Non est aliquam est. Neque non voluptatem est sed consectetur dolor. Velit eius etincidunt neque adipisci."
            },
            {
                "_id": "E00019E",
                "name": "miR\u2010181d, miR\u2010518b, miR\u2010524\u20105p, miR\u2010566, and miR\u20101227",
                "abreviations": [
                    "1FDC",
                    "24D9",
                    "6E4"
                ],
                "categoryId": "Stem cells",
                "description": "Non modi etincidunt voluptatem adipisci modi. Quaerat modi aliquam dolor. Porro quaerat adipisci magnam consectetur. Eius tempora non ipsum eius. Aliquam porro ut aliquam neque. Neque eius est non numquam. Ipsum numquam eius ipsum. Modi sed ut dolore quiquia aliquam. Quisquam tempora voluptatem dolor porro. Est labore eius amet velit aliquam dolore."
            },
            {
                "_id": "E00019F",
                "name": "EGFR amplification/expression, p53 immunoreactivity",
                "abreviations": [
                    "1A07",
                    "6DF",
                    "1CEB"
                ],
                "categoryId": "Protein",
                "description": "Etincidunt dolore etincidunt neque amet aliquam sit quiquia. Sit eius tempora ut quaerat quaerat velit. Aliquam aliquam neque amet consectetur magnam. Quisquam sit consectetur voluptatem non ut. Sed ut dolorem sed dolor. Dolore est aliquam neque ipsum dolore. Dolor est labore magnam modi. Quisquam quiquia dolor sit est consectetur."
            },
            {
                "_id": "E0001A0",
                "name": "Aspartate-\u03b2-hydroxylase",
                "abreviations": [],
                "categoryId": "Aminopeptidase",
                "description": "Non ipsum adipisci velit porro sed dolor adipisci. Tempora velit ut labore. Sed labore sed velit dolorem voluptatem. Neque quaerat adipisci quiquia tempora modi ut. Est numquam porro dolore etincidunt sit dolorem. Consectetur magnam tempora quaerat. Voluptatem dolore magnam dolorem ipsum. Etincidunt aliquam quiquia dolorem ipsum porro labore etincidunt. Voluptatem labore tempora porro numquam aliquam."
            },
            {
                "_id": "E0001A1",
                "name": "hsa-miR-938",
                "abreviations": [
                    "1F23",
                    "139"
                ],
                "categoryId": "Stem cells",
                "description": "Etincidunt aliquam modi velit dolore labore non. Sit adipisci voluptatem neque. Est sed dolorem sed adipisci eius adipisci ipsum. Velit modi velit quaerat velit. Voluptatem sed numquam modi. Dolore aliquam quaerat dolorem sit. Ipsum dolor labore ut numquam. Etincidunt quisquam etincidunt etincidunt tempora tempora. Est neque quaerat dolore neque modi magnam."
            },
            {
                "_id": "E0001A2",
                "name": "Three miRNA signature",
                "abreviations": [
                    "B83",
                    "B08",
                    "FC"
                ],
                "categoryId": "Cytokine",
                "description": "Amet quisquam numquam sed neque aliquam eius. Porro eius sit quaerat amet. Porro ut amet consectetur. Magnam labore magnam porro. Amet labore ipsum sed quaerat. Quiquia aliquam magnam aliquam dolore ipsum. Dolorem est velit eius voluptatem velit etincidunt. Neque neque quisquam modi."
            },
            {
                "_id": "E0001A3",
                "name": "GT1b",
                "abreviations": [
                    "26C3"
                ],
                "categoryId": "Aminopeptidase",
                "description": "Quiquia dolor quiquia voluptatem. Est ipsum adipisci ut. Sed ipsum neque modi. Non non dolor non consectetur ipsum. Dolor sed magnam etincidunt dolor dolore dolore sit. Eius adipisci ipsum ipsum etincidunt quiquia neque. Ipsum ut eius numquam dolore magnam. Magnam dolorem labore eius. Quaerat aliquam neque velit velit. Sed quaerat non numquam non tempora dolor tempora."
            },
            {
                "_id": "E0001A4",
                "name": "Aurora-B kinase",
                "abreviations": [
                    "11AD",
                    "1028",
                    "40E",
                    "171",
                    "2093"
                ],
                "categoryId": "Cytokine",
                "description": "Dolorem modi aliquam eius. Velit dolor aliquam quisquam. Neque sit amet adipisci modi. Ipsum labore adipisci quiquia voluptatem. Amet porro dolorem dolore sed non quisquam numquam. Quisquam adipisci voluptatem etincidunt magnam voluptatem."
            },
            {
                "_id": "E0001A5",
                "name": "miR-9",
                "abreviations": [
                    "502",
                    "7E9",
                    "25A8",
                    "7A",
                    "117E"
                ],
                "categoryId": "Aminopeptidase",
                "description": "Quisquam consectetur neque amet velit eius. Sed dolor sed eius porro quisquam dolorem. Ipsum adipisci est magnam aliquam ut tempora. Aliquam dolore voluptatem velit adipisci numquam voluptatem. Quaerat dolorem modi porro etincidunt porro. Porro voluptatem dolore non dolor ipsum. Ipsum adipisci consectetur quaerat quiquia. Quiquia eius dolor etincidunt quisquam. Labore consectetur sed quiquia. Voluptatem est non sed adipisci adipisci."
            },
            {
                "_id": "E0001A6",
                "name": "PRPS1",
                "abreviations": [
                    "339",
                    "2662",
                    "130C"
                ],
                "categoryId": "Labelling index",
                "description": "Voluptatem adipisci numquam quiquia velit dolorem aliquam neque. Consectetur sit magnam porro magnam quaerat adipisci. Dolore modi dolor ipsum. Sed neque ipsum eius adipisci dolore. Labore dolorem tempora adipisci sed dolorem quiquia neque. Quisquam magnam modi eius sed. Quisquam neque est ipsum sit quaerat tempora."
            },
            {
                "_id": "E0001A7",
                "name": "hsa-miR-524-5p",
                "abreviations": [
                    "22F0",
                    "A4B",
                    "1E8E",
                    "13B4",
                    "187B"
                ],
                "categoryId": "Others",
                "description": "Voluptatem velit aliquam ipsum numquam. Adipisci amet est ut quaerat sed neque. Ut quisquam labore ipsum ipsum eius. Numquam quiquia eius quiquia ut non dolore. Magnam dolore quisquam quisquam ut. Dolorem amet neque consectetur labore aliquam consectetur magnam. Dolorem quiquia quaerat est. Porro quaerat labore numquam est dolorem. Quisquam magnam amet neque dolore porro. Voluptatem quiquia numquam consectetur velit ipsum amet."
            },
            {
                "_id": "E0001A8",
                "name": "HOXA13",
                "abreviations": [
                    "1417",
                    "B99",
                    "F96"
                ],
                "categoryId": "DNA",
                "description": "Quiquia porro ut amet voluptatem magnam eius dolorem. Voluptatem dolore sed est. Sit quaerat ut tempora amet eius voluptatem modi. Quisquam magnam voluptatem numquam consectetur. Magnam sed tempora tempora quiquia est. Velit adipisci aliquam sit sit sed sit quiquia. Quisquam sit sed dolor aliquam. Dolorem non quisquam etincidunt magnam modi labore modi."
            },
            {
                "_id": "E0001A9",
                "name": "POZ/BTB And AT Hook Containing Zinc Finger 1",
                "abreviations": [],
                "categoryId": "Lipid",
                "description": "Labore ipsum quisquam neque dolore numquam adipisci. Numquam dolorem est ut aliquam etincidunt porro. Aliquam amet consectetur voluptatem etincidunt labore eius magnam. Quisquam dolor amet velit amet. Adipisci dolorem tempora est. Quisquam velit ipsum consectetur aliquam."
            },
            {
                "_id": "E0001AA",
                "name": "B7-H1 (PD-L1, CD274)",
                "abreviations": [],
                "categoryId": "DNA",
                "description": "Tempora est voluptatem sed modi non. Non etincidunt eius aliquam voluptatem. Aliquam non etincidunt est quisquam magnam dolore etincidunt. Neque dolore quiquia quisquam tempora dolor voluptatem. Dolore non consectetur dolor velit dolor consectetur."
            },
            {
                "_id": "E0001AB",
                "name": "EDN/RB",
                "abreviations": [
                    "DB7",
                    "1712",
                    "1DE9",
                    "11C0"
                ],
                "categoryId": "Others",
                "description": "Sed numquam quisquam quiquia quisquam. Etincidunt quiquia tempora etincidunt modi aliquam dolore. Labore non velit est dolor aliquam. Velit voluptatem ut velit quiquia porro. Numquam tempora porro labore non. Amet tempora quiquia magnam. Dolorem velit modi non dolorem dolor neque. Quaerat etincidunt dolorem etincidunt modi amet. Sed velit voluptatem consectetur dolor quisquam numquam dolorem."
            },
            {
                "_id": "E0001AC",
                "name": "Cancer-testis antigen OIP5",
                "abreviations": [
                    "D5B"
                ],
                "categoryId": "Labelling index",
                "description": "Labore magnam quaerat velit modi consectetur amet. Modi dolorem adipisci ipsum. Dolore aliquam dolorem dolore ipsum. Tempora sed ipsum est velit modi quisquam. Velit voluptatem eius quisquam sed. Aliquam quiquia eius etincidunt quiquia quiquia sed velit. Neque labore etincidunt consectetur. Quiquia consectetur non neque dolore quisquam sit. Dolor ipsum etincidunt porro. Sit est modi quiquia non dolorem."
            },
            {
                "_id": "E0001AD",
                "name": "Ki-67 expression",
                "abreviations": [],
                "categoryId": "DNA",
                "description": "Quaerat amet dolor sed. Ut adipisci dolor sit quaerat est aliquam. Numquam tempora magnam amet. Ipsum neque voluptatem dolor. Quiquia dolor aliquam ut dolor. Velit non dolore sed. Dolorem numquam eius non magnam non modi sed. Ipsum adipisci velit tempora."
            },
            {
                "_id": "E0001AE",
                "name": "Serglycin",
                "abreviations": [
                    "2293",
                    "1772"
                ],
                "categoryId": "DNA",
                "description": "Neque ut porro non velit neque. Quisquam eius labore sed neque. Porro dolore quiquia ut consectetur. Dolorem velit modi eius adipisci. Quiquia est dolor aliquam eius. Ipsum velit etincidunt neque. Modi quiquia porro porro."
            },
            {
                "_id": "E0001AF",
                "name": "Inhibitor of DNA binding protein-1",
                "abreviations": [
                    "8BD",
                    "BB7",
                    "17D3",
                    "12F9",
                    "11C0"
                ],
                "categoryId": "Cytokine",
                "description": "Est sit porro quaerat eius. Quisquam aliquam dolor etincidunt. Dolore amet ipsum numquam quisquam velit tempora quiquia. Modi eius dolore ut tempora. Etincidunt velit amet aliquam dolorem eius amet dolore. Quaerat quaerat tempora velit etincidunt. Dolor sit quisquam magnam."
            },
            {
                "_id": "E0001B0",
                "name": "RAR\ud835\udefd",
                "abreviations": [
                    "2467",
                    "22E0",
                    "940"
                ],
                "categoryId": "Other",
                "description": "Ipsum adipisci modi magnam ipsum tempora. Eius labore ipsum non quiquia numquam quisquam porro. Eius sit velit velit amet. Velit est adipisci quisquam quiquia etincidunt. Amet labore modi aliquam porro labore neque. Non consectetur ipsum adipisci adipisci modi dolore. Consectetur amet dolore est ut magnam est. Voluptatem aliquam sit aliquam. Non porro dolor ipsum aliquam amet consectetur velit. Est etincidunt non amet numquam adipisci."
            },
            {
                "_id": "E0001B1",
                "name": "Class III beta-tubulin isotype",
                "abreviations": [
                    "262",
                    "1DE5",
                    "E06",
                    "1948"
                ],
                "categoryId": "Enzyme",
                "description": "Velit dolore voluptatem quaerat aliquam neque est. Sed velit non sed labore sit. Dolorem magnam ut dolore. Numquam voluptatem quisquam eius velit non. Ut labore consectetur quisquam quisquam est dolore adipisci. Non velit quisquam ut non sit adipisci voluptatem. Ipsum porro magnam adipisci modi quiquia dolore sit. Amet eius est velit aliquam etincidunt."
            },
            {
                "_id": "E0001B2",
                "name": "peIF4E",
                "abreviations": [
                    "DD6",
                    "138A",
                    "163F"
                ],
                "categoryId": "RNA",
                "description": "Quisquam eius amet modi porro. Magnam sit quiquia magnam quisquam dolorem. Quiquia ipsum aliquam neque neque velit quiquia velit. Modi consectetur etincidunt quisquam quaerat non dolor dolor. Neque labore amet adipisci dolorem eius dolor. Neque labore etincidunt labore dolore dolor eius. Sed voluptatem modi voluptatem eius. Quaerat sit voluptatem velit quaerat modi. Consectetur modi magnam quaerat est quiquia amet voluptatem."
            },
            {
                "_id": "E0001B3",
                "name": "hsa-miR-346",
                "abreviations": [
                    "864"
                ],
                "categoryId": "RNA",
                "description": "Aliquam ut ut neque etincidunt. Magnam dolorem neque amet voluptatem aliquam adipisci. Labore aliquam velit non sit consectetur aliquam modi. Aliquam quiquia ut aliquam dolor etincidunt ipsum. Porro modi velit velit. Voluptatem quisquam dolore dolore quisquam dolor etincidunt. Ipsum ipsum sed quaerat dolorem modi quisquam. Aliquam est voluptatem non aliquam modi. Aliquam dolorem numquam est. Sed eius consectetur quisquam sed ut."
            },
            {
                "_id": "E0001B4",
                "name": "miR-9-3p",
                "abreviations": [
                    "24FA",
                    "1CCF"
                ],
                "categoryId": "Enzyme",
                "description": "Adipisci quisquam velit quiquia tempora neque velit. Non numquam consectetur etincidunt. Est sit voluptatem quaerat tempora magnam labore. Modi etincidunt ipsum labore sit velit. Sit tempora modi ipsum magnam tempora adipisci magnam. Adipisci est ipsum magnam aliquam quiquia non."
            },
            {
                "_id": "E0001B5",
                "name": "ZNF734",
                "abreviations": [
                    "26AA"
                ],
                "categoryId": "Enzyme",
                "description": "Quiquia quaerat dolore tempora magnam est sit sit. Tempora amet voluptatem sed sit. Magnam dolorem ipsum labore. Quiquia numquam dolorem adipisci etincidunt. Quiquia numquam neque neque. Quisquam sit neque etincidunt neque velit velit."
            },
            {
                "_id": "E0001B6",
                "name": "CD151-\u03b13\u03b21 integrin complexes",
                "abreviations": [
                    "2348",
                    "2CB",
                    "182F",
                    "2310",
                    "1DD3"
                ],
                "categoryId": "Protein",
                "description": "Sit dolore ut numquam consectetur ipsum non. Quiquia voluptatem voluptatem adipisci. Numquam velit aliquam porro. Dolorem porro sit porro magnam ut. Dolorem porro numquam adipisci adipisci. Quiquia tempora voluptatem aliquam. Sed porro aliquam non quaerat. Quaerat labore adipisci velit. Quisquam ipsum voluptatem etincidunt magnam. Etincidunt magnam eius quaerat etincidunt dolor quisquam dolor."
            },
            {
                "_id": "E0001B7",
                "name": "Mitogen-activated protein kinase kinase 2",
                "abreviations": [
                    "12A9"
                ],
                "categoryId": "Labelling index",
                "description": "Modi quiquia adipisci eius voluptatem. Aliquam modi sit porro. Porro neque non neque amet non aliquam consectetur. Sed ut modi porro est sed neque. Aliquam modi quiquia velit ut. Voluptatem adipisci sit velit. Numquam modi dolor tempora. Dolore dolorem non etincidunt amet neque magnam aliquam. Etincidunt modi tempora amet dolore ut eius. Est neque voluptatem ipsum ut."
            },
            {
                "_id": "E0001B8",
                "name": "hsa-miR-125a-5p",
                "abreviations": [
                    "94"
                ],
                "categoryId": "Metabolite",
                "description": "Est quisquam velit neque eius quaerat. Numquam etincidunt velit consectetur consectetur amet. Sit dolore quisquam dolorem magnam est magnam sed. Etincidunt numquam dolore quiquia sed non. Ipsum quiquia consectetur etincidunt sit numquam."
            },
            {
                "_id": "E0001B9",
                "name": "1p19q co-deletion",
                "abreviations": [
                    "CC3",
                    "F75"
                ],
                "categoryId": "Protein",
                "description": "Dolore eius adipisci labore. Adipisci ipsum aliquam sed magnam quiquia quaerat dolorem. Sit neque amet tempora eius velit labore non. Aliquam ut voluptatem neque velit dolorem. Ut magnam ipsum neque dolor labore quisquam. Velit amet velit adipisci etincidunt. Neque numquam dolore modi velit ut aliquam sit. Quisquam dolor velit consectetur dolor sit ipsum. Quisquam dolore porro etincidunt etincidunt est ipsum."
            },
            {
                "_id": "E0001BA",
                "name": "Isocitrate dehydrogenase 1 and 2 (IDH1/2)",
                "abreviations": [
                    "20AB",
                    "1FDC",
                    "C30",
                    "15A2"
                ],
                "categoryId": "Enzyme",
                "description": "Ipsum voluptatem sed dolore dolorem ut sit. Numquam eius non voluptatem modi numquam. Ipsum est neque sit numquam quaerat labore dolore. Adipisci numquam adipisci magnam consectetur. Porro sit velit ipsum. Neque voluptatem velit sit magnam tempora numquam. Amet quiquia sed ut."
            },
            {
                "_id": "E0001BB",
                "name": "NLrp3",
                "abreviations": [
                    "11A3"
                ],
                "categoryId": "DNA",
                "description": "Etincidunt aliquam dolor velit. Dolore sed etincidunt quiquia porro aliquam quiquia. Quaerat sed etincidunt numquam. Porro tempora non labore quisquam dolor aliquam. Ut eius sit ut velit porro amet. Est quiquia est voluptatem quaerat modi velit. Etincidunt sit velit quisquam quisquam est adipisci sed. Aliquam porro neque sed. Velit dolor est non voluptatem modi."
            },
            {
                "_id": "E0001BC",
                "name": "miR-10b",
                "abreviations": [
                    "24B3"
                ],
                "categoryId": "Protein",
                "description": "Aliquam porro consectetur tempora porro magnam. Dolor consectetur aliquam ut sed. Numquam amet porro numquam voluptatem quisquam. Dolore neque aliquam numquam consectetur quiquia sed. Amet eius numquam neque ut amet modi dolorem. Adipisci labore quiquia ipsum labore. Quiquia consectetur labore eius adipisci eius velit aliquam. Dolor quaerat numquam sed adipisci etincidunt neque velit."
            },
            {
                "_id": "E0001BD",
                "name": "PTEN",
                "abreviations": [
                    "2231",
                    "1833",
                    "1D50"
                ],
                "categoryId": "Aminopeptidase",
                "description": "Quaerat modi sit porro. Voluptatem consectetur aliquam dolor. Voluptatem amet magnam eius etincidunt non. Etincidunt numquam dolore voluptatem labore. Porro consectetur dolore modi sed consectetur non. Quisquam ipsum velit aliquam etincidunt."
            },
            {
                "_id": "E0001BE",
                "name": "NeuN",
                "abreviations": [
                    "1A3",
                    "1BD2",
                    "25DB",
                    "21FF"
                ],
                "categoryId": "Labelling index",
                "description": "Quaerat sed sed quisquam numquam velit etincidunt dolore. Dolore quiquia dolorem dolor sed dolorem velit. Neque quisquam dolor sit dolore consectetur. Labore dolorem voluptatem porro. Modi modi quisquam sed numquam adipisci non. Amet porro sed dolor sed neque tempora quiquia. Eius dolore ipsum sed sit."
            },
            {
                "_id": "E0001BF",
                "name": "Neuron navigator 3 deletions",
                "abreviations": [
                    "FD",
                    "D6",
                    "204A"
                ],
                "categoryId": "DNA",
                "description": "Eius velit quaerat sed. Quisquam dolor numquam consectetur non etincidunt porro modi. Voluptatem tempora sit quaerat ut eius etincidunt dolor. Est labore velit sit sit voluptatem neque. Quiquia neque eius amet sit velit ut neque. Tempora sit dolore dolor labore eius."
            },
            {
                "_id": "E0001C0",
                "name": "ATF5",
                "abreviations": [
                    "111D",
                    "2466",
                    "10AA"
                ],
                "categoryId": "Others",
                "description": "Etincidunt dolor ipsum dolorem quisquam porro quiquia ipsum. Eius quiquia dolor ipsum. Labore non sed quisquam ut voluptatem est. Dolorem voluptatem ut dolore dolor velit ipsum. Numquam aliquam neque ipsum velit porro. Numquam voluptatem neque ipsum adipisci sit labore. Etincidunt porro ut neque quisquam sed. Labore quisquam est ipsum neque ut neque. Etincidunt magnam quaerat aliquam."
            },
            {
                "_id": "E0001C1",
                "name": "WDR1",
                "abreviations": [
                    "2477",
                    "9AF"
                ],
                "categoryId": "Enzyme",
                "description": "Modi labore dolore porro labore numquam. Ut dolore tempora quaerat aliquam. Ut consectetur quaerat dolor dolor numquam. Tempora ut ut neque sit velit tempora. Amet consectetur magnam eius etincidunt sed. Dolor modi labore aliquam quiquia non. Sed etincidunt quaerat etincidunt ipsum dolor. Etincidunt amet porro est adipisci non quiquia."
            },
            {
                "_id": "E0001C2",
                "name": "CD44",
                "abreviations": [],
                "categoryId": "Protein",
                "description": "Tempora porro amet dolore. Modi velit ipsum modi. Dolorem labore quisquam velit ut velit dolor modi. Quaerat dolor adipisci quisquam eius adipisci. Dolorem magnam est etincidunt ipsum adipisci. Est velit sit dolorem ut labore. Aliquam sed porro non eius consectetur. Quaerat neque ipsum quisquam consectetur velit etincidunt ut. Numquam magnam quisquam dolor dolore neque ipsum. Consectetur quisquam non consectetur adipisci ut."
            },
            {
                "_id": "E0001C3",
                "name": "Galectin-1",
                "abreviations": [
                    "3D5",
                    "1726",
                    "247F",
                    "1481"
                ],
                "categoryId": "Protein",
                "description": "Ut dolor quisquam tempora. Quaerat sed neque quiquia eius ut consectetur. Non adipisci sed numquam. Amet porro non non amet porro. Ipsum aliquam eius ut labore ipsum sit tempora. Quiquia tempora quaerat est quaerat."
            },
            {
                "_id": "E0001C4",
                "name": "RP4-635E18.7",
                "abreviations": [
                    "F63"
                ],
                "categoryId": "Enzyme",
                "description": "Ipsum modi quisquam aliquam porro etincidunt dolorem quisquam. Amet consectetur quisquam quiquia amet dolorem ut. Porro etincidunt dolorem quiquia tempora sed ut. Non quiquia sed sed non etincidunt ipsum velit. Dolor dolore aliquam quaerat eius ut. Dolorem porro dolorem numquam. Aliquam sed magnam quisquam voluptatem neque ipsum modi. Modi dolorem labore labore velit quiquia neque."
            },
            {
                "_id": "E0001C5",
                "name": "ErbB gene",
                "abreviations": [
                    "13F",
                    "10C9"
                ],
                "categoryId": "Cytokine",
                "description": "Neque dolorem sed aliquam voluptatem dolorem. Ut est quaerat quiquia dolorem non etincidunt. Dolore eius dolor quisquam adipisci adipisci modi porro. Sit ipsum tempora ut. Ipsum adipisci ipsum neque est. Tempora numquam voluptatem dolore tempora. Amet quisquam non voluptatem. Voluptatem eius labore eius amet. Dolore amet sit quisquam dolore dolorem magnam labore."
            },
            {
                "_id": "E0001C6",
                "name": "AK098425",
                "abreviations": [
                    "BDD",
                    "542",
                    "1CAB",
                    "107E"
                ],
                "categoryId": "Labelling index",
                "description": "Voluptatem sed quaerat aliquam. Numquam voluptatem est tempora. Dolore quaerat eius quaerat. Adipisci magnam neque tempora velit magnam non modi. Amet voluptatem quaerat sit. Tempora quiquia aliquam numquam adipisci adipisci. Non sit modi sit ut quisquam labore. Quiquia porro dolorem ipsum dolore. Porro dolore aliquam ipsum. Etincidunt magnam dolor quiquia ipsum neque."
            },
            {
                "_id": "E0001C7",
                "name": "miR-195",
                "abreviations": [
                    "1320",
                    "2192",
                    "1B0",
                    "297"
                ],
                "categoryId": "Others",
                "description": "Sed quiquia est quaerat sit. Quiquia voluptatem numquam magnam est quiquia. Voluptatem non consectetur ut ut velit ipsum. Dolore ut modi modi quisquam adipisci velit ut. Est dolore dolore dolore non porro eius. Ut velit ut quaerat. Ut ipsum porro eius magnam dolore magnam quiquia. Velit ut eius velit velit non dolorem etincidunt."
            },
            {
                "_id": "E0001C8",
                "name": "Anti-Human Epithelial Receptor Type 2 expression",
                "abreviations": [],
                "categoryId": "Metabolite",
                "description": "Est labore velit sed numquam. Sed numquam adipisci sed etincidunt porro tempora. Sit quisquam quisquam numquam aliquam sit numquam. Quiquia etincidunt quaerat dolore eius eius est sed. Eius non amet ut sit adipisci. Consectetur magnam dolore etincidunt. Etincidunt non numquam tempora dolore tempora. Neque quisquam dolorem amet voluptatem. Dolor modi magnam numquam numquam adipisci sit porro."
            },
            {
                "_id": "E0001C9",
                "name": "hMLH1",
                "abreviations": [
                    "1EC0"
                ],
                "categoryId": "Labelling index",
                "description": "Quiquia quisquam dolor quaerat velit porro aliquam tempora. Quiquia numquam etincidunt sed dolore labore etincidunt. Voluptatem numquam ut neque. Aliquam non dolore ut labore. Porro dolor non labore dolore non adipisci voluptatem. Labore consectetur quaerat ut non etincidunt consectetur. Voluptatem magnam eius aliquam consectetur. Velit eius numquam modi modi. Labore dolor modi modi tempora."
            },
            {
                "_id": "E0001CA",
                "name": "SOX6",
                "abreviations": [
                    "E96",
                    "392"
                ],
                "categoryId": "Others",
                "description": "Est voluptatem est est. Numquam amet etincidunt ipsum etincidunt. Amet dolorem amet magnam dolorem amet voluptatem. Dolorem amet dolor ipsum est numquam eius sed. Etincidunt porro adipisci velit. Etincidunt numquam neque sit neque. Consectetur labore quaerat dolor dolore dolorem eius dolorem. Sed etincidunt adipisci non aliquam adipisci. Consectetur labore aliquam labore ut. Neque sit velit numquam sit quaerat dolore."
            },
            {
                "_id": "E0001CB",
                "name": "Forkhead box M1",
                "abreviations": [
                    "156B",
                    "1E0D",
                    "1DB6",
                    "259F",
                    "24F4"
                ],
                "categoryId": "Lipid",
                "description": "Dolore quisquam voluptatem consectetur ut consectetur. Dolore dolore modi quaerat etincidunt neque sed. Quiquia magnam consectetur porro. Numquam eius ut dolorem labore voluptatem voluptatem. Dolorem numquam modi amet magnam dolorem etincidunt quisquam. Non dolor dolorem adipisci velit adipisci tempora dolorem."
            },
            {
                "_id": "E0001CC",
                "name": "Laminin\u20108",
                "abreviations": [],
                "categoryId": "Metabolite",
                "description": "Non eius adipisci quiquia. Dolore non labore magnam dolor numquam. Dolor etincidunt dolore dolore quisquam neque. Sit neque quisquam amet voluptatem quisquam etincidunt neque. Modi modi aliquam non consectetur numquam. Adipisci dolore velit ut magnam velit. Non modi neque est quaerat eius. Ipsum ut porro voluptatem etincidunt neque."
            },
            {
                "_id": "E0001CD",
                "name": "Cripto-1 expression",
                "abreviations": [
                    "1BB6",
                    "20D2",
                    "169E",
                    "240F",
                    "1D16"
                ],
                "categoryId": "Protein",
                "description": "Aliquam quaerat dolore labore neque. Adipisci numquam ut dolor amet dolore amet quaerat. Neque eius dolore ut. Porro velit ipsum est adipisci. Neque quisquam aliquam labore consectetur non ipsum velit. Dolor tempora amet est. Quiquia neque amet quaerat dolore dolore. Dolorem amet eius dolore."
            },
            {
                "_id": "E0001CE",
                "name": "Annexin A2 pseudogenes",
                "abreviations": [],
                "categoryId": "Lipid",
                "description": "Dolore magnam numquam est. Ut adipisci eius quiquia voluptatem porro porro ipsum. Est quisquam modi non ut modi amet quiquia. Dolor tempora consectetur voluptatem etincidunt. Ut quiquia sed ut dolor. Porro amet etincidunt neque dolor velit quisquam etincidunt. Velit est aliquam modi labore voluptatem. Dolore dolor aliquam dolore tempora numquam magnam."
            },
            {
                "_id": "E0001CF",
                "name": "PGP expression",
                "abreviations": [
                    "108D",
                    "95B"
                ],
                "categoryId": "Labelling index",
                "description": "Adipisci eius velit quaerat magnam dolor neque dolore. Numquam est labore amet tempora magnam. Tempora tempora etincidunt sed tempora modi numquam amet. Non ipsum sit est consectetur quisquam. Quisquam quisquam magnam dolore numquam. Porro porro non consectetur numquam modi. Est dolorem magnam dolorem. Ipsum tempora voluptatem non."
            },
            {
                "_id": "E0001D0",
                "name": "miR-454-3p",
                "abreviations": [
                    "1980",
                    "697"
                ],
                "categoryId": "Aminopeptidase",
                "description": "Quisquam quiquia sed amet ut magnam velit porro. Numquam quiquia quiquia velit sed. Magnam non non tempora sit porro. Modi adipisci consectetur adipisci eius. Quaerat aliquam aliquam eius. Non velit voluptatem magnam. Sit dolor adipisci dolore dolorem quisquam dolorem eius. Dolorem ut labore dolorem numquam. Sed tempora eius quiquia ut."
            },
            {
                "_id": "E0001D1",
                "name": "\u03b1v\u03b23 Integrin",
                "abreviations": [
                    "1132",
                    "1AD7",
                    "2103",
                    "1B25"
                ],
                "categoryId": "Aminopeptidase",
                "description": "Neque neque amet numquam. Magnam quisquam magnam dolore sed dolore voluptatem. Quisquam ut dolor consectetur labore aliquam porro sit. Magnam amet ut ut est numquam labore tempora. Eius amet non ut sit velit dolore. Est non sit dolor tempora ut dolore voluptatem. Dolor neque velit dolorem. Etincidunt voluptatem quisquam velit. Voluptatem sed est eius. Sit ut amet etincidunt sed ipsum."
            },
            {
                "_id": "E0001D2",
                "name": "circular RNAs",
                "abreviations": [
                    "BC6",
                    "1114",
                    "1003"
                ],
                "categoryId": "RNA",
                "description": "Dolore voluptatem modi ut quaerat neque velit. Eius ipsum numquam modi amet. Dolore sit est etincidunt dolore. Porro eius voluptatem tempora est velit aliquam quiquia. Dolore quaerat dolore sed tempora velit eius. Porro tempora ipsum magnam velit dolorem numquam voluptatem. Consectetur sit quiquia modi. Adipisci modi quaerat numquam est velit. Dolor dolorem eius ut etincidunt quiquia."
            },
            {
                "_id": "E0001D3",
                "name": "2',3'-Cyclic-nucleotide 3'-phosphodiesterase expression",
                "abreviations": [
                    "1863"
                ],
                "categoryId": "Enzyme",
                "description": "Quisquam amet ipsum ipsum numquam est dolorem. Non dolorem non sit labore quaerat ipsum. Amet sit est non. Dolor porro velit ut velit. Dolorem consectetur est quisquam porro quiquia quisquam. Ut est labore velit."
            },
            {
                "_id": "E0001D4",
                "name": "MMAC/PTEN",
                "abreviations": [
                    "784",
                    "12F0"
                ],
                "categoryId": "Others",
                "description": "Modi neque porro voluptatem dolore quaerat. Voluptatem dolore tempora dolor sed adipisci. Quiquia consectetur aliquam amet amet. Est ut neque non quisquam dolore. Eius numquam neque tempora. Etincidunt est quiquia non porro. Labore adipisci tempora non modi dolor. Quiquia dolore consectetur non velit porro numquam quiquia."
            },
            {
                "_id": "E0001D5",
                "name": "BMI1 protein expression",
                "abreviations": [
                    "1706"
                ],
                "categoryId": "RNA",
                "description": "Dolor dolore adipisci porro consectetur. Consectetur neque quiquia amet quaerat ipsum. Velit amet ipsum consectetur. Voluptatem consectetur non sit numquam eius. Sit velit numquam magnam est neque. Adipisci neque consectetur dolorem. Modi neque dolorem neque adipisci quisquam numquam. Non est quiquia amet. Magnam modi numquam quisquam sit tempora sed."
            },
            {
                "_id": "E0001D6",
                "name": "mdm2",
                "abreviations": [
                    "2243",
                    "1E13",
                    "172A",
                    "7D1",
                    "1A82"
                ],
                "categoryId": "DNA",
                "description": "Quiquia voluptatem sed velit sit magnam. Ut tempora quaerat quaerat modi. Dolore tempora sit aliquam. Consectetur neque voluptatem dolore voluptatem. Quiquia dolore dolor quaerat consectetur dolorem consectetur. Ipsum etincidunt porro dolorem ut. Eius labore eius adipisci dolor dolore. Eius est quisquam numquam consectetur eius sit. Tempora neque aliquam sit adipisci consectetur tempora. Neque non non numquam modi non."
            },
            {
                "_id": "E0001D7",
                "name": "hsa-miR-548x_st",
                "abreviations": [
                    "15AC",
                    "5C2",
                    "97C",
                    "108D"
                ],
                "categoryId": "Others",
                "description": "Dolorem sed magnam tempora dolor non ipsum eius. Neque magnam magnam sed quaerat quaerat sit velit. Velit amet consectetur numquam labore eius sit. Velit modi dolorem dolor numquam magnam dolorem etincidunt. Aliquam etincidunt quaerat dolor. Numquam quisquam tempora neque adipisci. Quiquia eius ipsum quaerat aliquam ut. Eius quisquam adipisci ut amet tempora quisquam. Numquam ut tempora quiquia amet dolor."
            },
            {
                "_id": "E0001D8",
                "name": "CREB1",
                "abreviations": [
                    "12DC",
                    "A26"
                ],
                "categoryId": "Aminopeptidase",
                "description": "Est quisquam ipsum sed. Quisquam amet dolor est etincidunt tempora tempora sit. Quisquam amet aliquam sed non. Dolore quisquam adipisci dolore etincidunt ut modi porro. Dolorem quisquam labore dolor porro magnam eius. Dolore tempora etincidunt etincidunt aliquam eius modi. Voluptatem sit dolor consectetur dolore. Sed est dolorem magnam dolorem. Voluptatem velit est magnam non. Labore neque quaerat quiquia modi."
            },
            {
                "_id": "E0001D9",
                "name": "miRNA-196",
                "abreviations": [
                    "15E2",
                    "1F0E",
                    "E15",
                    "572"
                ],
                "categoryId": "Other",
                "description": "Neque numquam quiquia voluptatem sed neque est. Quiquia quisquam tempora quiquia. Adipisci sit magnam aliquam porro modi. Ipsum porro modi numquam voluptatem sed neque. Adipisci aliquam dolor dolore quaerat neque quiquia quaerat. Quisquam neque amet non aliquam ut. Dolore dolore magnam ut adipisci voluptatem aliquam numquam."
            },
            {
                "_id": "E0001DA",
                "name": "TMS1/ASC hypermethylation",
                "abreviations": [
                    "1869"
                ],
                "categoryId": "Others",
                "description": "Tempora quisquam non neque modi neque. Consectetur ipsum amet sed dolor quisquam. Ipsum neque sit non sit quaerat labore. Etincidunt est ipsum aliquam sed velit aliquam. Modi numquam sit ipsum dolor neque ut etincidunt. Non tempora amet quisquam. Quaerat neque quisquam etincidunt dolor labore ipsum. Ipsum porro consectetur neque quiquia neque. Sit neque quiquia quaerat adipisci. Quiquia velit neque aliquam adipisci quiquia quaerat."
            },
            {
                "_id": "E0001DB",
                "name": "Carbonic anhydrase IX",
                "abreviations": [
                    "1D1C",
                    "800"
                ],
                "categoryId": "Metabolite",
                "description": "Est sit est labore est quaerat sed porro. Dolor quaerat dolore quiquia amet amet neque. Dolor adipisci neque dolorem. Etincidunt dolore dolorem magnam magnam est quiquia. Quaerat sed non sed quiquia labore porro. Aliquam dolor adipisci porro porro sed ut eius. Aliquam est sed quisquam quaerat. Adipisci tempora non labore. Velit dolorem quaerat aliquam modi numquam sed. Dolore numquam dolorem ipsum dolorem numquam non quisquam."
            },
            {
                "_id": "E0001DC",
                "name": "Growth factors",
                "abreviations": [],
                "categoryId": "Others",
                "description": "Velit neque amet dolor est. Dolor numquam velit est consectetur dolor sit adipisci. Voluptatem modi quisquam ut. Consectetur modi etincidunt aliquam dolor. Etincidunt amet tempora voluptatem etincidunt labore quiquia. Velit sit eius quiquia neque magnam modi. Consectetur labore voluptatem labore voluptatem voluptatem non neque."
            },
            {
                "_id": "E0001DD",
                "name": "Cathepsin B",
                "abreviations": [
                    "1242",
                    "2409",
                    "21BC",
                    "E5E"
                ],
                "categoryId": "Cytokine",
                "description": "Eius labore etincidunt magnam non quiquia. Aliquam labore sit etincidunt. Aliquam quisquam sed aliquam porro. Sed neque sed dolor amet. Dolore sed ut ut quaerat adipisci dolorem. Non dolor adipisci consectetur adipisci amet modi. Numquam aliquam amet adipisci numquam neque."
            },
            {
                "_id": "E0001DE",
                "name": "Calcyclin-binding protein",
                "abreviations": [],
                "categoryId": "Protein",
                "description": "Dolorem amet quaerat ut sit amet quisquam. Neque dolore non numquam neque sit eius adipisci. Eius dolorem consectetur porro quisquam. Etincidunt dolorem velit quiquia numquam tempora labore. Est adipisci quiquia porro. Modi eius voluptatem voluptatem consectetur quiquia. Tempora aliquam tempora modi modi magnam adipisci aliquam. Labore modi sed magnam ipsum dolorem porro magnam."
            },
            {
                "_id": "E0001DF",
                "name": "Neuronal marker expression",
                "abreviations": [
                    "D43",
                    "2549",
                    "1C07",
                    "946"
                ],
                "categoryId": "Others",
                "description": "Neque non dolore dolor aliquam eius etincidunt. Eius est amet aliquam porro. Labore non ut dolor tempora etincidunt modi. Non consectetur quisquam est ut voluptatem dolor. Velit quisquam porro dolorem dolore non magnam. Quisquam amet sed dolor porro ut. Est consectetur sed dolor. Ut consectetur magnam modi sed modi dolor. Amet modi consectetur aliquam sit tempora neque numquam."
            },
            {
                "_id": "E0001E0",
                "name": "AK056155",
                "abreviations": [
                    "1979",
                    "1A3A",
                    "872",
                    "6",
                    "ACB"
                ],
                "categoryId": "Stem cells",
                "description": "Ipsum consectetur ut etincidunt ipsum non modi. Dolor ipsum dolorem sed sit tempora etincidunt amet. Dolorem dolor ipsum labore eius. Quiquia amet neque etincidunt quaerat. Ut est magnam magnam dolore consectetur porro."
            },
            {
                "_id": "E0001E1",
                "name": "4E-BP1",
                "abreviations": [
                    "277"
                ],
                "categoryId": "RNA",
                "description": "Porro neque dolore ut quaerat dolorem. Voluptatem modi voluptatem ipsum. Porro sed ut tempora tempora. Labore quisquam quaerat ut porro eius adipisci non. Etincidunt eius velit ut modi quisquam voluptatem."
            },
            {
                "_id": "E0001E2",
                "name": "ACST2",
                "abreviations": [
                    "176D",
                    "1C9E",
                    "13FC"
                ],
                "categoryId": "Labelling index",
                "description": "Sit tempora est labore quisquam neque sit. Est etincidunt aliquam voluptatem voluptatem tempora. Sit ipsum magnam quisquam dolore. Modi voluptatem numquam dolorem. Modi sed quisquam ipsum sed sed non numquam. Aliquam amet porro adipisci numquam. Labore neque amet labore porro velit adipisci adipisci. Eius dolor dolore etincidunt dolore porro dolor labore. Numquam quiquia est labore etincidunt consectetur. Eius etincidunt velit labore dolore dolorem."
            },
            {
                "_id": "E0001E3",
                "name": "CDK4 amplification",
                "abreviations": [
                    "20A"
                ],
                "categoryId": "Enzyme",
                "description": "Numquam quisquam consectetur sed. Eius quisquam ipsum tempora dolor quaerat neque. Dolorem amet quisquam dolor. Neque consectetur quaerat velit adipisci tempora est. Dolore voluptatem numquam non etincidunt eius. Labore neque voluptatem ipsum non numquam eius amet. Modi quaerat voluptatem ipsum magnam non etincidunt."
            },
            {
                "_id": "E0001E4",
                "name": "Gli1 expression",
                "abreviations": [
                    "1079"
                ],
                "categoryId": "Labelling index",
                "description": "Quiquia voluptatem consectetur quaerat. Velit sed modi ipsum porro. Ipsum magnam magnam sit quisquam numquam. Numquam quaerat voluptatem etincidunt ut quisquam magnam sit. Dolorem modi tempora dolorem. Sed quisquam quaerat etincidunt quaerat. Modi non quaerat consectetur consectetur dolor ipsum numquam."
            },
            {
                "_id": "E0001E5",
                "name": "Gene panel",
                "abreviations": [
                    "D56",
                    "CAC",
                    "18F0",
                    "247A",
                    "A72"
                ],
                "categoryId": "Other",
                "description": "Voluptatem etincidunt numquam ipsum quisquam ipsum eius. Adipisci ipsum neque sed dolore dolore neque etincidunt. Magnam quiquia ipsum tempora dolorem porro consectetur dolorem. Amet quisquam velit quisquam. Sit sed aliquam non."
            },
            {
                "_id": "E0001E6",
                "name": "Isocitratate dehydrogenase 1",
                "abreviations": [
                    "14DE",
                    "AF6",
                    "381"
                ],
                "categoryId": "Cytokine",
                "description": "Dolore magnam neque etincidunt. Labore sed dolor aliquam consectetur ut. Etincidunt quiquia non etincidunt dolore sed. Quisquam adipisci sit numquam. Dolorem consectetur sed sed ipsum ipsum. Ut neque tempora ut velit labore est."
            },
            {
                "_id": "E0001E7",
                "name": "SPATA6",
                "abreviations": [],
                "categoryId": "Cytokine",
                "description": "Velit modi neque voluptatem dolorem amet. Quisquam ipsum etincidunt dolorem adipisci. Quaerat dolore quiquia amet consectetur. Quisquam ut dolorem numquam consectetur sed numquam. Voluptatem neque est amet. Modi eius neque labore."
            },
            {
                "_id": "E0001E8",
                "name": "c-erbB-1-4 receptor proteins",
                "abreviations": [
                    "26D9",
                    "1C9D"
                ],
                "categoryId": "DNA",
                "description": "Voluptatem velit porro amet non sit ut numquam. Adipisci etincidunt eius ipsum ipsum dolorem aliquam amet. Sit modi porro amet voluptatem magnam. Non tempora ipsum ipsum consectetur. Non ut magnam sit velit quiquia. Velit quisquam aliquam amet. Dolor neque magnam voluptatem voluptatem amet."
            },
            {
                "_id": "E0001E9",
                "name": "Nuclear and spindle-associated protein 1",
                "abreviations": [
                    "196D",
                    "634",
                    "2540",
                    "1740"
                ],
                "categoryId": "Other",
                "description": "Consectetur sit adipisci neque tempora numquam. Voluptatem consectetur ipsum consectetur quisquam consectetur est aliquam. Amet ipsum ipsum ut numquam tempora. Numquam aliquam ut magnam velit quisquam. Consectetur non labore quaerat sit modi porro. Adipisci amet non dolore est numquam ipsum. Tempora amet quisquam magnam quisquam. Adipisci sed dolore dolor. Labore sed non porro eius neque."
            },
            {
                "_id": "E0001EA",
                "name": "Olig2",
                "abreviations": [
                    "865",
                    "CCA",
                    "2114",
                    "2651"
                ],
                "categoryId": "Cytokine",
                "description": "Numquam magnam numquam neque adipisci magnam. Consectetur quiquia tempora tempora quaerat adipisci labore. Eius etincidunt labore tempora. Dolor ut modi magnam ut. Numquam aliquam consectetur ipsum velit labore."
            },
            {
                "_id": "E0001EB",
                "name": "TIMP-1 and CD63 coexpression",
                "abreviations": [
                    "1C77",
                    "E7",
                    "62B",
                    "1639"
                ],
                "categoryId": "Lipid",
                "description": "Velit velit eius modi numquam modi est. Non labore modi sed voluptatem. Dolorem quisquam ut quisquam. Numquam eius modi voluptatem modi quiquia quisquam. Quaerat non est labore non."
            },
            {
                "_id": "E0001EC",
                "name": "Spondin 1",
                "abreviations": [
                    "1185",
                    "962"
                ],
                "categoryId": "Lipid",
                "description": "Quaerat sed dolorem quiquia non aliquam. Aliquam ut non est amet aliquam consectetur. Consectetur velit eius modi ipsum. Quiquia sed eius quaerat quisquam quisquam sit aliquam. Non neque voluptatem consectetur amet ut. Quaerat tempora sed magnam quiquia. Dolore labore dolor non. Ipsum ipsum est dolorem amet. Amet tempora quiquia velit. Dolorem adipisci aliquam sed dolor eius velit."
            },
            {
                "_id": "E0001ED",
                "name": "YKL-40 expression",
                "abreviations": [
                    "FE8",
                    "DA8",
                    "2469"
                ],
                "categoryId": "Labelling index",
                "description": "Ipsum ipsum tempora amet adipisci. Magnam etincidunt porro dolor amet voluptatem voluptatem. Dolorem modi magnam labore etincidunt labore eius etincidunt. Dolor quaerat quiquia aliquam est. Labore amet numquam dolorem adipisci ut ut labore."
            },
            {
                "_id": "E0001EE",
                "name": "Cytochrome C oxidase",
                "abreviations": [
                    "18F7",
                    "47",
                    "6BB",
                    "21C4",
                    "8F5"
                ],
                "categoryId": "Other",
                "description": "Quaerat eius eius sit modi consectetur dolore. Ut tempora adipisci ipsum dolorem etincidunt non amet. Est etincidunt modi est ut voluptatem. Est dolorem dolore non modi numquam sed eius. Quaerat dolore ut dolore ut dolorem quaerat sit."
            },
            {
                "_id": "E0001EF",
                "name": "Forkhead box transcription factor",
                "abreviations": [
                    "1EB"
                ],
                "categoryId": "Enzyme",
                "description": "Ut quisquam est dolorem magnam aliquam voluptatem amet. Amet magnam neque aliquam dolore non velit. Dolor porro quaerat sed etincidunt neque modi. Neque dolor neque labore tempora dolore voluptatem dolor. Eius modi adipisci quiquia labore voluptatem. Adipisci est quaerat voluptatem adipisci eius ut numquam. Dolor dolorem est etincidunt labore numquam sed sed."
            },
            {
                "_id": "E0001F0",
                "name": "Collapsin response mediator protein 5",
                "abreviations": [
                    "23A7",
                    "72E",
                    "1956"
                ],
                "categoryId": "Cytokine",
                "description": "Amet ut consectetur sit quaerat. Ut adipisci neque etincidunt dolorem amet. Porro tempora dolore porro. Sit etincidunt tempora sed modi non neque. Quiquia non adipisci quisquam aliquam dolorem dolore adipisci. Ut tempora ipsum est dolore. Dolore amet voluptatem est adipisci numquam consectetur consectetur. Sit modi neque sed voluptatem numquam consectetur sed. Non ut dolore dolorem."
            },
            {
                "_id": "E0001F1",
                "name": "RP5-1172N10.2",
                "abreviations": [],
                "categoryId": "Labelling index",
                "description": "Dolorem porro porro quisquam quisquam. Amet velit non dolorem dolore ut modi. Neque consectetur aliquam est dolor magnam ipsum. Tempora dolore consectetur ut quaerat. Modi labore labore dolor voluptatem dolor amet. Est ipsum neque porro adipisci aliquam amet. Eius sit dolor modi amet quaerat quaerat est. Dolorem labore tempora dolorem eius etincidunt porro."
            },
            {
                "_id": "E0001F2",
                "name": "ALDH1A3 promoter methylation",
                "abreviations": [
                    "16CE"
                ],
                "categoryId": "Stem cells",
                "description": "Neque non adipisci consectetur sit. Porro magnam sit numquam eius consectetur sed non. Ipsum adipisci numquam sed dolor labore. Voluptatem non tempora quiquia dolorem consectetur. Tempora quaerat velit dolore dolor modi consectetur eius. Voluptatem eius ut eius tempora neque. Quisquam est dolorem dolore."
            },
            {
                "_id": "E0001F3",
                "name": "SPI1",
                "abreviations": [
                    "6DD",
                    "4EB"
                ],
                "categoryId": "Other",
                "description": "Neque modi sit ipsum aliquam ipsum. Eius dolore sit adipisci velit numquam magnam. Amet sit non quaerat sit velit est. Neque etincidunt eius dolor quisquam etincidunt amet. Consectetur sed quisquam quisquam labore est. Dolorem tempora quiquia amet magnam dolore. Ut porro sit labore consectetur amet quiquia. Etincidunt neque quiquia dolorem dolorem aliquam sed etincidunt."
            },
            {
                "_id": "E0001F4",
                "name": "Cox-2",
                "abreviations": [],
                "categoryId": "Cytokine",
                "description": "Dolore non dolor sit magnam ipsum aliquam. Dolorem numquam sed amet. Est consectetur ipsum est amet adipisci adipisci ut. Est est numquam quaerat amet adipisci labore. Ut eius dolorem sed dolor. Amet quaerat aliquam etincidunt magnam quiquia velit etincidunt. Quaerat porro dolor dolor ipsum quaerat consectetur. Ut modi non dolorem. Dolore eius dolorem non dolor tempora."
            },
            {
                "_id": "E0001F5",
                "name": "hsa-miR-595",
                "abreviations": [
                    "E5C"
                ],
                "categoryId": "Metabolite",
                "description": "Tempora porro aliquam velit numquam. Dolore non aliquam quisquam dolore voluptatem. Sed ut modi non sit dolor porro. Voluptatem eius consectetur quisquam adipisci. Ut quiquia eius adipisci dolorem labore quiquia eius. Sit adipisci sit quaerat sit dolor ipsum quiquia. Sit labore aliquam dolorem dolor neque etincidunt. Ut modi quiquia quiquia non est. Dolor quaerat quiquia sit."
            },
            {
                "_id": "E0001F6",
                "name": "miR-223",
                "abreviations": [
                    "2260"
                ],
                "categoryId": "Other",
                "description": "Etincidunt aliquam numquam ipsum neque neque eius etincidunt. Quiquia quisquam dolore adipisci ut eius magnam labore. Quiquia tempora tempora voluptatem numquam ipsum magnam porro. Quiquia sit dolore voluptatem adipisci quisquam tempora. Aliquam quisquam dolorem tempora modi quaerat ut magnam. Consectetur labore tempora labore sit ut quisquam amet. Voluptatem sit magnam amet est tempora. Adipisci ut non sit. Sed labore amet etincidunt quisquam consectetur magnam porro."
            },
            {
                "_id": "E0001F7",
                "name": "miR-373",
                "abreviations": [
                    "1393",
                    "1A9A",
                    "D72"
                ],
                "categoryId": "Other",
                "description": "Porro numquam voluptatem ut quisquam labore. Etincidunt eius non ut est est dolore labore. Consectetur neque quiquia numquam dolorem numquam dolore. Tempora labore numquam amet consectetur quaerat labore. Velit eius quaerat ut."
            },
            {
                "_id": "E0001F8",
                "name": "ATP-binding cassette",
                "abreviations": [
                    "1DF",
                    "26A5",
                    "22CB",
                    "F79"
                ],
                "categoryId": "Metabolite",
                "description": "Amet voluptatem porro non adipisci dolore quiquia quaerat. Neque magnam amet dolore velit amet consectetur. Dolore tempora porro non labore. Neque sed magnam non. Dolor est est quaerat non dolor aliquam. Aliquam voluptatem numquam numquam. Numquam aliquam etincidunt sit dolorem ut. Quiquia amet ut dolorem non porro ut aliquam."
            },
            {
                "_id": "E0001F9",
                "name": "WT1",
                "abreviations": [
                    "2556"
                ],
                "categoryId": "Lipid",
                "description": "Sed quaerat etincidunt dolore. Est tempora dolor porro. Velit consectetur eius adipisci velit. Quisquam tempora neque porro modi tempora amet. Labore quiquia est eius. Etincidunt quisquam sed amet adipisci consectetur consectetur. Etincidunt consectetur modi modi tempora quaerat consectetur dolor. Tempora eius modi eius sed. Velit quisquam magnam aliquam. Quisquam tempora dolore porro consectetur."
            },
            {
                "_id": "E0001FA",
                "name": "Dichotomized MRI-derived clinical features",
                "abreviations": [],
                "categoryId": "Metabolite",
                "description": "Porro aliquam aliquam ut dolorem ipsum non adipisci. Ut ut dolore velit sed velit labore numquam. Modi dolor voluptatem sed. Dolore porro numquam etincidunt adipisci aliquam est. Labore quaerat numquam adipisci porro numquam. Dolor sed dolore ipsum. Neque voluptatem sit velit tempora non porro voluptatem. Quaerat quaerat labore quisquam dolor dolore ut."
            },
            {
                "_id": "E0001FB",
                "name": "Calreticulin",
                "abreviations": [
                    "22B0",
                    "443",
                    "B58"
                ],
                "categoryId": "DNA",
                "description": "Sed porro tempora ipsum modi. Adipisci etincidunt tempora quisquam sit eius. Modi velit labore amet quisquam modi. Numquam consectetur est porro dolorem dolore non velit. Dolore porro numquam quisquam consectetur sed. Numquam sed consectetur velit amet dolor quaerat. Ut dolorem adipisci dolore. Dolorem labore adipisci sit. Porro amet consectetur voluptatem. Sed porro ut modi quisquam dolore quaerat adipisci."
            },
            {
                "_id": "E0001FC",
                "name": "Myristoylated alanine-rich C-kinase substrate",
                "abreviations": [
                    "8F7",
                    "2A9"
                ],
                "categoryId": "Metabolite",
                "description": "Numquam quaerat tempora tempora velit neque neque est. Dolor dolore neque magnam quisquam. Dolorem sit neque sit eius. Etincidunt dolore quiquia dolorem magnam magnam adipisci sit. Dolor dolore aliquam velit tempora etincidunt. Dolore dolorem neque labore non. Quaerat adipisci sit sed eius. Dolorem quiquia tempora voluptatem tempora sit tempora est."
            },
            {
                "_id": "E0001FD",
                "name": "miR-31",
                "abreviations": [
                    "A91"
                ],
                "categoryId": "Enzyme",
                "description": "Voluptatem velit neque quiquia non neque. Amet ipsum neque quisquam. Modi dolorem labore aliquam. Consectetur amet adipisci labore ipsum non etincidunt modi. Dolore ut est ut est. Modi quiquia numquam adipisci porro amet. Quaerat dolore dolor ut dolor. Voluptatem quiquia dolorem neque magnam quiquia velit."
            },
            {
                "_id": "E0001FE",
                "name": "Notch ligands Delta-like 4 expression",
                "abreviations": [
                    "1C4D",
                    "1EDE",
                    "10DB"
                ],
                "categoryId": "Metabolite",
                "description": "Est quiquia tempora dolor dolor adipisci est. Etincidunt dolore porro ut. Dolore velit numquam dolore. Quaerat neque est sed. Dolorem dolore eius ut. Voluptatem adipisci non velit amet adipisci eius numquam. Aliquam consectetur adipisci consectetur quaerat non non amet."
            },
            {
                "_id": "E0001FF",
                "name": "Cyclin A",
                "abreviations": [
                    "D76",
                    "1027",
                    "1E2F",
                    "23FC"
                ],
                "categoryId": "DNA",
                "description": "Consectetur quiquia voluptatem velit dolorem eius ut dolor. Ut tempora non quaerat consectetur neque. Quaerat dolorem quaerat velit neque sit. Consectetur quisquam est ipsum non modi dolore. Dolor consectetur quisquam adipisci."
            },
            {
                "_id": "E000200",
                "name": "PROX1",
                "abreviations": [
                    "1C15",
                    "1227",
                    "1567",
                    "1832"
                ],
                "categoryId": "Metabolite",
                "description": "Magnam non sit quiquia etincidunt numquam tempora magnam. Ipsum quiquia dolor dolore etincidunt. Etincidunt dolor sit labore ut porro ipsum. Non dolore magnam quaerat tempora. Labore numquam velit modi consectetur. Amet neque tempora amet sed. Quaerat dolore neque quisquam dolor amet ut. Amet porro tempora tempora aliquam."
            },
            {
                "_id": "E000201",
                "name": "P21ras",
                "abreviations": [],
                "categoryId": "Cytokine",
                "description": "Velit ut voluptatem quaerat ipsum. Velit magnam ipsum modi dolore dolore non adipisci. Sit dolor numquam tempora labore dolore porro. Dolorem quiquia sed modi aliquam. Dolorem quiquia modi non dolor. Modi sit sed neque ut quisquam amet voluptatem. Eius numquam non sed etincidunt velit labore."
            },
            {
                "_id": "E000202",
                "name": "HER-2/neu",
                "abreviations": [
                    "B6B",
                    "E72",
                    "1287",
                    "26EE"
                ],
                "categoryId": "RNA",
                "description": "Dolorem sit sit ut non dolor voluptatem labore. Aliquam non quisquam magnam quisquam adipisci dolore. Amet labore dolor quisquam magnam etincidunt quaerat. Sit etincidunt quiquia consectetur adipisci adipisci eius quaerat. Non eius ipsum adipisci. Etincidunt ipsum non modi adipisci dolorem tempora. Adipisci velit dolor quaerat modi. Voluptatem quaerat non labore sed consectetur adipisci non. Ipsum dolore porro etincidunt velit est."
            },
            {
                "_id": "E000203",
                "name": "NES mRNAs",
                "abreviations": [
                    "6C7",
                    "1D32",
                    "6B0",
                    "692"
                ],
                "categoryId": "Cytokine",
                "description": "Adipisci voluptatem adipisci ipsum consectetur. Tempora quaerat est dolore numquam quaerat. Sed sed neque numquam eius. Porro sit etincidunt amet. Est adipisci non modi porro magnam. Etincidunt neque aliquam quisquam etincidunt porro. Magnam ut est non adipisci. Velit dolore numquam sit dolore quisquam quiquia neque."
            },
            {
                "_id": "E000204",
                "name": "miR-29a/b/c",
                "abreviations": [
                    "152B"
                ],
                "categoryId": "Other",
                "description": "Dolorem sed aliquam consectetur dolor voluptatem. Porro sit ipsum eius non neque etincidunt porro. Velit adipisci quaerat ut dolore. Numquam sit est adipisci. Ipsum consectetur numquam voluptatem eius neque ipsum. Labore non magnam labore amet."
            },
            {
                "_id": "E000205",
                "name": "Paxilin",
                "abreviations": [],
                "categoryId": "Lipid",
                "description": "Sit modi sed amet ut. Non eius labore modi non etincidunt. Ut sit magnam voluptatem adipisci. Aliquam non porro magnam neque. Porro etincidunt velit dolore consectetur ut."
            },
            {
                "_id": "E000206",
                "name": "miR-105",
                "abreviations": [],
                "categoryId": "Protein",
                "description": "Ipsum est neque tempora. Dolor sit magnam voluptatem adipisci sit. Dolore adipisci est labore neque modi consectetur quaerat. Voluptatem quaerat quiquia magnam consectetur quisquam. Non magnam quaerat est voluptatem sed adipisci. Neque neque magnam labore etincidunt voluptatem quiquia. Sed eius ipsum sit sit quisquam sed quisquam. Tempora sed amet voluptatem velit dolore ipsum."
            },
            {
                "_id": "E000207",
                "name": "Hedgehog-interacting protein",
                "abreviations": [
                    "80C",
                    "12C",
                    "208C",
                    "19F3"
                ],
                "categoryId": "RNA",
                "description": "Dolor labore ut magnam ut voluptatem dolor modi. Quisquam labore consectetur dolore quisquam. Dolorem eius labore dolorem voluptatem velit porro. Voluptatem numquam ipsum tempora. Labore est dolor numquam dolor dolor velit labore."
            },
            {
                "_id": "E000208",
                "name": "CDKN2A G500 allele",
                "abreviations": [
                    "2143"
                ],
                "categoryId": "Protein",
                "description": "Neque aliquam dolore non amet quisquam labore. Eius dolorem dolor modi. Voluptatem ut est adipisci sit. Ipsum ut tempora aliquam. Neque non sed porro quiquia aliquam labore etincidunt."
            },
            {
                "_id": "E000209",
                "name": "Isocitrate dehydrogenase 1 codon 132 mutation",
                "abreviations": [
                    "1F48"
                ],
                "categoryId": "RNA",
                "description": "Non ipsum dolorem magnam. Sit aliquam ut est. Magnam labore quisquam tempora sit numquam. Sed aliquam dolorem neque velit quiquia. Magnam sit est etincidunt numquam sit. Dolore amet quaerat dolor ipsum ut consectetur. Dolorem ipsum ut aliquam amet non. Dolore voluptatem voluptatem ipsum neque. Tempora sed eius eius sit sed."
            },
            {
                "_id": "E00020A",
                "name": "CPEB1",
                "abreviations": [
                    "344",
                    "2197",
                    "2624",
                    "DC4"
                ],
                "categoryId": "Protein",
                "description": "Dolore quisquam voluptatem magnam non porro etincidunt. Consectetur sit sit consectetur dolor consectetur adipisci aliquam. Labore dolore magnam dolor. Quaerat ipsum sit non aliquam. Consectetur etincidunt consectetur sed quaerat. Eius neque sed neque dolorem adipisci neque quiquia. Ipsum modi tempora adipisci. Dolore voluptatem tempora modi dolore est adipisci amet."
            },
            {
                "_id": "E00020B",
                "name": "Microsatellite instability",
                "abreviations": [],
                "categoryId": "Protein",
                "description": "Labore etincidunt labore magnam quiquia porro. Magnam sed ipsum ipsum porro. Amet adipisci non eius. Dolor adipisci tempora modi dolore. Sit neque dolore magnam. Quisquam quiquia modi dolore consectetur sit. Aliquam consectetur sed tempora quaerat. Sit modi dolor adipisci non sit quaerat. Etincidunt quaerat amet adipisci labore."
            },
            {
                "_id": "E00020C",
                "name": "TNC mRNAs",
                "abreviations": [
                    "1ABB"
                ],
                "categoryId": "Metabolite",
                "description": "Labore numquam quiquia amet. Quaerat numquam quiquia etincidunt. Tempora dolor dolore voluptatem. Amet est sed aliquam dolor dolorem. Dolor etincidunt etincidunt modi ipsum dolore porro. Adipisci dolorem tempora modi consectetur aliquam. Ipsum labore ipsum tempora voluptatem. Sed eius velit sed ipsum ut amet. Dolore consectetur quiquia quisquam neque tempora magnam. Neque ipsum porro est sit quaerat quaerat."
            },
            {
                "_id": "E00020D",
                "name": "Hypoxia-inducible factor 1",
                "abreviations": [
                    "FA4",
                    "253D",
                    "A83",
                    "C8B",
                    "A39"
                ],
                "categoryId": "Lipid",
                "description": "Velit sit quiquia consectetur quiquia sit tempora. Consectetur velit est etincidunt dolore. Consectetur quiquia magnam est. Quiquia sit ipsum quisquam. Ut adipisci voluptatem modi. Quaerat modi aliquam voluptatem quisquam neque. Eius quiquia ut porro amet. Quaerat quiquia sed magnam. Est est est quiquia quisquam quaerat voluptatem dolore."
            },
            {
                "_id": "E00020E",
                "name": "miR-672",
                "abreviations": [],
                "categoryId": "Other",
                "description": "Labore dolore etincidunt adipisci aliquam. Quiquia etincidunt amet sit ipsum numquam. Porro quiquia dolore labore. Sit amet etincidunt ipsum sit. Labore ut ipsum non dolore. Adipisci porro non labore quaerat porro adipisci. Magnam dolore labore sit ut sit voluptatem consectetur. Quaerat non adipisci modi porro. Aliquam tempora neque velit etincidunt dolore. Adipisci etincidunt ut quisquam eius amet magnam."
            },
            {
                "_id": "E00020F",
                "name": "MYB-related protein B",
                "abreviations": [
                    "B80"
                ],
                "categoryId": "Protein",
                "description": "Aliquam sit etincidunt amet dolorem non sed. Labore eius labore labore quaerat. Voluptatem est consectetur numquam. Sit neque sit quiquia dolorem. Porro non quiquia magnam ut sed dolorem. Est sed dolor neque. Velit dolor aliquam ut. Quaerat ut quisquam numquam. Est tempora dolor non."
            },
            {
                "_id": "E000210",
                "name": "SPARC",
                "abreviations": [
                    "192",
                    "20F2",
                    "87"
                ],
                "categoryId": "DNA",
                "description": "Consectetur dolor neque quisquam labore magnam. Eius sed dolore etincidunt quiquia. Eius eius tempora modi amet eius dolorem porro. Ut labore etincidunt voluptatem sit eius ipsum etincidunt. Modi amet porro etincidunt quaerat ipsum. Sed labore ut non aliquam sit. Dolore magnam consectetur amet. Aliquam quaerat porro non."
            },
            {
                "_id": "E000211",
                "name": "Tumor necrosis factor receptor 1 TNFR1-associated death domain protein",
                "abreviations": [
                    "1683",
                    "1EDA"
                ],
                "categoryId": "Lipid",
                "description": "Consectetur tempora dolorem voluptatem aliquam neque eius. Tempora ut dolor adipisci eius adipisci dolor est. Aliquam quisquam est sed porro. Tempora aliquam ipsum sit sed. Ipsum dolorem dolorem non non porro."
            },
            {
                "_id": "E000212",
                "name": "Glucose Regulated Protein 78",
                "abreviations": [
                    "B49",
                    "1EED",
                    "D3D",
                    "361",
                    "1A49"
                ],
                "categoryId": "Aminopeptidase",
                "description": "Porro numquam quisquam tempora est non. Quiquia neque modi numquam. Ut dolore porro non dolorem. Est quiquia sed dolor dolor. Numquam quiquia quaerat quiquia sed voluptatem. Quiquia modi sit ut amet consectetur etincidunt voluptatem."
            },
            {
                "_id": "E000213",
                "name": "KIT receptor tyrosine kinase",
                "abreviations": [
                    "2275",
                    "1F64",
                    "14B"
                ],
                "categoryId": "Lipid",
                "description": "Consectetur etincidunt magnam quiquia dolor. Velit amet quisquam porro dolorem modi. Etincidunt sit amet dolorem sit etincidunt amet. Non dolore amet dolore adipisci. Quisquam neque porro etincidunt modi. Aliquam ut etincidunt ut."
            },
            {
                "_id": "E000214",
                "name": "Deleted in colorectal carcinoma gene",
                "abreviations": [],
                "categoryId": "Protein",
                "description": "Numquam quaerat voluptatem consectetur consectetur. Voluptatem sit dolorem adipisci amet sit. Quaerat magnam est magnam quiquia. Quiquia modi amet dolore etincidunt. Sit porro adipisci amet velit amet."
            },
            {
                "_id": "E000215",
                "name": "CD40/CD40L",
                "abreviations": [
                    "122B",
                    "1A96",
                    "5E8",
                    "2A0"
                ],
                "categoryId": "Metabolite",
                "description": "Ipsum tempora etincidunt voluptatem. Non neque voluptatem ut sit velit. Eius eius numquam dolor. Ipsum magnam quisquam modi quaerat. Consectetur quaerat numquam sed numquam sit modi neque. Consectetur adipisci magnam eius labore. Numquam velit labore velit modi non aliquam. Etincidunt aliquam voluptatem ipsum aliquam. Etincidunt sit tempora neque est eius ipsum."
            },
            {
                "_id": "E000216",
                "name": "O6-methylguanine DNA methyltransferase protein expression",
                "abreviations": [
                    "22E6"
                ],
                "categoryId": "Metabolite",
                "description": "Aliquam adipisci quaerat neque sit consectetur quisquam. Dolorem ut dolorem adipisci ipsum ut. Dolor dolor dolorem dolore quaerat sit. Eius dolor dolorem non ipsum. Numquam aliquam etincidunt porro quiquia labore."
            },
            {
                "_id": "E000217",
                "name": "MGMT protein expression",
                "abreviations": [
                    "21F8",
                    "C92",
                    "2606"
                ],
                "categoryId": "Metabolite",
                "description": "Numquam amet consectetur sed velit sit magnam. Sit tempora neque adipisci sed. Ipsum est numquam quiquia quaerat porro eius porro. Labore ipsum eius eius non dolor. Magnam consectetur adipisci consectetur quisquam dolor quisquam eius."
            },
            {
                "_id": "E000218",
                "name": "EGFR -191C/A",
                "abreviations": [],
                "categoryId": "Others",
                "description": "Velit voluptatem ipsum ut ut quisquam labore consectetur. Consectetur eius quiquia dolor numquam. Porro consectetur quiquia eius. Dolor sit etincidunt voluptatem est quisquam quiquia ipsum. Eius neque adipisci dolorem quaerat est amet. Adipisci numquam porro quaerat etincidunt est magnam est."
            },
            {
                "_id": "E000219",
                "name": "xCT expression",
                "abreviations": [
                    "23E7",
                    "1FCE",
                    "1DDB",
                    "E12",
                    "A3D"
                ],
                "categoryId": "Protein",
                "description": "Dolorem amet quaerat voluptatem labore etincidunt. Aliquam consectetur porro voluptatem neque modi. Porro amet labore est labore adipisci tempora porro. Adipisci ut ipsum dolor aliquam dolore consectetur ut. Magnam neque voluptatem magnam. Consectetur voluptatem magnam dolor labore ipsum non porro. Porro neque voluptatem quisquam. Ut ipsum non dolor modi numquam."
            },
            {
                "_id": "E00021A",
                "name": "IDH",
                "abreviations": [
                    "1FC9",
                    "1BD",
                    "1C1B",
                    "44B"
                ],
                "categoryId": "Cytokine",
                "description": "Dolor eius velit non dolor sed. Quisquam aliquam labore etincidunt. Eius ut voluptatem quisquam etincidunt adipisci. Dolore quiquia dolore neque neque velit numquam. Neque quaerat voluptatem labore porro aliquam. Quiquia ipsum ipsum non velit neque non. Quiquia quiquia non dolorem porro. Adipisci amet dolorem modi dolorem etincidunt ipsum. Amet porro quiquia est magnam quaerat."
            },
            {
                "_id": "E00021B",
                "name": "ZEB2",
                "abreviations": [
                    "1502",
                    "DC"
                ],
                "categoryId": "Protein",
                "description": "Dolorem aliquam labore consectetur. Tempora amet velit adipisci porro tempora. Sit ipsum aliquam numquam amet est. Adipisci tempora est magnam est ipsum amet labore. Aliquam consectetur consectetur dolor dolore non quisquam."
            },
            {
                "_id": "E00021C",
                "name": "Downregulation of miR-544",
                "abreviations": [
                    "16C6"
                ],
                "categoryId": "DNA",
                "description": "Amet sed aliquam est quiquia. Sed consectetur ut adipisci amet. Labore magnam amet consectetur velit sed magnam. Aliquam dolor amet sit. Dolore quiquia non velit. Dolore neque sit quaerat. Etincidunt quiquia dolorem non non. Ipsum dolore sed ipsum etincidunt ipsum eius consectetur."
            },
            {
                "_id": "E00021D",
                "name": "MDM2",
                "abreviations": [
                    "78D",
                    "D6C",
                    "1C1F",
                    "79A",
                    "166A"
                ],
                "categoryId": "Metabolite",
                "description": "Dolorem aliquam sed est numquam sit. Magnam quiquia dolore velit quisquam tempora etincidunt quaerat. Ipsum tempora dolore magnam. Aliquam velit dolorem sit quisquam tempora sit quisquam. Labore aliquam dolore numquam."
            },
            {
                "_id": "E00021E",
                "name": "miR-663",
                "abreviations": [],
                "categoryId": "Enzyme",
                "description": "Labore voluptatem ut neque sed sed. Velit eius non quisquam. Non etincidunt ut tempora dolorem dolore non. Est sed sit dolorem ut magnam aliquam. Dolore dolore magnam est non quaerat. Porro quisquam adipisci magnam non."
            },
            {
                "_id": "E00021F",
                "name": "Target of methylation-associated silencing 1",
                "abreviations": [
                    "1185",
                    "1827",
                    "2332",
                    "25B7"
                ],
                "categoryId": "DNA",
                "description": "Aliquam labore labore sit dolore labore. Sed numquam velit ut. Porro dolorem consectetur ut quaerat. Consectetur consectetur porro voluptatem. Eius ipsum quisquam quisquam sed quisquam dolorem etincidunt. Labore eius aliquam dolorem."
            },
            {
                "_id": "E000220",
                "name": "CD44 expression",
                "abreviations": [
                    "245E",
                    "182D",
                    "8DE",
                    "15F"
                ],
                "categoryId": "DNA",
                "description": "Porro voluptatem labore ut quiquia ipsum amet. Ipsum sed amet est non sit. Etincidunt numquam sit quiquia neque neque. Neque numquam quaerat velit labore voluptatem. Etincidunt eius eius velit etincidunt. Ut porro numquam est porro velit. Modi adipisci porro adipisci dolore sit adipisci. Dolore ut dolore neque numquam."
            },
            {
                "_id": "E000221",
                "name": "Nestin",
                "abreviations": [],
                "categoryId": "Aminopeptidase",
                "description": "Voluptatem eius porro dolorem numquam aliquam amet dolorem. Labore quisquam amet quiquia dolor ipsum quiquia. Ut quisquam consectetur etincidunt velit dolore neque. Ipsum quisquam etincidunt dolorem etincidunt. Consectetur dolore dolorem velit amet."
            },
            {
                "_id": "E000222",
                "name": "microRNA-21",
                "abreviations": [
                    "1528",
                    "679"
                ],
                "categoryId": "Metabolite",
                "description": "Aliquam adipisci porro etincidunt. Dolore magnam amet consectetur labore est quisquam non. Adipisci amet sit quisquam eius dolore. Tempora dolore modi quaerat ut non sit est. Eius labore neque est non aliquam amet dolorem. Dolorem quiquia labore aliquam dolor sed quisquam quisquam. Quisquam eius quiquia quisquam neque sit amet dolore. Ipsum etincidunt aliquam dolor adipisci dolorem numquam. Eius est velit labore sit quiquia porro. Sit consectetur ipsum amet."
            },
            {
                "_id": "E000223",
                "name": "ALDH1",
                "abreviations": [
                    "235D",
                    "19FD",
                    "1FFB",
                    "1C50"
                ],
                "categoryId": "Labelling index",
                "description": "Sed numquam eius quaerat porro tempora. Tempora eius ut tempora voluptatem neque. Ipsum neque etincidunt sed. Velit modi consectetur consectetur eius. Ut modi magnam dolor labore non quiquia sit. Est quisquam non numquam sit dolorem ut labore."
            },
            {
                "_id": "E000224",
                "name": "SNAPC2",
                "abreviations": [
                    "2180",
                    "321"
                ],
                "categoryId": "Protein",
                "description": "Quisquam magnam dolor quaerat adipisci. Quiquia dolorem amet voluptatem. Consectetur amet sed consectetur. Aliquam numquam quiquia dolorem ut. Ut dolor etincidunt magnam eius sed. Porro sit ut etincidunt sed amet numquam. Aliquam etincidunt dolor labore modi ipsum quaerat."
            },
            {
                "_id": "E000225",
                "name": "Rab27b",
                "abreviations": [
                    "1AFC",
                    "1485"
                ],
                "categoryId": "Aminopeptidase",
                "description": "Labore aliquam dolor dolorem numquam numquam velit non. Quisquam ut sit quiquia sed sit labore. Ut labore consectetur amet est non quiquia quaerat. Ipsum voluptatem non amet porro. Sed dolore quiquia porro quiquia ut quisquam sit. Porro eius quaerat consectetur dolore."
            },
            {
                "_id": "E000226",
                "name": "EGFR",
                "abreviations": [
                    "1BC4",
                    "1C57",
                    "19E8"
                ],
                "categoryId": "Lipid",
                "description": "Quiquia velit magnam tempora ipsum etincidunt. Velit sit non dolor dolor. Magnam dolor est velit ut est. Voluptatem aliquam porro adipisci ut neque. Modi modi ut adipisci neque."
            },
            {
                "_id": "E000227",
                "name": "RPS20",
                "abreviations": [
                    "1474",
                    "BFB",
                    "26B",
                    "BF",
                    "1AF"
                ],
                "categoryId": "Enzyme",
                "description": "Eius non sit eius ipsum. Sed labore quisquam quisquam est ut. Neque consectetur consectetur voluptatem non. Dolorem dolorem porro voluptatem magnam ipsum. Neque velit aliquam quisquam dolore quisquam ipsum numquam. Est tempora dolor est consectetur."
            },
            {
                "_id": "E000228",
                "name": "Positive PR expression",
                "abreviations": [
                    "215C",
                    "5BF",
                    "23E2",
                    "5EB",
                    "22C7"
                ],
                "categoryId": "Labelling index",
                "description": "Velit non dolore dolor. Aliquam est dolorem quiquia adipisci. Labore dolorem neque non dolorem dolor. Magnam est adipisci velit amet sed. Porro amet dolore dolor dolor dolorem etincidunt. Quaerat porro labore est tempora amet tempora sit. Quaerat voluptatem ipsum magnam aliquam porro labore dolor. Voluptatem adipisci magnam est dolor non etincidunt. Ut dolore magnam amet. Modi non adipisci quaerat ut ipsum."
            },
            {
                "_id": "E000229",
                "name": "Forkhead box transcription factor O3a",
                "abreviations": [
                    "270E",
                    "F61",
                    "241C"
                ],
                "categoryId": "Aminopeptidase",
                "description": "Velit labore etincidunt tempora modi. Aliquam consectetur etincidunt ut dolorem dolorem quisquam. Dolore aliquam numquam ipsum neque numquam est amet. Modi amet est porro sit neque quaerat numquam. Consectetur etincidunt labore etincidunt voluptatem est. Eius quisquam eius sed eius non voluptatem amet. Ipsum magnam labore etincidunt etincidunt porro."
            },
            {
                "_id": "E00022A",
                "name": "Endothelial cell marker CDH5",
                "abreviations": [
                    "54D"
                ],
                "categoryId": "Lipid",
                "description": "Magnam magnam non amet. Voluptatem magnam modi tempora ipsum porro eius porro. Dolore neque porro eius quiquia eius modi dolorem. Consectetur etincidunt sit aliquam dolor velit adipisci. Dolor dolore sed magnam."
            },
            {
                "_id": "E00022B",
                "name": "miR-224",
                "abreviations": [
                    "7B8",
                    "1FAD",
                    "147"
                ],
                "categoryId": "Others",
                "description": "Dolorem magnam modi quaerat velit magnam porro quiquia. Numquam non dolor non magnam dolore quaerat. Consectetur ut labore ipsum ut. Dolor sed quaerat sed. Quisquam amet voluptatem neque magnam labore amet. Non dolor quaerat quaerat voluptatem numquam voluptatem modi. Aliquam amet porro voluptatem labore porro consectetur adipisci. Ut consectetur labore ipsum non tempora est amet. Sit dolore amet dolorem magnam ipsum voluptatem. Dolor quaerat dolore dolor."
            },
            {
                "_id": "E00022C",
                "name": "Histone H1 (B419)",
                "abreviations": [
                    "187F",
                    "FF1"
                ],
                "categoryId": "Labelling index",
                "description": "Consectetur tempora quaerat ut eius consectetur. Amet tempora quisquam tempora quisquam. Ipsum consectetur ipsum labore consectetur eius voluptatem non. Quaerat aliquam dolor consectetur labore quaerat ipsum quisquam. Magnam magnam tempora porro modi neque adipisci. Etincidunt est adipisci labore aliquam ut. Ipsum numquam neque velit labore. Consectetur sed etincidunt eius velit. Etincidunt est adipisci dolore amet quaerat eius consectetur. Velit tempora est voluptatem dolor est ipsum."
            },
            {
                "_id": "E00022D",
                "name": "20 small molecule metabolites",
                "abreviations": [],
                "categoryId": "DNA",
                "description": "Ut porro adipisci ipsum neque quisquam quiquia consectetur. Dolorem tempora non est tempora aliquam amet sed. Magnam magnam magnam aliquam quaerat. Sit velit etincidunt dolore ipsum sed voluptatem numquam. Amet numquam est sit ut dolor tempora aliquam. Eius quaerat sed tempora consectetur velit voluptatem. Modi neque ut est."
            },
            {
                "_id": "E00022E",
                "name": "G-CIMP",
                "abreviations": [
                    "26A4",
                    "23AB",
                    "E41",
                    "13C3",
                    "14AD"
                ],
                "categoryId": "Labelling index",
                "description": "Voluptatem etincidunt porro magnam. Magnam dolore dolor consectetur. Sit dolorem amet velit aliquam dolore ipsum. Numquam porro eius adipisci modi ipsum. Non dolorem sit aliquam aliquam. Ipsum aliquam quisquam dolor. Consectetur dolore porro quaerat amet amet consectetur neque. Numquam non numquam quisquam eius velit quiquia. Quaerat quisquam aliquam dolore aliquam non eius sed."
            },
            {
                "_id": "E00022F",
                "name": "Ubiquitin-conjugating enzyme E2C",
                "abreviations": [
                    "1FA9",
                    "24F6"
                ],
                "categoryId": "Protein",
                "description": "Aliquam eius non ut amet dolorem. Amet labore tempora tempora sed. Non eius ipsum quiquia magnam sed tempora. Quaerat voluptatem modi non dolore dolore voluptatem quiquia. Modi etincidunt sed modi magnam aliquam adipisci adipisci. Quaerat numquam ipsum est numquam adipisci eius ut."
            },
            {
                "_id": "E000230",
                "name": "SLC22A18 protein expression",
                "abreviations": [
                    "1AB3",
                    "17C7",
                    "96D",
                    "19EA"
                ],
                "categoryId": "Enzyme",
                "description": "Voluptatem sed quiquia dolorem neque etincidunt neque quiquia. Quiquia dolorem sed ut eius dolorem. Quisquam modi quisquam adipisci etincidunt velit tempora. Ipsum dolorem labore numquam adipisci adipisci labore voluptatem. Quaerat tempora numquam numquam dolorem consectetur magnam ut. Dolore labore amet labore aliquam. Etincidunt quisquam dolorem numquam sed. Voluptatem quaerat adipisci porro sit."
            },
            {
                "_id": "E000231",
                "name": "Pentraxin",
                "abreviations": [
                    "33F",
                    "15DC",
                    "22BD",
                    "231C",
                    "24E5"
                ],
                "categoryId": "Protein",
                "description": "Eius sit magnam sed ipsum porro numquam. Sed quisquam neque est adipisci. Sit velit sit quisquam tempora dolore quiquia aliquam. Quiquia ipsum est porro est. Tempora numquam ipsum amet non. Aliquam consectetur etincidunt velit aliquam amet porro. Dolore adipisci modi sed labore eius. Quiquia magnam amet labore. Velit amet tempora modi quiquia dolorem voluptatem."
            },
            {
                "_id": "E000232",
                "name": "Cysteine-rich protein 61",
                "abreviations": [],
                "categoryId": "Stem cells",
                "description": "Numquam quiquia magnam sit etincidunt adipisci. Tempora aliquam numquam ut. Porro labore dolore sit quiquia velit etincidunt tempora. Labore magnam numquam labore porro amet voluptatem magnam. Etincidunt eius labore dolorem quiquia consectetur sed ipsum."
            },
            {
                "_id": "E000233",
                "name": "PDLI4 expression",
                "abreviations": [],
                "categoryId": "Metabolite",
                "description": "Quisquam eius quisquam sit dolor. Dolorem dolorem ut neque quisquam etincidunt. Aliquam adipisci magnam porro magnam quisquam eius. Velit quiquia quiquia modi. Quaerat quiquia labore numquam."
            },
            {
                "_id": "E000234",
                "name": "p Met",
                "abreviations": [
                    "1C5A",
                    "254C",
                    "13CD"
                ],
                "categoryId": "Others",
                "description": "Porro numquam adipisci sit est sit porro. Dolore velit numquam porro. Velit est dolorem etincidunt etincidunt magnam. Sit dolore tempora adipisci dolor eius numquam labore. Non etincidunt quiquia porro numquam. Sit etincidunt velit dolorem amet est numquam ipsum."
            },
            {
                "_id": "E000235",
                "name": "TM7SF4",
                "abreviations": [
                    "D39"
                ],
                "categoryId": "Protein",
                "description": "Quisquam dolore ipsum eius magnam labore voluptatem. Est dolor quiquia aliquam. Amet labore labore eius dolore consectetur. Ut quaerat non quaerat. Amet magnam etincidunt magnam dolorem. Est dolorem ut dolorem voluptatem labore quisquam dolor."
            },
            {
                "_id": "E000236",
                "name": "MSN",
                "abreviations": [
                    "1E17",
                    "2298"
                ],
                "categoryId": "Cytokine",
                "description": "Dolorem labore tempora dolor neque est. Sit quiquia consectetur labore adipisci non magnam voluptatem. Tempora amet amet quisquam sit. Eius aliquam magnam aliquam ipsum amet non quaerat. Sed consectetur numquam voluptatem. Sed magnam velit aliquam. Adipisci ipsum est dolorem dolore non numquam quisquam. Quiquia numquam eius sed quisquam tempora dolorem. Labore numquam eius dolorem. Tempora sit adipisci tempora dolore."
            },
            {
                "_id": "E000237",
                "name": "miR-34a",
                "abreviations": [
                    "14C",
                    "59A"
                ],
                "categoryId": "Other",
                "description": "Quiquia adipisci non est eius adipisci neque magnam. Dolor quiquia sit consectetur. Magnam tempora dolore magnam dolorem numquam magnam. Porro non aliquam amet numquam velit dolore tempora. Voluptatem sed amet amet quaerat. Quiquia aliquam amet etincidunt voluptatem. Eius amet amet quaerat voluptatem sit dolorem dolor."
            },
            {
                "_id": "E000238",
                "name": "Glycosyltransferase mRNA",
                "abreviations": [
                    "34E",
                    "3B7",
                    "1D06"
                ],
                "categoryId": "Lipid",
                "description": "Sit dolorem tempora eius tempora modi ipsum. Quiquia ipsum quaerat dolore neque. Non dolore voluptatem ipsum. Modi quisquam numquam dolor est. Adipisci non magnam consectetur. Tempora amet porro ut dolore neque. Non dolor sed eius magnam magnam. Porro numquam ipsum non sit."
            },
            {
                "_id": "E000239",
                "name": "Tenascin-C",
                "abreviations": [
                    "22E5",
                    "25F6",
                    "2F1",
                    "E1C"
                ],
                "categoryId": "Others",
                "description": "Quaerat amet quaerat non. Voluptatem labore dolorem adipisci. Est modi etincidunt magnam sit ut. Sed non tempora velit voluptatem tempora est neque. Neque labore etincidunt dolorem sed. Ipsum voluptatem sit sit ut quiquia ipsum. Numquam neque labore adipisci numquam dolore est. Eius ut aliquam dolore velit. Voluptatem dolore dolorem voluptatem."
            },
            {
                "_id": "E00023A",
                "name": "IDH1 mutations",
                "abreviations": [
                    "1C0B",
                    "5B1"
                ],
                "categoryId": "Lipid",
                "description": "Labore voluptatem consectetur velit dolore. Dolorem voluptatem neque adipisci modi ipsum. Ipsum adipisci consectetur est ut non ut. Ut tempora consectetur sit labore dolorem. Dolor neque ipsum dolorem aliquam ipsum ipsum labore. Ipsum sit ipsum velit. Amet neque quiquia voluptatem dolore. Quaerat amet dolor porro dolorem. Aliquam amet quiquia dolore quiquia quaerat aliquam magnam."
            },
            {
                "_id": "E00023B",
                "name": "microRNA-15b",
                "abreviations": [
                    "1CD9",
                    "2132"
                ],
                "categoryId": "Enzyme",
                "description": "Magnam neque etincidunt velit non. Adipisci non velit est quaerat neque velit neque. Numquam velit magnam velit adipisci sit velit modi. Dolorem magnam voluptatem amet porro aliquam. Dolor quaerat adipisci ipsum quiquia. Eius numquam modi dolor eius quisquam. Magnam modi numquam adipisci sed ut magnam quisquam. Velit eius ut velit magnam magnam numquam. Sed velit adipisci quisquam."
            },
            {
                "_id": "E00023C",
                "name": "microRNA-218",
                "abreviations": [
                    "17F2",
                    "470"
                ],
                "categoryId": "Other",
                "description": "Quiquia magnam dolore labore quaerat quaerat quiquia. Labore adipisci amet eius. Dolorem etincidunt tempora quisquam labore porro. Neque est sed tempora labore amet. Magnam dolore quiquia velit neque quaerat. Quisquam adipisci ipsum voluptatem aliquam etincidunt labore voluptatem. Neque magnam labore porro labore etincidunt. Est tempora magnam modi consectetur velit. Dolore quaerat dolorem ipsum adipisci. Numquam labore dolore numquam voluptatem etincidunt sed."
            },
            {
                "_id": "E00023D",
                "name": "Caspase-3",
                "abreviations": [
                    "13E2",
                    "979",
                    "1BF9",
                    "191D",
                    "1970"
                ],
                "categoryId": "Aminopeptidase",
                "description": "Dolor voluptatem non aliquam ut sit quisquam velit. Quisquam quiquia numquam neque. Velit dolor quaerat tempora velit. Magnam dolore adipisci sed. Aliquam dolorem labore neque labore. Adipisci neque tempora dolore dolor est quisquam. Magnam adipisci eius porro sit. Quisquam non quaerat quiquia consectetur."
            },
            {
                "_id": "E00023E",
                "name": "TES",
                "abreviations": [
                    "1804",
                    "24D6"
                ],
                "categoryId": "DNA",
                "description": "Tempora porro amet quaerat tempora. Eius dolorem ipsum adipisci. Modi aliquam ipsum etincidunt. Consectetur modi adipisci velit quiquia consectetur. Amet amet aliquam ipsum non sed. Porro quaerat eius non sed quiquia. Quisquam dolor sit sed. Aliquam consectetur etincidunt sed consectetur quaerat amet. Consectetur dolore consectetur est est consectetur quaerat adipisci."
            },
            {
                "_id": "E00023F",
                "name": "MMP2",
                "abreviations": [
                    "20E9"
                ],
                "categoryId": "Stem cells",
                "description": "Voluptatem est magnam eius dolore. Quiquia aliquam porro porro porro. Eius ut voluptatem sit. Ipsum quaerat neque modi quiquia. Non labore dolorem etincidunt ut dolor amet voluptatem. Aliquam magnam dolore voluptatem aliquam ipsum est."
            },
            {
                "_id": "E000240",
                "name": "Glutamine Synthetase",
                "abreviations": [
                    "19EC",
                    "1028",
                    "6E7"
                ],
                "categoryId": "Enzyme",
                "description": "Etincidunt magnam eius porro non sed est tempora. Voluptatem adipisci neque etincidunt labore modi tempora neque. Magnam dolor ipsum quiquia dolor. Magnam dolor dolorem sed magnam est consectetur. Modi etincidunt numquam etincidunt dolore quisquam. Dolorem ut neque eius. Neque consectetur modi ipsum dolor. Tempora adipisci dolorem eius magnam sit magnam magnam. Quisquam ipsum consectetur tempora neque. Dolore dolor tempora labore voluptatem non magnam."
            },
            {
                "_id": "E000241",
                "name": "Plexin-B2",
                "abreviations": [],
                "categoryId": "Labelling index",
                "description": "Porro ut velit ipsum quiquia. Quisquam ut modi aliquam non sit labore. Etincidunt non non neque eius. Amet ipsum quisquam ut consectetur consectetur. Ipsum dolorem labore dolor non eius sit. Aliquam etincidunt amet tempora tempora dolorem sit adipisci."
            },
            {
                "_id": "E000242",
                "name": "Aurora A expression",
                "abreviations": [
                    "BE",
                    "1AFC"
                ],
                "categoryId": "Stem cells",
                "description": "Quaerat magnam porro tempora ut ut magnam quiquia. Eius etincidunt neque neque. Ut modi amet velit etincidunt neque numquam. Ut aliquam adipisci quiquia. Labore sit etincidunt modi. Ut ut non amet tempora dolorem amet aliquam. Quiquia ipsum quisquam aliquam ipsum numquam."
            },
            {
                "_id": "E000243",
                "name": "DNA topoisomerase II\u03b1",
                "abreviations": [
                    "74E",
                    "E4"
                ],
                "categoryId": "Protein",
                "description": "Etincidunt adipisci labore tempora quaerat. Amet ipsum modi adipisci neque. Ipsum non ut quaerat velit numquam aliquam. Tempora eius labore tempora. Quaerat labore quiquia ipsum magnam. Sit quaerat quisquam modi velit neque porro. Voluptatem numquam adipisci velit voluptatem neque. Ipsum dolor porro aliquam quiquia quaerat. Dolore aliquam ipsum modi. Ipsum magnam dolorem velit non."
            },
            {
                "_id": "E000244",
                "name": "miR-17-5p",
                "abreviations": [
                    "1F84"
                ],
                "categoryId": "Labelling index",
                "description": "Numquam quiquia ut porro quisquam. Ipsum modi eius sit quiquia quaerat etincidunt magnam. Etincidunt adipisci dolore porro. Aliquam non sed etincidunt. Est ut ipsum sed. Numquam ut adipisci tempora consectetur numquam sit. Consectetur dolore amet quiquia adipisci. Quisquam numquam neque non. Quiquia quiquia porro non ipsum. Adipisci ut quisquam adipisci sit magnam."
            },
            {
                "_id": "E000245",
                "name": "MGMT promoter methylation",
                "abreviations": [
                    "1C68"
                ],
                "categoryId": "Labelling index",
                "description": "Sit ipsum porro sed velit sit. Magnam ut labore non. Dolorem eius tempora modi numquam numquam. Etincidunt sed est ipsum. Adipisci modi dolorem labore eius. Etincidunt porro amet voluptatem dolor ipsum ut voluptatem. Ipsum sit amet tempora adipisci aliquam quisquam. Consectetur numquam porro dolore voluptatem. Neque amet neque ipsum modi numquam."
            },
            {
                "_id": "E000246",
                "name": "DJ-1",
                "abreviations": [
                    "1045",
                    "1470",
                    "22E5",
                    "2184",
                    "D84"
                ],
                "categoryId": "Lipid",
                "description": "Quaerat modi numquam quiquia sed adipisci. Porro consectetur velit non. Eius etincidunt etincidunt porro amet. Quiquia sed voluptatem amet eius. Quisquam dolor tempora ipsum eius. Labore sit labore porro aliquam. Tempora quiquia eius voluptatem sed porro quiquia. Adipisci quaerat etincidunt quiquia porro voluptatem labore."
            },
            {
                "_id": "E000247",
                "name": "MIB1 index",
                "abreviations": [
                    "600",
                    "10E8"
                ],
                "categoryId": "Lipid",
                "description": "Dolor sit etincidunt sed magnam labore. Magnam consectetur non quiquia amet est. Dolor eius quisquam voluptatem tempora. Aliquam velit quiquia dolorem adipisci amet. Ut sit quaerat labore numquam ipsum sit. Etincidunt quaerat modi voluptatem. Neque tempora tempora numquam porro eius amet. Quiquia voluptatem numquam neque sit sit porro dolore. Sit eius porro sit eius. Etincidunt quiquia non dolorem velit porro consectetur."
            },
            {
                "_id": "E000248",
                "name": "Parkin",
                "abreviations": [
                    "1440",
                    "26DB",
                    "8",
                    "2695"
                ],
                "categoryId": "Others",
                "description": "Adipisci modi amet magnam ut dolore consectetur amet. Est tempora quiquia sed amet ipsum tempora quiquia. Consectetur modi modi est amet modi consectetur quaerat. Voluptatem dolore etincidunt ipsum non. Non tempora amet sed eius dolorem sed. Ut tempora consectetur quisquam quiquia dolorem dolor. Est sed velit dolor neque ut est. Dolore quisquam tempora eius dolorem porro eius. Ut neque quaerat aliquam magnam magnam porro. Labore sit labore quaerat neque dolore amet."
            },
            {
                "_id": "E000249",
                "name": "Epidermal growth factor receptor gene",
                "abreviations": [
                    "2349",
                    "2390",
                    "C8",
                    "1E46"
                ],
                "categoryId": "Aminopeptidase",
                "description": "Velit eius dolor quaerat ut. Quisquam dolor eius quiquia amet tempora quaerat dolor. Voluptatem ipsum ut consectetur sit voluptatem consectetur. Neque porro amet voluptatem consectetur neque aliquam. Aliquam amet quaerat amet quaerat sit. Eius etincidunt labore adipisci neque modi voluptatem. Dolore quiquia velit sit dolore voluptatem. Magnam porro numquam consectetur eius est voluptatem. Neque tempora neque est. Non magnam labore sit ut porro dolore voluptatem."
            },
            {
                "_id": "E00024A",
                "name": "MDM2 amplification",
                "abreviations": [
                    "ECD",
                    "83C",
                    "A91",
                    "1A8E"
                ],
                "categoryId": "Aminopeptidase",
                "description": "Quisquam numquam aliquam eius non non ut consectetur. Modi quiquia eius sit eius. Dolore non ipsum sed. Aliquam dolor ut porro. Tempora tempora quaerat dolore dolorem. Ipsum aliquam dolorem non consectetur."
            },
            {
                "_id": "E00024B",
                "name": "microRNA-124a",
                "abreviations": [
                    "1B85",
                    "762",
                    "90",
                    "2164",
                    "8A5"
                ],
                "categoryId": "DNA",
                "description": "Consectetur quisquam amet non magnam dolorem sed. Eius voluptatem dolorem numquam adipisci adipisci etincidunt amet. Velit eius quaerat sed etincidunt. Est dolor dolorem ut sed ipsum tempora. Adipisci sit quiquia aliquam. Consectetur consectetur amet porro quiquia."
            },
            {
                "_id": "E00024C",
                "name": "Rad51",
                "abreviations": [
                    "13FD"
                ],
                "categoryId": "Stem cells",
                "description": "Quaerat tempora ipsum adipisci numquam magnam. Voluptatem dolore dolorem magnam quisquam est dolor. Numquam neque ipsum quiquia ipsum. Voluptatem sed tempora neque ipsum eius numquam modi. Ut quaerat ipsum labore est."
            },
            {
                "_id": "E00024D",
                "name": "miR-93",
                "abreviations": [],
                "categoryId": "Others",
                "description": "Amet quaerat dolore est tempora voluptatem quaerat. Magnam ipsum etincidunt dolore adipisci velit adipisci. Adipisci eius est etincidunt magnam tempora porro. Quaerat eius modi adipisci quisquam sit. Velit eius consectetur dolore aliquam porro. Sit labore neque numquam quisquam."
            },
            {
                "_id": "E00024E",
                "name": "Wingless-type MMTV integration site family member 6",
                "abreviations": [
                    "1EC5"
                ],
                "categoryId": "Other",
                "description": "Ut numquam quiquia sed sit dolorem etincidunt tempora. Amet porro consectetur voluptatem quisquam consectetur. Modi adipisci adipisci velit etincidunt. Non porro velit sit etincidunt. Etincidunt quisquam dolore ipsum porro. Eius voluptatem aliquam amet. Sit etincidunt ut ipsum tempora magnam numquam. Voluptatem quisquam quaerat voluptatem."
            },
            {
                "_id": "E00024F",
                "name": "PAI-1",
                "abreviations": [
                    "26E",
                    "624",
                    "2C4",
                    "1498",
                    "1130"
                ],
                "categoryId": "Cytokine",
                "description": "Consectetur amet etincidunt voluptatem etincidunt est modi adipisci. Sit modi consectetur non dolor. Quaerat consectetur tempora dolorem non. Dolore consectetur aliquam labore. Aliquam dolore neque amet. Voluptatem neque porro dolor sed ipsum quaerat. Dolore quiquia consectetur sit modi numquam. Dolore quiquia numquam tempora quisquam sed. Eius adipisci ipsum consectetur numquam voluptatem porro."
            },
            {
                "_id": "E000250",
                "name": "N-myc (and STAT) interactor expression",
                "abreviations": [
                    "26D0",
                    "1624",
                    "1DD7",
                    "1FD0",
                    "78"
                ],
                "categoryId": "DNA",
                "description": "Est dolorem eius sit. Adipisci ut neque quiquia consectetur. Adipisci sit porro non adipisci dolorem voluptatem. Ut sed velit voluptatem. Non magnam quiquia dolor magnam. Dolore dolore ut modi porro numquam quaerat."
            },
            {
                "_id": "E000251",
                "name": "poly(ADP-ribose)polymerase 1",
                "abreviations": [
                    "1C23"
                ],
                "categoryId": "Aminopeptidase",
                "description": "Aliquam numquam ut quisquam amet velit labore labore. Consectetur velit numquam velit etincidunt dolorem ut. Ut dolore dolorem amet. Consectetur amet labore eius ut labore sit neque. Consectetur dolorem magnam dolorem dolore dolore neque ipsum. Adipisci modi tempora numquam etincidunt velit. Amet eius etincidunt adipisci numquam dolorem quiquia ut. Eius tempora sit velit non sed porro. Amet modi amet adipisci."
            },
            {
                "_id": "E000252",
                "name": "Msh2",
                "abreviations": [
                    "1CAA",
                    "171A",
                    "4E5",
                    "4C8",
                    "10FD"
                ],
                "categoryId": "Other",
                "description": "Velit dolore eius dolore ut eius sed dolor. Dolorem est voluptatem etincidunt dolorem. Ipsum sit eius modi. Aliquam tempora modi adipisci etincidunt sit quiquia ipsum. Velit etincidunt labore eius sed etincidunt. Modi ipsum non quaerat voluptatem. Consectetur quisquam modi porro. Amet quiquia ipsum amet neque dolorem est. Quisquam ipsum ut non quisquam."
            },
            {
                "_id": "E000253",
                "name": "IGFBP-3",
                "abreviations": [],
                "categoryId": "DNA",
                "description": "Labore amet aliquam sit. Sit ut modi dolore labore tempora velit. Est dolorem numquam dolorem modi sed consectetur. Neque ut velit labore est. Ipsum aliquam quiquia numquam numquam quaerat dolorem. Amet numquam voluptatem dolore consectetur quiquia est. Numquam modi amet est."
            },
            {
                "_id": "E000254",
                "name": "Cell division cycle 5-like",
                "abreviations": [
                    "175E",
                    "BAE"
                ],
                "categoryId": "Enzyme",
                "description": "Quaerat adipisci etincidunt quaerat aliquam consectetur. Magnam ipsum numquam dolor eius ipsum. Est magnam dolor ipsum voluptatem adipisci ipsum. Aliquam neque quaerat voluptatem labore magnam tempora. Numquam sed numquam voluptatem labore non dolorem sit. Porro porro quisquam ipsum est labore. Quaerat labore tempora porro est modi dolor adipisci."
            },
            {
                "_id": "E000255",
                "name": "miR-1238",
                "abreviations": [
                    "A77",
                    "22F2",
                    "1C06"
                ],
                "categoryId": "RNA",
                "description": "Consectetur porro neque sit neque. Porro aliquam consectetur aliquam ipsum quaerat sed ut. Aliquam aliquam quisquam tempora numquam non. Sed quiquia numquam dolor. Neque sit voluptatem quisquam consectetur. Sit consectetur velit est dolorem. Numquam non voluptatem quaerat sed. Magnam non sed non ut."
            },
            {
                "_id": "E000256",
                "name": "hsa-let-7b-5p",
                "abreviations": [
                    "275",
                    "2302",
                    "1FEB"
                ],
                "categoryId": "Stem cells",
                "description": "Ut porro etincidunt quaerat tempora est neque. Quaerat etincidunt modi numquam dolore consectetur dolor adipisci. Est dolorem eius dolore modi etincidunt sit non. Etincidunt neque velit numquam numquam voluptatem. Dolor dolor dolore eius porro. Labore etincidunt quisquam adipisci dolorem eius voluptatem. Aliquam sit numquam amet porro tempora dolorem."
            },
            {
                "_id": "E000257",
                "name": "PTDSR",
                "abreviations": [
                    "15D9",
                    "2293",
                    "19C3",
                    "1D02"
                ],
                "categoryId": "Others",
                "description": "Tempora modi eius numquam. Sit neque sit eius adipisci ut quiquia ipsum. Sit quiquia est dolorem tempora. Tempora etincidunt tempora neque numquam. Non adipisci adipisci eius. Tempora adipisci consectetur non. Sit modi magnam numquam quiquia ut quisquam numquam. Dolore aliquam ipsum ut non quiquia."
            },
            {
                "_id": "E000258",
                "name": "WEE1 Kinase",
                "abreviations": [],
                "categoryId": "Protein",
                "description": "Quaerat modi porro dolor. Quiquia amet dolor etincidunt. Quiquia voluptatem sit dolor numquam neque dolore. Amet quaerat quaerat adipisci dolore eius est modi. Labore aliquam neque magnam adipisci."
            },
            {
                "_id": "E000259",
                "name": "Minichromosome Maintenance Protein 7",
                "abreviations": [
                    "1A0",
                    "748"
                ],
                "categoryId": "Others",
                "description": "Ut sit velit est sit sit consectetur eius. Aliquam aliquam quisquam consectetur neque modi. Dolorem etincidunt dolor tempora etincidunt sed numquam. Dolore quaerat sit sit porro etincidunt. Dolore numquam sed sit amet sed. Velit quaerat eius non. Magnam quiquia voluptatem adipisci adipisci quisquam ut non. Modi etincidunt quaerat velit ipsum adipisci."
            },
            {
                "_id": "E00025A",
                "name": "p27",
                "abreviations": [
                    "16E5",
                    "826",
                    "2CF"
                ],
                "categoryId": "Others",
                "description": "Numquam labore quiquia sed velit non amet. Ut ipsum sed voluptatem ipsum velit consectetur ut. Etincidunt voluptatem sit dolor. Sit sed est quiquia porro. Voluptatem tempora etincidunt numquam non. Adipisci magnam sed etincidunt."
            },
            {
                "_id": "E00025B",
                "name": "Cadherin 2 expression",
                "abreviations": [
                    "1BFC",
                    "1D0D",
                    "BE9",
                    "1598"
                ],
                "categoryId": "Other",
                "description": "Dolorem dolor tempora quaerat adipisci. Ut dolor quiquia quiquia dolor amet. Modi est tempora eius quisquam neque est modi. Sit etincidunt eius magnam modi. Modi dolor voluptatem aliquam adipisci sit modi. Dolore quisquam numquam consectetur voluptatem amet dolore voluptatem."
            },
            {
                "_id": "E00025C",
                "name": "Decoy receptor 3",
                "abreviations": [
                    "8C9",
                    "1D17",
                    "1107"
                ],
                "categoryId": "Other",
                "description": "Sit modi quaerat dolor. Neque tempora adipisci aliquam velit sit magnam non. Etincidunt magnam magnam porro dolore magnam. Modi non aliquam quiquia etincidunt. Adipisci dolor ut voluptatem sed voluptatem adipisci quaerat. Amet neque neque adipisci amet sit magnam. Dolor aliquam sed magnam quiquia sit. Velit dolorem sed numquam velit porro voluptatem aliquam. Dolor neque neque consectetur magnam labore numquam dolore. Numquam modi adipisci dolor dolor."
            },
            {
                "_id": "E00025D",
                "name": "EphA2 expression",
                "abreviations": [
                    "AE9",
                    "BBE",
                    "11CE",
                    "146F"
                ],
                "categoryId": "Cytokine",
                "description": "Numquam aliquam quaerat magnam tempora numquam aliquam est. Amet ut tempora porro eius tempora. Numquam consectetur etincidunt quaerat magnam dolor ipsum. Quaerat porro voluptatem quiquia amet sit tempora ipsum. Dolor etincidunt porro neque sed. Dolor neque dolore numquam labore voluptatem ipsum. Quaerat voluptatem quisquam quaerat est non. Tempora adipisci est quiquia est."
            },
            {
                "_id": "E00025E",
                "name": "Collagen-VI-alpha1",
                "abreviations": [
                    "1401",
                    "CF0",
                    "14A7"
                ],
                "categoryId": "Cytokine",
                "description": "Magnam consectetur adipisci etincidunt modi est velit etincidunt. Tempora amet etincidunt est amet dolore velit. Dolor modi sed quisquam. Modi numquam quaerat eius eius. Amet ut porro eius ipsum. Quaerat non consectetur labore. Neque labore tempora velit eius velit."
            },
            {
                "_id": "E00025F",
                "name": "ANGPT1/ANGPT2 balance",
                "abreviations": [
                    "1CF4",
                    "388"
                ],
                "categoryId": "Enzyme",
                "description": "Eius numquam consectetur labore sed. Adipisci tempora tempora dolore ut ut quaerat dolore. Voluptatem aliquam modi tempora est eius. Numquam voluptatem dolor ut. Quaerat tempora neque amet."
            },
            {
                "_id": "E000260",
                "name": "AMPK1",
                "abreviations": [
                    "1304",
                    "142C"
                ],
                "categoryId": "Aminopeptidase",
                "description": "Tempora sed quaerat quiquia. Dolorem ut sed dolore labore neque ipsum voluptatem. Labore tempora dolore aliquam. Magnam quaerat amet quisquam adipisci quisquam. Quaerat sed tempora neque est sit."
            },
            {
                "_id": "E000261",
                "name": "Autocrine motility factor mRNA",
                "abreviations": [
                    "885",
                    "1FA9",
                    "1CDB",
                    "1B20"
                ],
                "categoryId": "Other",
                "description": "Modi labore velit aliquam. Eius est sit adipisci tempora. Est magnam non ut. Est dolorem porro amet. Velit sed eius modi eius etincidunt etincidunt. Ipsum etincidunt adipisci amet ut eius. Quaerat velit sed adipisci voluptatem. Aliquam sed etincidunt etincidunt ipsum sed dolor dolorem."
            },
            {
                "_id": "E000262",
                "name": "5-hydroxymethylcytosine",
                "abreviations": [],
                "categoryId": "Protein",
                "description": "Eius labore voluptatem quisquam eius. Magnam voluptatem consectetur numquam sit. Adipisci numquam adipisci ut eius ut. Etincidunt eius adipisci dolorem voluptatem sit labore. Aliquam quisquam quisquam velit aliquam labore. Etincidunt neque amet amet etincidunt quaerat. Numquam dolore consectetur ut quaerat consectetur."
            },
            {
                "_id": "E000263",
                "name": "Nestin expression",
                "abreviations": [
                    "18E4",
                    "CF3",
                    "22C3",
                    "2136"
                ],
                "categoryId": "Others",
                "description": "Neque sit neque est dolor sit neque. Labore neque sed modi ut voluptatem adipisci. Consectetur dolore neque numquam tempora. Modi dolorem ut quisquam ipsum voluptatem neque amet. Sit consectetur eius sit etincidunt etincidunt. Non quiquia ut modi est numquam ut. Dolorem adipisci dolorem velit modi. Aliquam sed neque velit quisquam. Modi adipisci tempora non. Porro porro neque ipsum modi neque neque numquam."
            },
            {
                "_id": "E000264",
                "name": "Telomerase reverse transcriptase",
                "abreviations": [],
                "categoryId": "Enzyme",
                "description": "Aliquam voluptatem dolor aliquam quisquam sed consectetur magnam. Neque modi sed dolor dolore non ipsum. Consectetur dolor numquam velit numquam. Neque numquam etincidunt dolore neque est aliquam eius. Quisquam aliquam sit voluptatem dolore sit. Non labore dolor consectetur non velit sit. Porro ipsum magnam aliquam porro. Eius ut eius ut neque dolor."
            },
            {
                "_id": "E000265",
                "name": "Genetic losses from chromosomes 19q",
                "abreviations": [
                    "2390",
                    "9D7",
                    "18CC"
                ],
                "categoryId": "DNA",
                "description": "Numquam modi est quiquia. Eius non quiquia quisquam. Porro quaerat sed tempora tempora. Dolore neque numquam quiquia sed porro quisquam. Dolor sit est non sed aliquam. Dolore quaerat quaerat quaerat. Adipisci neque numquam ipsum dolor. Est adipisci magnam quaerat est eius. Quiquia aliquam numquam dolore labore non sit."
            },
            {
                "_id": "E000266",
                "name": "Telomerase reverse transcriptase promoter",
                "abreviations": [],
                "categoryId": "Stem cells",
                "description": "Velit quisquam tempora quiquia sed tempora aliquam. Porro dolor modi est ut dolorem quisquam. Dolor sit porro magnam eius. Adipisci ut quisquam dolore velit tempora. Labore consectetur ut velit."
            },
            {
                "_id": "E000267",
                "name": "miR-423-5p",
                "abreviations": [
                    "B13",
                    "1163",
                    "E8F",
                    "193B"
                ],
                "categoryId": "Others",
                "description": "Magnam labore magnam magnam amet adipisci magnam dolor. Ipsum dolorem eius quisquam aliquam consectetur eius ipsum. Dolore ipsum dolor sit. Non adipisci quaerat modi dolore porro aliquam porro. Quiquia neque dolorem ipsum. Quaerat porro etincidunt quisquam quisquam modi sed quaerat. Numquam magnam adipisci non."
            },
            {
                "_id": "E000268",
                "name": "p53 expression",
                "abreviations": [],
                "categoryId": "Other",
                "description": "Voluptatem adipisci quaerat neque. Tempora adipisci adipisci quisquam aliquam porro neque modi. Eius velit numquam eius sed. Eius dolore quaerat ipsum. Sit ipsum quaerat adipisci etincidunt quiquia adipisci. Quiquia est numquam amet voluptatem amet adipisci. Numquam sit sed quisquam porro magnam magnam non. Labore neque tempora porro non modi est. Voluptatem dolorem porro quisquam numquam dolore eius. Est non aliquam quisquam sit."
            },
            {
                "_id": "E000269",
                "name": "RhoA",
                "abreviations": [
                    "5B2",
                    "2094",
                    "B82"
                ],
                "categoryId": "RNA",
                "description": "Voluptatem amet quisquam quiquia numquam tempora quisquam adipisci. Porro voluptatem dolorem quaerat amet quisquam amet est. Numquam etincidunt ut sit modi numquam velit. Amet tempora adipisci voluptatem tempora neque etincidunt. Sit quaerat adipisci ipsum adipisci ut labore dolore. Quiquia velit quisquam tempora sed. Quiquia sit velit modi. Dolorem amet voluptatem quaerat."
            },
            {
                "_id": "E00026A",
                "name": "LOC283731 promoter methylation",
                "abreviations": [
                    "968"
                ],
                "categoryId": "Others",
                "description": "Dolorem ipsum numquam neque ipsum sed. Dolorem consectetur dolor dolorem. Porro neque magnam dolorem ipsum quiquia aliquam. Aliquam tempora labore dolore dolor. Est quisquam labore quiquia."
            },
            {
                "_id": "E00026B",
                "name": "WDFY3-AS2",
                "abreviations": [
                    "1495",
                    "C7E",
                    "13F8"
                ],
                "categoryId": "Lipid",
                "description": "Velit velit modi ipsum ipsum. Magnam eius ut adipisci eius numquam. Dolorem etincidunt eius labore porro eius quiquia. Quisquam aliquam modi dolorem quiquia etincidunt. Amet dolore sed quisquam. Modi etincidunt sit aliquam. Tempora dolorem quisquam aliquam sed. Dolorem tempora porro numquam. Velit eius adipisci dolorem sit velit quiquia."
            },
            {
                "_id": "E00026C",
                "name": "pMAPK",
                "abreviations": [],
                "categoryId": "Labelling index",
                "description": "Voluptatem modi eius eius modi modi sit etincidunt. Etincidunt dolorem dolorem magnam est modi etincidunt etincidunt. Sed magnam sit magnam dolor aliquam quisquam. Dolor tempora quaerat amet neque magnam. Velit consectetur etincidunt magnam sed."
            },
            {
                "_id": "E00026D",
                "name": "miR-299",
                "abreviations": [
                    "1396",
                    "408",
                    "1999",
                    "391"
                ],
                "categoryId": "RNA",
                "description": "Est etincidunt magnam sed dolorem ut. Labore adipisci quiquia velit neque amet modi consectetur. Dolor magnam non dolorem. Est numquam quisquam modi consectetur quiquia quaerat. Consectetur adipisci adipisci est quaerat ut ipsum tempora. Etincidunt modi quisquam sit aliquam non. Non est magnam ut dolorem est velit voluptatem. Voluptatem neque tempora quiquia ut. Numquam tempora est numquam numquam voluptatem dolorem dolore."
            },
            {
                "_id": "E00026E",
                "name": "Capillary morphogenesis protein 2",
                "abreviations": [
                    "2671",
                    "B9E",
                    "D37",
                    "617",
                    "1AFD"
                ],
                "categoryId": "Metabolite",
                "description": "Magnam porro quaerat ut quaerat consectetur sit. Non voluptatem dolorem voluptatem dolor ut quaerat ut. Neque porro magnam neque voluptatem. Porro neque eius non modi numquam neque ipsum. Quisquam dolor quaerat ipsum. Etincidunt quaerat ut magnam consectetur porro voluptatem. Tempora est dolor sed consectetur voluptatem non sed. Ut numquam ipsum labore etincidunt. Sed consectetur etincidunt dolore modi consectetur. Amet velit quiquia neque numquam est."
            },
            {
                "_id": "E00026F",
                "name": "Phospholipase C beta 1",
                "abreviations": [
                    "12EC",
                    "24A5",
                    "21E2",
                    "177D",
                    "21C2"
                ],
                "categoryId": "Lipid",
                "description": "Dolor sed quisquam porro sed sed. Neque amet ut porro quiquia. Velit eius non dolorem consectetur ut adipisci consectetur. Neque quaerat porro quaerat sed consectetur consectetur tempora. Eius quisquam dolorem voluptatem eius. Aliquam neque aliquam modi sed. Quaerat dolor sit est porro numquam. Dolorem porro magnam consectetur ut velit eius. Neque dolorem consectetur numquam porro aliquam. Quaerat velit modi amet ipsum sed est."
            },
            {
                "_id": "E000270",
                "name": "Telomerase activity",
                "abreviations": [],
                "categoryId": "Cytokine",
                "description": "Ipsum aliquam adipisci consectetur numquam. Sed velit labore porro porro quaerat dolor aliquam. Dolor numquam ut adipisci quisquam sit. Labore tempora amet velit neque. Sit velit consectetur ut sed. Porro sed non numquam tempora."
            },
            {
                "_id": "E000271",
                "name": "Neuroglobin",
                "abreviations": [
                    "FAB",
                    "733",
                    "20D6",
                    "BB",
                    "139A"
                ],
                "categoryId": "Lipid",
                "description": "Quaerat voluptatem non eius quisquam etincidunt. Non dolorem voluptatem adipisci etincidunt magnam. Magnam tempora ipsum aliquam. Quiquia dolore tempora amet est. Neque neque neque etincidunt. Adipisci dolore velit neque eius aliquam aliquam. Voluptatem dolorem eius aliquam."
            },
            {
                "_id": "E000272",
                "name": "CD9",
                "abreviations": [
                    "A8E",
                    "FB3",
                    "1DE3",
                    "176D",
                    "9ED"
                ],
                "categoryId": "RNA",
                "description": "Dolor quiquia dolor labore quisquam etincidunt aliquam sit. Numquam est consectetur dolor. Neque sit sed eius non amet. Consectetur magnam magnam amet tempora quiquia. Velit sed quaerat est dolorem. Sit quiquia numquam quisquam adipisci sit."
            },
            {
                "_id": "E000273",
                "name": "miR-196b",
                "abreviations": [
                    "18D6",
                    "14BC",
                    "4E4",
                    "1D47"
                ],
                "categoryId": "Labelling index",
                "description": "Etincidunt ipsum voluptatem est ipsum labore. Dolor sed amet sed neque sed. Dolore dolorem magnam dolor. Non etincidunt adipisci quiquia dolorem quaerat quisquam dolor. Sit tempora ipsum voluptatem. Modi sit consectetur dolor sed porro. Sit neque adipisci sed quaerat. Amet dolorem eius etincidunt est."
            },
            {
                "_id": "E000274",
                "name": "Notch",
                "abreviations": [],
                "categoryId": "Protein",
                "description": "Dolore etincidunt quisquam ut. Non dolor sed porro ipsum numquam dolorem ipsum. Numquam neque etincidunt velit quisquam etincidunt. Neque etincidunt dolor magnam. Dolore ipsum modi numquam numquam adipisci. Quisquam sit quisquam ipsum. Tempora labore quisquam modi non velit neque."
            },
            {
                "_id": "E000275",
                "name": "Aldehyde dehydrogenase 1A1",
                "abreviations": [
                    "15EA",
                    "2539",
                    "1FFC"
                ],
                "categoryId": "Enzyme",
                "description": "Aliquam velit labore consectetur tempora. Ut etincidunt numquam numquam quiquia sit consectetur quiquia. Velit eius non numquam quaerat. Etincidunt quaerat ipsum aliquam quiquia dolor adipisci. Etincidunt neque modi voluptatem sed."
            },
            {
                "_id": "E000276",
                "name": "Isocitrate dehydrogenase 1/2",
                "abreviations": [
                    "1501"
                ],
                "categoryId": "Other",
                "description": "Porro dolore numquam modi adipisci tempora non. Velit neque numquam ipsum aliquam neque labore. Adipisci quisquam velit adipisci dolor neque quisquam. Numquam velit quiquia ipsum numquam adipisci dolore dolore. Porro labore dolorem neque amet. Consectetur dolor dolor ut. Tempora modi consectetur sit ut. Sit voluptatem non voluptatem tempora. Labore neque numquam non modi eius aliquam."
            },
            {
                "_id": "E000277",
                "name": "O6-methyl guanine O6-methylatransferase promoter methylation",
                "abreviations": [
                    "15D1",
                    "864",
                    "769",
                    "46A",
                    "3DA"
                ],
                "categoryId": "Other",
                "description": "Ipsum sed etincidunt ut quiquia adipisci etincidunt. Adipisci porro etincidunt quisquam consectetur adipisci. Ut quaerat modi magnam non amet. Consectetur est sed dolorem labore velit eius amet. Numquam voluptatem sed magnam labore est adipisci. Modi modi tempora non modi ut quiquia ipsum. Aliquam adipisci ipsum etincidunt."
            },
            {
                "_id": "E000278",
                "name": "HAR1B",
                "abreviations": [
                    "1801",
                    "1CC8",
                    "125C",
                    "66B",
                    "86D"
                ],
                "categoryId": "Protein",
                "description": "Sed est velit aliquam porro eius. Non dolor ipsum consectetur modi numquam porro. Quiquia sed voluptatem non velit quisquam velit. Sit velit labore voluptatem etincidunt labore ipsum etincidunt. Quaerat est adipisci eius dolorem quisquam porro."
            },
            {
                "_id": "E000279",
                "name": "O6-methylguanine O6-methylatransferase promoter methylation",
                "abreviations": [
                    "2136",
                    "25F3",
                    "A08",
                    "2227"
                ],
                "categoryId": "Labelling index",
                "description": "Etincidunt dolorem est velit non etincidunt quaerat. Quisquam ut sed est. Quisquam dolorem velit magnam sed tempora dolore magnam. Ipsum ipsum ut consectetur quiquia dolorem modi etincidunt. Dolorem sit neque neque neque aliquam ipsum aliquam. Voluptatem quaerat adipisci labore est voluptatem quiquia. Quaerat aliquam tempora quiquia quiquia sit dolor. Quaerat aliquam adipisci labore quaerat non quisquam labore. Modi numquam tempora sit quisquam dolore. Modi quisquam quisquam magnam adipisci sit sit quiquia."
            },
            {
                "_id": "E00027A",
                "name": "Telomerase-associated parameters",
                "abreviations": [],
                "categoryId": "Others",
                "description": "Est porro neque quaerat. Etincidunt sit magnam consectetur non aliquam neque etincidunt. Aliquam tempora labore modi etincidunt est velit dolor. Voluptatem dolore aliquam amet velit porro sed consectetur. Numquam est labore modi tempora. Modi etincidunt velit etincidunt. Quaerat ut aliquam dolorem numquam dolorem etincidunt. Ut ipsum eius porro tempora. Dolorem eius est ipsum. Amet etincidunt etincidunt magnam quiquia."
            },
            {
                "_id": "E00027B",
                "name": "Aldehyde dehydrogenase 1A1 expression",
                "abreviations": [],
                "categoryId": "Enzyme",
                "description": "Neque porro voluptatem porro. Est quaerat sed sed magnam voluptatem magnam eius. Neque consectetur neque adipisci. Non amet quiquia quisquam. Magnam dolor velit magnam sit dolorem ut numquam. Labore neque modi numquam quisquam. Porro sed amet dolor quisquam dolore velit. Quaerat labore dolor ut. Non sed numquam voluptatem ipsum dolorem eius numquam. Ut quiquia numquam velit adipisci."
            },
            {
                "_id": "E00027C",
                "name": "Sorcin",
                "abreviations": [
                    "4D4",
                    "217B"
                ],
                "categoryId": "Cytokine",
                "description": "Dolorem adipisci quiquia voluptatem porro consectetur sit etincidunt. Ipsum aliquam velit quaerat eius. Amet neque ipsum numquam dolorem non. Eius eius amet quisquam velit. Quaerat dolorem eius magnam est. Labore non magnam labore numquam non. Sit etincidunt sed eius sed. Amet ut amet sed."
            },
            {
                "_id": "E00027D",
                "name": "Dynein",
                "abreviations": [
                    "D14",
                    "1AF1",
                    "2477",
                    "C00",
                    "394"
                ],
                "categoryId": "Others",
                "description": "Porro ipsum labore etincidunt tempora magnam dolore eius. Ut dolor non modi modi quiquia. Eius voluptatem voluptatem voluptatem consectetur. Numquam quiquia quiquia quiquia non dolor. Quiquia consectetur dolorem quisquam eius. Adipisci non consectetur amet voluptatem aliquam velit neque. Non quaerat tempora tempora labore porro porro. Non adipisci quisquam dolorem velit. Dolore dolore velit aliquam."
            },
            {
                "_id": "E00027E",
                "name": "Lysosome-associatedd protein transmembrane-4 beta 35",
                "abreviations": [
                    "25E6",
                    "10B9",
                    "155B"
                ],
                "categoryId": "DNA",
                "description": "Aliquam modi non neque dolor neque voluptatem consectetur. Tempora ipsum aliquam non quaerat. Sit voluptatem eius modi dolor. Eius sed consectetur dolor. Sed quaerat modi amet etincidunt. Adipisci magnam voluptatem tempora porro consectetur amet."
            },
            {
                "_id": "E00027F",
                "name": "Her-2/neu",
                "abreviations": [],
                "categoryId": "Metabolite",
                "description": "Adipisci non ipsum magnam modi etincidunt. Dolore numquam sed voluptatem. Quiquia numquam quisquam eius adipisci labore tempora. Dolore est labore voluptatem velit velit. Aliquam dolor amet aliquam. Quiquia adipisci labore adipisci est dolorem neque. Dolorem labore magnam tempora. Non ut labore numquam ut adipisci. Dolore magnam adipisci voluptatem quaerat."
            },
            {
                "_id": "E000280",
                "name": "Caveolin-1",
                "abreviations": [
                    "22BB",
                    "1854"
                ],
                "categoryId": "Metabolite",
                "description": "Dolore est ut dolorem etincidunt. Quisquam velit sit quiquia dolor numquam ipsum adipisci. Eius quisquam neque voluptatem modi quisquam aliquam dolorem. Etincidunt adipisci neque porro modi neque. Numquam modi quisquam modi dolorem numquam consectetur. Quisquam velit quiquia neque numquam aliquam quisquam dolor. Amet est adipisci ipsum etincidunt tempora. Dolore sed est est sit voluptatem modi non."
            },
            {
                "_id": "E000281",
                "name": "MGMT expression",
                "abreviations": [],
                "categoryId": "Cytokine",
                "description": "Velit eius modi dolore aliquam quiquia dolor. Non quiquia sed porro dolore ipsum. Voluptatem consectetur dolor velit. Amet non non numquam non aliquam tempora dolore. Neque voluptatem aliquam est labore magnam aliquam est."
            },
            {
                "_id": "E000282",
                "name": "TERT promoter",
                "abreviations": [
                    "2B9"
                ],
                "categoryId": "RNA",
                "description": "Ipsum etincidunt porro etincidunt. Non modi tempora sit dolorem voluptatem. Adipisci aliquam porro aliquam ut ut dolore ipsum. Modi amet sed quiquia non. Sit ipsum numquam neque numquam voluptatem non. Voluptatem consectetur non magnam non eius sit."
            },
            {
                "_id": "E000283",
                "name": "p Jun",
                "abreviations": [
                    "62C"
                ],
                "categoryId": "Cytokine",
                "description": "Ipsum ipsum ut sit. Amet consectetur velit magnam amet. Neque ut adipisci amet numquam. Quisquam tempora dolorem dolorem non. Aliquam sed voluptatem etincidunt eius quaerat. Eius dolor labore non sit ut aliquam. Non quaerat labore sed neque porro. Tempora neque numquam etincidunt sit tempora dolore. Porro quaerat neque quaerat eius labore. Quaerat amet dolorem eius sit neque sit quisquam."
            },
            {
                "_id": "E000284",
                "name": "HLA-G",
                "abreviations": [
                    "11BC",
                    "19BE"
                ],
                "categoryId": "Protein",
                "description": "Quiquia etincidunt voluptatem est porro dolor eius. Modi sed aliquam modi numquam labore ut. Adipisci est sed ipsum quiquia. Consectetur quiquia ipsum dolor. Labore amet dolore amet. Adipisci tempora velit porro ipsum voluptatem sed."
            },
            {
                "_id": "E000285",
                "name": "Cancer-testis antigen ACTL8",
                "abreviations": [
                    "1817",
                    "2593",
                    "2669",
                    "70A",
                    "B9D"
                ],
                "categoryId": "Others",
                "description": "Quiquia neque dolore ipsum porro voluptatem. Dolore consectetur velit sed. Non amet sit dolore dolor tempora quiquia. Sit velit dolor non. Neque sed magnam velit quaerat. Tempora dolore neque sit ipsum quisquam. Dolor ipsum magnam quiquia quiquia modi consectetur. Ipsum consectetur aliquam dolorem tempora neque eius. Dolore numquam quiquia non."
            }
        ]
    },
    {
        "model": "Biomarker",
        "documents": [
            {
                "_id": "B000000",
                "entityIds": [
                    "E00009A"
                ]
            },
            {
                "_id": "B000001",
                "entityIds": [
                    "E0000A1",
                    "E00011F",
                    "E0000E3"
                ]
            },
            {
                "_id": "B000002",
                "entityIds": [
                    "E00025B"
                ]
            },
            {
                "_id": "B000003",
                "entityIds": [
                    "E000125"
                ]
            },
            {
                "_id": "B000004",
                "entityIds": [
                    "E000239"
                ]
            },
            {
                "_id": "B000005",
                "entityIds": [
                    "E000005"
                ]
            },
            {
                "_id": "B000006",
                "entityIds": [
                    "E000082",
                    "E000245"
                ]
            },
            {
                "_id": "B000007",
                "entityIds": [
                    "E000003",
                    "E000056"
                ]
            },
            {
                "_id": "B000008",
                "entityIds": [
                    "E0001B0"
                ]
            },
            {
                "_id": "B000009",
                "entityIds": [
                    "E000245"
                ]
            },
            {
                "_id": "B00000A",
                "entityIds": [
                    "E000169"
                ]
            },
            {
                "_id": "B00000B",
                "entityIds": [
                    "E000000"
                ]
            },
            {
                "_id": "B00000C",
                "entityIds": [
                    "E000170"
                ]
            },
            {
                "_id": "B00000D",
                "entityIds": [
                    "E00008B"
                ]
            },
            {
                "_id": "B00000E",
                "entityIds": [
                    "E000120"
                ]
            },
            {
                "_id": "B00000F",
                "entityIds": [
                    "E00019F"
                ]
            },
            {
                "_id": "B000010",
                "entityIds": [
                    "E000015"
                ]
            },
            {
                "_id": "B000011",
                "entityIds": [
                    "E000196"
                ]
            },
            {
                "_id": "B000012",
                "entityIds": [
                    "E00019B"
                ]
            },
            {
                "_id": "B000013",
                "entityIds": [
                    "E0000B9"
                ]
            },
            {
                "_id": "B000014",
                "entityIds": [
                    "E000218"
                ]
            },
            {
                "_id": "B000015",
                "entityIds": [
                    "E0001CD"
                ]
            },
            {
                "_id": "B000016",
                "entityIds": [
                    "E000115"
                ]
            },
            {
                "_id": "B000017",
                "entityIds": [
                    "E00005D",
                    "E000100",
                    "E0001C7",
                    "E000273",
                    "E000069"
                ]
            },
            {
                "_id": "B000018",
                "entityIds": [
                    "E00020B"
                ]
            },
            {
                "_id": "B000019",
                "entityIds": [
                    "E000153",
                    "E0000E3",
                    "E0000C4"
                ]
            },
            {
                "_id": "B00001A",
                "entityIds": [
                    "E00022A"
                ]
            },
            {
                "_id": "B00001B",
                "entityIds": [
                    "E0001D2"
                ]
            },
            {
                "_id": "B00001C",
                "entityIds": [
                    "E00006C"
                ]
            },
            {
                "_id": "B00001D",
                "entityIds": [
                    "E000270"
                ]
            },
            {
                "_id": "B00001E",
                "entityIds": [
                    "E000059",
                    "E000268"
                ]
            },
            {
                "_id": "B00001F",
                "entityIds": [
                    "E0001B3",
                    "E0001A7",
                    "E0001F5",
                    "E00008C",
                    "E0001A1"
                ]
            },
            {
                "_id": "B000020",
                "entityIds": [
                    "E00019E"
                ]
            },
            {
                "_id": "B000021",
                "entityIds": [
                    "E000046"
                ]
            },
            {
                "_id": "B000022",
                "entityIds": [
                    "E000071",
                    "E000006"
                ]
            },
            {
                "_id": "B000023",
                "entityIds": [
                    "E00011E"
                ]
            },
            {
                "_id": "B000024",
                "entityIds": [
                    "E000097"
                ]
            },
            {
                "_id": "B000025",
                "entityIds": [
                    "E000246"
                ]
            },
            {
                "_id": "B000026",
                "entityIds": [
                    "E00008F"
                ]
            },
            {
                "_id": "B000027",
                "entityIds": [
                    "E0001A8"
                ]
            },
            {
                "_id": "B000028",
                "entityIds": [
                    "E00022B",
                    "E0001FD",
                    "E000192",
                    "E0001D0",
                    "E00020E",
                    "E0000EA"
                ]
            },
            {
                "_id": "B000029",
                "entityIds": [
                    "E00001B"
                ]
            },
            {
                "_id": "B00002A",
                "entityIds": [
                    "E000147"
                ]
            },
            {
                "_id": "B00002B",
                "entityIds": [
                    "E00025D"
                ]
            },
            {
                "_id": "B00002C",
                "entityIds": [
                    "E00003C"
                ]
            },
            {
                "_id": "B00002D",
                "entityIds": [
                    "E0000C1"
                ]
            },
            {
                "_id": "B00002E",
                "entityIds": [
                    "E000189"
                ]
            },
            {
                "_id": "B00002F",
                "entityIds": [
                    "E00014C",
                    "E0000ED"
                ]
            },
            {
                "_id": "B000030",
                "entityIds": [
                    "E000023"
                ]
            },
            {
                "_id": "B000031",
                "entityIds": [
                    "E00001D",
                    "E0000B4",
                    "E0000A8",
                    "E0001D7"
                ]
            },
            {
                "_id": "B000032",
                "entityIds": [
                    "E0001B1"
                ]
            },
            {
                "_id": "B000033",
                "entityIds": [
                    "E000027"
                ]
            },
            {
                "_id": "B000034",
                "entityIds": [
                    "E0000F4"
                ]
            },
            {
                "_id": "B000035",
                "entityIds": [
                    "E000202"
                ]
            },
            {
                "_id": "B000036",
                "entityIds": [
                    "E000163"
                ]
            },
            {
                "_id": "B000037",
                "entityIds": [
                    "E00018A"
                ]
            },
            {
                "_id": "B000038",
                "entityIds": [
                    "E0001C5"
                ]
            },
            {
                "_id": "B000039",
                "entityIds": [
                    "E000211"
                ]
            },
            {
                "_id": "B00003A",
                "entityIds": [
                    "E0000D7"
                ]
            },
            {
                "_id": "B00003B",
                "entityIds": [
                    "E000279"
                ]
            },
            {
                "_id": "B00003C",
                "entityIds": [
                    "E00018B"
                ]
            },
            {
                "_id": "B00003D",
                "entityIds": [
                    "E0000CC"
                ]
            },
            {
                "_id": "B00003E",
                "entityIds": [
                    "E0001E4",
                    "E000207"
                ]
            },
            {
                "_id": "B00003F",
                "entityIds": [
                    "E0001F9"
                ]
            },
            {
                "_id": "B000040",
                "entityIds": [
                    "E000171"
                ]
            },
            {
                "_id": "B000041",
                "entityIds": [
                    "E000191"
                ]
            },
            {
                "_id": "B000042",
                "entityIds": [
                    "E000027"
                ]
            },
            {
                "_id": "B000043",
                "entityIds": [
                    "E0000B8"
                ]
            },
            {
                "_id": "B000044",
                "entityIds": [
                    "E00001A"
                ]
            },
            {
                "_id": "B000045",
                "entityIds": [
                    "E00003E"
                ]
            },
            {
                "_id": "B000046",
                "entityIds": [
                    "E000047"
                ]
            },
            {
                "_id": "B000047",
                "entityIds": [
                    "E00009B",
                    "E000144"
                ]
            },
            {
                "_id": "B000048",
                "entityIds": [
                    "E00018A",
                    "E00005D"
                ]
            },
            {
                "_id": "B000049",
                "entityIds": [
                    "E00004E"
                ]
            },
            {
                "_id": "B00004A",
                "entityIds": [
                    "E000120"
                ]
            },
            {
                "_id": "B00004B",
                "entityIds": [
                    "E00011A",
                    "E000150"
                ]
            },
            {
                "_id": "B00004C",
                "entityIds": [
                    "E00025A"
                ]
            },
            {
                "_id": "B00004D",
                "entityIds": [
                    "E000247",
                    "E000021"
                ]
            },
            {
                "_id": "B00004E",
                "entityIds": [
                    "E000019",
                    "E0000B2"
                ]
            },
            {
                "_id": "B00004F",
                "entityIds": [
                    "E000110"
                ]
            },
            {
                "_id": "B000050",
                "entityIds": [
                    "E00023F",
                    "E00019A"
                ]
            },
            {
                "_id": "B000051",
                "entityIds": [
                    "E00005D",
                    "E000102"
                ]
            },
            {
                "_id": "B000052",
                "entityIds": [
                    "E000180",
                    "E0001FE"
                ]
            },
            {
                "_id": "B000053",
                "entityIds": [
                    "E000008"
                ]
            },
            {
                "_id": "B000054",
                "entityIds": [
                    "E000041"
                ]
            },
            {
                "_id": "B000055",
                "entityIds": [
                    "E000230"
                ]
            },
            {
                "_id": "B000056",
                "entityIds": [
                    "E000079"
                ]
            },
            {
                "_id": "B000057",
                "entityIds": [
                    "E00016B",
                    "E000256",
                    "E0001B8",
                    "E00017C"
                ]
            },
            {
                "_id": "B000058",
                "entityIds": [
                    "E0000CD"
                ]
            },
            {
                "_id": "B000059",
                "entityIds": [
                    "E000243",
                    "E00016D"
                ]
            },
            {
                "_id": "B00005A",
                "entityIds": [
                    "E000107",
                    "E000098",
                    "E00012F"
                ]
            },
            {
                "_id": "B00005B",
                "entityIds": [
                    "E0001EB"
                ]
            },
            {
                "_id": "B00005C",
                "entityIds": [
                    "E000109"
                ]
            },
            {
                "_id": "B00005D",
                "entityIds": [
                    "E000215"
                ]
            },
            {
                "_id": "B00005E",
                "entityIds": [
                    "E0000D3"
                ]
            },
            {
                "_id": "B00005F",
                "entityIds": [
                    "E0000B6",
                    "E000138",
                    "E000165"
                ]
            },
            {
                "_id": "B000060",
                "entityIds": [
                    "E000219"
                ]
            },
            {
                "_id": "B000061",
                "entityIds": [
                    "E0000E0",
                    "E00012D"
                ]
            },
            {
                "_id": "B000062",
                "entityIds": [
                    "E0001ED"
                ]
            },
            {
                "_id": "B000063",
                "entityIds": [
                    "E00027F"
                ]
            },
            {
                "_id": "B000064",
                "entityIds": [
                    "E000226"
                ]
            },
            {
                "_id": "B000065",
                "entityIds": [
                    "E0001E8"
                ]
            },
            {
                "_id": "B000066",
                "entityIds": [
                    "E000012",
                    "E000146"
                ]
            },
            {
                "_id": "B000067",
                "entityIds": [
                    "E000145"
                ]
            },
            {
                "_id": "B000068",
                "entityIds": [
                    "E0001DE"
                ]
            },
            {
                "_id": "B000069",
                "entityIds": [
                    "E0001DB"
                ]
            },
            {
                "_id": "B00006A",
                "entityIds": [
                    "E00002D"
                ]
            },
            {
                "_id": "B00006B",
                "entityIds": [
                    "E00007C"
                ]
            },
            {
                "_id": "B00006C",
                "entityIds": [
                    "E0000B1",
                    "E000226",
                    "E00021D",
                    "E00013C",
                    "E00017B"
                ]
            },
            {
                "_id": "B00006D",
                "entityIds": [
                    "E000027"
                ]
            },
            {
                "_id": "B00006E",
                "entityIds": [
                    "E000259"
                ]
            },
            {
                "_id": "B00006F",
                "entityIds": [
                    "E0001B9",
                    "E0000E3",
                    "E000245"
                ]
            },
            {
                "_id": "B000070",
                "entityIds": [
                    "E000189",
                    "E000245"
                ]
            },
            {
                "_id": "B000071",
                "entityIds": [
                    "E0000B6"
                ]
            },
            {
                "_id": "B000072",
                "entityIds": [
                    "E000232"
                ]
            },
            {
                "_id": "B000073",
                "entityIds": [
                    "E0001E6"
                ]
            },
            {
                "_id": "B000074",
                "entityIds": [
                    "E00021F"
                ]
            },
            {
                "_id": "B000075",
                "entityIds": [
                    "E0001A9"
                ]
            },
            {
                "_id": "B000076",
                "entityIds": [
                    "E0000E4",
                    "E000173"
                ]
            },
            {
                "_id": "B000077",
                "entityIds": [
                    "E00006F"
                ]
            },
            {
                "_id": "B000078",
                "entityIds": [
                    "E0000C8"
                ]
            },
            {
                "_id": "B000079",
                "entityIds": [
                    "E000254"
                ]
            },
            {
                "_id": "B00007A",
                "entityIds": [
                    "E00005C"
                ]
            },
            {
                "_id": "B00007B",
                "entityIds": [
                    "E00018E"
                ]
            },
            {
                "_id": "B00007C",
                "entityIds": [
                    "E000242"
                ]
            },
            {
                "_id": "B00007D",
                "entityIds": [
                    "E0000BC"
                ]
            },
            {
                "_id": "B00007E",
                "entityIds": [
                    "E00014B"
                ]
            },
            {
                "_id": "B00007F",
                "entityIds": [
                    "E0000EB"
                ]
            },
            {
                "_id": "B000080",
                "entityIds": [
                    "E000156"
                ]
            },
            {
                "_id": "B000081",
                "entityIds": [
                    "E0001D3"
                ]
            },
            {
                "_id": "B000082",
                "entityIds": [
                    "E00019A",
                    "E0001BD"
                ]
            },
            {
                "_id": "B000083",
                "entityIds": [
                    "E000027"
                ]
            },
            {
                "_id": "B000084",
                "entityIds": [
                    "E00004A"
                ]
            },
            {
                "_id": "B000085",
                "entityIds": [
                    "E000262"
                ]
            },
            {
                "_id": "B000086",
                "entityIds": [
                    "E000229"
                ]
            },
            {
                "_id": "B000087",
                "entityIds": [
                    "E00027A"
                ]
            },
            {
                "_id": "B000088",
                "entityIds": [
                    "E000260",
                    "E0000D5",
                    "E0001F4",
                    "E000188",
                    "E000064",
                    "E000045",
                    "E000159",
                    "E000116",
                    "E000283",
                    "E000234",
                    "E00007F",
                    "E0000C9",
                    "E000049"
                ]
            },
            {
                "_id": "B000089",
                "entityIds": [
                    "E00026A"
                ]
            },
            {
                "_id": "B00008A",
                "entityIds": [
                    "E0001BA"
                ]
            },
            {
                "_id": "B00008B",
                "entityIds": [
                    "E0001DF"
                ]
            },
            {
                "_id": "B00008C",
                "entityIds": [
                    "E00027B"
                ]
            },
            {
                "_id": "B00008D",
                "entityIds": [
                    "E000245"
                ]
            },
            {
                "_id": "B00008E",
                "entityIds": [
                    "E00011B"
                ]
            },
            {
                "_id": "B00008F",
                "entityIds": [
                    "E00023A"
                ]
            },
            {
                "_id": "B000090",
                "entityIds": [
                    "E00001A"
                ]
            },
            {
                "_id": "B000091",
                "entityIds": [
                    "E000261",
                    "E00016A"
                ]
            },
            {
                "_id": "B000092",
                "entityIds": [
                    "E00002B",
                    "E000062",
                    "E00012B",
                    "E000084",
                    "E00013D",
                    "E0001C9"
                ]
            },
            {
                "_id": "B000093",
                "entityIds": [
                    "E00008D"
                ]
            },
            {
                "_id": "B000094",
                "entityIds": [
                    "E000141"
                ]
            },
            {
                "_id": "B000095",
                "entityIds": [
                    "E00005D",
                    "E0001CF",
                    "E000228",
                    "E000058",
                    "E00007D"
                ]
            },
            {
                "_id": "B000096",
                "entityIds": [
                    "E0000B5"
                ]
            },
            {
                "_id": "B000097",
                "entityIds": [
                    "E000173",
                    "E000216"
                ]
            },
            {
                "_id": "B000098",
                "entityIds": [
                    "E000114"
                ]
            },
            {
                "_id": "B000099",
                "entityIds": [
                    "E0000C6"
                ]
            },
            {
                "_id": "B00009A",
                "entityIds": [
                    "E0001D1"
                ]
            },
            {
                "_id": "B00009B",
                "entityIds": [
                    "E000065"
                ]
            },
            {
                "_id": "B00009C",
                "entityIds": [
                    "E000130"
                ]
            },
            {
                "_id": "B00009D",
                "entityIds": [
                    "E000200"
                ]
            },
            {
                "_id": "B00009E",
                "entityIds": [
                    "E0001C2",
                    "E000221"
                ]
            },
            {
                "_id": "B00009F",
                "entityIds": [
                    "E000126",
                    "E00001C"
                ]
            },
            {
                "_id": "B0000A0",
                "entityIds": [
                    "E000063"
                ]
            },
            {
                "_id": "B0000A1",
                "entityIds": [
                    "E000043"
                ]
            },
            {
                "_id": "B0000A2",
                "entityIds": [
                    "E00024A"
                ]
            },
            {
                "_id": "B0000A3",
                "entityIds": [
                    "E000181"
                ]
            },
            {
                "_id": "B0000A4",
                "entityIds": [
                    "E00022E",
                    "E00021A",
                    "E000075"
                ]
            },
            {
                "_id": "B0000A5",
                "entityIds": [
                    "E000027"
                ]
            },
            {
                "_id": "B0000A6",
                "entityIds": [
                    "E000176"
                ]
            },
            {
                "_id": "B0000A7",
                "entityIds": [
                    "E0001EF"
                ]
            },
            {
                "_id": "B0000A8",
                "entityIds": [
                    "E0001CB",
                    "E00020F"
                ]
            },
            {
                "_id": "B0000A9",
                "entityIds": [
                    "E000133"
                ]
            },
            {
                "_id": "B0000AA",
                "entityIds": [
                    "E000197",
                    "E00009C",
                    "E0001A3"
                ]
            },
            {
                "_id": "B0000AB",
                "entityIds": [
                    "E000149"
                ]
            },
            {
                "_id": "B0000AC",
                "entityIds": [
                    "E00004D"
                ]
            },
            {
                "_id": "B0000AD",
                "entityIds": [
                    "E000151"
                ]
            },
            {
                "_id": "B0000AE",
                "entityIds": [
                    "E000204"
                ]
            },
            {
                "_id": "B0000AF",
                "entityIds": [
                    "E000060"
                ]
            },
            {
                "_id": "B0000B0",
                "entityIds": [
                    "E000033"
                ]
            },
            {
                "_id": "B0000B1",
                "entityIds": [
                    "E00018A"
                ]
            },
            {
                "_id": "B0000B2",
                "entityIds": [
                    "E000090"
                ]
            },
            {
                "_id": "B0000B3",
                "entityIds": [
                    "E00016E"
                ]
            },
            {
                "_id": "B0000B4",
                "entityIds": [
                    "E000276",
                    "E000266"
                ]
            },
            {
                "_id": "B0000B5",
                "entityIds": [
                    "E00013A",
                    "E000009",
                    "E000108",
                    "E00022C",
                    "E000093",
                    "E000035",
                    "E00007A",
                    "E000055",
                    "E00013C"
                ]
            },
            {
                "_id": "B0000B6",
                "entityIds": [
                    "E0000EF"
                ]
            },
            {
                "_id": "B0000B7",
                "entityIds": [
                    "E000036"
                ]
            },
            {
                "_id": "B0000B8",
                "entityIds": [
                    "E0000EC"
                ]
            },
            {
                "_id": "B0000B9",
                "entityIds": [
                    "E000209"
                ]
            },
            {
                "_id": "B0000BA",
                "entityIds": [
                    "E0000F3"
                ]
            },
            {
                "_id": "B0000BB",
                "entityIds": [
                    "E0000FC"
                ]
            },
            {
                "_id": "B0000BC",
                "entityIds": [
                    "E00024E"
                ]
            },
            {
                "_id": "B0000BD",
                "entityIds": [
                    "E000279"
                ]
            },
            {
                "_id": "B0000BE",
                "entityIds": [
                    "E0000AE"
                ]
            },
            {
                "_id": "B0000BF",
                "entityIds": [
                    "E000139",
                    "E000185",
                    "E000052",
                    "E000194",
                    "E000042",
                    "E000235",
                    "E0001B5"
                ]
            },
            {
                "_id": "B0000C0",
                "entityIds": [
                    "E00012E"
                ]
            },
            {
                "_id": "B0000C1",
                "entityIds": [
                    "E000066"
                ]
            },
            {
                "_id": "B0000C2",
                "entityIds": [
                    "E0001FA",
                    "E000189",
                    "E000277",
                    "E000282"
                ]
            },
            {
                "_id": "B0000C3",
                "entityIds": [
                    "E000112",
                    "E000078",
                    "E000278",
                    "E0000BA",
                    "E00009F",
                    "E0001C4",
                    "E0001F1",
                    "E0000CF",
                    "E00006A"
                ]
            },
            {
                "_id": "B0000C4",
                "entityIds": [
                    "E000022"
                ]
            },
            {
                "_id": "B0000C5",
                "entityIds": [
                    "E000148"
                ]
            },
            {
                "_id": "B0000C6",
                "entityIds": [
                    "E000064"
                ]
            },
            {
                "_id": "B0000C7",
                "entityIds": [
                    "E000172"
                ]
            },
            {
                "_id": "B0000C8",
                "entityIds": [
                    "E0001E5"
                ]
            },
            {
                "_id": "B0000C9",
                "entityIds": [
                    "E00003B",
                    "E00021B"
                ]
            },
            {
                "_id": "B0000CA",
                "entityIds": [
                    "E00026E"
                ]
            },
            {
                "_id": "B0000CB",
                "entityIds": [
                    "E0001CE"
                ]
            },
            {
                "_id": "B0000CC",
                "entityIds": [
                    "E000203",
                    "E00020C"
                ]
            },
            {
                "_id": "B0000CD",
                "entityIds": [
                    "E000037"
                ]
            },
            {
                "_id": "B0000CE",
                "entityIds": [
                    "E00015F",
                    "E0000C3"
                ]
            },
            {
                "_id": "B0000CF",
                "entityIds": [
                    "E0001E0",
                    "E0001C6",
                    "E0000E2",
                    "E00001E"
                ]
            },
            {
                "_id": "B0000D0",
                "entityIds": [
                    "E0001A2"
                ]
            },
            {
                "_id": "B0000D1",
                "entityIds": [
                    "E000072"
                ]
            },
            {
                "_id": "B0000D2",
                "entityIds": [
                    "E0000FA"
                ]
            },
            {
                "_id": "B0000D3",
                "entityIds": [
                    "E00026D"
                ]
            },
            {
                "_id": "B0000D4",
                "entityIds": [
                    "E00005D"
                ]
            },
            {
                "_id": "B0000D5",
                "entityIds": [
                    "E0001AE"
                ]
            },
            {
                "_id": "B0000D6",
                "entityIds": [
                    "E000168"
                ]
            },
            {
                "_id": "B0000D7",
                "entityIds": [
                    "E00007B"
                ]
            },
            {
                "_id": "B0000D8",
                "entityIds": [
                    "E000184"
                ]
            },
            {
                "_id": "B0000D9",
                "entityIds": [
                    "E0000B6",
                    "E000091"
                ]
            },
            {
                "_id": "B0000DA",
                "entityIds": [
                    "E000050",
                    "E00015E",
                    "E000095"
                ]
            },
            {
                "_id": "B0000DB",
                "entityIds": [
                    "E00027E"
                ]
            },
            {
                "_id": "B0000DC",
                "entityIds": [
                    "E0001A0",
                    "E00015D",
                    "E000274"
                ]
            },
            {
                "_id": "B0000DD",
                "entityIds": [
                    "E000158"
                ]
            },
            {
                "_id": "B0000DE",
                "entityIds": [
                    "E00026F"
                ]
            },
            {
                "_id": "B0000DF",
                "entityIds": [
                    "E000111"
                ]
            },
            {
                "_id": "B0000E0",
                "entityIds": [
                    "E000205"
                ]
            },
            {
                "_id": "B0000E1",
                "entityIds": [
                    "E00025C"
                ]
            },
            {
                "_id": "B0000E2",
                "entityIds": [
                    "E00004B"
                ]
            },
            {
                "_id": "B0000E3",
                "entityIds": [
                    "E0001E1",
                    "E00014C",
                    "E00005A",
                    "E000034",
                    "E00026C",
                    "E0000F7",
                    "E0001B2"
                ]
            },
            {
                "_id": "B0000E4",
                "entityIds": [
                    "E00024B",
                    "E000068",
                    "E0000FC",
                    "E00023B",
                    "E000222",
                    "E00023C",
                    "E000007"
                ]
            },
            {
                "_id": "B0000E5",
                "entityIds": [
                    "E0001BC"
                ]
            },
            {
                "_id": "B0000E6",
                "entityIds": [
                    "E0001C1"
                ]
            },
            {
                "_id": "B0000E7",
                "entityIds": [
                    "E000223",
                    "E000113",
                    "E000191"
                ]
            },
            {
                "_id": "B0000E8",
                "entityIds": [
                    "E000099"
                ]
            },
            {
                "_id": "B0000E9",
                "entityIds": [
                    "E000276"
                ]
            },
            {
                "_id": "B0000EA",
                "entityIds": [
                    "E000121"
                ]
            },
            {
                "_id": "B0000EB",
                "entityIds": [
                    "E0000C8"
                ]
            },
            {
                "_id": "B0000EC",
                "entityIds": [
                    "E000100"
                ]
            },
            {
                "_id": "B0000ED",
                "entityIds": [
                    "E0000F1"
                ]
            },
            {
                "_id": "B0000EE",
                "entityIds": [
                    "E0000A4",
                    "E0000B7",
                    "E00019D",
                    "E0000E6",
                    "E000224"
                ]
            },
            {
                "_id": "B0000EF",
                "entityIds": [
                    "E0000A5",
                    "E000227"
                ]
            },
            {
                "_id": "B0000F0",
                "entityIds": [
                    "E000054"
                ]
            },
            {
                "_id": "B0000F1",
                "entityIds": [
                    "E00018D"
                ]
            },
            {
                "_id": "B0000F2",
                "entityIds": [
                    "E00002A",
                    "E0000EE",
                    "E000103"
                ]
            },
            {
                "_id": "B0000F3",
                "entityIds": [
                    "E000206"
                ]
            },
            {
                "_id": "B0000F4",
                "entityIds": [
                    "E0001B6"
                ]
            },
            {
                "_id": "B0000F5",
                "entityIds": [
                    "E0000B3"
                ]
            },
            {
                "_id": "B0000F6",
                "entityIds": [
                    "E0001B7"
                ]
            },
            {
                "_id": "B0000F7",
                "entityIds": [
                    "E000225"
                ]
            },
            {
                "_id": "B0000F8",
                "entityIds": [
                    "E000264"
                ]
            },
            {
                "_id": "B0000F9",
                "entityIds": [
                    "E0001F0"
                ]
            },
            {
                "_id": "B0000FA",
                "entityIds": [
                    "E000138"
                ]
            },
            {
                "_id": "B0000FB",
                "entityIds": [
                    "E000131"
                ]
            },
            {
                "_id": "B0000FC",
                "entityIds": [
                    "E0000F9"
                ]
            },
            {
                "_id": "B0000FD",
                "entityIds": [
                    "E000275"
                ]
            },
            {
                "_id": "B0000FE",
                "entityIds": [
                    "E000011"
                ]
            },
            {
                "_id": "B0000FF",
                "entityIds": [
                    "E00021E"
                ]
            },
            {
                "_id": "B000100",
                "entityIds": [
                    "E000183"
                ]
            },
            {
                "_id": "B000101",
                "entityIds": [
                    "E000129"
                ]
            },
            {
                "_id": "B000102",
                "entityIds": [
                    "E0000C2",
                    "E00006B",
                    "E000255",
                    "E000038",
                    "E000267",
                    "E00024D",
                    "E0000F5"
                ]
            },
            {
                "_id": "B000103",
                "entityIds": [
                    "E0000F0"
                ]
            },
            {
                "_id": "B000104",
                "entityIds": [
                    "E000164",
                    "E000226"
                ]
            },
            {
                "_id": "B000105",
                "entityIds": [
                    "E00003F"
                ]
            },
            {
                "_id": "B000106",
                "entityIds": [
                    "E000032"
                ]
            },
            {
                "_id": "B000107",
                "entityIds": [
                    "E000241"
                ]
            },
            {
                "_id": "B000108",
                "entityIds": [
                    "E00003D"
                ]
            },
            {
                "_id": "B000109",
                "entityIds": [
                    "E00018A",
                    "E0001C2"
                ]
            },
            {
                "_id": "B00010A",
                "entityIds": [
                    "E000136"
                ]
            },
            {
                "_id": "B00010B",
                "entityIds": [
                    "E00004C",
                    "E0001F3",
                    "E000165"
                ]
            },
            {
                "_id": "B00010C",
                "entityIds": [
                    "E00023E"
                ]
            },
            {
                "_id": "B00010D",
                "entityIds": [
                    "E000113"
                ]
            },
            {
                "_id": "B00010E",
                "entityIds": [
                    "E00025E"
                ]
            },
            {
                "_id": "B00010F",
                "entityIds": [
                    "E0001D8"
                ]
            },
            {
                "_id": "B000110",
                "entityIds": [
                    "E000157"
                ]
            },
            {
                "_id": "B000111",
                "entityIds": [
                    "E00009E"
                ]
            },
            {
                "_id": "B000112",
                "entityIds": [
                    "E000212"
                ]
            },
            {
                "_id": "B000113",
                "entityIds": [
                    "E000186"
                ]
            },
            {
                "_id": "B000114",
                "entityIds": [
                    "E000070",
                    "E0001F6",
                    "E0000DA",
                    "E0001F7",
                    "E0000D9"
                ]
            },
            {
                "_id": "B000115",
                "entityIds": [
                    "E0000AD",
                    "E00010F",
                    "E000241",
                    "E00013B",
                    "E0001EC"
                ]
            },
            {
                "_id": "B000116",
                "entityIds": [
                    "E000061"
                ]
            },
            {
                "_id": "B000117",
                "entityIds": [
                    "E00010E"
                ]
            },
            {
                "_id": "B000118",
                "entityIds": [
                    "E000187",
                    "E0000BE",
                    "E00002C",
                    "E0000CA",
                    "E000166",
                    "E00011C"
                ]
            },
            {
                "_id": "B000119",
                "entityIds": [
                    "E00016C",
                    "E0000E7",
                    "E0000D1",
                    "E0001E7",
                    "E00014D"
                ]
            },
            {
                "_id": "B00011A",
                "entityIds": [
                    "E000101"
                ]
            },
            {
                "_id": "B00011B",
                "entityIds": [
                    "E00018A"
                ]
            },
            {
                "_id": "B00011C",
                "entityIds": [
                    "E000248"
                ]
            },
            {
                "_id": "B00011D",
                "entityIds": [
                    "E0001AD"
                ]
            },
            {
                "_id": "B00011E",
                "entityIds": [
                    "E0001EE"
                ]
            },
            {
                "_id": "B00011F",
                "entityIds": [
                    "E000285",
                    "E000167",
                    "E0001AC",
                    "E000083"
                ]
            },
            {
                "_id": "B000120",
                "entityIds": [
                    "E000091"
                ]
            },
            {
                "_id": "B000121",
                "entityIds": [
                    "E0000CB"
                ]
            },
            {
                "_id": "B000122",
                "entityIds": [
                    "E0000E1"
                ]
            },
            {
                "_id": "B000123",
                "entityIds": [
                    "E000040"
                ]
            },
            {
                "_id": "B000124",
                "entityIds": [
                    "E0001AF"
                ]
            },
            {
                "_id": "B000125",
                "entityIds": [
                    "E0000FE",
                    "E0000A7",
                    "E000123",
                    "E000178",
                    "E00010A"
                ]
            },
            {
                "_id": "B000126",
                "entityIds": [
                    "E0000FD"
                ]
            },
            {
                "_id": "B000127",
                "entityIds": [
                    "E00021C"
                ]
            },
            {
                "_id": "B000128",
                "entityIds": [
                    "E00017D"
                ]
            },
            {
                "_id": "B000129",
                "entityIds": [
                    "E0001BF"
                ]
            },
            {
                "_id": "B00012A",
                "entityIds": [
                    "E000016"
                ]
            },
            {
                "_id": "B00012B",
                "entityIds": [
                    "E0000A2",
                    "E0000C7"
                ]
            },
            {
                "_id": "B00012C",
                "entityIds": [
                    "E0000EF",
                    "E000135"
                ]
            },
            {
                "_id": "B00012D",
                "entityIds": [
                    "E0001F2"
                ]
            },
            {
                "_id": "B00012E",
                "entityIds": [
                    "E0001BE",
                    "E0000FB",
                    "E000177"
                ]
            },
            {
                "_id": "B00012F",
                "entityIds": [
                    "E00020D"
                ]
            },
            {
                "_id": "B000130",
                "entityIds": [
                    "E000138"
                ]
            },
            {
                "_id": "B000131",
                "entityIds": [
                    "E0000FB"
                ]
            },
            {
                "_id": "B000132",
                "entityIds": [
                    "E000263"
                ]
            },
            {
                "_id": "B000133",
                "entityIds": [
                    "E0001AD"
                ]
            },
            {
                "_id": "B000134",
                "entityIds": [
                    "E000001"
                ]
            },
            {
                "_id": "B000135",
                "entityIds": [
                    "E000119"
                ]
            },
            {
                "_id": "B000136",
                "entityIds": [
                    "E0000B1",
                    "E00023D"
                ]
            },
            {
                "_id": "B000137",
                "entityIds": [
                    "E000182",
                    "E000284"
                ]
            },
            {
                "_id": "B000138",
                "entityIds": [
                    "E0001D9"
                ]
            },
            {
                "_id": "B000139",
                "entityIds": [
                    "E000253"
                ]
            },
            {
                "_id": "B00013A",
                "entityIds": [
                    "E000024"
                ]
            },
            {
                "_id": "B00013B",
                "entityIds": [
                    "E00022D"
                ]
            },
            {
                "_id": "B00013C",
                "entityIds": [
                    "E0000A3"
                ]
            },
            {
                "_id": "B00013D",
                "entityIds": [
                    "E0001DC"
                ]
            },
            {
                "_id": "B00013E",
                "entityIds": [
                    "E000200"
                ]
            },
            {
                "_id": "B00013F",
                "entityIds": [
                    "E000213",
                    "E0000A9"
                ]
            },
            {
                "_id": "B000140",
                "entityIds": [
                    "E000081"
                ]
            },
            {
                "_id": "B000141",
                "entityIds": [
                    "E0001DD",
                    "E00024F"
                ]
            },
            {
                "_id": "B000142",
                "entityIds": [
                    "E000280"
                ]
            },
            {
                "_id": "B000143",
                "entityIds": [
                    "E0000DF",
                    "E0001A4"
                ]
            },
            {
                "_id": "B000144",
                "entityIds": [
                    "E00024C"
                ]
            },
            {
                "_id": "B000145",
                "entityIds": [
                    "E00014A"
                ]
            },
            {
                "_id": "B000146",
                "entityIds": [
                    "E000082"
                ]
            },
            {
                "_id": "B000147",
                "entityIds": [
                    "E00014C"
                ]
            },
            {
                "_id": "B000148",
                "entityIds": [
                    "E000029"
                ]
            },
            {
                "_id": "B000149",
                "entityIds": [
                    "E0000A6"
                ]
            },
            {
                "_id": "B00014A",
                "entityIds": [
                    "E00000D"
                ]
            },
            {
                "_id": "B00014B",
                "entityIds": [
                    "E00005F",
                    "E00017E",
                    "E000190",
                    "E000026"
                ]
            },
            {
                "_id": "B00014C",
                "entityIds": [
                    "E00012A"
                ]
            },
            {
                "_id": "B00014D",
                "entityIds": [
                    "E0000D4",
                    "E00016F",
                    "E0000F6"
                ]
            },
            {
                "_id": "B00014E",
                "entityIds": [
                    "E0000C0"
                ]
            },
            {
                "_id": "B00014F",
                "entityIds": [
                    "E000238"
                ]
            },
            {
                "_id": "B000150",
                "entityIds": [
                    "E00013A"
                ]
            },
            {
                "_id": "B000151",
                "entityIds": [
                    "E00018F"
                ]
            },
            {
                "_id": "B000152",
                "entityIds": [
                    "E0001C0",
                    "E00007E",
                    "E000094",
                    "E000048",
                    "E000257"
                ]
            },
            {
                "_id": "B000153",
                "entityIds": [
                    "E000051"
                ]
            },
            {
                "_id": "B000154",
                "entityIds": [
                    "E000089"
                ]
            },
            {
                "_id": "B000155",
                "entityIds": [
                    "E000151"
                ]
            },
            {
                "_id": "B000156",
                "entityIds": [
                    "E0001CA"
                ]
            },
            {
                "_id": "B000157",
                "entityIds": [
                    "E000137"
                ]
            },
            {
                "_id": "B000158",
                "entityIds": [
                    "E0001CC"
                ]
            },
            {
                "_id": "B000159",
                "entityIds": [
                    "E0000D2"
                ]
            },
            {
                "_id": "B00015A",
                "entityIds": [
                    "E000073",
                    "E000265",
                    "E000199",
                    "E00000F"
                ]
            },
            {
                "_id": "B00015B",
                "entityIds": [
                    "E000270"
                ]
            },
            {
                "_id": "B00015C",
                "entityIds": [
                    "E0001E2",
                    "E000018"
                ]
            },
            {
                "_id": "B00015D",
                "entityIds": [
                    "E00000E"
                ]
            },
            {
                "_id": "B00015E",
                "entityIds": [
                    "E00008A"
                ]
            },
            {
                "_id": "B00015F",
                "entityIds": [
                    "E000014",
                    "E000120"
                ]
            },
            {
                "_id": "B000160",
                "entityIds": [
                    "E000226",
                    "E000201",
                    "E0000DB",
                    "E0001D6"
                ]
            },
            {
                "_id": "B000161",
                "entityIds": [
                    "E00017B"
                ]
            },
            {
                "_id": "B000162",
                "entityIds": [
                    "E000269",
                    "E000161"
                ]
            },
            {
                "_id": "B000163",
                "entityIds": [
                    "E000093"
                ]
            },
            {
                "_id": "B000164",
                "entityIds": [
                    "E00002E"
                ]
            },
            {
                "_id": "B000165",
                "entityIds": [
                    "E0000DE"
                ]
            },
            {
                "_id": "B000166",
                "entityIds": [
                    "E000270"
                ]
            },
            {
                "_id": "B000167",
                "entityIds": [
                    "E0001F8",
                    "E0000A0",
                    "E00001F",
                    "E0000D0",
                    "E0000AA",
                    "E000210",
                    "E000174",
                    "E000124"
                ]
            },
            {
                "_id": "B000168",
                "entityIds": [
                    "E000226"
                ]
            },
            {
                "_id": "B000169",
                "entityIds": [
                    "E0001D4"
                ]
            },
            {
                "_id": "B00016A",
                "entityIds": [
                    "E000214"
                ]
            },
            {
                "_id": "B00016B",
                "entityIds": [
                    "E000041"
                ]
            },
            {
                "_id": "B00016C",
                "entityIds": [
                    "E00014C",
                    "E000191",
                    "E00017B"
                ]
            },
            {
                "_id": "B00016D",
                "entityIds": [
                    "E00017B"
                ]
            },
            {
                "_id": "B00016E",
                "entityIds": [
                    "E00018C"
                ]
            },
            {
                "_id": "B00016F",
                "entityIds": [
                    "E000270"
                ]
            },
            {
                "_id": "B000170",
                "entityIds": [
                    "E00014C"
                ]
            },
            {
                "_id": "B000171",
                "entityIds": [
                    "E000191",
                    "E00017B"
                ]
            },
            {
                "_id": "B000172",
                "entityIds": [
                    "E00010C"
                ]
            },
            {
                "_id": "B000173",
                "entityIds": [
                    "E000122"
                ]
            },
            {
                "_id": "B000174",
                "entityIds": [
                    "E000249",
                    "E000191"
                ]
            },
            {
                "_id": "B000175",
                "entityIds": [
                    "E000122"
                ]
            },
            {
                "_id": "B000176",
                "entityIds": [
                    "E000191"
                ]
            },
            {
                "_id": "B000177",
                "entityIds": [
                    "E000198",
                    "E00000A"
                ]
            },
            {
                "_id": "B000178",
                "entityIds": [
                    "E00012C",
                    "E0000D8",
                    "E000039",
                    "E000004",
                    "E000236",
                    "E0001A6",
                    "E000162",
                    "E000028"
                ]
            },
            {
                "_id": "B000179",
                "entityIds": [
                    "E000272"
                ]
            },
            {
                "_id": "B00017A",
                "entityIds": [
                    "E0000DD"
                ]
            },
            {
                "_id": "B00017B",
                "entityIds": [
                    "E0001BB"
                ]
            },
            {
                "_id": "B00017C",
                "entityIds": [
                    "E00000B"
                ]
            },
            {
                "_id": "B00017D",
                "entityIds": [
                    "E000074"
                ]
            },
            {
                "_id": "B00017E",
                "entityIds": [
                    "E0000B0"
                ]
            },
            {
                "_id": "B00017F",
                "entityIds": [
                    "E00013F"
                ]
            },
            {
                "_id": "B000180",
                "entityIds": [
                    "E000067"
                ]
            },
            {
                "_id": "B000181",
                "entityIds": [
                    "E0000CE"
                ]
            },
            {
                "_id": "B000182",
                "entityIds": [
                    "E000237"
                ]
            },
            {
                "_id": "B000183",
                "entityIds": [
                    "E0001FC"
                ]
            },
            {
                "_id": "B000184",
                "entityIds": [
                    "E000251"
                ]
            },
            {
                "_id": "B000185",
                "entityIds": [
                    "E0000E8"
                ]
            },
            {
                "_id": "B000186",
                "entityIds": [
                    "E00026B"
                ]
            },
            {
                "_id": "B000187",
                "entityIds": [
                    "E00005B"
                ]
            },
            {
                "_id": "B000188",
                "entityIds": [
                    "E0001E9"
                ]
            },
            {
                "_id": "B000189",
                "entityIds": [
                    "E00008E"
                ]
            },
            {
                "_id": "B00018A",
                "entityIds": [
                    "E00014E"
                ]
            },
            {
                "_id": "B00018B",
                "entityIds": [
                    "E000279"
                ]
            },
            {
                "_id": "B00018C",
                "entityIds": [
                    "E0000DC"
                ]
            },
            {
                "_id": "B00018D",
                "entityIds": [
                    "E0001E5"
                ]
            },
            {
                "_id": "B00018E",
                "entityIds": [
                    "E00015B"
                ]
            },
            {
                "_id": "B00018F",
                "entityIds": [
                    "E0001C3"
                ]
            },
            {
                "_id": "B000190",
                "entityIds": [
                    "E00000C",
                    "E00005D"
                ]
            },
            {
                "_id": "B000191",
                "entityIds": [
                    "E000132"
                ]
            },
            {
                "_id": "B000192",
                "entityIds": [
                    "E0000BB"
                ]
            },
            {
                "_id": "B000193",
                "entityIds": [
                    "E00017F",
                    "E000013"
                ]
            },
            {
                "_id": "B000194",
                "entityIds": [
                    "E00010D"
                ]
            },
            {
                "_id": "B000195",
                "entityIds": [
                    "E000002",
                    "E0000F0",
                    "E000244",
                    "E0001B4"
                ]
            },
            {
                "_id": "B000196",
                "entityIds": [
                    "E00004F"
                ]
            },
            {
                "_id": "B000197",
                "entityIds": [
                    "E0000BF"
                ]
            },
            {
                "_id": "B000198",
                "entityIds": [
                    "E000031"
                ]
            },
            {
                "_id": "B000199",
                "entityIds": [
                    "E000179"
                ]
            },
            {
                "_id": "B00019A",
                "entityIds": [
                    "E000118"
                ]
            },
            {
                "_id": "B00019B",
                "entityIds": [
                    "E000271"
                ]
            },
            {
                "_id": "B00019C",
                "entityIds": [
                    "E000077"
                ]
            },
            {
                "_id": "B00019D",
                "entityIds": [
                    "E00013E",
                    "E000104"
                ]
            },
            {
                "_id": "B00019E",
                "entityIds": [
                    "E000195"
                ]
            },
            {
                "_id": "B00019F",
                "entityIds": [
                    "E00005D"
                ]
            },
            {
                "_id": "B0001A0",
                "entityIds": [
                    "E00020A",
                    "E00015A"
                ]
            },
            {
                "_id": "B0001A1",
                "entityIds": [
                    "E00022F"
                ]
            },
            {
                "_id": "B0001A2",
                "entityIds": [
                    "E00005E"
                ]
            },
            {
                "_id": "B0001A3",
                "entityIds": [
                    "E000173"
                ]
            },
            {
                "_id": "B0001A4",
                "entityIds": [
                    "E0000AB"
                ]
            },
            {
                "_id": "B0001A5",
                "entityIds": [
                    "E000258"
                ]
            },
            {
                "_id": "B0001A6",
                "entityIds": [
                    "E000117"
                ]
            },
            {
                "_id": "B0001A7",
                "entityIds": [
                    "E0001D5",
                    "E000085"
                ]
            },
            {
                "_id": "B0001A8",
                "entityIds": [
                    "E000217"
                ]
            },
            {
                "_id": "B0001A9",
                "entityIds": [
                    "E000044",
                    "E00006D",
                    "E000017"
                ]
            },
            {
                "_id": "B0001AA",
                "entityIds": [
                    "E0001FB",
                    "E00003A",
                    "E0000E9"
                ]
            },
            {
                "_id": "B0001AB",
                "entityIds": [
                    "E0000D6"
                ]
            },
            {
                "_id": "B0001AC",
                "entityIds": [
                    "E000091"
                ]
            },
            {
                "_id": "B0001AD",
                "entityIds": [
                    "E000152"
                ]
            },
            {
                "_id": "B0001AE",
                "entityIds": [
                    "E000100"
                ]
            },
            {
                "_id": "B0001AF",
                "entityIds": [
                    "E000226",
                    "E00017A"
                ]
            },
            {
                "_id": "B0001B0",
                "entityIds": [
                    "E000126"
                ]
            },
            {
                "_id": "B0001B1",
                "entityIds": [
                    "E0000FF"
                ]
            },
            {
                "_id": "B0001B2",
                "entityIds": [
                    "E000128"
                ]
            },
            {
                "_id": "B0001B3",
                "entityIds": [
                    "E0000BD"
                ]
            },
            {
                "_id": "B0001B4",
                "entityIds": [
                    "E000076"
                ]
            },
            {
                "_id": "B0001B5",
                "entityIds": [
                    "E000143"
                ]
            },
            {
                "_id": "B0001B6",
                "entityIds": [
                    "E0001A5"
                ]
            },
            {
                "_id": "B0001B7",
                "entityIds": [
                    "E000154"
                ]
            },
            {
                "_id": "B0001B8",
                "entityIds": [
                    "E0001AB",
                    "E00010B",
                    "E000233",
                    "E000092"
                ]
            },
            {
                "_id": "B0001B9",
                "entityIds": [
                    "E00019C"
                ]
            },
            {
                "_id": "B0001BA",
                "entityIds": [
                    "E0000E5"
                ]
            },
            {
                "_id": "B0001BB",
                "entityIds": [
                    "E000231"
                ]
            },
            {
                "_id": "B0001BC",
                "entityIds": [
                    "E0001FF",
                    "E0000F2"
                ]
            },
            {
                "_id": "B0001BD",
                "entityIds": [
                    "E000240"
                ]
            },
            {
                "_id": "B0001BE",
                "entityIds": [
                    "E000105"
                ]
            },
            {
                "_id": "B0001BF",
                "entityIds": [
                    "E000080"
                ]
            },
            {
                "_id": "B0001C0",
                "entityIds": [
                    "E000056"
                ]
            },
            {
                "_id": "B0001C1",
                "entityIds": [
                    "E00005D",
                    "E000102"
                ]
            },
            {
                "_id": "B0001C2",
                "entityIds": [
                    "E000025"
                ]
            },
            {
                "_id": "B0001C3",
                "entityIds": [
                    "E000010"
                ]
            },
            {
                "_id": "B0001C4",
                "entityIds": [
                    "E00027B"
                ]
            },
            {
                "_id": "B0001C5",
                "entityIds": [
                    "E000030"
                ]
            },
            {
                "_id": "B0001C6",
                "entityIds": [
                    "E000220"
                ]
            },
            {
                "_id": "B0001C7",
                "entityIds": [
                    "E000208"
                ]
            },
            {
                "_id": "B0001C8",
                "entityIds": [
                    "E000053"
                ]
            },
            {
                "_id": "B0001C9",
                "entityIds": [
                    "E00009D",
                    "E000106"
                ]
            },
            {
                "_id": "B0001CA",
                "entityIds": [
                    "E00011D"
                ]
            },
            {
                "_id": "B0001CB",
                "entityIds": [
                    "E000102"
                ]
            },
            {
                "_id": "B0001CC",
                "entityIds": [
                    "E0000AC",
                    "E000095"
                ]
            },
            {
                "_id": "B0001CD",
                "entityIds": [
                    "E000020"
                ]
            },
            {
                "_id": "B0001CE",
                "entityIds": [
                    "E00015C",
                    "E000096",
                    "E000155"
                ]
            },
            {
                "_id": "B0001CF",
                "entityIds": [
                    "E00018A"
                ]
            },
            {
                "_id": "B0001D0",
                "entityIds": [
                    "E000193"
                ]
            },
            {
                "_id": "B0001D1",
                "entityIds": [
                    "E0000AF"
                ]
            },
            {
                "_id": "B0001D2",
                "entityIds": [
                    "E000221"
                ]
            },
            {
                "_id": "B0001D3",
                "entityIds": [
                    "E000027"
                ]
            },
            {
                "_id": "B0001D4",
                "entityIds": [
                    "E0001E5"
                ]
            },
            {
                "_id": "B0001D5",
                "entityIds": [
                    "E000216"
                ]
            },
            {
                "_id": "B0001D6",
                "entityIds": [
                    "E00002F"
                ]
            },
            {
                "_id": "B0001D7",
                "entityIds": [
                    "E000175"
                ]
            },
            {
                "_id": "B0001D8",
                "entityIds": [
                    "E000127"
                ]
            },
            {
                "_id": "B0001D9",
                "entityIds": [
                    "E000086"
                ]
            },
            {
                "_id": "B0001DA",
                "entityIds": [
                    "E000082"
                ]
            },
            {
                "_id": "B0001DB",
                "entityIds": [
                    "E000142"
                ]
            },
            {
                "_id": "B0001DC",
                "entityIds": [
                    "E0001AA"
                ]
            },
            {
                "_id": "B0001DD",
                "entityIds": [
                    "E0001E3",
                    "E0000F8"
                ]
            },
            {
                "_id": "B0001DE",
                "entityIds": [
                    "E00025F"
                ]
            },
            {
                "_id": "B0001DF",
                "entityIds": [
                    "E000093"
                ]
            },
            {
                "_id": "B0001E0",
                "entityIds": [
                    "E000087",
                    "E0001EA"
                ]
            },
            {
                "_id": "B0001E1",
                "entityIds": [
                    "E00014F"
                ]
            },
            {
                "_id": "B0001E2",
                "entityIds": [
                    "E0001C8"
                ]
            },
            {
                "_id": "B0001E3",
                "entityIds": [
                    "E000057"
                ]
            },
            {
                "_id": "B0001E4",
                "entityIds": [
                    "E000245"
                ]
            },
            {
                "_id": "B0001E5",
                "entityIds": [
                    "E0001DA"
                ]
            },
            {
                "_id": "B0001E6",
                "entityIds": [
                    "E000281"
                ]
            },
            {
                "_id": "B0001E7",
                "entityIds": [
                    "E000160"
                ]
            },
            {
                "_id": "B0001E8",
                "entityIds": [
                    "E000140",
                    "E00027D",
                    "E00027C"
                ]
            },
            {
                "_id": "B0001E9",
                "entityIds": [
                    "E000226",
                    "E00006E",
                    "E000252",
                    "E00017B"
                ]
            },
            {
                "_id": "B0001EA",
                "entityIds": [
                    "E000088"
                ]
            },
            {
                "_id": "B0001EB",
                "entityIds": [
                    "E000134"
                ]
            },
            {
                "_id": "B0001EC",
                "entityIds": [
                    "E000250"
                ]
            },
            {
                "_id": "B0001ED",
                "entityIds": [
                    "E0000C5"
                ]
            }
        ]
    },
    {
        "model": "Evidence",
        "documents": [
            {
                "_id": "V000000",
                "pmid": "23429371",
                "biomarkerId": "B000000",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": 0.0,
                    "max": 18.0,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "I",
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": "2007",
                "region": [
                    "Germany"
                ],
                "research": {
                    "methods": [
                        "Pyrosequencing analysis"
                    ],
                    "results": [
                        "3F3A K27M mutations are restricted to pediatric diffuse high-grade astrocytomas"
                    ],
                    "conclusions": [
                        "H3F3A K27M mutation occurs exclusively in diffuse high-grade pediatric astrocytomas"
                    ]
                },
                "application": {
                    "validated": "no",
                    "diagnosis": "YES",
                    "prognosis": "NO",
                    "predictive": "NO",
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": "YES",
                "curator": "ANA"
            },
            {
                "_id": "V000001",
                "pmid": "26452024",
                "biomarkerId": "B000001",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": 17.0,
                    "max": 35.0,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": "2007",
                "region": [
                    "China"
                ],
                "research": {
                    "methods": [
                        "Molecular analysis",
                        "Flourescence in situ hybridization",
                        "IHC",
                        "ANOVA",
                        "Kaplan-Meier curves",
                        "Log-rank test",
                        "Cox model"
                    ],
                    "results": [
                        "BRAF\u00a0mutation exhibited better prognosis than WT",
                        "IDH1 mutation showed favorable prognosis comparing to IDH1 WT",
                        "H3F3A-K27M mutation was associated with poor prognosis",
                        "Tumors with positive PDGFRA expression showed shorter survival than those with negative expression"
                    ],
                    "conclusions": [
                        "BRAF,\u00a0H3F3A-K27M,\u00a0IDH1\u00a0and PDGFRA demonstrated prognostic relevance in young adult glioblastomas"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": "YES",
                    "prognosis": "YES",
                    "predictive": "NO",
                    "therapeutic": "YES"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": "Yes"
                },
                "comments": "YES",
                "curator": "RF"
            },
            {
                "_id": "V000002",
                "pmid": "29731893",
                "biomarkerId": "B000002",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": 30.0,
                    "max": 45.0,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": "Post 2010",
                "region": [
                    "China"
                ],
                "research": {
                    "methods": [
                        "n the present study, the association between CDH2 expression and clinical features was investigated based on the Chinese Glioma Genome Atlas (CGGA), the Rembrandt datasets and The Cancer Genome Atlas datasets (TCGA). Medical statistical methods, including Kaplan-Meier analysis and Cox regression model were used. The expression of CDH2 was identified to be strongly associated with glioma World Health Organization grade in the CGGA and Rembrandt datasets. Primary Methods: RT-PCR",
                        "Statistical analysis"
                    ],
                    "results": [
                        "The expression of CDH2 was identified to be strongly associated with glioma World Health Organization grade in the CGGA and Rembrandt datasets. Patients with low CDH2 expression had an improved prognosis and benefited from temozolomide therapy."
                    ],
                    "conclusions": [
                        "these findings revealed that CDH2 may serve as a prognostic and predictive molecular biomarker for the grading and treatment of glioma."
                    ]
                },
                "application": {
                    "validated": "Potential",
                    "diagnosis": null,
                    "prognosis": "Potential",
                    "predictive": "Potential",
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Erik Samuelsson"
            },
            {
                "_id": "V000003",
                "pmid": "23411595",
                "biomarkerId": "B000003",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": 14.0,
                    "max": 56.0,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": "2007",
                "region": [
                    "China"
                ],
                "research": {
                    "methods": [
                        "Immunohistochemistry",
                        "Cox model",
                        "Kaplan Meier method"
                    ],
                    "results": [
                        "Positive cells of CD137L and IL-17 in glioblastoma tissue samples were 46.3% and 73.2% respectively",
                        "Expression of CD137L was not correlated with overall survival of GBM patients, while significantly longer survival rate was seen in patients with high expression of IL-17, compared to those with low expression of IL-17",
                        "IL-17 expression was significantly correlated with Progression-free survival and death rate",
                        "IL-17 (P=0.018) and progression free survival were independent factors affecting the overall survival probability",
                        "Progression free survival of high expression of IL-17 group were significantly longer than low expression group with GBM"
                    ],
                    "conclusions": [
                        "High levels of IL-17 expression in the tumor tissues may be a good prognostic marker for patients with GBM"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": "NO",
                    "prognosis": "Potential",
                    "predictive": "NO",
                    "therapeutic": "NO"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": "NO",
                "curator": "ANA"
            },
            {
                "_id": "V000004",
                "pmid": "25469866",
                "biomarkerId": "B000004",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": 18.0,
                    "max": 57.0,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "I",
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": "2007",
                "region": [
                    "USA",
                    "Thailand"
                ],
                "research": {
                    "methods": [
                        "Immunohistochemistry",
                        "Double-immunofluorescence",
                        "Western blot",
                        "Cell sorting and limiting dilution assay",
                        "Flow cytometry",
                        "t-test"
                    ],
                    "results": [
                        "TNC expression was found to be highly associated with the grade of astrocytoma",
                        "High expression level in most of the grade III astrocytomas and GBMs analyzed and a very low expression in most grade II astrocytomas, whereas it is undetectable in grade I astrocytomas and normal brain tissues",
                        "Double-immunofluorescence staining for TNC and CD133 in GBM tissues revealed that there was a high overlap between theses two positive populations"
                    ],
                    "conclusions": [
                        "TNC is not only a potential prognostic marker for GBM but also a potential marker for glioma CSCs, where the TNC+ population is identified as a CSC population overlapping with part of the CD133\u2013 cell population"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": null,
                    "prognosis": "Potential",
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "BP"
            },
            {
                "_id": "V000005",
                "pmid": "29156757",
                "biomarkerId": "B000005",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": 25.0,
                    "max": 57.0,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "II",
                    "IV"
                ],
                "whoclass": null,
                "region": [
                    "China"
                ],
                "research": {
                    "methods": [
                        "Transcriptome sequencing"
                    ],
                    "results": [
                        "PTEN-COL17A1 fusion gene does not lead to in measurable fusion protein production",
                        "PTEN-COL17A1 fusion gene accopanied with high levels of COL17A1 expression",
                        "novel regulatory mechanism of Collagen XVII expression by PTEN-COL17A1 gene fusion revealed"
                    ],
                    "conclusions": [
                        "new PTEN-COL17A1 fusion gene and its novel regulatory role in Collagen XVII expression and GBM malignance revealed",
                        "COL17A1 could serve as a useful prognostic biomarker and therapeutic targets for GBM"
                    ]
                },
                "application": {
                    "validated": "Potential",
                    "diagnosis": null,
                    "prognosis": "Potential",
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": "COL17A1 could serve as a therapeutic targets for GBM"
                },
                "comments": null,
                "curator": "Vanessa"
            },
            {
                "_id": "V000006",
                "pmid": "25455102",
                "biomarkerId": "B000006",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": 51.0,
                    "max": 59.0,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": "2007",
                "region": [
                    "Turkey"
                ],
                "research": {
                    "methods": [
                        "PCR",
                        "MS-HRM analysis",
                        "Chi-square test",
                        "Two tailed Fisher's test",
                        "Log-rank test",
                        "Kaplan-Meier method"
                    ],
                    "results": [
                        "IDH1 mutations were detected in 5 of 40 primary GBMs",
                        "Primary GBM patients carrying IDH1 mutations were significantly younger, mean age of 41 \u00b1 5.06 years, than patients with wild-type IDH1, mean age of 57 \u00b1 2,29 years",
                        "Mean survival time of all GBM patients with and without IDH1 mutations was 19 months (5 cases) and 16 months (35 cases), respectively",
                        "MGMT methylation was detected in 13 of the 40 patients",
                        "MGMT-promoter methylation did not correlate with overall survival"
                    ],
                    "conclusions": [
                        "First study to investigate the IDH1 mutation status and MGMT methylation in primary GBMs in Turkish population and confirmed IDH1 mutation as a genetic marker for also primary GBMs",
                        "Data are still insufficient for definite ascertainment",
                        "Preliminary results suggest that IDH1 status shows an association with younger age and there is a lack of association between IDH1 mutation and survival time",
                        "MGMT promoter methylation had no prognostic value and lower frequency in primary glioblastomas"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": null,
                    "prognosis": "Potential",
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "BP"
            },
            {
                "_id": "V000007",
                "pmid": "30096248",
                "biomarkerId": "B000007",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": 45.77,
                    "max": 59.38,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": "Post 2010",
                "region": [
                    "Egypt",
                    "Saudi Arabia"
                ],
                "research": {
                    "methods": [
                        "Qiagen miRNeasy FFPE Kit",
                        "RT-PCR",
                        "Methylation-specific PCR of O(6)-methylguanine-DNA methyltransferase (MGMT) promoter"
                    ],
                    "results": [
                        "Relative expression levels of miR-326 were not found to be significantly altered in GBM patients",
                        "H19 was consistently over-expressed in all GBM patients, and was correlated with poorer overall survival (OS) and progression-free survival (PFS)"
                    ],
                    "conclusions": [
                        "Despite our in silico data, expression level analysis for both ncRNAs were not significantly correlated",
                        "Data suggest a role for H19 in the pathogenesis of GBM and could be a potential prognostic biomarker for GBM"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": null,
                    "prognosis": "Potential (H19)",
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Erik Samuelsson"
            },
            {
                "_id": "V000008",
                "pmid": "27358635",
                "biomarkerId": "B000008",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": 47.0,
                    "max": 61.0,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": "2007",
                "region": [
                    "Turkey"
                ],
                "research": {
                    "methods": [
                        "MS-HRM analysis",
                        "Chi-square test",
                        "Two-tailed Fisher's exact test",
                        "t-test"
                    ],
                    "results": [
                        "RAR\u03b2 methylation was detected in 24  out of 40 cases with glioblastoma multiforme in different quantitative ratios",
                        "3 were 25% methylated, 5 were 50% methylated, 4 were 75% methylated and 12 cases showed 100% RAR\u03b2 gene hypermethylation",
                        "The mean survival time of the patients with RAR\u03b2 methylation was calculated to be 19 months and the survival time for unmethylated cases was calculated as 15 months",
                        "RAR\u03b2 methylated patients who received both chemotherapy and radiotherapy treatment combined had a survival time of 25 months",
                        "The patients who received only radiotherapy or had no treatment protocol had a survival time between 15\u201320 months, which demonstrates a significant difference (P<0.05)"
                    ],
                    "conclusions": [
                        "Results demonstrate the role of the RAR\u03b2 gene in glioma tumorigenesis, with RAR\u03b2 promoter methylation being of prognostic value for glioblastoma patients"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": "NO",
                    "prognosis": "Potential",
                    "predictive": "Potential",
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": "NO",
                "curator": "BP"
            },
            {
                "_id": "V000009",
                "pmid": "25655102",
                "biomarkerId": "B0001E4",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": 21.0,
                    "max": 62.0,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": "2007",
                "region": [
                    "Germany",
                    "Switzerland"
                ],
                "research": {
                    "methods": [
                        "Prospective, open-label, randomized, two arm trial of two competing temozolomide dosing regimens for patients with GBM at first relapse or progression",
                        "Central pathology review",
                        "DNA extraction",
                        "MGMT promoter methylation analysis",
                        "Cox model"
                    ],
                    "results": [
                        "Because of withdrawal of support, the trial was prematurely closed to accrual after 105 patients",
                        "There was a similar outcome in both arms for median TTF (A: 1.8 months, 95% confidence intervals (CI), 1.8\u20133.2 vs. B: 2.0 months, 95% CI, 1.8\u20133.5) and overall survival (A: 9.8 months (95% CI, 6.7\u201313.0) vs. B: 10.6 months (95% CI, 8.1\u201311.6))",
                        "Median TTF in patients with MGMT-methylated tumors was 3.2 months (95% CI, 1.8\u20137.4) versus 1.8 months (95% CI, 1.8\u20132) in MGMT-unmethylated glioblastoma",
                        "Progression-free survival rates at 6 months (PFS-6) were 39.7% with versus 6.9% without MGMT promoter methylation"
                    ],
                    "conclusions": [
                        "Temozolomide rechallenge is a treatment option for MGMT promoter-methylated recurrent glioblastoma",
                        "Alternative strategies need to be considered for patients with progressive glioblastoma without MGMT promoter methylation"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": null,
                    "prognosis": null,
                    "predictive": "YES",
                    "therapeutic": "YES"
                },
                "clinical": {
                    "relevance": "Predictive of Temozolomode rechallenge as a treatment option for MGMT promoter methylated recurrent glioblastoma;Trials underway",
                    "implication": null,
                    "treatment": "Temozolomide treatment if marker present"
                },
                "comments": null,
                "curator": "BP"
            },
            {
                "_id": "V00000A",
                "pmid": "21786013",
                "biomarkerId": "B00000A",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": 37.0,
                    "max": 63.0,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "I",
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": null,
                "region": [
                    "China"
                ],
                "research": {
                    "methods": [
                        "Immunohistochemistry",
                        "Western blot",
                        ""
                    ],
                    "results": [
                        "No TAG-72 expression was found in the non-cancerous brain tissues",
                        "TAG-72 protein expression was identified in 80 patients with glioma (52.6%)",
                        "The expression level of TAG-72 protein was increased from gliomas with low grades to those with high grades",
                        "The highest mean value of TAG-72 protein was found in patients with GBM, whereas the lowest mean values were found in those with grade I astrocytoma"
                    ],
                    "conclusions": [
                        "Provide convincing evidence for the first time that the expression of TAG-72 is up-regulated in human gliomas",
                        "The expression levels of TAG-72 in gliomas were associated with the severity of the tumor"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": null,
                    "prognosis": null,
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": null
            },
            {
                "_id": "V00000B",
                "pmid": "24523440",
                "biomarkerId": "B00000B",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": 1.0,
                    "max": 64.0,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "I",
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": "2007",
                "region": [
                    "China"
                ],
                "research": {
                    "methods": [
                        "Real tome RT-PCR",
                        "Westen blot",
                        "Gene cloning and lentiviral vector generation",
                        "Immunohistochemistry",
                        "Kolmogorov-Smirnov test",
                        "ANOVA",
                        "Cox model",
                        "Kaplan Meier Curves"
                    ],
                    "results": [
                        "miR-663 is associated with bettwer prognosis in human GBM",
                        "miR-663 inhibits the proliferation and invasion of GBM cells in vitro and in vivo",
                        "miR-663 directly targets PIK3CD and inhibits its signaling",
                        "Reduced miR-663 expression correlates with the high level of PIK3CD in human GBM"
                    ],
                    "conclusions": [
                        "miR-663 is a novel prognostic biomarker and a potential therapeutic candidate for glioblastoma"
                    ]
                },
                "application": {
                    "validated": "Yes",
                    "diagnosis": null,
                    "prognosis": "YES",
                    "predictive": null,
                    "therapeutic": "Potential"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": null
            },
            {
                "_id": "V00000C",
                "pmid": "17264249",
                "biomarkerId": "B00000C",
                "sourceIds": [
                    "Tissue",
                    "Cell line"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": 22.0,
                    "max": 64.0,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": "2000",
                "region": [
                    "USA"
                ],
                "research": {
                    "methods": [
                        "Immunohistochemistry",
                        "Western blot",
                        "Fluorescence in situ hybridisation"
                    ],
                    "results": [
                        "Aurora B expression levels were markedly correlated with a shortened survival",
                        "Aurora B expression was not directly related to age, tumour proliferation status or to several common molecular changes found in GBMs"
                    ],
                    "conclusions": [
                        "Aurora B may be a prognostic feature of impaired survival and a novel therapeutic target in some patients"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": null,
                    "prognosis": "Potential",
                    "predictive": null,
                    "therapeutic": "Potential"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "BP"
            },
            {
                "_id": "V00000D",
                "pmid": "9870820",
                "biomarkerId": "B00000D",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo sapiens"
                ],
                "age": {
                    "min": 22.0,
                    "max": 64.0,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": null,
                "whoclass": null,
                "region": [
                    "USA"
                ],
                "research": {
                    "methods": [
                        "Immunochemistry"
                    ],
                    "results": [
                        "PI did not correlate with survival after either initial or recurrent surgery for any tumor type. PI difference between specimens also did not correlate with survival"
                    ],
                    "conclusions": [
                        "Ki-67 PI does not confer additional prognostic informa- tion for patients with recurrent astroglial neoplasms"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": null,
                    "prognosis": null,
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Cristian"
            },
            {
                "_id": "V00000E",
                "pmid": "11882906",
                "biomarkerId": "B00004A",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo sapiens"
                ],
                "age": {
                    "min": 4.0,
                    "max": 65.0,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": null,
                "whoclass": "Pre 2007",
                "region": [
                    "India"
                ],
                "research": {
                    "methods": [
                        "Immunochemistry"
                    ],
                    "results": [
                        "Higher the MIB-1 LI, shorter was the interval to recurrence"
                    ],
                    "conclusions": [
                        "Potential role of MIB-1 LI of the initial tumor in determining interval to recurrence"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": null,
                    "prognosis": null,
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Cristian"
            },
            {
                "_id": "V00000F",
                "pmid": "20702468",
                "biomarkerId": "B00000F",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": 18.0,
                    "max": 65.0,
                    "med": 47.0,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": "Pre 2010",
                "region": [
                    "India"
                ],
                "research": {
                    "methods": [
                        "Tumours from a uniformly treated prospective cohort of adult patients with newly diagnosed glioblastoma (n=140) were examined for EGFR amplification by fluorescence in situ hybridisation and EGFR/p53 expression by immunohistochemistry. Statistical methods were employed to assess the degree of association between EGFR amplification/overexpression and p53 immunopositivity. Survival analyses were performed by employing Cox proportional hazard models to assess the independent prognostic value of EGFR/p53 alterations and test the propensity for risk with age by assessing their interaction with patient age."
                    ],
                    "results": [
                        "A strong positive correlation between EGFR amplification and EGFR overexpression (rho=0.5157",
                        "p<0.0001",
                        "CI 0.3783 to 0.6309) and a negative association of EGFR amplification (rho=-0.3417",
                        "p<0.0001",
                        "CI -0.4842 to -0.1816) and EGFR overexpression (rho=-0.3095",
                        "p<0.001",
                        "CI -0.4561 to -0.1465) with p53 immunopositivity was observed. Only patient age (HR: 1.029",
                        "p=0.004",
                        "CI 1.009 to 1.049) was associated with shorter survival by univariate Cox regression analysis. Multivariable Cox proportional hazards models revealed a statistically significant interaction between EGFR overexpression and age to be associated with shorter survival (HR: 1.001",
                        "p<0.0001",
                        "CI 1.000 to 1.002), thus predicting a higher hazard with increasing age. No age interaction of EGFR amplification status (HR: 1.001",
                        "p=0.642",
                        "CI 0.995 to 1.008) and p53 immunopositivity (HR: 1.000",
                        "p=0.841",
                        "CI 0.999 to 1.001) was noted in this cohort."
                    ],
                    "conclusions": [
                        "The prognostic value of EGFR overexpression is age-dependent, and there is a propensity for a higher hazard with increasing patient age. Identifying such groups of patients with more aggressive disease becomes mandatory, since they would benefit from intense therapeutic protocols targeting EGFR."
                    ]
                },
                "application": {
                    "validated": "Yes",
                    "diagnosis": null,
                    "prognosis": "Potential",
                    "predictive": null,
                    "therapeutic": "Potential"
                },
                "clinical": {
                    "relevance": "The receptor for epidermal growth factor (EGFR) is a prime target for cancer therapy across a broad variety of tumor types.",
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Erik Samelsson"
            },
            {
                "_id": "V000010",
                "pmid": "16575014",
                "biomarkerId": "B000010",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": 20.0,
                    "max": 65.0,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": "2000",
                "region": [
                    "USA"
                ],
                "research": {
                    "methods": [
                        "PCR",
                        "Karnofsky performance status",
                        "Cox model",
                        "Survival curves"
                    ],
                    "results": [
                        "Overall survival differed significantly by hTERT MNS16A genotype, with median survivals of 25.1, 14.7, and 14.6 months for the SS, SL, and LL genotypes, respectively",
                        "Compared with the SS genotype, the hazard ratios for the SL and LL genotypes were 1.69 and 1.87, respectively, after adjustment for other factors",
                        "Multivariate Cox regression analysis showed an independent statistically significant association between the hTERT MNS16A variant genotype and outcome"
                    ],
                    "conclusions": [
                        "A functional hTERT MNS16A genotype is a potential biomarker for assessment of survival outcome of GBM"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": null,
                    "prognosis": "Potential",
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "BP"
            },
            {
                "_id": "V000011",
                "pmid": "22169598",
                "biomarkerId": "B000011",
                "sourceIds": [
                    "Tissue",
                    "Cell line"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": 28.0,
                    "max": 65.0,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": "2007",
                "region": [
                    "China"
                ],
                "research": {
                    "methods": [
                        "Immunohistochemistry",
                        "Enzyme-linked immunosorbent assay",
                        "ELISA",
                        "Kaplan-Meier curves",
                        "Cox model"
                    ],
                    "results": [
                        "There was a high significant difference in both progression-free survival and overall survival between TLR9+ and TLR9\u2212 patients, with poorer outcome in TLR9+ patients",
                        "In in vitro glioma cells, there was a positive correlation between the protein levels of TLR9 and both matrix metalloproteinase (MMP)-2 and MMP-9, but no relationship between TLR9 levels and levels of interleukin-6, transforming growth factor-\u03b22 or signal transducer and activator of transcription (STAT)-3"
                    ],
                    "conclusions": [
                        "Data indicate that TLR9 expression correlates with PFS and OS in patients with GBM",
                        "Immune microenvironment of TLR9 can be simulated in vitro",
                        "Because the CpG ODN is a TLR9 agonist, caution is recommended when injecting the TLR9 agonist CpG ODN directly into glioma tissues as part of glioma immunotherapy"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": null,
                    "prognosis": "Potential",
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": null
            },
            {
                "_id": "V000012",
                "pmid": "20353279",
                "biomarkerId": "B000012",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": 28.0,
                    "max": 65.0,
                    "med": 55.0,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": "Pre 2010",
                "region": [
                    "Czech Republic"
                ],
                "research": {
                    "methods": [
                        "In this study, we examined the expression levels of selected microRNAs in 22 primary glioblastomas and six specimens of adult brain tissue by real-time PCR method. In addition, we examined methylation status of MGMT promoter by methylation-specific real-time PCR, as this has been shown to be a predictive marker in glioblastomas."
                    ],
                    "results": [
                        "MGMT methylation status was not correlated with response to concomitant chemoradiotherapy with temozolomide (RT/TMZ). MiR-221 (p=0.016), miR-222 (p=0.038), miR-181b (p=0.036), miR-181c (p=0.043) and miR-128a (p=0.001) were significantly down-regulated in glioblastomas. The most significant change was observed for up-regulation in miR-21 expression in glioblastomas (p<0.001). MiR-181b and miR-181c were significantly down-regulated in patients who responded to RT/TMZ (p=0.016",
                        "p=0.047, respectively) in comparison to patients with progredient disease."
                    ],
                    "conclusions": [
                        "Our data indicate for the first time that expression levels of miR-181b and miR-181c could serve as a predictive marker of response to RT/TMZ therapy in glioblastoma patients."
                    ]
                },
                "application": {
                    "validated": "Potential",
                    "diagnosis": null,
                    "prognosis": null,
                    "predictive": "Potential",
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Erik Samelsson"
            },
            {
                "_id": "V000013",
                "pmid": "20126476",
                "biomarkerId": "B000013",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": 24.0,
                    "max": 66.0,
                    "med": 46.5,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": "Pre 2010",
                "region": [
                    "Canada"
                ],
                "research": {
                    "methods": [
                        "GBM patient samples were examined by three-dimensional fluorescent in situ hybridization of telomeres using two independent three-dimensional telomere-measurement tools (TeloView program [P(1)] and SpotScan system [P(2)]). These measurements identified three patients categories (categories 1-3), displaying significant differences in telomere numbers/nucleus (P(1) = .0275",
                        "P(2) <or= .0001), telomere length (P(1) and P(2) = .0275), and number of telomeric aggregates (P(1) = .0464",
                        "P(2) <or= .0001)."
                    ],
                    "results": [
                        "These categories corresponded to patients with long-term, intermediate, and short-term survival, respectively (P = .0393). The time to progression analyses showed significant differences between the three categories (P = .0167). There was a correlation between time to progression, median survival, and nuclear telomere architecture."
                    ],
                    "conclusions": [
                        "Our study suggests a link between patient outcome and three-dimensional nuclear-telomere organization and highlights the potential clinical power of telomere signatures as a new prognostic, predictive, and potentially pharmacodynamic biomarker in GBM. Furthermore, novel automated three-dimensional high-throughput scanning as developed here permits to obtain data from 300 nuclei in 20 minutes. This method is applicable to any cell type and scanning application."
                    ]
                },
                "application": {
                    "validated": "Potential",
                    "diagnosis": null,
                    "prognosis": "Potential",
                    "predictive": "Potential",
                    "therapeutic": "Potential"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": "NA "
                },
                "comments": null,
                "curator": "Erik Samelsson"
            },
            {
                "_id": "V000014",
                "pmid": "21960689",
                "biomarkerId": "B000014",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": 28.0,
                    "max": 66.0,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": "2007",
                "region": [
                    "Portugal"
                ],
                "research": {
                    "methods": [
                        "Genotyping",
                        "Unconditional multivariate logistic regression",
                        "Cox regression",
                        "Chi-square test"
                    ],
                    "results": [
                        "None of the EGFR \u2212216G/T variants was significantly associated with glioma risk",
                        "The \u2212191C/A genotype was associated with higher risk for glioma when the (CA)n alleles were classified as short for \u226416 or \u226417 repeats",
                        "Independently of the (CA)n repeat cutoff point used, shorter (CA)n repeat variants were significantly associated with increased risk for glioma, particularly glioblastoma and oligodendroglioma",
                        "In all tested models with different (CA)n cutoff points, only \u2212191C/A genotype was consistently associated with improved survival of patients with GBM"
                    ],
                    "conclusions": [
                        "Findings implicate EGFR \u2212191C/A and the (CA)n repeat polymorphisms as risk factors for gliomas, and suggest \u2212191C/A as a prognostic marker in GBM"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": null,
                    "prognosis": "YES",
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": null
            },
            {
                "_id": "V000015",
                "pmid": "24521322",
                "biomarkerId": "B000015",
                "sourceIds": [
                    "Tissue",
                    "Cell line",
                    "Blood"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens",
                    "Mus musculus"
                ],
                "age": {
                    "min": 60.0,
                    "max": 66.0,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV",
                    "I",
                    "II"
                ],
                "whoclass": "2007",
                "region": [
                    "Denmark"
                ],
                "research": {
                    "methods": [
                        "Xenograft model",
                        "RT-PCR",
                        "Western blot",
                        "ELISA",
                        "Immunohistochemistry",
                        "Mantel-Cox test",
                        "Kaplan Meier curves"
                    ],
                    "results": [
                        "CR\u20101 transcript was identified in nine representative GBM tumor samples, with amplicon size comparable with that found in the positive control, U87 37",
                        "CR\u20101 transcript was differentially expressed in a group of representative GBM tumor samples with an average relative expression level of 2.9, and expression levels in some instances were twofold higher than that found in the positive control, U87 37",
                        "Elevated CR-1 protein in the blood of GBM patients",
                        "CR\u20101\u2010positive tumor cells have dual phenotypes",
                        "Within the patient cohort, we found high CR\u20101 protein levels in blood plasma to significantly correlate with a shorter overall survival"
                    ],
                    "conclusions": [
                        "Data suggest that CR\u20101 could be a prognostic biomarker for GBM with the potential of being a therapeutic target"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": null,
                    "prognosis": "Potential",
                    "predictive": null,
                    "therapeutic": "Potential"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": null
            },
            {
                "_id": "V000016",
                "pmid": "27466078",
                "biomarkerId": "B000016",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": 27.0,
                    "max": 67.0,
                    "med": 46.0,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": null,
                "region": [
                    "China"
                ],
                "research": {
                    "methods": [
                        "RT-qPCR",
                        "Immunohistochemical assessment"
                    ],
                    "results": [
                        "expression level of ART1 mRNA in glioma tissues 4-fold higher than that in normal brain tissues"
                    ],
                    "conclusions": null
                },
                "application": {
                    "validated": "Concrete",
                    "diagnosis": null,
                    "prognosis": "YES",
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": "ART1 overexpression in U251 glioblastoma cells could significantly decrease the susceptibility to vincristine (VCR)"
                },
                "comments": null,
                "curator": "Vanessa"
            },
            {
                "_id": "V000017",
                "pmid": "21895872",
                "biomarkerId": "B000017",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": 28.0,
                    "max": 67.0,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": null,
                "region": [
                    "Czech Republic"
                ],
                "research": {
                    "methods": [
                        "Stem-loop RT-PCR",
                        "Bisulfite conversion of DNA",
                        "High-resolution melting analysis",
                        "Mann-Whitney U-test",
                        "Kaplan Meier method",
                        "Log-rank test",
                        "Fischer's exact test"
                    ],
                    "results": [
                        "MGMT methylation status correlated with progression\u2010free survival as well as with overall survival",
                        "MiR\u2010195 and miR\u2010196b positively correlated with overall survival",
                        "Evaluation of miR\u2010181c in combination with miR\u201021 predicted time to progression within 6 months of diagnosis with 92% sensitivity and 81% specificity"
                    ],
                    "conclusions": [
                        "Data confirmed that the methylation status of MGMT but also miR\u201021, miR\u2010181c, miR\u2010195, and miR\u2010196b to be associated with survival of GBM patients",
                        "Suggests that the combination of miR\u2010181c and miR\u201021 could be a very sensitive and specific test to identify patients at high risk of early progression after surgery"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": null,
                    "prognosis": "Potential",
                    "predictive": "Potential",
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": "Confirmed the impact of MGMT promoter methylation status on the favorable outcome after RT/TMZ therapy in GBM patients",
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": null
            },
            {
                "_id": "V000018",
                "pmid": "12908754",
                "biomarkerId": "B000018",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo sapiens"
                ],
                "age": {
                    "min": 2.0,
                    "max": 68.0,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": null,
                "whoclass": "Pre 2007",
                "region": [
                    "Poland"
                ],
                "research": {
                    "methods": [
                        "Immunochemistry",
                        "PCR"
                    ],
                    "results": [
                        "Low-level microsatellite instability was observed in 40% pediatric cases and 67% adult GBM"
                    ],
                    "conclusions": [
                        "MSI occurs predominantly in malignant astrocytic tumors of young patients"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": null,
                    "prognosis": null,
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Cristian"
            },
            {
                "_id": "V000019",
                "pmid": "23494873",
                "biomarkerId": "B000019",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": 13.0,
                    "max": 68.0,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": "2007",
                "region": [
                    "china"
                ],
                "research": {
                    "methods": [
                        "FISH",
                        "MS-PCR",
                        "sequencing"
                    ],
                    "results": [
                        "IDH1 mutation and MGMT promoter methylation were significantly more frequent in the long-term survivors group (GBM patients who live more than 36 months)"
                    ],
                    "conclusions": [
                        "IDH1 mutation and MGMT promoter methylation might be independent, significant, and favorable factors for LTSs with GBM."
                    ]
                },
                "application": {
                    "validated": "no",
                    "diagnosis": "NO",
                    "prognosis": "YES",
                    "predictive": null,
                    "therapeutic": "NO"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": "NO",
                "curator": "ANA"
            },
            {
                "_id": "V00001A",
                "pmid": "23645533",
                "biomarkerId": "B00001A",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": 24.0,
                    "max": 68.0,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": null,
                "region": [
                    "China"
                ],
                "research": {
                    "methods": [
                        "primary GBM cell line",
                        "real time-PCR",
                        "Western blotting",
                        "immunohistochemistry",
                        "cell sorting",
                        "xenograft tumors"
                    ],
                    "results": [
                        "CDH5 is overexpressed in GBM and play a role in angiogensis"
                    ],
                    "conclusions": [
                        "CDH5 Expression Levels Are Associated With Glioma Grades: higher expression is associated with poorer prognosis"
                    ]
                },
                "application": {
                    "validated": "yes",
                    "diagnosis": "NO",
                    "prognosis": "YES",
                    "predictive": "YES",
                    "therapeutic": "Potential"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": "target CDH5 may have a therapeutic benefit for glioma patients"
                },
                "comments": "NO",
                "curator": "ANA"
            },
            {
                "_id": "V00001B",
                "pmid": "29920451",
                "biomarkerId": "B00001B",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": 50.0,
                    "max": 68.0,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": "Post 2010",
                "region": [
                    "China"
                ],
                "research": {
                    "methods": [
                        "Human circular RNA microarray",
                        "qRT-PCR",
                        "bioinformatics/statistics"
                    ],
                    "results": [
                        "ompared with the adjacent normal brain tissues, 254 circRNAs were upregulated and 361 circRNAs were downregulated in IDH-wt glioblastoma with a \u22651.5-fold change. A total of 12 differentially expressed circRNAs were randomly selected and validated a good correlation of results from circRNA-seq with qRT-PCR. Gene Ontology (GO) analysis revealed the differentially expressed circRNAs possibly involved in cell division, DNA damage repair, cytoskeleton, and protein ubiquitination. 46 and 50 miRNAs were predicted to be adsorbed by the top 10 upregulated circRNAs and top 10 downregulated circRNAs, respectively."
                    ],
                    "conclusions": [
                        "Differential expression of circRNAs may be associated with IDH-wt glioblastoma development and progression, and these circRNAs can be identified as biomarkers for prognosis prediction and targets for treatment."
                    ]
                },
                "application": {
                    "validated": "Potential",
                    "diagnosis": null,
                    "prognosis": "Potential",
                    "predictive": null,
                    "therapeutic": "Potential"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Erik Samuelsson"
            },
            {
                "_id": "V00001C",
                "pmid": "12888899",
                "biomarkerId": "B00001C",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo sapiens"
                ],
                "age": {
                    "min": 29.0,
                    "max": 69.0,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": null,
                "whoclass": null,
                "region": [
                    "Germany"
                ],
                "research": {
                    "methods": [
                        "Immunochemistry"
                    ],
                    "results": [
                        "MAPK expression was found in 80.8% of the tumors"
                    ],
                    "conclusions": [
                        "Expression of MAPK and activated pMAPK was significantly correlated with survival time"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": null,
                    "prognosis": null,
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Cristian"
            },
            {
                "_id": "V00001D",
                "pmid": "14612923",
                "biomarkerId": "B00016F",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo sapiens"
                ],
                "age": {
                    "min": 10.0,
                    "max": 70.0,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": null,
                "whoclass": null,
                "region": [
                    "Italy"
                ],
                "research": {
                    "methods": [
                        "Immunochemistry",
                        "FISH",
                        "TRAP assay"
                    ],
                    "results": [
                        "Telomere number was inversely correlated with TA"
                    ],
                    "conclusions": [
                        "TeNo seems to be inversely correlated to tumor proliferation and lifetime in GBM"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": null,
                    "prognosis": null,
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Cristian"
            },
            {
                "_id": "V00001E",
                "pmid": "18821037",
                "biomarkerId": "B00001E",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": 11.0,
                    "max": 70.0,
                    "med": -1,
                    "avg": 35.02,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "I",
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": "Pre 2010",
                "region": [
                    "Egypt"
                ],
                "research": {
                    "methods": [
                        "This retrograde study included 45 cases with astrocytomas in the form of paraffin blocks. Sections were stained with hematoxylin and eosin to determine the type and histological grade according to WHO (2007) classification of CNS tumors. Immunostaining was done using anti p53 and CD31 and the results were measured as labeling index (LI) using image analyzer system CAS-200."
                    ],
                    "results": [
                        "Both p53 and CD31 expressions were correlated well with the histopathological grades of different subtypes of astrogliomas with good discrimination between low and high grades. Overall, a highly significant statistical correlation was observed between the grades of astrocytomas and the p53 and CD31 labeling indices. The expressions of p53 and CD31 were markedly increased in glioblastoma multiforme (GBM) with mean values (59.7 +/- 13.5) (P = 0.0001) and (40.7 +/- 8.9) (P = 0.001), respectively. Obviously, these observations demonstrate that the co-expression and increased levels of p53 and CD31 in astrogliomas are increasing as the tumor grade is increasing."
                    ],
                    "conclusions": [
                        "The estimation of p53 and CD31 could be used as good tools to assess the grade, prognosis, and aggressiveness of the astroglial tumors. Thus, the two markers can be used as adjunct to the diagnosis and stratification of the high grade from the low-grade intrinsic brain astrogliomas."
                    ]
                },
                "application": {
                    "validated": "Potential",
                    "diagnosis": null,
                    "prognosis": "Potential",
                    "predictive": "Potential",
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": "CD31 is a marker of microvascularity, while p53 is a cancer suppressor.",
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Erik Samelsson"
            },
            {
                "_id": "V00001F",
                "pmid": "24194606",
                "biomarkerId": "B00001F",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": 12.0,
                    "max": 70.0,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": "2007",
                "region": [
                    "China"
                ],
                "research": {
                    "methods": [
                        "Differential expression analysis",
                        "Construction of FMRN by integrative computational method",
                        "Unsupervised hierarchial clustering",
                        "miRNA risk scoring system development and validation",
                        "Cox model",
                        "Functional analysis of miRNAs via their targets in the FMRN"
                    ],
                    "results": [
                        "After randomly dividing GBM patients into training and test sets with equal number in each group a five-miRNA signature was identified",
                        "Of these five miRNAs, hsa-miR-628-5p and hsa-miR-524-5p were found to be protective miRNAs and other three (hsa-miR-938, hsa-miR-595 and hsa-miR-346) were noted to act as risky factors in GBM",
                        "Segregared samples in training set into high- and low-risk groups exhibited significantly different survival times",
                        "The median survival time of high-risk group was 9.68 months and that of low-risk group was 17.77 months",
                        "The five-miRNA signature also showed better prediction of survival than age, sex and IDH1 mutation status with regard to overall survival in the combined GBM patients"
                    ],
                    "conclusions": [
                        "Functional analysis of these miRNA signatures highlighted their critical roles in cell cycle and cell proliferation in GBM malignant progression, especially hsa-miR-524-5p and hsa-miR-628-5p exhibited dominant regulatory activities",
                        "Therefore, network-based biomarkers are expected to be more effective and provide deep insights into the molecular mechanism of glioma malignant progression"
                    ]
                },
                "application": {
                    "validated": "Yes",
                    "diagnosis": null,
                    "prognosis": "YES",
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": null
            },
            {
                "_id": "V000020",
                "pmid": "22990979",
                "biomarkerId": "B000020",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": 17.0,
                    "max": 70.0,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": "2007",
                "region": [
                    "China"
                ],
                "research": {
                    "methods": [
                        "miRNA expression profiling",
                        "qRT-PCR",
                        "Pyrosequencing",
                        "Cox model",
                        "ROC curve analysis",
                        "Kaplan-Meier method"
                    ],
                    "results": [
                        "Patients who had high risk scores according to the 5-microRNA signature had poor overall survival and progression-free survival compared with patients who had low risk scores",
                        "The 5-microRNA signature was an independent prognostic biomarker after adjusting for other clinicopathologic and genetic factors, such as extent of resection, temozolomide chemotherapy, preoperative Karnofsky performance status score, isocitrate dehydrogenase 1 (IDH1) mutation, and O-6-methylguanine-DNA methyltransferase (MGMT) promoter methylation status"
                    ],
                    "conclusions": [
                        "The 5-microRNA signature was identified as an independent risk predictor that identified patients who had a high risk of unfavorable outcome, demonstrating its potential for personalizing cancer management"
                    ]
                },
                "application": {
                    "validated": "Yes",
                    "diagnosis": null,
                    "prognosis": "YES",
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Ahmed"
            },
            {
                "_id": "V000021",
                "pmid": "22570426",
                "biomarkerId": "B000021",
                "sourceIds": [
                    "Tissue",
                    "Cell line"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": 17.0,
                    "max": 70.0,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": null,
                "region": [
                    "China",
                    "USA"
                ],
                "research": {
                    "methods": [
                        "DNA, RNA and miRNA profiling",
                        "Immunoblotting",
                        "Cox model"
                    ],
                    "results": [
                        "An association of miR-181d with survival was evident in patients who underwent TMZ treatment but was not observed in patients without TMZ therapy",
                        "Bioinformatic analysis of potential genes regulated by miR-181d revealed methyl-guanine-methyl-transferase (MGMT) as a downstream target",
                        "Transfection of miR-181d downregulated MGMT mRNA and protein expression",
                        "Exhibited a direct interaction between miR-181d and MGMT 3\u2032UTR",
                        "The suppressive effect of miR-181d on MGMT expression was rescued by the introduction of an MGMT cDNA. MGMT expression inversely correlated with miR-181d expression in independent GBM cohorts"
                    ],
                    "conclusions": [
                        "Results suggest that miR-181d is a predictive biomarker for TMZ response and that its role is mediated, in part, by posttranscriptional regulation of MGMT"
                    ]
                },
                "application": {
                    "validated": "Yes",
                    "diagnosis": null,
                    "prognosis": null,
                    "predictive": "Yes (Of TMZ response)",
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Ahmed"
            },
            {
                "_id": "V000022",
                "pmid": "30129426",
                "biomarkerId": "B000022",
                "sourceIds": [
                    "Tissue",
                    "Cell line"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": 18.0,
                    "max": 70.0,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": null,
                "region": [
                    "Germany"
                ],
                "research": {
                    "methods": [
                        "Immunoblot",
                        "Immunohistochemistry",
                        "Univariate survival analysis"
                    ],
                    "results": [
                        "In this retrospective analysis of treatment-na\u00efve samples of the OSAG 101-BSA-05 trial cohort, EGFR signaling activity markers phosphorylated PRAS40 and phosphorylated ribosomal protein S6 are identified as predictive markers for treatment efficacy of the EGFR-blocking antibody nimotuzumab in MGMT promoter unmethylated GBs"
                    ],
                    "conclusions": [
                        "Study report markers for the selection of patients that might benefit from the EGFR-blocking antibody nimotuzumab",
                        "Results constitute a basis for further investigation of nimotuzumab or other EGFR- and mTOR-inhibitors in selected patient cohorts using the reported criteria as candidate predictive biomarkers"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": null,
                    "prognosis": "Potential",
                    "predictive": "Potential",
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": "Potential patient cohort selector",
                    "implication": "Potential method to successfully divide patient cohorts for nimotuzumab treatment.",
                    "treatment": "Could lead to new method of defining patient cohorts for EGFR target treatment studies."
                },
                "comments": null,
                "curator": "Erik Samuelsson"
            },
            {
                "_id": "V000023",
                "pmid": "22926763",
                "biomarkerId": "B000023",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": 38.0,
                    "max": 70.0,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "I",
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": "2007",
                "region": [
                    "Republic of Korea"
                ],
                "research": {
                    "methods": [
                        "Immunohistochemistry",
                        "Methylation specific PCR",
                        "Fisher's exact test",
                        "Kaplan-Meier method",
                        "Cox model",
                        "Log-rank test"
                    ],
                    "results": [
                        "Overexpression of CD151 was observed in a significant proportion (55.6%) of GBMs, while CD151 was rarely overexpressed in most of grade I to III glial tumors",
                        "CD151 overexpression was closely associated with MGMT methylation and it was a prognostic factor for predicting worse overall survival (OS) and progression\u2010free survival (PFS)",
                        "Combination of CD151 overexpression and MGMT methylation better stratified the patients' OS and PFS",
                        "CD151 overexpression was an independent prognostic factor for predicting OS over MGMT methylation"
                    ],
                    "conclusions": [
                        "CD151 seems to have a critical role for high\u2010grade progression in astroglial tumors",
                        "CD151 is a good tissue marker that can be used easily in a daily practice for predicting worse prognosis in patients with glioblastoma"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": null,
                    "prognosis": "YES",
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Ahmed"
            },
            {
                "_id": "V000024",
                "pmid": "27495233",
                "biomarkerId": "B000024",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": 9.0,
                    "max": 71.0,
                    "med": -1,
                    "avg": 39.0,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "I",
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": null,
                "region": null,
                "research": {
                    "methods": [
                        "Multiplex real-time PCR",
                        "RT-qPCR"
                    ],
                    "results": [
                        "miRNA-363 upregulated in all tumorspecimen",
                        "miRNa-363 expression correlates with tumo grading"
                    ],
                    "conclusions": null
                },
                "application": {
                    "validated": null,
                    "diagnosis": null,
                    "prognosis": null,
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Vanessa"
            },
            {
                "_id": "V000025",
                "pmid": "23902708",
                "biomarkerId": "B000025",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": 12.0,
                    "max": 71.0,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": "2000",
                "region": [
                    "Egypt"
                ],
                "research": {
                    "methods": [
                        "Immunohistochemistry",
                        "Interpretation of immunohistochemical satining of MIB-1 and DJ-1",
                        "ROC curves",
                        "ANOVA",
                        "Chi-square test",
                        "Fisher's exact test",
                        "Kaplan-Meier method",
                        "Log-rank test",
                        "Cox model"
                    ],
                    "results": [
                        "The statistical analysis revealed a significant correlation between each of DJ-1 and MIB-1 and the histological grade of astrocytomas",
                        "The univariate analysis showed that high grade, high DJ-1 score and MIB-1 labeling index\u2009\u2265\u200910.1 were associated with poor survival",
                        "Multivariate analysis for all the studied astrocytomas proved the independent prognostic significance of the histological grade and DJ-1 score",
                        "Multivariate analysis for each grade emphasized that DJ-1 was the only independent prognostic indicator in high-grade astrocytomas"
                    ],
                    "conclusions": [
                        "Study emphasized the effectiveness of high DJ-1 expression in predicting poor survival of astrocytoma patients, when compared to MIB-1",
                        "DJ-1 could be particularly important in cases with discrepancies between the morphologic criteria and clinical parameters"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": "Potential",
                    "prognosis": "Potential",
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": "Potential",
                "curator": null
            },
            {
                "_id": "V000026",
                "pmid": "23510544",
                "biomarkerId": "B000026",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": 12.0,
                    "max": 71.0,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "I",
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": null,
                "region": [
                    "China"
                ],
                "research": {
                    "methods": [
                        "Immunohistochemistry assay",
                        "real time-PCR",
                        "western blotting"
                    ],
                    "results": [
                        "FOXA1 is overexpressed in glioma tissues compared with non-neoplastic brain tissues"
                    ],
                    "conclusions": [
                        "FOXA1 might be a potential regulator of progression of human gliomas and its upregulation might be closely associated with poor clinical outcome"
                    ]
                },
                "application": {
                    "validated": "no",
                    "diagnosis": "NO",
                    "prognosis": "YES",
                    "predictive": "Potential",
                    "therapeutic": "Potential"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": "NO",
                "curator": "ANA"
            },
            {
                "_id": "V000027",
                "pmid": "26356815",
                "biomarkerId": "B000027",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": 23.0,
                    "max": 71.0,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "II",
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": "2007",
                "region": [
                    "China"
                ],
                "research": {
                    "methods": [
                        "WB",
                        "PCR",
                        "IHC",
                        "Immunoflourescence"
                    ],
                    "results": [
                        "HOXA13 genes expression is directly associated with high grade glioma"
                    ],
                    "conclusions": [
                        "high levels of HOXA13 is associated with GBM and poor prognosis. The down-regulation of HOXA13 decreased invasion and metastasis by inhibiting Wnt/\u03b2-catenin and TGF-\u03b2 induced EMT.\u00a0In vivo, inhibition of HOXA13 inhibited tumor growth and prolonged animal survival."
                    ]
                },
                "application": {
                    "validated": null,
                    "diagnosis": "YES",
                    "prognosis": "YES",
                    "predictive": "NO",
                    "therapeutic": "NO"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": "YES",
                "curator": "RF"
            },
            {
                "_id": "V000028",
                "pmid": "25322872",
                "biomarkerId": "B000028",
                "sourceIds": [
                    "Tissue",
                    "Cell line"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": 24.0,
                    "max": 71.0,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": "2007",
                "region": [
                    "Czech Republic"
                ],
                "research": {
                    "methods": [
                        "MicroRNA expression profiling",
                        "Bisulfite conversion of DNA",
                        "MTT assay",
                        "Cox model",
                        "Kaplan Meier curves",
                        "t-test"
                    ],
                    "results": [
                        "Subsequent analysis revealed 28 significantly deregulated miRNAs in GBM tissue, which were able to precisely classify all examined samples",
                        "Correlation with clinical data led to identification of six-miRNA signature significantly associated with progression free survival (hazard ratio (HR) 1.98) and overa all survival (HR 2.86)",
                        "MGMT methylation status was evaluated as reference method and Risk Score based on six-miRNA signature indicated significant superiority in prediction of clinical outcome in GBM patients",
                        "Risk Score based on six-miRNA signature is an independent prognostic classifier of GBM patients"
                    ],
                    "conclusions": [
                        "Risk Score presents promising prognostic algorithm with potential for individualized treatment decisions in clinical management of GBM patients"
                    ]
                },
                "application": {
                    "validated": "Yes",
                    "diagnosis": null,
                    "prognosis": "YES",
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "BP"
            },
            {
                "_id": "V000029",
                "pmid": "21242845",
                "biomarkerId": "B000029",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": 24.0,
                    "max": 71.0,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": "2000",
                "region": [
                    "China"
                ],
                "research": {
                    "methods": [
                        "Immunohistochemical staining",
                        "Kaplan Meier analysis",
                        "Log-rank test",
                        "Cox regression analysis"
                    ],
                    "results": [
                        "14-3-3zeta positive expression was observed in approximately 74.5% of patients with GBM",
                        "Patients in the 14-3-3zeta positive group had lower overall survival rates and median survival time than those in the 14-3-3zeta negative group (overall 2-year actuarial survival rates, 8.6% for the 14-3-3zeta positive group vs 16.7% for the 14-3-3zeta negative group,overall 2-year median survival time, 12.9 months for the 14-3-3zeta positive group vs 17.9 months for the 14-3-3zeta negative group)",
                        "14-3-3zeta positive expression in tumor cells also was correlated with a shorter interval to tumor recurrence (median interval to recurrence, 5.9 months in the 14-3-3zeta positive group vs 8.3 months in the 14-3-3zeta negative group)",
                        "Univariate and multivariate analyses showed that 14-3-3zeta positive expression was an independent prognostic factor"
                    ],
                    "conclusions": [
                        "14-3-3zeta positive expression can be used as a potential molecular risk factor in patients with GBM"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": null,
                    "prognosis": "Potential",
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": null
            },
            {
                "_id": "V00002A",
                "pmid": "24466377",
                "biomarkerId": "B00002A",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": 27.0,
                    "max": 71.0,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": "2007",
                "region": [
                    "Australia"
                ],
                "research": {
                    "methods": [
                        "PCR",
                        "Relative quantification of miR-132",
                        "Kaplan Meier curves",
                        "Cox model",
                        "k-fold validation test"
                    ],
                    "results": [
                        "Tumor miR-132 levels ranged from 0.07- to 40.4-fold increase (mean = 5.5-fold increase) relative to normal brain",
                        "High-level miR-132 (above the mean) independently predicted for a significantly shorter overall survival",
                        "miR-132 was a stronger prognostic indicator than ECOG score and age at diagnosis but did not correlate with MGMT methylation status or extent of tumor resection",
                        "Cox regression analysis confirmed high miR-132 as the strongest predictor of outcome with a hazard ratio of 2.8"
                    ],
                    "conclusions": [
                        "Study identified high miR-132 expression as a biomarker of poor prognosis in patients with primary GBM treated with the Stupp regimen"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": null,
                    "prognosis": "YES",
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": null
            },
            {
                "_id": "V00002B",
                "pmid": "18097589",
                "biomarkerId": "B00002B",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": 31.0,
                    "max": 71.0,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": "2007",
                "region": [
                    "Germany"
                ],
                "research": {
                    "methods": [
                        "Immunohistochemistry",
                        "x400 Microscopy",
                        "Microvessel score",
                        "Survival curves",
                        "Chi-square test",
                        "Log-rank test"
                    ],
                    "results": [
                        "A high level expression of EphA2 was demonstrated in 24 (60%) of the primary and recurrent GBM analyzed",
                        "Increased expression of the EphA2 protein was significantly associated with the adverse outcome of GBM patients (p<0.01 for overall survival)",
                        "High microvascular density was noted in those areas where the overexpression of EphA2 was marked",
                        "No significant correlation between the expression of EphA2 and microvascular density was reported"
                    ],
                    "conclusions": [
                        "EphA2 may be a potential therapeutic target for anti-tumorigenic and anti-angiogenic therapies",
                        "Data in this study indicated that EphA2 may be a valuable candidate as a prognostic marker and a new targeted therapeutic assessment in primary and recurrent GBM"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": "NO",
                    "prognosis": "Potential",
                    "predictive": "NO",
                    "therapeutic": "Potential"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": "NO",
                "curator": "BP"
            },
            {
                "_id": "V00002C",
                "pmid": "29782850",
                "biomarkerId": "B00002C",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": 13.0,
                    "max": 72.0,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": "Post 2010",
                "region": [
                    "China"
                ],
                "research": {
                    "methods": [
                        "IHC staining",
                        "RNA extraction and RT-qPCR",
                        ". Overexpression and knock-down of HDAC1 in glioblastoma cell line",
                        "Western Blotting"
                    ],
                    "results": [
                        "In this study, our findings demonstrated that protein and mRNA levels of HDAC1 were increased in glioma cell lines and glioma tissues compared to normal glial cell lines and non-neoplastic brain tissues, respectively."
                    ],
                    "conclusions": [
                        "For the first time, we have demonstrated that HDAC1 promotes proliferation and invasion in glioblastoma cells by activating PI3K/AKT and MEK/ERK signaling pathways in vitro and in vivo. These results suggest that HDAC1 may be a novel biomarker and potential therapeutic target in glioblastoma."
                    ]
                },
                "application": {
                    "validated": "Potential",
                    "diagnosis": null,
                    "prognosis": "Potential",
                    "predictive": null,
                    "therapeutic": "Potential"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Erik Samuelsson"
            },
            {
                "_id": "V00002D",
                "pmid": "25849941",
                "biomarkerId": "B00002D",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": 18.0,
                    "max": 72.0,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": null,
                "whoclass": "2007",
                "region": [
                    "Switzerland"
                ],
                "research": {
                    "methods": [
                        "RT-PCR",
                        "IHC"
                    ],
                    "results": [
                        "all three isoforms of TGF-\u03b2 are expressed and biologically active, (ii) their expression seems to be commonly controlled, and (iii)  mRNA expression levels of the TGF-\u03b2 isoforms were remarkably similar among newly diagnosed and recurrent tumors"
                    ],
                    "conclusions": [
                        "(I)targeted approaches focusing on a particular isoform are unlikely to be successful in glioblastoma",
                        "(III)ntercurrent treatment in this patient population with radiotherapy or radiochemotherapy does not durably down- or up-regulate TGF-\u03b2 pathway activity"
                    ]
                },
                "application": {
                    "validated": null,
                    "diagnosis": "NO",
                    "prognosis": "NO",
                    "predictive": "YES",
                    "therapeutic": "YES"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": "NO",
                "curator": "RF"
            },
            {
                "_id": "V00002E",
                "pmid": "22034964",
                "biomarkerId": "B00002E",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": 20.0,
                    "max": 72.0,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": "2000",
                "region": [
                    "China"
                ],
                "research": {
                    "methods": [
                        "High resolution melting analysis",
                        "Methylation specific PCR",
                        "Fluorescence in situ hybridization",
                        "Evaluation of response to TMZ",
                        "t-test",
                        "Kaplan Meier analysis",
                        "Cox model"
                    ],
                    "results": [
                        "IDH (IDH1 or IDH2) mutations were found in 58/79 patients",
                        "IDH mutation, MGMT promoter methylation, and 1p19q codeletion were associated with prolonged progression\u2010free survival in univariate and multivariate analysis",
                        "IDH mutation and MGMT promoter methylation were correlated with a higher rate of objective response to temozolomide",
                        "Further analysis of response to temozolomide showed that patients with both IDH mutation and MGMT promoter methylation had the best response rate to temozolomide"
                    ],
                    "conclusions": [
                        "IDH mutation appears to be a significant marker of positive chemosensitivity in secondary glioblastoma",
                        "Use of IDH status combined with MGMT promoter status as a stratification factor seems appropriate in future clinical trials involving temozolomide for the treatment of patients with secondary glioblastoma"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": null,
                    "prognosis": null,
                    "predictive": "YES",
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": "Use of IDH status combined with MGMT promoter status as a stratification factor seems appropriate in future clinical trials involving temozolomide for the treatment of patients with secondary glioblastoma",
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": null
            },
            {
                "_id": "V00002F",
                "pmid": "7507162",
                "biomarkerId": "B00002F",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo sapiens"
                ],
                "age": {
                    "min": 22.0,
                    "max": 72.0,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": null,
                "whoclass": null,
                "region": [
                    "USA"
                ],
                "research": {
                    "methods": [
                        "Immunochemistry"
                    ],
                    "results": [
                        "100% long term survivors were considered to be EGF-R negative/scant, while 62% short term survivors were EGF-R positive. 76% of the cases were either double negative or positive for EGF-R and c-neu/erbB2"
                    ],
                    "conclusions": [
                        "Increased expression of these proteins in glioblastomas may be associated with aggressive clinical behavior"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": null,
                    "prognosis": null,
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Cristian"
            },
            {
                "_id": "V000030",
                "pmid": "18192970",
                "biomarkerId": "B000030",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": 31.0,
                    "max": 72.0,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "III",
                    "IV"
                ],
                "whoclass": "2007",
                "region": [
                    "United Kingdom"
                ],
                "research": {
                    "methods": [
                        "Immunohistochemistry",
                        "Western blot",
                        "Confocal microscopy"
                    ],
                    "results": [
                        "Endosialin is not expressed in normal human adult brain but is strongly upregulated in the angiogenic vasculature of all high-grade glioma specimens examined",
                        "Endosialin is not expressed by the glioma endothelial cells but on closely associated perivascular cells"
                    ],
                    "conclusions": [
                        "Targeting endosialin or pathways associated with this receptor offer an attractive therapeutic opportunity",
                        "This may be particularly relevant to GBM, which is characterized by extensive microvascular proliferation, but for which there is currently little targeted treatments"
                    ]
                },
                "application": {
                    "validated": "No (This study is a validation for previous works)",
                    "diagnosis": "NO",
                    "prognosis": "NO",
                    "predictive": "NO",
                    "therapeutic": "Potential"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": "NO",
                "curator": "BP"
            },
            {
                "_id": "V000031",
                "pmid": "29136645",
                "biomarkerId": "B000031",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": 37.0,
                    "max": 72.0,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": "2007",
                "region": [
                    "Denmark",
                    "USA"
                ],
                "research": {
                    "methods": [
                        "Immunohistochemistry",
                        "Microarray",
                        "Leave one out cross validation",
                        "t-testLog-rank test",
                        "Fischer's exact tes",
                        "Cox model",
                        "ANOVA"
                    ],
                    "results": [
                        "The expression patterns of miRNAs, particularly the four miRNAs: hsa-miR-107_st, hsa-miR-548x_st, hsa-miR-3125_st and hsa-miR-331-3p_st could determine short- and long-term survival with a predicted accuracy of 78%",
                        "Heatmap dendrograms dichotomized GBMs into prognostic subgroups with a significant association to survival in univariate and multivariate analysis",
                        "Similar tendency was seen in TCGA using a 2-miRNA signature of miR-107 and miR-331 (miR sum score), which were the only miRNAs available in TCGA",
                        "In TCGA, patients with MGMT unmethylated tumors and low miR sum score had the shortest survival",
                        "Adjusting for age and MGMT status, low miR sum score was associated with a poorer prognosis"
                    ],
                    "conclusions": [
                        "The biology of miRNAs is complex, but the identified 4-miRNA expression pattern could comprise promising biomarkers in glioblastoma stratifying patients into short- and long-term survivors"
                    ]
                },
                "application": {
                    "validated": "Partially validated",
                    "diagnosis": null,
                    "prognosis": "Potential",
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Vanessa"
            },
            {
                "_id": "V000032",
                "pmid": "11300931",
                "biomarkerId": "B000032",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo sapiens"
                ],
                "age": {
                    "min": 2.0,
                    "max": 73.0,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "I",
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": "Pre 2007",
                "region": [
                    "USA"
                ],
                "research": {
                    "methods": [
                        "Immunochemistry"
                    ],
                    "results": [
                        "\u03b2III immunoreactivity was significantly greater in high-grade astrocytomas"
                    ],
                    "conclusions": [
                        "\u03b2III immunoreactivity is associated with an ascending gradient of malignancy"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": "Potential",
                    "prognosis": null,
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": "Potential",
                "curator": "Cristian"
            },
            {
                "_id": "V000033",
                "pmid": 0,
                "biomarkerId": "B0001D3",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": 16.0,
                    "max": 73.0,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": null,
                "region": [
                    "China"
                ],
                "research": {
                    "methods": [
                        "MRI",
                        "Immunohistochemical assessment",
                        "VLSM analysis"
                    ],
                    "results": [
                        "tumors with low expression of MGMT protein and those with high expression of MGMT protein showed not significant differences in tumor size on T2 imaging",
                        "VLSM analysis demonstrated that tumors with low expression of MGMT protein were more likely to occur in the right temporal-parietal lobe, while tumors with high expression of MGMT protein occurred more often in the left frontal lobe",
                        "based upon VLSM data, our results suggest that the epigenetic changes, which occur during tumorigenesis, may have anatomical specificity"
                    ],
                    "conclusions": [
                        "identifed correlation between molecular biomarkers and anatomical dsitribution underscores current udnerstanding of biological characteristics of GBM"
                    ]
                },
                "application": {
                    "validated": null,
                    "diagnosis": null,
                    "prognosis": null,
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Vanessa"
            },
            {
                "_id": "V000034",
                "pmid": "23178488",
                "biomarkerId": "B000034",
                "sourceIds": [
                    "Tissue",
                    "Cell line"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens",
                    "Mus musculus"
                ],
                "age": {
                    "min": 24.0,
                    "max": 73.0,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": null,
                "region": [
                    "USA"
                ],
                "research": {
                    "methods": [
                        "qRT-PCR",
                        "Immunohistochemistry",
                        "Western blot",
                        "Tumorigenicity assay in immunosupressed mice",
                        "t-test",
                        "ANOVA"
                    ],
                    "results": [
                        "TRIM11 is over-expressed in human high-grade glioma tumors and glioma-derived GSCs but not in NSCs, low-grade glioma-derived GSCs or stable malignant glioma cell lines",
                        "TRIM11 mRNA levels correlate with differentiation status and CD133 mRNA levels in gliomas",
                        "Down-regulation of TRIM11 suppresses proliferation, migration and invasion of glioma cells, and inhibits EGFR expression, MAPK signaling pathway, and transcription of HB-EGF and CCND1",
                        "Over-expression of TRIM11 promotes tumorsphere formation and proliferation in vitro and tumor growth in vivo"
                    ],
                    "conclusions": [
                        "Demonstrated for the first time that TRIM11 acts as a malignant glioma marker, but provided evidences that TRIM11 may exert its oncogenic function through promoting cell proliferation, migration and invasion",
                        "TRIM11 exerts its effect through EGFR oncogenic pathway and MAPK pathway"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": null,
                    "prognosis": null,
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Ahmed"
            },
            {
                "_id": "V000035",
                "pmid": "15565811",
                "biomarkerId": "B000035",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo sapiens"
                ],
                "age": {
                    "min": 41.0,
                    "max": 73.0,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "I",
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": "Pre 2007",
                "region": [
                    "USA"
                ],
                "research": {
                    "methods": [
                        "Immunochemistry"
                    ],
                    "results": [
                        "10.4% of the tumors showed presence of HER-2/neu overexpression . The HER-2/neu overexpression predicted significantly increased mortality"
                    ],
                    "conclusions": [
                        "HER-2/neuoverexpression seen appears to predict a slight increased mortality in patients with primary malignant brain tumors"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": null,
                    "prognosis": null,
                    "predictive": "Potential",
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Cristian"
            },
            {
                "_id": "V000036",
                "pmid": "22816225",
                "biomarkerId": "B000036",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": 1.0,
                    "max": 74.0,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": "2007",
                "region": [
                    "Croatia"
                ],
                "research": {
                    "methods": [
                        "Light microscopic analysis",
                        "Immunohistochemistry",
                        "Multiple regression",
                        "Kaplan-Meier method",
                        "Cox model"
                    ],
                    "results": [
                        "Qunatitative analysis for Cath D expression in the cytoplasm of brain tumor cells and endothelial cells as well as the percentage of brain tumor cells, endothelial cells and stromal cells immunopositive for Cath D showed that there was difference between analyzed brain tumor groups, but according to statistical tests the difference was not statistically significant",
                        "Survival correlated with the percentage of stromal cells immunopositive for Cath D",
                        "Survival prognosis was influenced by the percentage of stromal cells immunopositive for Cath D and tumor grade",
                        "Percentage of stromal cells were immunopositive for Cath D as an independent parameter"
                    ],
                    "conclusions": [
                        "The results of this research on the prognostic value of Cath D in some primary brain tumors of neuroepithelial origin indicate that there is real possibility to use Cath D as an independent prognostic factor in human glioma progression"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": null,
                    "prognosis": "Potential",
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Ahmed"
            },
            {
                "_id": "V000037",
                "pmid": "20135187",
                "biomarkerId": "B0001CF",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": 8.0,
                    "max": 74.0,
                    "med": 58.5,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": "Pre 2010",
                "region": [
                    "Japan"
                ],
                "research": {
                    "methods": [
                        "We tested in this study for an association between the expression of stem cell marker CD133 and the risk of dissemination in 26 cases of glioblastoma (16 with dissemination and 10 without dissemination). The protein expression of CD133 was examined by western blot analysis of tumor specimens, and the CD133 expression levels were quantified by densitometry and normalized to beta-actin."
                    ],
                    "results": [
                        "The results indicated that CD133 expression levels are significantly higher in glioblastomas with dissemination (mean 10.3, range 0.20-27.8) than in those without (mean 1.18, range 0.07-3.58)."
                    ],
                    "conclusions": [
                        "The results suggest that CD133 could be a molecular predictor of glioblastoma dissemination, and also give rise to an intriguing idea that CD133-positive cancer stem cells may be implicated in the initiation of disseminated lesions."
                    ]
                },
                "application": {
                    "validated": "Potential",
                    "diagnosis": null,
                    "prognosis": null,
                    "predictive": "Potential",
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Erik Samelsson"
            },
            {
                "_id": "V000038",
                "pmid": "7760096",
                "biomarkerId": "B000038",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo sapiens"
                ],
                "age": {
                    "min": 28.0,
                    "max": 74.0,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": "Pre 2007",
                "region": [
                    "Germany"
                ],
                "research": {
                    "methods": [
                        "Sourthen/Western blot/Immunochemistry"
                    ],
                    "results": [
                        "Amplification of the EGFR gene in 49% of GBM but not in the astrocytomas WHO II/III.\u00a0There was overexpression of the EGF receptor in 86% by WB and 92% by immunocytochemistry"
                    ],
                    "conclusions": [
                        "ERBB2 expression in GBM is closely correlated with EGF receptor levels and is not useful as an independent prognostic parameter"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": null,
                    "prognosis": null,
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Cristian"
            },
            {
                "_id": "V000039",
                "pmid": "23908590",
                "biomarkerId": "B000039",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": 29.0,
                    "max": 74.0,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": null,
                "region": [
                    "USA"
                ],
                "research": {
                    "methods": [
                        "Western blot",
                        "RNA interference",
                        "Immunohistochemistry",
                        "Annexin FACS",
                        "ANOVA",
                        "Kaplan-Meier analysis",
                        "Cox model"
                    ],
                    "results": [
                        "TRADD is commonly expressed at high levels in GBM and is detected in both cytoplasmic and nuclear distribution",
                        "Cytoplasmic IHC TRADD scoring is significantly associated with worse progression-free survival (PFS) both in univariate and multivariate analysis but is not associated with overall survival",
                        "PFS is a marker for responsiveness to treatment",
                        "TRADD-mediated NF-\u03baB activation confers chemoresistance and thus a worse PFS in GBM",
                        "Consistent with the effect on PFS, silencing TRADD in glioma cells results in decreased NF-\u03baB activity, decreased proliferation of cells, and increased sensitivity to temozolomide",
                        "Silencing TRADD in GBM-initiating stem cell cultures results in decreased viability of stem cells, suggesting that TRADD may be required for maintenance of GBM stem cell populations"
                    ],
                    "conclusions": [
                        "Study suggests that increased expression of cytoplasmic TRADD is both an important biomarker and a key driver of NF-\u03baB activation in GBM and supports an oncogenic role for TRADD in GBM"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": null,
                    "prognosis": "YES",
                    "predictive": null,
                    "therapeutic": "Potential"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": null
            },
            {
                "_id": "V00003A",
                "pmid": "11207049",
                "biomarkerId": "B00003A",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo sapiens"
                ],
                "age": {
                    "min": 31.0,
                    "max": 74.0,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": "Pre 2007",
                "region": [
                    "Italy"
                ],
                "research": {
                    "methods": [
                        "Immunochemistry"
                    ],
                    "results": [
                        "Patients with high levels of manganese superoxide dismutase show a less median survival time than with low amount of MnSOD"
                    ],
                    "conclusions": [
                        "GBM can be divided into two distinct groups on the basis of their content of MnSOD, having 'better' or 'worse' prognosis, respectively."
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": null,
                    "prognosis": null,
                    "predictive": null,
                    "therapeutic": "Potential"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Cristian"
            },
            {
                "_id": "V00003B",
                "pmid": "29806672",
                "biomarkerId": "B00018B",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": 33.0,
                    "max": 74.0,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": "Post 2018",
                "region": [
                    "Chile"
                ],
                "research": {
                    "methods": [
                        "IHC staining"
                    ],
                    "results": [
                        "he median number of cells counted per case was 692 (interquartile range [IQR] 492-928). Fifteen cases (52%) were positive for MGMT expression. Median overall survival was 5.3 months (IQR 3.4-12-8). The effect of MGMT expression on the therapeutic response was not studied since only 3 patients received chemotherapy."
                    ],
                    "conclusions": [
                        "Our results are similar to international reports, but we were not able to determine the association between MGMT expression and therapeutic response."
                    ]
                },
                "application": {
                    "validated": "Yes",
                    "diagnosis": null,
                    "prognosis": "YES",
                    "predictive": "YES",
                    "therapeutic": "Potential"
                },
                "clinical": {
                    "relevance": "O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation has been firmly established as a biomarker in patients diagnosed with gliomas, for both clinical trials and routine clinical management.",
                    "implication": "Use in companion diagnostics and predicting patient outcome.",
                    "treatment": "Methylation status of the MGMT gene is crucial to promoting DNA repair. If the MGMT gene is methylated, cancer patients tend to respond better to alkylating drug therapy."
                },
                "comments": null,
                "curator": "Erik Samuelsson"
            },
            {
                "_id": "V00003C",
                "pmid": "24055034",
                "biomarkerId": "B00003C",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": 15.0,
                    "max": 75.0,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "I",
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": "2000",
                "region": [
                    "China"
                ],
                "research": {
                    "methods": [
                        "Immunohistochemistry",
                        "Immunoblotting",
                        "RT-PCR",
                        "Bands analysis for immunoblotting and RT-PCR",
                        "ANOVA",
                        "Tamhane's t2 test"
                    ],
                    "results": [
                        "AQP8 is mainly distributed in the cytoplasm of human astrocytoma",
                        "AQP8 is over-expressed in human astrocytomas, especially in GBM",
                        "The up-regulation of AQP8 is related to the pathological grade of human astrocytomas"
                    ],
                    "conclusions": [
                        "AQP8 may contribute to the proliferation of astrocytomas, and may be a biomarker and candidate therapy target for patients with astrocytomas"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": "Potential",
                    "prognosis": null,
                    "predictive": null,
                    "therapeutic": "Potential"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": "Potential",
                "curator": null
            },
            {
                "_id": "V00003D",
                "pmid": "30038102",
                "biomarkerId": "B00003D",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": 20.0,
                    "max": 75.0,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": "2007",
                "region": [
                    "India"
                ],
                "research": {
                    "methods": [
                        "Histology",
                        "Immunohistochemistry",
                        "Methylation-specific PCR",
                        "Fluorescence in-situ hybridization",
                        "Fisher's exact test",
                        "Logistic regression analysis",
                        "Multivariate regression"
                    ],
                    "results": [
                        "MGMT gene promoter methylation was identified in 49.2% (66/134) GBMs, and was significantly associated with IDH1R132H mutation (14/66) and ATRX loss (15/66)",
                        "Confluent necrosis was found to be significantly associated with MGMT unmethylation status",
                        "Necrosis emerged as a single independent predictor (odds ratio= 2.5) of MGMT unmethylation status among all the parameters studied"
                    ],
                    "conclusions": [
                        "The frequency of MGMT promoter methylation in GBMs was 49.2%, which was significantly associated with IDHR132H mutation and ATRX loss",
                        "In addition, the presence of confluent necrosis was significantly associated with MGMT unmethylation and was found to be an independent predictor of the same"
                    ]
                },
                "application": {
                    "validated": "Yes (It is a validation study)",
                    "diagnosis": null,
                    "prognosis": "Yes",
                    "predictive": "Yes",
                    "therapeutic": "Yes"
                },
                "clinical": {
                    "relevance": "O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation has been firmly established as a biomarker in patients diagnosed with gliomas, for both clinical trials and routine clinical management.",
                    "implication": "Use in companion diagnostics and predicting patient outcome.",
                    "treatment": "Methylation status of the MGMT gene is crucial to promoting DNA repair. If the MGMT gene is methylated, cancer patients tend to respond better to alkylating drug therapy."
                },
                "comments": null,
                "curator": "Erik Samuelsson"
            },
            {
                "_id": "V00003E",
                "pmid": "26482617",
                "biomarkerId": "B00003E",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": 20.0,
                    "max": 75.0,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": "2007",
                "region": [
                    "China"
                ],
                "research": {
                    "methods": [
                        "IHC",
                        "Spearman rank analysis",
                        "Univariate analysis",
                        "Multivariate analysis"
                    ],
                    "results": [
                        "HHIP expression is reduced and Gli1 expression is increased in GBM",
                        "Patients with low Gli1 expression had longer overall survival than those with high Gli1 expression",
                        "Overall survival of the patients with HHIP-positive GBM was significantly longer than that of the patients with HHIP-negative GBM"
                    ],
                    "conclusions": [
                        "Data suggested that expression of HHIP could be considered as significant prognostic marker for patients with GBM"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": "NO",
                    "prognosis": "YES",
                    "predictive": "NO",
                    "therapeutic": "Potential"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": "NO",
                "curator": "RF"
            },
            {
                "_id": "V00003F",
                "pmid": "20425045",
                "biomarkerId": "B00003F",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": 20.0,
                    "max": 75.0,
                    "med": 49.0,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": "Pre 2010",
                "region": [
                    "Japan"
                ],
                "research": {
                    "methods": [
                        "We investigated the role of WT1 protein expression level (score 1-4) and MIB-1 staining index in predicting survival outcome after therapy in patients with recurrent or progressive glioblastoma multiforme. Tumor samples from 37 patients enrolled in a phase II clinical trial on WT1 immunotherapy were immunohistochemically analyzed for WT1 levels and MIB-1 index."
                    ],
                    "results": [
                        "Results showed that median progression-free survival (PFS) was longer in the WT1 high expression group (score 3 and 4) compared with that of the low expression group (score 1 and 2) (20.0 weeks vs. 8.0 weeks",
                        "P = 0.022), and that the median overall survival (OS) was likewise longer in the former compared to the latter group (54.4 weeks vs. 28.4 weeks",
                        "P = 0.035). Furthermore, within the WT1 high expression group, tumors with intermediate staining intensity (WT1 score 3) have both the longest median PFS and OS, 24.4 weeks and 69.4 weeks, respectively. On the other hand, no significant correlation was noted between MIB-1 staining index and survival."
                    ],
                    "conclusions": [
                        "In conclusion, our study has shown that WT1 protein expression level, not MIB-1 staining index, can be used as a prognostic marker to foretell outcome after immunotherapy, and that patients whose tumors have intermediate WT1 expression have the best survival outcome."
                    ]
                },
                "application": {
                    "validated": "Potential",
                    "diagnosis": null,
                    "prognosis": "Potential",
                    "predictive": "Potential",
                    "therapeutic": "Potential"
                },
                "clinical": {
                    "relevance": "WT1 protein expression staining index could be a predictor of response to WT1 immunotherapy in glioblastoma patients.",
                    "implication": "Could provide patient stratification, to determine if a treatment is applicable.",
                    "treatment": "TBD"
                },
                "comments": null,
                "curator": "Erik Samelsson"
            },
            {
                "_id": "V000040",
                "pmid": "19637364",
                "biomarkerId": "B000040",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": 35.0,
                    "max": 75.0,
                    "med": 59.0,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": "Pre 2010",
                "region": [
                    "France"
                ],
                "research": {
                    "methods": [
                        "Twenty-two patients who had recurrent GBM and who underwent surgery with carmustine wafer implantation were enrolled prospectively between 2005 and 2007. The authors investigated the correlation between MGMT silencing in the tumor at recurrence and survival taking into account other clinically recognized prognostic factors. MGMT status was determined by using methylation-specific polymerase chain reaction analysis, a high-throughput quantitative methylation assay, and immunohistochemistry. In addition, expression analyses of human mutL homolog 1, human mutS homolog 2, and tumor necrosis factor alpha-induced protein 3 at recurrence were conducted with regard to their prognostic impact."
                    ],
                    "results": [
                        "The median progression-free survival (PFS) and overall survival (OS) rates after recurrence were 3.6 months and 9.9 months, respectively, and the 6-month PFS rate after recurrence was 27.2%. On multivariate analysis, only age (P=.04) and MGMT promoter hypermethylation at recurrence, as determined by MethyLight technology (P=.0012) and methylation-specific polymerase chain reaction (MSP) analysis (P=.004), were correlated with better PFS. On multivariate analysis, only MGMT promoter hypermethylation at recurrence, as determined by using MethyLight technology (P=.019) and MSP analysis (P=.046), was associated with better OS."
                    ],
                    "conclusions": [
                        "MGMT methylation status was an important prognostic factor in patients with recurrent GBM who underwent surgery plus carmustine wafer implantation",
                        "therefore, it was useful in predicting the outcome of GBM therapy at recurrence."
                    ]
                },
                "application": {
                    "validated": "Yes",
                    "diagnosis": "NO",
                    "prognosis": "YES",
                    "predictive": "YES",
                    "therapeutic": "YES"
                },
                "clinical": {
                    "relevance": "O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation has been firmly established as a biomarker in patients diagnosed with gliomas, for both clinical trials and routine clinical management.",
                    "implication": "Use in companion diagnostics and predicting patient outcome.",
                    "treatment": "Methylation status of the MGMT gene is crucial to promoting DNA repair. If the MGMT gene is methylated, cancer patients tend to respond better to alkylating drug therapy."
                },
                "comments": "NO",
                "curator": "Erik Samelsson"
            },
            {
                "_id": "V000041",
                "pmid": "18666438",
                "biomarkerId": "B000176",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": 45.0,
                    "max": 75.0,
                    "med": 60.0,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": "Pre 2010",
                "region": [
                    "Sweden"
                ],
                "research": {
                    "methods": [
                        "Immunohistochemical stainings of Ki-67 and hTERT were evaluated in 39 formaldehyde-fixed, paraffin-embedded surgical samples of glioblastoma multiforme diagnosed during 2004, comprising all specimens with sufficient amount of vital tissue sent to the Department of Pathology during this year. Ki-67 counting and hTERT evaluation was assessed on whole tumor sections and on selected areas within each section. Age and length of survival were analyzed in relation to these parameters."
                    ],
                    "results": [
                        "We found that different methods of evaluating the stained sections yielded different results regarding Ki-67, but less marked differences for hTERT. With Ki-67 counting on whole sections (non-selected areas), we found a statistically significant correlation with length of survival. There was no corresponding information in the hTERT assessment. We could also confirm a significant inverse correlation between age and length of survival, as previously published."
                    ],
                    "conclusions": [
                        "Our data demonstrate that different methods of Ki-67 evaluation may give markedly dissimilar results. The significant correlation found between survival and one but not with two other methods of Ki-67 assessment, implicate the value of standardized quantification methods. Our data indicate a possible prognostic use of immunohistochemical Ki-67 proliferation index in glioblastoma multiforme."
                    ]
                },
                "application": {
                    "validated": "Potential",
                    "diagnosis": null,
                    "prognosis": "Potential",
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": "USed as a tool for clinical assessment in GBM.",
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Erik Samelsson"
            },
            {
                "_id": "V000042",
                "pmid": "20232102",
                "biomarkerId": "B0001D3",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": 3.0,
                    "max": 76.0,
                    "med": 53.0,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": "Pre 2010",
                "region": [
                    "Japan"
                ],
                "research": {
                    "methods": [
                        "Seventy-three patients with glioblastomas treated with alkylating agents were analyzed for MGMT expression by immunohistochemistry. Genomic DNA was isolated from frozen surgical specimens obtained from 62 of 73 patients. MGMT promoter methylation was determined by methylation-specific polymerase chain reaction. The prognostic significance of MGMT was evaluated together with other well-known prognostic factors."
                    ],
                    "results": [
                        "MGMT promoter hypermethylation was detected in 35 of 62 patients (56.4%). MGMT immunoreactivity was low in 26 (35.6%) tumors, moderate in 24 (32.9%), and high in 23 (31.5%). Significant correlation was observed between MGMT expression and MGMT promoter methylation (P < 0.001). Both MGMT promoter methylation and low MGMT expression were independently associated with better progression-free survival but not with longer overall survival. However, in the subgroup analysis, MGMT promoter hypermethylation was significantly associated with longer overall survival in patients treated with temozolomide (TMZ) after nimustine hydrochloride (ACNU) treatment."
                    ],
                    "conclusions": [
                        "Low MGMT expression and MGMT promoter methylation are both predictive markers for slower tumor progression in patients with glioblastoma."
                    ]
                },
                "application": {
                    "validated": "Yes",
                    "diagnosis": "NO",
                    "prognosis": "YES",
                    "predictive": "YES",
                    "therapeutic": "YES"
                },
                "clinical": {
                    "relevance": "O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation has been firmly established as a biomarker in patients diagnosed with gliomas, for both clinical trials and routine clinical management.",
                    "implication": "Use in companion diagnostics and predicting patient outcome.",
                    "treatment": "Methylation status of the MGMT gene is crucial to promoting DNA repair. If the MGMT gene is methylated, cancer patients tend to respond better to alkylating drug therapy."
                },
                "comments": "NO",
                "curator": "Erik Samelsson"
            },
            {
                "_id": "V000043",
                "pmid": "28351326",
                "biomarkerId": "B000043",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": 8.0,
                    "max": 76.0,
                    "med": -1,
                    "avg": 49.38,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "I",
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": null,
                "region": [
                    "China"
                ],
                "research": {
                    "methods": [
                        "Immunohistochemical assessment",
                        "Kaplan-Meier method",
                        "Cox proportional hazard model"
                    ],
                    "results": [
                        "PIG3 expression suppressed in GBM tissue",
                        "expression of PIG3 significantly associated with WHO grade",
                        "lower survival rate for patients with high PIG3 expression"
                    ],
                    "conclusions": [
                        "high expression of PIG3 significant for GBM inhibition",
                        "PIG3 independently indicates good prognosis in patients",
                        "PIG3 might be a novel prognostic biomarker or potential therapeutic target in GBM"
                    ]
                },
                "application": {
                    "validated": "Potential",
                    "diagnosis": null,
                    "prognosis": "Potential",
                    "predictive": null,
                    "therapeutic": "Potential"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Vanessa"
            },
            {
                "_id": "V000044",
                "pmid": "23934769",
                "biomarkerId": "B000090",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": 18.0,
                    "max": 76.0,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "I",
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": "2000",
                "region": [
                    "Poland"
                ],
                "research": {
                    "methods": [
                        "Immunohistochemistry",
                        "Sanger sequencing",
                        "COLD PCR HRM",
                        "Kolmogorov-Smirnov test",
                        "Kaplan Meier method"
                    ],
                    "results": [
                        "Wild-type (WT) IDH1 was detected in cases with grade I astrocytoma",
                        "The IDH1 c.G395A, p.R132H mutation was observed in 56 and 94 % of grade II and grade III astrocytoma cases, respectively",
                        "Significant differences in the median overall survival were observed in astrocytoma patients grouped on the basis of the presence of IDH1 mutation: survival was 24 months longer in grade II astrocytoma and 12 months longer in GBM",
                        "Interestingly, lower R132H expression correlated with better overall survival"
                    ],
                    "conclusions": [
                        "Presence or absence of the R132H mutation can help pathologists to distinguish pilocytic astrocytomas (IDH1 WT) from diffuse ones (R132H IDH1/WT)",
                        "Low IDH1 p.R132H expression was related to better prognosis",
                        "This clinical implication appears to be important for personalization of prognosis and treatment by oncologists"
                    ]
                },
                "application": {
                    "validated": "This is itself a validation study",
                    "diagnosis": null,
                    "prognosis": "YES",
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": null
            },
            {
                "_id": "V000045",
                "pmid": "23619925",
                "biomarkerId": "B000045",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": 19.0,
                    "max": 76.0,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": "2007",
                "region": [
                    "Greece"
                ],
                "research": {
                    "methods": [
                        "primary GBM cell lines",
                        "immunohistochemical staining",
                        "MS-PCR"
                    ],
                    "results": [
                        "Sox11 is overexpressed in GBM patients"
                    ],
                    "conclusions": [
                        "Sox11 expression as a favourable prognosticator in glioblastomas"
                    ]
                },
                "application": {
                    "validated": "yes",
                    "diagnosis": "Potential",
                    "prognosis": "YES",
                    "predictive": "Potential",
                    "therapeutic": "Potential"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": "potential for personalizing cancer management"
                },
                "comments": "Potential",
                "curator": "ANA"
            },
            {
                "_id": "V000046",
                "pmid": "17504928",
                "biomarkerId": "B000046",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": 21.0,
                    "max": 76.0,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": "2000",
                "region": [
                    "USA"
                ],
                "research": {
                    "methods": [
                        "Methylation-specific PCR",
                        "PTEN sequencing",
                        "Westen blot",
                        "Immunohistochemistry",
                        "Hazard ratios"
                    ],
                    "results": [
                        "Grade II astrocytomas, oligodendrogliomas, and oligoastrocytomas commonly display methylation of the PTEN promoter, a finding that is absent in nontumor brain specimens and rare in de novo GBMs",
                        "Frequent methylation of the PTEN promoter in grade III astrocytomas and secondary GBMs, consistent with the hypothesis that these tumors arise from lower grade precursors",
                        "PTEN methylation is rare in de novo GBMs and is mutually exclusive with PTEN mutations",
                        "Methylation of the PTEN promoter correlates with protein kinase B (PKB/Akt) phosphorylation, reflecting functional activation of the PI3K pathway"
                    ],
                    "conclusions": [
                        "Methylation of the PTEN promoter may represent an alternate mechanism by which PI3K signaling is increased in grade II and III gliomas as well as secondary GBMs, a finding that offers new therapeutic approaches in these patients"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": "NO",
                    "prognosis": "NO",
                    "predictive": "NO",
                    "therapeutic": "Potential"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": "NO",
                "curator": "BP"
            },
            {
                "_id": "V000047",
                "pmid": "19809523",
                "biomarkerId": "B000047",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": 25.0,
                    "max": 76.0,
                    "med": 58.14,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "II",
                    "IV"
                ],
                "whoclass": "Pre 2010",
                "region": [
                    "Greece"
                ],
                "research": {
                    "methods": [
                        "Immunohistochemical localization of IL-6, IL-8, COX-2, and VEGF expression levels was performed in formalin-fixed paraffin-embedded tissue sections of all patients. Genomic DNA from frozen tissues was extracted by NucleoSpin Tissue (Macherey-Nagel, D\u00fcren, Germany) according to the manufacturer\u2019s instructions. DNA concentration was estimated by spectrophotometry. DNA (500 ng) obtained from tissue samples, or cell line DNA was chemically modified using the EpiTect Bisulfite kit (Qiagen, West Sussex, UK) according to the manufacturer\u2019s protocol. The modified DNA was used as a template for polymerase chain reaction (PCR) analysis.The methylation status of the genes was determined by the method of methylation-specific PCR (MSP). For basic statistical calculations, IL-6, IL-8, VEGF, and COX-2 expression were treated as continuous variables. The association of the above parameters with grade, necrosis, and methylation status was tested with Kruskal\u2013Wallis ANOVA or Mann\u2013Whitney U test. The correlations among IL-6, IL-8, VEGF and COX-2 expression and gene methylation status were examined with Spearman correlation coefficient. Survival analysis was performed using death by disease as the endpoint. The effect of various parameters on clinical outcome was assessed by plotting survival curves according to the Kaplan\u2013Meier method and comparing groups using the log-rank test, as appropriate."
                    ],
                    "results": [
                        "RARbeta and MGMT genes were more frequently methylated in 70.58% and 58.8% of glioblastomas, respectively. RASSF1A and CDH13 displayed a similar methylation frequency (23.52%) in glioblastomas. No gene methylation was observed in grade II astrocytomas. Tumor grade correlated positively with MGMT and RARbeta methylation (P = 0.005 and P = 0.019, respectively) and the extent of necrosis (P = 0.001 and P = 0.003). Interestingly, the marker of chronic inflammation, IL-6, was positively associated with methylation of MGMT (P = 0.004), RARbeta (P = 0.002), and RASSF1A (P = 0.0081) as well as the total number of methylated genes (P < 0.0001), indicating the important role of IL-6 in maintaining promoter methylation of these genes. VEGF expression correlated positively with MGMT and RARbeta methylation although these relationships were of marginal significance (P = 0.0679 and P = 0.0757). Kaplan-Meier univariate survival analysis indicated an unfavorable survival period in patients with MGMT methylation compared with those without methylation (P = 0.0474)."
                    ],
                    "conclusions": [
                        "Our study highlights the implication of MGMT and RARbeta methylation in the aggressive phenotype of primary glioblastomas. The association of MGMT methylation with clinical outcome indicates its potential prognostic value."
                    ]
                },
                "application": {
                    "validated": "Yes/Potential",
                    "diagnosis": "NO",
                    "prognosis": "YES",
                    "predictive": "YES",
                    "therapeutic": "YES"
                },
                "clinical": {
                    "relevance": "O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation has been firmly established as a biomarker in patients diagnosed with gliomas, for both clinical trials and routine clinical management.",
                    "implication": "Use in companion diagnostics and predicting patient outcome.",
                    "treatment": "Methylation status of the MGMT gene is crucial to promoting DNA repair. If the MGMT gene is methylated, cancer patients tend to respond better to alkylating drug therapy."
                },
                "comments": "NO",
                "curator": "Erik Samelsson"
            },
            {
                "_id": "V000048",
                "pmid": "21769436",
                "biomarkerId": "B000048",
                "sourceIds": [
                    "Tissue",
                    "Cell line"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": 37.0,
                    "max": 76.0,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "III",
                    "IV"
                ],
                "whoclass": "2000",
                "region": [
                    "China"
                ],
                "research": {
                    "methods": [
                        "RT-PCR",
                        "siRNA transfection",
                        "Western blot",
                        "Flow cytometry",
                        "Immunohistochemistry",
                        "Immunocytochemistry",
                        "Methylation specific PCR",
                        "Chi-square test",
                        "Kaplan-Meier method",
                        "Log-rank test",
                        "Partial correlation analysis"
                    ],
                    "results": [
                        "MGMT exhibited resistance to radiation in the SHG-44-GSCs using siRNA transfection",
                        "In vitro, SHG-44-GSCs exhibited a characteristic resistance to radiation that was not observed in SHG-44 cells",
                        "This resistance was attributed to the unmethylated status of the MGMT promoter and to high expression levels of MGMT mRNA in the glioma cells",
                        "In these patients, the CD133 marker, but not MGMT promoter methylation or MGMT protein level, was associated with resistance to radiotherapy",
                        "The median progression-free survival (PFS) among patients with the CD133 marker was 14 months, whereas it was 35 months in patients without CD133",
                        "Co-expression of the methylated MGMT promoter and the CD133 marker was associated with the poorest outcome in patients with gliomas treated by radiotherapy",
                        "in these patients, PFS was 7 months."
                    ],
                    "conclusions": [
                        "Results suggest that assessment of GSC MGMT and CD133 levels will guide future clinical targeted therapies and stratify glioma patient treatment regimens",
                        "High expression levels of the CD133 protein could be used as a predictor for poor survival in patients treated with radiotherapy"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": null,
                    "prognosis": null,
                    "predictive": "Potential",
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": null
            },
            {
                "_id": "V000049",
                "pmid": "8605096",
                "biomarkerId": "B000049",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo sapiens"
                ],
                "age": {
                    "min": 3.0,
                    "max": 77.0,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "I",
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": "Pre 2007",
                "region": [
                    "Finland"
                ],
                "research": {
                    "methods": [
                        "Immunochemistry"
                    ],
                    "results": [
                        "Less than 20% of the tumors showed reactivity (p185 protein) or amplification of the c-erbB2 gene"
                    ],
                    "conclusions": [
                        "p185 overexpression is infrequent in astrocytomas and has no important diagnostic or prognostic value. c-erbB-2 oncogene amplification is not seen in the few cases in which there is overexpression"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": null,
                    "prognosis": null,
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Cristian"
            },
            {
                "_id": "V00004A",
                "pmid": "22734595",
                "biomarkerId": "B00004A",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": 16.0,
                    "max": 77.0,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "III",
                    "IV"
                ],
                "whoclass": "2007",
                "region": [
                    "Japan"
                ],
                "research": {
                    "methods": [
                        "Immunohistochemistry",
                        "Concomitant and adjuvant chemotherapy to 111 patients",
                        "Assessment of recurrence patterns",
                        "Kaplan-Meier method",
                        "Log-rank method",
                        "Cox model"
                    ],
                    "results": [
                        "The median follow-up durations were 13\u2009months for all patients and 19\u2009months for those remaining alive",
                        "Among AA patients, the 2-year progression-free and overall survival rates were 23.1% and 39.2%, respectively, while in GB patients, the rates were 13.3% and 27.6%, respectively",
                        "The median survival time was 20\u2009months for AA patients and 15\u2009months for GB patients",
                        "Among AA patients, recurrences were central in 68.7% of patients, in-field, 18.8%",
                        "and distant, 12.5%, while among GB patients, 69.0% of recurrences were central, 15.5% were in-field, 12.1% were marginal, and 3.4% were distant",
                        "The MIB-1 LI medians were 18.2% in AA and 29.8% in GBM",
                        "In patients with GBM, the MIB-1 LI had a strong effect on the pattern of failure while the extent of surgical removal  and regimens of chemotherapy did not"
                    ],
                    "conclusions": [
                        "MIB-1 LI predominantly affected the pattern of failure in GB patients treated with a multimodal approach, and it might be a useful tool for the management of the disease"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": null,
                    "prognosis": "NO",
                    "predictive": "Potential(for patterns of failure after multimodal treatment for GBM)",
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Ahmed"
            },
            {
                "_id": "V00004B",
                "pmid": "28945172",
                "biomarkerId": "B00004B",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": 18.0,
                    "max": 77.0,
                    "med": 52.0,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": 52.0,
                        "under": 38.0,
                        "over": 36.0
                    }
                },
                "gender": {
                    "male": 36.0,
                    "female": 36.0,
                    "other": -1
                },
                "stage": [
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": null,
                "region": [
                    "Russia"
                ],
                "research": {
                    "methods": [
                        "Immunohistochemical assessment",
                        "RT-qPCR",
                        "Kaplan-Meier methodCox proportional hazard model"
                    ],
                    "results": [
                        "Grade III gliomas showed 2-fold difference in NG2 expression between AA and OA",
                        "for grade IV gliomas, upregulated NG2 expression associated with poor GBM prognosis compared with GBM patients with good prognosis",
                        "high NG2 expression associated with low survival of the patients, whereas age), tumour resection and sex do not show significant association with prognosis",
                        "positive correlation shown for NG2 and CD44 expression in GBM, no significant association of the increased CD44 expression or high Ki-67 proliferation index with the disease prognosis"
                    ],
                    "conclusions": [
                        "upregulation of NG2/CSPG4 rather than changes in CD44 or Ki-67 expression associated with low overall survival in GBM patients",
                        "NG2/CSPG4 potential prognostic marker in GBM"
                    ]
                },
                "application": {
                    "validated": "Potential",
                    "diagnosis": null,
                    "prognosis": "Potential",
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Vanessa"
            },
            {
                "_id": "V00004C",
                "pmid": "12548606",
                "biomarkerId": "B00004C",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo sapiens"
                ],
                "age": {
                    "min": 21.0,
                    "max": 77.0,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "III",
                    "IV"
                ],
                "whoclass": "Pre 2007",
                "region": [
                    "Finland"
                ],
                "research": {
                    "methods": [
                        "Immunochemistry"
                    ],
                    "results": [
                        "The p27 labeling index was < 30% in 36% of tumors, 30-50% in 25% of tumors, and > 50% in 39% of tumors."
                    ],
                    "conclusions": [
                        "p27 has independent prognostic value in patients with malignant astrocytomas"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": null,
                    "prognosis": "Potential",
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Cristian"
            },
            {
                "_id": "V00004D",
                "pmid": "14642363",
                "biomarkerId": "B00004D",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo sapiens"
                ],
                "age": {
                    "min": 23.0,
                    "max": 77.0,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": null,
                "whoclass": null,
                "region": [
                    "Japan"
                ],
                "research": {
                    "methods": [
                        "LOH analysis"
                    ],
                    "results": [
                        "LOH at one or more loci was found in ~77%"
                    ],
                    "conclusions": [
                        "PTEN mutations were found in 26 of 39 patients with GBM and MIB-1 LI in 38 of the 39"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": null,
                    "prognosis": null,
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Cristian"
            },
            {
                "_id": "V00004E",
                "pmid": "20821342",
                "biomarkerId": "B00004E",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": 29.0,
                    "max": 77.0,
                    "med": 58.0,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": "Post 2010",
                "region": [
                    "USA"
                ],
                "research": {
                    "methods": [
                        "We conducted a Phase I study of vatalanib, a small molecule inhibitor of VEGFR, PDGFR, and c-kit in patients with newly diagnosed GBM receiving radiation, temozolomide, and an enzyme-inducing anti-epileptic drug in order to determine the MTD of vatalanib in this patient population. We incorporated circulating biomarker and SNP analyses and pharmacokinetic studies. Nineteen patients were enrolled and the MTD was not reached at the time of study termination."
                    ],
                    "results": [
                        "Vatalanib was well tolerated with only 2 DLTs (thrombocytopenia and elevated transaminases). Other grade 3/4 toxicities included leukopenia, lymphopenia, neutropenia, and hand-foot syndrome. There were no wound-healing complications. Of the 13 patients evaluable for a radiographic response, 2 had a partial response and 9 had stable disease. Vatalanib significantly increased PlGF and sVEGFR1 in plasma circulation and decreased sVEGFR2 and sTie2. Plasma collagen IV increased significantly by day 50 of treatment."
                    ],
                    "conclusions": [
                        "Vatalanib was well tolerated and this study demonstrates the safety of oral small molecule inhibitors in newly diagnosed GBM patients. Blood biomarkers may be useful as pharmacodynamic markers of response to anti-angiogenic therapies."
                    ]
                },
                "application": {
                    "validated": "Yes",
                    "diagnosis": null,
                    "prognosis": null,
                    "predictive": null,
                    "therapeutic": "Potential"
                },
                "clinical": {
                    "relevance": "Targeting VEGF-driven abnormal tumor angiogenesis is a promising mechanism to control GBM growth. ",
                    "implication": "Vatalanib was well tolerated and this study demonstrates the safety of oral small molecule inhibitors in newly diagnosed GBM patients. Blood biomarkers may be useful as pharmacodynamic markers of response to anti-angiogenic therapies.",
                    "treatment": "Phase I study was discontinued."
                },
                "comments": null,
                "curator": "Erik Samelsson"
            },
            {
                "_id": "V00004F",
                "pmid": "25862796",
                "biomarkerId": "B00004F",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": 30.0,
                    "max": 77.0,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": null,
                "whoclass": "2007",
                "region": [
                    "Italy"
                ],
                "research": {
                    "methods": [
                        "RT-PCR"
                    ],
                    "results": [
                        "PFS was inversely correlated both with VEGF-121 levels and with the ratio VEGF-121/total VEGF"
                    ],
                    "conclusions": [
                        "patients with low levels of VEGF-121 and of total VEGF, a greater amount of bevacizumab may be available to target the heavier and intermediate isoforms of VEGF"
                    ]
                },
                "application": {
                    "validated": null,
                    "diagnosis": "NO",
                    "prognosis": "NO",
                    "predictive": "NO",
                    "therapeutic": "YES"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": "NO",
                "curator": "RF"
            },
            {
                "_id": "V000050",
                "pmid": "26142442",
                "biomarkerId": "B000050",
                "sourceIds": [
                    "Blood"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": 32.0,
                    "max": 77.0,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "III",
                    "III",
                    "IV"
                ],
                "whoclass": "2007",
                "region": [
                    "France"
                ],
                "research": {
                    "methods": [
                        "Elisa"
                    ],
                    "results": [
                        "MMP2 significantly increased during bevacizumab treatment from baseline to the last point prior to progression and decreased at the time of progression",
                        "MMP9 decreased during bevacizumab treatment and tended to increase at P"
                    ],
                    "conclusions": [
                        "the increase in the plasma level of MMP2 8 hours after the administration of cediranib was associated with a reduced PFS and OS."
                    ]
                },
                "application": {
                    "validated": null,
                    "diagnosis": "NO",
                    "prognosis": "NO",
                    "predictive": "YES",
                    "therapeutic": "NO"
                },
                "clinical": {
                    "relevance": "YES",
                    "implication": "YES",
                    "treatment": "YES"
                },
                "comments": "NO",
                "curator": "RF"
            },
            {
                "_id": "V000051",
                "pmid": "22359215",
                "biomarkerId": "B0001C1",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": 33.0,
                    "max": 77.0,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": "2007",
                "region": [
                    "France"
                ],
                "research": {
                    "methods": [
                        "Immunohistochemistry",
                        "Methylation\u2010specific PCR",
                        "Kaplan-Meier method",
                        "Cox model",
                        "Bootstrap"
                    ],
                    "results": [
                        "For the whole cohort, the median overall survival (OS) was 17.5 months, and the progression-free survival was 10.3 months",
                        "Patients with tumors that harbored MGMT methylation had a significantly longer OS compared with patients who had wild-type MGMT (21.7 months vs 15.1 months)",
                        "Patients who had low MGMT protein expression (\u226415%) had a significantly improved OS compared with patients who had high MGMT expression (27.0 months vs 15.1 months)",
                        "The extent of resection was the strongest clinical predictor of outcome",
                        "In multivariate Cox models that were adjusted for sex, performance status, and extent of surgery, both MGMT methylation and protein expression were identified as independent prognosticators, and the finding was validated internally using a bootstrap resampling technique",
                        "Discrepancies were identified between protein expression and MGMT methylation status, thus suggesting that the 2 assays probably assess different biologic features"
                    ],
                    "conclusions": [
                        "MGMT promoter methylation status and low MGMT expression both were identified as positive prognosticators in patients with newly diagnosed glioblastoma who underwent surgical resection and received Gliadel wafer implants followed by adjuvant radiotherapy and concomitant oral TMZ chemotherapy"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": null,
                    "prognosis": null,
                    "predictive": "Yes (for carmustine wafer implants)",
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Ahmed"
            },
            {
                "_id": "V000052",
                "pmid": "22296176",
                "biomarkerId": "B000052",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": 33.0,
                    "max": 77.0,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": "2007",
                "region": [
                    "UK"
                ],
                "research": {
                    "methods": [
                        "In-situ hybridization",
                        "Immunohistochemistry",
                        "Chi-square test"
                    ],
                    "results": [
                        "Dll4 expression was localized to the cytoplasm and membrane of endothelial cells in all GBMs",
                        "It was weak or absent in normal brain",
                        "Jag1 expression was observed in the cytoplasm and membrane of glomeruloid and non\u2010glomeruloid endothelial cells from 76% and 67% of GBMs, respectively",
                        "Endothelial Jag1 expression was less intense and less prevalent than Dll4",
                        "There was no association between Dll4 and Jag1 expression"
                    ],
                    "conclusions": [
                        "Dll4 and Jag1 are expressed in GBM vasculature",
                        "The data may define subsets of GBM that might be sensitive (Dll4+/Jag1+) or resistant (Dll4+/Jag1\u2013) to bevacizumab",
                        "Data also suggest that anti\u2010Dll4 therapy should be evaluated experimentally in GBM"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": null,
                    "prognosis": null,
                    "predictive": null,
                    "therapeutic": "Potential"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Ahmed"
            },
            {
                "_id": "V000053",
                "pmid": "19088037",
                "biomarkerId": "B000053",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": 35.0,
                    "max": 77.0,
                    "med": 57.0,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": "Pre 2010",
                "region": [
                    "Italy"
                ],
                "research": {
                    "methods": [
                        "We investigated the relationship between the in vitro growth potential of glioblastoma CSCs and patient death or disease progression in tumors of 44 consecutive glioblastoma patients treated with complete or partial tumorectomy followed by radiotherapy combined with temozolomide treatment. Moreover, we evaluated by immunohistochemistry and immunofluorescence the prognostic value of the relative presence of CD133+ and CD133+/Ki67+ cells in patient tumors."
                    ],
                    "results": [
                        "In vitro CSC generation and the presence of > or = 2% CD133+ cells in tumor lesions negatively correlated with overall (P = 0.0001 and 0.02, respectively) and progression-free (P = 0.0002 and 0.01, respectively) survival of patients. A very poor overall (P = 0.007) and progression-free (P = 0.001) survival was observed among patients whose tumors contained CD133+ cells expressing Ki67. Taking into account symptom duration, surgery type, age, O6-methylguanine-DNA methyltransferase promoter methylation, and p53 status, generation of CSCs and CD133/Ki67 coexpression emerged as highly significant independent prognostic factors, with an adjusted hazard ratio of 2.92 (95% confidence interval, 1.37-6.2",
                        "P = 0.005) and 4.48 (95% confidence interval, 1.68-11.9",
                        "P = 0.003), respectively."
                    ],
                    "conclusions": [
                        "The analysis of CSCs may predict the survival of glioblastoma patients. In vitro CSC generation and presence of CD133+/Ki67+ cells are two considerable prognostic factors of disease progression and poor clinical outcome."
                    ]
                },
                "application": {
                    "validated": "Potential",
                    "diagnosis": null,
                    "prognosis": "Potential",
                    "predictive": "Potential",
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": "Cancer stem cells are of significant current interest in GBM research, and the targets of various types of immunotherapy (also associated with the Mesenchymal subtype.)",
                    "implication": "See Current Relevance.",
                    "treatment": "See Current Relevance."
                },
                "comments": null,
                "curator": "Erik Samelsson"
            },
            {
                "_id": "V000054",
                "pmid": "18973197",
                "biomarkerId": "B00016B",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": 13.0,
                    "max": 78.0,
                    "med": -1,
                    "avg": 56.0,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": "Pre 2010",
                "region": [
                    "South Korea"
                ],
                "research": {
                    "methods": [
                        "Paraffin-embedded specimens of glioblastomas from 62 patients treated in a single institution were assessed by immunohistochemical (IHC) analysis of c-Met expression. On the basis of the clinical data for these patients, the association between c-Met expression and clinicobiologic features representing tumor invasiveness was analyzed."
                    ],
                    "results": [
                        "c-Met overexpression was detected in 29.0% (18 of 62) of glioblastomas. In patients with c-Met overexpression, the median survival was 11.7 months (95% confidence interval [95% CI], 9.9 months-13.5 months), compared with a median survival of 14.3 months (95% CI, 7.6 months-21.0 months) for patients whose tumors had no or little expression of c-Met (P=.031). On the radiographic analysis, 9 of 18 patients (50%) with tumors overexpressing c-Met demonstrated invasive and multifocal lesions on the initial magnetic resonance images, whereas only 9 of 44 patients (20.5%) with tumors that expressed no or little c-Met demonstrated these features (P=.030). Using immunohistochemistry, we also found a significant association between c-Met expression and matrix metalloproteinase-2,-9 (P=.020 and P=.013). Furthermore, Myc overexpression was found to be closely correlated with c-Met overexpression on IHC analysis (P=.004)."
                    ],
                    "conclusions": [
                        "The authors suggest that c-Met overexpression is associated with shorter survival time and poor treatment response in glioblastomas, the mechanism for which is elevated tumor invasiveness on the molecular and clinical phenotypes. This implies that more effective therapeutic strategies targeting c-Met receptors may have important clinical implication."
                    ]
                },
                "application": {
                    "validated": "Potential",
                    "diagnosis": null,
                    "prognosis": "Potential",
                    "predictive": "Potential",
                    "therapeutic": "Potential"
                },
                "clinical": {
                    "relevance": "The MET pathway plays an important role in cancer activation, angiogenesis and metastasis. ",
                    "implication": "Potential major cancer target. ",
                    "treatment": "Current potential target for immunotherapy (for MET-expressing cells) "
                },
                "comments": null,
                "curator": "Erik Samelsson"
            },
            {
                "_id": "V000055",
                "pmid": "23514245",
                "biomarkerId": "B000055",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": 14.0,
                    "max": 78.0,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": null,
                "region": [
                    "China"
                ],
                "research": {
                    "methods": [
                        "primary GBM cell line",
                        "Western blotting",
                        "MS-PCR"
                    ],
                    "results": [
                        "LC22A18 protein expression predicted a significantly shorter overall survival in 51 patients receiving TMZ therapy, whereas no differences in overall survival were observed in 35 patients without TMZ therapy."
                    ],
                    "conclusions": [
                        "The lack of SLC22A18 protein expression is superior to promoter methylation as a predictive tumor biomarker in GBM patients receiving temozolomide therapy"
                    ]
                },
                "application": {
                    "validated": "no",
                    "diagnosis": "NO",
                    "prognosis": "NO",
                    "predictive": "YES",
                    "therapeutic": "NO"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": "predictive value for the response of TMZ treatment"
                },
                "comments": "NO",
                "curator": "ANA"
            },
            {
                "_id": "V000056",
                "pmid": "25695077",
                "biomarkerId": "B000056",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": 22.0,
                    "max": 78.0,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "III",
                    "IV"
                ],
                "whoclass": "2007",
                "region": [
                    "Italy"
                ],
                "research": {
                    "methods": [
                        "Immunohistochemistry",
                        "Methylation specific PCR",
                        "Cox model",
                        "Kaplan Meier method"
                    ],
                    "results": [
                        "IMP3 expression was higher in glioblastomas (68%) than in grade III tumors (20%), and IMP3-positive high-grade gliomas showed a shorter overall and disease-free survival than negative ones",
                        "IMP3 expression was significantly associated with the absence of mutations of IDH1 gene and with the unmethylated phenotype of MGMT in high-grade gliomas",
                        "High Ki-67 levels were correlated with better prognosis in glioblastomas but IMP3 expression was not correlated with the proliferation index"
                    ],
                    "conclusions": [
                        "Findings confirm the role of IMP3 as a marker of poor outcome, also in consideration of its association with IDH1 wild-type phenotype and MGMT unmethylated status",
                        "Data suggest that IMP3 staining could identify a subgroup of patients with poor prognosis and at risk of recurrence in high-grade gliomas"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": null,
                    "prognosis": "YES",
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "BP"
            },
            {
                "_id": "V000057",
                "pmid": "27302927",
                "biomarkerId": "B000057",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": 34.0,
                    "max": 78.0,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": "2007",
                "region": [
                    "Germany"
                ],
                "research": {
                    "methods": [
                        "miRNA array analysis",
                        "Cox proportional hazards model",
                        "MiScript primer assays",
                        "miRNA-mRNA correlation and gene set enrichment analysis",
                        "MGMT promoter methylation typing"
                    ],
                    "results": [
                        "Expressions of miRNAs hsa-let-7a-5p, hsa-let-7b-5p and hsa-miR-125a-5p positively correlated with overall survival and and that of hsa-miR-615-5p negatively correlated with overall survival"
                    ],
                    "conclusions": [
                        "This signature may serve as a potential new marker for patient stratification independent of the MGMT methylation status"
                    ]
                },
                "application": {
                    "validated": "Yes",
                    "diagnosis": "Potential",
                    "prognosis": "YES",
                    "predictive": "Potential",
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": "Potential",
                "curator": "BP"
            },
            {
                "_id": "V000058",
                "pmid": "15541001",
                "biomarkerId": "B000058",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo sapiens"
                ],
                "age": {
                    "min": 35.0,
                    "max": 78.0,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": null,
                "whoclass": "Pre 2007",
                "region": [
                    "Austria"
                ],
                "research": {
                    "methods": [
                        "Immunochemistry"
                    ],
                    "results": [
                        "D110 immunolabelling in 85.1%  of samples"
                    ],
                    "conclusions": [
                        "D110 identifies immunocompetent cells, which positively influence survival of glioblastoma patients"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": null,
                    "prognosis": null,
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Cristian"
            },
            {
                "_id": "V000059",
                "pmid": "12091064",
                "biomarkerId": "B000059",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo sapiens"
                ],
                "age": {
                    "min": 35.0,
                    "max": 78.0,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": null,
                "whoclass": null,
                "region": [
                    "Austria"
                ],
                "research": {
                    "methods": [
                        "Immunochemistry"
                    ],
                    "results": [
                        "Survival analysis disclosed an association between high TII\u03b1 expression levels and prolonged surviva"
                    ],
                    "conclusions": [
                        "High expression of TII\u03b1 and Ki-67 appears to be associated with a prolonged survival"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": null,
                    "prognosis": null,
                    "predictive": "Potential",
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Cristian"
            },
            {
                "_id": "V00005A",
                "pmid": "15899794",
                "biomarkerId": "B00005A",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": 50.0,
                    "max": 78.0,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": "2000",
                "region": [
                    "USA"
                ],
                "research": {
                    "methods": [
                        "PCR based molecular analysis",
                        "Microarray chip RNA hybridization",
                        "Linear regression"
                    ],
                    "results": [
                        "No prognostic significance was associated with genetic changes in epidermal growth factor receptor (amplified in 17 of 41 patients), TP53 (mutated in 11 of 41 patients), p16INK4A (deleted in 15 of 33 patients), or phosphatase and tensin homologue (mutated in 15 of 41 patients)",
                        "Expression levels of Osteonectin, Doublecortex, and Semaphorin3B together associate with patient survival"
                    ],
                    "conclusions": [
                        "This gene expression study provides evidence that three genes which regulate cellular motility may contribute to the poor prognosis of patients with glioblastomas",
                        "No previous studies, of which we are aware of, have elucidated the conclusive links between expression of specific genes and survival of older glioblastoma patients"
                    ]
                },
                "application": {
                    "validated": "RT-PCR validation",
                    "diagnosis": null,
                    "prognosis": "Potential",
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "BP"
            },
            {
                "_id": "V00005B",
                "pmid": "29523123",
                "biomarkerId": "B00005B",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": 2.6,
                    "max": 78.5,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": null,
                "whoclass": "Post 2010",
                "region": [
                    "Denmark"
                ],
                "research": {
                    "methods": [
                        "CD63 expression was investigated immunohistochemically in a cohort of 111 astrocytomas and correlated to tumor grade and overall survival by semi-quantitative scoring. CD63 expression in tumor-associated microglia/macrophages was examined by double-immunofluorescence with ionized calcium-binding adapter molecule 1 (Iba1). The association between CD63 and TIMP-1 was investigated using previously obtained TIMP-1 data from our astrocytoma cohort. Cellular co-expression of TIMP-1 and CD63 as well as TIMP-1 and the tumor stem cell-related markers CD133 and Sox2 was investigated with immunofluorescence. TIMP-1 and CD63 protein interaction was detected by an oligonucleotide-based proximity ligation assay and verified using co-immunoprecipitation."
                    ],
                    "results": [
                        "The expression of CD63 was widely distributed in astrocytomas with a significantly increased level in glioblastomas. CD63 levels did not significantly correlate with patient survival at a protein level, and CD63 did not augment the prognostic significance of TIMP-1. Up to 38% of the CD63+ cells expressed Iba1",
                        "however, Iba1 did not appear to impact the prognostic value of CD63. A significant correlation was found between TIMP-1 and CD63, and the TIMP-1 and CD63 proteins were co-expressed at the cellular level and located in close molecular proximity, suggesting that TIMP-1 and CD63 could be co-players in glioblastomas. Some TIMP-1+ cells expressed CD133 and Sox2."
                    ],
                    "conclusions": [
                        "The present study suggests that CD63 is highly expressed in glioblastomas and that TIMP-1 and CD63 interact. CD63 does not add to the prognostic value of TIMP-1."
                    ]
                },
                "application": {
                    "validated": "Yes",
                    "diagnosis": null,
                    "prognosis": "NO",
                    "predictive": "NO",
                    "therapeutic": "NO"
                },
                "clinical": {
                    "relevance": "While TIMP-1 is a prominent biomarker for cancer research, it's expression is not correlated with CD63 expression. This paper presents a possible pathway for examining chemoresistance.",
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Erik Samuelsson"
            },
            {
                "_id": "V00005C",
                "pmid": "26757925",
                "biomarkerId": "B00005C",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": 2.0,
                    "max": 79.0,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": "2007",
                "region": [
                    "China"
                ],
                "research": {
                    "methods": [
                        "Methylation specific PCR",
                        "Immunohostochemistry",
                        "Kaplan Meier plots",
                        "Cox model"
                    ],
                    "results": [
                        "Methylation of the CD133 promoter was found in 106 of the 170 tumors",
                        "For grade 2 tumors the percentage of methylated and unmethylated CD133 were 74.2 and 25.8 percent respectively",
                        "With the progression to GBM, the percentage of methylation decreased to 49.4 % and the percentage of unmethylation increased to 50.6 %",
                        "CD133 methylation is a significant prognostic factor for longer OS, independent of WHO grade, age, and extent of resection",
                        "Similar results were obtained for PFS and methylation of CD133"
                    ],
                    "conclusions": [
                        "CD133 promoter methylation status in glioma is closely correlated with patient survival, which suggest CD133 promoter methylation pattern is a promising tool for prognostic purposes",
                        "Lack of association with CD133 IHC and with patient survival impede the use of CD133 IHC as a clinically useful biomarker for routine purposes and clinical decision making"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": null,
                    "prognosis": "Potential",
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "BP"
            },
            {
                "_id": "V00005D",
                "pmid": "26008605",
                "biomarkerId": "B00005D",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": 11.0,
                    "max": 79.0,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "III",
                    "III",
                    "IV"
                ],
                "whoclass": "2007",
                "region": [
                    "Japan"
                ],
                "research": {
                    "methods": [
                        "IHC",
                        "qPCR",
                        "Enzyme-Linked Immunosorbent Assay"
                    ],
                    "results": [
                        "grade III gliomas express higher levels of CD40/CD40L than does grade IV GBM"
                    ],
                    "conclusions": null
                },
                "application": {
                    "validated": null,
                    "diagnosis": "NO",
                    "prognosis": "YES",
                    "predictive": "NO",
                    "therapeutic": "NO"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": "NO",
                "curator": "RF"
            },
            {
                "_id": "V00005E",
                "pmid": "\u00a026369702",
                "biomarkerId": "B00005E",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": 20.0,
                    "max": 79.0,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "II",
                    "III"
                ],
                "whoclass": "2007",
                "region": [
                    "China"
                ],
                "research": {
                    "methods": [
                        "Fluorescence\u00a0in situ\u00a0hybridization",
                        "PCR"
                    ],
                    "results": [
                        "patients with\u00a0IDH1/2mutationand 1p/19q codeletio had more favorable overall survival than those without the marker. Patients with\u00a0TERTp mutated tumors showed trend of longer overall survival than those with\u00a0TERTp wild-type tumor.Tumors with\u00a0EGFR\u00a0amplification exhibited very short overall survival comparing to tumors without the gene amplification\u200b"
                    ],
                    "conclusions": [
                        "Most favorable prognosis was observed in IDHmut-OT gliomas (median OS = 11.8 years), followed by IDHmut gliomas (median OS\u00a0= 5.9 years) and IDHwt gliomas (median OS\u00a0= 5 years), and IDHwt-ET gliomas showed the poorest prognosis (median OS = 0.6 year)."
                    ]
                },
                "application": {
                    "validated": null,
                    "diagnosis": "NO",
                    "prognosis": "YES",
                    "predictive": "NO",
                    "therapeutic": "NO"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": "NO",
                "curator": "RF"
            },
            {
                "_id": "V00005F",
                "pmid": "27478330",
                "biomarkerId": "B00005F",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": 21.0,
                    "max": 79.0,
                    "med": 49.4,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": null,
                "region": [
                    "South Korea"
                ],
                "research": {
                    "methods": [
                        "Immunhistocheical assessment",
                        "Kaplan-Meier method"
                    ],
                    "results": [
                        "15.3% of enrolled GBMs demonstrated loss of ATRX expression (ATRX-)",
                        "10.4% expressed an aberrant IDH1 R132H protein (IDH1+)",
                        "48.4% exhibited p53 overexpression (p53+)"
                    ],
                    "conclusions": [
                        "Patients with each IDH1+, or ATRX-, or p53- GBMs showed better survival than patients with counterparts protein expressed GBMs.",
                        "in the case of double protein pairs, the patients with ATRX-/p53-, ATRX-/ IDH1+, and IDH1+/p53- GBMs revealed better survival than the patients with GBMs with the remained pairs",
                        "in the case of triple protein combinations, the patients with ATRX-/ p53-/IDH+ showed statistically significant survival gain than the patients with remained combination of proteins-expression status"
                    ]
                },
                "application": {
                    "validated": "Concrete",
                    "diagnosis": null,
                    "prognosis": "YES",
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Vanessa"
            },
            {
                "_id": "V000060",
                "pmid": "23096413",
                "biomarkerId": "B000060",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": 21.0,
                    "max": 79.0,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": null,
                "region": [
                    "Japan"
                ],
                "research": {
                    "methods": [
                        "Immunohistochemistry",
                        "Western blot",
                        "PCR",
                        "MRI",
                        "Fisher exact test",
                        "Kaplan-Meier method",
                        "Cox model"
                    ],
                    "results": [
                        "In invasive margins, xCT expression was weak in 20 patients and strong in 20 patients",
                        "A Karnofsky Performance Status Scale score less than 60 (hazard ratio [HR]: 4.525), partial removal (HR: 2.839) and strong xCT expression (HR: 4.134) were significantly associated with shorter progression-free survival and that partial removal (HR: 2.865), weak isocitrate dehydrogenase 1 R132H expression (HR: 15.729) and strong xCT expression (HR: 2.863) were significantly associated with shorter overall survival"
                    ],
                    "conclusions": [
                        "Findings suggest that xCT is an independent predictive factor in GBMs"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": null,
                    "prognosis": "Potential",
                    "predictive": "Potential",
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Ahmed"
            },
            {
                "_id": "V000061",
                "pmid": "25031733",
                "biomarkerId": "B000061",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": 26.0,
                    "max": 79.0,
                    "med": 56.0,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": null,
                "region": [
                    "China"
                ],
                "research": {
                    "methods": [
                        "Immunohistochemical assessment",
                        "Mann-Whitney U test",
                        "Spearman\u2019s rank correlation",
                        "log-rank test",
                        "kaplan-meier method",
                        "Cox proportional hazard model"
                    ],
                    "results": [
                        "Univariate analysis indicated significant correlations of high percentage of pSer727-STAT3 positive tumor cells with shorter PFS (P = 0.006) and OS (P = 0.002)",
                        "in multivariate analysis, high pSer727-STAT3 expression was demonstrated as an independent unfavorable prognostic indicator for PFS (HR 1.830, P = 0.022) and OS (HR 1.797, P = 0.040)",
                        "patients with high expression of both pTyr705-STAT3 and pSer727-STAT3 had a poorer prognosis compared with the remainder (P < 0.005)"
                    ],
                    "conclusions": [
                        "high proportion of pSer727-STAT3 positive neoplastic cells in GBM is an independent unfavorable prognostic factor",
                        "increased expression of both pTyr705-STAT3 and pSer727-STAT3 is predictive of poorer clinical outcome, thereby adding to the growing evidence that STAT3 inhibition may be a potential therapeutic strategy in glioblastoma"
                    ]
                },
                "application": {
                    "validated": "Potential",
                    "diagnosis": null,
                    "prognosis": "Potential",
                    "predictive": "Potential",
                    "therapeutic": "Potential"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": "STAT3 inhibition may be a potential therapeutic strategy in GBM"
                },
                "comments": null,
                "curator": "Vanessa"
            },
            {
                "_id": "V000062",
                "pmid": "22655594",
                "biomarkerId": "B000062",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": 26.0,
                    "max": 79.0,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": null,
                "region": [
                    "Italy"
                ],
                "research": {
                    "methods": [
                        "Semiquantitative immunohistochemical staining",
                        "Methylation specific PCR",
                        "Kaplan-Meier method",
                        "Log-rank test",
                        "Cox model"
                    ],
                    "results": [
                        "The MGMT promoter was methylated in 48 patients and nonmethylated in 57",
                        "The median PFS was 10.7 months (14.9 months in the gross-total removal subgroup), and the median OS was 12.5 months (17.4 months in the gross-total removal group)",
                        "OS was significantly correlated to the extent of resection, MGMT status, and YKL-40",
                        "All 3 factors reached statistical significance with respect to patient survival",
                        "Surgical removal contributed more than the 2 other factors to the survival prediction (\u03b2 = -0.625)",
                        "YKL-40 (\u03b2 = -0.3867) contributed more than MGMT (\u03b2 = -0.1705) to the predicted survival"
                    ],
                    "conclusions": [
                        "The extent of removal is the most important factor influencing the OS of patients harboring GBMs",
                        "When biological aggressiveness is taken into account, YKL-40 expression was found to be an independent prognostic factor that predicts OS better than MGMT status"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": null,
                    "prognosis": "Potential",
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Ahmed"
            },
            {
                "_id": "V000063",
                "pmid": "12902879",
                "biomarkerId": "B000063",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo sapiens"
                ],
                "age": {
                    "min": 26.0,
                    "max": 79.0,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": null,
                "whoclass": null,
                "region": [
                    "USA"
                ],
                "research": {
                    "methods": [
                        "Immunochemistry"
                    ],
                    "results": [
                        "Her-2/neu overexpression was detected in 15.4% patients and has less survival rate"
                    ],
                    "conclusions": [
                        "Her-2/neu overexpression may be a poor prognostic marker in patients with GBM"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": null,
                    "prognosis": "Potential",
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Cristian"
            },
            {
                "_id": "V000064",
                "pmid": "18507036",
                "biomarkerId": "B000168",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": 27.0,
                    "max": 79.0,
                    "med": -1,
                    "avg": 56.1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": "Pre 2010",
                "region": [
                    "Portugal"
                ],
                "research": {
                    "methods": [
                        "EGFR overexpression, EGFRvIII mutation and EGFR amplification were determined by immunohistochemistry and chromogenic in situ hybridization (CISH) in 27 primary glioblastomas (GBM), 24 anaplastic oligodendrogliomas (AO) and four anaplastic oligoastrocytomas (AOA)."
                    ],
                    "results": [
                        "EGFR overexpression was associated with EGFR amplification, being found in 48% and 53% GBM, 33% and 40% AO and 75% and 67% AOA, respectively. EGFRvIII was found in 22% GBM, 8% AO and was absent in AOA. No association was observed between EGFR alterations and patient survival"
                    ],
                    "conclusions": [
                        "We characterized, for the first time, EGFR molecular alterations in Portuguese patients with malignant glioma and identified a subpopulation of patients presenting putative biomarkers for EGFR-based therapies."
                    ]
                },
                "application": {
                    "validated": "Potential",
                    "diagnosis": null,
                    "prognosis": "Potential",
                    "predictive": "Potential",
                    "therapeutic": "Potential"
                },
                "clinical": {
                    "relevance": "Potential patient cohort selector",
                    "implication": "Potential method to successfully ddivide patient cohorts for nimotuzumab treatment.",
                    "treatment": "Could lead to new method of defining patient cohorts for EGFR target treatment studies."
                },
                "comments": null,
                "curator": "Erik Samelsson"
            },
            {
                "_id": "V000065",
                "pmid": "17987795",
                "biomarkerId": "B000065",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens",
                    "Mus musculus"
                ],
                "age": {
                    "min": 30.0,
                    "max": 79.0,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": null,
                "whoclass": "2000",
                "region": [
                    "Norway"
                ],
                "research": {
                    "methods": [
                        "Immunohistochemistry",
                        "Survival curves",
                        "Log rank-test"
                    ],
                    "results": [
                        "Nine of 21 tumours (43 %)were immunoreactive for c-erbB-2, 19 of 20 tumours (95 %) for c-erbB-3, and 21 of 21 for c-erbB-4",
                        "All glioblastomas were negative for the mutated variant of EGFR (i.e. EGFRvIII)",
                        "Kaplan-Meier plots as a function of growth factor receptor expression did not show any significant association with survival among the GBM patients"
                    ],
                    "conclusions": [
                        "Immunohistochemistry is well suited for detection of erbreceptor proteins in glioblastoma tissue and demonstrated abundant and simultaneous immunoreactivity of thesereceptors."
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": "Potential",
                    "prognosis": "NO",
                    "predictive": "NO",
                    "therapeutic": "Potential"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": "Potential",
                "curator": "BP"
            },
            {
                "_id": "V000066",
                "pmid": "23566417",
                "biomarkerId": "B000066",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": 38.0,
                    "max": 79.0,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": null,
                "region": [
                    "France"
                ],
                "research": {
                    "methods": [
                        "Patients treated with Tipifarnib",
                        "Overall survival (OS) and biomarker analysis by immunohistochemistry"
                    ],
                    "results": [
                        "FGFR1  and \u03b1v\u03b23 over-expressions were associated with reduced overall survival"
                    ],
                    "conclusions": [
                        "\u03b1v\u03b23 integrin and FGFR1 are bad prognostic factors of OS for patients with GBM, confirming their involvement in GBM radioresistance and aggressiveness"
                    ]
                },
                "application": {
                    "validated": null,
                    "diagnosis": "NO",
                    "prognosis": "YES",
                    "predictive": "YES",
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": "NO",
                "curator": "ANA"
            },
            {
                "_id": "V000067",
                "pmid": "23416698",
                "biomarkerId": "B000067",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": 8.0,
                    "max": 80.0,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": null,
                "region": [
                    "China"
                ],
                "research": {
                    "methods": [
                        "Quantitative real-time PCR",
                        "Cox model",
                        "Log-rank test"
                    ],
                    "results": [
                        "Data showed a very good correlation of miR-106a or U6 expression between fresh frozen and FFPE GBM specimens, with Pearson's correlation coefficients of 0.849 and 0.823, respectively",
                        "Their expression levels in archival FFPE samples were quite stable for at least 7 years when stored at room temperature",
                        "Expression level of miR-106a was an independent and significant predictor of overall survival in GBM patients"
                    ],
                    "conclusions": [
                        "MiR-106a expression was relatively abundant and stable in a large cohort of archival FFPE GBM specimens and could be used as an independent prognostic biomarker in those patients",
                        "Thus, miR-106a can be used to predict prognosis and treatment response in individual GBM patients"
                    ]
                },
                "application": {
                    "validated": "Yes(By in situ hybridization assay in the second cohort)",
                    "diagnosis": "NO",
                    "prognosis": "YES",
                    "predictive": "NO",
                    "therapeutic": "NO"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": "NO",
                "curator": "ANA"
            },
            {
                "_id": "V000068",
                "pmid": "21764585",
                "biomarkerId": "B000068",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo sapiens"
                ],
                "age": {
                    "min": 14.0,
                    "max": 80.0,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "I",
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": "2000",
                "region": [
                    "China"
                ],
                "research": {
                    "methods": [
                        "Western blot",
                        "Immunohistochemistry",
                        "Chi-square test",
                        "Kaplan-Meier method",
                        "Cox regression analysis"
                    ],
                    "results": [
                        "Of 77 tumors, 49 were negative for CacyBP/SIP expression",
                        "Loss of CacyBP/SIP expression was significantly associated with a high histological grade and with poor survival in univariate and multivariate analyses",
                        "Loss of CacyBP/SIP expression correlated with poor prognosis in patients with astrocytomas and was an independent prognostic factor",
                        "The mean survival time of patients with tumors that had lost expression of CacyBP/SIP was 25.58 months compared to a mean survival time of 36.37 months for patients with CacyBP/SIP-expressing tumors",
                        "CacyBP/SIP expression was also negatively correlated with PCNA expression in astrocytoma tissue"
                    ],
                    "conclusions": [
                        "Findings suggest that CacyBP/SIP may have an important role as a negative regulator of astrocytoma development and progression, and that CacyBP/SIP might be a useful molecular marker for predicting the prognosis of astrocytoma"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": null,
                    "prognosis": "Potential",
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": null
            },
            {
                "_id": "V000069",
                "pmid": "29952031",
                "biomarkerId": "B000069",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": 17.0,
                    "max": 80.0,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": null,
                "whoclass": "Post 2010",
                "region": [
                    "Turkey"
                ],
                "research": {
                    "methods": [
                        "IHC",
                        "statistical analysis for patient survival related to CA-IX expression"
                    ],
                    "results": [
                        "Overexpression of CA-IX in patients who had progressed in the first 3 months was higher than in those who had progressed after 3 months.The difference was statistically significant. Our findings indicated that CA-IX may be a potential prognostic biomarker in the treatment of GBM."
                    ],
                    "conclusions": [
                        "There was not a statistically significant difference in median PFS (3.5 vs. 8 months, P = 0.054) between patients with high or low levels of CA-IX expression. In multivariate analysis, the variables that were identified as significant prognostic factors for OS were preoperative Karnofsky performance scale score (KPS) (hazard ratio (HR), 3.703",
                        "P = 0.001), CA-IX overexpression (HR, 1.967",
                        "P = 0.019), and incomplete adjuvant temozolomide treatment (HR, 2.241",
                        "P = 0.003) and gross-total resection (HR, 1.956",
                        "P = 0.034)."
                    ]
                },
                "application": {
                    "validated": "Potential",
                    "diagnosis": null,
                    "prognosis": "Potential",
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Erik Samuelsson"
            },
            {
                "_id": "V00006A",
                "pmid": "24274717",
                "biomarkerId": "B00006A",
                "sourceIds": [
                    "Tissue",
                    "Glioma Stem Cells"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens",
                    "Mus musculus"
                ],
                "age": {
                    "min": 17.0,
                    "max": 80.0,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": "2007",
                "region": [
                    "Japan"
                ],
                "research": {
                    "methods": [
                        "Development of patient derived GSC lines",
                        "Western blot",
                        "Immunohistochemistry",
                        "Transplantation of GSCs into NOD-SCID mouse brain",
                        "Real-time PCR",
                        "ANOVA",
                        "Dunnett's tests"
                    ],
                    "results": [
                        "FABP7 was found to be highly enriched in GSCs and its localization was found in cytosol and nuclei",
                        "FABP7 expression was significantly downregulated in differentiated GSCs induced by the addition of serum",
                        "In the glioma surgical specimens, FABP7 was highly expressed in the majority of GBM",
                        "Double immunostaining for FABP7 and Sox2 showed that FABP7(+) Sox2(+) tumor cells were significantly increased in glioblastoma (grade IV) compared with diffuse astrocytoma (grade II) and anaplastic astrocytoma (grade III)"
                    ],
                    "conclusions": [
                        "Data introduces FABP7 as a marker for GSCs and further highlights its possible significance for glioma diagnosis and treatment"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": "Potential",
                    "prognosis": null,
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": "Potential",
                "curator": null
            },
            {
                "_id": "V00006B",
                "pmid": "20455002",
                "biomarkerId": "B00006B",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": 21.0,
                    "max": 80.0,
                    "med": 56.0,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": "Pre 2010",
                "region": [
                    "Japan"
                ],
                "research": {
                    "methods": [
                        "PEA-15 expression levels were immunohistochemically measured and categorized as no, low, or high expression. All tumors expressed PEA-15 in our study. Next, we evaluated prognosis and PEA-15 expression levels in 43 patients with high-grade astrocytomas based on the following parameters: age, gender, WHO grade, surgical resection extent, MIB-1 labeling index (LI), and PEA-15 expression level. Multivariable analyses revealed that high PEA-15 expression level displayed a significant correlation with longer overall survival (OS) in high-grade astrocytomas (P = 0.0024)."
                    ],
                    "results": [
                        "Twenty-three (35.4%) and 42 (64.6%) tumors expressed low and high PEA-15 levels, respectively. In grade II astrocytoma (diffuse astrocytoma) and grade III astrocytoma (anaplastic astrocytoma), 100% and 88.9% of patients expressed high PEA-15 levels, respectively, while a smaller number (50%) of patients with grade IV astrocytoma (glioblastoma) expressed high PEA-15 levels. PEA-15 expression level was inversely associated with WHO grade (P = 0.0006). Patients with total resection survived significantly longer (P = 0.0044) than those with lower resection extent, while patients with MIB-1 labeling index \u226425% indicated significant (P = 0.0434) correlation with OS as well."
                    ],
                    "conclusions": [
                        "In conclusion, PEA-15 expression level was inversely associated with WHO grade and may serve as an important prognostic factor for high-grade astrocytomas."
                    ]
                },
                "application": {
                    "validated": "Potential",
                    "diagnosis": null,
                    "prognosis": "Potential",
                    "predictive": null,
                    "therapeutic": "Potential"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Erik Samelsson"
            },
            {
                "_id": "V00006C",
                "pmid": "9804374",
                "biomarkerId": "B00006C",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo sapiens"
                ],
                "age": {
                    "min": 22.0,
                    "max": 80.0,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": "Pre 2007",
                "region": [
                    "USA"
                ],
                "research": {
                    "methods": [
                        "Immunochemistry"
                    ],
                    "results": [
                        "Survival testing with or without altered expression of p16, p53, EGFR, MDM2 or Bcl-2 showed no significant differences by age group or by gene expression"
                    ],
                    "conclusions": [
                        "These four proteins dont have any prognostic value for GBM"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": null,
                    "prognosis": null,
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Cristian"
            },
            {
                "_id": "V00006D",
                "pmid": "19861461",
                "biomarkerId": "B0001D3",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": 26.0,
                    "max": 80.0,
                    "med": 56.0,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": "Pre 2010",
                "region": [
                    "Germany"
                ],
                "research": {
                    "methods": [
                        "We conducted a translational study involving 67 newly diagnosed glioblastoma patients treated at our institution from 1998 to 2004. All patients were treated by open resection, followed by radiotherapy and adjuvant temozolomide chemotherapy. The tumors were investigated for MGMT promoter methylation, mRNA and protein expression, as well as presence of MGMT sequence polymorphisms. In addition, we screened for genetic aberrations of the EGFR, TP53, CDK4, MDM2, and PDGFRA genes as well as allelic losses on chromosomal arms 1p, 10q, and 19q. RT-PCR, IHC."
                    ],
                    "results": [
                        "Correlation of molecular findings with clinical data revealed significantly longer time to progression after onset of chemotherapy and longer overall survival of patients with MGMT-hypermethylated tumors. In contrast, MGMT protein expression, MGMT polymorphisms, and aberrations in any of the other genes and chromosomes were not significantly linked to patient outcome. Multivariate analysis identified MGMT promoter hypermethylation and near-complete tumor resection as the most important parameters associated with better prognosis."
                    ],
                    "conclusions": [
                        "Our study provides novel insights into the significance of molecular and clinical markers in predicting the prognosis of glioblastoma patients, which may improve stratification of patients into distinct prognostic subgroups"
                    ]
                },
                "application": {
                    "validated": "Yes",
                    "diagnosis": "NO",
                    "prognosis": "YES",
                    "predictive": "YES",
                    "therapeutic": "YES"
                },
                "clinical": {
                    "relevance": "O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation has been firmly established as a biomarker in patients diagnosed with gliomas, for both clinical trials and routine clinical management.",
                    "implication": "Use in companion diagnostics and predicting patient outcome.",
                    "treatment": "Methylation status of the MGMT gene is crucial to promoting DNA repair. If the MGMT gene is methylated, cancer patients tend to respond better to alkylating drug therapy."
                },
                "comments": "NO",
                "curator": "Erik Samelsson"
            },
            {
                "_id": "V00006E",
                "pmid": "16619508",
                "biomarkerId": "B00006E",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": 38.0,
                    "max": 80.0,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": "2000",
                "region": [
                    "Italy"
                ],
                "research": {
                    "methods": [
                        "Immunohistochemistry",
                        "Paired t-test"
                    ],
                    "results": [
                        "The samples examined were subdivided into 2 cytological subsets, small cell (SC) or multiforme cell (MC) glioblastoma, according to the predominant cell type defined in individual specimens",
                        "MCM7 detected more cells in the cycle than Ki67 and PCNA and all cases of SC glioblastoma, the most aggressive subset, displayed a significant increase of MCM7-stained nuclei versus those stained with Ki67"
                    ],
                    "conclusions": [
                        "Cell cycle-associated proteins MCM are not only useful markers of proliferation, but also valid aids for diagnosis in cerebral glioblastoma"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": "Potential",
                    "prognosis": "NO",
                    "predictive": "NO",
                    "therapeutic": "NO"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": "Potential",
                "curator": "BP"
            },
            {
                "_id": "V00006F",
                "pmid": "24160898",
                "biomarkerId": "B00006F",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": 3.0,
                    "max": 81.0,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": "2007",
                "region": [
                    "Japan"
                ],
                "research": {
                    "methods": [
                        "Methylation-specific PCR",
                        "Fluorescence in situ hybridization",
                        "t-test",
                        "KPS",
                        "Kaplan Meier analysis",
                        "Cox non-parametric model"
                    ],
                    "results": [
                        "In Group 1 (GBM+AA), patients with IDH1 mutations exhibited a significantly longer survival time than patients with wild-type IDH1",
                        "However, no significant difference was observed in Group 2 (AO+AOA), although patients with IDH1 mutations tended to show prolonged survival",
                        "For both Group 1 and Group 2, patients with MGMT methylation survived longer than those without this methylation",
                        "Further, patients with 1p/19q co-deletion showed significantly better outcome in Group 2"
                    ],
                    "conclusions": [
                        "Study confirms the utility of IDH1 mutations and MGMT methylation in predicting the prognosis of Group 1 patients (GBM\u2009+\u2009AA) and demonstrated that IDH1 mutations may serve as a more reliable prognostic factor for such patients",
                        "Study suggests that patients survive longer if they have IDH1 mutations and undergo total resection",
                        "Irrespective of MGMT promoter methylation status, the prognosis of glioma patients can be improved if total resection is performed"
                    ]
                },
                "application": {
                    "validated": "This is itself a validation study",
                    "diagnosis": null,
                    "prognosis": "YES",
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": null
            },
            {
                "_id": "V000070",
                "pmid": "26503470",
                "biomarkerId": "B000070",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": 18.0,
                    "max": 81.0,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": "2007",
                "region": [
                    "China"
                ],
                "research": {
                    "methods": [
                        "Surgery",
                        "Temozolomide treatment",
                        "Radiotherapy",
                        "Chemotherapy",
                        "DNA extraction and molecular evaluation",
                        "Surveillance",
                        "Isogenic IDH1-R132H expressing astrocytic and GBM lines",
                        "Cox model",
                        "Kaplan Meier analysis"
                    ],
                    "results": [
                        "For patients who underwent TMZ and Radiation Therapy, OS and PFS was most favorable for those with tumors harboring both mIDH and methMGMT (median OS: 35.8 mo, median PFS: 27.5 mo)",
                        "Patients afflicted GBMs with either mIDH or methMGMT exhibited intermediate OS and PFS (mOS: 36 and 17.1 mo",
                        "mPFS: 12.2 mo and 9.9 mo, respectively)",
                        "Poorest OS and PFS was observed in wild type IDH1 (wtIDH1) glioblastomas that were MGMT promoter unmethylated (mOS: 15 mo, mPFS: 9.7 mo)",
                        "For patients with wtIDH GBM TMZ+RT was associated with improved OS and PFS relative to patients treated with RT (OS: 15.4 mo v 9.6 mo, PFS: 9.9 mo v 6.5 mo)",
                        "While TMZ+RT and RT treated mIDH patients exhibited improved overall survival relative to those with wtIDH, there were no differences between the TMZ+RT or RT group",
                        "These results suggest that mIDH1 conferred resistance to TMZ",
                        "Supporting this hypothesis, exogenous expression of mIDH1 in independent astrocytoma/glioblastoma lines resulted in a 3\u201310 fold increase in TMZ resistance after long-term passage"
                    ],
                    "conclusions": [
                        "IDH mutation and MGMT promoter methylation status independently associate with favorable outcome in TMZ+RT treated glioblastoma patients",
                        "These biomarkers differentially impact clinical TMZ response"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": null,
                    "prognosis": null,
                    "predictive": "YES",
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "BP"
            },
            {
                "_id": "V000071",
                "pmid": "24810474",
                "biomarkerId": "B000071",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": 18.0,
                    "max": 81.0,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": "2007",
                "region": [
                    "China"
                ],
                "research": {
                    "methods": [
                        "whole transcriptome sequencing",
                        "PCR",
                        "pyrosequencing",
                        "Immunohistochemical assessment",
                        "RPKM method",
                        "Kaplan-Meier method",
                        "Student's t-test",
                        "ANOVA",
                        "Chi-square test"
                    ],
                    "results": [
                        "low ATRX mRNA expression was detected in 68% of A, 50% of AA and 41.6% of GBM",
                        "low ATRX expression closely overlapped with mutations in IDH1/2 (P<0.0001) in astrocytic tumors across WHO grades II\u2013IV",
                        "significant association between low ATRX expression and longer overall survival was identified in our cohort (P<0.01)",
                        "ATRX combined with IDH1/2 and Ki-67 was used to re-classify patients with astrocytic tumors: group A1 containing IDH1/2 mutations and low ATRX expression predicted a better prognostic outcome, whereas group A3 carrying wild-type IDH1/2 and high Ki-67 expression had the shortest overall survival",
                        "IDH-mutant tumors with low ATRX expression and IDH-wild-type tumors with high Ki-67 expression were grouped into group A2"
                    ],
                    "conclusions": [
                        "ATRX in cooperation with IDH1/2 and Ki-67 defines three subgroups of astrocytic tumors regardless of the conventional WHO grades consensus.",
                        "molecular stratification in astrocytic tumors may aid in treatment strategy selection, therapeutic trial design, and clinical prognosis evaluation"
                    ]
                },
                "application": {
                    "validated": "Potential",
                    "diagnosis": null,
                    "prognosis": "Potential",
                    "predictive": null,
                    "therapeutic": "Potential"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Vanessa"
            },
            {
                "_id": "V000072",
                "pmid": "26201842",
                "biomarkerId": "B000072",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": 19.0,
                    "max": 81.0,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": null,
                "whoclass": "2007",
                "region": [
                    "Japan"
                ],
                "research": {
                    "methods": [
                        "IHC",
                        "pyrosequencing"
                    ],
                    "results": [
                        "The median PFS and OS times in patients with positive MGMT expression were significantly shorter than in those with negative MGMT expression",
                        "The median PFS and OS times in patients with high CCN1 expression were significantly shorter than in those with low CCN1 expression"
                    ],
                    "conclusions": [
                        "High expression of CCN1 is asscoiated with shorter progression-free survival and overall survival"
                    ]
                },
                "application": {
                    "validated": null,
                    "diagnosis": "NO",
                    "prognosis": "YES",
                    "predictive": "NO",
                    "therapeutic": "NO"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": "NO",
                "curator": "RF"
            },
            {
                "_id": "V000073",
                "pmid": 0,
                "biomarkerId": "B000073",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": 20.0,
                    "max": 81.0,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "III"
                ],
                "whoclass": "2007",
                "region": [
                    "Canada"
                ],
                "research": {
                    "methods": [
                        "IHC",
                        "FISH"
                    ],
                    "results": null,
                    "conclusions": null
                },
                "application": {
                    "validated": null,
                    "diagnosis": null,
                    "prognosis": null,
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "RF"
            },
            {
                "_id": "V000074",
                "pmid": "15466382",
                "biomarkerId": "B000074",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo sapiens"
                ],
                "age": {
                    "min": 21.0,
                    "max": 81.0,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": "Pre 2007",
                "region": [
                    "USA"
                ],
                "research": {
                    "methods": [
                        "PCR",
                        "Bisulfite sequencing",
                        "Immunochemestry"
                    ],
                    "results": [
                        "TMS1 was aberrantly methylated in 43% of GBM specimens"
                    ],
                    "conclusions": [
                        "role for the epigenetic silencing of TMS1 in the\u00a0pathogenesis\u00a0of human GBM"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": null,
                    "prognosis": "Potential",
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Cristian"
            },
            {
                "_id": "V000075",
                "pmid": "28938636",
                "biomarkerId": "B000075",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": 22.0,
                    "max": 81.0,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": "2007",
                "region": [
                    "Italy"
                ],
                "research": {
                    "methods": [
                        "Immunohistochemical assessment",
                        "Fisher's exact test",
                        "Kaplan-Meier method"
                    ],
                    "results": [
                        "PATZ1 gene upregulated in gliomas compared to normal brain and, among GBMs, particularly enriched in the proneural subtype and co-localize with stemness markers",
                        "in GBM-derived glioma-initiating stem cells (GSCs) PATZ1 is overexpressed compared to differentiated tumor cells and its expression significantly correlates with the characteristic stem cell capacity to grow as neurospheres in vitro",
                        "PATZ1 lower levels show poor prognosis in GBM and in the proneural subgroup",
                        "PATZ1 might be diagnostic and prognostic biomarker for intra-subtype heterogeneity of proneural GBM",
                        "PATZ1 suppresses the expression of the mesenchyme-inducer CXCR4",
                        "PATZ1 and CXCR4 are inversely correlated in GSC and proneural GBM"
                    ],
                    "conclusions": [
                        "central role of PATZ1 in regulating malignancy of GBM"
                    ]
                },
                "application": {
                    "validated": "Potential",
                    "diagnosis": "Potential",
                    "prognosis": "Potential",
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": "Potential",
                "curator": "Vanessa"
            },
            {
                "_id": "V000076",
                "pmid": "23245659",
                "biomarkerId": "B000076",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": 24.0,
                    "max": 81.0,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": null,
                "region": [
                    "Spain"
                ],
                "research": {
                    "methods": [
                        "Bisulfite treatment",
                        "Methylation-specific PCR",
                        "Immunohistochemistry",
                        "MacDonald criteria",
                        "Kaplan-Meier method",
                        "Cox model",
                        "Fisher's exact test",
                        "McNemar test"
                    ],
                    "results": [
                        "The MGMT gene promoter was found to be methylated in 34 patients (44.7%) and unmethylated in 42 patients (55.3%)",
                        "A significant correlation was observed between MGMT promoter methylation and patients\u2019 survival",
                        "Among the unmethylated tumors, 52.4% showed low expression of MGMT and 47.6% showed high-expression",
                        "Among methylated tumors, 58.8% showed low-expression of MGMT and 41.2% showed high-expression",
                        "No correlation was found between MGMT promoter methylation and MGMT expression, or MGMT expression and survival",
                        "CD133 expression was not a predictive marker in GBM patients",
                        "Analyses of possible correlation between CD133 expression and MGMT protein expression or MGMT promoter methylation were negative"
                    ],
                    "conclusions": [
                        "MGMT promoter methylation status but not MGMT expression may be a predictive biomarker in the treatment of patients with GBM",
                        "CD133 should not be used for prognostic evaluation of these patients"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": null,
                    "prognosis": null,
                    "predictive": "Potential(MGMT);CD133 revoked",
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": "Can be used as a predictive marker for treatment with radiotherapy and TMZ in GBM"
                },
                "comments": null,
                "curator": "Ahmed"
            },
            {
                "_id": "V000077",
                "pmid": "18618497",
                "biomarkerId": "B000077",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": 40.7,
                    "max": 81.2,
                    "med": -1,
                    "avg": 62.47,
                    "sd": 11.26,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": "Pre 2010",
                "region": [
                    "USA"
                ],
                "research": {
                    "methods": [
                        "In this retrospective cohort study, patients who had lower grade astrocytomas were compared with patients who had GBM to verify that the methods used could establish differences between tumor grades. By using preoperative imaging, the amount of necrosis was established versus the overall tumor area. The authors also compared preoperative images with postoperative images to define the amount of tumor resected",
                        "and they compared molecular markers, proliferation, MVD, and imaging studies with survival among patients who had GBM."
                    ],
                    "results": [
                        "The hypoxia-regulated molecules (HRMs) and indices for MVD and cellular proliferation were associated significantly with tumor grade. Survival was improved when >or=95% of the tumor was resected. Although the total tumor area was associated with overall survival, no differences were observed when the amount of necrosis or a tumor necrosis index (area of necrosis/area of tumor) was compared with survival. The findings indicated that GLUT-1 and VEGF were correlated with survival after controlling for age."
                    ],
                    "conclusions": [
                        "Tumor grade was differentiated with HRMs, MVD, and proliferation, but only GLUT-1 predicted survival in this group of patients with GBM. The results suggested that GLUT-1 may be an important independent prognostic indicator."
                    ]
                },
                "application": {
                    "validated": "Potential",
                    "diagnosis": null,
                    "prognosis": "Potential",
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": "Hypoxia is an important feature of GBM and a potential indicator of tumor aggresiveness/patient survivability. As a biomarker of hypoxia, GLUT-1 is of potential research interest.",
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Erik Samelsson"
            },
            {
                "_id": "V000078",
                "pmid": "26914704",
                "biomarkerId": "B0000EB",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": 1.0,
                    "max": 82.0,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "I",
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": "2007",
                "region": [
                    "Portugal",
                    "Brazil"
                ],
                "research": {
                    "methods": [
                        "PCR",
                        "Direct Sanger sequencing",
                        "Multivariate logistic regression",
                        "Cox model"
                    ],
                    "results": [
                        "TERTp mutations are a major prognostic factor for shorter survival in GBM patients, independently of other known clinical prognostic factors, such as older age at diagnosis and poor Karnofsky Performance Status",
                        "Prognostic value of TERTp mutations depends on the status of the rs2853669 \u2212245A\u2009>\u2009G SNP"
                    ],
                    "conclusions": [
                        "TERTp mutations are a major indicator of poor survival in GBM, independently from other risk factors such as age and Karnofsky Performance Status",
                        "Effect promoted by TERTp mutations may be modified by a common SNP in the TERT promoter region"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": null,
                    "prognosis": "YES",
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "BP"
            },
            {
                "_id": "V000079",
                "pmid": "26490980",
                "biomarkerId": "B000079",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": 19.0,
                    "max": 82.0,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": "2007",
                "region": [
                    "China"
                ],
                "research": {
                    "methods": [
                        "WB",
                        "IHC",
                        "Univariate analysis",
                        "Multivariate analysis"
                    ],
                    "results": [
                        "CDC5L was overexpressed in glioma tissues"
                    ],
                    "conclusions": [
                        "Knockdown of CDC5L would inhibit proliferation of glioma cells"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": "NO",
                    "prognosis": "YES",
                    "predictive": "NO",
                    "therapeutic": "Potential"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": "NO",
                "curator": "RF"
            },
            {
                "_id": "V00007A",
                "pmid": "23673813",
                "biomarkerId": "B00007A",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": 27.0,
                    "max": 82.0,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": null,
                "region": [
                    "China"
                ],
                "research": {
                    "methods": [
                        "Nrf2 expression in GBM tissue samples through immunohistochemical analysis and investigation of its role in GBM human cell line and mice"
                    ],
                    "results": [
                        "higher protein levels of Nrf2 were significantly associated with poorer overall survival"
                    ],
                    "conclusions": null
                },
                "application": {
                    "validated": "no",
                    "diagnosis": "NO",
                    "prognosis": "YES",
                    "predictive": "NO",
                    "therapeutic": "Potential"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": "These findings support the potential use of Nrf2 siRNA gene therapy for GBM patients."
                },
                "comments": "NO",
                "curator": "ANA"
            },
            {
                "_id": "V00007B",
                "pmid": "22624064",
                "biomarkerId": "B00007B",
                "sourceIds": [
                    "Tissue",
                    "Cell line"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": 33.6,
                    "max": 82.5,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": null,
                "region": [
                    "USA",
                    "Germany"
                ],
                "research": {
                    "methods": [
                        "CIEF-nRPLC-MS proteomic profiling",
                        "Western blot",
                        "Immunostaining",
                        "NNAT sequencing",
                        "t-test",
                        "Kaplan-Meier method",
                        "Wilcoxon test",
                        "Cox model"
                    ],
                    "results": [
                        "Expression of NNAT is associated with significant increases in cellular proliferation",
                        "Paralleling the\u00a0in vitro\u00a0results, when NNAT levels were evaluated in tumor specimens from a consecutive cohort of 59 glioblastoma patients, the presence of increased levels of NNAT were found to be a an independent risk factor for decreased patient survival"
                    ],
                    "conclusions": [
                        "Findings indicate that NNAT may have utility as a prognostic biomarker, as well as a cell-surface target for chemotherapeutic agents"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": null,
                    "prognosis": "Potential",
                    "predictive": null,
                    "therapeutic": "Potential"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Ahmed"
            },
            {
                "_id": "V00007C",
                "pmid": "22274399",
                "biomarkerId": "B00007C",
                "sourceIds": [
                    "Tissue",
                    "Cell line"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": 0.3,
                    "max": 83.0,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "I",
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": null,
                "region": [
                    "USA"
                ],
                "research": {
                    "methods": [
                        "Western blot",
                        "Quantitative RT-PCR",
                        "Immunohistochemistry",
                        "Pearson's correlation",
                        "t-test",
                        "Kaplan Meier curves"
                    ],
                    "results": [
                        "Aurora A protein levels in oligodendrogliomas and anaplastic oligodendrogliomas are generally low, similar to control epilepsy cerebral tissue",
                        "In contrast, pilocytic astrocytomas and ependymomas express high Aurora A levels",
                        "Among grade II to grade III astrocytomas and GBM, Aurora A protein increases with increasing tumor grade",
                        "Aurora A expression is induced by hypoxia in cultured GBM cells and is overexpressed in hypoxic regions of GBM tumors",
                        "Both lower Aurora A protein and Aurora A mRNA levels are significantly associated with poorer patient survival in GBM",
                        "Selective Aurora A inhibitor MLN8237 is potently cytotoxic to GBM cells, and that MLN8237 cytotoxicty is potentiated by ionizing radiation",
                        "MLN8237 also appeared to induce senescence and differentiation of GBM cells"
                    ],
                    "conclusions": [
                        "Findings suggest that Aurora A represents a potential useful biomarker in GBM as a significant indicator of patient survival",
                        "Inhibition of Aurora A by MLN8237 or similar agents represents a potential new primary chemotherapeutic strategy and/or modulator of other therapies in GBM and perhaps other glial tumor types"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": null,
                    "prognosis": "Potential",
                    "predictive": null,
                    "therapeutic": "Potential"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": null
            },
            {
                "_id": "V00007D",
                "pmid": "25948789",
                "biomarkerId": "B00007D",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": 8.0,
                    "max": 83.0,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "I",
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": "2007",
                "region": [
                    "Italy"
                ],
                "research": {
                    "methods": [
                        "qRT-PCR",
                        "WB,Citotoxicity assay"
                    ],
                    "results": [
                        "Within GBM cell lines, the SNP rs12435998 down-regulates\u00a0SEL1L\u00a0expression only in NS and, at the same time, it increases the sensitivity to VPA,"
                    ],
                    "conclusions": [
                        "gnificant association of the\u00a0SEL1L\u00a0SNP rs12435998 constitutive genetic variant with an improved OS in GBM patients, especially after conventional treatment with TMZ-based RT-CHT."
                    ]
                },
                "application": {
                    "validated": null,
                    "diagnosis": "NO",
                    "prognosis": "YES",
                    "predictive": "NO",
                    "therapeutic": "NO"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": "NO",
                "curator": "RF"
            },
            {
                "_id": "V00007E",
                "pmid": "28787701",
                "biomarkerId": "B00007E",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": 14.0,
                    "max": 83.0,
                    "med": -1,
                    "avg": 54.76,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": null,
                "whoclass": null,
                "region": [
                    "China"
                ],
                "research": {
                    "methods": [
                        "RT-qPCR",
                        "Western blotting",
                        "Kaplan-Meier method"
                    ],
                    "results": [
                        "CBP2 expression markedly increased in higher stages of GBM compared with those in lower stages",
                        "high expression of PCBP2 associated with higher clinical stage and histological grade",
                        "PCBP2 upregulation connected with poorer prognosis in patients with GBM"
                    ],
                    "conclusions": [
                        "PCBP2 might be a novel prognostic biomarker and a potential therapeutic target of GBM"
                    ]
                },
                "application": {
                    "validated": "Potential",
                    "diagnosis": null,
                    "prognosis": "Potential",
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": "PCBP2 potential therapeutic target of GBM"
                },
                "comments": null,
                "curator": "Vanessa"
            },
            {
                "_id": "V00007F",
                "pmid": "22690797",
                "biomarkerId": "B00007F",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": 18.0,
                    "max": 83.0,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": "2007",
                "region": [
                    "Greece"
                ],
                "research": {
                    "methods": [
                        "Western Immunoblotting",
                        "Immunohistochemistry",
                        "ANOVA",
                        "Kaplan-Meier method",
                        "Cox model"
                    ],
                    "results": [
                        "p\u2010mTOR expression correlated with p\u20104E\u2010BP1 expression and marginally with p\u2010p70S6K expression",
                        "p\u20104E\u2010BP1 expression increased with tumour grade",
                        "Rapamycin induced a decline in phosphorylation levels of all three proteins",
                        "Nuclear p\u2010AKT and cytoplasmic p\u2010ERK1/2 immunoexpression correlated with p\u20104E\u2010BP1 expression, whereas cytoplasmic p\u2010AKT expression correlated with p\u2010p70S6K expression",
                        "All three proteins were associated with increased angiogenesis but not with IDH1\u2010R132H expression status",
                        "p\u2010mTOR adversely affected overall and disease\u2010free survival",
                        "The presence of p\u20104E\u2010BP1 predicted shortened overall survival in the entire cohort and GBMs"
                    ],
                    "conclusions": [
                        "mTOR signalling components are differentially involved in the acquisition of a more aggressive and angiogenic phenotype in astrocytic tumours",
                        "p\u20104E\u2010BP1 emerges as a novel prognostic marker, which might aid in the selection of patients who are more likely to benefit from therapy with mTOR inhibitors"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": null,
                    "prognosis": "YES",
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Ahmed"
            },
            {
                "_id": "V000080",
                "pmid": "30009411",
                "biomarkerId": "B000080",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": 22.0,
                    "max": 83.0,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": "2016",
                "region": [
                    "France"
                ],
                "research": {
                    "methods": [
                        "Tissue microarray",
                        "Immunohistochemistry",
                        "Cell viability assay",
                        "RT-qPCR",
                        "Cell fractionation",
                        "Western blot",
                        "Immunofluorescence",
                        "Transcriptome analysis",
                        "Kaplan-Meier method",
                        "Kruskal-Wallis test",
                        "Mann-Whitney test",
                        "Mantel-Cox log rank or Cox regression test"
                    ],
                    "results": [
                        "For the first time that YAP1 expression is related to glioma molecular subtypes and is associated with poor patient outcome",
                        "YAP1 may have prognostic significance for predicting patient survival, especially in low-grade gliomas",
                        "YAP1 was activated and that it controlled cell proliferation",
                        "Lower expression of YAP1 found in the proneural GBM subtype",
                        "Overexpression of YAP1 was sufficient to inhibit the OLIG2 proneural marker, suggesting its involvement in maintenance of the GBM phenotype"
                    ],
                    "conclusions": [
                        "Results showed that YAP1 could be a relevant prognostic biomarker and a potential therapeutic target in glioma"
                    ]
                },
                "application": {
                    "validated": "Yes (TCGA)",
                    "diagnosis": null,
                    "prognosis": "Potential",
                    "predictive": null,
                    "therapeutic": "Potential"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Erik Samuelsson"
            },
            {
                "_id": "V000081",
                "pmid": "22589395",
                "biomarkerId": "B000081",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens",
                    "Mus musculus"
                ],
                "age": {
                    "min": 12.0,
                    "max": 84.0,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": null,
                "region": [
                    "USA"
                ],
                "research": {
                    "methods": [
                        "Isolation of GSCs",
                        "Western analysis",
                        "Immunohistochemistry",
                        "Ki-67 indexing",
                        "Mouse survival plot",
                        "GBM tissue microarray",
                        "Kaplan-Meier method"
                    ],
                    "results": [
                        "Molecular classification of patient-derived GSCs using neural lineage markers show association with differential xenograft invasiveness, and also demonstrate significant correlation to survival in both the mouse model and human patients",
                        "Orthotopic implantation into immunodeficient mice demonstrated Ki-67 proliferative index independent xenograft infiltration: class I GSCs (OPC and NPC positive) established focal lesions, class II GSCs (NPC positive) formed minimally invasive lesions, and class III GSCs (APC positive) established highly infiltrative lesions",
                        "The OPC marker, CNP also exhibited high expression in focal xenografts versus low expression in invasive xenografts",
                        "Differential CNP expression correlated with mouse model survival, and CNP immunoassay of a large GBM tissue microarray also showed significant differential patient survival"
                    ],
                    "conclusions": [
                        "GSC classification with developmental neural lineage markers revealed CNP as a novel and potentially useful clinical prognosis marker, and suggests clinical importance for patient-specific GSC analysis"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": null,
                    "prognosis": "Potential",
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Ahmed"
            },
            {
                "_id": "V000082",
                "pmid": "19657395",
                "biomarkerId": "B000082",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": 23.0,
                    "max": 84.0,
                    "med": -1,
                    "avg": 57.8,
                    "sd": 13.3,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "III",
                    "IV"
                ],
                "whoclass": "Pre 2010",
                "region": [
                    "Italy"
                ],
                "research": {
                    "methods": [
                        "PTEN and MMP9 expression was further investigated in an additional panel of 16 anaplastic astrocytoma specimens and, in parallel, in different human normal and astrocytic tumor cell lines. PTEN and MMP9 mRNA levels were also employed to identify subgroups of specimens within the different glioma malignancy grades and to define a gene expression-based diagnostic classification scheme. The Instat v.3 software (GraphPad Software Inc., Mass, USA) was used for the statistical analysis of differences in gene expression between groups by one-way ANOVA and for the analysis of correlations among gene expression profiles, using the Pearson coefficient r. A P-value less than .05 was considered statistically significant. Methods: RT-PCR"
                    ],
                    "results": [
                        "In anaplastic astrocytomas PTEN expression was significantly higher than in glioblastoma multiforme, but no significant correlation was found between PTEN and MMP9 expression. PTEN and MMP9 mRNA levels were also employed to identify subgroups of specimens within the different glioma malignancy grades and to define a gene expression-based diagnostic classification scheme."
                    ],
                    "conclusions": [
                        "In conclusion, this gene expression survey highlighted that the combined measurement of PTEN and MMP9 transcripts might represent a novel reliable tool for the differential diagnosis of high-grade gliomas, and it also suggested a functional link involving these genes in glial tumors."
                    ]
                },
                "application": {
                    "validated": "Potential",
                    "diagnosis": "Potential",
                    "prognosis": "Potential",
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": "PTEN and MMP9 status are of current relevance in research for GBM subtyping.",
                    "implication": null,
                    "treatment": null
                },
                "comments": "Potential",
                "curator": "Erik Samelsson"
            },
            {
                "_id": "V000083",
                "pmid": "26347581",
                "biomarkerId": "B0001D3",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": 25.0,
                    "max": 84.0,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": null,
                "whoclass": "2007",
                "region": [
                    "Italy"
                ],
                "research": {
                    "methods": [
                        "Pyrosequencing for MGMT methylation"
                    ],
                    "results": [
                        "the risk of disease progression was reduced by 3% for each unit increase in percentage of MGMT methylation"
                    ],
                    "conclusions": [
                        "Higher MGMT methylation is associated with lower disease progression risk"
                    ]
                },
                "application": {
                    "validated": null,
                    "diagnosis": "NO",
                    "prognosis": "YES",
                    "predictive": "NO",
                    "therapeutic": "NO"
                },
                "clinical": {
                    "relevance": "molecular assay for the assessment of MGMT status in the management of all patients affected by newly diagnosed GBM",
                    "implication": null,
                    "treatment": null
                },
                "comments": "NO",
                "curator": "RF"
            },
            {
                "_id": "V000084",
                "pmid": "25752997",
                "biomarkerId": "B000084",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": 32.0,
                    "max": 84.0,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": null,
                "whoclass": "2007",
                "region": [
                    "Spain"
                ],
                "research": {
                    "methods": [
                        "Methylation-specific PCR"
                    ],
                    "results": [
                        "chemotherapy susceptibility of tumors is higher when MGMT promoter is methylated and HIN-1 promoter is unmethylated"
                    ],
                    "conclusions": [
                        "HIN-1 could be included in methylation studies before therapy treatment is selected for GBM patients and (ii) new or combined therapies must be implemented depending on the methylation status of both genes, probably through HIN-1 pathway effectors as paclitaxel."
                    ]
                },
                "application": {
                    "validated": null,
                    "diagnosis": "YES",
                    "prognosis": "YES",
                    "predictive": "NO",
                    "therapeutic": "NO"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": "YES",
                "curator": "RF"
            },
            {
                "_id": "V000085",
                "pmid": "26022161",
                "biomarkerId": "B000085",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": 7.0,
                    "max": 85.0,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": "2007",
                "region": [
                    "Germany"
                ],
                "research": {
                    "methods": [
                        "IHC"
                    ],
                    "results": [
                        "the number of 5hmC-positive cells is significantly decreased in GBM compared with normal brain. Quantifying the amount of 5hmC-positive cells in GBM, infiltration zones, and normal brain, infiltration zones show significantly increased numbers of 5hmC-positive cells compared to solid tumor regions, but significantly decreased numbers compared to normal brain"
                    ],
                    "conclusions": [
                        "GBMs show significantly less 5hmC compared to normal brain regions"
                    ]
                },
                "application": {
                    "validated": null,
                    "diagnosis": "NO",
                    "prognosis": "YES",
                    "predictive": "NO",
                    "therapeutic": "NO"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": "NO",
                "curator": "RF"
            },
            {
                "_id": "V000086",
                "pmid": "28295288",
                "biomarkerId": "B000086",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": 13.0,
                    "max": 85.0,
                    "med": 49.38,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": null,
                "whoclass": null,
                "region": [
                    "China"
                ],
                "research": {
                    "methods": [
                        "Western blotting",
                        "Immunohistochemical assessment",
                        "Kaplan-meier method",
                        "log-rank test"
                    ],
                    "results": [
                        "high nuclear FoxO3a expression in human GBM tissues associated with poor prognosis",
                        "results of in vivo GBM models further confirme that FoxO3a knockdown inhibited GBM progression",
                        "pro-oncogenic effects of FoxO3a in GBM mediated by the activation of c-Myc, microtubule-associated protein 1 light chain 3 beta (LC3B) and Beclin1 in a mixed-lineage leukemia 2 (MLL2)-dependent manner"
                    ],
                    "conclusions": [
                        "FoxO3a expression associated with GBM progression",
                        "FoxO3a independently indicates poor prognosis in patients"
                    ]
                },
                "application": {
                    "validated": "Potential",
                    "diagnosis": null,
                    "prognosis": "Potential",
                    "predictive": null,
                    "therapeutic": "Potential"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Vanessa"
            },
            {
                "_id": "V000087",
                "pmid": "23393205",
                "biomarkerId": "B000087",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": 15.0,
                    "max": 85.0,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": null,
                "region": [
                    "Austria"
                ],
                "research": {
                    "methods": [
                        "Quantitative PCR",
                        "Telomeric repeat amplification assay",
                        "RT-PCR",
                        "Methylation specific PCR",
                        "Linear regression",
                        "t-test",
                        "Kaplan-Meier test"
                    ],
                    "results": [
                        "Of 100 GBM tissues, 61 were positive for both hTERT mRNA and TA, with a highly significant correlation between both parameters",
                        "Telomere length determination revealed a significant difference between the hTERT/TA-positive and -negative subgroups, with markedly longer telomeres in the hTERT/TA-negative cohort",
                        "Significantly shorter telomeres were detected in GBM tissues derived from older patients (>60 y at diagnosis)",
                        "No association of telomere parameters with MGMT promoter status was found, all tumors with IDH1 mutation (6/100) were negative for both hTERT expression and TA and harbored significantly longer telomeres",
                        "Patients with tumors lacking hTERT expression/TA showed a significant survival benefit, which, however, was based exclusively on the younger patient subgroup (\u226460 y)"
                    ],
                    "conclusions": [
                        "Telomerase activation is not an independent prognostic parameter in GBM but predicts aggressive tumor behavior solely in a younger patient cohort"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": "NO",
                    "prognosis": "Potential",
                    "predictive": "NO",
                    "therapeutic": "NO"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": "NO",
                "curator": "ANA"
            },
            {
                "_id": "V000088",
                "pmid": "27143410",
                "biomarkerId": "B000088",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": 18.0,
                    "max": 85.0,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV",
                    "I",
                    "II"
                ],
                "whoclass": null,
                "region": [
                    "USA"
                ],
                "research": {
                    "methods": [
                        "Cox proportional hazards model",
                        "Elastic net regularization",
                        "Wald test"
                    ],
                    "results": [
                        "13 proteins signature significantly associated with overall survival in GBM patients",
                        "Implicates Cox-2 and Annexin 1 proteins involved in inflammatory response as important predictors of survival in GBM"
                    ],
                    "conclusions": [
                        "The PORTGLIO model is a simple and effective predictor of overall survival in GBM patients, making it potentially useful in clinical practice"
                    ]
                },
                "application": {
                    "validated": "Yes",
                    "diagnosis": "NO",
                    "prognosis": "YES",
                    "predictive": "NO",
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": "NO",
                "curator": "BP"
            },
            {
                "_id": "V000089",
                "pmid": "26934681",
                "biomarkerId": "B000089",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": 20.0,
                    "max": 85.0,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": "2007",
                "region": [
                    "Germany"
                ],
                "research": {
                    "methods": [
                        "MCIp and CpG island microarray analysis",
                        "Quantitative DNA methylation analysis",
                        "Cox regression",
                        "t-test"
                    ],
                    "results": null,
                    "conclusions": [
                        "Successful identifcation of promoter hypermethylation of LOC283731 as a novel, independent prognostic biomarker in GBM patients associated with a better patient survival"
                    ]
                },
                "application": {
                    "validated": "Yes",
                    "diagnosis": null,
                    "prognosis": "YES",
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "BP"
            },
            {
                "_id": "V00008A",
                "pmid": "29031038",
                "biomarkerId": "B00008A",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": 21.0,
                    "max": 85.0,
                    "med": 57.0,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": "2016",
                "region": [
                    "Czech Republic"
                ],
                "research": {
                    "methods": [
                        "competitive amplification of differentially melting amplicons (CADMA) polymerase chain reaction (PCR)",
                        "Chi-square test",
                        "Fisher tests",
                        "logistic regression analyzsis",
                        "log-rank test"
                    ],
                    "results": [
                        "36 of 145 harbored IDH1 R132H mutation and 1 IDH1 R132C mutation",
                        "no IDH2 R172K mutation detected",
                        "IDH1 mutations positively associated with MGMT methylation, 1p/19q co-loss and negatively associated with epidermal growth factor receptor amplification and 10p loss",
                        "overall survival of IDH-mutant 25 months, but only 9 months in IDH-wild type gliomas",
                        "survival associated with methylated vs. unmethylated MGMT promoter does not significantly differ"
                    ],
                    "conclusions": [
                        "Despite IDH1 mutations being closely associated with MGMT methylation in glioma patients, IDH1 mutations in GBM patients are stronger marker of overall survival than MGMT methylation",
                        "should be the marker of choice, especially when using genotyping by CADMA PCR"
                    ]
                },
                "application": {
                    "validated": "Determined",
                    "diagnosis": null,
                    "prognosis": "YES",
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Vanessa"
            },
            {
                "_id": "V00008B",
                "pmid": "20298476",
                "biomarkerId": "B00008B",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": 11.0,
                    "max": 86.0,
                    "med": 55.0,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": "Pre 2010",
                "region": [
                    "USA"
                ],
                "research": {
                    "methods": [
                        "Immunoexpression for synaptophysin, neurofilament protein, neuronal nuclear antigen, chromogranin and glial fibrillary acidic protein was analysed in 82 GBM including 11 fibrillary, 8 gemistocytic, 40 giant cell and 23 small cell examples. Survival was compared between tumours exhibiting (GBMpos) or lacking (GBMneg) neuronal markers and also between tumours expressing only one vs. two or more neuronal markers."
                    ],
                    "results": [
                        "Forty-five of the 82 tumours (54.8%) including 5 fibrillary, 5 gemistocytic, 30 giant cell and 5 small cell GBMs expressed at least one neuronal marker, synaptophysin being the most frequent (96%). There was no statistically significant difference in survival between GBMpos and GBMneg tumours, all cytologic subtypes combined (P = 0.22). The same was true when cytologic categories were compared. When only GBMpos tumours were analysed, there was a marginally significant difference in outcome between tumours positive for one vs. multiple markers (P = 0.05). This difference was influenced primarily by giant cell GBMs among which the survival time was significantly shorter in the multiple vs. single marker category (median 123 vs. 295 days, P = 0.014). This difference was not observed in the other GBM cell types. Ultrastructurally, rare neurosecretory granules in glial filament-rich cells were identified in one of four tumours studied."
                    ],
                    "conclusions": [
                        "Neuronal marker expression is a frequent feature of GBM. Its prognostic significance is limited to the giant cell GBMs expressing two or more neuronal markers, these being associated with shorter survival."
                    ]
                },
                "application": {
                    "validated": "Potential",
                    "diagnosis": null,
                    "prognosis": "Potential",
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Erik Samelsson"
            },
            {
                "_id": "V00008C",
                "pmid": "22417385",
                "biomarkerId": "B0001C4",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": 33.0,
                    "max": 86.0,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": "2007",
                "region": [
                    "Germany"
                ],
                "research": {
                    "methods": [
                        "Immunohistochemistry",
                        "Real-time PCR",
                        "GeneChip analysis",
                        "Kaplan-Meier method",
                        "Log-rank test",
                        "Cox model"
                    ],
                    "results": [
                        "ALDH1A1 was absent in the stem cell niches at varying stages of CNS development, but strong ALDH1A1 expression was observed in mature astrocytes coexpressing GFAP and S100",
                        "There were 92 out of 93 glioblastomas (99%) that showed ALDH1A1 protein expression in up to 49% of tumor cells",
                        "The majority of these cells co\u2010expressed GFAP, but not established stem cell markers such as Nestin, OLIG2 or SOX2",
                        "Strong expression of ALDH1A1 correlated with a significantly better survival of the patients and proved to be an independent prognostic marker in this series"
                    ],
                    "conclusions": [
                        "Evidence for ALDH1A1 as a marker of astrocytic differentiation during brain development and of better prognosis in patients suffering from primary GBM"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": null,
                    "prognosis": "YES",
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Ahmed"
            },
            {
                "_id": "V00008D",
                "pmid": "22139906",
                "biomarkerId": "B0001E4",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": 70.0,
                    "max": 86.6,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": "2007",
                "region": [
                    "Germany"
                ],
                "research": {
                    "methods": [
                        "Pyrosequencing",
                        "Chi-square test",
                        "Kruskal-Wallis test",
                        "Mann-Whitney-U test",
                        "Cox regression model",
                        "Log-rank test"
                    ],
                    "results": [
                        "MGMT promoter methylation was detected by MSP in 134 patients (57.5%)",
                        "For the whole cohort, PFS was 5.2 versus 4.7 months and OS was 8.4 versus 6.4 months in patients with versus without MGMT promoter methylation",
                        "Patients with MGMT methylated tumors had longer PFS when treated with radiotherapy (RT) plus CT or CT alone compared to patients treated with RT alone",
                        "Patients with MGMT unmethylated tumors appeared to derive no survival benefit from CT, regardless of whether given at diagnosis together with RT or as a salvage treatment",
                        "Patients treated with RT plus CT or CT alone demonstrated longer OS when pyrosequencing revealed >25% MGMT methylated alleles"
                    ],
                    "conclusions": [
                        "MGMT promoter methylation may be a useful biomarker to stratify elderly glioblastoma patients for treatment with versus without alkylating agent CT"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": null,
                    "prognosis": null,
                    "predictive": "YES",
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": "A useful biomarker to stratify elderly glioblastoma patients for treatment with versus without alkylating agent CT",
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": null
            },
            {
                "_id": "V00008E",
                "pmid": "28212808",
                "biomarkerId": "B00008E",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": 20.0,
                    "max": 87.0,
                    "med": 56.5,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": null,
                "whoclass": "2016",
                "region": [
                    "Italy"
                ],
                "research": {
                    "methods": [
                        "Tissue microarray",
                        "immunophenotyping",
                        "FISH analysis"
                    ],
                    "results": [
                        "6% of GBM exhibited high MDM2 amplification (in vivo) with a pattern related to the known double minutes/chromothripsis phenomenon (in situ)",
                        "only cases with low amplification showed genomic heterogeneity"
                    ],
                    "conclusions": [
                        "rate of MDM2 gene amplification can be a useful predictive biomarker to improve patient selection"
                    ]
                },
                "application": {
                    "validated": "Potential",
                    "diagnosis": null,
                    "prognosis": null,
                    "predictive": "Potential",
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": "biomarker can improve patient selection",
                    "treatment": null
                },
                "comments": null,
                "curator": "Vanessa"
            },
            {
                "_id": "V00008F",
                "pmid": "29662659",
                "biomarkerId": "B00008F",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": 35.0,
                    "max": 87.0,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": null,
                "whoclass": "Post 2010",
                "region": [
                    "Czech Republic"
                ],
                "research": {
                    "methods": [
                        "52 patients with a diagnosis of GBM were included into the study. IDH1 R132H mutation was assessed by RT-PCR from FFPE tumor samples obtained during surgery. The expression of markers of hypoxia (HIF2\u03b1), angiogenesis (VEGF), tumor microvascularity (CD31, CD34, vWF, CD105), and proliferation (Ki-67) were assessed immunohistochemically (IHC). IDH1 mutation and IHC markers were correlated with the patient survival."
                    ],
                    "results": [
                        "20 from 52 GBM tumor samples comprised IDH1 R132H mutation (38.5%). The majority of mutated tumors were classified as secondary glioblastomas (89.9%). Patients with IDH1 mutated tumors experienced better progression-free survival (P = 0.037) as well as overall survival (P = 0.035) compared with wild type tumors. The significantly lower expression of VEGF was observed in GBM with IDH1 mutation than in wild type tumors (P = 0.01). No such association was found for microvascular markers. The increased expression of newly-formed microvessels (ratio CD105/CD31) in tumor samples was associated with worse patient's progression-free survival (P = 0.026)."
                    ],
                    "conclusions": [
                        "No increase in HIF/VEGF-mediated angiogenesis was observed in IDH1-mutated GBM compared with IDH1 wild type tumors. The histological assessment of the portion of newly-formed microvessels in tumor tissue can be used for the prediction of GBM patient's prognosis."
                    ]
                },
                "application": {
                    "validated": "Validated",
                    "diagnosis": null,
                    "prognosis": "Potential",
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": "Utilizing established biomarkers as a means of finding subpopulations for patient stratification, potentially helping to define populations for prognosis.",
                    "implication": "Subpopulation definitions for selecting in prognosis.",
                    "treatment": "IDH WT versus mutant status is important in defining patient outcomes. "
                },
                "comments": null,
                "curator": "Erik Samuelsson"
            },
            {
                "_id": "V000090",
                "pmid": "24511544",
                "biomarkerId": "B000090",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": 35.0,
                    "max": 87.0,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": "2007",
                "region": [
                    "Czech Republic"
                ],
                "research": {
                    "methods": [
                        "Mutation detection assays",
                        "Wilcoxon test",
                        "Kaplan Meier curves",
                        "RT-PCR"
                    ],
                    "results": [
                        "The IDH1 R132H mutation was identified in 20 from 44\u2009GBM tumor samples",
                        "Majority of mutated tumors were secondary GBMs (16 in 18)",
                        "Low frequency of IDH1 mutations was observed in primary GBMs (4 in 26)",
                        "Patients with IDH R132H mutation had longer PFS, 136 versus 51 days (P < 0.021, Wilcoxon), and OS, 270 versus 130 days (P < 0.024, Wilcoxon test)"
                    ],
                    "conclusions": [
                        "The prognostic value of IDH1 R132H mutation in GBM patients was verified",
                        "Patients with mutation had significantly longer PFS and OS than patients with wild-type IDH1 and suffered more likely from secondary GBMs"
                    ]
                },
                "application": {
                    "validated": null,
                    "diagnosis": null,
                    "prognosis": "YES",
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": null
            },
            {
                "_id": "V000091",
                "pmid": "16930331",
                "biomarkerId": "B000091",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": 21.0,
                    "max": 88.0,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "III",
                    "IV"
                ],
                "whoclass": "2000",
                "region": [
                    "Japan"
                ],
                "research": {
                    "methods": [
                        "In situ hybridization",
                        "Chi-square test",
                        "Log-rank test"
                    ],
                    "results": [
                        "The expression of AMF mRNA was detected in 27 of 32 GBMs and 11 of 23 AA",
                        "The positivity of AMF mRNA was significantly higher in glioblastomas than in anaplastic astrocytomas but gp78 mRNA was detected in most cases and no statistical significance was observed",
                        "The overall survival of patients with AMF expression was significantly shorter than patients without AMF expression",
                        "In anaplastic astrocytomas, the overall survival of patients with AMF expression was also significantly shorter than in patients without AMF expression"
                    ],
                    "conclusions": [
                        "Demonstrated that expression of AMF and gp78 mRNA was detected in tumor cells of high\u2010grade astrocytomas, and that their function was predicted from their localization in tumor tissues and from previous studies",
                        "Suggested that expression of AMF mRNA is a useful predictor for the prognosis of patients with astrocytoma"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": null,
                    "prognosis": "Potential",
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "BP"
            },
            {
                "_id": "V000092",
                "pmid": "23624749",
                "biomarkerId": "B000092",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": 26.0,
                    "max": 88.0,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": "2007",
                "region": [
                    "Lithuania"
                ],
                "research": {
                    "methods": [
                        "MS-PCR"
                    ],
                    "results": [
                        "DNA methylation analysis showed 47\u201367 % of promoter methylation of studied genes (AREG, HOXA11, NDRG2, NPTX2 and Tes), except hMLH1 (only 2 %) in GBM tissue."
                    ],
                    "conclusions": [
                        "gene methylation is associated with survival and patient age"
                    ]
                },
                "application": {
                    "validated": "no",
                    "diagnosis": "NO",
                    "prognosis": "YES",
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": "NO",
                "curator": "ANA"
            },
            {
                "_id": "V000093",
                "pmid": "27229531",
                "biomarkerId": "B000093",
                "sourceIds": [
                    "Tissue",
                    "Blood"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": 10.0,
                    "max": 89.0,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": null,
                "region": [
                    "USA",
                    "China"
                ],
                "research": {
                    "methods": [
                        "Hypergeometric test",
                        "univariate Cox regression",
                        "Kaplan-Meier survival analysis"
                    ],
                    "results": [
                        "lncRNA MCM3AP-AS was involved in RNA processing and cell cycle-related functions, and was correlated with patient survival",
                        "MCM3AP-AS and MIR17HG acted synergistically to regulate mRNAs in a network module of the competitive LMCN"
                    ],
                    "conclusions": [
                        "Survival analyses demonstrated that the lncRNAs and network module are potential prognostic biomarkers for GBM"
                    ]
                },
                "application": {
                    "validated": "Potential",
                    "diagnosis": "NO",
                    "prognosis": "Potential",
                    "predictive": "NO",
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": "NO",
                "curator": "BP"
            },
            {
                "_id": "V000094",
                "pmid": "22472960",
                "biomarkerId": "B000094",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": 18.0,
                    "max": 89.0,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": "2007",
                "region": [
                    "USA"
                ],
                "research": {
                    "methods": [
                        "Fluorescence in situ hybridization",
                        "MGMT promoter methylation assay",
                        "10q LOH analysis",
                        "Immunohistochemistry",
                        "TCGA data analysis",
                        "Kaplan-Meier method",
                        "Log-rank test",
                        "Cox model"
                    ],
                    "results": [
                        "While there was no difference in survival by EGFR amplification, stratification by amount of EGFR amplification showed that, median survival was 39% longer in the high-amplifier group (EGFR: chromosome 7 ratio > 20) versus non-amplified GBMs, and 43% longer versus GBMs with low-to-moderate EGFRamplification (EGFR:chromosome 7 ratio = 2-20)",
                        "Stratifying by postsurgical treatment regimens, this difference was seen only when temozolomide (TMZ) was used",
                        "Tumors without amplification and high EGFR amplification both responded better to TMZ than those with low-to-moderate amplification, whereas those without adjuvant therapy or adjuvant therapy without TMZ showed no survival differences"
                    ],
                    "conclusions": [
                        "Results suggest that glioblastomas with EGFRamplification are a heterogeneous group of tumors, and that behavior might differ according to degree of amplification, but not in a straightforward dose-response manner"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": null,
                    "prognosis": "Paradoxical (ProgNOstic only when startified as per the degree of amplification)",
                    "predictive": "Predictive only when TMZ is involved in treatment",
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Ahmed"
            },
            {
                "_id": "V000095",
                "pmid": "26933808",
                "biomarkerId": "B000095",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": 21.0,
                    "max": 89.0,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": "2007",
                "region": [
                    "USA"
                ],
                "research": {
                    "methods": [
                        "Immunohistochemistry",
                        "FISH",
                        "Chromogenic in situ hybrodization",
                        "NGS",
                        "Cox model"
                    ],
                    "results": [
                        "Within GBM patients younger than 70 years old, MGMT-Me and positive PR expression were significantly associated with longer survival, and TOPO1 expression was associated with shorter survival",
                        "In patients who were older than 70 years old, PR remained associated with a longer survival but MGMT-Me and TOPO1 were not",
                        "Instead, PGP expression was associated with longer survival and TS expression with shorter survival"
                    ],
                    "conclusions": [
                        "Results provide a biomarker database for therapy consideration and clinical trial design"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": null,
                    "prognosis": "YES",
                    "predictive": null,
                    "therapeutic": "Potential"
                },
                "clinical": {
                    "relevance": "Prospective trials are underway to confirm the clinical merit of this approach",
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "BP"
            },
            {
                "_id": "V000096",
                "pmid": "28379477",
                "biomarkerId": "B000096",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": 4.0,
                    "max": 90.0,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": "2007",
                "region": [
                    "Finland"
                ],
                "research": {
                    "methods": [
                        "Immunohistochemical assessment",
                        "targeted sequencing"
                    ],
                    "results": [
                        "Moderate to strong FGFR3 staining detected in gliomas of all grades",
                        "more common in females",
                        "associated with poor survival in diffuse astrocytomas",
                        "FGFR3-TACC3 fusions and FGFR3-CAMK2A fusion in 10 of 15 strongly stained cases",
                        "no fusions found in 36 negatively to moderately stained cases",
                        "fusion-positive cases predominantly female and negative for IDH and EGFR/PDGFRA/MET alterations",
                        "these and moderately stained cases show lower MIB-1 proliferation index than negatively to weakly stained cases",
                        "stronger FGFR3 expression commonly observed in malignant tissue regions of lower cellularity in fusion-negative cases",
                        "subregional negative FGFR3 staining observed in a few fusion-positive cases"
                    ],
                    "conclusions": [
                        "srong FGFR3 protein expression is indicative of FGFR3 fusions and may serve as a clinically applicable predictive marker for treatment regimens based on FGFR inhibitors"
                    ]
                },
                "application": {
                    "validated": "Potential",
                    "diagnosis": null,
                    "prognosis": null,
                    "predictive": "Potential",
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Vanessa"
            },
            {
                "_id": "V000097",
                "pmid": "23328811",
                "biomarkerId": "B000097",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": 22.3,
                    "max": 90.0,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": null,
                "region": [
                    "USA"
                ],
                "research": {
                    "methods": [
                        "Immunohistochemistry",
                        "Methylation-specific PCR",
                        "Bisulfite sequencing",
                        "IDH1 genotype sequencing",
                        "Kaplan Meier method",
                        "Cox model",
                        "Log-rank test"
                    ],
                    "results": [
                        "With use of the median percentage of cells staining by IHC as the threshold, patients with <30% staining had progression-free survival (PFS) of 10.9 months and overall survival (OS) of 20.5 months, compared with PFS of 7.8 months and OS of 16.7 months among patients with \u226530% staining",
                        "Inter- and intrareader correlation of IHC staining was high",
                        "Promoter methylation status by MSP was correlated with IHC staining",
                        "Low IHC staining was frequently observed in the absence of promoter methylation",
                        "Increased methylation density correlated with both decreased IHC staining and increased survival, providing a practical semiquantitative alternative to MSP",
                        "Patients with tandem promoter methylation and low expression demonstrated improved OS and PFS, compared with the other combinations"
                    ],
                    "conclusions": [
                        "Optimal assessment of MGMT status as a prognostic biomarker for patients with newly diagnosed GBM treated with chemoradiation requires determination of both promoter methylation and IHC protein expression"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": null,
                    "prognosis": "YES",
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "ANA"
            },
            {
                "_id": "V000098",
                "pmid": "26887055",
                "biomarkerId": "B000098",
                "sourceIds": [
                    "Tissue",
                    "Cell line"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": 50.0,
                    "max": 90.0,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": "2007",
                "region": [
                    "Germany"
                ],
                "research": {
                    "methods": [
                        "qPCR",
                        "Immunofluorescence microscopy",
                        "Western blot analysis",
                        "siRNA mediated silencing",
                        "One way ANOVA",
                        "Dunnett's multiple comparision test"
                    ],
                    "results": [
                        "mRNA expression levels of S1P1, S1P2 and S1P3 were significantly up-regulated compared to control brain from 0.88 to 4.23 (S1P1), from 0.19 to 24.78 (S1P2) and from 0.79 to 4.51 (S1P3) fold",
                        "for S1P5 mRNA a slight down-regulation from 0.77 to 0.49 fold was observed in GBM specimens, and S1P4 expression was below the detection limit",
                        "mRNA expression of the S1P generating enzyme SphK1 was significantly up-regulated in GBM compared to control brain from 1.31 to 3.18 fold",
                        "Expression of SphK2 as well as of the S1P degrading enzymes SGPP1/2 and SGPL1 in GBM was not significantly altered in comparison to that in non-malignant brain",
                        "S1P1 and S1P2 showed a positive and negative association respectively with the patients' survival",
                        "High expression of S1P dephosphorylating SGPP1 was associated with a poor survival compared to a low SGPP1 mRNA expression"
                    ],
                    "conclusions": [
                        "Data argue for a participation of S1P signaling in proliferation and migration of GBM cells",
                        "Individual components of the S1P pathway represent prognostic factors for survival of patients with GBM",
                        "Results implicate a very complex interplay between S1P receptors, S1P signaling and other tumor-promoting signaling cascades in GBM making it difficult to directly link in vivo to in vitro data"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": "NO",
                    "prognosis": "Potential",
                    "predictive": "NO",
                    "therapeutic": "Potential"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": "NO",
                "curator": "BP"
            },
            {
                "_id": "V000099",
                "pmid": "18698034",
                "biomarkerId": "B000099",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": 4.0,
                    "max": 91.0,
                    "med": 44.0,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": "Pre 2010",
                "region": [
                    "USA"
                ],
                "research": {
                    "methods": [
                        "We measured the incidence of Tregs in 135 glial tumors (including all pathologic types) in a glioma microarray using immunohistochemical analysis. Results were categorized according to the total number of Tregs within the tumors. Correlation of the presence of Tregs with prognosis was evaluated using univariate and multivariate analyses."
                    ],
                    "results": [
                        "Tregs were not present in normal brain tissue and were very rarely found in low-grade gliomas and oligodendrogliomas. We observed significant differences in the prevalence of Tregs between astrocytic and oligodendroglial tumors, between tumors of different grades, and between different pathologic types of tumors. We identified Tregs most frequently in glioblastoma multiforme (GBM) but very rarely in low-grade astrocytomas. The presence of Tregs within GBMs did not alter the median survival in patients from whom the tumors were obtained."
                    ],
                    "conclusions": [
                        "Treg infiltration differed significantly in the tumors according to lineage, pathology, and grade. Tregs seemed to have the highest predilection for tumors of the astrocytic lineage and specifically in the high-grade gliomas, such as GBM. In both univariate and multivariate analysis, the presence of Tregs in GBMs seemed to be prognostically neutral."
                    ]
                },
                "application": {
                    "validated": "Potential",
                    "diagnosis": null,
                    "prognosis": "Potential",
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Erik Samelsson"
            },
            {
                "_id": "V00009A",
                "pmid": "23399898",
                "biomarkerId": "B00009A",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": 10.0,
                    "max": 91.0,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": null,
                "region": [
                    "Germany"
                ],
                "research": {
                    "methods": [
                        "Tissue microarray",
                        "Immunohistochemistry",
                        "Methylation-specific PCR",
                        "Wilcoxon test",
                        "Kruskal-Wallis test",
                        "Logistic regression",
                        "Kaplan-Meier method",
                        "Log-rank test"
                    ],
                    "results": [
                        "Expression of integrins generally increased with grade of malignancy",
                        "Integrins \u03b1v\u03b23 and \u03b1v\u03b25 were expressed in many glioma vessels",
                        "The intensity of vascular expression of \u03b1v\u03b23 increased with grade of malignancy, whereas \u03b1v\u03b28 was absent",
                        "Analysis of gene expression in an independent cohort showed a similar increase in integrin expression with tumor grade, particularly of ITGB3 and ITGB8",
                        "ITGB6 was not expressed, consistent with the IHC data",
                        "Parenchymal \u03b1v\u03b23 expression and ITGB3 gene overexpression in GBMs were associated with a poor prognosis"
                    ],
                    "conclusions": [
                        "Used newly developed rabbit monoclonal antibodies for fast automated histopathologic determination of \u03b1v integrin complexes in long-term archival glioma specimens",
                        "Overexpression of \u03b1v\u03b23 integrin overtly signifies a poor prognosis in glioma and might help in stratifying patients for anti-integrin treatment by IHC, whereas other integrins of the \u03b1v series do not",
                        "Detailed semi-automated quantification of parenchymal \u03b1v expression in paraffin blocks will allow us to easily correlate integrin expression data from individual patients with their therapeutic response to integrin inhibitor treatment"
                    ]
                },
                "application": {
                    "validated": "Yes",
                    "diagnosis": "NO",
                    "prognosis": "Potential",
                    "predictive": "NO",
                    "therapeutic": "NO"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": "NO",
                "curator": "ANA"
            },
            {
                "_id": "V00009B",
                "pmid": "26163539",
                "biomarkerId": "B00009B",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": 17.0,
                    "max": 91.0,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": "2007",
                "region": [
                    "Finland"
                ],
                "research": {
                    "methods": [
                        "IHC"
                    ],
                    "results": [
                        "TWIST was more highly expressed in glioblastoma than lower grade gliomas"
                    ],
                    "conclusions": [
                        "Twist expression was associated with both tumour grade and\u00a0IDH1\u00a0mutation"
                    ]
                },
                "application": {
                    "validated": null,
                    "diagnosis": "NO",
                    "prognosis": "YES",
                    "predictive": "NO",
                    "therapeutic": "NO"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": "NO",
                "curator": "RF"
            },
            {
                "_id": "V00009C",
                "pmid": 0,
                "biomarkerId": "B00009C",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": 18.0,
                    "max": 999.0,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": "Post 2010",
                "region": [
                    "France"
                ],
                "research": {
                    "methods": [
                        "A six-CpG panel was identified by incorporating genome-wide DNA methylation data and clinical information of three distinct discovery sets and was combined using a risk-score model. Different validation sets of GBMs and lower-grade gliomas and different statistical methods were implemented for prognostic evaluation. An integrative analysis of multidimensional TCGA data was performed to molecularly characterize different risk tumors."
                    ],
                    "results": [
                        "The six-CpG risk-score signature robustly predicted overall survival (OS) in all discovery and validation cohorts and in a treatment-independent manner. It also predicted progression-free survival (PFS) in available patients. The multimarker epigenetic signature was demonstrated as an independent prognosticator and had better performance than known molecular indicators such as glioma-CpG island methylator phenotype (G-CIMP) and proneural subtype. The defined risk subgroups were molecularly distinct",
                        "high-risk tumors were biologically more aggressive with concordant activation of proangiogenic signaling at multimolecular levels. Accordingly, we observed better OS benefits of bevacizumab-contained therapy to high-risk patients in independent sets, supporting its implication in guiding usage of antiangiogenic therapy. Finally, the six-CpG signature refined the risk classification based on G-CIMP and MGMT methylation status."
                    ],
                    "conclusions": [
                        "The novel six-CpG signature is a robust and independent prognostic indicator for GBMs and is of promising value to improve personalized management."
                    ]
                },
                "application": {
                    "validated": "Potential",
                    "diagnosis": null,
                    "prognosis": "Potential",
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": "There have been fewer multi-maker epigenetic biomarkers for GBM prognostication. ",
                    "implication": null,
                    "treatment": "The epigenetic signature also had potential to improve the current risk classification. The six-CpGs signature showed no discriminating value in the small subgroup of GBMs with G-CIMP (about 10%), characterized by mutations in IDH and favorable OS [25], as all G-CIMP+ tumors were low-risk. However, it was useful for identifying patients with different prognoses among the majority of GBMs without GCIMP. The six-CpGs signature also showed great discriminating value in stratified RT/TMZ cohorts with each MGMT methylation status."
                },
                "comments": null,
                "curator": "Erik Samuelsson"
            },
            {
                "_id": "V00009D",
                "pmid": "27626492",
                "biomarkerId": "B00013E",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": 18.0,
                    "max": 999.0,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "III",
                    "IV"
                ],
                "whoclass": null,
                "region": [
                    "Sweden"
                ],
                "research": {
                    "methods": [
                        "Tissue array",
                        "RT-qPCR"
                    ],
                    "results": [
                        "no correlation between PROX1 protein and survival for patients with primary GBM",
                        "high expression of PROX1 protein predicted shorter survival in the group of patients with IDH-mutant AA and secondary GBM"
                    ],
                    "conclusions": [
                        "PROX1 is a new prognostic biomarker for 1p19q non-codeleted high-grade astrocytomas that have progressed from pre-existing low grade tumors and harbor IDH mutations"
                    ]
                },
                "application": {
                    "validated": "Concrete",
                    "diagnosis": null,
                    "prognosis": "YES",
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Vanessa"
            },
            {
                "_id": "V00009E",
                "pmid": "27450656",
                "biomarkerId": "B00009E",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": 18.0,
                    "max": 999.0,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": null,
                "whoclass": "2007",
                "region": null,
                "research": {
                    "methods": [
                        "Immunohistochemical assessment of membrane",
                        "cytoplasmic nestin staining"
                    ],
                    "results": [
                        "CD44 and nestin signals correlate",
                        "different impacts on survival",
                        "enhanced CD44 expression associatd with poor survival (not statistically relevant!)"
                    ],
                    "conclusions": [
                        "nestin signal valid prognostic factor",
                        "CD44 in GB could be predicitive marker"
                    ]
                },
                "application": {
                    "validated": "Potential",
                    "diagnosis": null,
                    "prognosis": "YES",
                    "predictive": "Potential",
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Vanessa"
            },
            {
                "_id": "V00009F",
                "pmid": "23015095",
                "biomarkerId": "B00009F",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": 18.0,
                    "max": 999.0,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "III",
                    "IV"
                ],
                "whoclass": "2007",
                "region": [
                    "Germany"
                ],
                "research": {
                    "methods": [
                        "Direct sequencing",
                        "Methylation specific PCR",
                        "Kaplan-Meier method"
                    ],
                    "results": [
                        "The median survival time after malignant progression of all patients with sHGG and with an IDH mutation was 4 years, which is significantly longer than in patients with wild-type IDH (1.2 years)",
                        "Patients' survival was not significantly influenced by the tumors' MGMT promoter status, both in Group 1- 9.7 years vs. 6.1 years, methylated vs. unmethylated promoter as well as in Group 2-1.5 years vs. 1.6 years, methylated versus unmethylated promoter",
                        "IDH mutation status was not associated with increased PFS or median survival time in sGBM patients",
                        "Patients with secondary anaplastic glioma and IDH mutation had a significantly improved outcome",
                        "IDH mutations are a more powerful prognostic marker concerning both PFS and MS than the MGMT promoter status in secondary anaplastic gliomas"
                    ],
                    "conclusions": [
                        "IDH mutation status was not associated with increased PFS or median survival time in sGBM patients",
                        "IDH mutations are a more powerful prognostic marker concerning both PFS and MS than the MGMT promoter status in secondary anaplastic gliomas patients"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": null,
                    "prognosis": "No (IDH and MGMT for sGBM);Yes(IDH for secondary anaplastic gliomas)",
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Ahmed"
            },
            {
                "_id": "V0000A0",
                "pmid": "22772608",
                "biomarkerId": "B0000A0",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": 18.0,
                    "max": 999.0,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": "2007",
                "region": [
                    "Germany"
                ],
                "research": {
                    "methods": [
                        "Immunohistochemistry",
                        "Cox model"
                    ],
                    "results": [
                        "Karyopherin a2 expression correlated significantly with histological grade, with proliferative activity as assessed by the MIB1 index, with IDH1 mutation status, and with Nijmegen breakage syndrome 1 protein expression",
                        "Recurrent tumors expressed significantly higher levels of karyopherin a2 than primary growths",
                        "Identified low karyopherin a2 expression (defined as less than 5 %) as an independent prognostic predictor of overall and progression-free surviva",
                        "Survival of GBM patients >5 years was seen only in those with KPNA2 expression levels \u22641 %"
                    ],
                    "conclusions": [
                        "KPNA2 expression may have potential as a novel diagnostic and prognostic biomarker for astrocytic gliomas"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": "Potential",
                    "prognosis": "Potential",
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": "Potential",
                "curator": "Ahmed"
            },
            {
                "_id": "V0000A1",
                "pmid": "20219118",
                "biomarkerId": "B0000A1",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": 18.0,
                    "max": 999.0,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": "Pre 2010",
                "region": [
                    "France"
                ],
                "research": {
                    "methods": [
                        "We set up a specific and sensitive enzyme linked immunosorbent assay (ELISA) test for PSA-NCAM quantification, which correlated well with PSA-NCAM semi quantitative analysis by immunohistochemistry, and thus provides an accurate quantitative measurement of PSA-NCAM content for the 56 GBM biopsies analyzed. For statistics, the Spearman correlation coefficient was used to evaluate the consistency between the immunohistochemistry and ELISA data. Patients' survival was estimated by using the Kaplan-Meier method, and curves were compared using the log-rank test. On multivariate analysis, the effect of potential risk factors on the DFS and OS were evaluated using the cox regression proportional hazard models. The threshold for statistical significance was p = 0.05."
                    ],
                    "results": [
                        "We showed that PSA-NCAM was expressed by approximately two thirds of the GBM at variable levels. On univariate analysis, PSA-NCAM content was an adverse prognosis factor for both OS (p = 0.04) and DFS (p = 0.0017). On multivariate analysis, PSA-NCAM expression was an independent negative predictor of OS (p = 0.046) and DFS (p = 0.007). Furthermore, in glioma cell lines, PSA-NCAM level expression was correlated to the one of olig2, a transcription factor required for gliomagenesis."
                    ],
                    "conclusions": [
                        "PSA-NCAM represents a valuable biomarker for the prognosis of GBM patie"
                    ]
                },
                "application": {
                    "validated": "Potential",
                    "diagnosis": null,
                    "prognosis": null,
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Erik Samelsson"
            },
            {
                "_id": "V0000A2",
                "pmid": "16568472",
                "biomarkerId": "B0000A2",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": 18.0,
                    "max": 999.0,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": "2000",
                "region": [
                    "France"
                ],
                "research": {
                    "methods": [
                        "Real time PCR",
                        "Cox model"
                    ],
                    "results": [
                        "MDM2\u00a0amplification correlated with poor outcome on both univariate and multivariate analysis",
                        "Nonrandom associations were found between EGFR amplification and LOH10q, LOH9p, and INK4A/ARF deletion, LOH1p and LOH19q, and MDM2 and CDK4 amplification, whereas mutual exclusions were found between p53 expression and EGFR amplification, LOH 9p/INK4A/ARF homozygous deletion, and MDM2 and CDK4 amplification"
                    ],
                    "conclusions": [
                        "Despite their limited prognostic impact, the genetic markers investigated here outline distinct molecular pathways involved in glioblastoma tumorigenesis and warrant broader molecular screening"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": null,
                    "prognosis": "YES",
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "BP"
            },
            {
                "_id": "V0000A3",
                "pmid": "16103458",
                "biomarkerId": "B0000A3",
                "sourceIds": [
                    "Blood"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": 20.0,
                    "max": 999.0,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": "2000",
                "region": [
                    "USA"
                ],
                "research": {
                    "methods": [
                        "Whole genome amplification",
                        "Molecular genotyping",
                        "PCR",
                        "Cox Model",
                        "Kaplan-Meier curves"
                    ],
                    "results": [
                        "B*13 and the B*07-Cw*07 haplotype were positively associated with glioblastoma multiforme whereas Cw*01 was the only variant showing a negative association",
                        "Among glioblastoma multiforme patients, progression to death after diagnosis was slower in those with A*32 and faster in those with B*55"
                    ],
                    "conclusions": [
                        "Occurrence and the prognosis of glioblastoma multiforme could be associated with specific but different HLA genotypes",
                        "B*07 and the B*07-Cw*07 haplotype are much more common in Caucasians than other ethnic groups in the U.S., which may partially explain the higher incidence of glioblastoma multiforme in Caucasians"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": null,
                    "prognosis": "Potential",
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "BP"
            },
            {
                "_id": "V0000A4",
                "pmid": "23595628",
                "biomarkerId": "B0000A4",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": 65.0,
                    "max": 999.0,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "117 grade IV",
                    "9 low grade gliomas (grade no specified)"
                ],
                "whoclass": null,
                "region": [
                    "Germany"
                ],
                "research": {
                    "methods": [
                        "study population",
                        "sequencing",
                        "MassARRAY analysis"
                    ],
                    "results": [
                        "IDH1 mutations were detected in only 3/126 patients, precluding determination of an association between IDH mutation and outcome",
                        "These 3 patients also displayed the G-CIMP phenotype",
                        "APNG promoter revealed generally low methylation levels",
                        "PRDX1 promoter methylation show differential methylation or association with outcome in this cohort."
                    ],
                    "conclusions": [
                        "IDH mutation, G-CIMP, or PRDX1 methylation are virtually absent in malignant astrocytic tumors of the elderly, which may partially account for the worsened prognosis of these patients"
                    ]
                },
                "application": {
                    "validated": "yes",
                    "diagnosis": "Potential",
                    "prognosis": "YES",
                    "predictive": "Potential",
                    "therapeutic": "Potential"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": "potential for personalizing cancer management"
                },
                "comments": "Potential",
                "curator": "ANA"
            },
            {
                "_id": "V0000A5",
                "pmid": "19884580",
                "biomarkerId": "B0001D3",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": 70.0,
                    "max": 999.0,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": "Pre 2010",
                "region": [
                    "USA"
                ],
                "research": {
                    "methods": [
                        "After receiving approval from our institutional review board, we reviewed MGMT methylation status and clinical characteristics of 64 patients \u226570 with newly diagnosed GBM who underwent resection at our institution from 1998 to 2009. Patients were included if they had enough tissue for MGMT analysis, so this excluded patients who only had a biopsy (consistent with the prior study in younger patients). MGMT analysis was performed by extracting tumor genomic DNA from fixed, paraffin-embedded sections for bisulfite conversion (EZ DNA Methylation-Gold Kit, Zymo Research, Orange, CA). MGMT methylation-specific PCR was performed using PCR primer sets specific for methylated and unmethylated MGMT promoter sequences.6 Kaplan Meier curves and the log-rank test were used to compare median progression free (mPFS) and median overall survival (mOS) in patients who had methylated (ME) MGMT vs unmethylated (UN) MGMT."
                    ],
                    "results": [
                        "Of the 64 patients identified, 37 (57.8%) had ME MGMT and 27 (42.2%) did not (table). These results were slightly higher than the 44.7% of patients who had ME MGMT and the 55.3% who had UN MGMT in the Hegi et al.1 study but similar to a small study in very elderly patients (\u226580) where 13/22 patients (59%) had ME MGMT.2 Potential explanations for this small discrepancy include age-related increase in genomic methylation that includes the MGMT promoter or the reduced ability to retrieve usable DNA from archived paraffin-embedded blocks. Initial treatments for patients in our cohort included chemoradiation (35), radiation alone (16), or chemotherapy alone (3). In ME patients, 24/37 patients received an alkylating agent (temozolomide in 23, BCNU in 1) either as first-line therapy (21) or at recurrence (3). Sixteen of the 27 UN patients received an alkylating agent (all temozolomide): 15 as first-line therapy and 1 at recurrence. A total of 10 patients had no or unknown therapy (6 ME, 4 UN). In patients who received an alkylating agent, mOS in ME patients was 489 days vs 263 days in UN patients (p = 0.0021) and mPFS was 405 days vs 246 days (p = 0.2742) (figure e-1 on the Neurology\u00ae Web site at www.neurology.org). In an analysis including all 64 patients, mPFS in ME patients was 328 days vs 173 days in UN patients (p = 0.0241) and mOS was 345 days in ME patients and 223 days in UN patients (p = 0.0178). A univariate Cox proportional hazards model including all 64 patients showed that MGMT methylation was associated with reduced hazard for progression (hazard ratio [HR] 0.427, 95% confidence interval [CI] 0.199, 0.914, p = 0.0283) and death (HR 0.475, 95% CI 0.254, 0.890, p = 0.0283). In a multivariate Cox model including age, extent of resection, Karnofsky performance score, and alkylator use, MGMT methylation was significantly associated with a reduced hazard for progression (HR 0.374, 95% CI 0.138, 1.0, p = 0.0521) and death (HR 0.243, 95% CI 0.097, 0.608, p = 0.0025). These results suggest that MGMT methylation is a positive prognostic biomarker in the elderly GBM patient population independent of treatment received."
                    ],
                    "conclusions": [
                        "Since MGMT methylation was previously thought to be a predictive marker associated with improved response to temozolomide, further work will need to be done to clarify if MGMT methylation is also a predictive marker in elderly patients. We were unable to address this question specifically in our study because of the small number of patients not treated with an alkylating agent.  Tumor tissue markers such as MGMT that may influence prognosis or clinical trial design are just as valid in the elderly population as in younger patients. Although our study was retrospective, it is the largest study of MGMT methylation status in this population. MGMT appears to be a useful prognostic marker in elderly GBM patients and its role in guiding treatment choices as a potential predictive biomarker should be explored in prospective studies."
                    ]
                },
                "application": {
                    "validated": "Yes",
                    "diagnosis": "NO",
                    "prognosis": "YES",
                    "predictive": "YES",
                    "therapeutic": "YES"
                },
                "clinical": {
                    "relevance": "O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation has been firmly established as a biomarker in patients diagnosed with gliomas, for both clinical trials and routine clinical management.",
                    "implication": "Use in companion diagnostics and predicting patient outcome.",
                    "treatment": "Methylation status of the MGMT gene is crucial to promoting DNA repair. If the MGMT gene is methylated, cancer patients tend to respond better to alkylating drug therapy."
                },
                "comments": "NO",
                "curator": "Erik Samelsson"
            },
            {
                "_id": "V0000A6",
                "pmid": "20150644",
                "biomarkerId": "B0000A6",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": "Pre 2010",
                "region": [
                    "China"
                ],
                "research": {
                    "methods": [
                        "Microarray analyses of clinical specimens from glioblastoma patients were used to identify potential tumor markers. Expression of candidate genes was analyzed by real-time reverse transcription-polymerase chain reaction and by immunoblotting and immunohistochemistry."
                    ],
                    "results": [
                        "Five potential markers (CD44 antigen (CD44), growth arrest and DNA-damage-inducible, alpha (GADD45A), fibronectin 1 (FN1), CD63 antigen (CD63) and secreted phosphoprotein 1 (SPP1)) showed expression patterns that correlated significantly with malignant glioma. In particular, expression of the CD44 antigen was elevated in more severe tumor types, and higher in tumor cores than in peripheral regions. However, lower levels of CD44 expression surprisingly correlated with lower survival."
                    ],
                    "conclusions": [
                        "The CD44 antigen is a promising candidate for further development as a prognostic and therapeutic tool."
                    ]
                },
                "application": {
                    "validated": "Potential",
                    "diagnosis": null,
                    "prognosis": "Potential",
                    "predictive": null,
                    "therapeutic": "Potential"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Erik Samelsson"
            },
            {
                "_id": "V0000A7",
                "pmid": "25977169",
                "biomarkerId": "B0000A7",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": null,
                "whoclass": "2007",
                "region": [
                    "UK"
                ],
                "research": {
                    "methods": [
                        "microarray gene profiling"
                    ],
                    "results": [
                        "Low FOXA2 mRNA, low FOXN2 mRNA, low FOXN3 mRNA and high FOXG1 mRNA were associated with poor survival"
                    ],
                    "conclusions": [
                        "Low expression of\u00a0FOXA2\u00a0mRNA,\u00a0FOXN2\u00a0mRNA and\u00a0FOXN3\u00a0mRNA were associated with poor survival",
                        "conversely, high expression of\u00a0FOXG1\u00a0mRNA was associated with poor survival."
                    ]
                },
                "application": {
                    "validated": null,
                    "diagnosis": "NO",
                    "prognosis": "YES",
                    "predictive": "NO",
                    "therapeutic": "NO"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": "NO",
                "curator": "RF"
            },
            {
                "_id": "V0000A8",
                "pmid": "28784160",
                "biomarkerId": "B0000A8",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "I",
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": null,
                "region": [
                    "China"
                ],
                "research": {
                    "methods": [
                        "RT-PCR",
                        "Western blotting",
                        "immunostaining"
                    ],
                    "results": [
                        "MYBL2 and FoxM1 expression significantly associated with clinical stages and overall survival of glioma patients",
                        "in cohorts of TCGA, patients with high MYBL2 but without radio-chemotherapy had the highest hazard ratio",
                        "MYBL2 closely related to the FoxM1 expression in 79 glioma tissues and low and high ghrade glioma cohorts of TCGA"
                    ],
                    "conclusions": [
                        "MYBL2 is a key downstream factor of Akt/FoxM1 signaling to promote progression of human glioma",
                        "could be a new candidate gene for molecular targeting therapy and biomarker for radiotherapy of glioma"
                    ]
                },
                "application": {
                    "validated": "Potential",
                    "diagnosis": null,
                    "prognosis": null,
                    "predictive": null,
                    "therapeutic": "Potential"
                },
                "clinical": {
                    "relevance": null,
                    "implication": "TRIAL REGISTRATION: CTXY-1300041-3-2. ChiCTR-COC-15006186;registered date: 13 September 2013",
                    "treatment": null
                },
                "comments": null,
                "curator": "Vanessa"
            },
            {
                "_id": "V0000A9",
                "pmid": "26451167",
                "biomarkerId": "B0000A9",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": "2007",
                "region": [
                    "China"
                ],
                "research": {
                    "methods": [
                        "DNA methylation assays",
                        "Methylation specific PCR",
                        "Pyrosequencing",
                        "Telomere length mesurement",
                        "Multivariate linear regression",
                        "Mann-Whitney U test"
                    ],
                    "results": [
                        "Significant increase in subtelomeric methylation level was observed for all the chromosomes in the glioma patients"
                    ],
                    "conclusions": [
                        "Tumorogenesis is associated with increased DNA methylation"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": "Potential",
                    "prognosis": "NO",
                    "predictive": "YES",
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": "Potential",
                "curator": "RF"
            },
            {
                "_id": "V0000AA",
                "pmid": "7954264",
                "biomarkerId": "B0000AA",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": null,
                "whoclass": null,
                "region": [
                    "USA"
                ],
                "research": {
                    "methods": [
                        "Immunochemistry"
                    ],
                    "results": [
                        "Histologic grade correlated with a progressive loss of 1b gangliosides. GQ1b was higher in LGs than in AA. Both GT1b and GD1b were higher in AA than GBM"
                    ],
                    "conclusions": [
                        "Patterns of gangliosides could be of considerable value in refining the classification and diagnosis of brain tumors"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": null,
                    "prognosis": null,
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Cristian"
            },
            {
                "_id": "V0000AB",
                "pmid": "11147905",
                "biomarkerId": "B0000AB",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "I",
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": "Pre 2007",
                "region": [
                    "France"
                ],
                "research": {
                    "methods": [
                        "Immunochemistry",
                        "PCR"
                    ],
                    "results": [
                        "GBMs displayed a significantly higher level of IL-6 expression than other types of glioma"
                    ],
                    "conclusions": [
                        "IL-6 gene expression is related to glioma aggressiveness"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": null,
                    "prognosis": null,
                    "predictive": null,
                    "therapeutic": "Potential"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Cristian"
            },
            {
                "_id": "V0000AC",
                "pmid": "27409829",
                "biomarkerId": "B0000AC",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": null,
                "whoclass": null,
                "region": [
                    "Germany"
                ],
                "research": {
                    "methods": [
                        "Immunohistochemical assessment of FZD7 and IDH1 in tissue microarray",
                        "methylation-specific polymerase chain reaction",
                        "Kaplan-Meier estimate",
                        "log-rank test",
                        "Cox proportional hazard regression"
                    ],
                    "results": [
                        "High levels of FZD7 (FZD7high) associated with shorter survival in GBM patients",
                        "FZD7high significant predictor of poor survival only in male patients",
                        "IDH1 mutation significantly associated with longer survival in male but not female patients",
                        "methylated MGMT promoter significantly associated with longer survival only in female patients",
                        "combination of FZD7 with MGMT enhanced the prognostic accuracy and abrogated the sex differences observed upon single marker analysis",
                        "combination of FZD7 with IDH1 a significant predictor of survival in male GBM patients only"
                    ],
                    "conclusions": [
                        "Identification of novel individual and combination markers with prognostic and psosibly therapeutic relevance in GBM"
                    ]
                },
                "application": {
                    "validated": "Potential",
                    "diagnosis": null,
                    "prognosis": "YES",
                    "predictive": null,
                    "therapeutic": "Potential"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Vanessa"
            },
            {
                "_id": "V0000AD",
                "pmid": "18371184",
                "biomarkerId": "B000155",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "I",
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": "2007",
                "region": [
                    "Germany"
                ],
                "research": {
                    "methods": [
                        "Immunohistochemistry",
                        "Weighted Kappa statistic"
                    ],
                    "results": [
                        "WT1 expression in normal brain is restricted to endothelial cells",
                        "In astrocytomas, WT1\u2010positive tumor cells were found in pilocytic astrocytomas (66.7% of cases), diffuse astrocytomas (52.7%) WHO grade II (52.7%), anaplastic astrocytomas (83.4%) and glioblastomas (98.1%)"
                    ],
                    "conclusions": [
                        "WT1 immunohistochemistry is a valid and promising diagnostic tool to distinguish neoplastic astrocytes from normal or reactive astrocytes in routinely paraffin\u2010embedded tissue"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": "Potential",
                    "prognosis": "NO",
                    "predictive": "NO",
                    "therapeutic": "NO"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": "Potential",
                "curator": "BP"
            },
            {
                "_id": "V0000AE",
                "pmid": "28787434",
                "biomarkerId": "B0000AE",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "I",
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": "2016",
                "region": [
                    "China"
                ],
                "research": {
                    "methods": [
                        "in situ hybridization",
                        "Immunohsitochemical assessment",
                        "Kaplan-Meier method"
                    ],
                    "results": [
                        "miR-29a/b/c expressions inversely correlated with glioma grades, but positively correlated with patients' survival",
                        "two distinct subgroups of grade I-IV glioma patients with different prognoses identified according to miR-29a/b/c expressions",
                        "CDC42 expression positively correlated with glioma grades, but inversely correlated with miR-29a/b/c expressions and patients' survival"
                    ],
                    "conclusions": null
                },
                "application": {
                    "validated": "Concrete",
                    "diagnosis": null,
                    "prognosis": "YES",
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": "CDC42 might be potential therapeutic candidate for malignant gliomas"
                },
                "comments": null,
                "curator": "Vanessa"
            },
            {
                "_id": "V0000AF",
                "pmid": "28662073",
                "biomarkerId": "B0000AF",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "I",
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": "2007",
                "region": [
                    "Denmark"
                ],
                "research": {
                    "methods": [
                        "quantitative Immunohistochemical assessment",
                        "IHC/gIHC double staining",
                        "quantitative double-immunofluorescnece (IF) assay",
                        "mRNA expression analysis of TCGA data"
                    ],
                    "results": [
                        "high levels of APNG correlate to better overll survival (OS)",
                        "patients with methylated MGMT promoter and high APNG expression show better OS than patients with methylated MGMT promoter and low APNG expression",
                        "results supported by TCGA database data"
                    ],
                    "conclusions": [
                        "Using two different assays combined with quantitative image analysis excluding non-tumour cells, APNG was an independent prognostic factor among patients with a methylated MGMT promoter",
                        "APNG qIHC expected to potentially identify GBM patients who will not benefit from treatment with temozolomide"
                    ]
                },
                "application": {
                    "validated": null,
                    "diagnosis": null,
                    "prognosis": "YES",
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": "APNG qIHC can potentially identify GBM patients who will not benefit from treatment with temozolomide"
                },
                "comments": null,
                "curator": "Vanessa"
            },
            {
                "_id": "V0000B0",
                "pmid": "24026199",
                "biomarkerId": "B0000B0",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": null,
                "region": [
                    "China"
                ],
                "research": {
                    "methods": [
                        "Immunohistochemistry",
                        "Gene Ontology analysis",
                        "Gene set variation analysis",
                        "t-test",
                        "Chi-square testKaplan Meier analysis",
                        "Log-rank test"
                    ],
                    "results": [
                        "High RAB38 expression was mainly increased in high-grade gliomas, and high RAB38 expression also conferred high mortality of glioma in the CGGA cohort",
                        "RAB38 showed a mesenchymal subtype, G3 subtype and isocitrate dehydrogenase 1 (IDH1) wild-type preference",
                        "GO and GSVA analysis showed that RAB38 was significantly correlated with migration",
                        "The expression levels of RAB38 were significantly associated with grade progression as well as prognosis in gliomas"
                    ],
                    "conclusions": [
                        "RAB38 is an important prognostic biomarker and potential therapeutic target in gliomas"
                    ]
                },
                "application": {
                    "validated": "Yes",
                    "diagnosis": null,
                    "prognosis": "YES",
                    "predictive": null,
                    "therapeutic": "Potential"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": null
            },
            {
                "_id": "V0000B1",
                "pmid": "18761091",
                "biomarkerId": "B0001CF",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": "Pre 2010",
                "region": [
                    "Germany"
                ],
                "research": {
                    "methods": [
                        "The amount of CD133(+) cells within the bulk tumor mass, analyzed by immunostaining and Western blotting, showed a clear quantitative correlation with glioma grade (WHO degrees II, III and IV)."
                    ],
                    "results": [
                        "Most of CD133(+) cells were arranged in clusters frequently associated to tumor vessels. Protein analysis revealed high cellular coexpression of CD133 with Musashi-I but not CD34 indicating a neural, i.e. local origin of these cells. In vitro, no differences in stem cell properties concerning self-renewal and multi-lineage differentiation have been found for CD133(+) cells isolated from gliomas of different grades."
                    ],
                    "conclusions": [
                        "These findings indicate a solely quantitative correlation of glioma grade with the presence of neural CD133(+) cells within tumors supporting the concept of a CD133(+) stem cell dependent gliomagenesis."
                    ]
                },
                "application": {
                    "validated": "Potential",
                    "diagnosis": null,
                    "prognosis": "Potential",
                    "predictive": "Potential",
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": "CD133 is the most commonly used marker for isolation of cancer stem cell (CSC) population from different tumors, mainly from various gliomas and carcinomas.",
                    "implication": "Target of various types of immunotherapy",
                    "treatment": null
                },
                "comments": null,
                "curator": "Erik Samelsson"
            },
            {
                "_id": "V0000B2",
                "pmid": "24970813",
                "biomarkerId": "B0000B2",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "I",
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": null,
                "region": [
                    "China"
                ],
                "research": {
                    "methods": [
                        "Microarray",
                        "Kaplan-Meier method",
                        "two sided log-rank test",
                        "Cox proportional hazard model",
                        "Cox multivariate analysis"
                    ],
                    "results": [
                        "In GEO data set, patients predicted to be radiosensitive(RS) had an improved overall survival when compared with radioresistant(RR) patients in either radiotherapy(RT)-treated or non radiotherapy(RT)-treated subgroups(p<0.0001 in the RT-treated group)",
                        "gene signature is the strongest predictor(p=0.0093) in the RT-treated subgroup of patients but not significant (p=0.7668) in non radiotherapy-treated group when adjusting for age and Karnofsky performance score (KPS) as covariates",
                        "in the TCGA data set, radiotherapy-treated glioblastoma multiforme(GBM) patients assigned to RS group had an improved overall survival compared with RR group(p<0.0001)",
                        "enrichment of epithelial mesenchymal transition(EMT) pathway was observed with radioresistant phenotype"
                    ],
                    "conclusions": [
                        "results suggest that the signature is a predictive biomarker for radiation-treated glioma patients' prognostic"
                    ]
                },
                "application": {
                    "validated": "Potential",
                    "diagnosis": null,
                    "prognosis": null,
                    "predictive": "Potential",
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Vanessa"
            },
            {
                "_id": "V0000B3",
                "pmid": "29409474",
                "biomarkerId": "B0000B3",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": "Post 2010",
                "region": [
                    "Sweden"
                ],
                "research": {
                    "methods": [
                        "Data from The Cancer Genome Atlas and the Gene Expression Omnibus database were analyzed to assess ETBR expression. For survival analysis, glioblastoma samples from 25 Swedish patients were immunostained for ETBR, and the findings were correlated with clinical history. The druggability of ETBR was assessed by protein-protein interaction network analysis. ERAs were analyzed for toxicity in in vitro assays with GBM and breast cancer cells."
                    ],
                    "results": [
                        "By bioinformatics analysis, ETBR was found to be upregulated in glioblastoma patients, and its expression levels were correlated with reduced survival. ETBR interacts with key proteins involved in cancer pathogenesis, suggesting it as a druggable target. In vitro viability assays showed that ERAs may hold promise to treat glioblastoma and breast cancer."
                    ],
                    "conclusions": [
                        "ETBR is overexpressed in glioblastoma and other cancers and may be a prognostic marker in glioblastoma. ERAs may be useful for treating cancer patients."
                    ]
                },
                "application": {
                    "validated": "Potential",
                    "diagnosis": "NO",
                    "prognosis": "Potential",
                    "predictive": null,
                    "therapeutic": "Potential"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": "NO",
                "curator": "Erik Samuelsson"
            },
            {
                "_id": "V0000B4",
                "pmid": "24722048",
                "biomarkerId": "B0000B4",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": "2007",
                "region": null,
                "research": {
                    "methods": [
                        "Sequencing",
                        "PCR",
                        "Sanger sequencing",
                        "Kaplan-Meier method",
                        "multivariable Cox model",
                        "Fisher exact test"
                    ],
                    "results": [
                        "mutations in the TERT promoter occurred in 74.2% of GBM, but occurred in a minority of Grade II-III A",
                        "IDH1/2 mutations were observed in 78.4% of Grade II-III A, but were uncommon in primary GBM",
                        "in O, TERT promoter and IDH1/2 mutations co-occurred in 79% of cases",
                        "patients whose Grade III-IV gliomas exhibit TERT promoter mutations alone predominately have primary GBMs associated with poor median OS (11.5 months)",
                        "patients whose Grade III-IV gliomas exhibit IDH1/2 mutations alone predominately have astrocytic morphologies and exhibit a median OS of 57 months while patients whose tumors exhibit both TERT promoter and IDH1/2 mutations predominately exhibit oligodendroglial morphologies and exhibit median OS of 125 months"
                    ],
                    "conclusions": [
                        "analyzing gliomas based on their genetic signatures allows for the stratification of these patients into distinct cohorts, with unique prognosis and survival"
                    ]
                },
                "application": {
                    "validated": null,
                    "diagnosis": null,
                    "prognosis": null,
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Vanessa"
            },
            {
                "_id": "V0000B5",
                "pmid": "22179774",
                "biomarkerId": "B0000B5",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": null,
                "region": [
                    "South Korea"
                ],
                "research": {
                    "methods": [
                        "Tissue microarray",
                        "Immunohistochemistry",
                        "Normalization",
                        "Hierarchial clustering",
                        "Kaplan-Meier analysis",
                        "Cox model",
                        "Supervised classification"
                    ],
                    "results": [
                        "Based on H-score and hierarchical clustering methods, GBMs were divided into two groups (n=19 and 37) that had significantly different survival lengths",
                        "In the two groups, expression of nine proteins (survivin, cyclin E, DCC, TGF-\u03b2, CDC25B, histone H1, p-EGFR, p-VEGFR2/3, p16) was significantly changed",
                        "Prognosis-predicting potential of these proteins were validated with another independent library of 82 GBM TMAs and a public GBM DNA microarray dataset"
                    ],
                    "conclusions": [
                        "10 biomarkers are proven powerful to predict prognosis of GBM by analyzing three independent datasets",
                        "Suggested biomarkers are optimal for practical use in pathology laboratories with respect to cost and time of prognostic evaluations"
                    ]
                },
                "application": {
                    "validated": "Yes",
                    "diagnosis": null,
                    "prognosis": "YES",
                    "predictive": "Potential",
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": null
            },
            {
                "_id": "V0000B6",
                "pmid": "23361281",
                "biomarkerId": "B0000B6",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "I",
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": "2007",
                "region": [
                    "India"
                ],
                "research": {
                    "methods": [
                        "Tissue microarray",
                        "Labeled sterptavidin avidin biotin LSAB method"
                    ],
                    "results": [
                        "The frequency of mutant IDH1 detection by immunohistochemistry on formalin-fixed, paraffin-embedded tissue was in 29/184 tumors found suitable for evaluation",
                        "DA, O and GBM showed IDH1 expression in 17/40, 5/22  and 7/72 cases, respectively",
                        "Of all the GBMs, prim-GBM showed immunoexpression in 1/7 while sec-GBM showed IDH1 expression in 6/7",
                        "PA and EPEN did not react with anti-IDH1 antibody",
                        "DA and GBM showed positive correlation with p53, but IDH1 and EGFR coexpression was rare"
                    ],
                    "conclusions": [
                        "Monoclonal antibody to IDH1 (R132) is a useful and less-labor-intensive method to detect mutations in gliomas",
                        "IDH1 is a useful immunohistochemical marker to differentiate reactive gliosis from low-grade astrocytoma, has potential as an independent prognostic marker and also helps in distinguishing primary from secondary GBM",
                        "Its sensitivity and specificity need to be assessed by simultaneous sequencing and its validation on clinically annotated samples"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": "NO",
                    "prognosis": "Potential",
                    "predictive": "NO",
                    "therapeutic": "NO"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": "NO",
                "curator": "ANA"
            },
            {
                "_id": "V0000B7",
                "pmid": "29642484",
                "biomarkerId": "B0000B7",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "Primary and Secondary"
                ],
                "whoclass": "Post 2010",
                "region": [
                    "Canada"
                ],
                "research": {
                    "methods": [
                        "We hypothesized that TGF-\u03b2 gene expression could correlate with overall survival (OS) and serve as a prognostic biomarker. TGF-\u03b2\u2081 and -\u03b2\u2082 expression were analyzed by qPCR in 159 GBM tumor specimens. Kaplan-Meier and multivariate analyses were used to correlate expression with OS and progression-free survival (PFS)."
                    ],
                    "results": [
                        "In GBM, TGF-\u03b2\u2081 and -\u03b2\u2082 levels were 33- and 11-fold higher respectively than in non-tumoral samples. Kaplan-Meier and multivariate analyses revealed that high to moderate expressions of TGF-\u03b2\u2081 significantly conferred a strikingly poorer OS and PFS in newly diagnosed patients. Interestingly, at relapse, neither isoforms had meaningful impact on clinical evolution."
                    ],
                    "conclusions": [
                        "We demonstrate that TGF-\u03b2\u2081 is the dominant isoform in newly diagnosed GBM rather than the previously acknowledged TGF-\u03b2\u2082. We believe our study is the first to unveil a significant relationship between TGF-\u03b2\u2081 expression and OS or PFS in newly diagnosed GBM. TGF-\u03b2\u2081 could serve as a prognostic biomarker or target affecting treatment planning and patient follow-up."
                    ]
                },
                "application": {
                    "validated": "Potential",
                    "diagnosis": null,
                    "prognosis": "Potential",
                    "predictive": null,
                    "therapeutic": "Potential"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Erik Samuelsson"
            },
            {
                "_id": "V0000B8",
                "pmid": "19430729",
                "biomarkerId": "B0000B8",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": "Pre 2010",
                "region": [
                    "Denmark"
                ],
                "research": {
                    "methods": [
                        "In the present study, the TIMP-1 expression was investigated immunohistochemically in 112 formalin-fixed paraffin embedded astrocytomas and related to tumour grade and overall patient survival by scoring the TIMP-1 immunoreactivity of both tumour cells and blood vessels. Moreover, TIMP-1 in situ hybridisation was performed on ten of the glioblastomas."
                    ],
                    "results": [
                        "In the vast majority of the tumours TIMP-1 protein was expressed in both tumour cells and blood vessels. In situ hybridisation for TIMP-1 mRNA on glioblastomas confirmed the immunohistochemical expression of TIMP-1. The percentage of TIMP-1 positive tumour cells and blood vessels as well as the staining intensity varied between tumours of the same grade, but the total staining score increased with tumour grade. The multivariate Cox regression test showed that glioblastoma patients with the lowest TIMP-1 expression had a significantly longer overall survival (HR (95% CI) = 3.2 (1.5-6.7), P = 0.004) when compared to the patients with higher TIMP-1 protein expression."
                    ],
                    "conclusions": [
                        "In conclusion, this study showed that low TIMP-1 immunohistochemical expression predicts longer overall survival in glioblastoma patients, suggesting a role for TIMP-1 as a biomarker in glioblastoma."
                    ]
                },
                "application": {
                    "validated": "Potential",
                    "diagnosis": null,
                    "prognosis": "Potential",
                    "predictive": "Potential",
                    "therapeutic": "19141386"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Erik Samelsson"
            },
            {
                "_id": "V0000B9",
                "pmid": "19636000",
                "biomarkerId": "B0000B9",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": null,
                "whoclass": "Pre 2010",
                "region": [
                    "France"
                ],
                "research": {
                    "methods": [
                        "IDH1 codon 132 sequencing was performed in a series of 404 patients with glioma (100 grade 2, 121 grade 3, and 183 grade 4 gliomas) and correlated with histology, genomic profile, methylguanyl methyltransferase (MGMT) promoter methylation status, and outcome."
                    ],
                    "results": [
                        "A total of 155 codon 132 mutations were found, of which 131 were Arg132His (88.5%). The IDH1 mutation was inversely correlated with grade, affecting 77% of grade 2, 55% of grade 3, and 6% of grade 4 gliomas (P < 10(-15)). The IDH1 mutation was tightly associated with a 1p19q codeleted genotype (P < 10(-14)) and an MGMT methylated status (P < .001) but mutually exclusive with EGFR amplification (P < 10(-15)) and loss of chromosome 10 (P < 10(-15)). The presence (v absence) of IDH1 mutation was associated with a better outcome in grade 2 (150.9 v 60.1 months, respectively",
                        "P = .01), grade 3 (81.1 v 19.4 months, respectively",
                        "P < .001), and grade 4 gliomas (27.4 v 14 months, respectively",
                        "P < .01). After adjustment for grade, age, MGMT status, genomic profile, and treatment, multivariate analysis confirmed that IDH1 mutation was an independent favorable prognostic marker (hazard ratio = 0.297",
                        "95% CI, 0.157 to 0.564, P = .00021)."
                    ],
                    "conclusions": [
                        "This study indicates that IDH1 codon 132 mutation is closely linked to the genomic profile of the tumor and constitutes an important prognostic marker in grade 2 to 4 gliomas."
                    ]
                },
                "application": {
                    "validated": "Yes",
                    "diagnosis": "Potential",
                    "prognosis": "YES",
                    "predictive": "YES",
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": "Testing for IDH1 mutations is a current clinical backbone for GBM patient stratification. ",
                    "implication": null,
                    "treatment": null
                },
                "comments": "Potential",
                "curator": "Erik Samelsson"
            },
            {
                "_id": "V0000BA",
                "pmid": "30311408",
                "biomarkerId": "B0000BA",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": "2010",
                "region": [
                    "China"
                ],
                "research": {
                    "methods": [
                        "Protein extraction and western blot",
                        "Immunohistochemistry",
                        "TCGA, CGGA, Rembrant and GSE16011 data analysis",
                        "ROC curve",
                        "PCA",
                        "Microenvironment cell populations\u2010counter (MCP\u2010counter)",
                        "Gene ontology analysis",
                        "Gene set enrichment analysis",
                        "Gene set variation analysis",
                        "Kaplan-Meier method",
                        "Log-rank test",
                        "ANOVA",
                        "Tukey post test"
                    ],
                    "results": [
                        "CAVIN1 expression was elevated in GBM compared with that in low\u2010grade glioma and nontumor brain samples and was correlated with unfavorable outcomes in glioma patients",
                        "CAVIN1 could serve as an independent predictive factor for progressive malignancy in GBM",
                        "CAVIN1 was associated with disrupted angiogenesis and immune response in the tumor microenvironment of GBM"
                    ],
                    "conclusions": [
                        "Identified CAVIN1 as a prognostic biomarker and potential target for developing novel therapeutic strategies against GBM"
                    ]
                },
                "application": {
                    "validated": "Yes",
                    "diagnosis": null,
                    "prognosis": "YES",
                    "predictive": null,
                    "therapeutic": "Potential"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Erik Samuelsson"
            },
            {
                "_id": "V0000BB",
                "pmid": "30290990",
                "biomarkerId": "B0000BB",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": null,
                "region": [
                    "China"
                ],
                "research": {
                    "methods": [
                        "Meta-analysis of PubMed, Web of Science and Embase databases"
                    ],
                    "results": [
                        "Pooled analyses showed that low miR-139 expression was related to worse OS (HR=\u202f2.27) in solid tumors, including HCC and GBM, consisting with the results of TCGA",
                        "However, results of CRC showed that low miR-139 expression was associated with poor OS which was contradictory with the results in TCGA database and need larger samples to validate the phenomenon",
                        "For CRC patients, high miR-139 expression predicted poor RFS, which was in good accordance with TCGA results",
                        "The results of 27 microarrays from GEO database showed that miR-139 expression levels were lower in tumor tissues compared to adjacent non-tumor tissues or healthy tissues",
                        "Decreased miR-139 expression was also significantly correlated with poor differentiation grade (OR\u202f=\u202f3.57)",
                        "Combined data indicated that no associations between miR-139 expression and the following parameters such as age (pooled OR\u202f=\u202f1.50), gender (pooled OR\u202f=\u202f0.92), tumor size (pooled OR\u202f=\u202f1.59), late tumor-node-metastasis stage (pooled OR\u202f=\u202f1.63)and lymph-node-metastasis (pooled OR\u202f=\u202f0.66)"
                    ],
                    "conclusions": [
                        "Low miR-139 expression was related to poor prognosis in HCC and GBM, which could be regarded as a potential prognostic biomarker",
                        "Its precise functional role in CRC still need to be further investigated through larger samples and multicenter studies"
                    ]
                },
                "application": {
                    "validated": "Yes (GEO and TCGA data)",
                    "diagnosis": null,
                    "prognosis": "Potential",
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Erik Samuelsson"
            },
            {
                "_id": "V0000BC",
                "pmid": "30279739",
                "biomarkerId": "B0000BC",
                "sourceIds": [
                    "Tissue",
                    "Cell line"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": "2007",
                "region": [
                    "Portugal",
                    "France",
                    "Brazil"
                ],
                "research": {
                    "methods": [
                        "TCGA data analysis",
                        "Immunohistochemistry",
                        "WNT6 silencing by shRNA in GBM cells",
                        "WNT6 overexpression in GBM cells",
                        "Immunofluorescence",
                        "Cell viability assays",
                        "Cell proliferation and cell migration",
                        "Assessment of cell death and cell invasion",
                        "Colony formation assay",
                        "Cell viability assay under stem cell conditions",
                        "Neurosphere formation assay",
                        "Limiting dilution assay",
                        "Stereotactic orthotopic xenograft model",
                        "Human phospho-kinase antibody array",
                        "Western blot",
                        "TCF/LEF reporter assay",
                        "Gene set enrichment analysis",
                        "ANOVA",
                        "Sidak's test",
                        "Tukey's test",
                        "Log-rank test",
                        "Cox model"
                    ],
                    "results": [
                        "WNT6 is significantly overexpressed in GBMs, as compared to lower-grade gliomas and normal brain, at mRNA and protein levels",
                        "Functionally, WNT6 increases typical oncogenic activities in GBM cells, including viability, proliferation, glioma stem cell capacity, invasion, migration, and resistance to temozolomide chemotherapy",
                        "Concordantly, in in vivo orthotopic GBM mice models, using both overexpressing and silencing models, WNT6 expression was associated with shorter overall survival, and increased features of tumor aggressiveness",
                        "Mechanistically, WNT6 contributes to activate typical oncogenic pathways, including Src and STAT, which intertwined with the WNT pathway may be critical effectors of WNT6-associated aggressiveness in GBM",
                        "Clinically, WNT6 is established as an independent prognostic biomarker of shorter survival in GBM patients from several independent cohorts"
                    ],
                    "conclusions": [
                        "Findings establish WNT6 as a novel oncogene in GBM, opening opportunities to develop more rational therapies to treat this highly aggressive tumor"
                    ]
                },
                "application": {
                    "validated": "Yes (TCGA)",
                    "diagnosis": null,
                    "prognosis": "YES",
                    "predictive": null,
                    "therapeutic": "Potential"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Erik Samuelsson"
            },
            {
                "_id": "V0000BD",
                "pmid": "30277538",
                "biomarkerId": "B00018B",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": "2016",
                "region": [
                    "Germany"
                ],
                "research": {
                    "methods": [
                        "Open-label, multicenter, phase I/IIa umbrella trial for patients with newly diagnosed isocitrate dehydrogenase (IDH) wildtype glioblastoma without MGMT promoter hypermethylation",
                        "Neuropathological diagnostics",
                        "Molecular diagnostics and bioinformatic evaluation",
                        "Startification for treatment in 5 subtrials",
                        "Randomization between subtrials",
                        "Bayesian criteia for toxicity",
                        "PFS calculation"
                    ],
                    "results": [
                        "Molecular diagnostics and bioinformatic evaluation are performed within 4 weeks, allowing a timely initiation of postoperative treatment",
                        "Stratification for treatment takes place in 5 subtrials, including alectinib, idasanutlin, palbociclib, vismodegib, and temsirolimus as targeted therapies, according to the best matching molecular alteration",
                        "Patients without matching alterations are randomized between subtrials without strong biomarkers using atezolizumab and asinercept (APG101) and the standard of care, TMZ",
                        "For the phase I parts, a Bayesian criterion is used for continuous monitoring of toxicity",
                        "In the phase II trials, progression-free survival at 6 months is used as endpoint for efficacy"
                    ],
                    "conclusions": [
                        "Molecularly informed trials may provide the basis for the development of predictive biomarkers and help to understand and select patient subgroups who will benefit"
                    ]
                },
                "application": {
                    "validated": null,
                    "diagnosis": null,
                    "prognosis": "YES",
                    "predictive": "YES",
                    "therapeutic": "YES"
                },
                "clinical": {
                    "relevance": "O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation has been firmly established as a biomarker in patients diagnosed with gliomas, for both clinical trials and routine clinical management.",
                    "implication": "Use in companion diagnostics and predicting patient outcome.",
                    "treatment": "Methylation status of the MGMT gene is crucial to promoting DNA repair. If the MGMT gene is methylated, cancer patients tend to respond better to alkylating drug therapy."
                },
                "comments": null,
                "curator": "Erik Samuelsson"
            },
            {
                "_id": "V0000BE",
                "pmid": "30146921",
                "biomarkerId": "B0000BE",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": null,
                "region": [
                    "India"
                ],
                "research": {
                    "methods": [
                        "RT-PCR",
                        "Western Blot",
                        "Immunohistochemistry",
                        "Kaplan-Meier method",
                        "Log-rank test"
                    ],
                    "results": [
                        "Nck1 RNA and protein was upregulated significantly in high grade tissues as compared to low grade and control tissue samples",
                        "Logrank test and Kaplan-Meier analysis signified the use of Nck1 as independent prognostic marker for astrocytoma progression and its expression levels were correlated with poor survival in surgically resected human tissue samples (Chi square\u2009=\u200910.7, p\u2009=\u20090.001)",
                        "GBM was noticed to be predominant at frontal and temporal lobe"
                    ],
                    "conclusions": [
                        "On account of it's over expression, Nck1 appears as possible biomarker for astrocytoma progression and may serve as an important therapeutic target",
                        "Prominent origin of GBM at frontal and temporal lobe suggests possible involvement of tissue specific developmental or transcriptional factors in origin of tumors"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": null,
                    "prognosis": "Potential",
                    "predictive": null,
                    "therapeutic": "Potential"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Erik Samuelsson"
            },
            {
                "_id": "V0000BF",
                "pmid": "30132538",
                "biomarkerId": "B0000BF",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": null,
                "region": [
                    "China"
                ],
                "research": {
                    "methods": [
                        "Differential gene expression analysis",
                        "Gene Ontology and pathway enrichment analysis",
                        "Integration of protein-protein interaction"
                    ],
                    "results": [
                        "In total, 9,341 DEGs were identified in the GBM samples, including 9,175 upregulated genes and 166 downregulated genes",
                        "After verification, the top four genes RANBP17, ZNF734, NLRP2 and GPR1 were identified as prognostic biomarkers for GBM",
                        "The top four prognostic genes affected by sex were also identified and were as follows: CCDC81, NLRP2, SH3RF1 and TM7SF4"
                    ],
                    "conclusions": [
                        "The identified DEGs and hub genes contribute to the understanding of the molecular mechanisms underlying the development of GBM and they may be used as diagnostic and prognostic biomarkers and molecular targets for the treatment of patients with GBM in the future"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": null,
                    "prognosis": "Yes",
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Erik Samuelsson"
            },
            {
                "_id": "V0000C0",
                "pmid": "30080989",
                "biomarkerId": "B0000C0",
                "sourceIds": [
                    "Tissue",
                    "Cell line"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": "2007",
                "region": [
                    "Italy"
                ],
                "research": {
                    "methods": [
                        "X-ray irradiation",
                        "Establishment of radioresistant cel lines",
                        "Clonogenic assay",
                        "Western blot",
                        "Telomerase activity assay",
                        "Real-time PCR",
                        "Kaplan-Meier curves",
                        "Pearson test"
                    ],
                    "results": [
                        "ACD expression appeared strongly upregulated in higher grade gliomas, and its expression was significantly correlated to grading and poor prognosis",
                        "In glioma cell lines, ACD expression pattern was similar to those observed in glioma tissues",
                        "In irradiated cells, ACD expression was increased in an ionizing radiation dose-dependent manner",
                        "A higher expression of ACD was observed in the radioresistant clones than parental cells",
                        "Silencing of ACD led to the enhanced radiation sensitivity, decreased telomerase activity and cyclin D1 expression, reduced expression of BIRC1, and finally to the upregulation of caspase-3"
                    ],
                    "conclusions": [
                        "Study represents the first report, which demonstrated the expression pattern of ACD in gliomas and its prognostic value",
                        "Results suggested that ACD is involved in glioblastoma radioresistance, likely through the modulation of telomerase activity, proliferation, and apoptosis",
                        "ACD might represent a potential molecular biomarker and a novel therapeutic target in glioblastoma"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": null,
                    "prognosis": "Potential",
                    "predictive": null,
                    "therapeutic": "Potential"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Erik Samuelsson"
            },
            {
                "_id": "V0000C1",
                "pmid": "30005851",
                "biomarkerId": "B0000C1",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": "2007",
                "region": [
                    "China"
                ],
                "research": {
                    "methods": [
                        "The expression data of a total of 516\u202fGBM samples were downloaded from TCGA (The Cancer Genome Atlas). We identified the differentially expressed lncRNAs between cancer and normal tissues and performed annotation of differentially expressed lncRNAs to figure out the functions and pathways they were enriched in. Finally, cluster analysis was performed on the expression data of lncRNA and the samples were divided into four kinds, which were then used in the survival analysis. A total of 90 down-regulated lncRNAs and 224 up-regulated lncRNAs were screened out, which were mostly enriched in pathways of Alzhermer's disease and apoptosis."
                    ],
                    "results": [
                        "Their neighborhood genes were mostly enriched in genes sets of RTN1 and MAPK10.The characterization of differentially expressed lncRNAs was found out and the mostly enriched pathways were obtained to figure out the regulation mechanism of lncRNA."
                    ],
                    "conclusions": [
                        "Our findings may provide evidence of the potential role of lncRNA in the diagnosis, prognosis and target therapy of GBM."
                    ]
                },
                "application": {
                    "validated": "Potential",
                    "diagnosis": "Potential",
                    "prognosis": "Potential",
                    "predictive": null,
                    "therapeutic": "Potential"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": "Potential",
                "curator": "Erik Samuelsson"
            },
            {
                "_id": "V0000C2",
                "pmid": "29984907",
                "biomarkerId": "B0000C2",
                "sourceIds": [
                    "Tissue",
                    "Imaging"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": "Post 2010",
                "region": [
                    "China"
                ],
                "research": {
                    "methods": [
                        "Sanger sequencing",
                        "pyrosequencing",
                        "MRI",
                        "Statistical Analysis"
                    ],
                    "results": [
                        "Wild-type IDH was present in 89.8% of the adult glioblastoma samples, and TERT promoter mutations and MGMT promoter methylation were observed in 66.42% and 38.49% of all adult primary glioblastomas, respectively. Age and MGMT promoter methylation were identified as independent prognostic biomarkers, and the TERT promoter mutation status and MGMT promoter methylation status, when combined with other tumor-related factors, generated several different survival subgroups. None of the factors investigated in this study predicted the MGMT promoter status, and MRI-detected necrosis was positively associated with TERT promoter mutations."
                    ],
                    "conclusions": [
                        "MGMT promoter methylation and TERT promoter mutations, combined with MRI-derived and clinical features, revealed different survival subgroups with distinct responses to current treatments, and this information increases the ability to predict the survival of adult primary glioblastoma patients. MRI-detected necrosis often indicates the presence of TERT promoter mutations."
                    ]
                },
                "application": {
                    "validated": "Concrete;Potential",
                    "diagnosis": null,
                    "prognosis": "YES",
                    "predictive": "NO",
                    "therapeutic": "Potential"
                },
                "clinical": {
                    "relevance": "Utilizing established biomarkers as a means of finding subpopulations for therapeutics, potentially helping to define populations for clinical trials.",
                    "implication": "Subpopulation definitions for selecting cohorts in drug trials. ",
                    "treatment": "Potential"
                },
                "comments": null,
                "curator": "Erik Samuelsson"
            },
            {
                "_id": "V0000C3",
                "pmid": "29959764",
                "biomarkerId": "B0000C3",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "III"
                ],
                "whoclass": "Post 2010",
                "region": [
                    "USA"
                ],
                "research": {
                    "methods": [
                        "multivariate Cox regression analysis",
                        "Pearson correlation coefficient and z test"
                    ],
                    "results": [
                        "Univariate Cox regression analysis revealed 19 lncRNAs with survival time dependency. These nine lncRNAs were used to construct our survival model via multivariate Cox regression analysis.The result showed these genes were enriched with ion binding, transport, cell-cell signaling, plasma membrane parts, and more, and they were mainly related to neuroactive ligand-receptor interaction pathway, calcium signaling pathway, and the mitogen-activated protein kinase signaling pathway."
                    ],
                    "conclusions": [
                        "The nine lncRNAs were a set of biomarkers for the prognosis of patients with GBM, enabling a more accurate prediction of survival and revealing more biological functions."
                    ]
                },
                "application": {
                    "validated": "Potential",
                    "diagnosis": null,
                    "prognosis": null,
                    "predictive": "Potential",
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Erik Samuelsson"
            },
            {
                "_id": "V0000C4",
                "pmid": "29781781",
                "biomarkerId": "B0000C4",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": null,
                "whoclass": "Post 2010",
                "region": [
                    "China"
                ],
                "research": {
                    "methods": [
                        "receiver operating characteristic (ROC) curve analysis for all the genes based on gene expression value and the survival time of patients.",
                        "Protein\u2013protein interaction (PPI) network construction and module analysis",
                        ""
                    ],
                    "results": [
                        "A total of 598 genes were identified as significant risk genes for prognosis. Moreover, the genes in the network module mainly participated in the pathways such as cell cycle and cell cycle, mitotic. Drug target analysis showed that seven genes were recorded in Drugbank database, and there were as many as 32 drug records of CHEK1."
                    ],
                    "conclusions": null
                },
                "application": {
                    "validated": "Potential",
                    "diagnosis": null,
                    "prognosis": "Potential",
                    "predictive": null,
                    "therapeutic": "Potential"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Erik Samuelsson"
            },
            {
                "_id": "V0000C5",
                "pmid": "29753008",
                "biomarkerId": "B0000C5",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": "Post 2010",
                "region": [
                    "China"
                ],
                "research": {
                    "methods": [
                        "Analysis of transcriptional levels and prognostic value of MCMs in 325 gliomas from the Chinese Glioma Genome Atlas (CGGA).",
                        "IHC",
                        "Statistical analysis"
                    ],
                    "results": [
                        "MCM6 presented high expression and was associated with poor survival. Immunohistochemistry analysis of an independent data set of 423 glioma tissues confirmed the overexpression of MCM6 protein, especially in glioblastomas with shorter overall survival. Importantly, a combination of MCM6 overexpression with IDH1 mutation further improved the prediction of the prognosis of glioblastomas. Patients with IDH1 mutation and low MCM6 expression exhibited the longest survival, whereas those with high MCM6 expression and wild-type IDH1 showed the shortest."
                    ],
                    "conclusions": [
                        ". Collectively, our observation indicates that MCM6 is a novel potential biomarker for predicting poor prognosis of the patients with glioma."
                    ]
                },
                "application": {
                    "validated": "Potential",
                    "diagnosis": null,
                    "prognosis": "Potential",
                    "predictive": "Potential",
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Erik Samuelsson"
            },
            {
                "_id": "V0000C6",
                "pmid": "29721393",
                "biomarkerId": "B0000C6",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": "Post 2010",
                "region": [
                    "China"
                ],
                "research": {
                    "methods": [
                        "IHD",
                        "Student\u2019s t-test",
                        "Chi-square test",
                        "Kaplan\u2013Meier survival curve and log-rank tests",
                        "PCA"
                    ],
                    "results": [
                        "e found that IGFBP2 expression was upregulated in high-grade glioma and GBM and downregulated in IDH mutant glioma. Increased IGFBP2 accompanied PTEN loss and EGFR amplification. Bioinformatic analysis revealed that IGFBP2 is related to immunological processes. We further selected specific immunologic related gene sets and found IGFBP2 predominated immunosuppressive activities in GBM. Furthermore, we explored the relationship between IGFBP2 and genes that were well-characterized glioma-mediated immunosuppressive molecules to investigate the potential effect of IGFBP2. We discovered that IGFBP2 was correlated with CHI3L1, TNFRSF1A, LGALS1, TIMP1, VEGFA, ANXA1 and LGALS3, which were classic immunosuppressive biomarkers."
                    ],
                    "conclusions": [
                        "Higher IGFBP2 expression predicted unfavorable survival for patients with GBM. Our findings implied that IGFBP2 is involved in immunosuppressive activities and is an independent unfavorable prognostic biomarker for patients with GBM. IGFBP2 is a potential immunotherapeutic target for GBM in future clinical trials."
                    ]
                },
                "application": {
                    "validated": "Potential",
                    "diagnosis": null,
                    "prognosis": "Potential",
                    "predictive": null,
                    "therapeutic": "Potential"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Erik Samuelsson"
            },
            {
                "_id": "V0000C7",
                "pmid": "29625108",
                "biomarkerId": "B0000C7",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": "Post 2010",
                "region": [
                    "China"
                ],
                "research": {
                    "methods": [
                        "qRT-PCR, Cell proliferation assay, Trypan blue staining, Western blot analysis, Chromatin immunoprecipitation (CHIP) assay"
                    ],
                    "results": [
                        "The findings of the current study demonstrate presence of the IDH1 R132H mutation in primary human glioblastoma cell lines with upregulated HIF-1\u03b1 expression, downregulating c-MYC activity and resulting in a consequential decrease in miR-20a, which is responsible for cell proliferation and resistance to standard temozolomide treatment."
                    ],
                    "conclusions": [
                        "Elucidating the mechanism underlying oncogenic miR-20a activity establishes its role among well-established signaling pathways (i.e. HIF/c-MYC), and may be a meaningful prognostic biomarker or target for novel therapies, among patients with IDH1-mutant glioma."
                    ]
                },
                "application": {
                    "validated": "Potential",
                    "diagnosis": null,
                    "prognosis": "Potential",
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Erik Samuelsson"
            },
            {
                "_id": "V0000C8",
                "pmid": "29614978",
                "biomarkerId": "B0001D4",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": "Post 2010",
                "region": [
                    "South Africa"
                ],
                "research": {
                    "methods": [
                        "Genes with high expression variance was subjected to pathway enrichment analysis and those having roles in chemoradioresistance pathways were used in expression-based feature selection. A modified Support Vector Machine Recursive Feature Elimination algorithm was employed to select a subset of these genes that discriminated between rapidly-progressing and slowly-progressing patients."
                    ],
                    "results": [
                        "Survival analysis on TCGA samples not used in feature selection and samples from four GBM subclasses, as well as from an entirely independent study, showed that the 35-gene signature discriminated between the survival groups in all cases (p<0.05) and could accurately predict survival irrespective of the subtype. In a multivariate analysis, the signature predicted progression-free and overall survival independently of other factors considered."
                    ],
                    "conclusions": [
                        "We propose that the performance of the signature makes it an attractive candidate for further studies to assess its utility as a clinical prognostic and predictive biomarker in GBM patients. Additionally, the signature genes may also be useful therapeutic targets to improve both progression-free and overall survival in GBM patients."
                    ]
                },
                "application": {
                    "validated": "Potential",
                    "diagnosis": null,
                    "prognosis": "Potential",
                    "predictive": "Potential",
                    "therapeutic": "Potential"
                },
                "clinical": {
                    "relevance": "The genes in the panel cover most of the common pathways seen in GBM (see Verhaak 2010).",
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Erik Samuelsson"
            },
            {
                "_id": "V0000C9",
                "pmid": "29476046",
                "biomarkerId": "B0000C9",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": "Post 2010",
                "region": [
                    "China"
                ],
                "research": {
                    "methods": [
                        "We detected the expression of ZEB1 and ZEB2 in 91 cases of GBM with immunohistochemistry and investigated the correlation between clinicopathological factors and ZEB family expression with Fisher test. By univariate analysis with Kaplan-Meier test, we explored the prognostic significance of ZEB1/2 expression and the clinicopathological factors in GBM. By multivariate analysis with the Cox regression model, we identified the independent prognostic factors in GBM."
                    ],
                    "results": [
                        "The percentages of ZEB1 high expression and ZEB2 high expression were 31.9% (29/91) and 41.9% (36/91), respectively. High expression of ZEB2 was significantly associated with lower survival rate of GBM patients (P=0.001). ZEB2, lower KPS score (P=0.004), gross total resection (P<0.001) and higher Ki67 percentage (P=0.001) were notably correlated to worse prognosis of GBM. With multivariate analysis, high expression of ZEB2 was demonstrated to be an independent prognostic factor indicating unfavorable prognosis of GBM (P=0.001, HR=3.86, and 95%CI=1.61-9.23)."
                    ],
                    "conclusions": [
                        "High expression of ZEB2 is an independent prognostic factor predicting unfavorable prognosis of GBM, indicating that ZEB2 or its downstream proteins may be potential drug targets of GBM therapy."
                    ]
                },
                "application": {
                    "validated": "Potential",
                    "diagnosis": "NO",
                    "prognosis": "Potential",
                    "predictive": "Potential",
                    "therapeutic": "Potential"
                },
                "clinical": {
                    "relevance": "This study examines the well known stimulators ZEB1 and ZEB2, involved in EMT.",
                    "implication": null,
                    "treatment": null
                },
                "comments": "NO",
                "curator": "Erik Samuelsson"
            },
            {
                "_id": "V0000CA",
                "pmid": "29473166",
                "biomarkerId": "B0000CA",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": "Post 2010",
                "region": [
                    "China"
                ],
                "research": {
                    "methods": [
                        "Transcriptomic analysis of GBM cells with or without CMG2 overexpression indicated that a panel of oncogenic signaling pathways was altered with CMG2 upregulation, implying that CMG2 might orchestrate these signaling pathways to regulate the growth of GBM cells. Yes-associated protein 1 (YAP1) activity was enhanced by CMG2 overexpression but suppressed with CMG2 deficiency.  Methods: IHC, immunofluorescence, EdU assay, RNA sequencing"
                    ],
                    "results": [
                        "CMG2 overexpression was associated with increased tumor grade and poor patient survival. CMG2 promoted G2/M-phase transition during the cell cycle of GBM cells in vitro and contributed to tumor growth in vivo. We also observed that CMG2 is implicated in the activation of extracellular signal-regulated kinases (ERKs), epithelial-mesenchymal transition (EMT), migration, and invasion in GBM cells. CMG2 overexpression predicts poor prognosis for glioma patients"
                    ],
                    "conclusions": [
                        "Altogether, CMG2 functioned as an oncogene in glioma cells and is a potential prognostic biomarker or therapeutic target for the clinical treatment of glioma."
                    ]
                },
                "application": {
                    "validated": "Potential",
                    "diagnosis": "NO",
                    "prognosis": "Potential",
                    "predictive": null,
                    "therapeutic": "Potential"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": "NO",
                "curator": "Erik Samuelsson"
            },
            {
                "_id": "V0000CB",
                "pmid": "29291003",
                "biomarkerId": "B0000CB",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": "Post 2010",
                "region": [
                    "China"
                ],
                "research": {
                    "methods": [
                        "In this study, Differentially Expressed Pseudogenes (DEPs) between glioblastomas and non-tumor controls were found by bioinformatics analysis, of which the annexin A2 pseudogenes (ANXA2P1, ANXA2P2 and ANXA2P3) were significantly up-regulated, along with the parent gene annexin A2 (ANXA2). Among four glioblastoma subtypes, ANXA2P1 and ANXA2P2 were preferentially expressed in mesenchymal subtype and less expressed in proneural subtype. Meanwhile, Pearson's correlation analysis revealed that the expression level of ANXA2 was positively correlated with ANXA2 pseudogenes expression. Then, the expression patterns of ANXA2 and its pseudogenes were validated in diffuse glioma specimens (n=99) and non-tumor tissues (n=12) by quantitative real-time PCR (qRT-PCR). Additionally, Kaplan-Meier analysis revealed that highly expressed ANXA2 and annexin A2 pseudogenes were associated with the poor survival outcome of glioma patients. Cox regression analyses suggested that ANXA2, ANXA2P1 and ANXA2P2 were the independent prognosis factors for gliomas. Furthermore, down-regulation of ANXA2 and ANXA2 pseudogenes might contribute to the improvement of patients' survival who received chemotherapy and radiotherapy."
                    ],
                    "results": [
                        "Highly expressed ANXA2 and its pseudogenes were associated with poor survival, and could be the independent prognosis factors for glioma patients. Additionally, down-regulation of ANXA2, ANXA2P1 and ANXA2P2 might contribute to the improvement of the OS for glioma patients who received chemotherapy and radiotherapy. These results implied that ANXA2 pseudogenes and ANXA2 could be potentially used as prognosis biomarkers and therapeutic targets for gliomas."
                    ],
                    "conclusions": [
                        "In summary, this study demonstrated that ANXA2 pseudogenes and ANXA2 were up-regulated in diffuse gliomas tissue compared to normal brain tissue, and preferentially expressed in mesenchymal subtypes of glioblastoma."
                    ]
                },
                "application": {
                    "validated": "Potential",
                    "diagnosis": "Potential",
                    "prognosis": "Potential",
                    "predictive": null,
                    "therapeutic": "Potential"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": "Potential",
                "curator": "Erik Samuelsson"
            },
            {
                "_id": "V0000CC",
                "pmid": "29228611",
                "biomarkerId": "B0000CC",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": "Post 2010",
                "region": [
                    "China"
                ],
                "research": {
                    "methods": [
                        "Here, we performed proteomic profiling of 8 GBM and paired normal brain tissues. In parallel, comprehensive integrative genomic analysis of GBM was performed in silico using mRNA microarray and sequencing data. Two whole transcript expression profiling cohorts were used - a set of 3 normal brain tissues and 22 glioma tissue samples and a cohort of 5 normal brain tissues and 49 glioma tissue samples. A validation cohort included 529 GBM patients from The Cancer Genome Atlas datasets."
                    ],
                    "results": [
                        "We identified 36 molecules commonly changed at the level of the gene and protein, including up-regulated TGFBI and NES and down-regulated SNCA and HSPA12A. Single amino acid variant analysis identified 200 proteins with high mutation rates in GBM samples. We further identified 14 differentially expressed genes with high-level protein modification, among which NES and TNC showed differential expression at the protein level."
                    ],
                    "conclusions": [
                        "Moreover, higher expression of NES and TNC mRNAs correlated with shorter overall survival, suggesting that these genes constitute potential biomarkers for GBM."
                    ]
                },
                "application": {
                    "validated": "Potential",
                    "diagnosis": null,
                    "prognosis": "Potential",
                    "predictive": null,
                    "therapeutic": "Potential"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Erik Samuelsson"
            },
            {
                "_id": "V0000CD",
                "pmid": "29169920",
                "biomarkerId": "B0000CD",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": "Post 2010",
                "region": [
                    "China (TCGA Database, USA)"
                ],
                "research": {
                    "methods": [
                        "Herein, based on glioma datasets including TCGA (The Cancer Genome Atlas), REMBRANDT (Repository for Molecular Brain Neoplasia Data) and GSE16011, we established a glycolytic gene expression signature score (GGESS) by incorporating ten glycolytic genes. Then we performed survival analyses and investigated the correlations between GGESS and IDH1 mutation as well as the molecular subtypes in GBMs."
                    ],
                    "results": [
                        "The results showed that GGESS independently predicted unfavorable prognosis and poor response to chemotherapy of GBM patients. Notably, GGESS was high in GBMs of mesenchymal subtype but low in IDH1-mutant GBMs. Furthermore, we found that the promoter regions of tumor-promoting glycolytic genes were hypermethylated in IDH1-mutant GBMs. Finally, we found that high GGESS also predicted poor prognosis and poor response to chemotherapy when investigating IDH1-wildtype GBM patients only."
                    ],
                    "conclusions": [
                        "Collectively, glycolysis represented by GGESS predicts unfavorable clinical outcome of GBM patients and is closely associated with mesenchymal subtype and IDH1 mutation in GBMs."
                    ]
                },
                "application": {
                    "validated": "Potential",
                    "diagnosis": null,
                    "prognosis": "Potential",
                    "predictive": "Potential",
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Erik Samuelsson"
            },
            {
                "_id": "V0000CE",
                "pmid": "29168083",
                "biomarkerId": "B0000CE",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": null,
                "whoclass": null,
                "region": null,
                "research": {
                    "methods": [
                        "Microarray analysis",
                        "Kaplan-Meier method"
                    ],
                    "results": [
                        "more than 40% of GBM samples highly positive for IL-13R\u03b12 mRNA",
                        "less than 16% samples highly positive for IL-13R\u03b11 mRNA",
                        "subjects with high IL-13R\u03b11 and \u03b12 mRNA expressing tumors associated with a significantly lower survival rate irrespective of their treatment compared to subjects with IL-13R\u03b11 and \u03b12 mRNA negative tumors",
                        "IL-13R\u03b12 gene expression associated with GBM resistance to temozolomide (TMZ) chemotherapy",
                        "expression of IL-13R\u03b12 gene does not correlate with the expression of genes for other chains involved in the formation of IL-13R complex (IL-13R\u03b11 or IL-4R\u03b1) in GBM",
                        "positive correlation observed between IL-4R\u03b1 and IL-13R\u03b11 gene expression",
                        "IL-13R\u03b12 gene expression microarray data verified by RNA-Seq data",
                        "In depth analysis of TCGA data reveales that immunosuppressive genes (such as FMOD, CCL2, OSM, etc.) highly expressed in IL-13R\u03b12 positive tumors, but not in IL-13R\u03b12 negative tumors"
                    ],
                    "conclusions": [
                        "direct correlation between high level of IL-13R mRNA expression and poor patient prognosis",
                        "immunosuppressive genes associated with IL-13R\u03b12 may play a role in tumor progression",
                        "important implications in understanding the role of IL-13R in the pathogenesis of GBM and potentially other cancers"
                    ]
                },
                "application": {
                    "validated": "Potential",
                    "diagnosis": null,
                    "prognosis": "Potential",
                    "predictive": null,
                    "therapeutic": "Potential"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Vanessa"
            },
            {
                "_id": "V0000CF",
                "pmid": "28978068",
                "biomarkerId": "B0000CF",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "I",
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": "2007",
                "region": [
                    "China"
                ],
                "research": {
                    "methods": [
                        "Significance analysis of microarrays",
                        "Unsupervised hierarchial clustering",
                        "Chi-square test",
                        "Kaplan Meier analysis",
                        "Cox regression",
                        "Time-dependent ROC curve analysis"
                    ],
                    "results": [
                        "Identified a novel four-lncRNA signature which was closely related to the prognosis of patients with GBM",
                        "The prognostic value of this signature was verified in the test set of 80 patients",
                        "Functional analysis suggested that the four lncRNAs associated with survival of patients with GBM may be involved in cancer-related biological processes and pathways and their deregulation may lead to GBM tumorigenesis and progression",
                        "The AUC for the four-lncRNA signature prognostic model was 0.843 at 36 months of overall survival"
                    ],
                    "conclusions": [
                        "These novel lncRNA biomarkers will improve our understanding of the molecular mechanisms during the development and progression of glioma and provide novel diagnostic or prognostic markers and therapeutic targets for gliomas"
                    ]
                },
                "application": {
                    "validated": "Yes",
                    "diagnosis": "Potential",
                    "prognosis": "Potential",
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": "Potential",
                "curator": "Vanessa"
            },
            {
                "_id": "V0000D0",
                "pmid": "28938564",
                "biomarkerId": "B0000D0",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": "2007",
                "region": [
                    "USA",
                    "China"
                ],
                "research": {
                    "methods": [
                        "Principal component analysis",
                        "LASSO method",
                        "Multivariate logistic regression",
                        "Cox regression analysis",
                        "Kaplan-Meier curves",
                        "ROC curve analysis"
                    ],
                    "results": [
                        "The area under the ROC curve (AUC) for the three miRNA signature predicting 5-year survival was 0.894 in the testing set and 0.841 in all GBM patients",
                        "High risk patients had significantly shorter OS than patients with low risk"
                    ],
                    "conclusions": [
                        "The results from this study support a three miRNA signature for outcome prediction of GBM",
                        "These results provided a new prospect for prognostic biomarker of GBM"
                    ]
                },
                "application": {
                    "validated": "Yes",
                    "diagnosis": null,
                    "prognosis": "Potential",
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Vanessa"
            },
            {
                "_id": "V0000D1",
                "pmid": "28778566",
                "biomarkerId": "B0000D1",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": null,
                "whoclass": null,
                "region": null,
                "research": {
                    "methods": [
                        "Microarray analysis",
                        "Kaplan-Meier method"
                    ],
                    "results": [
                        "miR-524-5p and miR-524-3p supression in GBM associated with EGFR overexpression and EGFRvIII mutations",
                        "miRNAs improve overall survival (OS) of glioma patients",
                        "miRNAs overexpression can re4strain glioma cell migration, proliferation and cell cycle and control tumor formation",
                        "both miRNAs have synergistic inhibitory effect",
                        "GFR amplification/EGFRvIII mutation can repress the expression of Pri-miR-524 by histone modification",
                        "miRNAs inhibt TGF/\u03b2, Notch and the Hippo pathway by targeting Smad2, Hes1 and Tead1, respectively",
                        "pathways repressed their common downstream transcription factor, C-myc",
                        "C-myc binds to the promoter region of EGFR/EGFRvIII and activates its expression"
                    ],
                    "conclusions": [
                        "miR-524 mediates EGFR/EGFRvIII stimulating effecrt",
                        "may serve as potential therapeutic agent and classical-specific biomarker for glioma development"
                    ]
                },
                "application": {
                    "validated": "Potential",
                    "diagnosis": null,
                    "prognosis": null,
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Vanessa"
            },
            {
                "_id": "V0000D2",
                "pmid": "28602620",
                "biomarkerId": "B0000D2",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": null,
                "whoclass": null,
                "region": null,
                "research": {
                    "methods": [
                        "mRNA analysis"
                    ],
                    "results": [
                        "ITGA7 expression negatively correlates with survival of patients with both low-and high grade glioma",
                        "ITGA7 oplays keyrole in growth and invasiveness of GSCs"
                    ],
                    "conclusions": [
                        "ITGA7 can be a GBM biomarker and a candidate therapeutic target"
                    ]
                },
                "application": {
                    "validated": "Potential",
                    "diagnosis": null,
                    "prognosis": null,
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": "targeting of ITGA7 by RNAi or by blocking mABs impaires laminin-indcued signallinf and leads to significant delay in tumor engraftment and strong reduction in tumor size and onvasion"
                },
                "comments": null,
                "curator": "Vanessa"
            },
            {
                "_id": "V0000D3",
                "pmid": "28531325",
                "biomarkerId": "B0000D3",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": null,
                "whoclass": null,
                "region": null,
                "research": {
                    "methods": [
                        "Microarray",
                        "RT-qPCR",
                        "target gene prediction software (DIANA-TarBase, Targetscan and miRDB)",
                        "RT-qPCR for fresh samples",
                        "Kaplan-Meier method"
                    ],
                    "results": [
                        "miR-299 upregulated in GBM",
                        "patietns with low miR-299 expression show longer overall survival (OS) compared to those with high exoression",
                        "RNA polymerase II elongation factor ELL2 identified as miR-299 direct target",
                        "high expression of ELL2+miR-299 downreulation correlate with shorter median OS"
                    ],
                    "conclusions": [
                        "ELL2 is direct target of miR-299",
                        "increased ELL2 expression and miR-299 downregulation associated with GBM progression and poor prognosis",
                        "ELL2 and miR-299 might have prognostic value",
                        "could be used as tumor biomarker for GBM diagnosis"
                    ]
                },
                "application": {
                    "validated": "Potential",
                    "diagnosis": "Potential",
                    "prognosis": null,
                    "predictive": "Potential",
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": "Potential",
                "curator": "Vanessa"
            },
            {
                "_id": "V0000D4",
                "pmid": "28484518",
                "biomarkerId": "B00019F",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": "2007",
                "region": [
                    "Germany",
                    "USA"
                ],
                "research": {
                    "methods": [
                        "Clinical trial",
                        "MS-PCR",
                        "Comparative genomic hybridisation",
                        "Kaplan-Meier curves",
                        "Two-sided log-rank test",
                        "Univariate Cox regression"
                    ],
                    "results": [
                        "Age of onset of the disease showed a significant effect on overall survival (OS)",
                        "Additional treatment with carmustine wafer (group B) compared to the control group (group A) did not result in improved OS",
                        "Patients with a methylated MGMT promotor showed a significant longer OS compared to those patients with unmethylated MGMT promotor",
                        "Subgroup analyses revealed that patients with methylated p15 showed a significant shorter OS when administered to group B rather than in group A",
                        "In patients additionally treated with carmustine wafer an amplification of 4q12 showed a significant impact on a reduced OS",
                        "In group B, a loss of 13q was significantly associated with a longer OS",
                        "If a loss of chromosome 10 occurred, patients in group B showed a significantly longer OS"
                    ],
                    "conclusions": [
                        "A clinical benefit for the widespread use of additional carmustine wafer implantation could not be found",
                        "However, carmustine wafer implantation shows a significantly improved overall survival if parts of chromosome 10 or chromosome 13 are deleted",
                        "In cases of 4q12 amplification and in cases of a methylated p15 promotor, the use of carmustine wafers is especially not recommended",
                        "The MGMT promoter methylation is a strong prognostic biomarker for benefit from temozolomide and BCNU chemotherapy"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": null,
                    "prognosis": "YES",
                    "predictive": "YES",
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": "A strong prognostic marker of benefit from TMZ and BCNU chemotherapy",
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Vanessa"
            },
            {
                "_id": "V0000D5",
                "pmid": "28445977",
                "biomarkerId": "B0000D5",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": "2007",
                "region": [
                    "Sweden",
                    "UK"
                ],
                "research": {
                    "methods": [
                        "qPCR",
                        "Immunohistochemistry and immunofluorescence",
                        "ANOVA",
                        "Kaplan-Meier analysis",
                        "Log-rank test"
                    ],
                    "results": [
                        "Demonstrated that serglycin is expressed in glioma and that increased expression predicts poor survival of patients",
                        "Analysis of serglycin expression in a large cohort of low- and high-grade human glioma samples reveals that its expression is grade dependent and is positively correlated with mast cell (MC) infiltration",
                        "Serglycin expression in patient-derived glioma cells is significantly increased upon MC co-culture",
                        "This is also accompanied by increased expression of CXCL12, CXCL10, as well as markers of cancer progression, including CD44, ZEB1 and vimentin"
                    ],
                    "conclusions": [
                        "Findings indicate the importance of infiltrating MCs in glioma by modulating signaling cascades involving serglycin, CD44 and ZEB1",
                        "The present investigation reveals serglycin as a potential prognostic marker for glioma and demonstrates an association with the extent of MC recruitment and glioma progression, uncovering potential future therapeutic opportunities for patients"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": null,
                    "prognosis": "Potential",
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Vanessa"
            },
            {
                "_id": "V0000D6",
                "pmid": "28430038",
                "biomarkerId": "B0000D6",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": null,
                "whoclass": null,
                "region": null,
                "research": {
                    "methods": [
                        "Immunohistochemical assessment of survivin location (nuclear, cytoplasmic, or both)",
                        "relationship between survivin localization and overall survival (OS) was assessed with uni- and multivariate analyses including other clinicopathological factors (age, sex, Karnofsky Performance Scale [KPS] score, extent of resection, the use of second-line bevacizumab, O6-methylguanine-DNA methyltransferase [MGMT] status, and MIB-1 labeling index)"
                    ],
                    "results": [
                        "patient age, KPS score, extent of resection, MGMT status, and survivin localization significantly correlat with OS",
                        "patients with nuclear localization of survivin have significantly shorter OS than those in whom survivin expression was exclusively cytoplasmic",
                        "no  significant difference in OS between patents whose survivin expression was exclusively nuclear or nuclear/cytoplasmic"
                    ],
                    "conclusions": [
                        "nuclear expression of survivin is a factor for a poor prognosis in GBM patients",
                        "subcellular localization of survivin can help to predict OS in GBM patients treated with the standard protocol"
                    ]
                },
                "application": {
                    "validated": "Concrete",
                    "diagnosis": null,
                    "prognosis": null,
                    "predictive": "YES",
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Vanessa"
            },
            {
                "_id": "V0000D7",
                "pmid": "28371892",
                "biomarkerId": "B0000D7",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": null,
                "whoclass": null,
                "region": [
                    "China"
                ],
                "research": {
                    "methods": [
                        "Gene expression analysis",
                        "high troughput screening",
                        "Kaplan-Meier method",
                        "lo-rank test"
                    ],
                    "results": [
                        "increased MIR155HG associated with glioma grade, mesenchymal transition, and poor prognosis",
                        "protocadherin 9 and protocadherin 7, which act as tumor suppressors by inhibiting the Wnt/\u03b2-catenin pathway, direct targets of miR-155-5p and miR-155-3p",
                        "NSC141562 identified as a potent small-molecule inhibitor of the MIR155HG/miR-155 axis"
                    ],
                    "conclusions": [
                        "MIR155HG/miR-155 axis plays critical role in facilitating glioma progression and serves as a prognostic factor for patient survival in GBM",
                        "MIR155HG/miR-155 axis inhibitor NSC141562 may be a useful candidate anti-glioma drug"
                    ]
                },
                "application": {
                    "validated": "Potential",
                    "diagnosis": null,
                    "prognosis": "Potential",
                    "predictive": null,
                    "therapeutic": "Potential"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": "MIR155HG/miR-155 axis inhibitor NSC141562 may be a useful candidate anti-glioma drug"
                },
                "comments": null,
                "curator": "Vanessa"
            },
            {
                "_id": "V0000D8",
                "pmid": "28351300",
                "biomarkerId": "B0000D8",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": null,
                "whoclass": null,
                "region": null,
                "research": {
                    "methods": [
                        "Immunohistochemical assessment",
                        "Kaplan-Meier method",
                        "log-rank test"
                    ],
                    "results": [
                        "messenger RNA and protein expressions of ZHX1  higher in the tissues of GBM patients than in normal brain tissues",
                        "overexpression was associated with reduced survival"
                    ],
                    "conclusions": [
                        "ZHX1 plays crucial roles in the progression of glioblastoma",
                        "ZHX1 can be potential prognostic maker and therapeutic target of glioblastoma"
                    ]
                },
                "application": {
                    "validated": "Potential",
                    "diagnosis": null,
                    "prognosis": "Potential",
                    "predictive": null,
                    "therapeutic": "Potential"
                },
                "clinical": {
                    "relevance": null,
                    "implication": "the downregulation of ZHX1 decreased the proliferation, migration, and invasion of glioblastoma cells, whereas its upregulation had the opposite effects",
                    "treatment": null
                },
                "comments": null,
                "curator": "Vanessa"
            },
            {
                "_id": "V0000D9",
                "pmid": "28255664",
                "biomarkerId": "B0000D9",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": "2016",
                "region": null,
                "research": {
                    "methods": [
                        "Assignment of cases into different groups ((1) Oligodendroglioma, IDH-mutant and 1p/19q-codeleted",
                        "(2) Astrocytoma, IDH-mutant",
                        "(3) Glioblastoma, IDH-mutant",
                        "(4) Glioblastoma, IDH-wildtype",
                        "and (5) Astrocytoma, IDH-wildtype)",
                        "Cox proportional hazard model"
                    ],
                    "results": [
                        "Among Group 1 IDH-mutant 1p/19q-codeleted oligodendrogliomas, the TERT-WT group had significantly worse overall survival than the TERT-MUT group",
                        "in both Group 2, IDH-mutant astrocytomas and Group 3, IDH-mutant glioblastomas, neither TERT mutations nor ATRX alterations were significantly associated with survival",
                        "among Group 4, IDH-wildtype glioblastomas, ATRX alterations were associated with favorable outcomes",
                        "among Group 5, IDH-wildtype astrocytomas, the TERT-WT group had significantly better overall survival than the TERT-MUT group"
                    ],
                    "conclusions": [
                        "esting for TERT promoter mutations or ATRX alterations may provide additional useful prognostic information"
                    ]
                },
                "application": {
                    "validated": "Potential",
                    "diagnosis": null,
                    "prognosis": "Potential",
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Vanessa"
            },
            {
                "_id": "V0000DA",
                "pmid": "28160566",
                "biomarkerId": "B0000DA",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": null,
                "whoclass": "2016",
                "region": [
                    "China"
                ],
                "research": {
                    "methods": [
                        "ISH",
                        "IHC",
                        "RT-qPCR",
                        "Western blotting",
                        "one-way ANOVA test",
                        "Student t test",
                        "Pearson correlation analysis, Kaplan-Meier method",
                        "log-rank test",
                        "Cox's proportional hazards regression model"
                    ],
                    "results": [
                        "miR-320a expression decreased in human glioma tissue",
                        "miR-320a expression inversely correlated with glioma grades and Ki-67 index, but positively correlated with patients' survival",
                        "SND1 and \u03b2-catenin expression positively correlated with glioma grades and Ki-67 index, but inversely correlated with miR-320a expression and patients' survival",
                        "miR-320a and SND1 independent predictors and \u03b2-catenin auxiliary predictor for patients' survival",
                        "miR-320a overexpression suppresses the G1/S phase transition, proliferation, migration and invasion of glioblastoma cells",
                        "SND1 and \u03b2-catenin validated as direct targets of miR-320a",
                        "miR-320a overexpression increases SND1-inhibited tumor suppressor p21WAF1 and decreases Smad2, Smad4, MMP2, MMP7 and cyclinD1, the pivotal downstream effectors of SND1 or \u03b2-catenin"
                    ],
                    "conclusions": [
                        "potential values of miR-320a, SND1 and \u03b2-catenin as prognostic biomarkers and therapeutic candidates for malignant gliomas"
                    ]
                },
                "application": {
                    "validated": "Potential",
                    "diagnosis": null,
                    "prognosis": "Potential",
                    "predictive": null,
                    "therapeutic": "Potential"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Vanessa"
            },
            {
                "_id": "V0000DB",
                "pmid": "28097442",
                "biomarkerId": "B0000DB",
                "sourceIds": [
                    "TIssue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": "2007",
                "region": [
                    "Japan"
                ],
                "research": {
                    "methods": [
                        "Immunohistochemical assessment"
                    ],
                    "results": [
                        "LAPTM4B-35 expression score of Grade II gliomas was lower than those of Grade III\u2013IV gliomas, while the difference between Grade III and IV gliomas was not statistically significant",
                        "of the 43 patients with glioblastoma (GBM), 27 (62.8%) had high LAPTM4B-35 expression, which was associated with high tumor micro-vessel density and pAkt activation",
                        "the median progression-free survival (PFS) of GBM patients with high LAPTM4B-35 expression was 5.13 months",
                        "significantly shorter than that of those with low LAPTM4B-35 expression",
                        "median overall survival (OS) of GBM patients with high LAPTM4B-35 expression was 12.5 months, again significantly shorter than that of those with low LAPTM4B-35 expression (29.6 months)",
                        "multivariate analysis indicated LAPTM4B-35 to be an independent prognostic factor for PFS and OS of GBM patients"
                    ],
                    "conclusions": [
                        "LAPTM4B-35might be strongly associated with tumor proliferation, tumor angiogenesis and poor outcomes of GBM patients, suggesting LAPTM4B-35 to potentially be applicable as a novel prognostic marker and even to possibly play a role in improving GBM treatment"
                    ]
                },
                "application": {
                    "validated": "Potential",
                    "diagnosis": null,
                    "prognosis": "Potential",
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Vanessa"
            },
            {
                "_id": "V0000DC",
                "pmid": "27981247",
                "biomarkerId": "B0000DC",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": "2011-2012",
                "region": [
                    "USA"
                ],
                "research": {
                    "methods": [
                        "Immunohistochemical assessment",
                        "mRNA expression analysis"
                    ],
                    "results": [
                        "The highest grade astrocytoma, i.e. GBM was associated with the highest levels of ASPH and HIF1\u03b1, and both proteins were more abundantly distributed in hypoxic compared with normoxic regions of tumor",
                        "mining of the TCGA database revealed higher levels of ASPH expression in the mesenchymal subtype of GBM, which is associated with more aggressive and invasive behavior. In contrast, lower grade astrocytomas had low expression levels of ASPH and HIF1\u03b1"
                    ],
                    "conclusions": [
                        "increased ASPH expression could serve as a prognostic biomarker of gliomas and may assist in assigning tumor grade when biopsy specimens are scant"
                    ]
                },
                "application": {
                    "validated": "Potential",
                    "diagnosis": null,
                    "prognosis": "Potential",
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": " GBM treatment strategies could be made more effective by including small molecule inhibitors of ASPH"
                },
                "comments": null,
                "curator": "Vanessa"
            },
            {
                "_id": "V0000DD",
                "pmid": "27926792",
                "biomarkerId": "B0000DD",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": null,
                "whoclass": null,
                "region": null,
                "research": {
                    "methods": [
                        "Immunoblotting",
                        "RT-qPCR",
                        "immunohistochemical assessment",
                        "Mann\u2013Whitney test",
                        "Fisher\u2019s exact test",
                        "Kaplan-Meier method",
                        "log-rank test"
                    ],
                    "results": [
                        "PPARa significantly overexpressed in GBM",
                        "gene expression was found to be enriched in the classical glioblastoma subtype within TCGA dataset",
                        "although not associated with overall survival when assessed by immunohistochemistry, cross-validation with the TCGA dataset and multivariate analyses identi\ufb01ed PPARA gene expression as an independent prognostic marker for overall survival",
                        "hierarchical clustering revealed novel, signi\ufb01cant associations between high PPARA expression and a putative set of glioblastoma molecular mediators including EMX2, AQP4, and NTRK2"
                    ],
                    "conclusions": [
                        "PPARa is overexpressed in primary glioblastoma and high PPARA expression functions as an independent prognostic marker in the glioblastoma TCGA dataset",
                        "further studies are required to explore genetic associations with high PPARA expression and to analyse the predictive role of PPARa expression in glioblastoma models in response to PPARa agonists"
                    ]
                },
                "application": {
                    "validated": "Potential",
                    "diagnosis": null,
                    "prognosis": "Potential",
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Vanessa"
            },
            {
                "_id": "V0000DE",
                "pmid": "26614510",
                "biomarkerId": "B0000DE",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": null,
                "whoclass": null,
                "region": null,
                "research": {
                    "methods": [
                        "Immunohistochemical assessment,Kaplan-Meier method"
                    ],
                    "results": [
                        "PLC\u03b21 expression is significantly higher in grade III gliomas than that in grade IV gliomas from GDS1815 (n=24 vs. 76), GDS1962 (n=19 vs. 81), and GDS1975 (n=26 vs. 59)",
                        "in GDS1815, PLC\u03b21 expression correlates with several known proneural (PN) signature genes",
                        "its expression from PN subtype (n=15) is significantly higher than that from mesenchymal (Mes) subtype (n=33) HGG",
                        "in GDS1962, PLC\u03b21 expression is the highest in nontumor brain tissue (n=23) and is significantly higher than its expression in grade II gliomas [A (n=7) and O (n=37)]",
                        "Kaplan-Meier survival curve from a REMBRANDT cohort demonstrates that glioma patients with intermediate PLC\u03b21 expression(n=103)survived significantly longer than PLC\u03b21 downregulated (2X) groups (n=226)",
                        "From TCGA data, PLC\u03b21 RNA-Seq signal inversely correlates with the pathological grades, and PLC\u03b21 expression in PN ( n=8)is of significantly higher levels than that in Mes (n=8) subtypes of glioblastoma",
                        "top 50 % of PLC\u03b21 expression subgroup (n=294) of gliomas (grades II to IV merged) survived significantly longer than the low 50 percentile of the PLC\u03b21 expression subgroup (n=293)"
                    ],
                    "conclusions": [
                        "PLC\u03b21 isa candidate signature gene for PN subtype HGG, and its expression inversely correlates with glioma pathological grade and is a potential prognostic factor"
                    ]
                },
                "application": {
                    "validated": "Potenital",
                    "diagnosis": null,
                    "prognosis": "Potential",
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Vanessa"
            },
            {
                "_id": "V0000DF",
                "pmid": "27705947",
                "biomarkerId": "B0000DF",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": null,
                "whoclass": null,
                "region": null,
                "research": {
                    "methods": [
                        "Microarray",
                        "ANOVA",
                        "post-hoc least significant difference analysis",
                        "student\u2019s t-test"
                    ],
                    "results": [
                        "miRNA203 expression correlates with patient survival",
                        "STAT1 is functional target of miRNA-203",
                        "ectopic miRNA203 expression in vivo inhibites tumorigenesis"
                    ],
                    "conclusions": [
                        "miR203 acts as tumor suppressorby suppressing STAT1",
                        "miRNA-203 may serve as predictive biomarker and potential therapeuthic agent in patients with low miR-203 expression"
                    ]
                },
                "application": {
                    "validated": "Potential",
                    "diagnosis": null,
                    "prognosis": null,
                    "predictive": "Potential",
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Vanessa"
            },
            {
                "_id": "V0000E0",
                "pmid": "27637748",
                "biomarkerId": "B0000E0",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": null,
                "region": [
                    "China"
                ],
                "research": {
                    "methods": [
                        "Immunohistochemical assessment",
                        "Kaplan-Meier method",
                        "Cox analysis"
                    ],
                    "results": [
                        "PXN overexpression was signi\ufb01cantly associated with high-grade glioma as well as the higher mortality in survival analysis",
                        "PXN also served as an independent prognostic biomarker in glioblastoma patients",
                        "functional assays showed that PXN contributed to glioma cell proliferation and invasion"
                    ],
                    "conclusions": [
                        ": PXN plays as an oncogene in glioma progression and suggests a new potential biotarget for therapy"
                    ]
                },
                "application": {
                    "validated": "Concrete",
                    "diagnosis": null,
                    "prognosis": "YES",
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Vanessa"
            },
            {
                "_id": "V0000E1",
                "pmid": "27510663",
                "biomarkerId": "B0000E1",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": null,
                "region": [
                    "China"
                ],
                "research": {
                    "methods": [
                        "Immunohistochemical assessment",
                        "binary logisitc regression method"
                    ],
                    "results": [
                        "expression of TLR4 and DcR3 significantly higher in GBM than in AA",
                        "DcR3 can discriminate AA from GBM with high sensitivity (93.8%), specificity (90%), and accuracy (92.3%)"
                    ],
                    "conclusions": [
                        "DcR3 may be a useful marker for discriminating anaplastic astrocytomas from glioblastomas"
                    ]
                },
                "application": {
                    "validated": "Potential",
                    "diagnosis": "Potential",
                    "prognosis": null,
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": "Potential",
                "curator": "Vanessa"
            },
            {
                "_id": "V0000E2",
                "pmid": "27506939",
                "biomarkerId": "B0000E2",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": null,
                "whoclass": null,
                "region": null,
                "research": {
                    "methods": [
                        "Tissue array",
                        "RT-qPCR"
                    ],
                    "results": [
                        "Plexin-A1 highly expressed in GBM",
                        "highet expression level correlates with worse survival"
                    ],
                    "conclusions": [
                        "creening Plexin-A1 expression and targeting Plexin-A1 in glioblastoma patients exhibit diagnostic and therapeutic value"
                    ]
                },
                "application": {
                    "validated": "Concrete",
                    "diagnosis": "YES",
                    "prognosis": null,
                    "predictive": null,
                    "therapeutic": "YES"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": "YES",
                "curator": "Vanessa"
            },
            {
                "_id": "V0000E3",
                "pmid": "27440383",
                "biomarkerId": "B0000E3",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": "2007",
                "region": [
                    "Spain"
                ],
                "research": {
                    "methods": [
                        "Immunohistochemical assessment",
                        "PCR",
                        "chi- square",
                        "Student\u2019s t",
                        "Pearson correlation",
                        "Spearman\u2019s rho",
                        "Mann\u2013Whitney",
                        "ROC",
                        "Kaplan\u2013 Meier method"
                    ],
                    "results": [
                        "significant increase was observed between grades for expression of total and phosphorylated 4E-BP1 and for eIF4E, Ki67, EGFR, and cyclin D1",
                        "expression of EGFR, eIF4E, and Ki67 correlates with survival",
                        "only peIF4E was an independent predictor of survival in the multivariate analysis"
                    ],
                    "conclusions": [
                        "cell signaling pathways are activated in DIAs",
                        "peIF4E is an independent prognostic factor and a promising therapeutic target"
                    ]
                },
                "application": {
                    "validated": "Concrete",
                    "diagnosis": "Potential",
                    "prognosis": null,
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": "Potential",
                "curator": "Vanessa"
            },
            {
                "_id": "V0000E4",
                "pmid": "27438144",
                "biomarkerId": "B0000E4",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": null,
                "whoclass": null,
                "region": [
                    "China"
                ],
                "research": {
                    "methods": [
                        "Microarray",
                        "log-rank test",
                        "Kaplan-Meier method",
                        "LASSO model"
                    ],
                    "results": [
                        "miRNAs have prognostic and prognostic accuracy",
                        "verified by independent set of glioma samples from the Affiliated People\u2019s Hospital of Jiangsu University"
                    ],
                    "conclusions": null
                },
                "application": {
                    "validated": "Potential",
                    "diagnosis": "YES",
                    "prognosis": null,
                    "predictive": "YES",
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": "classifier could be used  in the stratification and individualized management of patients with glioma",
                    "treatment": null
                },
                "comments": "YES",
                "curator": "Vanessa"
            },
            {
                "_id": "V0000E5",
                "pmid": "27347488",
                "biomarkerId": "B0000E5",
                "sourceIds": [
                    "Cell line"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": null,
                "region": [
                    "USA",
                    "China"
                ],
                "research": {
                    "methods": [
                        "WST-1 assay",
                        "TUNEL assay",
                        "Matrigel invasion assays",
                        "Western blot assay",
                        "t-test"
                    ],
                    "results": [
                        "MiR-10b alters the radiation induced inhibitory effect on proliferation of glioblastoma cells",
                        "MiR-10b inhibits radiation-induced apoptosis in glioblastoma cells",
                        "MiR-10b enhances migration and invasion in glioblastoma cells",
                        "MiR-10b increases p-AKT expression"
                    ],
                    "conclusions": [
                        "MiR-10b might be a potential biomarker to predict the radiotherapy response and prognosis in glioblastomas"
                    ]
                },
                "application": {
                    "validated": "Potential",
                    "diagnosis": "NO",
                    "prognosis": "Potential",
                    "predictive": "Potential",
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": "NO",
                "curator": "BP"
            },
            {
                "_id": "V0000E6",
                "pmid": "27158412",
                "biomarkerId": "B0000E6",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": "2007",
                "region": [
                    "China"
                ],
                "research": {
                    "methods": [
                        "Affymetrix microarray",
                        "Immunohistochemistry staining",
                        "Cox regression model"
                    ],
                    "results": [
                        "Gene microarray analysis reveals WDR1 has the potential of prognostic predictor in glioma",
                        "TCGA dataset analysis shows WDR1 is highly expressed and acts as a risk factor for GBM survival",
                        "Large sample TMA proves WDR1 is overexpressed in primary GBM",
                        "High expression of WDR1 correlates with poorer survival and is an independent prognostic factor of primary GBM patients"
                    ],
                    "conclusions": [
                        "High WDR1 expression is associated with shorter OS and PFS after surgery and WDR1 can work as an independent risk factor to help define the subset of primary GBM patients"
                    ]
                },
                "application": {
                    "validated": "Concrete",
                    "diagnosis": "NO",
                    "prognosis": "YES",
                    "predictive": "NO",
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": "NO",
                "curator": "BP"
            },
            {
                "_id": "V0000E7",
                "pmid": "27136105",
                "biomarkerId": "B0000E7",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "I",
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": "2007",
                "region": [
                    "Egypt"
                ],
                "research": {
                    "methods": [
                        "Immunohistochemical analysis",
                        "Mann Whitney U test",
                        "Kruskal-Wallis H test"
                    ],
                    "results": [
                        "Significant positive correlation was found between ALDH1 and EZH2 as well as between ALDH1, EZH2 & Ki-67"
                    ],
                    "conclusions": [
                        "Expression of ALDH1, EZH2 and Ki-67 was found to be increase significantly with astrocytic glioma progression and increased expression levels were associated with short patient survival",
                        "ALDH1, EZH2 and Ki-67 can be considered as potential biomarkers to detect astrocytic glioma patients with unfavorable outcome"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": "NO",
                    "prognosis": "Potential",
                    "predictive": "NO",
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": "NO",
                "curator": "BP"
            },
            {
                "_id": "V0000E8",
                "pmid": "27119233",
                "biomarkerId": "B0000E8",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": null,
                "region": [
                    "China"
                ],
                "research": {
                    "methods": [
                        "RNA isolation and qRT-PCR",
                        "Immunohistochemistry",
                        "Cell proliferation assays",
                        "Wound healing assay",
                        "Invasion assay",
                        "Cox proportional hazards regression",
                        "Kaplan-Meirer analysis"
                    ],
                    "results": [
                        "Overexpression of CCL11 and CCR3 in GBM tissues and cell lines",
                        "CCL11/CCR3 promote tumor cell proliferation, migration, and invasion",
                        "Overexpression of CCL11 and CCR3 correlates with poor overall survival"
                    ],
                    "conclusions": [
                        "The chemokine, CCL11, along with its cognate receptor, CCR3, have been identified as major factors influencing GBM tumor development",
                        "A prognostic index using CCL11 and CCR3 expression combined with KPS is remarkably valuable in predicting one-year survival in GBM patients"
                    ]
                },
                "application": {
                    "validated": "Yes",
                    "diagnosis": "NO",
                    "prognosis": "Potential",
                    "predictive": "NO",
                    "therapeutic": "Potential"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": "NO",
                "curator": "BP"
            },
            {
                "_id": "V0000E9",
                "pmid": "26945349",
                "biomarkerId": "B0000E9",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "I",
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": "2007",
                "region": [
                    "China"
                ],
                "research": {
                    "methods": [
                        "Hazard ratios",
                        "Random effects model",
                        "Mantel-Haenszel method",
                        "Egger test"
                    ],
                    "results": [
                        "The pooled HR of 0.358 indicated that IDH1 or IDH1/2 mutations were associated with better OS",
                        "When patients were stratified by surgery versus no surgery or IDH1 versus IDH1/2 mutations, the results also indicated that the presence of IDH mutations was associated with better OS",
                        "The pooled HR of 0.322 indicated that IDH1 or IDH1/2 mutations were associated with better PFS",
                        "When patients were stratified by surgery versus no surgery or IDH1 versus IDH1/2 mutations, the results also indicated that the presence of IDH mutations was associated with better PFS"
                    ],
                    "conclusions": [
                        "The results of this meta-analysis indicate that IDH1/2 mutations are associated with improved survival in patients with glioblastomas"
                    ]
                },
                "application": {
                    "validated": "Yes",
                    "diagnosis": null,
                    "prognosis": "YES",
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "BP"
            },
            {
                "_id": "V0000EA",
                "pmid": "26828136",
                "biomarkerId": "B0000EA",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": "2007",
                "region": [
                    "China"
                ],
                "research": {
                    "methods": [
                        "Quantitative real timePCR",
                        "Western blotting",
                        "Nude mouse glioma intracranial model",
                        "Immunohistochemical analysis",
                        "ANOVA",
                        "Cox model",
                        "Cluster analysis"
                    ],
                    "results": [
                        "Identification of the lncRNA HOXA11-AS in a mRNA microarray database",
                        "HOXA11-AS expression correlates with glioma grade",
                        "HOXA11-AS is a marker for glioma molecular subtype",
                        "HOXA11-AS over-expression confers a poor prognosis in glioma patients",
                        "HOXA11-AS is an independent prognostic factor in GBM patients",
                        "HOXA11-AS promotes glioma progression in vivo"
                    ],
                    "conclusions": [
                        "Evidence for the involvement of HOXA11-AS in carcinogenesis via the regulation of the cell cycle in vitro and in vivo",
                        "Highlights a role for HOXA11-AS as a prognostic marker of glioma patient survival and as a candidate therapeutic target in gliomas"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": null,
                    "prognosis": "YES",
                    "predictive": null,
                    "therapeutic": "Potential"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "BP"
            },
            {
                "_id": "V0000EB",
                "pmid": "26765760",
                "biomarkerId": "B0000EB",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "I",
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": null,
                "region": [
                    "China"
                ],
                "research": {
                    "methods": [
                        "Meta-analysis",
                        "Pooled hazard ratios",
                        "Egger test"
                    ],
                    "results": [
                        "TERT mutations were found in 42% of patients with low-grade gliomas compared to 60% of patients with high-grade gliomas",
                        "Confirmed poor survival time of patients with TERT promoter mutations",
                        "For patients diagnosed with glioblastoma multiforme, the HR was 1.74"
                    ],
                    "conclusions": [
                        "TERT promoter mutations confer a poor prognosis for glioma patients and TERT promoter mutation frequency varies across World Health Organization grades and histopathological classifications",
                        "TERT rs2736100 polymorphisms may increase the risk of gliomagenesis"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": null,
                    "prognosis": "YES",
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "BP"
            },
            {
                "_id": "V0000EC",
                "pmid": "26682928",
                "biomarkerId": "B0001AE",
                "sourceIds": [
                    "Tissue",
                    "Cell line"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": "2007",
                "region": [
                    "China"
                ],
                "research": {
                    "methods": [
                        "qRT-PCR",
                        "Western blot",
                        "Immunohistochemistry",
                        "t-test",
                        "Srvival curves"
                    ],
                    "results": [
                        "miR-181c was down-regulated in the majority of glioblastoma tissues",
                        "MiR-181c was also down-regulated in U251, U87, T98G and SHG44 glioblastoma cell lines compared with normal astrocyte cell line HEB",
                        "patients with tumors expressing elevated miR-181c levels had significantly longer OS and PFS than those with tumors expressing low miR-181c levels uggesting that miR-181c was a critical prognostic marker in high-grade GBM patients",
                        "MiR-181c suppresses invasion, migration and EMT of T98G cells",
                        "Increased miR-181c expression in T98G suppresses invasion, migration and EMT via TGF-\u03b2 signaling",
                        ""
                    ],
                    "conclusions": [
                        "Study found that miR-181c plays a key role in glioblastoma cell invasion, migration and mesenchymal transition suggesting potential therapeutic applications"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": "NO",
                    "prognosis": "Potential",
                    "predictive": "NO",
                    "therapeutic": "Potential"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": "NO",
                "curator": "BP"
            },
            {
                "_id": "V0000ED",
                "pmid": "26616112",
                "biomarkerId": "B0000ED",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": "2007",
                "region": [
                    "India"
                ],
                "research": {
                    "methods": [
                        "Immunohistochemistry",
                        "Kruskal-Wallis one way ANOVA",
                        "Cox model",
                        "Survival curves"
                    ],
                    "results": [
                        "Significantly increased protein expression of MnSOD was observed among malignant astrocytomas (GBM and AA) in comparison with either DA or non-tumor brain tissues",
                        "Among the GBM cases it was noted that the IDH1 immunopositive tumors (R132H mutant protein) had a low MnSOD expression as opposed to IDH1 immunonegative tumors, which had high expression of MnSOD",
                        "Protein expression of MnSOD was associated with both poor OS and early PFS",
                        "Stratification of GBM cases based on p53 expression status revealed a strong association of MnSOD with OS"
                    ],
                    "conclusions": [
                        "Increased expression of MnSOD in AA and GBM compared to low grade astrocytoma and control brain",
                        "An increase in MnSOD expression following GBM tumor recurrence strengthens its putative role in tumor aggressiveness",
                        "MnSOD emerges as a poor prognostic biomarker in p53 expressing GBMs, rendering this molecule as a potential therapeutic target in such patients."
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": "NO",
                    "prognosis": "YES",
                    "predictive": "NO",
                    "therapeutic": "Potential"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": "NO",
                "curator": "BP"
            },
            {
                "_id": "V0000EE",
                "pmid": "26506879",
                "biomarkerId": "B0000EE",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": "2007",
                "region": [
                    "China"
                ],
                "research": {
                    "methods": [
                        "DNA methylation analysis",
                        "qRT-PCR",
                        "Hierarchial clustering",
                        "t-test"
                    ],
                    "results": [
                        "Microarray analysis identified a total of 1421 CpG sites with a significant difference at methylation status, between short term survival and long term survival groups",
                        "10 most hypermethylated genes, include  IL11, RRAD, MS4A6A, SNAPC2, ALDH1A3, ADCY1, MMS19L, NDUFB8, POMC, and THSD4 genes"
                    ],
                    "conclusions": [
                        "Epigenetic silencing of IL11, RRAD, MS4A6A, SNAPC2, and ALDH1A3 is common in GBM and could be used as novel tumor suppressor and biomarker for prognosis of GBM"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": "NO",
                    "prognosis": "Potential",
                    "predictive": "NO",
                    "therapeutic": "NO"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": "NO",
                "curator": "BP"
            },
            {
                "_id": "V0000EF",
                "pmid": "26506620",
                "biomarkerId": "B0000EF",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": "2007",
                "region": [
                    "USA",
                    "China"
                ],
                "research": {
                    "methods": [
                        "Probe Set Analyzer",
                        "Immunohistochemical analysis",
                        "Cox model"
                    ],
                    "results": [
                        "Ribosomal protein S11 (RPS11), RPS20, individually and together, consistently predicted poor survival of newly diagnosed primary GBM tumors when overexpressed at the RNA or protein level",
                        "Tumors that exhibited unmethylated O-6-methylguanine-DNA methyltransferase or wild-type isocitrate dehydrogenase 1  were associated with higher RPS11 expression levels"
                    ],
                    "conclusions": [
                        "Increased expression of RPS11 and RPS20 predicts shorter patient survival",
                        "The screening of TRGC signatures may represent a novel alternative strategy for identifying new prognostic biomarkers"
                    ]
                },
                "application": {
                    "validated": "Yes",
                    "diagnosis": "NO",
                    "prognosis": "YES",
                    "predictive": "NO",
                    "therapeutic": "NO"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": "NO",
                "curator": "BP"
            },
            {
                "_id": "V0000F0",
                "pmid": "26493598",
                "biomarkerId": "B0000F0",
                "sourceIds": [
                    "Tissue",
                    "Cell line"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": "2007",
                "region": [
                    "Israel"
                ],
                "research": {
                    "methods": [
                        "qRT-PCR",
                        "Immunoluorescence"
                    ],
                    "results": [
                        "High metallothionein\u00a0expression is associated with poor survival whereas low\u00a0metallothionein evels correspond to good prognosis",
                        "In U87 GBM cell line,\u00a0p53\u00a0is found to be in an inactive mutant-like conformation concurrently with more than 4 times higher\u00a0metallothionein3\u00a0expression level than normal astrocytes and U251GBM cell line"
                    ],
                    "conclusions": [
                        "Metallothionein expression may be a potential novel prognostic biomarker for GBM",
                        "U87 cells may be a good model for patients with non active WT p53 resulting from high levels of MTs."
                    ]
                },
                "application": {
                    "validated": "Yes",
                    "diagnosis": "NO",
                    "prognosis": "Potential",
                    "predictive": "NO",
                    "therapeutic": "NO"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": "NO",
                "curator": "BP"
            },
            {
                "_id": "V0000F1",
                "pmid": "26456023",
                "biomarkerId": "B0000F1",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "I",
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": "2007",
                "region": [
                    "USA"
                ],
                "research": {
                    "methods": [
                        "IHC"
                    ],
                    "results": [
                        "Significant correlation of expression of Eg5 with higher WHO histopathological grades",
                        ""
                    ],
                    "conclusions": [
                        "overexpression of Eg5 associates with high-grade astrocytic neoplasm  and it may represent an independent diagnostic and prognostic factor in grading astrocytic tumors and predicting prognosis of astrocytic tumor patients"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": "Potential",
                    "prognosis": "Potential",
                    "predictive": "NO",
                    "therapeutic": "NO"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": "Potential",
                "curator": "RF"
            },
            {
                "_id": "V0000F2",
                "pmid": "26421425",
                "biomarkerId": "B0000F2",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "I",
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": "2007",
                "region": [
                    "Germany"
                ],
                "research": {
                    "methods": [
                        "IHC, Flow citometry, autoradiography"
                    ],
                    "results": [
                        "Anticalins detect ED\u2010B expression on glioblastoma tissue, but not in lower grade tumors nor controls"
                    ],
                    "conclusions": [
                        "ED\u2010B directed Anticalins can be use to differenciate GBM grade iV from lower grade tumours"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": "YES",
                    "prognosis": "YES",
                    "predictive": "NO",
                    "therapeutic": "YES"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": "YES",
                "curator": "RF"
            },
            {
                "_id": "V0000F3",
                "pmid": "26379879",
                "biomarkerId": "B0000F3",
                "sourceIds": [
                    "TIssue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": "2007",
                "region": [
                    "China"
                ],
                "research": {
                    "methods": [
                        "q-RT-PCR"
                    ],
                    "results": [
                        "miR-105 had decreased expression in gliomas compared to controls. And grade IV gliomas had significantly lower miR-105 expression compared with lower grades.,"
                    ],
                    "conclusions": [
                        "Low miR-105 expression was statistically associated with advanced tumor grade"
                    ]
                },
                "application": {
                    "validated": null,
                    "diagnosis": "YES",
                    "prognosis": "YES",
                    "predictive": "NO",
                    "therapeutic": "NO"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": "YES",
                "curator": "RF"
            },
            {
                "_id": "V0000F4",
                "pmid": "\u00a026377974",
                "biomarkerId": "B0000F4",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": null,
                "region": null,
                "research": {
                    "methods": [
                        "IHC",
                        "FACS",
                        "IMMUNOPRECIPITATION",
                        "TMA",
                        "XENOGRAFTS"
                    ],
                    "results": [
                        "D151 and \u03b13 integrin were significantly elevated in glioblastomas at both protein and mRNA levels, and exhibited strong inverse correlation with patient survival"
                    ],
                    "conclusions": [
                        "CD151-\u03b13\u03b21 integrin complexes levels correlate with patient survival"
                    ]
                },
                "application": {
                    "validated": null,
                    "diagnosis": "NO",
                    "prognosis": "YES",
                    "predictive": "YES",
                    "therapeutic": "NO"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": "NO",
                "curator": "RF"
            },
            {
                "_id": "V0000F5",
                "pmid": "26190195",
                "biomarkerId": "B0000F5",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": "2007",
                "region": [
                    "USA"
                ],
                "research": {
                    "methods": [
                        "FISH",
                        "IHC"
                    ],
                    "results": null,
                    "conclusions": [
                        "NF1\u00a0loss was associated with worse overall and disease-specific survival in the lower-grade glioma, but not GBM"
                    ]
                },
                "application": {
                    "validated": "NO",
                    "diagnosis": "NO",
                    "prognosis": "YES",
                    "predictive": "NO",
                    "therapeutic": "NO"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": "NO",
                "curator": "RF"
            },
            {
                "_id": "V0000F6",
                "pmid": "26189368",
                "biomarkerId": "B0000F6",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": null,
                "whoclass": "2007",
                "region": [
                    "China"
                ],
                "research": {
                    "methods": [
                        "RT-PCR",
                        "flow citometry",
                        "microarrays",
                        "IHC",
                        "WB"
                    ],
                    "results": [
                        "MEK2 was upregulated specifically in resistant glioma cells but not in sensitive tumor cells or non-tumor tissues",
                        "MEK2 knockdown inhibited cell proliferation and enhanced the sensitivity of cells toward TMZ treatment"
                    ],
                    "conclusions": [
                        "The level of MEK2 expression is positively correlated with\u00a0glioma grades and negatively correlated with disease outcome"
                    ]
                },
                "application": {
                    "validated": null,
                    "diagnosis": "NO",
                    "prognosis": "YES",
                    "predictive": "YES",
                    "therapeutic": "YES"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": "NO",
                "curator": "RF"
            },
            {
                "_id": "V0000F7",
                "pmid": "26165699",
                "biomarkerId": "B0000F7",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": null,
                "whoclass": "2007",
                "region": [
                    "China"
                ],
                "research": {
                    "methods": [
                        "DNA methylation",
                        "IHC",
                        "BSP",
                        "WB",
                        "Transwell invasion assay"
                    ],
                    "results": [
                        "Rab27b was significantly hypomethylated in high-grade gliomas compared with low-grade gliomas"
                    ],
                    "conclusions": [
                        "Rab27b promoter hypomethylation and expression are significantly correlated with the tumor grade progression of glioma"
                    ]
                },
                "application": {
                    "validated": null,
                    "diagnosis": "NO",
                    "prognosis": "YES",
                    "predictive": "NO",
                    "therapeutic": "NO"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": "NO",
                "curator": "RF"
            },
            {
                "_id": "V0000F8",
                "pmid": "26143636",
                "biomarkerId": "B0000F8",
                "sourceIds": [
                    "Tissue",
                    "Blood"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": null,
                "whoclass": "2007",
                "region": [
                    "Sweden"
                ],
                "research": {
                    "methods": [
                        "RT-PCR",
                        "SNP genotyoing"
                    ],
                    "results": [
                        "TERT\u00a0SNPs are associated with an increased risk of developing GBM, and an association between somatic\u00a0TERT\u00a0promoter mutations also results in a reduced OS"
                    ],
                    "conclusions": [
                        "TERT\u00a0and\u00a0IL-6\u00a0plays a significant role in GBM, where specific SNPs increase the risk of developing GBM while the rs2853669 SNP and specific mutations in the\u00a0TERT\u00a0promoter of the tumor lead to shorter survival."
                    ]
                },
                "application": {
                    "validated": null,
                    "diagnosis": "NO",
                    "prognosis": "YES",
                    "predictive": "YES",
                    "therapeutic": "NO"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": "NO",
                "curator": "RF"
            },
            {
                "_id": "V0000F9",
                "pmid": "26122847",
                "biomarkerId": "B0000F9",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": null,
                "whoclass": "2007",
                "region": [
                    "France"
                ],
                "research": {
                    "methods": [
                        "PCR",
                        "WB",
                        "Luciferase assay",
                        "immunostaining"
                    ],
                    "results": [
                        "CRMP5 controls Notch-dependent GBM proliferation",
                        "CRMP5 controls Notch and Akt activations in GBM tumors",
                        "CRMP5 and Itch control Notch lysosomal degradation"
                    ],
                    "conclusions": [
                        "CRMP5 expression in GBM predicts lower patient survival and is related to tumor proliferation"
                    ]
                },
                "application": {
                    "validated": null,
                    "diagnosis": "NO",
                    "prognosis": "YES",
                    "predictive": "NO",
                    "therapeutic": "NO"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": "NO",
                "curator": "RF"
            },
            {
                "_id": "V0000FA",
                "pmid": "26115094",
                "biomarkerId": "B000130",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "II"
                ],
                "whoclass": "2007",
                "region": [
                    "China"
                ],
                "research": {
                    "methods": [
                        "Pyrosequencing"
                    ],
                    "results": [
                        "OS was significantly longer in patients with\u00a0IDH1-mutated tumors than in patients with\u00a0IDH1\u00a0wild-type tumors"
                    ],
                    "conclusions": [
                        "prognostic significance of\u00a0IDH1\u00a0mutation in patients with oligodendroglioma or oligoastrocytoma, but not in patients with astrocytoma."
                    ]
                },
                "application": {
                    "validated": null,
                    "diagnosis": "YES",
                    "prognosis": "YES",
                    "predictive": "NO",
                    "therapeutic": "NO"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": "YES",
                "curator": "RF"
            },
            {
                "_id": "V0000FB",
                "pmid": "26108996",
                "biomarkerId": "B0000FB",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": "2007",
                "region": [
                    "China"
                ],
                "research": {
                    "methods": [
                        "WB,Microarray",
                        "qPCR",
                        "Soft agar assays"
                    ],
                    "results": [
                        "GRP94 was overexpressed at both mRNA and protein levels in high-grade glioblastoma as compared with normal brain tissues. High GRP94 levels also predict shorter overall survival of glioma patients."
                    ],
                    "conclusions": [
                        "GRP94 is associated with jhigher grade and poorer prognosis in glioma"
                    ]
                },
                "application": {
                    "validated": null,
                    "diagnosis": "NO",
                    "prognosis": "YES",
                    "predictive": "YES",
                    "therapeutic": "YES"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": "NO",
                "curator": "RF"
            },
            {
                "_id": "V0000FC",
                "pmid": "26108672",
                "biomarkerId": "B0000FC",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "I",
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": "2007",
                "region": null,
                "research": {
                    "methods": [
                        "WB",
                        "RT-PCR",
                        "Mass spectometry",
                        "IHC",
                        "Strong cation exchange fractionantion"
                    ],
                    "results": [
                        "HSPB1 was highly expressed in GBM-short survival, especially when compared to GBM-long survival"
                    ],
                    "conclusions": [
                        "HSPB1/HSP27, as a predictive factor of poor prognosis for GBM"
                    ]
                },
                "application": {
                    "validated": null,
                    "diagnosis": "NO",
                    "prognosis": "YES",
                    "predictive": "NO",
                    "therapeutic": "NO"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": "NO",
                "curator": "RF"
            },
            {
                "_id": "V0000FD",
                "pmid": "26101711",
                "biomarkerId": "B0000FD",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "I",
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": "2007",
                "region": [
                    "China"
                ],
                "research": {
                    "methods": [
                        "ALDEFLUOR assay",
                        "FACS",
                        "RT-PCR",
                        "WB",
                        "CK8 assay"
                    ],
                    "results": [
                        "ADLH1A1 was frequently overexpressed in the high-grade glioma (WHO grade III-IV) as compared to the low-grade glioma (WHO grade I-II) patients"
                    ],
                    "conclusions": [
                        "ALDH1A1 is an independent prognostic indicator for the outcome and disease-free survival of glioma patients,"
                    ]
                },
                "application": {
                    "validated": null,
                    "diagnosis": "NO",
                    "prognosis": "YES",
                    "predictive": "NO",
                    "therapeutic": "YES"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": "NO",
                "curator": "RF"
            },
            {
                "_id": "V0000FE",
                "pmid": "26032848",
                "biomarkerId": "B0000FE",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "I",
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": "2007",
                "region": [
                    "Lithuania"
                ],
                "research": {
                    "methods": [
                        "WB,RT-PCR"
                    ],
                    "results": [
                        "protein levels of Sema3C were markedly increased in glioblastomas compared to grade I-III astrocytoma tissues and were significantly associated with the shorter overall survival of patients."
                    ],
                    "conclusions": null
                },
                "application": {
                    "validated": null,
                    "diagnosis": "NO",
                    "prognosis": "YES",
                    "predictive": "NO",
                    "therapeutic": "NO"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": "NO",
                "curator": "RF"
            },
            {
                "_id": "V0000FF",
                "pmid": "26023083",
                "biomarkerId": "B0000FF",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": null,
                "whoclass": "2007",
                "region": [
                    "Denmark"
                ],
                "research": {
                    "methods": [
                        "WB,IHC,RT-PCR,Microarray",
                        "FACS"
                    ],
                    "results": [
                        "miR-663 significantly inhibits the effects of CXCR4 on the growth and invasion of GBM cells."
                    ],
                    "conclusions": [
                        "miR-663 impairs CXCR4-promoted GBM cell proliferation and invasion"
                    ]
                },
                "application": {
                    "validated": null,
                    "diagnosis": "NO",
                    "prognosis": "YES",
                    "predictive": "YES",
                    "therapeutic": "NO"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": "NO",
                "curator": "RF"
            },
            {
                "_id": "V000100",
                "pmid": "26014517",
                "biomarkerId": "B000100",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": "2007",
                "region": [
                    "China"
                ],
                "research": {
                    "methods": [
                        "IHC"
                    ],
                    "results": [
                        "SEMA6A low expression (Hazard ratio 1.896",
                        "95\u00a0% CI 1.147\u20132.768",
                        "P\u2009=\u20090.009) was independent unfavorable prognostic factors for PFS"
                    ],
                    "conclusions": [
                        "patients expressing high SEMA6A protein levels had a significantly longer overall survival (OS, P\u2009=\u20090.013) and progression-free survival (PFS, P\u2009=\u20090.005) compared to those with low SEMA6A expression level."
                    ]
                },
                "application": {
                    "validated": null,
                    "diagnosis": "NO",
                    "prognosis": "YES",
                    "predictive": "NO",
                    "therapeutic": "NO"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": "NO",
                "curator": "RF"
            },
            {
                "_id": "V000101",
                "pmid": "25939439",
                "biomarkerId": "B000101",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": null,
                "whoclass": "2007",
                "region": [
                    "China"
                ],
                "research": {
                    "methods": [
                        "WB",
                        "qRT-PCR",
                        "IHC"
                    ],
                    "results": [
                        "ectopic expression of miR-137 significantly inhibited GBM cell proliferation and angiogenesis. In addition, ectopic expression of miR-137 inhibited tumor growth and angiogenesis in a SCID mouse xenograft model."
                    ],
                    "conclusions": [
                        "miR-137 is downregulated in glioblastoma (GBM) cell lines and that low levels of miR-137 are associated with a poor prognostic phenotype of GBM patients."
                    ]
                },
                "application": {
                    "validated": null,
                    "diagnosis": "NO",
                    "prognosis": "YES",
                    "predictive": "YES",
                    "therapeutic": "NO"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": "NO",
                "curator": "RF"
            },
            {
                "_id": "V000102",
                "pmid": "25869098",
                "biomarkerId": "B000102",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": null,
                "whoclass": "2007",
                "region": [
                    "China"
                ],
                "research": {
                    "methods": [
                        "qRT-PCR",
                        "MicroRNA"
                    ],
                    "results": [
                        "miR-1280, miR-1238, miR-938 and miR-423-5p (overexpressed in the TCR subgroup)",
                        "and let-7i, miR-93 and mi-151-3p (downregulated in the TCR subtype)"
                    ],
                    "conclusions": [
                        "two distinct subclasses of pGBMs: the temozolomide (TMZ) chemoresistant subtype (TCR subtype) and the TMZ chemosensitive subtype (TCS subtype)"
                    ]
                },
                "application": {
                    "validated": null,
                    "diagnosis": "NO",
                    "prognosis": "YES",
                    "predictive": "NO",
                    "therapeutic": "NO"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": "NO",
                "curator": "RF"
            },
            {
                "_id": "V000103",
                "pmid": "25833697",
                "biomarkerId": "B000103",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": null,
                "whoclass": "2007",
                "region": [
                    "China"
                ],
                "research": {
                    "methods": [
                        "qPCR",
                        "WB",
                        "Transwell assay",
                        "wound healing assay"
                    ],
                    "results": [
                        "miR-139-5p expression is significantly downregulated in tumor tissue compared to normal tissue and shorter overall survival rates in patients with lower miR-139-5p expression"
                    ],
                    "conclusions": [
                        "this study identifies a novel role of miR-139-5p in inhibition of GBM cell migration and invasion"
                    ]
                },
                "application": {
                    "validated": "YES",
                    "diagnosis": "NO",
                    "prognosis": "YES",
                    "predictive": "YES",
                    "therapeutic": "NO"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": "NO",
                "curator": "RF"
            },
            {
                "_id": "V000104",
                "pmid": "25821789",
                "biomarkerId": "B000104",
                "sourceIds": [
                    "Tissue",
                    "Blood"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": "2007",
                "region": [
                    "Italy"
                ],
                "research": {
                    "methods": [
                        "IHC",
                        "WB"
                    ],
                    "results": [
                        "the two main immunoreactivity patterns observed were H-EGFR/L-Beclin1 and L-EGFR/H-Beclin1 the former being the dominant pattern in the majority of cases"
                    ],
                    "conclusions": [
                        "combined evaluation of EGFR and Beclin1 autophagic protein expression in tumor tissue sections could add valuable information to the prognostic molecular profile of GB."
                    ]
                },
                "application": {
                    "validated": null,
                    "diagnosis": "NO",
                    "prognosis": "YES",
                    "predictive": "YES",
                    "therapeutic": "NO"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": "NO",
                "curator": "RF"
            },
            {
                "_id": "V000105",
                "pmid": "25817794",
                "biomarkerId": "B000105",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "I",
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": "2007",
                "region": [
                    "China"
                ],
                "research": {
                    "methods": [
                        "RT-PCR",
                        "WB",
                        "MTS assay"
                    ],
                    "results": [
                        "miR-340 plays an oncosuppressive role in glioblastoma, and that its\u00a0ectopic expression\u00a0causes significant defect in glioblastoma\u00a0cell growth.  it specifically targets the 3\u2032UTRs of CDK6,\u00a0cyclin-D1and\u00a0cyclin-D2, leading to glioblastoma cell cycle arrest"
                    ],
                    "conclusions": [
                        "miR-340 is downregulated in glioblastoma samples and cell lines",
                        "inhibits cell proliferation and targets CDKs"
                    ]
                },
                "application": {
                    "validated": null,
                    "diagnosis": "NO",
                    "prognosis": "YES",
                    "predictive": "NO",
                    "therapeutic": "NO"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": "NO",
                "curator": "RF"
            },
            {
                "_id": "V000106",
                "pmid": "25813152",
                "biomarkerId": "B000106",
                "sourceIds": [
                    "Blood"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "I",
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": "2007",
                "region": [
                    "Portugal"
                ],
                "research": {
                    "methods": [
                        "PCR"
                    ],
                    "results": [
                        "associations between each polymorphic variant and risk for developing gliomas or GBMs were found"
                    ],
                    "conclusions": [
                        "cRMP5 expression in GBM predicts lower patient survival and is related to tumor proliferation"
                    ]
                },
                "application": {
                    "validated": null,
                    "diagnosis": "NO",
                    "prognosis": "YES",
                    "predictive": "NO",
                    "therapeutic": "NO"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": "NO",
                "curator": "RF"
            },
            {
                "_id": "V000107",
                "pmid": "25762646",
                "biomarkerId": "B000107",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": null,
                "whoclass": "2007",
                "region": [
                    "USA"
                ],
                "research": {
                    "methods": [
                        "Immunolabeling",
                        "Lentiviral KD",
                        "wound healing assay"
                    ],
                    "results": [
                        "Plexin-B2 is upregulated in glioma,  promotes mobility and invasiveness of glioma cells in vitro and is associated with shorter survival"
                    ],
                    "conclusions": [
                        "Plexin-B2 is consistently upregulated in all types of human gliomas and that its expression levels correlate with glioma grade and poor survival"
                    ]
                },
                "application": {
                    "validated": null,
                    "diagnosis": "NO",
                    "prognosis": "YES",
                    "predictive": "YES",
                    "therapeutic": "NO"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": "NO",
                "curator": "RF"
            },
            {
                "_id": "V000108",
                "pmid": "25755767",
                "biomarkerId": "B000108",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "III",
                    "III",
                    "IV"
                ],
                "whoclass": "2007",
                "region": [
                    "China"
                ],
                "research": {
                    "methods": [
                        "RT-PCR"
                    ],
                    "results": [
                        "MiR-504 showed significant decreased expression levels both in AAs and GBMs relative to non-neoplastic brains"
                    ],
                    "conclusions": [
                        "low expression level of miR-504 was significantly associated with advanced WHO grade and poorer prognostic"
                    ]
                },
                "application": {
                    "validated": null,
                    "diagnosis": "NO",
                    "prognosis": "YES",
                    "predictive": "NO",
                    "therapeutic": "NO"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": "NO",
                "curator": "RF"
            },
            {
                "_id": "V000109",
                "pmid": "25749043",
                "biomarkerId": "B000109",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": null,
                "whoclass": null,
                "region": null,
                "research": {
                    "methods": [
                        "FACS"
                    ],
                    "results": [
                        "CD133-M patients had significantly improved survival from radiotherapy treatment whereas CD44-M patients received a greater survival benefit from temozolomide treatment"
                    ],
                    "conclusions": [
                        "CD44 and CD133 coexpression signatures predict temozolomide and radiation response"
                    ]
                },
                "application": {
                    "validated": null,
                    "diagnosis": "YES",
                    "prognosis": "NO",
                    "predictive": "NO",
                    "therapeutic": "NO"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": "YES",
                "curator": "RF"
            },
            {
                "_id": "V00010A",
                "pmid": "25572712",
                "biomarkerId": "B00010A",
                "sourceIds": [
                    "Tissue",
                    "Cell line"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": "2007",
                "region": [
                    "China"
                ],
                "research": {
                    "methods": [
                        "Luciferase reporter assay",
                        "Cell proliferation assays",
                        "Western blot",
                        "Cell cycle analysis",
                        "Kaplan Meier survival curves",
                        "Log-rank test",
                        "Two tailed t-test"
                    ],
                    "results": [
                        "miR-206 is downregulated in GBM and associated with poor prognosis in patients with glioma",
                        "CyclinD2 is a direct target of miR-206",
                        "CyclinD2 is increased in HGGs and is correlated with poor prognosis",
                        "miR-206 inhibits cell proliferation and arrests G1/S transition in the cell cycle via targeting cyclinD2 in glioma cell lines"
                    ],
                    "conclusions": [
                        "miR-206 acts as a tumor suppressor in glioma and regulates cell proliferation and cell cycle arrest by targeting cyclinD2",
                        "miR-206 was suggested to be a novel candidate for use as a prognostic marker in patients with glioma and to have potential for use as a therapeutic target in gliomas"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": null,
                    "prognosis": "Potential",
                    "predictive": null,
                    "therapeutic": "Potential"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "BP"
            },
            {
                "_id": "V00010B",
                "pmid": "25514975",
                "biomarkerId": "B00010B",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": "2007",
                "region": [
                    "China"
                ],
                "research": {
                    "methods": [
                        "Analysis of DEGs",
                        "Functional enrichment analysis",
                        "Weight of regulatory network",
                        "Screening of sub-networks",
                        ""
                    ],
                    "results": [
                        "A total of 676 DEGs were identified, of which 190 were upregulated and 496 were downregulated",
                        "Gene Ontology analysis demonstrated that the majority of these DEGs were functionally enriched in synaptic transmission, regulation of vesicle-mediated transport and ion-gated channel activity",
                        "TP53, SP1, JUN, STAT3, and SPI1 were identified as crucial TFs involved in the development of GBM"
                    ],
                    "conclusions": [
                        "TP53 and JUN may act as potential biomarkers for the prognosis of GBM",
                        "SPI1 may also be a potential biomarker or therapeutic target for GBM"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": null,
                    "prognosis": "Potential",
                    "predictive": null,
                    "therapeutic": "Potential"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "BP"
            },
            {
                "_id": "V00010C",
                "pmid": "25498217",
                "biomarkerId": "B00010C",
                "sourceIds": [
                    "Tissue",
                    "Cell line"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": "2007",
                "region": [
                    "China"
                ],
                "research": {
                    "methods": [
                        "DNA methylation profiling",
                        "Immunohistochemistry",
                        "Western blot",
                        "Flow cytometry",
                        "Cox model",
                        "Kaplan Meier curves"
                    ],
                    "results": [
                        "TES promoter was hypermethylated in GBM compared to normal\u2008brain\u2008tissues under DNA promoter methylation microarray analysis",
                        "GBM patients with TES hypermethylation had a short overall survival",
                        "Among GBM samples, reduced TES protein level was detected in 33 (89.2%) of 37 tumor tissues",
                        "Down regulation of TES was also correlated with worse patient outcome"
                    ],
                    "conclusions": [
                        "TES gene is a novel tumor suppressor gene and might represent a valuable prognostic marker for glioblastoma, indicating a potential target for future GBM therapy"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": null,
                    "prognosis": "Potential",
                    "predictive": null,
                    "therapeutic": "Potential"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "BP"
            },
            {
                "_id": "V00010D",
                "pmid": "25444902",
                "biomarkerId": "B00010D",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "I",
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": "2007",
                "region": [
                    "China"
                ],
                "research": {
                    "methods": [
                        "Pyrosequencing",
                        "Immunohistochemistry",
                        "Western blot",
                        "Real-time PCR",
                        "Xenograft model",
                        "ANOVA",
                        "Kaplan Meier analysis"
                    ],
                    "results": [
                        "increased EZH2 expression was associated with tumor grade",
                        "High expression of EZH2 in GBM was determined to be a strong and independent predictor of short overall survival",
                        "Repression of EZH2 induced cell cycle arrest and inhibited tumor growth in vivo",
                        "This event represents a positive feedback loop with \u03b2-catenin/TCF4 and STAT3 signaling"
                    ],
                    "conclusions": [
                        "EZH2 could be an independent prognostic factor and potential therapeutic target for GBM"
                    ]
                },
                "application": {
                    "validated": "Yes",
                    "diagnosis": null,
                    "prognosis": "Potential",
                    "predictive": null,
                    "therapeutic": "Potential"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "BP"
            },
            {
                "_id": "V00010E",
                "pmid": "25325876",
                "biomarkerId": "B00010E",
                "sourceIds": [
                    "Cell line",
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "I",
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": "2007",
                "region": [
                    "Belgium",
                    "Italy"
                ],
                "research": {
                    "methods": [
                        "nanoHPLC-MS/MS Analysis",
                        "K-means clustering",
                        "Mann-Whitney U-Test",
                        "Shapiro-Wilk test",
                        "Log-rank test",
                        "Kaplan-Meier curves",
                        "Western blot",
                        "Immunohistochemistry",
                        "Immunofluorescence"
                    ],
                    "results": [
                        "Immunohistochemical analysis of glioma samples from 61 patients demonstrated that COL6A1 is a significant and consistent feature of high-grade glioma",
                        "Deposits of COL6A1 were evidenced in the perivascular regions of the tumor-associated vasculature and in glioma cells found in pseudopalisade structures",
                        "Retrospective analysis of public gene-expression data sets from over 300 glioma patients demonstrated a significant correlation of poor patient outcome and high COL6A1 expression"
                    ],
                    "conclusions": [
                        "Present data associate for the first time collagens in high-grade glioma with accessibility as an important feature for therapeutic application",
                        "The identification of COL6A1 is particularly relevant because this protein has low expression in most normal human tissues, qualifying it as a promising target for antibody-based tumor therapy",
                        "The present data show that COL6A1 expression in glioblastomas is to a great extent limited to the perivascular region"
                    ]
                },
                "application": {
                    "validated": "Yes (Immunohistochemical validation)",
                    "diagnosis": null,
                    "prognosis": "YES",
                    "predictive": null,
                    "therapeutic": "Potential"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "BP"
            },
            {
                "_id": "V00010F",
                "pmid": "25084773",
                "biomarkerId": "B00010F",
                "sourceIds": [
                    "Tissue",
                    "Cell line"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": null,
                "region": [
                    "Spain"
                ],
                "research": {
                    "methods": [
                        "RNA extraction",
                        "Retrotranscription",
                        "Quantitative Rearl-Time PCR",
                        "Western blot",
                        "ELISA",
                        "Luciferase assays",
                        "Immunohistochemical staining",
                        "Chromatin Immunoprecipitation",
                        "Itracranial tumor assay",
                        "t-test",
                        "Spearman correlation test"
                    ],
                    "results": [
                        "TGF\u03b2 can induce TGF\u03b22, generating an autocrine loop leading to aberrantly high levels of TGF\u03b22",
                        "Identified cAMP-responsive element\u2013binding protein 1 (CREB1) as the critical mediator of the induction of TGF\u03b22 by TGF\u03b2",
                        "CREB1 binds to the TGFB2 gene promoter in cooperation with SMAD3 and is required for TGF\u03b2 to activate transcription",
                        "PI3K\u2013AKT and RSK pathways regulate the TGF\u03b22 autocrine loop through CREB1",
                        "Levels of CREB1 and active phosphorylated CREB1 correlate with TGF\u03b22 in GBM",
                        "In patient-derived in vivo models of GBM, CREB1 levels determine the expression of TGF\u03b22"
                    ],
                    "conclusions": [
                        "CREB1 can be considered a biomarker to stratify patients for anti-TGF\u03b2 treatments and a therapeutic target in glioblastoma"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": null,
                    "prognosis": null,
                    "predictive": "Potential",
                    "therapeutic": "Potential"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "BP"
            },
            {
                "_id": "V000110",
                "pmid": "25038272",
                "biomarkerId": "B000110",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": "2007",
                "region": [
                    "Italy"
                ],
                "research": {
                    "methods": [
                        "FISH analysis",
                        "TUNEL",
                        "Immunohistochemical assessment",
                        "RT-PCR",
                        "Western Blotting",
                        "Newman-Keuls multiple comparison post test"
                    ],
                    "results": [
                        "frequency of 36.6% of Bcl-6 translocation in GBM patients and a decreased expression in low-grade glioma patients, correlated with the severity of the disease",
                        "Bcl-6 translocation induced an overexpression of both Bcl-6 protein and messenger in GBM, inhibiting apoptotic processes and caspases 3 expression",
                        "in low-grade gliomas and meningiomas Bcl-6 expression was reduced, resulting in an increase of apoptotic processes.p53 expression levels in brain tumors were comparable to Bcl-6 levels"
                    ],
                    "conclusions": [
                        "Bcl-6 gene translocates in GBM patients and that its translocation and expression are correlated with apoptosis inhibition, indicating a key role for this gene in the control of cellular proliferation",
                        "study supports Bcl-6 as a new diagnostic marker to evaluate the disease severity"
                    ]
                },
                "application": {
                    "validated": "Potential",
                    "diagnosis": "Potential",
                    "prognosis": null,
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": "Potential",
                "curator": "Vanessa"
            },
            {
                "_id": "V000111",
                "pmid": "24927751",
                "biomarkerId": "B000111",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": null,
                "region": [
                    "China"
                ],
                "research": {
                    "methods": [
                        "RT-PCR",
                        "mRNA in situ hybridization",
                        "Immunohistochemical assessment",
                        "Western Blotting"
                    ],
                    "results": [
                        "overexpression of the p42.3 gene is detected in gliomas, but not in normal brain tissues",
                        "p42.3 mRNA expression is correlated with the pathological features of gliomas",
                        "p42.3 protein is expressed in both the cytoplasm and the nucleus in astrocytomas, whereas this protein appeared in the cytoplasm in glioblastomas"
                    ],
                    "conclusions": [
                        "p42.3 might be involved in carcinogenesis as a potential molecular marker for malignant gliomas"
                    ]
                },
                "application": {
                    "validated": "Potential",
                    "diagnosis": null,
                    "prognosis": null,
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Vanessa"
            },
            {
                "_id": "V000112",
                "pmid": "26207187",
                "biomarkerId": "B000112",
                "sourceIds": [
                    "Cell line"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": null,
                "region": [
                    "USA"
                ],
                "research": {
                    "methods": [
                        "2D-DIGE",
                        "Mass Spectroscopy",
                        "Microarray analysis",
                        "Microarray hybridization"
                    ],
                    "results": [
                        "Glucose Regulated Protein 78 (GRP78) is a differentially expressed protein in the GBM cell line compared to human normal Astrocyte cells"
                    ],
                    "conclusions": [
                        "GRP78 expression may serve as a biomarker for tumor behavior and treatment response"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": null,
                    "prognosis": "Potential",
                    "predictive": "Potential",
                    "therapeutic": "Potential"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": null
            },
            {
                "_id": "V000113",
                "pmid": "24472318",
                "biomarkerId": "B000113",
                "sourceIds": [
                    "Tissue",
                    "Cell line"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": "2007",
                "region": [
                    "India"
                ],
                "research": {
                    "methods": [
                        "Immunohistochemistry",
                        "Transfection and luciferase assay",
                        "ChIP assay",
                        "Western blot",
                        "Real-time PCR",
                        "t-test",
                        "Mann-Whitney U test"
                    ],
                    "results": [
                        "First time demonstration of a negative correlation (r = 0.632) between DPP III and IL\u20106 in both human tumors and cultured glioblastoma cells",
                        "Treatment of U87MG cells with IL\u20106 significantly decreased DPP III expression with a concomitant increase in the levels of transcription factor CCAAT/enhancer binding protein beta (C/EBP\u2010\u03b2)",
                        "Deletion/mutagenesis of C/EBP\u2010\u03b2 binding motif of DPP III promoter significantly increased its activity and abolished its responsiveness to IL\u20106"
                    ],
                    "conclusions": [
                        "Demonstrates C/EBP\u2010\u03b2 mediated transcriptional downregulation of DPP III by IL\u20106",
                        "The results demonstrating a negative correlation between IL\u20106 and DPP III taken together with the previously reported prognostic significance of this cytokine in glioblastoma suggests that DPP III may prove useful as a prognostic marker"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": null,
                    "prognosis": "Potential",
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": null
            },
            {
                "_id": "V000114",
                "pmid": "24438238",
                "biomarkerId": "B000114",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": "2007",
                "region": [
                    "China"
                ],
                "research": {
                    "methods": [
                        "RT-PCR",
                        "Kaplan-Meier analysis",
                        "Cox regression analysis",
                        "Risk-score analysis"
                    ],
                    "results": [
                        "Patients who had high-risk scores had poor overall survival compared with patients who had low-risk scores",
                        "The prognostic miRNA signature for the Mesenchymal subtype (four risky miRNAs: miR-373, miR-296, miR-191, miR-602",
                        "one protective miRNA: miR-223) was further validated in an independent cohort containing 41 samples"
                    ],
                    "conclusions": [
                        "Reported novel diagnostic tools for deeper prognostic sub-stratification in GBM intrinsic subtypes based upon miRNA expression profiles and believe that such signature could lead to more individualized therapies to improve survival rates and provide a potential platform for future studies on gene treatment for GBM"
                    ]
                },
                "application": {
                    "validated": "Yes (only for Mesenchymal type GBM)",
                    "diagnosis": null,
                    "prognosis": "Potential",
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": null
            },
            {
                "_id": "V000115",
                "pmid": "24158112",
                "biomarkerId": "B000115",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "I",
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": "2007",
                "region": [
                    "USA"
                ],
                "research": {
                    "methods": [
                        "Immunohistochemistry",
                        "Gene Expression Analysis",
                        "Welch 2-sample t test",
                        "Global microarray meta-analysis"
                    ],
                    "results": [
                        "Identified 5 potential biomarkers\u2014spondin1, Plexin-B2, SLIT3, fibulin-1, and LINGO1\u2014that were validated as proteins highly expressed on the surface of human gliomas using immunohistochemistry",
                        "Expression of spondin1, Plexin-B2, and SLIT3 was significantly higher in high-grade gliomas than in low-grade gliomas",
                        "These biomarkers were significant discriminators in grade IV gliomas compared with either grade III or II tumors and also distinguished between GBM subclasses"
                    ],
                    "conclusions": [
                        "This study strongly suggests that this type of bioinformatics approach has high translational potential to rapidly discern which poorly characterized proteins may be of clinical relevance."
                    ]
                },
                "application": {
                    "validated": "Yes",
                    "diagnosis": "YES",
                    "prognosis": null,
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": "YES",
                "curator": null
            },
            {
                "_id": "V000116",
                "pmid": "24146797",
                "biomarkerId": "B000116",
                "sourceIds": [
                    "Tissue",
                    "Cell line"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "I",
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": "2007",
                "region": [
                    "USA",
                    "Australia",
                    "Italy"
                ],
                "research": {
                    "methods": [
                        "Serial Analysis of Gene Expression",
                        "qRT-PCR",
                        "Flow cytometry",
                        "Fluorescence-activated cell sorting",
                        "Immunohistochemistry",
                        "Kaplan-Meier curves",
                        "Cox model",
                        "t-test"
                    ],
                    "results": [
                        "The loss of PODXL expression upon differentiation of GBM stem-like cell lines was confirmed by quantitative real-time PCR and flow cytometry",
                        "Analytical flow cytometry of numerous GBM oncosphere lines demonstrated PODXL expression in all lines examined",
                        "Knockdown studies and flow cytometric cell sorting experiments demonstrated that PODXL is involved in GBM stem-like cell proliferation and oncosphere formation",
                        "Compared to PODXL-negative cells, PODXL-positive cells had increased expression of the progenitor/stem cell markers Musashi1, SOX2, and BMI1",
                        "PODXL expression directly correlated with increasing glioma grade and was a marker for poor outcome in patients with GBM"
                    ],
                    "conclusions": [
                        "Demonstrate PODXL is expressed in undifferentiated GBM stem-like cells",
                        "PODXL expression correlates with cellular proliferation and oncosphere formation and PODXL-positive cells express higher levels of stem cell markers compared to their PODXL-negative counterparts",
                        "High PODXL expression correlates with glioma grade and poorer outcome in patients with GBM"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": "Potential",
                    "prognosis": "Potential",
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": "Potential",
                "curator": null
            },
            {
                "_id": "V000117",
                "pmid": "23826410",
                "biomarkerId": "B000117",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": "2000",
                "region": [
                    "Denmark"
                ],
                "research": {
                    "methods": [
                        "LAMP-1 immunohistochemistry",
                        "Scoring of LAMP-1 staining",
                        "Double immunofluorescence staining",
                        "ANOVA",
                        "Cox regression analysis",
                        "Kaplan-Meier curves"
                    ],
                    "results": [
                        "Most tumors expressed the LAMP-1 protein in the cytoplasm of the tumor cells, while the blood vessels were positive in all tumors",
                        "The percentage of LAMP-1 positive tumor cells and staining intensities increased with tumor grade but variations in tumors of the same grade were also found",
                        "No association was found between LAMP-1 expression and patient overall survival in the individual tumor grades",
                        "LAMP-1/GFAP showed pronounced co-expression and LAMP-1/CD133 was co-expressed as well suggesting that tumor cells including the proposed tumor stem cells contain lysosomes"
                    ],
                    "conclusions": [
                        "Results suggest that high amounts of lysosomes are present in GBMs and in the proposed tumor stem cells",
                        "Targeting of lysosomes may be a promising novel therapeutic strategy against this highly malignant neoplasm"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": null,
                    "prognosis": "NO",
                    "predictive": null,
                    "therapeutic": "Potential"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": null
            },
            {
                "_id": "V000118",
                "pmid": "23726844",
                "biomarkerId": "B000118",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": null,
                "region": null,
                "research": {
                    "methods": [
                        "lncRNA expression profiling (microarray)",
                        "sample-splitting method",
                        "Cox regression analysis"
                    ],
                    "results": [
                        "identification of a set comprised by six lncRNAs that were significantly correlated with patients' overall survival: KIAA0495 is related with shorter survival whereas  PART1, MGC21881, MIAT, GAS5, and PAR5 were associated with prolonged survival."
                    ],
                    "conclusions": [
                        "The six-lncRNA signature is a significant determinant of survival in GBM and is an independent prognostic factor in GBM"
                    ]
                },
                "application": {
                    "validated": "Yes",
                    "diagnosis": "NO",
                    "prognosis": "YES",
                    "predictive": "Potential",
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": "may be helpful in predicting treatment outcome"
                },
                "comments": "NO",
                "curator": "ANA"
            },
            {
                "_id": "V000119",
                "pmid": "23663361",
                "biomarkerId": "B000119",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": null,
                "region": null,
                "research": {
                    "methods": [
                        "Microarray (they download the results of a microarray, they don't use samples)",
                        "Cox regression analysis"
                    ],
                    "results": [
                        "These genes have high expression in malignant tumours"
                    ],
                    "conclusions": [
                        "they could divide patients into high\u2010 and low\u2010risk groups with significant prognosis"
                    ]
                },
                "application": {
                    "validated": "yes",
                    "diagnosis": "NO",
                    "prognosis": "YES",
                    "predictive": "Potential",
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": "potential for personalizing cancer management"
                },
                "comments": "NO",
                "curator": "ANA"
            },
            {
                "_id": "V00011A",
                "pmid": "23658650",
                "biomarkerId": "B00011A",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": null,
                "region": null,
                "research": {
                    "methods": [
                        "primary GBM cell lines",
                        "immunoblotting",
                        "immunohistochemistry analysis"
                    ],
                    "results": [
                        "CD97 is expressed in glioma, has functional effects on invasion, and is associated with poor overall survival"
                    ],
                    "conclusions": [
                        "CD97 is associated with decreased survival in GBM patients"
                    ]
                },
                "application": {
                    "validated": "no",
                    "diagnosis": "NO",
                    "prognosis": "YES",
                    "predictive": "Potential",
                    "therapeutic": "Potential"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": "They want to check if a blockade of CD97 can have effects on treatment"
                },
                "comments": "NO",
                "curator": "ANA"
            },
            {
                "_id": "V00011B",
                "pmid": "23658323",
                "biomarkerId": "B0001CF",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": null,
                "region": [
                    "Japan"
                ],
                "research": {
                    "methods": [
                        "CD133 expression by Western blots and immunohistochemistry, clinical (age, sex, KPS, Ki67 labeling index, surgery, ventricular entry) and genetic (IDH1, 7p, 9p, 10q, MGMT) factors."
                    ],
                    "results": [
                        "CD133 expression was significantly higher in distant than in local recurrence. Of the factors to predict the timing of recurrence, high CD133 expression was associated with shorter time to distant recurrence"
                    ],
                    "conclusions": [
                        "The expression of CD133 may be a predictor of the pattern and timing of recurrence of primary glioblastoma."
                    ]
                },
                "application": {
                    "validated": "no",
                    "diagnosis": "NO",
                    "prognosis": "YES",
                    "predictive": "Potential",
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": "NO",
                "curator": "ANA"
            },
            {
                "_id": "V00011C",
                "pmid": "23644658",
                "biomarkerId": "B00011C",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": null,
                "region": [
                    "France"
                ],
                "research": {
                    "methods": [
                        "western blotting",
                        "real time-PCR",
                        "analysis in mice"
                    ],
                    "results": [
                        "parkin protein and mRNA levels are decreased as tumor grades increase and  these levels are inversely correlate with p53 expression, particularly in those cases where samples harbor a p53 mutation"
                    ],
                    "conclusions": [
                        "Parkin expression is often reduced in tumors and it is demonstrated that this can be accounted for by decreased p53-mediated transcriptional control"
                    ]
                },
                "application": {
                    "validated": "yes",
                    "diagnosis": "NO",
                    "prognosis": "YES",
                    "predictive": "NO",
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": "NO",
                "curator": "ANA"
            },
            {
                "_id": "V00011D",
                "pmid": "23643983",
                "biomarkerId": "B000133",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": null,
                "whoclass": null,
                "region": [
                    "China"
                ],
                "research": {
                    "methods": [
                        "miRNA and mRNA expression profiling",
                        "Immunohistochemisty",
                        "Immunofluorescence staining",
                        "statistical analysis"
                    ],
                    "results": [
                        "Ki-67 protein may be regulated by specific miRNA\u2013mRNA interactions which may contribute to the proliferation of glioma cells."
                    ],
                    "conclusions": [
                        "High expression levels of Ki-67 protein suggest a short survival time for patients with AA."
                    ]
                },
                "application": {
                    "validated": "yes",
                    "diagnosis": "NO",
                    "prognosis": "YES",
                    "predictive": "Potential",
                    "therapeutic": "Potential"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": "NO",
                "curator": "ANA"
            },
            {
                "_id": "V00011E",
                "pmid": "23593382",
                "biomarkerId": "B00011E",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": null,
                "region": [
                    "USA",
                    "Switzerland"
                ],
                "research": {
                    "methods": [
                        "measure enzymatic activity",
                        "MS-PCR"
                    ],
                    "results": [
                        "Cytochrome c Oxidase is related with poor prognosis"
                    ],
                    "conclusions": [
                        "Cytochrome c Oxidase is related with poor prognosis"
                    ]
                },
                "application": {
                    "validated": "yes",
                    "diagnosis": "NO",
                    "prognosis": "YES",
                    "predictive": null,
                    "therapeutic": "Potential"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": "potential for personalizing cancer management"
                },
                "comments": "NO",
                "curator": "ANA"
            },
            {
                "_id": "V00011F",
                "pmid": "23592437",
                "biomarkerId": "B00011F",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": null,
                "region": [
                    "Brasil"
                ],
                "research": {
                    "methods": [
                        "qRT-PCR",
                        "microarray"
                    ],
                    "results": [
                        "ACTL8 (57%), OIP5 (54%), XAGE3 (44%) and CTCFL (15%) were frequently expressed in GBM, while over 85% of the tumors expressed at least 1 of these four CTA"
                    ],
                    "conclusions": [
                        "GBM frequently express ACTL8, OIP5, XAGE3 and CTCFL",
                        "mRNA positivity for 3-4 CTA is an independent predictor of better OS for GBM patients."
                    ]
                },
                "application": {
                    "validated": "yes",
                    "diagnosis": "NO",
                    "prognosis": "YES",
                    "predictive": null,
                    "therapeutic": "Potential"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": "potential for personalizing cancer management"
                },
                "comments": "NO",
                "curator": "ANA"
            },
            {
                "_id": "V000120",
                "pmid": "23544166",
                "biomarkerId": "B0001AC",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": null,
                "region": [
                    "USA"
                ],
                "research": {
                    "methods": [
                        "Sanger sequencing"
                    ],
                    "results": [
                        "Pediatric primary GBMs rarely contained TERT mutations (11%), whereas adult primary GBMs frequently did (83%).  Primary GBM patients without TERT mutations had a longer survival"
                    ],
                    "conclusions": [
                        "TERT mutation could be a prognosis marker for overall survival in primary GBM patients"
                    ]
                },
                "application": {
                    "validated": "no",
                    "diagnosis": "Potential",
                    "prognosis": "YES",
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": "Potential",
                "curator": "ANA"
            },
            {
                "_id": "V000121",
                "pmid": "23504125",
                "biomarkerId": "B000121",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "II",
                    "IV"
                ],
                "whoclass": null,
                "region": [
                    "Japan"
                ],
                "research": {
                    "methods": [
                        "immunohistochemistry"
                    ],
                    "results": [
                        "grade II tumors were negative for actinin-4, whereas 20 of 22 tumors with strong actinin-4 expression were WHO grade IV."
                    ],
                    "conclusions": [
                        "actinin-4 may help distinguish between astro- cytic and oligodendroglial lines of differentiation."
                    ]
                },
                "application": {
                    "validated": "no",
                    "diagnosis": "Potential",
                    "prognosis": "YES",
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": "Potential",
                "curator": "ANA"
            },
            {
                "_id": "V000122",
                "pmid": "23467707",
                "biomarkerId": "B000122",
                "sourceIds": [
                    "Tissue",
                    "Cell line"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": null,
                "whoclass": "2007",
                "region": [
                    "China"
                ],
                "research": {
                    "methods": [
                        "microarray",
                        "gene ontology analysis",
                        "cell culture",
                        "invasion assay",
                        "western blotting"
                    ],
                    "results": [
                        "POSTN is relative to glioma grade progression and confers a poor prognosis of high-grade glioma patients"
                    ],
                    "conclusions": [
                        "POSTN expression correlated with glioma patient survival, as well as to glioma grade and is an independent prognostic factor in high-grade glioma patients"
                    ]
                },
                "application": {
                    "validated": "yes",
                    "diagnosis": "NO",
                    "prognosis": "YES",
                    "predictive": "YES",
                    "therapeutic": "Potential"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": "potential target for anti-invasion and anti-proliferation therapies in glioma patients"
                },
                "comments": "NO",
                "curator": "ANA"
            },
            {
                "_id": "V000123",
                "pmid": "23426156",
                "biomarkerId": "B000123",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": "2007",
                "region": [
                    "Japan"
                ],
                "research": {
                    "methods": [
                        "Immunohistochemistry",
                        "IDO expression scoring",
                        "Kaplan Meier method",
                        "Log-rank test",
                        "Cox model"
                    ],
                    "results": [
                        "Expression of IDO was found in 72 of 75 gliomas at varying intensities",
                        "Stronger expression of IDO was more likely to be observed in malignant gliomas compared with low-grade gliomas",
                        "IDO expression in the 6 cases of secondary glioblastoma was stronger than in the initial low-grade glioma",
                        "Grade IV patients with strong IDO expression had significantly worse overall survival rates than patients with weak IDO expression"
                    ],
                    "conclusions": [
                        "IDO is expressed more strongly in both primary and secondary glioblastoma tissue than low-grade glioma and may affect clinical outcome",
                        "If IDO promotes glioma cells to escape from the immune system, IDO may be a crucial therapeutic target for malignant gliomas"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": "NO",
                    "prognosis": "NO",
                    "predictive": "NO",
                    "therapeutic": "Potential"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": "NO",
                "curator": "ANA"
            },
            {
                "_id": "V000124",
                "pmid": "23377983",
                "biomarkerId": "B000124",
                "sourceIds": [
                    "Tissue",
                    "Cell line"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": "2007",
                "region": [
                    "China"
                ],
                "research": {
                    "methods": [
                        "Cox model",
                        "Western blot",
                        "Real-time PCR",
                        "Clonogenic assay",
                        "Immunofluorescent statining",
                        "Cell cycle analysis",
                        "Newman-Keuls test"
                    ],
                    "results": [
                        "Patients with high ID1 expression had better survival than patients with low ID1 expression, and a strong correlation was found between radiotherapy efficacy, ID1 expression, and overall survival",
                        "The clonogenic formation assay showed that U87 ID1-shRNA cells were much less sensitive to radiation",
                        "Both the results of the \u03b3H2AX foci staining assay and the comet assay further revealed that ID1 negatively regulates DNA repair processes by downregulating the expression of genes such as DNA ligase IV (LIG4) and ataxia-telangiectasia-mutated",
                        "ID1 induces G2/M arrest in U87 cells"
                    ],
                    "conclusions": [
                        "These results suggest that ID1 may be a new prognostic marker for GBM and have important implications for the therapeutic strategies used to treat GBM patients"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": "NO",
                    "prognosis": "Potential",
                    "predictive": "NO",
                    "therapeutic": "NO"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": "NO",
                "curator": "ANA"
            },
            {
                "_id": "V000125",
                "pmid": "23338717",
                "biomarkerId": "B000125",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": "2007",
                "region": [
                    "Turkey"
                ],
                "research": {
                    "methods": [
                        "RNA isolation and expression for 26 genes measured",
                        "qRT-PCR"
                    ],
                    "results": [
                        "There was a significant relationship between the overexpression of Rho-kinase pathway-related genes LIMK1, CFL1, CFL2, and BCL2 and low expression of MAPK1 gene and the survival of the patients",
                        "The patients who survived for more than 6 months with the therapy in the postoperative period had a higher level of expression in LIMK1, CFL1, CFL2, and BCL2 genes and a lower level of expression in MAPK1 gene compared to the patients who survived for less than 6 months with the therapy in the postoperative period"
                    ],
                    "conclusions": [
                        "LIMK1, CFL1, CFL2, BCL2, MAPK1 could be good biomarkers for therapeutics response in GBM"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": "NO",
                    "prognosis": "Potential",
                    "predictive": "Potential",
                    "therapeutic": "Potential"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": "NO",
                "curator": "ANA"
            },
            {
                "_id": "V000126",
                "pmid": "23216891",
                "biomarkerId": "B000126",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": null,
                "region": [
                    "USA"
                ],
                "research": {
                    "methods": [
                        "Transcriptional analysis",
                        "Consensus clustering",
                        "Gene set enrichment analysis",
                        "Kaplan_meier analysis",
                        "Molecular classification comparision",
                        "Copy number analysis"
                    ],
                    "results": [
                        "Patients with \u201cREST Enhanced Malignancies\u201d (REM) tumors present with a shorter disease free survival compared to non-REM gliomas",
                        "REM tumors are refractory to multiple rounds of chemotherapy and patients fail to respond to this line of treatment"
                    ],
                    "conclusions": [
                        "This report is the first to describe a REST gene signature that predicts response to multiple rounds of chemotherapy, the mainline therapy for this disease",
                        "The REST gene signature may have important clinical implications for the treatment of glioblastoma"
                    ]
                },
                "application": {
                    "validated": "Yes",
                    "diagnosis": null,
                    "prognosis": null,
                    "predictive": "Yes (multiple rounds of chemotherapy)",
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Ahmed"
            },
            {
                "_id": "V000127",
                "pmid": "23205130",
                "biomarkerId": "B000127",
                "sourceIds": [
                    "Tissue",
                    "Serum"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "I",
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": "2007",
                "region": [
                    "China"
                ],
                "research": {
                    "methods": [
                        "miRNA microarray",
                        "Reverse transcription and qPCR",
                        "t-test",
                        "Pearson correlation"
                    ],
                    "results": [
                        "Expression levels of miR-544 decreased significantly in anaplastic gliomas or GBM compared with low-grade gliomas",
                        "In an independent cohort of glioma patients, miR-544 exhibited a progression-associated downregulation in glioma tumors",
                        "The levels of miR-544 in serum samples tended to be lower in anaplastic and GBM patients compared with low-grade gliomas, but with no significant difference",
                        "A weak positive correlation between tissue and serum levels of miR-544"
                    ],
                    "conclusions": [
                        "Data support a significant role for miR-544 aberration in the malignant transformation of glioma",
                        "The downregulation of miR-544 in tissue may be used as a novel biomarker"
                    ]
                },
                "application": {
                    "validated": "Yes",
                    "diagnosis": "Yes (for malignant transformation but NOt for GBM itself)",
                    "prognosis": null,
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": "Yes (for malignant transformation but NOt for GBM itself)",
                "curator": "Ahmed"
            },
            {
                "_id": "V000128",
                "pmid": "23104517",
                "biomarkerId": "B000128",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "I",
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": "2007",
                "region": [
                    "Denmark"
                ],
                "research": {
                    "methods": [
                        "In\u00a0situ hybridization (ISH) using LNA-DNA chimeric probes",
                        "Advanced image analysis",
                        "Intra- and interindividual variance"
                    ],
                    "results": [
                        "MiR-21 is expressed in tumor cells and tumor-associated vasculature",
                        "MiR-21 increases with tumor grade and is inversely correlated with OS",
                        "Tumor cell miR-21 is associated with poor prognosis"
                    ],
                    "conclusions": [
                        "miR-21 is located in both tumor cells and tumor blood vessels and that its level in the tumor cell compartment holds unfavorable prognostic value in gliomas"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": null,
                    "prognosis": "Potential",
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Ahmed"
            },
            {
                "_id": "V000129",
                "pmid": "23097141",
                "biomarkerId": "B000129",
                "sourceIds": [
                    "Tissue",
                    "Cell line"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "I",
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": null,
                "region": [
                    "Finland"
                ],
                "research": {
                    "methods": [
                        "FISH",
                        "Array comparative genomic hybridization",
                        "Gene expression microarrays",
                        "Microarray analysis",
                        "Immunohistochemistry",
                        "Fisher's exact test",
                        "Kaplan-Meier method",
                        "Cox model"
                    ],
                    "results": [
                        "Found\u00a0NAV3amplifications to dominate in neuronally differentiated tumors, whereas glial tumors showed almost equal proportions of\u00a0NAV3\u00a0deletion and amplification",
                        "Grade IV gliomas had more frequent\u00a0NAV3\u00a0deletions than grades I\u2013III gliomas",
                        "Silencing of\u00a0NAV3\u00a0in glioma cell lines led to the upregulation of receptor genes associated with gonadotropin\u2010releasing hormone and Jak\u2010Stat signaling pathways",
                        "Observed association between\u00a0NAV3\u00a0amplifications and favorable prognosis, as well as\u00a0NAV3\u00a0deletions and unfavorable prognosis",
                        "A hazard ratio of 0.51 was observed for\u00a0NAV3\u00a0amplifications and 1.36 for\u00a0NAV3deletions"
                    ],
                    "conclusions": [
                        "NAV3 may be a potential new prognostic biomarker and a potential therapeutic target"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": null,
                    "prognosis": "Potential",
                    "predictive": null,
                    "therapeutic": "Potential"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Ahmed"
            },
            {
                "_id": "V00012A",
                "pmid": "23077581",
                "biomarkerId": "B00012A",
                "sourceIds": [
                    "Tissue",
                    "Cell line"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "I",
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": "2007",
                "region": [
                    "China"
                ],
                "research": {
                    "methods": [
                        "miRNA expression analysis",
                        "Gene ontology analysis",
                        "Immunohistochemistry",
                        "Western blot",
                        "t-test",
                        "ANOVA",
                        "Kaplan-Meier method",
                        "Cox model"
                    ],
                    "results": [
                        "Expression of miR-328 was significantly decreased both in anaplastic and GBM cohorts and that low miR-328 expression also conferred poor survival in primary GBM (PGBM) patients",
                        "MiR-328 might, therefore, serve as an independent prognostic marker",
                        "Ectopic expression of miR-328 inhibited U87 cell proliferation and induced U87 cell cycle arrest"
                    ],
                    "conclusions": [
                        "First report showing that miR-328 is associated with patient\u2019s survival time and that miR-328 might serve as an independent prognostic biomarker for GBM"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": null,
                    "prognosis": "Potential",
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Ahmed"
            },
            {
                "_id": "V00012B",
                "pmid": "23065374",
                "biomarkerId": "B00012B",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": "2007",
                "region": [
                    "France"
                ],
                "research": {
                    "methods": [
                        "Terminal restriction fragment assay using tumor lysates",
                        "Real-time qPCR"
                    ],
                    "results": [
                        "Asignificant correlation between TL and the basal POT1 expression level and photon radioresistance, in vitro, and a significant increase in the OS of patients with long telomeres or a high POT1 level, in vivo",
                        "POT1 expression was predictive of patient response irrespective of the TL",
                        "These correlations were lost, in vitro, when considering carbon irradiation"
                    ],
                    "conclusions": [
                        "A model of the implications of telomeric damage in the cell response to both types of irradiation and assessment of the POT1 expression level and TL using patient tumor biopsies to identify radioresistant patients who could benefit from carbon hadrontherapy"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": "Yes (for identifying radioresistant patient of GBM)",
                    "prognosis": null,
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": "Yes (for identifying radioresistant patient of GBM)",
                "curator": "Ahmed"
            },
            {
                "_id": "V00012C",
                "pmid": "23041832",
                "biomarkerId": "B00012C",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": "2007",
                "region": [
                    "USA"
                ],
                "research": {
                    "methods": [
                        "Histologic review",
                        "Immunohistochemistry"
                    ],
                    "results": [
                        "OLIG2 was strongly expressed in all GBMs with oligodendroglial component, 98% of small cell GBMs, and all granular cell GBMs",
                        "In 74% of GBMs with PNET-like foci, OLIG2 expression was retained in the PNET-like foci, providing a useful distinction from central nervous system PNETs",
                        "The glial component of gliosarcomas was OLIG2 positive in 93% of cases, but only 14% retained focal expression in the sarcomatous component, as such this marker would not reliably distinguish these from pure sarcoma in most cases",
                        "OLIG2 was expressed in 67% of giant cell GBMs",
                        "IDH1 was expressed in 55% of GBMs with oligodendroglial component, 15% of GBMs with PNET-like foci, 7% of gliosarcomas, and none of the small cell, granular cell, or giant cell GBMs"
                    ],
                    "conclusions": [
                        "Study provides further support for the notion that most GBMs with oligodendroglial component are secondary, while small cell GBMs, granular cell GBMs, and giant cell GBMs are primary variants",
                        "Thus, in one of the most challenging differential diagnoses, IDH1 positivity could provide strong support for GBM with oligodendroglial component, while essentially excluding small cell GBM"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": "Yes (for NOn conventional GBMs)",
                    "prognosis": null,
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": "Yes (for NOn conventional GBMs)",
                "curator": "Ahmed"
            },
            {
                "_id": "V00012D",
                "pmid": "22960273",
                "biomarkerId": "B00012D",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": null,
                "region": [
                    "China"
                ],
                "research": {
                    "methods": [
                        "Genome wide DNA methylation profiling",
                        "Pyrosequencing",
                        "Immunohistochemistry",
                        "t-test",
                        "Chi-square test",
                        "Kaplan-Meier curves",
                        "Log-rank test"
                    ],
                    "results": [
                        "The differentially expressed CpG loci were identified between residual 18 short term survival and 9 long term survival G-CIMP- samples",
                        "Methylation levels of 11 CpG loci (10genes) were statistically significantly lower, and 43 CpG loci (40genes) were statistically significantly higher in the tumor tissues of long term survival than those of short term survival G-CIMP- samples",
                        "Of the 43 CpG loci that were hypermethylated in long term survival G-CIMP- samples, 3 CpG loci localized in the promoter of ALDH1A3",
                        "In GBM samples without IDH1 mutation and MGMT promoter methylation, the hypermethylation status of ALDH1A3 promoter predicted a better prognosis with an accompanied low expression of ALDH1A3 protein"
                    ],
                    "conclusions": [
                        "Results defined prognosis-related methylation signatures systematically for the first time in G-CIMP- primary GBMs",
                        "ALDH1A3 promoter methylation conferred a favorable prognosis in G-CIMP- primary GBMs"
                    ]
                },
                "application": {
                    "validated": "Yes",
                    "diagnosis": null,
                    "prognosis": "Yes (Only for G-CIMP primary GBM)",
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Ahmed"
            },
            {
                "_id": "V00012E",
                "pmid": "22922887",
                "biomarkerId": "B00012E",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": "2007",
                "region": [
                    "Republic of Korea"
                ],
                "research": {
                    "methods": [
                        "Immunohistochemistry for neuronal markers",
                        "Assessment of protein expression",
                        "Fisher\u2019s exact test"
                    ],
                    "results": [
                        "Sixty-one of the 88 tumors (69.3 %) were positive for at least one neuronal marker",
                        "Synaptophysin positivity was observed in 43 cases (48.9 %)",
                        "Neurofilament protein and NeuN were positive in 38 (43.2 %) and 42 cases (47.7 %), respectively",
                        "There was no statistically significant difference in overall survival and progression-free survival in association with neuronal marker expression",
                        "Gross total removal or combined radiotherapy and chemotherapy significantly prolonged survival",
                        "NeuN expression was the independent prognostic factors in progression-free survival"
                    ],
                    "conclusions": [
                        "Although the correlation of neuronal marker expression and clinical outcome in GBM is of considerable interest, the presented data support the limited prognostic value of neuronal marker expression in GBM"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": null,
                    "prognosis": "Yes (Limited and only NeuN)",
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Ahmed"
            },
            {
                "_id": "V00012F",
                "pmid": "22825389",
                "biomarkerId": "B00012F",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "III",
                    "IV"
                ],
                "whoclass": null,
                "region": [
                    "Germany"
                ],
                "research": {
                    "methods": [
                        "Immunohistochemistry",
                        "Image preparation and registration",
                        "Estimation of intercapillary distances",
                        "Calculation of diffuse-limited fractions",
                        "Colonization studies",
                        "Mann-Whitney U test",
                        "Wilcoxon test"
                    ],
                    "results": [
                        "HIF-1\u03b1-, GLUT-1- and CA IX-positive staining was found in all 11 GBMs, showing a preferential expression in tissue areas adjacent to necroses",
                        "A considerable spatial overlap between GLUT-1 and CA IX, and a colocalization of these proteins with areas of enlarged mean diffusion distances were observed",
                        "Conversely, 8 of the 10 anaplastic astrocytomas were completely negative for hypoxia-related markers",
                        "GBMs also showed significantly greater heterogeneity of intercapillary distances, larger diffusion-limited tissue fractions, significantly higher mTOR activity and a trend for higher proliferation rates",
                        "Microregionally, mTOR and proliferation showed a significant spatial overlap with areas of shorter mean diffusion distances"
                    ],
                    "conclusions": [
                        "Diffusion-limited hypoxia, leading to the expression of hypoxia-related markers is a pivotal element of the glioblastoma phenotype and may be driven by dysregulated growth and proliferation in normoxic subregions"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": "Yes (MiNOrity of AAs which exhibit an activation of the hypoxic response biologically already represent the decompensated pheNOtype of GBM)",
                    "prognosis": null,
                    "predictive": null,
                    "therapeutic": "Potential"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": "Yes (MiNOrity of AAs which exhibit an activation of the hypoxic response biologically already represent the decompensated pheNOtype of GBM)",
                "curator": "Ahmed"
            },
            {
                "_id": "V000130",
                "pmid": "22752663",
                "biomarkerId": "B000130",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": null,
                "region": [
                    "Japan"
                ],
                "research": {
                    "methods": [
                        "Survey of patients with GBM or GBMO who underwent biopsy or maximal tumor resection followed by concurrent RT and TMZ treatment",
                        "Direct sequencing"
                    ],
                    "results": [
                        "Eleven patients were discovered to have early radiological progression",
                        "Pseudoprogression was detected in two patients (6.3%) diagnosed with GBMO and one patient with GBM",
                        "Both of the GBMO patients with pseudoprogression had the IDH1 mutation, the one GBM patient with pseudoprogression and the other eight patients with early true progression with wild type",
                        "The sensitivity and specificity of the IDH1 mutation for detecting pseudoprogression  were 66.7 and 100%, respectively"
                    ],
                    "conclusions": [
                        "Study suggests the IDH1 mutation may become a novel molecular biomarker for pseudoprogression",
                        "Analyzing the IDH1 mutation, in the case of recognizing early radiological progression, may enable distinction of pseudoprogression from early true progression, and we could determine the need for second-look surgery"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": "Yes (for identifying pseudoprogression from early true progression)",
                    "prognosis": "Potential",
                    "predictive": "Potential",
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": "Yes (for identifying pseudoprogression from early true progression)",
                "curator": "Ahmed"
            },
            {
                "_id": "V000131",
                "pmid": "22725988",
                "biomarkerId": "B000131",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": null,
                "region": [
                    "France"
                ],
                "research": {
                    "methods": [
                        "Immunohistochemistry",
                        "Kaplan-Meier method",
                        "Cox model"
                    ],
                    "results": [
                        "Neurofilament-positive cells were identified in 177 GBMs (58.6%)",
                        "Patients with NFP-positive GBMs were younger and their GBMs presented with more temporal lobe tumor localization and more cortical involvement",
                        "Neurofilament-negative GBMs presented with more ventricular contact and more tumor midline crossing",
                        "Median overall survival and progression-free survival were 13.0 and 7.6 months, respectively, for NFP-positive GBMs, and 7.0 and 5.1 months, respectively, for NFP-negative GBMs",
                        "Multivariate analysis revealed NFP immunoexpression, tumor midline crossing, complete resection, and radiotherapy combined with chemotherapy as independent factors associated with overall survival",
                        "Neurofilament protein-positive immunoexpression was associated with longer overall survival (HR:0.54) and longer PFS (HR:0.71)"
                    ],
                    "conclusions": [
                        "Neurofilament protein-positive immunoexpression represents a strong, therapeutically independent prognostic factor for primary supratentorial GBM clinical outcome among adult patients",
                        "Neurofilament protein-GBM's unique pathological features are not only associated with distinct clinical and anatomical behavior, but are also predictive of overall patient survival and PFS",
                        "Neurofilament protein immunoexpression may help identify a distinct subgroup of primary GBMs with a favorable prognosis, which should be considered in the design of future targeted therapies"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": null,
                    "prognosis": "Potential",
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Ahmed"
            },
            {
                "_id": "V000132",
                "pmid": "22350668",
                "biomarkerId": "B000132",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": null,
                "region": [
                    "Japan"
                ],
                "research": {
                    "methods": [
                        "Tissue microarray",
                        "Immunohistochemistry",
                        "Wilcoxon rank sum test adjusted by Holm\u2019s method",
                        "Fisher\u2019s exact test",
                        "Kaplan\u2013Meier method"
                    ],
                    "results": [
                        "Nestin was frequently expressed in gliomas and schwannomas",
                        "Most of the gliomas that expressed high levels of nestin were high-grade gliomas (AA, AO, AOA and GBM)",
                        "A significantly different nestin expression between GBMs and other high-grade gliomas, and worse overall survival for high-grade gliomas with high nestin expression"
                    ],
                    "conclusions": [
                        "Nestin is a useful marker for diagnosis of high-grade gliomas",
                        "Nestin is helpful in diagnosis of schwannomas, and nestin expression is related to poor prognosis in high-grade gliomas."
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": "YES",
                    "prognosis": "Potential",
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": "YES",
                "curator": "Ahmed"
            },
            {
                "_id": "V000133",
                "pmid": "22040407",
                "biomarkerId": "B000133",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": null,
                "region": [
                    "China"
                ],
                "research": {
                    "methods": [
                        "Immunohistochemistry",
                        "Genome-wide microarray analysis",
                        "Significance analysis of microarrays",
                        "Gene ontology",
                        "KEGG pathway analysis",
                        "Survival analysis"
                    ],
                    "results": [
                        "Confirmed that Ki-67 was an independent prognostic indicator in the largest Chinese patient cohort of 156 GBM samples via immunohistochemical staining",
                        "Survival analysis of Ki-67 over-expression revealed a highly significant association with a worse clinical outcome",
                        "Comparative and integrated analysis between Tiantan and TCGA database identified a 247-gene \"proliferation signature\" (205 up-regulated and 42 down-regulated genes) that distinguished Ki-67 expression phenotypes",
                        "GO and KEGG Pathway analyses further indicated that Ki-67 expression phenotype was associated with distinct changes in gene expression associated with the regulation of cellular growth and proliferation"
                    ],
                    "conclusions": [
                        "Proliferation marker Ki-67 is an independent prognostic indicator in Chinese GBM patients",
                        "Ki-67 associated proliferation signature identified may provide potential targets for anti-proliferation therapy in GBM"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": null,
                    "prognosis": "YES",
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": null
            },
            {
                "_id": "V000134",
                "pmid": "20838435",
                "biomarkerId": "B000134",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": "Pre 2010",
                "region": [
                    "USA"
                ],
                "research": {
                    "methods": [
                        "Microarray and clinical data were acquired in un-normalized form from the Rembrandt [9] public data repository (https://caintegrator.nci.nih.gov/rembrandt/) using data available on November 11, 2009. Clinical data were derived from contributing center institutional diagnoses at Henry Ford Hospital, UCSF, Lee Moffitt Cancer Center, Dana Farber Cancer Center, University of Wisconsin, and NCI and are available as Table S1. Affymetrix HGU133 Plus 2.0 CEL files were normalized using the robust multi-array average (RMA) method [10] with default parameters from the Matlab Bioinformatics Toolbox. Of the 296 samples downloaded, 176 had associated survival data, 75 were oligodendrogliomas or astrocytomas with grades II or III, and 101 were GBMs. Copy number data was derived using Affymetrix 100K SNP arrays available from the Rembrandt public data repository. Of the 176 samples with survival data, 147 have associated SNP arrays for tumor tissue (85 GBMs, 34 Oligodendrogliomas grades II and III, and 28 Astrocytomas grades II and III). To classify Rembrandt samples within the TCGA classification schema, Rembrandt data for the probes from the Affymetrix U133 Plus 2.0 GeneChip were mapped to the TCGA class signature genes using HUGO gene symbol and Entrez gene ID number. Differences in gene expression between subtypes were determined using the comparative selection marker module of GenePattern 3.0. Cox proportional hazards (PH) models were used to examine the association between patient survival and four subtypes after adjusting for patient age at diagnosis as well as 1p/19q status whenever applicable."
                    ],
                    "results": [
                        "We demonstrate that the proneural signature predicts improved clinical outcome among 176 Rembrandt gliomas that includes all histologies and grades, including GBMs (log rank test p = 1.16e-6), but also among 75 grade II and grade III samples (p \u200a=\u200a 2.65e-4). This gene expression signature was enriched in tumors with oligodendroglioma histology and also predicted improved survival in this tumor type (n =\u200a 43, p \u200a=\u200a 1.25e-4). Thus, expression signatures identified in the TCGA analysis of GBMs also have intrinsic prognostic value for lower grade oligodendrogliomas, and likely represent important differences in tumor biology with implications for treatment and therapy."
                    ],
                    "conclusions": [
                        "Despite the richness of TCGA GBM data, the absence of lower grade gliomas in this data set prevents analysis genes related to progression and the uncovering of predictive signatures. Integrated DNA and RNA analysis of low-grade and high-grade proneural gliomas identified increased expression and gene amplification of several genes including GLIS3, TGFB2, TNC, AURKA, and VEGFA in proneural GBMs, with corresponding loss of DLL3 and HEY2. Pathway analysis highlights the importance of the Notch and Hedgehog pathways in the proneural subtype. This demonstrates that the expression signatures identified in the TCGA analysis of GBMs also have intrinsic prognostic value for low-grade oligodendrogliomas, and likely represent important differences in tumor biology with implications for treatment and therapy."
                    ]
                },
                "application": {
                    "validated": "Potential",
                    "diagnosis": null,
                    "prognosis": "Potential",
                    "predictive": "Potential",
                    "therapeutic": "Potential"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Erik Samelsson"
            },
            {
                "_id": "V000135",
                "pmid": "20827226",
                "biomarkerId": "B000135",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": "Pre 2010",
                "region": [
                    "USA"
                ],
                "research": {
                    "methods": [
                        "Immunohistochemistry of EMR-3, RT-PCR, Western Blotting"
                    ],
                    "results": [
                        "Immunohistochemistry for EMR-3 on eight primary glioblastoma tissue samples demonstrated robust expression (>25% of tumor cells) in 3/8, weak expression (1\u20135% of tumor cells) in 1/8, and no evidence expression in 4/8 (figure 2). Given the marked differences in EMR-3 expression, these data suggest that the variability in EMR-3 transcripts seen in microarrays might represent real differences at the protein expression level in human patients."
                    ],
                    "conclusions": [
                        "In summary, we provide evidence for the first time that that the adhesion G-protein coupled receptor EMR-3 is expressed in some human glioblastomas, and may mediate invasive behavior in these cells. These data serve to identify an interesting potential target for future investigations, and to expand our understanding of EMR-3 function."
                    ]
                },
                "application": {
                    "validated": "Potential",
                    "diagnosis": null,
                    "prognosis": null,
                    "predictive": null,
                    "therapeutic": "Potential"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Erik Samelsson"
            },
            {
                "_id": "V000136",
                "pmid": "20730317",
                "biomarkerId": "B000136",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": "Pre 2010",
                "region": [
                    "Brazil"
                ],
                "research": {
                    "methods": [
                        "The expression of caspase-3 and Bcl-2 in 30 samples of GBMs was evaluated by immunohistochemistry."
                    ],
                    "results": [
                        "The expression of caspase-3 (mean 17.67%) was lower than Bcl-2 (mean 30.92%), a statistically significant result (p<0.0001), suggesting low apoptotic activity in these tumors."
                    ],
                    "conclusions": [
                        "Other studies of proteins related to the intrinsic and extrinsic pathway of apoptosis are required to provide additional information of this mechanism in GBMs."
                    ]
                },
                "application": {
                    "validated": "Potential",
                    "diagnosis": null,
                    "prognosis": null,
                    "predictive": "Potential",
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Erik Samelsson"
            },
            {
                "_id": "V000137",
                "pmid": "20667016",
                "biomarkerId": "B000137",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": "Pre 2010",
                "region": [
                    "Czech Republic"
                ],
                "research": {
                    "methods": [
                        "Immunohistochemistry, statistical analysis"
                    ],
                    "results": [
                        "In this study, they evaluated the expression of HLA-G and HLA-E by neoplastic cells in 39 cases of glioblastoma. There was an unexpected positive correlation between the expression of HLA-E and length of survival."
                    ],
                    "conclusions": [
                        "The expression of this molecule by neoplastic cells may represent a coincidental selective pro-host advantage related to better response to subsequent therapeutic modalities. Mechanisms of glioblastoma cell pathophysiology and mechanisms of responses to therapeutic interventions in respect to the expression of these molecules deserves further study."
                    ]
                },
                "application": {
                    "validated": "Potential",
                    "diagnosis": null,
                    "prognosis": null,
                    "predictive": null,
                    "therapeutic": "Potential"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Erik Samelsson"
            },
            {
                "_id": "V000138",
                "pmid": "20601442",
                "biomarkerId": "B000138",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "III IV"
                ],
                "whoclass": "Pre 2010",
                "region": [
                    "Japan"
                ],
                "research": {
                    "methods": [
                        "In this study, we examined the expression levels of 365 mature human miRNAs in 12 malignant gliomas, including 8 glioblastomas and 4 anaplastic astrocytomas, using TaqMan real-time quantitative PCR arrays. A validation study was done to corroborate a subset of the results, including expression levels of miR-196a, -196b, -21, and -15b, by analyzing 92 malignant gliomas by conventional real-time PCR. We modeled the relationship between the expression levels of these miRNAs and the survival rate of 39 glioblastoma patients by Kaplan-Meier method and multivariate analysis."
                    ],
                    "results": [
                        "Expression profiles in glioblastomas and anaplastic astrocytomas suggested that 16 miRNAs were candidate markers associated with the malignant progression of gliomas. Among them, miR-196a showed the most significant difference (P = 0.0038), with miR-196b also having a high significance (P = 0.0371). Both miRNAs showed increased expression levels in glioblastomas relative to both anaplastic astrocytomas and normal brains in the validation study. Furthermore, patients with high miR-196 expression levels showed significantly poorer survival by the Kaplan-Meier method (P = 0.0073). Multivariate analysis showed that miR-196 expression levels were an independent predictor of overall survival in all 39 glioblastoma patients (P = 0.021",
                        "hazard ratio, 2.81)."
                    ],
                    "conclusions": [
                        "Our results suggest that miR-196 may play a role in the malignant progression of gliomas and may be a prognostic predictor in glioblastomas."
                    ]
                },
                "application": {
                    "validated": "Potential",
                    "diagnosis": null,
                    "prognosis": "Potential",
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Erik Samelsson"
            },
            {
                "_id": "V000139",
                "pmid": "20501753",
                "biomarkerId": "B000139",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": "Pre 2010",
                "region": [
                    "India"
                ],
                "research": {
                    "methods": [
                        "The expression of IGFBP isoforms was analyzed in diffusely infiltrating astrocytomas by real-time quantitative PCR (n = 203) and immunohistochemistry (n = 256). Statistical methods were used to assess their grade-specific expression pattern and mRNA-protein intercorrelation. Survival analyses were done on a uniformly treated, prospective cohort of adult patients with newly diagnosed glioblastoma (n = 136) by using Cox regression models."
                    ],
                    "results": [
                        "The mean transcript levels of IGFBP-2 and -3 were significantly higher in glioblastomas (GBM) relative to anaplastic astrocytoma (AA), diffuse astrocytoma (DA), and controls whereas IGFBP-5 mRNA was higher in GBM relative to AA and controls (P < 0.05). By immunohistochemistry, the mean labeling index of all isoforms was significantly higher in GBM compared with AA, DA, and control (P < 0.05). A strong positive correlation was observed between their respective mRNA and protein expressions (P < 0.01). Multivariate analysis revealed IGFBP-3 expression (hazard ratio, 1.021",
                        "P = 0.030) and patient age (hazard ratio, 1.027",
                        "P = 0.007) to be associated with shorter survival in glioblastoma."
                    ],
                    "conclusions": [
                        "This study shows the associations of IGFBP-2, -3, and -5 expression with increasing grades of malignancy in astrocytomas. IGFBP-3 is identified as a novel prognostic glioblastoma biomarker. The strong correlation between their mRNA and protein expression patterns suggests their role in the pathogenesis of these tumors."
                    ]
                },
                "application": {
                    "validated": "Potential",
                    "diagnosis": null,
                    "prognosis": "Potential",
                    "predictive": "Potential",
                    "therapeutic": "Potential"
                },
                "clinical": {
                    "relevance": null,
                    "implication": "IGFBP isoforms have emerged as biomarkers with diagnostic and prognostic utility in astrocytomas.",
                    "treatment": null
                },
                "comments": null,
                "curator": "Erik Samelsson"
            },
            {
                "_id": "V00013A",
                "pmid": "20395120",
                "biomarkerId": "B00013A",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": "Pre 2010",
                "region": [
                    "UK"
                ],
                "research": {
                    "methods": [
                        "So far, studies of Glut-1 in cancer have utilized conventional immunohistochemical analysis in a series of individual biopsy or surgical specimens. Tissue microarrays, however, provide a rapid, inexpensive means of profiling biomarker expression. To evaluate hypoxia markers, tissue cores must show the architectural features of hypoxia",
                        "i.e. viable tissue surrounding necrotic regions. Glut-1 may be a useful biomarker to validate tissue microarrays for use in studies of hypoxia-regulated genes in cancer. In this study, we carried out immunohistochemical detection of Glut-1 protein in many tumor and normal tissue types in a range of tissue microarrays."
                    ],
                    "results": [
                        "Glut-1 was frequently found in peri-necrotic regions, occurring in 9/34 lymphomas, 6/12 melanomas, and 5/16 glioblastomas",
                        "and in 43/54 lung, 22/84 colon, and 23/60 ovarian tumors. Expression was rare in breast (6/40) and prostate (1/57) tumors, and in normal tissue, was restricted to spleen, tongue, and CNS endothelium."
                    ],
                    "conclusions": [
                        "In conclusion, tissue microarrays enable the observation of Glut-1 expression in peri-necrotic regions, which may be linked to hypoxia, and reflect previous studies showing differential Glut-1 expression across tumor types and non-malignant tissue."
                    ]
                },
                "application": {
                    "validated": "Potential",
                    "diagnosis": null,
                    "prognosis": null,
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Erik Samelsson"
            },
            {
                "_id": "V00013B",
                "pmid": "20331867",
                "biomarkerId": "B00013B",
                "sourceIds": [
                    "Imaging"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": "Pre 2010",
                "region": [
                    "UK"
                ],
                "research": {
                    "methods": [
                        "High-resolution magic angle spinning (HRMAS) NMR spectroscopy"
                    ],
                    "results": [
                        "1D and 2D 1H HRMAS NMR was used to determine that 29 small molecule metabolites, along with 8 macromolecule signals, account for the majority of the HRMAS spectrum of the main types of brain tumour (astrocytoma grade II, grade III gliomas, glioblastomas, metastases, meningiomas and also lymphomas). Differences in concentration of 20 of these metabolites were statistically significant between these brain tumour types. During the course of an extended 2D data acquisition the HRMAS technique itself affects sample analysis: glycine, glutathione and glycerophosphocholine all showed small concentration changes",
                        "analysis of the sample after HRMAS indicated structural damage that may affect subsequent histopathological analysis."
                    ],
                    "conclusions": [
                        "A number of small molecule metabolites have been identified as potential biomarkers of tumour type that may enable development of more selective in-vivo 1H NMR acquisition methods for diagnosis and prognosis of brain tumours."
                    ]
                },
                "application": {
                    "validated": "Potential",
                    "diagnosis": "Potential",
                    "prognosis": "Potential",
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": "Potential",
                "curator": "Erik Samelsson"
            },
            {
                "_id": "V00013C",
                "pmid": "20210242",
                "biomarkerId": "B00013C",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": "Pre 2010",
                "region": [
                    "Croatia"
                ],
                "research": {
                    "methods": [
                        "Immunohistochemical staining was performed using a monoclonal antibody for the detection of HNE-modified proteins.The incidence of HNE-positive versus HNE-negative tissues depending on the type of tumor was evaluated using the chi-square test. Possible differences in staining intensity were determined with the Mann-Whitney test, using numerical description of positivity corresponding to the respective standard grading of positivity as described abov"
                    ],
                    "results": [
                        "HNE-protein adducts were found in all tumors. The incidence of HNE-immunopositive tumor cells increased with increasing grades of malignancy. Significantly higher HNE expression was found in tumor cells of glioblastomas multiforme than in cells of pilocytic astrocytomas (P < 0.005), and in anaplastic ependymomas than in benign ependymomas (P < 0.01). HNE-immunopositive tumor cells were distributed more diffusely than in perivascular locations (P < 0.05). Pronounced HNE-protein adducts were detected in mitotic, necrotic, and apoptotic cells. HNE was expressed in the endothelium of almost all tumor vessels, but its expression in the walls of the vessels was significantly higher in diffuse and anaplastic astrocytomas than in pilocytic astrocytomas and glioblastomas multiforme (P < 0.05). The number of microvessels containing HNE in their endothelium and walls was significantly associated with the grade of malignancy in both astrocytic (P < 0.001) and ependymal tumors (P < 0.05), although microvessels in pilocytic astrocytomas were significantly more numerous (P < 0.05) than in diffuse astrocytomas."
                    ],
                    "conclusions": [
                        "LPO seems to be a common pathological process in astrocytic and ependymal glial tumors, proportional to the level of malignancy and neovascularization. Therefore, HNE might be involved in the damage of brain cells and the induction of malignancy."
                    ]
                },
                "application": {
                    "validated": "Potential",
                    "diagnosis": null,
                    "prognosis": null,
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Erik Samelsson"
            },
            {
                "_id": "V00013D",
                "pmid": "20175962",
                "biomarkerId": "B00013D",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": "Pre 2010",
                "region": [
                    "Italy"
                ],
                "research": {
                    "methods": [
                        "The expression of vascular endothelial growth factor (VEGF), epidermal growth factor receptor (EGFR), tenascine, transforming growth factor (TGFbeta), isomeres, platelet-derived growth factor (PDGF) and p53 was studied in 40 primary brain tumors, both low-grade and high-grade, including astrocytomas, oligodendrogliomas, glioblastomas and ependymomas. The same GFs were also studied in 46 specimens of recurrent tumors from the same patients. The positivity and intensity of the immunohistochemical expression were correlated with the tumor grade, the interval and type of recurrence, and the survival."
                    ],
                    "results": [
                        "The expression of all GFs, excepting TGFbeta1, TGFbetaRI and tenascine, was found to be correlated with the tumor grade in all tumors of both astroglial and oligodendroglial origin, whereas ependymomas showed significant differences only for EGFR. Low-grade (Grade II) tumors recurring as anaplastic (Grade III) forms showed GF expression rather similar to initially high-grade gliomas and significantly higher than that of low-grade (Grade II) tumors in both initial surgery and recurrence. Besides, low-grade (Grade II) tumors recurring as low-grade showed significantly longer median recurrence time (5.4 vs. 3.5 years) and better median survival (8.3 vs. 5.4 years) than those recurring as anaplastic forms (WHO III)."
                    ],
                    "conclusions": [
                        "The immunohistochemical study of expression of VEGF, EGFR, TGFbeta2, TGFbeta3, PDGF and p53 in all low-grade (Grade II) brain gliomas at the first operation may help to differentiate cases with slower evolution and longer survival from those with higher potential of anaplastic transformation."
                    ]
                },
                "application": {
                    "validated": "Potential",
                    "diagnosis": null,
                    "prognosis": "Potential",
                    "predictive": "Potential",
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Erik Samelsson"
            },
            {
                "_id": "V00013E",
                "pmid": "20084020",
                "biomarkerId": "B00013E",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": "Pre 2010",
                "region": [
                    "Sweden"
                ],
                "research": {
                    "methods": [
                        "We investigated PROX1 expression patterns in 56 human astrocytic gliomas of different grades using immunohistochemistry."
                    ],
                    "results": [
                        "An average of 79% of cells in World Health Organization Grade IV (glioblastoma, n = 15) and 57% of cells in World Health Organization Grade III (anaplastic astrocytoma, n = 13) were strongly PROX1 positive",
                        "low-grade diffuse astrocytomas (Grade II, n = 13) had 21% of cells that were strongly positive",
                        "Grade I tumors (n = 15) had 1.5%",
                        "and non-neoplastic brain tissue (n = 15) had 3.7% of cells that were PROX1 positive. Double immunolabeling showed that PROX1+ cells in glioblastomas frequently coexpressed early neuronal proteins MAP2 and betaIII-tubulin but not the mature neuronal marker protein NeuN. Analyses of coexpression with proliferation markers suggest that PROX1+ cells have a marginally lower rate of proliferation than other tumor cells but are still mitotically active."
                    ],
                    "conclusions": [
                        "We conclude that PROX1 may constitute a useful tool for the diagnosis and grading ofastrocytic gliomas and for distinguishing Grade III and Grade IV tumors from Grade I and Grade II tumors"
                    ]
                },
                "application": {
                    "validated": "Potential",
                    "diagnosis": "Potential",
                    "prognosis": "Potential",
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": "NA "
                },
                "comments": "Potential",
                "curator": "Erik Samelsson"
            },
            {
                "_id": "V00013F",
                "pmid": "19912360",
                "biomarkerId": "B00013F",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": "Pre 2010",
                "region": [
                    "Finland"
                ],
                "research": {
                    "methods": [
                        "KIT and SCF expression were studied in 248 human tumours consisting of 15 different histological types using immunohistochemistry and in situ hybridization for KIT messenger RNA. Moderate to strong intratumoral endothelial cell KIT expression was present in 11 of the 15 tumour types, and was most common in glioblastoma (58%), mixed embryonal carcinoma with teratoma (33%) and renal clear cell carcinoma (29%)."
                    ],
                    "results": [
                        "Results of in situ hybridization were in line with those obtained with immunohistochemistry in the cases studied (n = 9). Marked SCF expression was uncommon in tumour endothelial cells, but frequent in perinecrotic tumour cells. Patients with glioblastoma with moderate to strong endothelial cell KIT expression had more favourable survival than those whose tumour showed little or no expression (P = 0.024). Glioblastoma patients whose tumour expressed SCF had an unfavourable outcome compared with those with tumour with weak or no expression (P = 0.034)."
                    ],
                    "conclusions": [
                        "Intratumoral microvessels of several types of human malignant tumours express KIT. Tumour cell SCF expression and absence of marked endothelial cell KIT expression are novel adverse prognostic features in glioblastoma."
                    ]
                },
                "application": {
                    "validated": "Potential",
                    "diagnosis": null,
                    "prognosis": "Potential",
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": "NA "
                },
                "comments": null,
                "curator": "Erik Samelsson"
            },
            {
                "_id": "V000140",
                "pmid": "19775291",
                "biomarkerId": "B000140",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": "Pre 2010",
                "region": [
                    "USA"
                ],
                "research": {
                    "methods": [
                        "IHC, Double labeling immunofluorescence (IF), and in the analysis of tissue biopsies, relationships among variables were evaluated using Fisher's exact test for count data with a significance level of 0.05. Concordance in the expression was quantified both calculating the overall agreement and the Cohen's kappa."
                    ],
                    "results": [
                        "We screened 87 human brain tumor biopsies using immunohistochemistry and detected leptin and ObR in 55.2% and 60.9% cases, respectively. In contrast, leptin and ObR were absent in 14 samples of normal brain tissue. The presence of leptin correlated with ObR with overall concordance 80.5%. The leptin/ObR system was highly expressed in glioblastomas and anaplastic astrocytomas, while lower expression of both markers was noted in low-grade astrocytomas and gangliogliomas. The association between leptin/ObR and the degree of tumor malignancy was highly significant (P < 0.001). Using double immunofluorescence of glioblastoma tissues, we found co-expression of leptin with ObR and with the proliferation marker Ki-67 in 87% and 64% of cells, respectively. The leptin/ObR-positive tissues also expressed activated forms of STAT3 and Akt. In line with this finding, ObR-positive glioblastoma cells responded to leptin with cell growth and induction of the STAT3 and Akt pathways as well as inactivation of the cell cycle suppressor Rb."
                    ],
                    "conclusions": [
                        "Statistical analyses were performed using R for Windows software. Cell growth experiments were analyzed using one-way analysis of variance."
                    ]
                },
                "application": {
                    "validated": "Potential",
                    "diagnosis": null,
                    "prognosis": null,
                    "predictive": null,
                    "therapeutic": "Potential"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Erik Samelsson"
            },
            {
                "_id": "V000141",
                "pmid": "19774387",
                "biomarkerId": "B000141",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": "Pre 2010",
                "region": [
                    "France"
                ],
                "research": {
                    "methods": [
                        "In this study, we have chosen to study using different technical approaches (Q-RT-PCR, in situ hybridization and immunohistochemistry) the expression of five molecules involved in extracellular matrix degradation (cathepsin B, MMP2, MMP9, uPA and PAI-1) in glioblastomas in order to determine their prognostic impact among grade IV gliomas. Pilocytic astrocytomas were used as controls."
                    ],
                    "results": [
                        "Q-RT-PCR showed that transcripts of uPA, PAI-1, cathepsin B and MMP9 were significantly more expressed in glioblastomas (n = 52), in comparison to pilocytic astrocytomas (n = 17) (P = 0.049, P < 0.0001, P = 0.03 and P < 0.0001, respectively). On both univariate and multivariate analyses, cathepsin B and PAI-1 were strong predictors of overall survival among the group of glioblastomas (P < 0.0001 and P = 0.01, respectively). Immunohistochemical expression of cathepsin B further confirmed its prognostic value in an independent cohort of patients with glioblastoma. In situ hybridization showed that uPA is detected at the invasive edge of glioblastomas, whereas PAI-1 is more abundant in microvascular proliferation and pseudo-palisading cells than at the infiltrative edges."
                    ],
                    "conclusions": [
                        "These results suggest that cathepsin B and PAI-1 are important biomarkers for the stratification of glioblastoma patients with respect to survival."
                    ]
                },
                "application": {
                    "validated": "Potential",
                    "diagnosis": null,
                    "prognosis": "Potential",
                    "predictive": "Potential",
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Erik Samelsson"
            },
            {
                "_id": "V000142",
                "pmid": "19716156",
                "biomarkerId": "B000142",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": "Pre 2010",
                "region": [
                    "Italy"
                ],
                "research": {
                    "methods": [
                        "Accordingly, the present study investigates caveolin-1 immunoexpression and correlation with the 1p/19q status, histologic grade, proliferation index, epidermal growth factor receptor, and p53 expression in a series of 73 diffuse gliomas."
                    ],
                    "results": [
                        "A membranous and cytoplasmic immunolabeling for caveolin-1 was detected in neoplastic cells of 60% of cases. No significant differences in terms of caveolin-1 expression were observed between astrocytomas, oligodendrogliomas, and oligoastrocytomas. In addition, caveolin-1 expression was not correlated with 1p/19q status in oligodendrogliomas and mixed oligoastrocytomas. Caveolin-1 was expressed in most high-grade (World Health Organization III and IV) gliomas. Low caveolin-1 expression correlated with a higher Ki-67 labeling index and the absence of p53 overexpression in glioblastomas, and it was significantly associated with epidermal growth factor receptor overexpression in anaplastic astrocytomas."
                    ],
                    "conclusions": [
                        "In conclusion, the present study indicates that caveolin-1 is not useful as diagnostic marker to differentiate grade II astrocytomas from oligodendrogliomas."
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": null,
                    "prognosis": null,
                    "predictive": "NO",
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": "NA "
                },
                "comments": null,
                "curator": "Erik Samelsson"
            },
            {
                "_id": "V000143",
                "pmid": "19616898",
                "biomarkerId": "B000143",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": "Pre 2010",
                "region": [
                    "Greece"
                ],
                "research": {
                    "methods": [
                        "This was a a comparative immunohistochemical analysis of aurora-A and aurora-B expression in 40 patients with primary glioblastomas, and attempted to identify any associations with Ki-67 index and the patients' clinical features. The impact of various treatment modalities and proliferative activity on patient outcome was also assessed. Immunohistochemistry was carried out using formalin-fixed and paraffin-embedded tissue sections. Associations among continuous variables were tested using Spearman\u2019s rank correlation coefficient, whereas categorical variables were tested by w2 or Fisher\u2019s exact test as appropriate. The relationship between a continuous and a categorical variable was examined using Kruskal\u2013Wallis ANOVA test or Mann\u2013Whitney U-test as appropriate. Univariate survival analysis was performed using death of disease as the endpoint."
                    ],
                    "results": [
                        "Aurora-A expression was higher in tumors with high Ki-67 expression (p=0.01) and was positively, though marginally, related to aurora-B expression (p=0.085). Aurora-B expression was not linked to Ki-67 expression (p=0.182). Lower aurora-A immunohistochemical expression, chemotherapy administration, and tumor localization in one lobe of the brain implied a greater probability of patient survival in univariate analysis (p=0.044, p=0.008, p=0.041, respectively). Ki-67 and aurora-B immunoreactivities were not associated with patient survival (p=0.918 and p=0.539, respectively)."
                    ],
                    "conclusions": null
                },
                "application": {
                    "validated": "Potential",
                    "diagnosis": null,
                    "prognosis": "Potential",
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Erik Samelsson"
            },
            {
                "_id": "V000144",
                "pmid": "19545791",
                "biomarkerId": "B000144",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": "Pre 2010",
                "region": [
                    "USA"
                ],
                "research": {
                    "methods": [
                        "A total of 68 patients with an initial diagnosis of GBM were retrospectively evaluated",
                        "for 10 of these patients, recurrent tumor specimens were used to construct a tissue microarray. Rad51 protein expression was then correlated with the actual and predicted survival using recursive partitioning analysis."
                    ],
                    "results": [
                        "Rad51 protein was elevated in 53% of the GBM specimens at surgery. The Rad51 levels correlated directly with survival, with a median survival of 15 months for patients with elevated Rad51 compared with 9 months for patients with low or absent levels of Rad51 (p = .05). At disease recurrence, 70% of patients had additional increases in Rad51 protein. Increased Rad51 levels at disease recurrence similarly predicted for improved overall survival, with a mean survival of 16 months from the second craniotomy compared with only 4 months for patients with low Rad51 levels (p = .13)."
                    ],
                    "conclusions": [
                        "Elevated levels of the double-stranded DNA repair protein Rad51 predicted for an increase survival duration in patients with GBM, at both initial tumor presentation and disease recurrence."
                    ]
                },
                "application": {
                    "validated": "Potential",
                    "diagnosis": null,
                    "prognosis": "Potential",
                    "predictive": "Potential",
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Erik Samelsson"
            },
            {
                "_id": "V000145",
                "pmid": "19536818",
                "biomarkerId": "B000145",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": "Pre 2010",
                "region": [
                    "Japan"
                ],
                "research": {
                    "methods": [
                        "Here, we performed real-time reverse transcriptase polymerase chain reaction (RT-PCR) assays on 43 glioma samples (17 glioblastoma, 6 anaplastic astrocytoma, 10 low-grade astrocytoma, 6 oligodendroglioma and 4 ependymoma) and 6 glioma cell lines."
                    ],
                    "results": [
                        "The expression levels of miR-10b were associated with higher grade glioma. In addition, mRNA expressions of RhoC and urokinase-type plasminogen activator receptor (uPAR), which were thought to be regulated by miR-10b via HOXD10, were statistically significantly correlated with the expression of miR-10b (p < 0.001, p = 0.001, respectively). Also, protein expression levels of RhoC and uPAR were associated with expression levels of miR-10b (p = 0.009, p = 0.014, respectively). Finally, multifocal lesions on enhanced MRI of 7 malignant gliomas were associated with higher expression levels of miR-10b (p = 0.02)."
                    ],
                    "conclusions": [
                        "Our data indicated that miR-10b might play some role in the invasion of glioma cells."
                    ]
                },
                "application": {
                    "validated": "Potenial",
                    "diagnosis": null,
                    "prognosis": "Potential",
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Erik Samelsson"
            },
            {
                "_id": "V000146",
                "pmid": "19435942",
                "biomarkerId": "B0001DA",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "I",
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": "Pre 2010",
                "region": [
                    "UK, Sweden"
                ],
                "research": {
                    "methods": [
                        "The genomewide copy number data were determined by comparative genomic hybridization on a 1-Mb array. A wild-type IDH1 expression vector construct with a 5\u2032 hemagglutinin (HA) tag was generated by amplifying cDNA synthesized from U251 cells (IDH1 wild type",
                        "see below) using primers PC5779 (TAGAATTCCACCATGGCTTACCCATACGATGTTCCAGATTACGCTATGTCCAAAAAAATCAGTGGC) and PC5778 (GTATGAATTCAAAGTTTGGCCTGAGCTAG) and subcloning the PCR product into pTracer-CMV2 (Invitrogen, Paisley, UK). Statistical analyses were performed using Statistical Package for Social Sciences (SPSS) version 16.0 (SPSS, Inc., Chicago, IL, USA). Significance of correlations between the parameters was assessed using either the chi-square test with Yates\u2019s correction or two-tailed Fisher\u2019s exact test. The log-rank test was used for univariate analysis, and Cox regression was used for multivariate analysis of potential association between IDH1 mutations and overall patient survival."
                    ],
                    "results": [
                        "Codon 132 mutation was seen in 54% of astrocytomas and 65% of oligodendroglial tumors but in only 6% of glioblastomas (3% of primary and 50% of secondary glioblastomas). There were no mutations in any other type of tumor studied. While mutations in the tumor protein p53 gene (TP53) and total 1p/19q deletions were mutually exclusive, IDH1 mutations were strongly correlated with these genetic abnormalities. All four types of mutant IDH1 proteins showed decreased enzymatic activity"
                    ],
                    "conclusions": [
                        "The data indicate that IDH1 mutation combined with either TP53 mutation or total 1p/19q loss is a frequent and early change in the majority of oligodendroglial tumors, diffuse astrocytomas, anaplastic astrocytomas, and secondary glioblastomas but not in primary glioblastomas."
                    ]
                },
                "application": {
                    "validated": "Yes",
                    "diagnosis": "Potential",
                    "prognosis": "YES",
                    "predictive": "YES",
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": "Testing for IDH1 mutations is a current clinical backbone for GBM patient stratification. ",
                    "implication": null,
                    "treatment": null
                },
                "comments": "Potential",
                "curator": "Erik Samelsson"
            },
            {
                "_id": "V000147",
                "pmid": "19127042",
                "biomarkerId": "B000170",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "I",
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": "Pre 2010",
                "region": [
                    "India"
                ],
                "research": {
                    "methods": [
                        "We investigated the immunohistochemical expression of EGFR and PCNA using the appropriate monoclonal antibodies in 40 cases of astrocytic tumors of which 21 cases were glioblastoma, eight cases were Grade III or anaplastic astrocytomas and six cases were Grade II or diffuse astrocytomas and five cases were Grade I or pilocytic astrocytomas."
                    ],
                    "results": [
                        "Both the EGFR expression and PCNA labeling index increase with increasing grades of astrocytomas with a significantly high percentage of cells showing positive staining for both EGFR and PCNA in GBM and Grade III astrocytomas compared to Grade II astrocytomas. The expression levels of both EGFR and PCNA were low in Grade I or pilocytic astrocytomas."
                    ],
                    "conclusions": [
                        "A significant correlation was found between EGFR overexpression and PCNA labeling index in Grade III and Grade II astrocytomas and glioblastoma. These suggest that the tumor proliferation, at least in higher grades of astrocytomas is dependent in some measure on EGF and EGFR-related signaling pathways."
                    ]
                },
                "application": {
                    "validated": "Potential",
                    "diagnosis": null,
                    "prognosis": "Potential",
                    "predictive": "Potential",
                    "therapeutic": "Potential"
                },
                "clinical": {
                    "relevance": "Potential patient cohort selector",
                    "implication": "Potential method to successfully ddivide patient cohorts for nimotuzumab treatment.",
                    "treatment": "Could lead to new method of defining patient cohorts for EGFR target treatment studies."
                },
                "comments": null,
                "curator": "Erik Samelsson"
            },
            {
                "_id": "V000148",
                "pmid": "19019178",
                "biomarkerId": "B000148",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "I",
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": "Pre 2010",
                "region": [
                    "Thailand"
                ],
                "research": {
                    "methods": [
                        "IHC of J1-31, GFAP, p53, and Ki-67."
                    ],
                    "results": [
                        "The anti-J1-31 antibody exhibited strong cytoplasmic staining of reactive gliosis in 17/17 (100%) cases with a higher intensity of staining than that observed in the adjacent normal astrocytes. The antibody showed reactivity with tumor cells in 12/15 (80%) cases of pilocytic astrocytoma, although intensity of staining was generally weaker and more focal than observed in reactive gliosis. J1-31-positive tumor cells were detected in only 9/26 (35%) cases of the low-grade diffuse astrocytoma and none of the cases of anaplastic astrocytoma and glioblastoma. Increasing Ki-67 indices paralleled advancing tumor grades. p53 protein was expressed more commonly in infiltrating astrocytomas compared to pilocytic astrocytoma. In conclusion, down-regulation of J1-31 expression correlates with advancing grade of astrocytomas."
                    ],
                    "conclusions": [
                        "The result suggests this protein plays some role in astrocytes that is progressively lost in malignant progression. The anti-J1-31 antibody may help further our understanding of astrocytes in disease and may be useful as an aid in the pathologic diagnosis of astrocytic lesions."
                    ]
                },
                "application": {
                    "validated": "Potential",
                    "diagnosis": null,
                    "prognosis": null,
                    "predictive": "Potential",
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Erik Samelsson"
            },
            {
                "_id": "V000149",
                "pmid": "18812968",
                "biomarkerId": "B000149",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": "Pre 2010",
                "region": [
                    "USA"
                ],
                "research": {
                    "methods": [
                        "Freshly resected tumor tissue samples were processed for immunohistochemical and quantitative polymerase chain reaction analyses to identify and quantify expression levels of CXCR4 and its corresponding ligand CXCL12. T1 postcontrast and T2-weighted magnetic resonance imaging brain scans were used to generate voxel signal intensity histograms that were quantitatively analyzed to determine the extent and intensity of peritumoral signal abnormality as a marker of disseminated disease in the brain."
                    ],
                    "results": [
                        "CXCR4 expression was markedly elevated in Grade III and IV tumors compared with Grade II gliomas. Significantly, when patients with glioblastoma multiforme were segregated into two groups based on CXCR4 expression level, we observed a statistically significant increase in the intensity and extent of peritumoral magnetic resonance imaging signal abnormalities associated with CXCR4 high-expressing gliomas."
                    ],
                    "conclusions": [
                        "Our data confirm that high-grade gliomas robustly express CXCR4 and demonstrate a correlative relationship between expression levels of the CXCR4 receptor and the magnetic resonance imaging-based finding of a diffuse and more extensive disease process in the brain. CXCR4 expression status may, therefore, prove useful as a marker of disseminated disease in patients with glioblastoma multiforme."
                    ]
                },
                "application": {
                    "validated": "Potential",
                    "diagnosis": null,
                    "prognosis": "Potential",
                    "predictive": "Potential",
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Erik Samelsson"
            },
            {
                "_id": "V00014A",
                "pmid": "18639524",
                "biomarkerId": "B00014A",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": "Pre 2010",
                "region": [
                    "Japan"
                ],
                "research": {
                    "methods": [
                        "In this study, 51 astrocytic tumors were investigated for podocalyxin expression using immunohistochemistry, Western blot analysis, and quantitative real-time PCR."
                    ],
                    "results": [
                        "Immunohistochemistry detected podocalyxin on the surface of tumor cells in six of 14 anaplastic astrocytomas (42.9%) and in 17 of 31 glioblastomas (54.8%), especially around proliferating endothelial cells. In diffuse astrocytoma, podocalyxin expression was observed only in vascular endothelial cells."
                    ],
                    "conclusions": [
                        "Podocalyxin might be associated with the malignant progression of astrocytic tumors, and be a useful prognostic marker for astrocytic tumors."
                    ]
                },
                "application": {
                    "validated": "Potential",
                    "diagnosis": null,
                    "prognosis": "Potential",
                    "predictive": "Potential",
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Erik Samelsson"
            },
            {
                "_id": "V00014B",
                "pmid": "18483363",
                "biomarkerId": "B00014B",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": "2007",
                "region": [
                    "India"
                ],
                "research": {
                    "methods": [
                        "qRT-PCR",
                        "Immunohistochemistry",
                        "Survival curves",
                        "Cox model"
                    ],
                    "results": [
                        "Independent validation by qRT-PCR  analysis found growth arrest and DNA-damage\u2013inducible \u03b1 (GADD45\u03b1) and follistatin-like 1 (FSTL1) to be up-regulated in most GBMs (both primary and secondary), whereas superoxide dismutase 2 and adipocyte enhancer binding protein 1 were up-regulated in the majority of primary GBM",
                        "Cytoplasmic overexpression of GADD45\u03b1 conferred better survival while the coexpression of FSTL1 with p53 was associated with poor survival"
                    ],
                    "conclusions": [
                        "Study reveals that GADD45\u03b1 and FSTLI are GBM-specific whereas superoxide dismutase 2 and adipocyte enhancer binding protein 1 are primary GBM-specific diagnostic markers",
                        "GADD45\u03b1 overexpression confers a favorable prognosis, FSTL1 overexpression is a hallmark of poor prognosis in GBM patients"
                    ]
                },
                "application": {
                    "validated": "Yes",
                    "diagnosis": "YES",
                    "prognosis": "YES",
                    "predictive": "NO",
                    "therapeutic": "NO"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": "YES",
                "curator": "BP"
            },
            {
                "_id": "V00014C",
                "pmid": "18403493",
                "biomarkerId": "B00014C",
                "sourceIds": [
                    "Tissue",
                    "Cell line"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": "2007",
                "region": [
                    "USA"
                ],
                "research": {
                    "methods": [
                        "Real time PCR",
                        "Immunohistochemistry",
                        "Western blot",
                        "t-test",
                        "Cox model"
                    ],
                    "results": [
                        "Expression of GRP78 was the highest in GBM as compared to specimens from control brains, low grade astrocytomas and oligodendrogliomas",
                        "Overexpression of GRP78 protects glioma cells from Etoposide- and Cisplatin-induced apoptosis",
                        "GRP78 silencing enhances the apoptotic effect of Cisplatin, Etoposide, and \u03b3-radiation in glioma cells"
                    ],
                    "conclusions": [
                        "Results demonstrate that GRP78 is a potential prognostic marker and a therapeutic target in gliomas, particularly GBM"
                    ]
                },
                "application": {
                    "validated": "Microarray results validated",
                    "diagnosis": "NO",
                    "prognosis": "Potential",
                    "predictive": "NO",
                    "therapeutic": "Potential"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": "NO",
                "curator": "BP"
            },
            {
                "_id": "V00014D",
                "pmid": "18172271",
                "biomarkerId": "B00014D",
                "sourceIds": [
                    "Tissue",
                    "Cell line"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": "2007",
                "region": [
                    "USA"
                ],
                "research": {
                    "methods": [
                        "Immunohistochemistry",
                        "Western blot",
                        "Cytotoxicity assay",
                        "One way ANOVA"
                    ],
                    "results": [
                        "Expression of all three proteins was significantly higher in GBM compared with normal brain, low-grade, and anaplastic astrocytomas",
                        "Greater than 95% of GBM overexpressed at least two of the three markers",
                        "Every GBM overexpressed at least one marker",
                        "Human GBM primary explant cells and cell lines were potently killed by IL-13.E13K",
                        "PE38QQR and ephrinA1-PE38QQR, in accordance with their level of expression of IL-13R\u03b12 and EphA2, respectively"
                    ],
                    "conclusions": [
                        "IL-13R\u03b12, EphA2, and Fra-1 are attractive therapeutic targets representing molecular denominators of high-grade astrocytomas",
                        "One hundred percent of GBM tumors overexpress at least one of these proteins, providing the basis for rational combinatorial targeted therapies/diagnostics suitable for all patients with this disease"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": "Potential",
                    "prognosis": "NO",
                    "predictive": "NO",
                    "therapeutic": "Potential"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": "Potential",
                "curator": "BP"
            },
            {
                "_id": "V00014E",
                "pmid": "17016233",
                "biomarkerId": "B00014E",
                "sourceIds": [
                    "Tissue",
                    "Fluid",
                    "Cell line"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": "2000",
                "region": [
                    "Germany"
                ],
                "research": {
                    "methods": [
                        "Polymorhism and LOH anaylysis and Sequencing",
                        "Western blot",
                        "Cochran-Armitage trend test",
                        "Kaplan and Meier estimates"
                    ],
                    "results": [
                        "No association between the CHEK2SNP and glioblastoma formation was observed",
                        "No CHEK2coding sequence aberrations or tumors completely lacking CHEK2 protein were identified",
                        "However, the presence of the CHEK2rs2017309 A allele was significantly associated with an adverse prognosis, particularly among patients undergoing postoperative chemotherapy and radiotherapy (n = 28, median survival 10.5 versus 15.5 mo)",
                        "Patients' age, Karnofsky Performance Scale score, and postoperative radiotherapy and chemotherapy  as decisive prognostic factors"
                    ],
                    "conclusions": [
                        "Data suggest that a CHEK2gene polymorphism might correlate with the prognosis of glioblastoma patients",
                        "These findings may point to an as yet unrecognized role for the CHEK2gene in glioblastomas"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": null,
                    "prognosis": "Potential",
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "BP"
            },
            {
                "_id": "V00014F",
                "pmid": "16866986",
                "biomarkerId": "B00014F",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "I",
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": "2000",
                "region": [
                    "USA"
                ],
                "research": {
                    "methods": [
                        "LightCycler real-time RT-PCR",
                        "Real-time PCR",
                        "Ganglioside anayses",
                        "Cox model"
                    ],
                    "results": [
                        "The ratio of GalNAcT to GM1 synthase mRNAs correlates with the percentage of gangliosides GM2 and GD2",
                        "High amounts of GD3 synthase and low amounts of GalNAcT mRNAs correlate with better survival in GBM patients",
                        "Higher amounts of GM3 and GD3 correlate with longer survival times in GBM patients",
                        "The measurement of GM1 synthase mRNA is useful for separating GBMs from other gliomas"
                    ],
                    "conclusions": [
                        "Measuring glycosyltransferase mRNA levels by real\u2010time PCR may be clinically useful for determining both diagnosis and prognosis in GBM patients"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": "Potential",
                    "prognosis": "Potential",
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": "Potential",
                "curator": "BP"
            },
            {
                "_id": "V000150",
                "pmid": "16803948",
                "biomarkerId": "B000150",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": "2000",
                "region": [
                    "Japan"
                ],
                "research": {
                    "methods": [
                        "Semiquantitative and real-time RT-PCR",
                        "Kaplan-Meier method",
                        "Immunohistochemistry",
                        "Cox model"
                    ],
                    "results": [
                        "High expression of CDC25B was identified in 18 of the 19 glioblastomas, in 10 of the 17 anaplastic astrocytomas, but not in any of the 21 low-grade astrocytomas",
                        "The CDC25B mRNA expression increased with the rise in histological grade",
                        "Increased CDC25B expression was correlated significantly with a shorter period of DFS"
                    ],
                    "conclusions": [
                        "Patients with an unfavourable clinical outcome are characterised by the increased expression of CDC25B in their glioma samples",
                        "Useful clinical information, especially on its relevance as a prognostic indicator, is provided by the evaluation of CDC25B expression in gliomas"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": null,
                    "prognosis": "Potential",
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "BP"
            },
            {
                "_id": "V000151",
                "pmid": "16326273",
                "biomarkerId": "B000151",
                "sourceIds": [
                    "Cell line"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": "2000",
                "region": [
                    "Taiwan"
                ],
                "research": {
                    "methods": [
                        "Real-time RT-PCR",
                        "Immunohistochemical stain"
                    ],
                    "results": [
                        "Median survival times were 16 months in patients with negative IL-6 expression and 7 months in those with positive IL-6 expression (P = 0.075)",
                        "Three of these patients with a relatively longer survival time (>1 year) did not express IL-6 in the tumor",
                        "Relatively more severe peri-focal edema on imaging was also noted in the glioblastomas with IL-6 expression",
                        "IL-6 was also found in the cytoplasm of endothelial cells of newly formed vessels and infiltrating inflammatory cells"
                    ],
                    "conclusions": [
                        "Preliminary results implicate IL-6 expression as a possible prognostic indicator in glioblastoma",
                        "This cytokine may also play a role in tissue edema, angiogenesis and inflammation of this tumor, but whether IL-6 expression promotes malignancy is uncertain"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": null,
                    "prognosis": "Potential",
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "BP"
            },
            {
                "_id": "V000152",
                "pmid": "16254489",
                "biomarkerId": "B000152",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": "2000",
                "region": [
                    "USA"
                ],
                "research": {
                    "methods": [
                        "Laser-Capture Microdissection and RNA Isolation and Amplification",
                        "cDNA microarray",
                        "Immunohistochemistry",
                        "Kaplan-Meier plots",
                        "Cox model",
                        "Wald test"
                    ],
                    "results": [
                        "A set of RNAs (including POFUT2, PTDSR, PLOD2, ATF5, and HK2) that were differentially expressed in 3 initially studied, micro-dissected glioblastomas also provided prognostic information in an independent set of 28 glioblastomas that did not all have perinecrotic palisades"
                    ],
                    "conclusions": [
                        "On validation in a second, larger independent series, this approach could be applied to other human glioma types to derive tissue biomarkers that could offer ancillary prognostic and predictive information alongside standard histopathologic examination"
                    ]
                },
                "application": {
                    "validated": "Yes",
                    "diagnosis": null,
                    "prognosis": "YES",
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "BP"
            },
            {
                "_id": "V000153",
                "pmid": "15958563",
                "biomarkerId": "B000153",
                "sourceIds": [
                    "Sera",
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": "2000",
                "region": [
                    "Japan"
                ],
                "research": {
                    "methods": [
                        "Real time RT-PCR",
                        "Immunohistochemistry",
                        "ELISA of patient sera",
                        "Kaplan-Meier method",
                        "Cox-Mantel log-rank test",
                        "Cox model"
                    ],
                    "results": [
                        "Cathepsin D transcript levels became significantly higher as the glioma grade advanced",
                        "Low expression of cathepsin D significantly correlated with long survival of the glioma patients",
                        "GBM patients with high gene expression of cathepsin D lived significantly shorter than those with low expression and frequently had leptomeningeal dissemination",
                        "Cathepsin D expression level was an independent predictor for short survival",
                        "Measurement of the serum cathepsin D concentrations by ELISA showed a significant increase in the patients with high-grade gliomas as compared with the low-grade tumors"
                    ],
                    "conclusions": [
                        "Cathepsin D could be a potential serum marker for the prediction of aggressive nature of human gliomas"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": null,
                    "prognosis": "Potential",
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "BP"
            },
            {
                "_id": "V000154",
                "pmid": "15788675",
                "biomarkerId": "B000154",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": "2000",
                "region": [
                    "USA"
                ],
                "research": {
                    "methods": [
                        "Immunohistochemistry",
                        "Wilcoxon-rank sum test",
                        "k-mean clustering"
                    ],
                    "results": [
                        "GBMs show strikingly more YKL-40 expression than anaplastic oligodendrogliomas",
                        "Only 2 of 37 glioblastomas showed completely negative YKL-40 staining in both tumor cells and extracellular matrix, whereas 18 of 29 anaplastic oligodendrogliomas were completely negative in non-microgemistocytic tumor cells and extracellular matrix",
                        "84% of glioblastomas showed strong staining intensities of 2+ or 3+ whereas 76% of anaplastic oligodendrogliomas either did not stain or stained at only 1+"
                    ],
                    "conclusions": [
                        "YKL-40 staining provided a better class distinction of GBM versus AO than glial fibrillary acidic protein, the current standard immunohistochemical marker used to distinguish diagnostically challenging gliomas",
                        "A combination of YKL-40 and glial fibrillary acidic protein immunohistochemistry afforded even greater diagnostic accuracy in AO"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": "YES",
                    "prognosis": null,
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": "YES",
                "curator": "BP"
            },
            {
                "_id": "V000155",
                "pmid": "15696971",
                "biomarkerId": "B000155",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": null,
                "whoclass": null,
                "region": [
                    "Japan"
                ],
                "research": {
                    "methods": [
                        "Immunochemistry",
                        "PCR"
                    ],
                    "results": [
                        "WT1 protein was immunohisto- chemically detected in 48 of 51 (94%) GBM samples"
                    ],
                    "conclusions": [
                        "WT1 may be closely associated with tumorigenesis GBM"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": "Potential",
                    "prognosis": null,
                    "predictive": null,
                    "therapeutic": "Potential"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": "Potential",
                "curator": "Cristian"
            },
            {
                "_id": "V000156",
                "pmid": "15696967",
                "biomarkerId": "B000156",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "I",
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": "Pre 2007",
                "region": [
                    "Japan"
                ],
                "research": {
                    "methods": [
                        "Immunochemistry",
                        "PCR",
                        "WB"
                    ],
                    "results": [
                        "Immunohistochemical analysis showed that all the glioma tissues analyzed express SOX6"
                    ],
                    "conclusions": [
                        "Transcription factor SOX6 may be a potential diagnostic marker for gliomas"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": "Potential",
                    "prognosis": null,
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": "Potential",
                "curator": "Cristian"
            },
            {
                "_id": "V000157",
                "pmid": "15671555",
                "biomarkerId": "B000157",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": null,
                "whoclass": null,
                "region": [
                    "USA"
                ],
                "research": {
                    "methods": [
                        "Immunochemistry"
                    ],
                    "results": [
                        "AP-2\u03b1 expression was lost on 99%  on GBM and 98%  on AA compared with LGA and normal brain"
                    ],
                    "conclusions": [
                        "AP-2\u03b1 expression correlates inversely with glioma grade, suggesting a direct role in glioma tumorigenicity"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": "Potential",
                    "prognosis": null,
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": "Potential",
                "curator": "Cristian"
            },
            {
                "_id": "V000158",
                "pmid": "15274074",
                "biomarkerId": "B000158",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": null,
                "whoclass": null,
                "region": [
                    "USA"
                ],
                "research": {
                    "methods": [
                        "Immunochemistry",
                        "WB"
                    ],
                    "results": [
                        "High levels of laminin\u20108 expression in ~ 75% of the GBM and was associated with shorter time to tumor recurrence and a decreased patient survival time"
                    ],
                    "conclusions": [
                        "laminin\u20108 may facilitate tumor invasion, contributes to tumor regrowth after therapy"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": null,
                    "prognosis": null,
                    "predictive": "Potential",
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Cristian"
            },
            {
                "_id": "V000159",
                "pmid": "15143086",
                "biomarkerId": "B000159",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": null,
                "whoclass": null,
                "region": [
                    "USA"
                ],
                "research": {
                    "methods": [
                        "WB"
                    ],
                    "results": [
                        "PI3K pathway members were significantly more frequent in GBM than in non-glioblastoma multiforme tumors and  PI3K activation may directly be associated with radiation resistance on GBM"
                    ],
                    "conclusions": [
                        "Activation of the PI3K pathway is significantly associated with increasing tumor grade and with adverse clinical outcome in GBM"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": null,
                    "prognosis": null,
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Cristian"
            },
            {
                "_id": "V00015A",
                "pmid": "15134623",
                "biomarkerId": "B00015A",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": null,
                "whoclass": null,
                "region": [
                    "USA"
                ],
                "research": {
                    "methods": [
                        "TMA-fluorescence in situ"
                    ],
                    "results": [
                        "Combined 1p and 19q losses are frequent and predictive of AA prolonged survival. 9p and 10q deletions were more frequent in GBM"
                    ],
                    "conclusions": [
                        "Long-term and short-term survival groups of high-grade astrocytomas appear to have dissimilar frequencies of 19q, 9p, and 10q deletions"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": null,
                    "prognosis": "Potential",
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Cristian"
            },
            {
                "_id": "V00015B",
                "pmid": "15115103",
                "biomarkerId": "B00016F",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": null,
                "whoclass": "Pre 2007",
                "region": [
                    "Malaysia"
                ],
                "research": {
                    "methods": [
                        "TRAP assay"
                    ],
                    "results": [
                        "The activity was detected in 30% of the samples analysed"
                    ],
                    "conclusions": [
                        "There was a significant association between telomerase activity status with tumor grade"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": null,
                    "prognosis": null,
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Cristian"
            },
            {
                "_id": "V00015C",
                "pmid": "15094455",
                "biomarkerId": "B00015C",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": null,
                "whoclass": "Pre 2007",
                "region": [
                    "Poland"
                ],
                "research": {
                    "methods": [
                        "RT-PCR"
                    ],
                    "results": [
                        "ASCT2 and SNAT3 expression from AA and GBM was \u223c3 times higher than in control tissue"
                    ],
                    "conclusions": [
                        "Primary malignant human gliomas over-express ASCT2"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": null,
                    "prognosis": null,
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Cristian"
            },
            {
                "_id": "V00015D",
                "pmid": "14609169",
                "biomarkerId": "B00015D",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": null,
                "whoclass": "Pre 2007",
                "region": [
                    "China"
                ],
                "research": {
                    "methods": [
                        "Immunochemistry"
                    ],
                    "results": [
                        "ANX7 expression was higher in those patients with higher KPS score"
                    ],
                    "conclusions": [
                        "Higher KPS score before surgery and ANX7 expression correlate with longer survival in patients with GBM"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": null,
                    "prognosis": null,
                    "predictive": "Potential",
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Cristian"
            },
            {
                "_id": "V00015E",
                "pmid": "12845671",
                "biomarkerId": "B00015E",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": null,
                "whoclass": null,
                "region": [
                    "China"
                ],
                "research": {
                    "methods": [
                        "NB",
                        "PCR",
                        "ISH"
                    ],
                    "results": [
                        "hNDRG2 gene transcript is expressed in normal brain tissue and low\u2010grade gliomas but is present at low levels in 56% human GBM tissues"
                    ],
                    "conclusions": [
                        "hNDRG2 may play a role in glioblastoma progression"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": null,
                    "prognosis": null,
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Cristian"
            },
            {
                "_id": "V00015F",
                "pmid": "12760291",
                "biomarkerId": "B00015F",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": null,
                "whoclass": "Pre 2007",
                "region": [
                    "China"
                ],
                "research": {
                    "methods": [
                        "Immunochemistry"
                    ],
                    "results": [
                        "MIB-1 and topoisomerase II\u03b1 LIs were related significantly to survival"
                    ],
                    "conclusions": [
                        "MIB-1 and topoisomerase II\u03b1 could help predict long-term survival of patients with GBM"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": null,
                    "prognosis": null,
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Cristian"
            },
            {
                "_id": "V000160",
                "pmid": "12187957",
                "biomarkerId": "B000160",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": null,
                "whoclass": null,
                "region": [
                    "Russia"
                ],
                "research": {
                    "methods": [
                        "Immunochemistry"
                    ],
                    "results": [
                        "Survival time in patients with SGB, EGFR and mdm2-positivity and PCNA LI >40% was significantly shorter, whereas presence of p21ras and AI >0.5% were associated with prolonged survival."
                    ],
                    "conclusions": [
                        "Immunohistochemical variables were found to be significant for GBM outcome"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": null,
                    "prognosis": null,
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Cristian"
            },
            {
                "_id": "V000161",
                "pmid": "12066196",
                "biomarkerId": "B00016D",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": null,
                "whoclass": null,
                "region": [
                    "Austria"
                ],
                "research": {
                    "methods": [
                        "Immunochemistry"
                    ],
                    "results": [
                        "Patients with p53 positive glioblastomas were significantly younger (mean age 54.4\u00b12 years) than those with p53 negative tumors . p53 protein expression was associated with significantly longer survival"
                    ],
                    "conclusions": [
                        "Detectable p53 protein expression has a significantly better overall survival"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": null,
                    "prognosis": null,
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Cristian"
            },
            {
                "_id": "V000162",
                "pmid": "11918088",
                "biomarkerId": "B000162",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": null,
                "whoclass": null,
                "region": [
                    "Canada"
                ],
                "research": {
                    "methods": [
                        "Immunochemistry"
                    ],
                    "results": [
                        "RhoA and RhoB decreased significantly in all brain tumors"
                    ],
                    "conclusions": [
                        "RhoA and RhoB expression levels are correlated to tumor malignancy"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": "Potential",
                    "prognosis": null,
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": "Potential",
                "curator": "Cristian"
            },
            {
                "_id": "V000163",
                "pmid": "11844831",
                "biomarkerId": "B0001DF",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": null,
                "whoclass": null,
                "region": [
                    "USA"
                ],
                "research": {
                    "methods": [
                        "WB"
                    ],
                    "results": [
                        "Patients with detectable survivin expression had significantly shorter overall survival times. Increasing levels of survivin expression significantly correlated with reduced survival times when all glioma patients were considered, and markedly so for GBM patients"
                    ],
                    "conclusions": [
                        "Survivin positivity and protein expression levels are of significant prognostic value in human gliomas"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": null,
                    "prognosis": "Potential",
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Cristian"
            },
            {
                "_id": "V000164",
                "pmid": "11550311",
                "biomarkerId": "B000164",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": null,
                "whoclass": null,
                "region": [
                    "USA"
                ],
                "research": {
                    "methods": [
                        "PCR"
                    ],
                    "results": [
                        "AAs show the highest rates of LOH at chromosomes 1p, 4q, 6p, 9p, 11p, 11q, 13q, 14q, 15p, 17p, 17q, and 19q. GBMs showed the greatest losses at 1p, 6q, 8p, 9p, 10p, 10q, 11p, 13q, 17p, 17q, 18p, 18q, and 19q."
                    ],
                    "conclusions": [
                        "Damage at the loci may either lead to de novo GBMs or permit existing AAs to progress to GBMs."
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": null,
                    "prognosis": "Potential",
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Cristian"
            },
            {
                "_id": "V000165",
                "pmid": "11389063",
                "biomarkerId": "B000165",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": null,
                "whoclass": null,
                "region": [
                    "USA"
                ],
                "research": {
                    "methods": [
                        "Immunochemistry"
                    ],
                    "results": [
                        "High COX-2 expression correlated with poor survival for the study group"
                    ],
                    "conclusions": [
                        "COX-2 expression was the strongest predictor of outcome and high COX-2 expression correlated with increasing histological grade"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": null,
                    "prognosis": null,
                    "predictive": "Potential",
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Cristian"
            },
            {
                "_id": "V000166",
                "pmid": "11014540",
                "biomarkerId": "B00016F",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": null,
                "whoclass": null,
                "region": [
                    "Japan"
                ],
                "research": {
                    "methods": [
                        "Northen/Southern blot/TRAP assay"
                    ],
                    "results": [
                        "Secondary GBMs displayed significantly higher levels of telomerase activity than primary GBMs. Tumors with a p53 gene mutation demonstrated significantly higher telomerase activity than those without a p53 mutation"
                    ],
                    "conclusions": [
                        "Telomerase activity and p53 mutations both play important roles in the multistep carcinogenesis of GBM"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": null,
                    "prognosis": null,
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Cristian"
            },
            {
                "_id": "V000167",
                "pmid": "10984457",
                "biomarkerId": "B000167",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": null,
                "whoclass": null,
                "region": [
                    "USA"
                ],
                "research": {
                    "methods": [
                        "Northen/Western blot/PCR"
                    ],
                    "results": [
                        "High levels of the seven candidates on PCR, WB"
                    ],
                    "conclusions": [
                        "The seven predited genes showed potential as possible tumor markers or antigens"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": null,
                    "prognosis": null,
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Cristian"
            },
            {
                "_id": "V000168",
                "pmid": "10645226",
                "biomarkerId": "B000168",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": null,
                "whoclass": "Pre 2007",
                "region": [
                    "Russia"
                ],
                "research": {
                    "methods": [
                        "Immunochemistry"
                    ],
                    "results": [
                        "Survival time in patients with EGFR positive tumours was found to be reduced"
                    ],
                    "conclusions": [
                        "EGFR immunoreactivity and apoptotic index were found to be useful for assessing prognosis of GBM"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": null,
                    "prognosis": null,
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Cristian"
            },
            {
                "_id": "V000169",
                "pmid": "10213484",
                "biomarkerId": "B000169",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": null,
                "whoclass": null,
                "region": [
                    "USA"
                ],
                "research": {
                    "methods": [
                        "Immunochemistry",
                        "PCR"
                    ],
                    "results": [
                        "There was significant difference between the expression of MMAC/PTEN in GBMs vs LGG and a better prognosis was detected on tumors that express high levels of MMAC/PTEN"
                    ],
                    "conclusions": [
                        "Altered expression of\u00a0MMAC/PTEN\u00a0may play a significant role in the progression of GBM and patient outcome"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": null,
                    "prognosis": null,
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Cristian"
            },
            {
                "_id": "V00016A",
                "pmid": "10066096",
                "biomarkerId": "B00016A",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": "Pre 2007",
                "region": [
                    "Japan"
                ],
                "research": {
                    "methods": [
                        "Immunochemistry",
                        "PCR"
                    ],
                    "results": [
                        "77% GBMs and 69% AAs revealed the reduced or absent DCC expression. The survival rate of patients without reduced DCC expression was significantly superior to that of patients with reduced DCC expression in overall malignant astrocytic tumors"
                    ],
                    "conclusions": [
                        "DCC expression is an important marker in tumor malignancy and recurrence in astrocytic tumors and that may be a useful prognostic factor"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": null,
                    "prognosis": "Potential",
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Cristian"
            },
            {
                "_id": "V00016B",
                "pmid": "10063359",
                "biomarkerId": "B00016B",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": null,
                "whoclass": "Pre 2007",
                "region": [
                    "USA"
                ],
                "research": {
                    "methods": [
                        "Immunochemistry"
                    ],
                    "results": [
                        "c-Met-positive cases occurred in high grade astrocytic tumors and  showed a significant shorter survival"
                    ],
                    "conclusions": [
                        "c-Met immunopositivity may be a parameter of biological aggressiveness in high grade astrocytic tumors"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": null,
                    "prognosis": "Potential",
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Cristian"
            },
            {
                "_id": "V00016C",
                "pmid": "9821169",
                "biomarkerId": "B00016C",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": null,
                "whoclass": "Pre 2007",
                "region": [
                    "France"
                ],
                "research": {
                    "methods": [
                        "Immunochemistry"
                    ],
                    "results": [
                        "Neither EGFR expression, p53 accumulation, nor Ki67 labelling index had any prognostic value"
                    ],
                    "conclusions": [
                        "Molecular distinction between primary and secondary glioblastomas is not so clear-cut based on EGFRexpression levels"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": null,
                    "prognosis": null,
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Cristian"
            },
            {
                "_id": "V00016D",
                "pmid": "9581814",
                "biomarkerId": "B00016D",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": null,
                "whoclass": null,
                "region": [
                    "Japan"
                ],
                "research": {
                    "methods": [
                        "Immunochemistry"
                    ],
                    "results": [
                        "The regrowth-free period after radiation was significantly longer for tumors with p53 mutations and p53 mutation was the sole independent factor predictive of radiotherapeutic response"
                    ],
                    "conclusions": [
                        "p53 mutation is a marker for better radiation response in GBM"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": null,
                    "prognosis": null,
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Cristian"
            },
            {
                "_id": "V00016E",
                "pmid": "9264362",
                "biomarkerId": "B00016E",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": "Pre 2007",
                "region": [
                    "USA"
                ],
                "research": {
                    "methods": [
                        "Immunochemistry"
                    ],
                    "results": [
                        "GBM stained strongly for galectin-3, whereas low grade astrocytomas did not express it. AA exhibited intermediate expression"
                    ],
                    "conclusions": [
                        "Galectin-3 expression correlates with the malignant potential of brain tumors"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": null,
                    "prognosis": null,
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Cristian"
            },
            {
                "_id": "V00016F",
                "pmid": "9241081",
                "biomarkerId": "B00016F",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": "Pre 2007",
                "region": [
                    "Japan"
                ],
                "research": {
                    "methods": [
                        "TRAP assay"
                    ],
                    "results": [
                        "60% GBMs and 100% OG demonstrated telomerase activity"
                    ],
                    "conclusions": [
                        "Telomerase activity may be an important marker of brain tumor malignancy"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": null,
                    "prognosis": null,
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Cristian"
            },
            {
                "_id": "V000170",
                "pmid": "8598357",
                "biomarkerId": "B000170",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": null,
                "whoclass": null,
                "region": [
                    "USA"
                ],
                "research": {
                    "methods": [
                        "Immunochemistry"
                    ],
                    "results": [
                        "EGFR positivity was related to reduced survival."
                    ],
                    "conclusions": [
                        "EGFR positivity appears to be a significant predictor of overall survival in patients with astrocytic gliomas."
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": null,
                    "prognosis": "Potential",
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Cristian"
            },
            {
                "_id": "V000171",
                "pmid": "7561922",
                "biomarkerId": "B000171",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": null,
                "whoclass": "Pre 2007",
                "region": [
                    "UK"
                ],
                "research": {
                    "methods": [
                        "Immunochemistry"
                    ],
                    "results": [
                        "Median Ki-67 LIs differed significantly between the types of astrocytic tumour, and tumours with a Ki-67 LI < 2% had a significantly better prognosis"
                    ],
                    "conclusions": [
                        "Ki-67 immunohistochemistry predicts survival in patients with astrocytic tumours"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": null,
                    "prognosis": null,
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Cristian"
            },
            {
                "_id": "V000172",
                "pmid": "8313368",
                "biomarkerId": "B000172",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": null,
                "whoclass": null,
                "region": [
                    "USA"
                ],
                "research": {
                    "methods": [
                        "Quantitative zymography and enzyme-linked immunosorbent assay"
                    ],
                    "results": [
                        "u-PA and PAI-1 antigen were undetectable in normal brain but significantly elevated in GBM"
                    ],
                    "conclusions": [
                        "Primary CNS neoplasms is associated with elevated levels of u-PA and PAI-1"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": null,
                    "prognosis": null,
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Cristian"
            },
            {
                "_id": "V000173",
                "pmid": "7681617",
                "biomarkerId": "B000175",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": null,
                "whoclass": null,
                "region": [
                    "Greece"
                ],
                "research": {
                    "methods": [
                        "Immunochemistry"
                    ],
                    "results": [
                        "MB were found to have the highest PCNA values"
                    ],
                    "conclusions": [
                        "PCNA LI values showed large discrepancies were noted in all tumor groups"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": null,
                    "prognosis": null,
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Cristian"
            },
            {
                "_id": "V000174",
                "pmid": "1414519",
                "biomarkerId": "B000174",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": null,
                "whoclass": "Pre 2007",
                "region": [
                    "Norway"
                ],
                "research": {
                    "methods": [
                        "Immunochemestry/Southern blot"
                    ],
                    "results": [
                        "Ki-67 LI was higher in the GBM group with EGFR gene amplification than in those without EGFR gene amplification. Ki-67 LI greater than 1.5 had a statistically significant shorter survival than those with Ki-67 LI less than 1.5"
                    ],
                    "conclusions": [
                        "GBM patients with EGFR gene amplification lived shorter time than those without EGFR gene amplification"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": null,
                    "prognosis": null,
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Cristian"
            },
            {
                "_id": "V000175",
                "pmid": "1374410",
                "biomarkerId": "B000175",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": null,
                "whoclass": "Pre 2007",
                "region": [
                    "Germany"
                ],
                "research": {
                    "methods": [
                        "Immunochemistry"
                    ],
                    "results": [
                        "PCNA values varied widely, ranging from 0.5% to 75%. Statistical analysis revealed no significant correlation between PCNA index and patient survival"
                    ],
                    "conclusions": [
                        "PCNA appears not to be a useful prognostic parameter for GBM"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": null,
                    "prognosis": null,
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Cristian"
            },
            {
                "_id": "V000176",
                "pmid": "1850599",
                "biomarkerId": "B000176",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": null,
                "whoclass": null,
                "region": [
                    "UK"
                ],
                "research": {
                    "methods": [
                        "Immunochemistry"
                    ],
                    "results": [
                        "Ki-67 labelling index demonstrates no relationship in the determination of prognosis in GBM"
                    ],
                    "conclusions": [
                        "Ki-67 index in this study offered no prognostic information even when individual sites were considered separately"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": null,
                    "prognosis": null,
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Cristian"
            },
            {
                "_id": "V000177",
                "pmid": "65176",
                "biomarkerId": "B000177",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": null,
                "whoclass": null,
                "region": [
                    "Denmark"
                ],
                "research": {
                    "methods": [
                        "Immunochemistry"
                    ],
                    "results": [
                        "S-100 was found in GBM in a1/10 the amount in whole brain homogenate, whereas GFA was found 2-4 times enriched. The 2 proteins were absent in MG"
                    ],
                    "conclusions": [
                        "GFA indicate that GBM cells belong to astroglial tumors"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": null,
                    "prognosis": null,
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Cristian"
            },
            {
                "_id": "V000178",
                "pmid": "26895104",
                "biomarkerId": "B000178",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens",
                    "Macaca mulatta"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": "2007",
                "region": [
                    "China"
                ],
                "research": {
                    "methods": [
                        "iTRAQ",
                        "Mascot software",
                        "Pearson correlation coefficient",
                        "Univariate Cox model"
                    ],
                    "results": [
                        "Eight genes were capable of accurately stratifying patients according to expression level for each gene",
                        "Six of eight genes were significant while the rest two genes' expression were also weakly related with PFS"
                    ],
                    "conclusions": [
                        "Protein expression better reflected the proteins' interaction compared with mRNA expression",
                        "These signatures identified from embryonic brain development might contribute to precise prediction of GBM prognosis and identification of novel drug targets in GBM therapies"
                    ]
                },
                "application": {
                    "validated": "Yes",
                    "diagnosis": null,
                    "prognosis": "YES",
                    "predictive": null,
                    "therapeutic": "Potential"
                },
                "clinical": {
                    "relevance": "TFRC and APEX1 were the known drug targets of ganite and lucanthone that were approved by FDA;lucanthone was used as a radiation sensitizer in the treatment of brain cancer",
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "BP"
            },
            {
                "_id": "V000179",
                "pmid": "26573230",
                "biomarkerId": "B000179",
                "sourceIds": [
                    "Tissue",
                    "Cell line"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens",
                    "Mus musculus"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "I",
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": "2007",
                "region": [
                    "Slovenia",
                    "Germany",
                    "Luxembourg"
                ],
                "research": {
                    "methods": [
                        "Western blot",
                        "Immunocytochemistry",
                        "ANOVA"
                    ],
                    "results": [
                        "Identified sensible up-regulation of CD9 gene",
                        "A more than two fold up-regulation correlates with shorter patient survival and confirms the prognostic value of CD9",
                        "No or low CD9 gene expression was observed in normal human astrocytes, normal brain tissue and neural stem cells"
                    ],
                    "conclusions": [
                        "Demonstrated relevance of CD9 as a prognostic GBM stem cell marker that can allow discrimination between GBM stem cells  and normal stem cells",
                        "In vitro and in vivo study demonstrated that CD9 is relevant for maintenance of their stemness potential and for invasion, although its role in GBM stem cell proliferation and survival is variable and possibly depends on the biological and genetic background of the cells",
                        "The CD9 up-regulation may enhance resistance of GBM to standard therapy as it was found to be prognostic and predictive for GBM patients' survival"
                    ]
                },
                "application": {
                    "validated": "Yes",
                    "diagnosis": "NO",
                    "prognosis": "YES",
                    "predictive": "Potential",
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": "NO",
                "curator": "BP"
            },
            {
                "_id": "V00017A",
                "pmid": "26558781",
                "biomarkerId": "B00017A",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens",
                    "Mus musculus"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": "2007",
                "region": [
                    "USA"
                ],
                "research": {
                    "methods": [
                        "In situ immunofluorescence",
                        "qRT-PCR",
                        "Western blot",
                        "Gene set enrichment analysis",
                        "Survival curves"
                    ],
                    "results": [
                        "MiR-21 targets the stemness regulator Sox2 in GBM",
                        "MiR-21\u2013Sox2 status stratifies GBM tumors into two subtypes",
                        "MiR-21 mechanistically suppresses Sox2 expression and MiR-21\u2013Sox2 forms a regulatory axis",
                        "Class A versus Class B classification delineates phenotypically distinct GBM tumors",
                        "Class A versus Class B classification represents molecularly distinct GBM tumors",
                        "The Class A patients had shorter survival than Class B patients, median survival: 380 d for Class A vs 459 d for Class B"
                    ],
                    "conclusions": [
                        "This mechanism-based classification suggests the presence of two distinct populations of GBM patients with distinguishable phenotypic characteristics and clinical outcomes"
                    ]
                },
                "application": {
                    "validated": "Yes",
                    "diagnosis": "NO",
                    "prognosis": "Potential",
                    "predictive": "NO",
                    "therapeutic": "NO"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": "NO",
                "curator": "BP"
            },
            {
                "_id": "V00017B",
                "pmid": "25628952",
                "biomarkerId": "B00017B",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens",
                    "Mus musculus"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": "2007",
                "region": [
                    "China"
                ],
                "research": {
                    "methods": [
                        "U87 xenograft model and treatments",
                        "Mouse GL261 model",
                        "Western blot",
                        "Kaplan Meier analysis",
                        "Cox model",
                        "t-test"
                    ],
                    "results": [
                        "Nlrp3 gene signature predicts glioma progression in radiotherapy-treated patients in GSE16011 data set",
                        "Nlrp3 gene signature predicts glioma progression in radiotherapy-treated patients in TCGA cohort",
                        "Nlrp3 inhibition reduces tumor growth and IR-induced senescence in U87 glioma xenografts and prolongs the survival of mouse with GL261 GBM tumors following IR treatment"
                    ],
                    "conclusions": [
                        "Nlrp3 inflammasome is an important molecular link between brain aging and glioma progression",
                        "Nlrp3 gene signature may serve as a predictive biomarker for glioma patients."
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": null,
                    "prognosis": null,
                    "predictive": "Potential",
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "BP"
            },
            {
                "_id": "V00017C",
                "pmid": "25204555",
                "biomarkerId": "B00017C",
                "sourceIds": [
                    "Tissue",
                    "Cell line"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens",
                    "Mus musculus"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": "2007",
                "region": [
                    "China"
                ],
                "research": {
                    "methods": [
                        "Tumorsphere formation assay",
                        "Western blot",
                        "Immunofluorescence staining",
                        "Immunohistochemistry",
                        "Terminal Deoxynucleotidyl transferase Dutp Nick-end labelling assay",
                        "Xenograft model",
                        "t-test",
                        "Kaplan Meier curves",
                        "Log-rank test"
                    ],
                    "results": [
                        "PTK7 is highly expressed in CD44-high GBM and predicts unfavorable prognosis",
                        "PTK7 knockdown attenuated cell proliferation, impaired tumorigenic potential, and induced apoptosis in CD44-high glioma cell lines",
                        "IIdentified inhibitor of DNA Binding 1 (Id1) gene as a potential downstream effector for PTK7",
                        "Overexpression of Id1 mostly restored the cell proliferation and colony formation attenuated by PTK7 depletion",
                        "PTK7 enhanced anchorage-independent growth in normal human astrocytes, which was attenuated by Id1 knockdown",
                        "PTK7 regulated Id1 expression through modulating TGF-\u03b2/Smad signaling, while pharmacological inhibition on TGF-\u03b2/Smad signaling or PTK7/Id1 depletion attenuated TGF-\u03b2\u2013stimulated cell proliferation",
                        "PTK7 depletion consistently reduced Id1 expression, suppressed tumor growth, and induced apoptosis in a murine orthotopic tumor model, which could be translated into prolonged survival in tumor-bearing mice"
                    ],
                    "conclusions": [
                        "PTK7 regulates Id1 expression in CD44-high glioma cell lines",
                        "Targeting PTK7 could be an effective strategy for treating glioma with high CD44 expression"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": null,
                    "prognosis": null,
                    "predictive": null,
                    "therapeutic": "Potential"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "BP"
            },
            {
                "_id": "V00017D",
                "pmid": "25155356",
                "biomarkerId": "B00017D",
                "sourceIds": [
                    "Tissue",
                    "Cell line"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens",
                    "Mus musculus"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": null,
                "region": [
                    "Belgium",
                    "The Netherlands",
                    "USA"
                ],
                "research": {
                    "methods": null,
                    "results": [
                        "The GJB6 gene was deleted in 25.8% of 751 analyzed tumors and mutated in 15.8% of 158 tumors",
                        "Cx30 immunoreactivity was absent in 28.9% of 145 tumors",
                        "Restoration of Cx30 expression in human GBM cells reduced their growth in vitro and as xenografts in the striatum of immunodeficient mice",
                        "Cx30 immunoreactivity was, however, found to adversely affect survival in 2 independent retrospective cohorts of GBM patients",
                        "Cx30 was found in clonogenic assays to protect glioblastoma cells against radiation-induced mortality and to decrease radiation-induced DNA damage",
                        "This radioprotection correlated with a heat shock protein 90\u2013dependent mitochondrial translocation of Cx30 following radiation and an improved ATP production following this genotoxic stress"
                    ],
                    "conclusions": [
                        "Results underline the complex relationship between potential tumor suppressors and treatment resistance in GBMs and single out GJB6/Cx30 as a potential biomarker and target for therapeutic intervention in these tumors"
                    ]
                },
                "application": {
                    "validated": "Yes",
                    "diagnosis": null,
                    "prognosis": "YES",
                    "predictive": null,
                    "therapeutic": "Potential"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "BP"
            },
            {
                "_id": "V00017E",
                "pmid": "24203894",
                "biomarkerId": "B00017E",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens",
                    "Mus musculus"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": "2007",
                "region": [
                    "China"
                ],
                "research": {
                    "methods": [
                        "Gene set enrichment analysis",
                        "Orthotopic Glioma model and treatment",
                        "Kaplan-Meier analysis",
                        "Cox model",
                        "Log-rank test"
                    ],
                    "results": [
                        "HOTAIR expression was closely associated with glioma grade and poor prognosis",
                        "Multivariate Cox regression analysis revealed that HOTAIR was an independent prognostic factor in GBM patients",
                        "HOTAIR expression correlated with glioma molecular subtype, including those of The Cancer Genome Atlas",
                        "HOTAIR was preferentially expressed in the classical and mesenchymal subtypes compared with the neural and proneural subtypes",
                        "A gene set enrichment analysis designed to show gene set differences between patients with high and low HOTAIR expression indicated that HOTAIR expression was associated with gene sets involved in cell cycle progression",
                        "HOTAIR reduction induced colony formation suppression, cell cycle G0/G1 arrest, and orthotopic tumor growth inhibition"
                    ],
                    "conclusions": [
                        "Data establish that HOTAIR is an important long noncoding RNA that primarily serves as a prognostic factor for glioma patient survival, as well as a biomarker for identifying glioma molecular subtypes, a critical regulator of cell cycle progression"
                    ]
                },
                "application": {
                    "validated": "Yes",
                    "diagnosis": "Only for identification of glioma molecular subtypes",
                    "prognosis": "Potential",
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": "Only for identification of glioma molecular subtypes",
                "curator": null
            },
            {
                "_id": "V00017F",
                "pmid": "24002581",
                "biomarkerId": "B00017F",
                "sourceIds": [
                    "Tissue",
                    "Cell line"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens",
                    "Mus musculus"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "I",
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": null,
                "region": [
                    "China"
                ],
                "research": {
                    "methods": [
                        "Genome-wide DNA methylation profiling",
                        "Immunohistochemistry",
                        "Western blot",
                        "Transwell invasion assay",
                        "Xenogradft model",
                        "Cox model",
                        "Kaplan-Meier curves",
                        "Chi-square test"
                    ],
                    "results": [
                        "Immunohistochemistry (IHC) of 91 glioma samples showed that the KAZALD1 expression scores of high-grade glioma samples were higher compared to the scores of low-grade gliomas",
                        "In high-grade gliomas, overall survival (OS) was shorter for patients with KAZALD1 hypomethylation or overexpression compared to those without",
                        "Decreased KAZALD1 expression in glioma inhibited cell proliferation and invasion both in vitro and in vivo."
                    ],
                    "conclusions": [
                        "KAZALD1 promoter hypomethylation is an important prognostic biomarker in glioma",
                        "KAZALD1 promotes glioma malignant progression through invasion and proliferation"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": null,
                    "prognosis": "YES",
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": null
            },
            {
                "_id": "V000180",
                "pmid": "23096411",
                "biomarkerId": "B000180",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens",
                    "Mus musculus"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "I",
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": null,
                "region": [
                    "USA"
                ],
                "research": {
                    "methods": [
                        "Rat glioma cell implantation",
                        "Synthesis of ELTD1 nanoprobes",
                        "MRI",
                        "Gene expression analysis",
                        "Western blot",
                        "t-test"
                    ],
                    "results": [
                        "ELTD1 was found to be significantly higher in high-grade gliomas (50 patients) compared to low-grade gliomas (21 patients), and compared well to traditional IHC markers including VEGF, GLUT-1,CAIX, and HIF-1\u03b1. ELTD1 gene expression indicates an association with grade, survival across grade, and an increase in the mesenchymal subtype",
                        "Significantly high in vivolevels of ELTD1 were additionally found in F98 tumors, compared to normal brain tissue"
                    ],
                    "conclusions": [
                        "Study strongly suggests that associative analysis was able to accurately identify ELTD1 as a putative glioma-associated biomarker",
                        "The detection of ELTD1 was also validated in both rodent and human gliomas, and may serve as an additional biomarker for gliomas in pre-clinical and clinical diagnosis of gliomas"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": "Potential",
                    "prognosis": null,
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": "Potential",
                "curator": "Ahmed"
            },
            {
                "_id": "V000181",
                "pmid": "23010083",
                "biomarkerId": "B000181",
                "sourceIds": [
                    "Tissue",
                    "Cell line"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens",
                    "Mus musculus"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": null,
                "region": [
                    "USA"
                ],
                "research": {
                    "methods": [
                        "Xenograft model",
                        "Immunohistochemistry",
                        "ELISA quantification",
                        "qRT-PCR",
                        "Meta-analysis",
                        "Kaplan-Meier method"
                    ],
                    "results": [
                        "Established a correlation between high TIP-1 expression levels and the poor prognosis of GBM patients",
                        "Study characterized TIP-1 as one contributing factor to the tumor-driven angiogenesis",
                        "TIP-1 utilizes multiple pathways including modulating fibronectin gene expression and uPA protein secretion, to establish or maintain a pro-angiogenic microenvironment within human GBM"
                    ],
                    "conclusions": [
                        "Work supports the hypothesis that TIP-1 represents a novel prognostic biomarker and a therapeutic target of human GBM"
                    ]
                },
                "application": {
                    "validated": "Yes",
                    "diagnosis": null,
                    "prognosis": "YES",
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Ahmed"
            },
            {
                "_id": "V000182",
                "pmid": "22750848",
                "biomarkerId": "B000182",
                "sourceIds": [
                    "Tissue",
                    "Cell line"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens",
                    "Mus musculus"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": "2007",
                "region": [
                    "USA"
                ],
                "research": {
                    "methods": [
                        "Context likelihood of relatedness algorithm",
                        "Copy number analysis",
                        "Kaplan-Meier method",
                        "Permutation test",
                        "Transcription factor analysis",
                        "miRNA in situ hybridization"
                    ],
                    "results": [
                        "Integrative\u00a0in silico\u00a0analyses, functional genetic screen and experimental validation identified miR-34a as a tumor suppressor in proneural subtype GBM",
                        "Mechanistically, in addition to its direct regulation of PDGFRA, promoter enrichment analysis of CLR-inferred mRNA nodes established miR-34a as a novel regulator of a Smad4 transcriptional network",
                        "Clinically, miR-34a expression level is shown to be prognostic, where miR-34a low-expressing GBMs exhibited better overall survival"
                    ],
                    "conclusions": [
                        "Computational network modeling of the complex inter-relationships among diverse genetic elements can generate a logical framework in which to explore and understand the genetics and biology of cancers, and when integrated with disease knowledge and clinical annotation, can lead to discovery of new pathogenetic insights in addition to potential prognostic biomarkers or therapeutic targets",
                        "The potent tumor suppressive activity in our preclinical models would suggest possible therapeutic benefit of miR-34a re-constitution by tumor-targeted delivery in low miR-34a expressing GBM."
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": null,
                    "prognosis": "Potential",
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Ahmed"
            },
            {
                "_id": "V000183",
                "pmid": "22619307",
                "biomarkerId": "B000183",
                "sourceIds": [
                    "Tissue",
                    "Cell line"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens",
                    "Mus musculus"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": null,
                "region": [
                    "USA"
                ],
                "research": {
                    "methods": [
                        "Immunoblotting",
                        "ANOVA"
                    ],
                    "results": [
                        "MARCKS protein expression was inversely correlated with GBM proliferation and intracranial xenograft growth rates",
                        "Genetic silencing of MARCKS promoted GBM proliferation and radiation resistance, while MARCKS overexpression greatly reduced GBM growth potential and induced senescence",
                        "MARCKS gene expression to be directly correlated with survival in both the REMBRANDT and TCGA databases",
                        "Specifically, patients with high MARCKS expressing tumors of the Proneural molecular subtype had significantly increased survival rates and this effect was most pronounced in tumors with unmethylated MGMT promoters, a traditionally poor prognostic factor"
                    ],
                    "conclusions": [
                        "MARCKS levels impact GBM growth and radiation sensitivity",
                        "High MARCKS expressing GBM tumors are associated with improved survival, particularly with unmethylated\u00a0MGMT\u00a0promoters",
                        "These findings suggest the use of MARCKS as a novel target and biomarker for prognosis in the Proneural subtype of GBM"
                    ]
                },
                "application": {
                    "validated": "Yes",
                    "diagnosis": null,
                    "prognosis": "Yes (Proneural subtype)",
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Ahmed"
            },
            {
                "_id": "V000184",
                "pmid": "26337803",
                "biomarkerId": "B000184",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Mus musculus"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": null,
                "whoclass": "2007",
                "region": null,
                "research": {
                    "methods": [
                        "IHC",
                        "protein quantification",
                        ""
                    ],
                    "results": [
                        "PARP1 is overexpressed in tumour tissue compared to healthy controls"
                    ],
                    "conclusions": [
                        "PARP1 can be used as a diagnose"
                    ]
                },
                "application": {
                    "validated": null,
                    "diagnosis": "YES",
                    "prognosis": "NO",
                    "predictive": "NO",
                    "therapeutic": "NO"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": "YES",
                "curator": "RF"
            },
            {
                "_id": "V000185",
                "pmid": "25710480",
                "biomarkerId": "B000185",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": null,
                "whoclass": "2007",
                "region": [
                    "Ukraine"
                ],
                "research": {
                    "methods": [
                        "IHC"
                    ],
                    "results": [
                        "CD150is expressed in 77.6% of human CNS tumors"
                    ],
                    "conclusions": [
                        "this study revealed a novel CD150 isoform that is a specific feature of primate genomes and is a new potential molecular marker of CNS tumors."
                    ]
                },
                "application": {
                    "validated": null,
                    "diagnosis": "NO",
                    "prognosis": "YES",
                    "predictive": "YES",
                    "therapeutic": "NO"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": "NO",
                "curator": "RF"
            },
            {
                "_id": "V000186",
                "pmid": "30069164",
                "biomarkerId": "B000186",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": 43.0,
                        "under": 166.0,
                        "over": 143.0
                    }
                },
                "gender": {
                    "male": 143.0,
                    "female": 143.0,
                    "other": -1
                },
                "stage": [
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": "2016",
                "region": [
                    "China"
                ],
                "research": {
                    "methods": [
                        "Pyrosequencing",
                        "Gene ontology and gene set enrichment analysis",
                        "Kaplan-Meier method",
                        "Log-rank test",
                        "Cox model"
                    ],
                    "results": [
                        "Expression profiling identified 169 aberrantly expressed antisense lncRNAs between lower grade glioma (LGG) (grade II and III) and GBM, 113 antisense lncRNAs between LGG IDH-wt and IDH-mut samples, and 70 antisense lncRNAs between GBM IDH-wt and IDH-mut samples, respectively",
                        "Three antisense lncRNAs (WDFY3-AS2, MCM3AP-AS1 and LBX2-AS1) were significantly associated with prognosis and malignant progression of patients",
                        "WDFY3-AS2, the top one of downregulated antisense lncRNAs in GBM with fold change of 0.44, showed specific decreased expression in classical, mesenchymal, LGG IDH-wt, GBM IDH-wt or MGMT promoter unmethylated stratified patients"
                    ],
                    "conclusions": [
                        "Findings provided convincing evidence that WDFY3-AS2 is a novel valuable prognostic biomarker for diffuse glioma"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": null,
                    "prognosis": "Yes",
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Erik Samuelsson"
            },
            {
                "_id": "V000187",
                "pmid": "30015879",
                "biomarkerId": "B000187",
                "sourceIds": [
                    "Tissue",
                    "Cell line"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": 60.0,
                        "under": 23.0,
                        "over": 37.0
                    }
                },
                "gender": {
                    "male": 37.0,
                    "female": 37.0,
                    "other": -1
                },
                "stage": [
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": null,
                "region": [
                    "China"
                ],
                "research": {
                    "methods": [
                        "CCK8 assay",
                        "RT-PCR",
                        "Apoptosis assay",
                        "In vitro migration and invasion assay",
                        "In vivo assay",
                        "Luciferase reprter assay",
                        "Kaplan-Meier method",
                        "Log-rank test",
                        "ANOVA",
                        "Tukey's test",
                        "ROC curve analysis"
                    ],
                    "results": [
                        "miR-500a-5p was highly expressed in malignant GBM tissues and cell lines",
                        "Overexpression of miR-500a-5p promoted GBM cell proliferation, migration and invasion in vitro",
                        "Knockdown of miR-500a-5p accelerated cell apoptosis",
                        "miR-500a-5p inhibition significantly impaired tumor growth in vivo",
                        "miR-500a-5p directly binds the 3\u2032-untranslated region of chromodomain helicase DNA binding protein 5 (CHD5) mRNA",
                        "miR-500a-5p markedly inhibited CHD5 expression in glioblastoma cells",
                        "CHD5 was downregulated in glioblastoma tissues, and the expression levels of miR-500a-5p and CHD5 were inversely correlated",
                        "Knockdown of CHD5 restored the inhibition of cell proliferation and migration triggered by miR-500a-5p silence"
                    ],
                    "conclusions": [
                        "Demonstrated that miR-500a-5p can serve as a novel biomarker for the diagnosis and prognosis of GBM patients",
                        "Taken together, the results of the present study indicated that miR-500a-5p may have promoted glioblastoma development and progression by targeting CHD5"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": null,
                    "prognosis": "Potential",
                    "predictive": "Potential",
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Erik Samuelsson"
            },
            {
                "_id": "V000188",
                "pmid": "29995176",
                "biomarkerId": "B000188",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": null,
                "region": [
                    "China"
                ],
                "research": {
                    "methods": null,
                    "results": [
                        "NUSAP1 was significantly up-regulated in GBM tissues compared with adult non-tumor brain tissues both in a validated cohort and a TCGA cohort",
                        "Patients with high NUSAP1 expression had significantly lower OS",
                        "In the TCGA cohort, NUSAP1 expression was relatively lower in GBM patients within the neural and mesenchymal subtypes compared to other subtypes, and associated with the status of several genetic aberrations such as PTEN deletion and wild type IDH1",
                        "Knockdown of NUSAP1 revealed its regulation on G2/M progression and cell proliferation (both in vitro and in vivo)"
                    ],
                    "conclusions": [
                        "Study provides new insights and evidence that NUSAP1 over-expression was significantly correlated with progression and prognosis of GBM",
                        "Data demonstrate that NUSAP1 could serve as a novel prognostic marker and a potential therapeutic target for GBM"
                    ]
                },
                "application": {
                    "validated": "Yes",
                    "diagnosis": null,
                    "prognosis": "Potential",
                    "predictive": null,
                    "therapeutic": "Potential"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Erik Samuelsson"
            },
            {
                "_id": "V000189",
                "pmid": "29642043",
                "biomarkerId": "B000189",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": 60.0,
                        "under": 70.0,
                        "over": 28.0
                    }
                },
                "gender": {
                    "male": 28.0,
                    "female": 28.0,
                    "other": -1
                },
                "stage": null,
                "whoclass": "Post 2010",
                "region": [
                    "China"
                ],
                "research": {
                    "methods": [
                        "We determined the expression of CPEB4 protein using immunohistochemistry in tissue microarrays containing 278 glioma patients (including 98 primary glioblastomas) and evaluated its association with pathological grades and clinical outcome by univariate and multivariate analyses using a tissue microarray and immunohistochemistry."
                    ],
                    "results": [
                        "CPEB4 expression was positively related to glioma pathological grade (p\u202f<\u202f0.01) and elevated in glioblastoma (p\u202f<\u202f0.01). High expression of CPEB4 was associated with significantly poor prognosis, and could be identified as an independent risk factor for overall survival (OS) and progression-free survival (PFS) of glioblastoma patients (hazard ratio (HR)\u202f=\u202f1.730, p\u202f=\u202f0.014 and HR\u202f=\u202f1.877, p\u202f=\u202f0.004, respectively). In vitro studies further showed that downregulation of CPEB4 significantly reduced the growth rate of T98G and U251 cells comparing with the controls."
                    ],
                    "conclusions": [
                        "Our study indicated that increased expression of CPEB4 in primary glioblastoma is a novel biomarker for predicting poor outcome of patients and suppression of CPEB4 inhibit tumor cell proliferation, suggesting a potential therapeutic target for glioblastoma."
                    ]
                },
                "application": {
                    "validated": "Potential",
                    "diagnosis": null,
                    "prognosis": null,
                    "predictive": "Potential",
                    "therapeutic": "Potential"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Erik Samuelsson"
            },
            {
                "_id": "V00018A",
                "pmid": "29631594",
                "biomarkerId": "B00018A",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": 50.0,
                        "under": 44.0,
                        "over": 52.0
                    }
                },
                "gender": {
                    "male": 52.0,
                    "female": 52.0,
                    "other": -1
                },
                "stage": [
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": "Post 2010",
                "region": [
                    "China"
                ],
                "research": {
                    "methods": [
                        "RNA extraction, reverse transcription, PCR, Telomere repeat amplification protocol (TRAP) assay, Western Blot"
                    ],
                    "results": [
                        "The \u03b2 splicing was verified in human gliomas and hTERT+\u03b2 was significantly correlated with higher telomerase activity, higher KPS, larger tumor size, and higher tumor grades. Meanwhile, glioma patients lacking hTERT+\u03b2 expression or telomerase activity showed a significant survival benefit. Notably, CX-5461 altered hTERT splicing patterns, leading to an increase of hTERT-\u03b2 transcript and a decrease of hTERT+\u03b2 transcript expression, which inhibits telomerase activity. In addition, CX-5461 had cytotoxic effects on GBM cells and caused telomere DNA damage response, induced G2/M arrest and apoptosis."
                    ],
                    "conclusions": [
                        "The hTERT+\u03b2 is verified to be correlated with clinical parameters in gliomas, and could serve as a prognostic marker or possibly therapeutic target for gliomas. CX-5461 can regulate the splicing pattern of hTERT, inhibit telomerase activity, and kill GBM cells."
                    ]
                },
                "application": {
                    "validated": "Potential",
                    "diagnosis": null,
                    "prognosis": "Potential",
                    "predictive": null,
                    "therapeutic": "Potential"
                },
                "clinical": {
                    "relevance": "pTERT mutations are an up-and-coming biomarker in assessing clinical course, and have potential for clinical use alongside IDH and 1p/19q codeletions.",
                    "implication": "Assessment of pTERT mutation status represents a valuable additive tool to IDH mutation and 1p19q co-deletion in order to refine the World Health Organization (WHO) 2016 classification of gliomas. ",
                    "treatment": "Primary opportunities as a prognostic biomarker."
                },
                "comments": null,
                "curator": "Erik Samuelsson"
            },
            {
                "_id": "V00018B",
                "pmid": "29483008",
                "biomarkerId": "B00018B",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": 61.0,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": "Post 2010",
                "region": [
                    "USA"
                ],
                "research": {
                    "methods": [
                        "We used the National Cancer Data Base (NCDB) to analyze completeness of coding for MGMT as well as to compare outcomes of GBM patients treated with adjuvant chemoradiation based on MGMT promoter methylation status (positive, negative, unknown). Patients diagnosed with GBM from 2010 to 2012 who received adjuvant chemoradiation were identified. MGMT promoter methylation status was obtained. The Kaplan-Meier method was used to assess overall survival (OS) by coding status of MGMT promoter methylation (positive, negative, unknown) and Cox regression analysis was used to assess impact of covariables on OS."
                    ],
                    "results": [
                        "Treatment at academic centers was strongly associated with MGMT promoter status testing (OR 2.23, p\u202f<\u202f0.001), as well as hospital facility within the Northeast (OR 1.55, p\u202f<\u202f0.001). The median and 2-year OS was 20\u202fmonths and 40.2% for MGMT+ compared to 15\u202fmonths and 24.1% for MGMT-, respectively (p\u202f<\u202f0.001). For those coded as MGMT unknown, median and 2-year OS was 14.6\u202fmonths and 27.5%, which was significantly worse compared to MGMT+ (p\u202f<\u202f0.001) but not compared to MGMT- (p\u202f=\u202f0.78). On multivariable analysis, MGMT+ was strongly associated with improved OS (HR 0.74, p\u202f<\u202f0.001)."
                    ],
                    "conclusions": [
                        "Despite convincing evidence that MGMT promoter methylation status has a strong influence on prognosis",
                        "it appears to be a highly underutilized test in United States hospitals."
                    ]
                },
                "application": {
                    "validated": "Yes",
                    "diagnosis": "NO",
                    "prognosis": "YES",
                    "predictive": "YES",
                    "therapeutic": "YES"
                },
                "clinical": {
                    "relevance": "O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation has been firmly established as a biomarker in patients diagnosed with gliomas, for both clinical trials and routine clinical management.",
                    "implication": "Use in companion diagnostics and predicting patient outcome.",
                    "treatment": "Methylation status of the MGMT gene is crucial to promoting DNA repair. If the MGMT gene is methylated, cancer patients tend to respond better to alkylating drug therapy."
                },
                "comments": "NO",
                "curator": "Erik Samuelsson"
            },
            {
                "_id": "V00018C",
                "pmid": "29399702",
                "biomarkerId": "B00018C",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": 60.0,
                        "under": 241.0,
                        "over": 44.0
                    }
                },
                "gender": {
                    "male": 44.0,
                    "female": 44.0,
                    "other": -1
                },
                "stage": [
                    "I",
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": null,
                "region": [
                    "China"
                ],
                "research": {
                    "methods": [
                        "IHC,qt-RTPCR, cell culture, Western blotting"
                    ],
                    "results": [
                        "The mRNA and protein levels of CapG were significantly increased in human glioma, and higher CapG expression was an independent prognostic factor for predicting unfavorable prognosis. The expression level of CapG was found to be associated with several common molecular features of glioblastoma (GBM",
                        "WHO grade IV glioma) in The Cancer Genome Atlas (TCGA) cohort. When analyzing the prognosis of GBM patients according to these molecular features, we observed that the prognostic value of CapG was affected by amplification of CDK6 or EGFR. However, overexpression of CapG markedly promoted cell growth in vitro, while depletion of CapG significantly inhibited cell proliferation by blocking the cell cycle in G1/S transition. Moreover, CapG manipulation in glioma cell lines U87 and U251 showed CapG-dependent cellular migration and invasiveness."
                    ],
                    "conclusions": [
                        "These data suggest that CapG may serve as a prognostic biomarker with potentially important therapeutic implications for glioma."
                    ]
                },
                "application": {
                    "validated": "Potential",
                    "diagnosis": "NO",
                    "prognosis": "Potential",
                    "predictive": null,
                    "therapeutic": "Potential"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": "NO",
                "curator": "Erik Samuelsson"
            },
            {
                "_id": "V00018D",
                "pmid": "29393370",
                "biomarkerId": "B0001D4",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": 59.84,
                    "avg": -1,
                    "sd": 13.54,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": "Post 2010",
                "region": [
                    "China (TCGA Database, USA)"
                ],
                "research": {
                    "methods": [
                        "ifferentially expressed genes (DEGs) were screened by comparing microarray data of tumor and normal tissue samples from The Cancer Genome Atlas (TCGA) and the Gene Expression Omnibus (GEO) dataset GSE22866. Subsequently, the prognosis\u2011associated DEGs were screened via Cox regression analysis, followed by construction of gene/protein/pathway interaction networks of these DEGs by calculating the correlation coefficient between the DEGs. Next, a prognostic prediction system was constructed using Bayes discriminant analysis, which was validated by the microarray data of samples from patients with good and bad prognosis from the TCGA and Chinese Glioma Genome Atlas (CGGA), as well as the GEO dataset. Finally, a co\u2011expression network of the signature genes in the prediction system was constructed in combination with the significant pathways. A total of 288 overlapping DEGs (false discovery rate <0.5 and |log2 of fold change|>1) were screened, 123 of which were identified to be associated with the prognosis of GBM patients. The co\u2011expression network of these prognosis\u2011associated DEGs included 1405 interactions and 112 DEGs, and 6 functional modules were identified in the network."
                    ],
                    "results": [
                        "The prognostic prediction system was comprised of 63 signature genes with a specificity value of 0.929 and a sensitivity value of 0.948. GBM samples with good and bad prognosis in the TCGA, CGGA and GEO datasets were distinguishable by these signature genes (P=1.33x10\u20116, 1.63x10\u20114 and 0.00534, respectively). The co\u2011expression network of signature genes with significant pathways was comprised of 56 genes and 361 interactions. Protein kinase C\u03b3 (PRKCG), protein kinase C\u03b2 (PRKCB) and calcium/calmodulin\u2011dependent protein kinase II\u03b1 (CAMK2A) were important genes in the network, and based on the expression of these genes, it was possible to distinguish between samples with significantly different survival risks."
                    ],
                    "conclusions": [
                        "In the present study, an effective prognostic prediction system for GBM patients was constructed and validated. PRKCG, PRKCB and CAMK2A may be potential prognostic factors for GBM."
                    ]
                },
                "application": {
                    "validated": "Potential",
                    "diagnosis": "NO",
                    "prognosis": "Potential",
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": "NO",
                "curator": "Erik Samuelsson"
            },
            {
                "_id": "V00018E",
                "pmid": "29383189",
                "biomarkerId": "B00018E",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": 40.0,
                        "under": 67.0,
                        "over": 386.0
                    }
                },
                "gender": {
                    "male": 386.0,
                    "female": 386.0,
                    "other": -1
                },
                "stage": [
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": "Post 2010",
                "region": [
                    "China"
                ],
                "research": {
                    "methods": [
                        "Clinicopathological analysis of HOXD4 expression in 453 glioma patients was performed in the current study. Expression of HOXD4 was evaluated by qPCR and immunohistochemical (IHC) staining. Univariate and multivariate analysis were conducted to investigate the prognostic role of HOXD4 in glioma patients."
                    ],
                    "results": [
                        "The data demonstrated that and the results demonstrated that HOXD4 was overexpressed in glioma tissues compared to that of normal brain tissues. patients with high HOXD4 expression had a significant shorter survival than those with low HOXD4 expression in total glioma cohort (p<0.001), WHO Grade II cohort (p=0.003) and Grade III cohort (p<0.001), but not in Grade IV cohort when OS (overall survival) was analyzed (p=0.216). The findings were confirmed by the large-scale omics data analysis including lower-grade glioma (LGG) and glioblastoma multiforme (GBM) in TCGA (the cancer genome atlas) and CGGA (Chinese glioma genome atlas). Moreover, it was revealed that the expression of HOXD4 have a significant impact on the OS of Grade IV glioma with IDH wild-type and 1p/19q intact according to TCGA data."
                    ],
                    "conclusions": [
                        "Expression of HOXD4 was closely related to the clinical outcomes of patients with gliomas, and HOXD4 may be a potential prognostic biomarker of gliomas."
                    ]
                },
                "application": {
                    "validated": "Potential",
                    "diagnosis": null,
                    "prognosis": "Potential",
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Erik Samuelsson"
            },
            {
                "_id": "V00018F",
                "pmid": "29378529",
                "biomarkerId": "B00018F",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": 50.0,
                        "under": 30.0,
                        "over": 15.0
                    }
                },
                "gender": {
                    "male": 15.0,
                    "female": 15.0,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": "Pre 2010",
                "region": [
                    "China"
                ],
                "research": {
                    "methods": [
                        "We included 45 patients with GBM who were treated with maximal safe surgical resection or biopsy alone followed by adjuvant RT of EQD2 (equivalent dose in 2-Gy fractions)\u2009>\u2009or\u2009=\u200960 Gy for homogeneous treatment. Paraffin-embedded tissues acquired from the Department of Pathology were analyzed using immunohistochemical staining for galectin-1 expression. The primary endpoint was overall survival (OS)."
                    ],
                    "results": [
                        "Patients with weak expression had a better median survival (27.9 months) than did those with strong expression (10.7 months",
                        "p\u2009=\u20090.009). We compared characteristics between weak and strong galectin-1 expression, and only the expression level of galectin-3 showed a correlation. The group with weak galectin-1 expression displayed a 3-year OS of 27.3% and a 3-year cancer-specific survival (CSS) of 27.3%",
                        "these values were only 5.9% and 7.6%, respectively, in the group with strong galectin-1 expression (p\u2009=\u20090.009 and 0.020, respectively). Cox regression was used to confirm that the expression level of galectin-1 (weak vs. strong) is a significant factor of OS (p\u2009=\u20090.020) and CSS (p\u2009=\u20090.022). Other parameters, such as the expression level of galectin-3, Eastern Cooperative Oncology Group (ECOG) performance, gender, surgical method, age\u2009\u2265\u200950 years, tumor size, or radiation field were not significant factors."
                    ],
                    "conclusions": [
                        "The expression level of galectin-1 affects survival in patients with GBM treated with adjuvant RT. Future studies are required to analyze the effect of other factors, such as O(6)-methylguanine-DNA methyltransferase (MGMT)-promoter methylation status, in patients with weak and strong galectin-1 expression. Ggalectin-1 expression is a poor prognostic factor for patients with GBM treated with adjuvant RT. Studies investigating the targeting of galectin-1 for radioresistance are encouraged in an effort to treat this aggressive brain tumor. The limitations of this study are its retrospective nature and limited sample size. According to the national law of human research, informed consent for research should be obtained for work performed in our country after 2002. As we could only include patients before 2002, and the sample size was therefore small. Because these patients were treated a long time ago, almost all were dead, their charts were destroyed, and the time to progression could not be confirmed. Nonetheless, the time to progression and the survival time were correlated in patients who underwent imaging follow-up",
                        "not all patients were evaluated for time to progression, yet galectin-1 remained a significant factor of GBM progression after RT. In addition, MGMT promoter methylation is associated with patient response to alkylating agents and OS. Because the proportion of MGMT promoter methylation in the included patients was undetermined, it remains unclear whether galectin-1 expression may affect the importance of the MGMT promoter methylation status for prognosis. Future studies are required to analyze the effect of other factors, such as MGMT methylation promoter status."
                    ]
                },
                "application": {
                    "validated": "Potential",
                    "diagnosis": null,
                    "prognosis": "NO",
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Erik Samuelsson"
            },
            {
                "_id": "V000190",
                "pmid": "29337169",
                "biomarkerId": "B000190",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": 70.0,
                        "under": 141.0,
                        "over": 28.0
                    }
                },
                "gender": {
                    "male": 28.0,
                    "female": 28.0,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": "Post 2010",
                "region": [
                    "Italy"
                ],
                "research": {
                    "methods": [
                        "We performed a prospective evaluation of the Project of Emilia Romagna on Neuro-Oncology (PERNO) registry to identify prognostic factors in patients with GBM who received standard treatment.O6-methylguanine-DNA methyltransferase (MGMT) methylation status, age, Karnofsky Performance Status (KPS), and extent of surgical resection are the most relevant prognostic factors."
                    ],
                    "results": [
                        "A total of 169 patients (99 males [58.6%] and 70 females [41.4%]) were evaluated prospectively. MGMT methylation was evaluable in 140 patients. Among the male patients, 36 were MGMT methylated (25.7%) and 47 were unmethylated (33.6%)",
                        "among the female patients, 32 were methylated (22.9%) and 25 were unmethylated (17.9%). Survival was longer in the methylated females compared with the methylated males (P = 0.028) but was not significantly different between the unmethylated females and the unmethylated males (P = 0.395). In multivariate analysis, gender and MGMT methylation status considered together (methylated females vs. methylated males",
                        "hazard ratio [HR], 0.459",
                        "95% confidence interval [CI], 0.242-0.827",
                        "P = 0.017), age (HR, 1.025",
                        "95% CI, 1.002-1.049",
                        "P = 0.032), and KPS (HR, 0.965",
                        "95% CI, 0.948-0.982",
                        "P < 0.001) were significantly correlated with survival."
                    ],
                    "conclusions": [
                        "Survival was consistently longer among MGMT methylated females compared with males. Gender can be considered as a further prognostic factor."
                    ]
                },
                "application": {
                    "validated": "DNA marker:yes. Gender: potential.",
                    "diagnosis": null,
                    "prognosis": "Potential",
                    "predictive": "YES",
                    "therapeutic": "YES"
                },
                "clinical": {
                    "relevance": "O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation has been firmly established as a biomarker in patients diagnosed with gliomas, for both clinical trials and routine clinical management.",
                    "implication": "Use in companion diagnostics and predicting patient outcome.",
                    "treatment": "Methylation status of the MGMT gene is crucial to promoting DNA repair. If the MGMT gene is methylated, cancer patients tend to respond better to alkylating drug therapy."
                },
                "comments": null,
                "curator": "Erik Samuelsson"
            },
            {
                "_id": "V000191",
                "pmid": "29305787",
                "biomarkerId": "B000191",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": "Post 2010",
                "region": [
                    "Copenhagen"
                ],
                "research": {
                    "methods": [
                        "A small proportion of patients present long survival over 3 years, but the underlying molecular background separating these long-term survivors (LTS) from short-term survivors (STS) are insufficiently understood. Accordingly, study aim was to identify independent prognostic biomarkers for survival. Study cohort consisted of 93 primary GBM patients treated with radiation-, chemo- and bevacizumab therapy, among which 14 STS (OS\u2009\u2264\u200912 months) and 6 LTS (OS\u2009\u2265\u200936 months) were identified, all confirmed being IDH wild-type. RNA expression levels in diagnostic tumor specimen for 792 genes were analyzed by NanoString technology."
                    ],
                    "results": [
                        "While no differences were found with regard to GBM subtype between LTS versus STS, comparative analysis of individual genes identified 14 significantly differently expressed candidate genes. Univariate analysis in the whole patient cohort found that 12 of these were significantly associated with OS, of which increased IFNG, CXCL9, LGALS4, CD34 and decreased MGMT levels remained significant associated with prolonged OS in multivariate analysis correcting for known prognostic variables. Validation analyses in an independent dataset from the AVAglio study confirmed CD34 as significant in comparative analysis between STS and LTS patients and as an independent prognostic factor. Analysis of this dataset further supported CD34 expression to be associated with improved bevacizumab efficacy, while CD34 immunohistochemistry indicated variation in CD34 expression to result primarily from varying tumor vascularization."
                    ],
                    "conclusions": [
                        "Collectively, CD34 expression candidates as a prognostic biomarker in GBM able to identify survival outliers and could also be predictive for efficacy of bevacizumab."
                    ]
                },
                "application": {
                    "validated": "Potential",
                    "diagnosis": null,
                    "prognosis": "Potential",
                    "predictive": "Potential",
                    "therapeutic": "Potential"
                },
                "clinical": {
                    "relevance": "Analysis of this dataset further supported CD34 expression to be associated with improved bevacizumab efficacy.",
                    "implication": "A potential biomarker for patient stratification for becacizumab clinical trials is potentially useful if validated.",
                    "treatment": null
                },
                "comments": null,
                "curator": "Erik Samuelsson"
            },
            {
                "_id": "V000192",
                "pmid": "28943957",
                "biomarkerId": "B000192",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": 56.0,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "I",
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": "2007",
                "region": [
                    "China"
                ],
                "research": {
                    "methods": [
                        "RT-qPCR",
                        "Cox proportional hazards model",
                        "Kaplan-Meier method"
                    ],
                    "results": [
                        "miR-141 aberrantly downregulated in GBM",
                        "in GBM patients, miR-141 downregulation closely associated with an advanced disease stage, poor clinicopathological properties and a shorter OS time",
                        "low miR-141 expression is effective prognostic biomarker for patients with glioblastoma."
                    ],
                    "conclusions": [
                        "miR-141 may be a functional cancer regulator and a prognostic biomarker for glioblastoma"
                    ]
                },
                "application": {
                    "validated": "Potential",
                    "diagnosis": null,
                    "prognosis": "Potential",
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Vanessa"
            },
            {
                "_id": "V000193",
                "pmid": "28926524",
                "biomarkerId": "B000193",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": 50.0,
                        "under": 52.0,
                        "over": 53.0
                    }
                },
                "gender": {
                    "male": 53.0,
                    "female": 53.0,
                    "other": -1
                },
                "stage": null,
                "whoclass": null,
                "region": [
                    "China"
                ],
                "research": {
                    "methods": [
                        "Immunohistochemical assessment",
                        "gene expression analysis",
                        "chi-square test,Kaplan-Meier method",
                        "Cox regression model"
                    ],
                    "results": [
                        "TRAF1 expression has no significant prognostic value for GBM",
                        "high expression of TRAF2 cna predict poor prognosis of GBM",
                        "TRAF2 identified as independent biomarker in GBM prognosis"
                    ],
                    "conclusions": [
                        "High expression of TRAF2 identified as an independent biomarker in GBM prognosis",
                        "TRAF2 novel drug target in GBM treatment"
                    ]
                },
                "application": {
                    "validated": "Concrete",
                    "diagnosis": null,
                    "prognosis": "YES",
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": "TRAF2 novel drug target in GBM treatment"
                },
                "comments": null,
                "curator": "Vanessa"
            },
            {
                "_id": "V000194",
                "pmid": "28887715",
                "biomarkerId": "B000194",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": 50.03,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "19 low Grade glioma",
                    "50 GBM"
                ],
                "whoclass": null,
                "region": null,
                "research": {
                    "methods": [
                        "Immunohistochemical assessment",
                        "Fisher\u2019s exact test",
                        "Mann-Whitney U test",
                        "Kaplan-Meier method",
                        "log-rank test",
                        "Cox proportional hazard regression",
                        "Pearson product-moment correlation coefficients"
                    ],
                    "results": [
                        "EMP2 expression was dichotomized to low or high expression scores and correlated with clinical data.",
                        "mean EMP2 expression was 1.68 in lower grade gliomas versus 2.20 in GBMs",
                        "percentage of samples with high EMP2 expression was greater in GBMs than lower grade gliomas",
                        "no significant difference found between median survival among patients with GBM tumors exhibiting high EMP2 expression and survival of those with low EMP2 expression",
                        "EMP2 expression \u22652 correlated with decreased survival",
                        "EMP2 expression level correlated with Ki-67 positivity",
                        "mortality hazard ratio for GBM patients with EMP2 score of 3 or higher is 1.92"
                    ],
                    "conclusions": [
                        "elevated EMP2 expression is associated with GBM",
                        "with other biomarkers, EMP2 may have use as a molecular target for the diagnosis and treatment of gliomas"
                    ]
                },
                "application": {
                    "validated": "Potential",
                    "diagnosis": "Potential",
                    "prognosis": null,
                    "predictive": null,
                    "therapeutic": "Potential"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": "Potential",
                "curator": "Vanessa"
            },
            {
                "_id": "V000195",
                "pmid": "28869437",
                "biomarkerId": "B000195",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": 60.0,
                        "under": 27.0,
                        "over": 21.0
                    }
                },
                "gender": {
                    "male": 21.0,
                    "female": 21.0,
                    "other": -1
                },
                "stage": null,
                "whoclass": null,
                "region": [
                    "China"
                ],
                "research": {
                    "methods": [
                        "RT-qPCR",
                        "Pyrosequencing",
                        "miRNA array analysis",
                        "Kaplan-Meier method"
                    ],
                    "results": [
                        "Six miRNAs upregulated in the long-term survival group",
                        "increase in let-7g-5p, miR-139-5p, miR-17-5p and miR-9-3p level in long-term survivors statistically significant",
                        "high expression of a prognostic 4-miRNA signature significantly associated with good patient survival",
                        "the signature regulated signaling pathways including Calcium, MAPK, ErbB, mTOR and cell cycle involved in carcinogenesis from glial progenitor cell to primary GBM."
                    ],
                    "conclusions": [
                        "4-miRNA signature identified as independent prognostic biomarker that identified patietns with favorable outcome"
                    ]
                },
                "application": {
                    "validated": "Concrete",
                    "diagnosis": null,
                    "prognosis": "YES",
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Vanessa"
            },
            {
                "_id": "V000196",
                "pmid": "28789454",
                "biomarkerId": "B000196",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": null,
                "whoclass": "2007",
                "region": null,
                "research": {
                    "methods": [
                        "Gene expression analysis",
                        "Kaplan-Meier method"
                    ],
                    "results": [
                        "FER1L4 significantly upregulated in high-grade glioma compared with low-grade glioma",
                        "high expression of FER1L4 significantly predictes poor prognosis in patients with glioma"
                    ],
                    "conclusions": [
                        "FER1L4 serves a role in occurrence and progression of glioma",
                        "could be used as a prognostic biomarker"
                    ]
                },
                "application": {
                    "validated": "Potential",
                    "diagnosis": null,
                    "prognosis": "Potential",
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": "glioma cell invasion and viability significantly inhibited by transfection with a FER1L4 siRNA, which promoted apoptosis;FER1L4 might have cancer-promoting effect in glioma and is a novel target for gene therapy"
                },
                "comments": null,
                "curator": "Vanessa"
            },
            {
                "_id": "V000197",
                "pmid": "28780604",
                "biomarkerId": "B000197",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": 40.0,
                        "under": 14.0,
                        "over": 21.0
                    }
                },
                "gender": {
                    "male": 21.0,
                    "female": 21.0,
                    "other": -1
                },
                "stage": [
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": "2007",
                "region": [
                    "China"
                ],
                "research": {
                    "methods": [
                        "RT-qPCR",
                        "Spearman correlation analysis"
                    ],
                    "results": [
                        "expression of miR-338-5p, normalized to hsnRNA U6, significantly higher in grade III and IV gliomas compared to that in NNB and grade II gliomas",
                        "TSHZ3 expression, normalized to GAPDH, inversely related to miR-338-5p",
                        "miR-338-5p has a function in promoting glioma cell invasion by targeting TSHZ3 suppression on MMP2"
                    ],
                    "conclusions": [
                        "miR-338-5p is a possible potential biomarker for the diagnosis and target for therapy of high-grade glioma"
                    ]
                },
                "application": {
                    "validated": "Potential",
                    "diagnosis": "Potential",
                    "prognosis": null,
                    "predictive": null,
                    "therapeutic": "Potential"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": "a therapeutic miRNA might provide a new insight into the development of therapeutic strategies against glioma by inhibiting miR-338-5p"
                },
                "comments": "Potential",
                "curator": "Vanessa"
            },
            {
                "_id": "V000198",
                "pmid": "28759950",
                "biomarkerId": "B000198",
                "sourceIds": [
                    "TIssue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": 50.0,
                        "under": 81.0,
                        "over": 65.0
                    }
                },
                "gender": {
                    "male": 65.0,
                    "female": 65.0,
                    "other": -1
                },
                "stage": null,
                "whoclass": null,
                "region": [
                    "China"
                ],
                "research": {
                    "methods": [
                        "Immunohistochemical assessment",
                        "multivariate analysis",
                        "Kaplan-Meier method",
                        "log-rank test",
                        "Cox regression analysis"
                    ],
                    "results": [
                        "high CXCR7 expression correlates to poor overall survival (OS) in GBM",
                        "age, KPS score, chemotherapy, IDH1 mutation, MGMT methylation and CXCR7 are independent factors in survival prognosis"
                    ],
                    "conclusions": [
                        "CXCR7 may invovle in clinical GBM progression",
                        "CXCR7 could be prognositc marker in GBM treatment"
                    ]
                },
                "application": {
                    "validated": "Potential",
                    "diagnosis": null,
                    "prognosis": "Potential",
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Vanessa"
            },
            {
                "_id": "V000199",
                "pmid": "28458560",
                "biomarkerId": "B000199",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": 50.0,
                        "under": 86.0,
                        "over": 94.0
                    }
                },
                "gender": {
                    "male": 94.0,
                    "female": 94.0,
                    "other": -1
                },
                "stage": [
                    "I",
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": "2007",
                "region": null,
                "research": {
                    "methods": [
                        "Immunohistochemical assessment of specimen",
                        "RT-qPCR",
                        "Kaplan-Meier method",
                        "log-rank test",
                        "Cox regression analysis",
                        "further validation by online Oncomine database"
                    ],
                    "results": [
                        "SERPINA3 was upregulated in glioma tissue at both mRNA and protein levels, compared with noncancerous brain tissues",
                        "high SERPINA3 expression in glioma tissue correlates significantly with WHO grade",
                        "ERPINA3 expression independent prognostic factor for poor overall survival of glioma patients"
                    ],
                    "conclusions": [
                        "SERPINA3 plays an oncogenic role in glioma progression",
                        "provides insight into the application of SERPINA3 as a novel predictor of clinical outcomes and a potential biomarker of glioma"
                    ]
                },
                "application": {
                    "validated": "Potential",
                    "diagnosis": null,
                    "prognosis": null,
                    "predictive": "Potential",
                    "therapeutic": "Potential"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Vanessa"
            },
            {
                "_id": "V00019A",
                "pmid": "28236760",
                "biomarkerId": "B00019A",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": 50.18,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": null,
                "whoclass": "2007",
                "region": [
                    "China"
                ],
                "research": {
                    "methods": [
                        "Illumina Hiseq",
                        "kaplan-Meier method",
                        "Cox analysis"
                    ],
                    "results": [
                        "1411 differentially expressed circRNAs identified in GBM patients including 206 upregulated circRNAs and 1205 downregulated circRNAs",
                        "differential expression of circRNAs closely associated with the biological process and molecular function",
                        "downregulated circRNAs mainly associated with ErbB and Neurotrophin signaling pathways",
                        "expression level of circBRAF in normal brain tissues  significantly higher than that in glioma tissues",
                        "CircBRAF significantly lower in glioma patients with high pathological grade (WHO III & IV) than those with low grade (WHO I & II)",
                        "high circBRAF expression independent biomarker for predicting good progression-free survival and overall survival in glioma patients"
                    ],
                    "conclusions": [
                        "rofile of dysregulated circRNAs in GBM identified",
                        "dysregulated circRNAs might be associated with tumorigenesis and development of GBM",
                        "circBRAF could severe as a biomarker for predicting pathological grade and prognosis in glioma patients"
                    ]
                },
                "application": {
                    "validated": "Potential",
                    "diagnosis": null,
                    "prognosis": null,
                    "predictive": "Potential",
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Vanessa"
            },
            {
                "_id": "V00019B",
                "pmid": "28103511",
                "biomarkerId": "B00019B",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": 50.0,
                        "under": 41.0,
                        "over": 45.0
                    }
                },
                "gender": {
                    "male": 45.0,
                    "female": 45.0,
                    "other": -1
                },
                "stage": [
                    "I",
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": null,
                "region": [
                    "China"
                ],
                "research": {
                    "methods": [
                        "Clinicopathological analysis",
                        "Kaplan-Meier method",
                        "multivalente Cox regression analysis"
                    ],
                    "results": [
                        "Ngb associated with histological type and WHO grade of glioma",
                        "Ngb overexpression leads to shorter survival",
                        "Ngb expression independent prognostic marker"
                    ],
                    "conclusions": [
                        "Ngb can be potentially used as promising biomarker and target for novel treatment of human glioma"
                    ]
                },
                "application": {
                    "validated": "Potential",
                    "diagnosis": null,
                    "prognosis": "Potential",
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": "Ngb knockdown significantly inhibited proliferation and facilitated apoptosis in U251 cells;In vivo experiments further confirmed that Ngb silencing notably prohibited the tumor growth of glioma in nude mice;Ngb overexpression prominently promoted proliferation and suppressed apoptosis in U87 cells"
                },
                "comments": null,
                "curator": "Vanessa"
            },
            {
                "_id": "V00019C",
                "pmid": "28079349",
                "biomarkerId": "B00019C",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": 54.0,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "I",
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": "2007",
                "region": [
                    "Japan"
                ],
                "research": {
                    "methods": [
                        "RT-qPCR,Kaplan-Meier method",
                        "e MannWhitney U test",
                        "Spearman test",
                        "log-rank test"
                    ],
                    "results": [
                        "IL13R\u03b12 expressed in a subset of cases with a progressive increase from low- to high-grade A",
                        "expression has significant positive correlation with the MIB-1 index and advanced patient age at diagnosis",
                        "overall survival (OS) of patients who have high grade A with higher levels of IL13R\u03b12 expression is significantly lower than the OS of those with high grade A with lower levels of IL13R\u03b12",
                        "median survival benefit in the lower expression group is 167.4 months",
                        "median OS (mOS) in high grade A group with lower IL13R\u03b12 expression is 186.4 months, while the mOS in the group with higher IL13R\u03b12 expression is 18.6 months"
                    ],
                    "conclusions": [
                        "IL13R\u03b12 may be used as a marker of poorer prognosis in high grade As, even among tumors of the same grade"
                    ]
                },
                "application": {
                    "validated": null,
                    "diagnosis": null,
                    "prognosis": "Potential",
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Vanessa"
            },
            {
                "_id": "V00019D",
                "pmid": "27655637",
                "biomarkerId": "B00019D",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": 45.0,
                        "under": 37.0,
                        "over": 20.0
                    }
                },
                "gender": {
                    "male": 20.0,
                    "female": 20.0,
                    "other": -1
                },
                "stage": [
                    "I",
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": null,
                "region": [
                    "China"
                ],
                "research": {
                    "methods": [
                        "significant analysis of microarray (SAM)",
                        "differentially expressed genes (DEGs) analysis",
                        "gene ontology (GO) enrichment analysis",
                        "RT-qPCR,Kaplan-meier method",
                        "log-rank test"
                    ],
                    "results": [
                        "46 differentially expressed genes (DEG) identified in GBM",
                        "RRM2 and COL3A1  increased and directly correlated with glioma grade",
                        "SH3GL2 and SNAP91 decreased in GBM and inversely correlated with glioma grade",
                        "COL3A1 and SNAP91 correlated with survival"
                    ],
                    "conclusions": [
                        "COL3A1 and SNAP91 may be suitable biomarkers for diagnostic or therapeutic strategies for GBM"
                    ]
                },
                "application": {
                    "validated": null,
                    "diagnosis": "Potential",
                    "prognosis": null,
                    "predictive": null,
                    "therapeutic": "Potential"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": "Potential",
                "curator": "Vanessa"
            },
            {
                "_id": "V00019E",
                "pmid": "27090900",
                "biomarkerId": "B00019E",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": null,
                "whoclass": null,
                "region": null,
                "research": {
                    "methods": null,
                    "results": null,
                    "conclusions": null
                },
                "application": {
                    "validated": null,
                    "diagnosis": null,
                    "prognosis": null,
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "BP"
            },
            {
                "_id": "V00019F",
                "pmid": "27029617",
                "biomarkerId": "B00019F",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": "2007",
                "region": [
                    "Italy"
                ],
                "research": {
                    "methods": [
                        "Pyrosequencing"
                    ],
                    "results": [
                        "Patients with a methylation status \u226530\u00a0% showed a median overall survival of 25.2\u00a0months compared to 15.2\u00a0months in all other patients when treated with radiotherapy followed by TMZ"
                    ],
                    "conclusions": [
                        "Predictive role of MGMT promoter methylation was maintained only with a cutoff value of greater than 30 percent"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": null,
                    "prognosis": null,
                    "predictive": "YES",
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "BP"
            },
            {
                "_id": "V0001A0",
                "pmid": "27000226",
                "biomarkerId": "B0001A0",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": 50.0,
                        "under": 18.0,
                        "over": 23.0
                    }
                },
                "gender": {
                    "male": 23.0,
                    "female": 23.0,
                    "other": -1
                },
                "stage": [
                    "I",
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": "2007",
                "region": [
                    "Iran"
                ],
                "research": {
                    "methods": [
                        "Quantitative real time PCR",
                        "immunohistochemistry",
                        "Kaplan-Meier survival curves",
                        "Cox regression"
                    ],
                    "results": [
                        "mRNA level of CPEB4 was strongly increased in tumor tissues",
                        "CPEB1 mRNA was significantly decreased in tumor tissues compared to normal tissues",
                        "High expression of CPEB4 was correlated with shorter overall survival and low expression of CPEB1 was linked to shorter overall survival",
                        "high CPEB1, low CPEB4 expressions and advanced tumor grade were independent predictor of overall survival"
                    ],
                    "conclusions": [
                        "Data indicated expressions levels of CPEB4 and CPEB1 are correlated with overall survival in patients with glioma"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": "NO",
                    "prognosis": "YES",
                    "predictive": "NO",
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": "NO",
                "curator": "BP"
            },
            {
                "_id": "V0001A1",
                "pmid": "26998166",
                "biomarkerId": "B0001A1",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": 48.0,
                        "under": 33.0,
                        "over": 47.0
                    }
                },
                "gender": {
                    "male": 47.0,
                    "female": 47.0,
                    "other": -1
                },
                "stage": [
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": "2007",
                "region": [
                    "China"
                ],
                "research": {
                    "methods": [
                        "RNA extraction and gene expression profiling",
                        "Immunohistochemical analysis",
                        "Fisher's exact test",
                        "Cox model"
                    ],
                    "results": [
                        "UBE2C expression, extent of resection, TMZ chemotherapy and IDH1 mutation status were independent prognostic factors of patient prognosis for GBM"
                    ],
                    "conclusions": [
                        "Expression level of UBEC1 may be a valuable prognostic marker for glioblastoma patients."
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": "NO",
                    "prognosis": "Potential",
                    "predictive": "NO",
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": "NO",
                "curator": "BP"
            },
            {
                "_id": "V0001A2",
                "pmid": "26980050",
                "biomarkerId": "B0001A2",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": 60.0,
                        "under": 41.0,
                        "over": 29.0
                    }
                },
                "gender": {
                    "male": 29.0,
                    "female": 29.0,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": "2007",
                "region": [
                    "China"
                ],
                "research": {
                    "methods": [
                        "Immunostaining",
                        "Light microscopy",
                        "Cox model",
                        "Kaplan-Meier curves",
                        "Spearman rank correlation"
                    ],
                    "results": [
                        "IFIT1 expression was essentially limited to the cytoplasm of the cells within tumor tissue",
                        "Among the 70 glioblastoma specimens inspected, the percentage of IFIT1-positive cells ranged from 0 to 65% with a median of 24% in tumor cells",
                        "Thirteen of 70 cases exhibited low IFIT1 expression and 57 cases showed high expression",
                        "IFIT1 and MGMT expression was negatively correlated",
                        "Confirmed high IFIT1 expression as a significant prognostic predictor for longer PFS  and OS  in patients with glioblastoma",
                        "High MGMT expression was confirmed to be a significant prognostic predictor for shorter PFS"
                    ],
                    "conclusions": [
                        "Demonstrated that the expression of IFIT1 significantly increased in newly diagnosed glioblastoma tissue, and the negative correlation of IFIT1 and MGMT expression may be triggered by IFN",
                        "Patients with high IFIT1 exhibited longer survival, and IFIT1 along with MGMT contributed to more accurate prognostic prediction of glioblastoma"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": "NO",
                    "prognosis": "Potential",
                    "predictive": "Potential",
                    "therapeutic": "Potential"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": "NO",
                "curator": "BP"
            },
            {
                "_id": "V0001A3",
                "pmid": "26885283",
                "biomarkerId": "B0001A3",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": 50.0,
                        "under": 61.0,
                        "over": 43.0
                    }
                },
                "gender": {
                    "male": 43.0,
                    "female": 43.0,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": "2007",
                "region": [
                    "South Korea"
                ],
                "research": {
                    "methods": [
                        "Pyrosequencing",
                        "PCR"
                    ],
                    "results": [
                        "Mean OS of GBM patients with an unmethylated\u00a0MGMT\u00a0promoter was 16.2 months and that of patients with a methylated\u00a0MGMT\u00a0promoter was 19.6 months",
                        "According to analysis by Pyrosequencing, the mean OS of total 104 GBM patients with unmethylated MGMT promoter was 14.1 months and that of patients with a methylated MGMT promoter was 20.9 months"
                    ],
                    "conclusions": [
                        "Both the status and extent of methylation of the MGMT promoter analyzed by PSQ were found to be associated with OS in patients with GBM",
                        "Pyrosequencing might be a promising technique for MGMT evaluation in daily practice"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": null,
                    "prognosis": "YES",
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "BP"
            },
            {
                "_id": "V0001A4",
                "pmid": "26740175",
                "biomarkerId": "B0001A4",
                "sourceIds": [
                    "Tissue",
                    "Cell line"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": 55.0,
                        "under": 58.0,
                        "over": 64.0
                    }
                },
                "gender": {
                    "male": 64.0,
                    "female": 64.0,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": "2007",
                "region": [
                    "China"
                ],
                "research": {
                    "methods": [
                        "Immunohistochemistry",
                        "Western blot",
                        "Quantitative real-time PCR",
                        "Paired t-test",
                        "Survival curves",
                        "Log rank test"
                    ],
                    "results": [
                        "Patients with low levels of CHAF1A had significantly longer overall survival relative to those with high levels of CHAF1A",
                        "Knockout of CHAF1A by CRISPR/CAS9 suppresses glioblastoma cell proliferation",
                        "Knockout of CHAF1A induce cell cycle and altered the apoptosis of glioblastoma cells",
                        "FOXO3a activity was altered in CHAF1A knockout glioblastoma cells"
                    ],
                    "conclusions": [
                        "Results show that CHAF1A contributes to the proliferation of glioblastoma cells and may be developed as a de novo drug target and prognosis biomarker of glioblastoma"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": null,
                    "prognosis": "Potential",
                    "predictive": null,
                    "therapeutic": "Potential"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "BP"
            },
            {
                "_id": "V0001A5",
                "pmid": "26738845",
                "biomarkerId": "B0001A5",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": "2007",
                "region": [
                    "Denmark"
                ],
                "research": {
                    "methods": [
                        "Immunohistochemistry",
                        ""
                    ],
                    "results": [
                        "WEE1 protein was localized in tumor cell nuclei and expressed in all glioma types and grades",
                        "Although WEE1 protein levels are higher in GBMs relative to grade III and grade II gliomas, high WEE1 protein was associated with better survival in GBMs"
                    ],
                    "conclusions": [
                        "Nuclear expression of WEE1 protein in all glioma grades and types",
                        "WEE1 positive nuclear area was correlated with malignancy grade but it was inversely associated with prognosis in GBM",
                        "Although WEE1 is a frequently occurring protein and has been proposed as a novel target in GBM, the role of WEE1 in glioma patient survival appears to be connected to the MGMT status and is more complex than previously anticipated"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": null,
                    "prognosis": "Potential",
                    "predictive": null,
                    "therapeutic": "Potential"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "BP"
            },
            {
                "_id": "V0001A6",
                "pmid": "26699864",
                "biomarkerId": "B0001A6",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "I",
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": "2007",
                "region": [
                    "The Netherlands"
                ],
                "research": {
                    "methods": [
                        "Cox proportional hazards model",
                        "ANOVA"
                    ],
                    "results": [
                        "PI3-kinase mutations are a marker of poor prognosis in\u00a0IDH-mutated\u2009+\u2009ATRX/TP53\u00a0mutated diffuse gliomas",
                        "IDH is the most important prognostic marker in diffuse gliomas",
                        "subgroup analysis largely confirms many of the currently used molecular classification schemes for diffuse gliomas (ATRX or TP53 mutations, 1p19q codeletion)"
                    ],
                    "conclusions": [
                        "Identified PI3K mutations as novel prognostic markers in gliomas",
                        "Demonstrate that the mutational load is associated with tumor grade."
                    ]
                },
                "application": {
                    "validated": "Yes",
                    "diagnosis": "NO",
                    "prognosis": "YES",
                    "predictive": "NO",
                    "therapeutic": "NO"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": "NO",
                "curator": "BP"
            },
            {
                "_id": "V0001A7",
                "pmid": "26690524",
                "biomarkerId": "B0001A7",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": 40.0,
                        "under": 7.0,
                        "over": 14.0
                    }
                },
                "gender": {
                    "male": 14.0,
                    "female": 14.0,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": "2007",
                "region": [
                    "India"
                ],
                "research": {
                    "methods": [
                        "qRT-PCR",
                        "Western blot",
                        "Cox model",
                        "Survival curves",
                        "Kruskal-Wallis test"
                    ],
                    "results": [
                        "Overexpression of CD133 mRNA and BMI1 protein was found in 47.6 and 76.2 percent patients respectively and TP53 mutations was seen in 57.1 percent of patients",
                        "High level of BMI1 expression was favourable for the patient survival and high CD133 mRNA expression was unfavourable for the patient survival",
                        "CD133 mRNA and BMI1 protein expression could independently predict the glioblastoma patient survival in multivariate analysis"
                    ],
                    "conclusions": [
                        "Overexpression of these stem cell markers is a common event in glioblastoma progression and could be used as potential prognostic markers"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": "NO",
                    "prognosis": "Potential",
                    "predictive": "NO",
                    "therapeutic": "NO"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": "NO",
                "curator": "BP"
            },
            {
                "_id": "V0001A8",
                "pmid": "26682634",
                "biomarkerId": "B0001A8",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": 50.0,
                        "under": 33.0,
                        "over": 40.0
                    }
                },
                "gender": {
                    "male": 40.0,
                    "female": 40.0,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": "2007",
                "region": [
                    "Egypt"
                ],
                "research": {
                    "methods": [
                        "Surgery",
                        "Chemotherapy",
                        "Radiotherapy",
                        "Immunohistochemistry",
                        "Cox model",
                        "Survival curves"
                    ],
                    "results": [
                        "For the whole cohort, the median OS was 15 months, and the progression-free survival was 10 months",
                        "Patients who had low MGMT protein expression (less than 15 percent) had a significantly improved OS and PFS compared with patients who had high MGMT expression (17.0 months vs 14 months) and (15.0 months vs 10 months) respectively",
                        "Age and extent of tumor resection were the strongest clinical predictors of outcome",
                        "MGMT protein expression, extent of tumor resection and age were identified as independent prognostic factors"
                    ],
                    "conclusions": [
                        "MGMT expression was identified as positive prognostic factor in patients with newly diagnosed glioblastoma who underwent surgical resection followed by adjuvant radiotherapy and concomitant oral TMZ chemotherapy"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": null,
                    "prognosis": "YES",
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "BP"
            },
            {
                "_id": "V0001A9",
                "pmid": "26662803",
                "biomarkerId": "B0001A9",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": null,
                "region": [
                    "India"
                ],
                "research": {
                    "methods": [
                        "Real-time PCR",
                        "2(-\u0394\u0394Ct) method",
                        ""
                    ],
                    "results": [
                        "The data revealed aberrant expression of Notch genes in GBM compared to normal brain",
                        "More than 85 % of samples showed high Notch1 gene expression and low HES1 and DTX1 gene expression"
                    ],
                    "conclusions": [
                        "Results clearly show aberrant expression of Notch genes in GBM which can be used as putative biomarkers together with histopathological observation to improve diagnosis, therapeutic strategies, and patient prognosis"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": "Potential",
                    "prognosis": null,
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": "Potential",
                "curator": "BP"
            },
            {
                "_id": "V0001AA",
                "pmid": "26646311",
                "biomarkerId": "B0001AA",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": null,
                "region": [
                    "Germany"
                ],
                "research": {
                    "methods": [
                        "Immunohistochemistry"
                    ],
                    "results": [
                        "HMGB1 was highly expressed in primary tumors with a significant reduction in the respective relapse",
                        "The extracellular HSP70 expression was significantly increased in the relapse compared to the primary tumor",
                        "CRT was generally highly expressed in the primary tumor, with a slight increase in the relapse"
                    ],
                    "conclusions": [
                        "The combination of a decreased expression of HMGB1, an increased expression of extracellular HSP70, and an increased expression of CRT in the relapse seems to be beneficial for patient survival. HMGB1, extracellular HSP70, and CRT could be taken into concerted consideration as potential biomarkers for the prognosis of patients with GBM"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": null,
                    "prognosis": "Potential",
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "BP"
            },
            {
                "_id": "V0001AB",
                "pmid": "26473374",
                "biomarkerId": "B0001AB",
                "sourceIds": [
                    "Tissue",
                    "Cell line"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": 47.0,
                        "under": 22.0,
                        "over": 21.0
                    }
                },
                "gender": {
                    "male": 21.0,
                    "female": 21.0,
                    "other": -1
                },
                "stage": [
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": "2007",
                "region": [
                    "China"
                ],
                "research": {
                    "methods": [
                        "IHC",
                        "WB",
                        "Tissue microarray",
                        "Immunoprecipitation",
                        "Gene-set enrichment analysis",
                        "t-test",
                        "ANOVA",
                        "Chi-square test"
                    ],
                    "results": [
                        "High Crk and low Abi1 gene expression correlates with poor patient survival",
                        "Abi1 and Crk reciprocally interact with Abl kinase to drive the malignant phenotypes in EGFR-expressing human GBM cells"
                    ],
                    "conclusions": [
                        "Data suggest that Crk Tyr251 phosphorylation regulate invasive cell phenotypes and may serve as a biomarker for aggressive GBM"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": "NO",
                    "prognosis": "Potential",
                    "predictive": "NO",
                    "therapeutic": "YES"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": "Patients that show a high level of CrkY251 phosphorylation and low level of Abi1, Imatinib treatment may prove beneficial to reduce invasive properties of tumor and improve overall survival"
                },
                "comments": "NO",
                "curator": "RF"
            },
            {
                "_id": "V0001AC",
                "pmid": "25681309",
                "biomarkerId": "B0001AC",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": 65.0,
                        "under": 61.0,
                        "over": 65.0
                    }
                },
                "gender": {
                    "male": 65.0,
                    "female": 65.0,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": "2007",
                "region": [
                    "Austria"
                ],
                "research": {
                    "methods": [
                        "DNA extraction and TERT Promoter mutation analysis",
                        "PCR",
                        "Cox model",
                        "Survival curves",
                        "Fisher's exact test"
                    ],
                    "results": [
                        "Seventy-three percent of GBM patients harbored TERT promoter mutations associated with enhanced telomerase activity and TERT mRNA expression but reduced telomere lengths",
                        "Patients with mutated tumors exhibited significantly shorter overall survival in the entire cohort (11.5 vs 23.1 months) and in the primary GBM patient subgroup lacking IDH1 mutations (n = 120)",
                        "Prognostic impact was confined to younger patients (aged <65 years), while the negative prognostic power of enhanced age at diagnosis was limited to those patients lacking TERT promoter mutations",
                        "Presence of the common single nucleotide polymorphism rs2853669, disrupting an endogenous Ets2 transcription factor-binding site, was associated with improved survival exclusively in patients with a wild-type TERT promoter",
                        "Shortest mean overall survival was detected in those patients harboring both an activating TERT promoter mutation and homozygous rs2853669 alleles"
                    ],
                    "conclusions": [
                        "TERT promoter mutations are powerful prognosticators for worse course of disease in human GBM patients but their prognostic value is influenced by the rs2853669 polymorphism and age at diagnosis"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": null,
                    "prognosis": "YES",
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "BP"
            },
            {
                "_id": "V0001AD",
                "pmid": "25665548",
                "biomarkerId": "B0001AD",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": "2007",
                "region": [
                    "Japan"
                ],
                "research": {
                    "methods": null,
                    "results": [
                        "Expressions of CD133-, Notch-1-, and VEGF-positive glioma cells were higher in recurrent glioblastoma after radiotherapy and chemotherapy",
                        "For 15 patients who had received bevacizumab therapy follwed by a second surgert at recurrence,OS was significantly longer in cases with Notch-1 negativity (8.8 months) than in those with I Notch-1 positivity (6.8 months)"
                    ],
                    "conclusions": [
                        "Glioma Stem Cells have the potential for endothelial differentiation with Notch activity",
                        "Notch-1 is a potential target and/or biomarker for antiangiogenic treatments"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": null,
                    "prognosis": null,
                    "predictive": "Potential",
                    "therapeutic": "Potential"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "BP"
            },
            {
                "_id": "V0001AE",
                "pmid": "25494473",
                "biomarkerId": "B0001AE",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": "2007",
                "region": [
                    "China"
                ],
                "research": {
                    "methods": [
                        "Quantitative RT-PCR",
                        "Cox model"
                    ],
                    "results": [
                        "A multivariate analysis showed that miR-181c was an independent prognostic indicator for GBM patients",
                        "qRT-PCR showed that miR-181c was expressed poorly in neurospheres of glioma cells that resemble glioma stem cells",
                        "miR-181c also blocked the proliferation and invasion abilities of glioma cells",
                        "miR-181c attenuated the self-renewal ability of glioma cells",
                        "Mechanism defined Notch2, a key molecule of Notch signaling, as the functional downstream target of miR-181c",
                        "Inverse correlation between miR-181c and Notch2 in glioma cells and verified in fresh glioma samples"
                    ],
                    "conclusions": [
                        "miR-181c can be considered a valuable indicator for the outcome of GBM patients",
                        "miR-181c acts as a tumor suppressor that attenuates proliferation, invasion, and self-renewal capacities by downregulation of Notch2 in glioma cells"
                    ]
                },
                "application": {
                    "validated": null,
                    "diagnosis": null,
                    "prognosis": "Potential",
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "BP"
            },
            {
                "_id": "V0001AF",
                "pmid": "25141189",
                "biomarkerId": "B0001AF",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": "2007",
                "region": [
                    "UK"
                ],
                "research": {
                    "methods": [
                        "FISH",
                        "Immunohistochemistry",
                        "RT-PCR",
                        ""
                    ],
                    "results": [
                        "Overall 22/51 samples (43%) were positive for EGFR, 16/51 (31%) were positive for EGFRvIII and 13/51 (25%) were positive for both",
                        "9/51 cases (18%) were positive for EGFR alone, and 3/51 (6%) were positive for EGFRvIII alone",
                        "Of the EGFR positive cases, 22/51 (43%) were positive by FISH, 24/51 (47%) were positive by IHC and 2/51 (4%) were discrepant between methods (positive by IHC but non-amplified by FISH)",
                        "Of the EGFRvIII positive cases, 16/51 (31%) were positive by RT-PCR, 17/51 (33%) were positive by IHC and 1/51 (2%) sample was discrepant (positive by IHC but not by RT-PCR)",
                        "Neither EGFRvIII or EGFR are predictive of overall survival in this cohort"
                    ],
                    "conclusions": [
                        "In this cohort, 25/51 (49%) of GBM showed EGFR alterations, including 16/51 (31%) with EGFRvIII",
                        "There was high concordance between IHC and FISH (96%) and IHC and RT-PCR (98%) as diagnostic methods",
                        "Neither EGFR or EGFRvIII is predictive of overall survival in this cohort",
                        "These results are key for selecting patients for novel individualised anti-EGFR therapies"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": null,
                    "prognosis": null,
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "BP"
            },
            {
                "_id": "V0001B0",
                "pmid": "24958096",
                "biomarkerId": "B0001B0",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": 46.0,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "II"
                ],
                "whoclass": null,
                "region": [
                    "Japan"
                ],
                "research": {
                    "methods": [
                        "PCR",
                        "methylation-specific PCR",
                        "multiple-ligation\u2013dependent probe amplification",
                        "Wester Blotting",
                        "Immunohistochemical assessment",
                        "Mann\u2013Whitney U test",
                        "Fisher' exact test",
                        "kaplan-meier method",
                        "Llog-rank test",
                        "Cox regression analysis",
                        "Fine-Gray proportional hazard model"
                    ],
                    "results": [
                        "Of the 86 patients with anaplastic gliomas, 58 carried IDH mutation, and 40 experienced recurrence",
                        "first recurrence was local in 25 patients and distant in 15",
                        "patients without IDH mutation exhibited significantly higher CD133 and SOX2 expression (P = .025 and .020, respectively) and more frequent distant recurrence than those with IDH mutation (P = .022)"
                    ],
                    "conclusions": [
                        "Patients with anaplastic gliomas without IDH mutation experienced distant recurrence and exhibited glioma stem cell markers, indicating that this subset may share some malignant characteristics with glioblastomas"
                    ]
                },
                "application": {
                    "validated": null,
                    "diagnosis": null,
                    "prognosis": null,
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Vanessa"
            },
            {
                "_id": "V0001B1",
                "pmid": "24935062",
                "biomarkerId": "B0001B1",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": 43.0,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": "2007",
                "region": [
                    "China"
                ],
                "research": {
                    "methods": [
                        "Immunohistochemcial assessment",
                        "RT-qPCR",
                        "Western Blotting,Fisher's exact test",
                        "Spearman rank correlation analysis",
                        "Kaplan-Meier method"
                    ],
                    "results": [
                        "Expression of HMGA2 protein was significantly higher in GBM and AA than in diffuse A",
                        "expression of HMGA2 correlated significantly with expression of Ki-67 (r = 0.415, P < .01) and matrix metalloproteinase-2 (r = 0.363, P < .01), but not with patient sex and age",
                        "RT-qPCR and Western blot analysis revealed similar results,patients with tumors expressing HMGA2 at a higher level had a significantly shorter progression-free survival time (11.2 months versus 18.8 months",
                        "P = .021)",
                        "expression of HMGA2 significantly correlates with tumor cell proliferation, invasion, and survival in gliomas"
                    ],
                    "conclusions": [
                        "HMGA2 has important role in treatment and prognosis of cancer"
                    ]
                },
                "application": {
                    "validated": "Potential",
                    "diagnosis": null,
                    "prognosis": "Potential",
                    "predictive": null,
                    "therapeutic": "Potential"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Vanessa"
            },
            {
                "_id": "V0001B2",
                "pmid": "24900981",
                "biomarkerId": "B0001B2",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": 65.0,
                        "under": 42.0,
                        "over": 64.0
                    }
                },
                "gender": {
                    "male": 64.0,
                    "female": 64.0,
                    "other": -1
                },
                "stage": [
                    "I",
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": null,
                "region": [
                    "Taiwan"
                ],
                "research": {
                    "methods": [
                        "Immunohistochemical assessment",
                        "Chi-square test",
                        "Kaplan-Meier method"
                    ],
                    "results": [
                        "LC3B, but not Beclin-1, protein expression was found to significantly correlate with resistance to radiation- or chemotherapy",
                        "high intensity of LC3B staining was predictive of poor prognosis",
                        "survival time of patients with high-level expression in both CD133 and LC3B was significantly shorter than those with weak expression in both CD133 and LC3B"
                    ],
                    "conclusions": [
                        "Astrocytoma cancer stem-like cells together with enhanced autophagy may cause resistance to radiation therapy/chemotherapy",
                        "targeting cancer stem-like cells in astrocytoma may offer viable therapeutic approach"
                    ]
                },
                "application": {
                    "validated": "Potential",
                    "diagnosis": null,
                    "prognosis": null,
                    "predictive": null,
                    "therapeutic": "Potential"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Vanessa"
            },
            {
                "_id": "V0001B3",
                "pmid": "24847385",
                "biomarkerId": "B0001B3",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": 50.0,
                        "under": 73.0,
                        "over": 64.0
                    }
                },
                "gender": {
                    "male": 64.0,
                    "female": 64.0,
                    "other": -1
                },
                "stage": [
                    "I",
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": "2007",
                "region": [
                    "Lithuania"
                ],
                "research": {
                    "methods": [
                        "Methylation-specific PCR",
                        "RT-qPCR",
                        "Wester Blotting",
                        "Kaplan-Meier method"
                    ],
                    "results": [
                        "NDRG2 gene methylation frequency increased whereas expression at both mRNA and protein levels markedly decreased in GBM specimens compared to the lower grade A",
                        "NDRG2 transcript and protein levels did not correlate with the promoter methylation state, suggesting the presence of alternative regulatory gene expression mechanisms that may operate in a tissue-specific manner in gliomas",
                        "significant differences in survival time in gliomas stratified by NDRG2 methylation status and mRNA and protein expression levels"
                    ],
                    "conclusions": [
                        "it is useful to combine epigentic data and gene expression patterns at mRNA and protein level in biomarker studies",
                        "NDRG2 downregulation might bear influence on glioma tumor progression while being associated with higher malignancy grade"
                    ]
                },
                "application": {
                    "validated": "Potential",
                    "diagnosis": "Potential",
                    "prognosis": null,
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": "Potential",
                "curator": "Vanessa"
            },
            {
                "_id": "V0001B4",
                "pmid": "24729345",
                "biomarkerId": "B0001B4",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": 47.0,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": "2007",
                "region": [
                    "China"
                ],
                "research": {
                    "methods": [
                        "RT-qPCR",
                        "Spearman correlation test"
                    ],
                    "results": [
                        "MiR-210 presents a differential expression depending on the origin of the glioma",
                        "Oligodendroglial tumours exhibit a significantly reduced level of miR-210 as compared with normal brain tissue",
                        "astrocytic tumours demonstrate significantly increased levels of miR-210",
                        "expression of miR-210 is positively correlated with the grade of astrocytic tumour, in the following order: grade IV > grade III > grade II > normal brain tissue"
                    ],
                    "conclusions": [
                        "MiR-210 levels can be potentially established as a biomarker for pathological diagnosis of malignant astrocytic tumour progression",
                        "expression of miR-210 can be utilized as an additional identification measure of glioma tumour origin"
                    ]
                },
                "application": {
                    "validated": "Potential",
                    "diagnosis": "Potential",
                    "prognosis": null,
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": "Potential",
                "curator": "Vanessa"
            },
            {
                "_id": "V0001B5",
                "pmid": "24691539",
                "biomarkerId": "B0001B5",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": "2007",
                "region": [
                    "Turkey"
                ],
                "research": {
                    "methods": [
                        "Magnetic separation",
                        "Real-time RT PCR",
                        "Immunohistochemistry"
                    ],
                    "results": [
                        "Low miR-181b and high miR-455-3p expression levels were detected in CSC (+) tumors",
                        "A significant correlation between miR-455-3p expression and Smad2 protein levels as analyzed by immunohistochemistry in CSC (+) tumors"
                    ],
                    "conclusions": [
                        "miR-455-3p may be involved in TMZ resistance in MGMT methylated CSC (+) GBM patients",
                        "This miRNA may provide novel therapeutic molecular targets for GBM treatment and new directions for the development of anticancer drugs"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": null,
                    "prognosis": null,
                    "predictive": null,
                    "therapeutic": "Potential"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Vanessa"
            },
            {
                "_id": "V0001B6",
                "pmid": "24122417",
                "biomarkerId": "B0001B6",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": null,
                "whoclass": "2007",
                "region": [
                    "China"
                ],
                "research": {
                    "methods": null,
                    "results": [
                        "The increased expression of miR-9 was more frequently observed in glioma tissues with high WHO grade than those with low WHO grade tissues",
                        "Expression levels of miR-9 in glioma tissues with low Karnofsky performance score (KPS) were also significantly higher than those with high KPS",
                        "Overall survival of glioma patients with high miR-9 expression was lower than that with low miR-9 expression",
                        "High miR-9 expression was an independent prognostic factor for overall survival in glioma patients",
                        "More importantly, the subgroup analyses indicated that the overall survival of glioma patients with high WHO grade (III\u2013IV) was significantly worse for high miR-9 expression group than for low miR-9 expression group, but no significant difference was found for patients with low WHO grade (I\u2013II)"
                    ],
                    "conclusions": [
                        "For the first time that the increased expression of miR-9 may play an important role in tumor progression in human gliomas",
                        "miR-9 might be a useful marker for predicting the clinical outcome of glioma patients, especially for advanced subtypes"
                    ]
                },
                "application": {
                    "validated": null,
                    "diagnosis": null,
                    "prognosis": "Potential",
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": null
            },
            {
                "_id": "V0001B7",
                "pmid": "24057325",
                "biomarkerId": "B0001B7",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": null,
                "whoclass": "2007",
                "region": [
                    "Denmark"
                ],
                "research": {
                    "methods": null,
                    "results": [
                        "In WHO grade III tumors high levels of Musashi-1 were associated with poor survival",
                        "Identified a sub-population of GBM patients with high levels of Musashi-1 and a superior prognosis",
                        "In addition patients with high levels of Musashi-1 benefitted most from post-surgical treatment, indicating that Musashi-1 may be a predictive marker in GBMs"
                    ],
                    "conclusions": [
                        "Results suggest that high levels of Musashi-1 are associated with poor survival in patients with WHO grade III tumors and that Musashi-1 may be a predictive marker in GBMs, although further validation is needed",
                        "The combination of immunofluorescence and automated quantitation is a feasible, robust, and reproducible approach for quantitative biomarker studies"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": null,
                    "prognosis": null,
                    "predictive": "Potential",
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": null
            },
            {
                "_id": "V0001B8",
                "pmid": "24039914",
                "biomarkerId": "B0001B8",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": 50.0,
                        "under": 28.0,
                        "over": 68.0
                    }
                },
                "gender": {
                    "male": 68.0,
                    "female": 68.0,
                    "other": -1
                },
                "stage": [
                    "III",
                    "IV"
                ],
                "whoclass": "2000",
                "region": [
                    "France",
                    "China"
                ],
                "research": {
                    "methods": [
                        "Immunohistochemical staining",
                        "Immunohistochemical quantification",
                        "PCR assay",
                        "Wilcoxon rank sum test",
                        "ROC curve analysis",
                        "Kaplan Meier analysis",
                        "Cox model"
                    ],
                    "results": [
                        "The levels of all four proteins differed significantly between grade III and grade IV tumours",
                        "The levels of the EDN/RB, HJURP and p60/CAF-1 proteins were strongly associated with overall survival whereas the one of PDLI4 was not (P=0.11)",
                        "A risk criterion defined as high levels of at least two of the EDN/RB, HJURP and p60/CAF-1 proteins accurately predicted the prognosis of patients",
                        "Multivariate analysis confirmed that this criterion was an independent negative prognostic marker"
                    ],
                    "conclusions": [
                        "The expression of the EDN/RB, HJURP, p60/CAF-1 and PDLI4 proteins is disrupted in high grade gliomas and increases in the levels of these proteins are closely linked to tumour aggressiveness and poor outcome"
                    ]
                },
                "application": {
                    "validated": "No (The study is itself a confirmation of previous findings by the same authors)",
                    "diagnosis": null,
                    "prognosis": "YES",
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": null
            },
            {
                "_id": "V0001B9",
                "pmid": "23955565",
                "biomarkerId": "B0001B9",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": null,
                "region": [
                    "France",
                    "Japan",
                    "South Korea",
                    "Switzerland"
                ],
                "research": {
                    "methods": null,
                    "results": [
                        "TERT promoter mutations (C228T, C250T) were detected in 55 % glioblastomas analysed",
                        "Of these, 73 % had a C228T mutation, and 27 % had a C250T mutation, only one GBM had both C228T and C250T mutations",
                        "TERT promoter mutations were significantly more frequent in primary (IDH1 wild-type) GBMs (187/322)  than in secondary (IDH1 mutated) glioblastomas (10/36)",
                        "They showed significant inverse correlations with IDH1 mutations and TP53 mutations, and a significant positive correlation with EGFR amplification",
                        "GBM patients with TERT mutations showed a shorter survival than those without TERT mutations in univariate analysis (median, 9.3 vs. 10.5 months) and multivariate analysis after adjusting for age and gender",
                        "However, TERT mutations had no significant impact on patients\u2019 survival in multivariate analysis after further adjusting for other genetic alterations, or when primary and secondary GBMs were separately analysed"
                    ],
                    "conclusions": [
                        "Prognostic value of TERT mutations for poor survival is largely due to their inverse correlation with IDH1 mutations, which are a significant prognostic marker of better survival in patients with secondary glioblastomas"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": null,
                    "prognosis": "Potential",
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": null
            },
            {
                "_id": "V0001BA",
                "pmid": "23828241",
                "biomarkerId": "B0001BA",
                "sourceIds": [
                    "Cell line",
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": 65.0,
                        "under": 41.0,
                        "over": 10.0
                    }
                },
                "gender": {
                    "male": 10.0,
                    "female": 10.0,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": "2007",
                "region": [
                    "China"
                ],
                "research": {
                    "methods": [
                        "Western blot",
                        "Real-time RT-PCR",
                        "Immunohistochemical analysis",
                        "Gene silencing and overexpression",
                        "Transwell invasion assay",
                        "In silico REMBRANDT analysis",
                        "Chi-square test",
                        "Kaplan Meier curves",
                        "Cox model"
                    ],
                    "results": [
                        "HMGB2 protein expression was significantly higher in GBM than in controlled brain tissues",
                        "HMGB2 overexpression was significantly correlated with shorter overall survival time, which was the only independent prognostic factor for overall survival in a multivariate analysis",
                        "HMGB2 knockdown by small interfering RNA decreased cell viability and invasion in vitro and significantly decreased tumor volume in vivo, which might be involved in the change of p53 expression and the balance of MMP2/TIMP2",
                        "Silencing of HMGB2 could significantly increase the sensitivity of GBM cells to temozolomide chemotherapy"
                    ],
                    "conclusions": [
                        "Present data suggest that HMGB2 expression is a significant prognostic factor and might play an important role in cell invasion and temozolomide-induced chemotherapeutic sensitivity of GBM",
                        "Study highlights the importance of HMGB2 as a novel prognostic marker and an attractive therapeutic target of GBM"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": null,
                    "prognosis": "YES",
                    "predictive": null,
                    "therapeutic": "Potential"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": null
            },
            {
                "_id": "V0001BB",
                "pmid": "23664694",
                "biomarkerId": "B0001BB",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": 44.9,
                    "avg": -1,
                    "sd": 12.9,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "19 grade IV",
                    "44 low grade gliomas (grade no specified)"
                ],
                "whoclass": "2007",
                "region": [
                    "italy"
                ],
                "research": {
                    "methods": [
                        "PTX3 expression through immunohistochemical analysis"
                    ],
                    "results": [
                        "PTX3 is differentially expressed in low and high-grade tumors and in tumors of astrocytic or oligodendroglial origin, reflecting malignancy and histological origin"
                    ],
                    "conclusions": [
                        "PTX3 is associated con inflammation and is expressed only in gliomas, non in healthy samples. A higher expression is correlated with higher tumor malignancy"
                    ]
                },
                "application": {
                    "validated": "no",
                    "diagnosis": "YES",
                    "prognosis": "YES",
                    "predictive": "NO",
                    "therapeutic": "NO"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": "YES",
                "curator": "ANA"
            },
            {
                "_id": "V0001BC",
                "pmid": "23477614",
                "biomarkerId": "B0001BC",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": "2007",
                "region": [
                    "UK"
                ],
                "research": {
                    "methods": null,
                    "results": null,
                    "conclusions": [
                        "Geminin and cyclin A, each show potential as independent prognostic markers in glioblastomas receiving adjuvant therapy",
                        "These markers could provide valuable prognostic information, even in small biopsies, especially if combined with O(6)MGMT expression and 1p",
                        "19q deletion status"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": "NO",
                    "prognosis": "Potential",
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": "NO",
                "curator": "ANA"
            },
            {
                "_id": "V0001BD",
                "pmid": "23410662",
                "biomarkerId": "B0001BD",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": 62.0,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": "2007",
                "region": [
                    "Italy"
                ],
                "research": {
                    "methods": [
                        "Immunohistochemistry",
                        "Methylation assay",
                        "Chi-square test",
                        "Kaplam Meier survival curves",
                        "Cox model"
                    ],
                    "results": [
                        "GS expression patterns in neoplastic cells were inversely correlated to the presence of epilepsy",
                        "RPA score, epilepsy, O6-methylguanine-DNA methyltransferase (MGMT) status, application of Stupp protocol, and GS intensity pattern had a significant impact on survival",
                        "Absent/low intensity of GS expression was significantly associated with a longer survival in both uni- (19 vs 8 months) and multivariate analyses"
                    ],
                    "conclusions": [
                        "Absent/low-intensity GS expression pattern represents a valuable biomarker of both epilepsy and overall survival in GBM"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": "NO",
                    "prognosis": "YES",
                    "predictive": "NO",
                    "therapeutic": "NO"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": "NO",
                "curator": "ANA"
            },
            {
                "_id": "V0001BE",
                "pmid": "23408368",
                "biomarkerId": "B0001BE",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": 53.0,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": null,
                "region": [
                    "China"
                ],
                "research": {
                    "methods": [
                        "Immunohistochemistry",
                        "Quantitative real-time PCR",
                        "Kaplan-Meier method",
                        "Cox model"
                    ],
                    "results": [
                        "Compared with normal tissues, GBM specimens had significantly increased expression of SLC7A7 at both mRNA and protein levels",
                        "Overexpression of SLC7A7 was a significant and independent indicator for predicting poor prognosis"
                    ],
                    "conclusions": [
                        "Results suggest, for the first time, that overexpression of SLC7A7 is correlated with worse outcomes in patients with GBM",
                        "SLC7A7 plays a critical role in GBM carcinogenesis and may be a potential prognosis predictor of GBM"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": "NO",
                    "prognosis": "Potential",
                    "predictive": "NO",
                    "therapeutic": "NO"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": "NO",
                "curator": "ANA"
            },
            {
                "_id": "V0001BF",
                "pmid": "23331016",
                "biomarkerId": "B0001BF",
                "sourceIds": [
                    "Tissue",
                    "Cell line"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": null,
                "region": [
                    "China"
                ],
                "research": {
                    "methods": null,
                    "results": [
                        "The most significant prognostic gene was DLX2 (OR = 1.744)",
                        "Overexpression of DLX2 indicated poor survival in the 83 GBM patients (low DLX2 vs high DLX2, 77.6 vs 44.7 weeks)",
                        "Annotation of mRNA profiling data on GBM from TCGA and MD Anderson Cancer Center showed the proneural and neural subtypes highly correlated with low and high DLX2 expression, respectively",
                        "Knocking down of DLX2 in GBM cell line-LN229 results in decreased cyclin D1 expression and cell proliferation"
                    ],
                    "conclusions": [
                        "Data identified high expression of DLX2 as a poor prognostic marker to GBM patients"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": "NO",
                    "prognosis": "YES",
                    "predictive": "NO",
                    "therapeutic": "NO"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": "NO",
                "curator": "ANA"
            },
            {
                "_id": "V0001C0",
                "pmid": "23292865",
                "biomarkerId": "B0001C0",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": null,
                "whoclass": null,
                "region": [
                    "China"
                ],
                "research": {
                    "methods": null,
                    "results": null,
                    "conclusions": null
                },
                "application": {
                    "validated": "No",
                    "diagnosis": null,
                    "prognosis": null,
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "ANA"
            },
            {
                "_id": "V0001C1",
                "pmid": "23282970",
                "biomarkerId": "B0001C1",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": null,
                "region": [
                    "Taiwan"
                ],
                "research": {
                    "methods": [
                        "Immunohistochemical analysis",
                        "Methylation-specific PCR"
                    ],
                    "results": [
                        "The MGMT protein expression was reversely associated with MGMT promoter methylation status in 83.7% of cases",
                        "Twenty-two of 24 (91.7%) IHC tumors did not respond to TMZ treatment",
                        "Combining MSP and IHC results, all the 15 MSP/IHC GBMs were TMZ resistant",
                        "The MGMT status detected by either IHC or MSP was significantly correlated with the TMZ treatment response and survival of GBM patients"
                    ],
                    "conclusions": null
                },
                "application": {
                    "validated": "No",
                    "diagnosis": null,
                    "prognosis": null,
                    "predictive": "YES",
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": "Predictive of TMZ treatment response"
                },
                "comments": null,
                "curator": "ANA"
            },
            {
                "_id": "V0001C2",
                "pmid": "23276796",
                "biomarkerId": "B0001C2",
                "sourceIds": [
                    "Tissue",
                    "Cell line"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": 60.0,
                        "under": 37.0,
                        "over": 26.0
                    }
                },
                "gender": {
                    "male": 26.0,
                    "female": 26.0,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": "2007",
                "region": [
                    "China"
                ],
                "research": {
                    "methods": [
                        "Rac1 activity assay and signaling analysis",
                        "Western blot",
                        "qRT-PCR",
                        "Transmission electron microscopy",
                        "Immunnohistochemistry",
                        "Human glioma xenograft model",
                        "t-test",
                        "Kaplan-Meier method",
                        "Log-rank test"
                    ],
                    "results": [
                        "RLIP76 messenger RNA and protein expression are positively correlated with glioma grade and that higher RLIP76 expression correlates with shorter patient survival",
                        "RLIP76 expression was positively correlated with the expression of Ki-67, a biomarker for cell proliferation",
                        "Inhibition of RLIP76 expression in U87 and U251 glioma cell lines by stable transfection of a targeted siRNA suppressed anchorage-independent growth and enhanced apoptosis in vitro",
                        "Overexpression of RLIP76 in SW1088 and U251 cell lines enhanced proliferation and reduced apoptosis",
                        "Inhibition of RLIP76 in U251 cells also significantly suppressed tumorigenicity and induced apoptosis in an endotopic xenograft mouse model",
                        "Knockdown of RLIP76 increases apoptosis in different human gliomas independently of p53 status",
                        "A constitutively active Rac1 reversed both the suppression of proliferation and the promotion of apoptosis induced by the RLIP76-targeted siRNA, indicating that RLIP76 is an upstream activator of Rac1",
                        "Rac1-mediated suppression of apoptosis and promotion of proliferation were dependent on intact c-jun N-terminal kinase (JNK) signaling",
                        "RLIP76 promotes proliferation and suppresses glioma cell apoptosis through a mechanism independent of Rho-selective GTPase-activating protein",
                        "Adenosine triphosphatase function of Rlip76 modulates Rac1 activity by regulating Rac1 protein ubiquitylation and degradation"
                    ],
                    "conclusions": [
                        "Data demonstrate that RLIP76 may suppress apoptosis and promote the proliferation of glioma cells by direct adenosine triphosphate-dependent xenobiotic transport and by activating the Rac1-JNK signaling pathway",
                        "Inhibition of RLIP76 signaling is a potential treatment for malignant glioma."
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": null,
                    "prognosis": null,
                    "predictive": null,
                    "therapeutic": "Potential"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "ANA"
            },
            {
                "_id": "V0001C3",
                "pmid": "23142225",
                "biomarkerId": "B0001C3",
                "sourceIds": [
                    "Tissue",
                    "Cell line"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": null,
                "region": [
                    "China"
                ],
                "research": {
                    "methods": null,
                    "results": [
                        "CCRL2 expression level is elevated in human glioma patient samples and cell lines",
                        "The magnitude of increase is positively associated with increasing tumor grade, with the highest level observed in grade IV glioblastoma",
                        "CCRL2 did not regulate the growth of human glioblatoma U87 and U373 cells",
                        "Over-expression of CCRL2 significantly enhanced the migration rate and invasiveness of the glioblastoma cells"
                    ],
                    "conclusions": [
                        "Results suggest for the first time that elevated CCRL2 in glioma promotes cell migration and invasion"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": "Potential",
                    "prognosis": null,
                    "predictive": null,
                    "therapeutic": "Potential"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": "Potential",
                "curator": "Ahmed"
            },
            {
                "_id": "V0001C4",
                "pmid": "23132408",
                "biomarkerId": "B0001C4",
                "sourceIds": [
                    "Tissue",
                    "Cell line"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": 60.0,
                        "under": 42.0,
                        "over": 28.0
                    }
                },
                "gender": {
                    "male": 28.0,
                    "female": 28.0,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": "2007",
                "region": [
                    "Germany"
                ],
                "research": {
                    "methods": [
                        "Western blot",
                        "Quantitative real time PCR",
                        "Kaplan-Meier method",
                        "Cox model"
                    ],
                    "results": [
                        "Sensitivity of ALDH1A1 positive/MGMT-positive cells to temozolomide could be restored by inhibition of ALDH1A1 by DEAB or by knockdown with shRNA, as indicated by increased cytotoxicity, reduced clonogenicity, and accumulation in the G2/M cell-cycle phase",
                        "The prognosis of patients with a high level of ALDH1A1 expression was poor compared with that of patients with low levels"
                    ],
                    "conclusions": [
                        "ALDH1A1 is a new mediator for resistance of GBM to temozolomide and a reliable predictor of clinical outcome and may serve as a potential target to improve treatment of human GBM"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": null,
                    "prognosis": null,
                    "predictive": "Yes (TMZ treatment)",
                    "therapeutic": "Potential"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Ahmed"
            },
            {
                "_id": "V0001C5",
                "pmid": "23074200",
                "biomarkerId": "B0001C5",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": 49.5,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": "2007",
                "region": [
                    "France"
                ],
                "research": {
                    "methods": [
                        "BAC-aCGH experiments",
                        "qPCR",
                        "RT-PCR",
                        "Microsatellite analysis",
                        "Fisher's exact test",
                        "Mann-Whitney U test",
                        "Kruskal-Wallis test",
                        "Kaplan-Meier method",
                        "Cox model"
                    ],
                    "results": [
                        "PDGFRA\u00a0was amplified and gained in 5.2% and 1.9% of samples, respectively",
                        "PDGFRA\u00a0was point-mutated, rearranged, and truncated in 2.9%, 0%, and 0.7% of cases, respectively",
                        "PDGFRApoint mutations were observed exclusively in grade IV gliomas and in 12.5% of\u00a0PDGFRA-amplified tumors",
                        "High-level\u00a0PDGFRA\u00a0amplification was associated with\u00a0PDGFRA\u00a0overexpression, high malignancy grade, and older patient age",
                        "High-level\u00a0PDGFRA\u00a0amplification has an independent negative prognostic value for progression-free survival and overall survival among patients with grade III tumors"
                    ],
                    "conclusions": [
                        "PDGFRA is altered through various genetic mechanisms in a subset of high-grade gliomas in patients who might be ideal candidates for PDGFRA inhibitor treatment, and PDGFRA gene amplification could be used as a prognostic biomarker in anaplastic gliomas"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": null,
                    "prognosis": "Potential",
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Ahmed"
            },
            {
                "_id": "V0001C6",
                "pmid": "22726066",
                "biomarkerId": "B0001C6",
                "sourceIds": [
                    "Tissue",
                    "Cell line"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "I",
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": "2007",
                "region": [
                    "Japan"
                ],
                "research": {
                    "methods": [
                        "Immunohistochemistry",
                        "Real-time PCR",
                        "Western blot",
                        "Immunofluorescence analysis",
                        "t-test",
                        "Mann-Whitney test"
                    ],
                    "results": [
                        "Normal brain tissues showed no or weak CD44 expression, while reactive astrocytes and astrocytoma cells expressed CD44 at variable levels",
                        "A higher percentage and intensity of CD44\u2010positive tumor cells were detected in high\u2010grade astrocytomas compared with low\u2010grade astrocytomas",
                        "GBM cells that express CD44 were localized in perivascular and perinecrotic lesions",
                        "The human glioma cell lines A172 and KG\u20101\u2010C expressed CD44 mRNA and protein",
                        "Administration of monoclonal anti\u2010human\u2010CD44 antibody inhibited the migration of A172 cells, which are GBM\u2010derived, but did not affect cell growth"
                    ],
                    "conclusions": [
                        "CD44 expression levels correlated with the histopathological grade of gliomas, and monoclonal anti\u2010CD44 antibody inhibited the migration of GBM cells",
                        "These findings suggest that CD44 is a potential therapeutic target of GBMs"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": null,
                    "prognosis": null,
                    "predictive": null,
                    "therapeutic": "Potential"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Ahmed"
            },
            {
                "_id": "V0001C7",
                "pmid": "22046342",
                "biomarkerId": "B0001C7",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": 59.16,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": null,
                "region": [
                    "New Zealand"
                ],
                "research": {
                    "methods": [
                        "Telomere maintenance mechanism analyzes",
                        "Polymorphism genotyping",
                        "Multiplex PCR",
                        "Fluorescent in situ hybridization",
                        "Immunohistochemistry",
                        "Cox model",
                        "Fisher's exact test",
                        "Unpaired t-test",
                        "ANOVA"
                    ],
                    "results": [
                        "The analysis of CDKN2A showed NDTMM GBMs had an increased minor allele frequency for the C500G (rs11515) polymorphism compared to those with telomerase and ALT positive GBMs",
                        "Patients with the G500 allele had reduced survival that was independent of age, extent of surgery, and treatment",
                        "In the NDTMM group G500 allele carriers had increased loss of CDKN2A gene dosage compared to C500 homozygotes",
                        "An analysis of IDH1 mutations showed the R132H mutation was associated with ALT positive tumors, and was largely absent in NDTMM and telomerase positive tumors",
                        "In the ALT positive tumors cohort, IDH1 mutations were associated with a younger age for the affected individual"
                    ],
                    "conclusions": [
                        "G500 CDKN2A allele was associated with NDTMM GBMs from older individuals with poorer survival",
                        "Mutations in IDH1 were not associated with NDTMM GBMs, and instead were a marker for ALT positive tumors in younger individuals"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": null,
                    "prognosis": "YES",
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": null
            },
            {
                "_id": "V0001C8",
                "pmid": "21984063",
                "biomarkerId": "B0001C8",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": null,
                "region": [
                    "China"
                ],
                "research": {
                    "methods": [
                        "Immunohistochemistry",
                        "Real-time qPCR",
                        ""
                    ],
                    "results": [
                        "Nuclear immunostaining of HMGA1 protein was not observed in normal brain tissues but was observed in 58 of 60 of malignant gliomas including high (+++) in 15, moderate (++) in 28, and negligible to low (0-+) in 17 samples",
                        "Expression of HMGA1 protein was significantly higher in glioblastoma multiforme than in WHO grade II and WHO grade III gliomas",
                        "HMGA1 protein expression correlated significantly with expression of Ki-67, MMP-9, VEGF-A and MVD but not with sex and age"
                    ],
                    "conclusions": [
                        "Results indicated that expression of HMGA1 correlates significantly with malignancy, proliferation, invasion, and angiogenesis of gliomas",
                        "HMGA1 may be a potential biomarker and rational therapeutic target for human tumors"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": "Potential",
                    "prognosis": null,
                    "predictive": null,
                    "therapeutic": "Potential"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": "Potential",
                "curator": null
            },
            {
                "_id": "V0001C9",
                "pmid": "21947269",
                "biomarkerId": "B0001C9",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": null,
                "region": [
                    "Italy"
                ],
                "research": {
                    "methods": [
                        "MassARRAY",
                        "Pyrosequencing",
                        ""
                    ],
                    "results": [
                        "Demonstrated a direct statistical correlation between the level of methylation of all HOXA genes examined and WHO grading",
                        "In GBM patients, higher level of HOXA9 and HOXA10 methylation significantly correlated with increased survival probability"
                    ],
                    "conclusions": [
                        "Study identifies HOXA3, 7, 9, and 10 as methylation targets mainly in high-grade glioma and hypermethylation of the HOXA9 and 10 as prognostic factor in GBM patients",
                        "Data indicate that these epigenetic changes may be biomarkers of clinically different subgroups of glioma patients that could eventually benefit from personalized therapeutic strategies"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": null,
                    "prognosis": "Potential",
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": null
            },
            {
                "_id": "V0001CA",
                "pmid": "21479688",
                "biomarkerId": "B0001CA",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": null,
                "region": [
                    "France"
                ],
                "research": {
                    "methods": [
                        "Real-time qRT-PCR",
                        ""
                    ],
                    "results": [
                        "On multivariate survival analysis, high CD133 mRNA expression was a significant prognostic factor for adverse progression-free and overall survival independent of extent of resection and MGMT methylation status",
                        "Patient age was also an independent prognosticator of overall survival",
                        "According to the conjoined expression of CD133 mRNA and MGMT status, the patients were categorized into 3 groups with homogenous prognosis"
                    ],
                    "conclusions": [
                        "The findings constitute conclusive evidence that the measurement of the mRNA expression of CD133 stem cell antigen actually impacts the survival of GBM patients"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": null,
                    "prognosis": null,
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": null
            },
            {
                "_id": "V0001CB",
                "pmid": "21331613",
                "biomarkerId": "B0001CB",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": "2007",
                "region": [
                    "Japan"
                ],
                "research": {
                    "methods": [
                        "Immunohistochemistry",
                        ""
                    ],
                    "results": [
                        "There were 28 MGMT-immunopositive and 25 negative GBMs",
                        "Patients with MGMT-immunonegative GBM showed significantly longer progression-free survival (PFS), but no statistically significant benefits on overall survival (OS) (P = 0.0825) were shown",
                        "In 41 GBMs treated with temozolomide (TMZ) therapy (MGMT-immunopositive: n = 22, negative: n = 19), both PFS and OS were significantly better in MGMT-immunonegative glioblastomas"
                    ],
                    "conclusions": [
                        "MGMT expression on immunohistochemistry (IHC) correlates with outcomes in patients with primary GBM receiving TMZ and suggest the use of MGMT-IHC as a surrogate marker for predicting tumor chemosensitivity"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": null,
                    "prognosis": null,
                    "predictive": "YES",
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": "Predictive of outcome in patients treated with TMZ",
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": null
            },
            {
                "_id": "V0001CC",
                "pmid": "21321483",
                "biomarkerId": "B0001CC",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": null,
                "region": [
                    "Italy"
                ],
                "research": {
                    "methods": [
                        "Immunohistochemistry",
                        "Linear regression models",
                        "Classification trees",
                        "bi-dimensional hierarchial clustering"
                    ],
                    "results": [
                        "Demonstrated that both \u03b2-catenin and, for the first time, Gli1 proteins are highly predictive markers of short survival, being found in 75 and 90% of the highly predictive trees, respectively, whereas Ki-67, p53 and EGFR were under 30% and thus, not considered as predictive"
                    ],
                    "conclusions": [
                        "Results indicate a role of \u03b2-catenin and Gli1 in GBM malignant behaviour, and suggest that inhibiting members of Wnt and Hedgehog pathways could be a valuable therapeutic strategy for GBM patients"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": null,
                    "prognosis": "YES",
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": null
            },
            {
                "_id": "V0001CD",
                "pmid": "21302000",
                "biomarkerId": "B0001CD",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "I",
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": null,
                "region": [
                    "China"
                ],
                "research": {
                    "methods": [
                        "Immunohistochemistry",
                        ""
                    ],
                    "results": null,
                    "conclusions": [
                        "Study suggests that glioma patients with lower \u03baB-Ras1 expression have a worse prognosis, which is partly due to NF-kappa-B pathway-mediated aberrant proliferation of tumor cells"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": null,
                    "prognosis": null,
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": null
            },
            {
                "_id": "V0001CE",
                "pmid": "21157891",
                "biomarkerId": "B0001CE",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "I",
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": "2007",
                "region": [
                    "USA"
                ],
                "research": {
                    "methods": [
                        "microRNA expression microarray analysis",
                        "Quantitative real-time PCR",
                        "Clustering analysis"
                    ],
                    "results": [
                        "MicroRNA\u2010129, miR\u2010142\u20105p, and miR\u201025 were differentially expressed in every pediatric brain tumor type compared to normal tissue controls as measured by microarray",
                        "When further examined by qRT\u2010PCR, these miRNAs demonstrated differential expression that significantly correlated with the microarray findings"
                    ],
                    "conclusions": [
                        "MicroRNAs are differentially expressed between pediatric CNS neoplasms and normal tissue suggesting that they may play a significant role in oncogenesis",
                        "The characterization of tumor\u2010specific miRNA signatures may aid in the discovery of biomarkers with diagnostic or prognostic utility"
                    ]
                },
                "application": {
                    "validated": "Yes",
                    "diagnosis": "Potential",
                    "prognosis": null,
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": "Potential",
                "curator": null
            },
            {
                "_id": "V0001CF",
                "pmid": "20806346",
                "biomarkerId": "B0001CF",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": 54.0,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": "Post 2010",
                "region": [
                    "Italy"
                ],
                "research": {
                    "methods": [
                        "The authors used immunohistochemistry to assess CD133 expression in 37 paired glioblastoma samples, including 1 primary tumor sample and 1 recurrent tumor sample, after patients received adjuvant radiochemotherapy. To assess the actual composition of the CD133-positive glioblastoma cell population, fluorescence-associated cell sorting (FACS) analysis was used to sort CD133-positive/CD45-negative cells that were assayed for tumor-specific chromosomal aberrations using interphase fluorescence in situ hybridization. To rule out endothelial precursor cells, CD133-positive fractions also were assayed with anti-CD34 by FACS."
                    ],
                    "results": [
                        "In recurrent glioblastomas, the percentage of CD133-positive cells was increased by 4.6-fold compared with the percentage in primary glioblastomas, although, in some tumors, it increased up to 10-fold and 20-fold. Unexpectedly, the increase in CD133 expression was associated significantly with longer survival after tumor recurrence. An analysis of tumor-specific chromosomal aberrations and in vivo studies revealed that the CD133-positive cell compartment of recurrent glioblastoma was composed of both cancer stem cells and nontumor neural stem cells. The latter cells represented from 20% to 60% of the CD133-positive cell population, and their relative percentage favorably affected the survival of patients with recurrent glioblastoma. Endothelial CD133-positive/CD34-positive precursors did not contribute to the CD133-positive cell population."
                    ],
                    "conclusions": [
                        "The authors hypothesized that, similar to the phenomenon described in glioblastoma models, neural stem/progenitor cells that are recruited by the tumor from surrounding brain may exert an antitumorigenic effect."
                    ]
                },
                "application": {
                    "validated": "Potential",
                    "diagnosis": null,
                    "prognosis": null,
                    "predictive": "Potential",
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Erik Samelsson"
            },
            {
                "_id": "V0001D0",
                "pmid": "20661133",
                "biomarkerId": "B0001D0",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": 60.0,
                        "under": 4.0,
                        "over": 9.0
                    }
                },
                "gender": {
                    "male": 9.0,
                    "female": 9.0,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": "Pre 2010",
                "region": [
                    "Japan"
                ],
                "research": {
                    "methods": [
                        "To identify glioblastoma (GBM) cells expressing glycoproteins that contain high levels of the bisecting N-acetylglucosamine (GlcNAc) structures, lectin histochemistry was carried out using erythroagglutinating phytohemagglutinin nonparametric. Differences in KI67 positivity among the groups with different E4PHA intensity were evaluated with the nonparametric Kruskal-Wallis test and the Mann-Whitney U testKruskal-Wallis test and the Mann-Whitney U test."
                    ],
                    "results": [
                        "Although GBM frequently expressed the bisecting GlcNAc, the lectin reactivity varied among tumor regions within individual specimens."
                    ],
                    "conclusions": [
                        "Since detailed histopathologic analysis revealed that oligosaccharides with bisecting GlcNAc structures were preferably expressed in tumor regions with low KI67 immunopositivity, immunodetection of the bisecting GlcNAc could be useful to indicate less proliferative regions in human GBM. Our study highlights the potential use of lectin histochemistry to develop new methods for diagnosis that would improve future antiglioma therapy."
                    ]
                },
                "application": {
                    "validated": "Potential",
                    "diagnosis": "Potential",
                    "prognosis": null,
                    "predictive": null,
                    "therapeutic": "Potential"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": "Potential",
                "curator": "Erik Samelsson"
            },
            {
                "_id": "V0001D1",
                "pmid": "20437865",
                "biomarkerId": "B0001D1",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": 58.9,
                    "sd": 13.8,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": "Pre 2010",
                "region": [
                    "Italy"
                ],
                "research": {
                    "methods": [
                        "The expression of HEY1 was studied by in situ hybridization on 62 cases of glioblastoma. Patients were treated with surgery followed by chemotherapy and radiotherapy. We considered as end points of the study the overall survival time and progression-free interval. Correlations between HEY1 expression and tumor grade/patient overall survival and free interval before recurrence were analyzed using univariate analysis"
                    ],
                    "results": [
                        "Based on the in situ hybridization results, HEY1 expression rate was reported as negative staining in 13 cases (20.6%), as weak staining in 11 cases (17.3%), as moderate staining in 21 cases (33.3%), and as strong staining in 17 cases. We considered in the analysis the cumulative expression of HEY1 at in situ hybridization (Hey Index) as negative in 13 cases and positive in 49 cases (77.78%). The overall survival (P = 0.002) and the free-interval (P = 0.012) were significantly longer in patients who were negative for HEY1 expression."
                    ],
                    "conclusions": [
                        "Our data suggest that expression of HEY1 might be used as a marker to distinguish glioblastoma patients with a relatively good prognosis from those at high-risk, and that, in the future, HEY1 might represent a therapeutic target."
                    ]
                },
                "application": {
                    "validated": "Potential",
                    "diagnosis": null,
                    "prognosis": "Potential",
                    "predictive": null,
                    "therapeutic": "Potential"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Erik Samelsson"
            },
            {
                "_id": "V0001D2",
                "pmid": "20425043",
                "biomarkerId": "B0001D2",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": "Pre 2010",
                "region": [
                    "Japan"
                ],
                "research": {
                    "methods": [
                        "We screened 65 archival, paraffin-embedded adult astrocytic tumors using immunohistochemical staining and computerized overlaid photographs. Normal biopsied brains and metastatic brain tumors were also examined."
                    ],
                    "results": [
                        "The intensity of nestin expression corresponded to the tumor grade. All 33 glioblastoma cases showed positive and extensive staining, which was less positive in diffuse astrocytoma. Overlaid images showed that nestin immunostaining delineated tumor invasion into adjacent gray and white matter."
                    ],
                    "conclusions": [
                        "Nestin is a useful marker for examining the infiltration of malignant cells into surrounding tissue."
                    ]
                },
                "application": {
                    "validated": "Potential",
                    "diagnosis": null,
                    "prognosis": "Potential",
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": "Nestin is now known as a biomarker for glioma stem cells.",
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Erik Samelsson"
            },
            {
                "_id": "V0001D3",
                "pmid": "20150378",
                "biomarkerId": "B0001D3",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": 58.1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": "Pre 2010",
                "region": [
                    "USA"
                ],
                "research": {
                    "methods": [
                        "Formalin-fixed, paraffin-embedded tumor samples from 225 patients with newly diagnosed GBM were analyzed via methylation-specific, quantitative real-time polymerase chain reaction following bisulfite treatment on isolated DNA to assess MGMT promoter methylation status."
                    ],
                    "results": [
                        "In patients who received radiotherapy alone following resection, methylation of the MGMT promoter correlated with an improved response to radiotherapy. Unmethylated tumors were twice as likely to progress during radiation treatment. The median time interval between resection and tumor progression of unmethylated tumors was also nearly half that of methylated tumors. Promoter methylation was also found to confer improved overall survival in patients who did not receive adjuvant alkylating chemotherapy. Multivariable analysis demonstrated that methylation status was independent of age, Karnofsky performance score, and extent of resection as a predictor of time to progression and overall survival."
                    ],
                    "conclusions": [
                        "Our data suggest that MGMT promoter methylation appears to be a predictive biomarker of radiation response. Since this biomarker has also been shown to predict response to alkylating agents, perhaps MGMT promoter methylation represents a general, favorable prognostic factor in GBM."
                    ]
                },
                "application": {
                    "validated": "Yes",
                    "diagnosis": "NO",
                    "prognosis": "YES",
                    "predictive": "YES",
                    "therapeutic": "YES"
                },
                "clinical": {
                    "relevance": "O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation has been firmly established as a biomarker in patients diagnosed with gliomas, for both clinical trials and routine clinical management.",
                    "implication": "Use in companion diagnostics and predicting patient outcome.",
                    "treatment": "Methylation status of the MGMT gene is crucial to promoting DNA repair. If the MGMT gene is methylated, cancer patients tend to respond better to alkylating drug therapy."
                },
                "comments": "NO",
                "curator": "Erik Samelsson"
            },
            {
                "_id": "V0001D4",
                "pmid": "20150367",
                "biomarkerId": "B0001D4",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": 54.0,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": "Pre 2010",
                "region": [
                    "USA"
                ],
                "research": {
                    "methods": [
                        "An analysis was performed using GBM microarray data from 4 independent data sets. An examination of the genes consistently associated with patient outcome, revealed a consensus 38-gene survival set. Worse outcome was associated with increased expression of genes associated with mesenchymal differentiation and angiogenesis. Application to formalin fixed-paraffin embedded (FFPE) samples using real-time reverse-transcriptase polymerase chain reaction assays resulted in a 9-gene subset which appeared robust in these samples. This 9-gene set was then validated in an additional independent sample set."
                    ],
                    "results": [
                        "Multivariate analysis confirmed that the 9-gene set was an independent predictor of outcome after adjusting for clinical factors and methylation of the methyl-guanine methyltransferase promoter. The 9-gene profile was also positively associated with markers of glioma stem-like cells, including CD133 and nestin."
                    ],
                    "conclusions": [
                        "In sum, a multigene predictor of outcome in glioblastoma was identified which appears applicable to routinely processed FFPE samples. The profile has potential clinical application both for optimization of therapy in GBM and for the identification of novel therapies targeting tumors refractory to standard therapy."
                    ]
                },
                "application": {
                    "validated": "Potential",
                    "diagnosis": null,
                    "prognosis": "Potential",
                    "predictive": "Potential",
                    "therapeutic": "Potential"
                },
                "clinical": {
                    "relevance": "Panel could be used for defining drug targets. ",
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Erik Samelsson"
            },
            {
                "_id": "V0001D5",
                "pmid": "20150365",
                "biomarkerId": "B0001D5",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": 45.0,
                        "under": 9.0,
                        "over": 62.0
                    }
                },
                "gender": {
                    "male": 62.0,
                    "female": 62.0,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": "Pre 2010",
                "region": [
                    "Austria"
                ],
                "research": {
                    "methods": [
                        "Here, we compared promoter methylation (by methylation-specific polymerase chain reaction) and protein expression (by Western blot) in tumor cell explants with respect to prediction of TMZ response and survival of GBM patients (n = 71)."
                    ],
                    "results": [
                        "Methylated MGMT gene promoter sequences were detected in 47 of 71 (66%) cases, whereas 37 of 71 (52%) samples were scored positive for MGMT protein expression. Although overall promoter methylation correlated significantly with protein expression (chi(2) test, P < .001), a small subgroup of samples did not follow this association. In the multivariate Cox regression model, a significant interaction between MGMT protein expression, but not promoter methylation, and TMZ therapy was observed (test for interaction, P = .015). In patients treated with TMZ (n = 42), MGMT protein expression predicted a significantly shorter overall survival (OS",
                        "hazard ratio [HR] for death 5.53, 95% confidence interval [CI] 1.76-17.37",
                        "P = .003), whereas in patients without TMZ therapy (n = 29), no differences in OS were observed (HR for death 1.00, 95% CI 0.45-2.20",
                        "P = .99)"
                    ],
                    "conclusions": [
                        "These data suggest that lack of MGMT protein expression is superior to promoter methylation as a predictive marker for TMZ response in GBM patients."
                    ]
                },
                "application": {
                    "validated": "Yes/Potential",
                    "diagnosis": "NO",
                    "prognosis": "YES",
                    "predictive": "YES",
                    "therapeutic": "YES"
                },
                "clinical": {
                    "relevance": "O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation has been firmly established as a biomarker in patients diagnosed with gliomas, for both clinical trials and routine clinical management.",
                    "implication": "Use in companion diagnostics and predicting patient outcome.",
                    "treatment": "Methylation status of the MGMT gene is crucial to promoting DNA repair. If the MGMT gene is methylated, cancer patients tend to respond better to alkylating drug therapy."
                },
                "comments": "NO",
                "curator": "Erik Samelsson"
            },
            {
                "_id": "V0001D6",
                "pmid": "20081802",
                "biomarkerId": "B0001D6",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": 50.0,
                        "under": 15.0,
                        "over": 24.0
                    }
                },
                "gender": {
                    "male": 24.0,
                    "female": 24.0,
                    "other": -1
                },
                "stage": [
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": "Pre 2010",
                "region": [
                    "France"
                ],
                "research": {
                    "methods": [
                        "We analyzed microsatellite markers in a region spanning the chromosome from the telomere to the centromere, to characterize the pattern of 1p and 19q loss of heterozygosity in 39 infiltrative gliomas, including astrocytomas, glioblastomas, oligoastrocytomas and oligodendrogliomas. We then studied the association between loss of heterozygosity and the expression of p53 protein and Olig2, as analyzed using immunohistochemistry, and epidermal growth factor receptor (EGFR) gene amplification, as investigated using fluorescence in situ hybridization (FISH). Finally, we assessed the influence of molecular markers on the overall survival of patients."
                    ],
                    "results": [
                        "We identified five different 1p19q loss of heterozygosity patterns among the tumors studied and found that loss of heterozygosity over the whole 1p arm was associated with loss of heterozygosity over the whole 19q arm in 90% of cases. 1p19q whole loss was present in all the classical oligodendrogliomas, whereas other 1p19q loss patterns predominated in oligoastrocytomas. 1p19q whole loss was also significantly associated with Olig2 overexpression, but was never observed in tumors overexpressing p53 protein. We also found that, among patients with contrast-enhancing tumors, those with 1p19q whole loss tended to survive for longer."
                    ],
                    "conclusions": [
                        "In combination with classical histological and immunohistochemical data, 1p19q status determination provides pertinent information useful for (1) discriminating between histological types of gliomas and (2) identifying a subgroup of tumors that are associated with a better prognosis."
                    ]
                },
                "application": {
                    "validated": "Yes",
                    "diagnosis": "YES",
                    "prognosis": "YES",
                    "predictive": "YES",
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": "According to the 2016 World Health Organization (WHO) Classification of Tumors of the Central Nervous System, the definitive diagnosis of grade II and grade III (anaplastic) oligodendroglioma requires the demonstration of both an IDH gene family mutation and 1p/19q-co-deletion.",
                    "implication": "While the function of 1p19q codeletion is unknown, it is an established biomarker for diagnostic, prognostic and predictive uses.",
                    "treatment": "Clinical guidelines frequently recommend that1p/19q-co-deletion be evaluated to support a diagnosis of oligodendroglioma and to predict the chemosensitivity and prognosis of these patients."
                },
                "comments": "YES",
                "curator": "Erik Samelsson"
            },
            {
                "_id": "V0001D7",
                "pmid": "19948061",
                "biomarkerId": "B0001D7",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": 57.2,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": "Pre 2010",
                "region": [
                    "USA"
                ],
                "research": {
                    "methods": [
                        "In situ hybridization (ISH), immunohistochemistry (IH) and immunofluorescence (IF) were used to localize TEM1/endosialin expression in grade II-IV astrocytomas and metastatic brain tumors on tissue microarrays."
                    ],
                    "results": [
                        "TEM1/endosialin was upregulated in primary and metastatic human brain tumors, where it localized primarily to the tumor vasculature and a subset of tumor stromal cells. Analysis of 275 arrayed grade II-IV astrocytomas demonstrated TEM1/endosialin expression in 79% of tumors. Robust TEM1/endosialin expression occurred in 31% of glioblastomas (grade IV astroctyomas). TEM1/endosialin expression was inversely correlated with patient age. TEM1/endosialin showed limited co-localization with CD31, alphaSMA and fibronectin in clinical specimens."
                    ],
                    "conclusions": [
                        "TEM1/endosialin was induced in the vasculature of high-grade brain tumors where its expression was inversely correlated with patient age. Although lack of TEM1/endosialin did not suppress growth of intracranial GBM xenografts, it did increase tumor vascularity. The cellular localization of TEM1/endosialin and its expression profile in primary and metastatic brain tumors support efforts to therapeutically target this protein, potentially via antibody mediated drug delivery strategies."
                    ]
                },
                "application": {
                    "validated": "Potential",
                    "diagnosis": null,
                    "prognosis": null,
                    "predictive": null,
                    "therapeutic": "Potential"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": "NA "
                },
                "comments": null,
                "curator": "Erik Samelsson"
            },
            {
                "_id": "V0001D8",
                "pmid": "19767728",
                "biomarkerId": "B0001D8",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "I",
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": "Pre 2010",
                "region": [
                    "Germany"
                ],
                "research": {
                    "methods": [
                        "We studied annexin-1 expression in 394 glial neoplasms of all grades of malignancy and 81 normal brain samples by immunohistochemistry using tissue microarrays. The results were validated using western blot and reverse transcription-PCR (RT-PCR). Survival analysis was performed with the Kaplan\u2013Meier curves and significance determined using log-rank test for selected groups of annexin-1-positive tumors and nuclear staining stratified for WHO grade."
                    ],
                    "results": [
                        "In the normal human brain, the expression of annexin-1 is limited to ependymal cells and subependymal astrocytes, but is also upregulated in reactive astrocytes. Ependymomas and astrocytomas showed significantly higher mean annexin-1 expression levels in the cytoplasm compared with oligodendrogliomas (both: P<0.0001). In addition, nuclear staining of annexin-1 in oligodendroglial tumor cells was significantly reduced (P=0.0002), which may be used as a diagnostic tool for differentiating between astrocytomas and oligodendrogliomas. Although annexin-1 expression in ependymomas decreased with the grade of malignancy, diffuse astrocytomas showed a significant increase in cytoplasmic annexin-1-positive tumor cells. However, survival analysis showed that the expression of annexin-1 is not associated with patient survival. Similar to the EGFR amplification profile, primary glioblastomas had a higher annexin-1 expression level compared with secondary glioblastomas."
                    ],
                    "conclusions": [
                        "Thus, annexin-1 upregulation in astrocytomas may contribute to tumor progression and its expression profile is similar to its substrate, EGFR, suggesting a possible regulation thereof."
                    ]
                },
                "application": {
                    "validated": "Potential",
                    "diagnosis": "Potential",
                    "prognosis": null,
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": "NA "
                },
                "comments": "Potential",
                "curator": "Erik Samelsson"
            },
            {
                "_id": "V0001D9",
                "pmid": "19765000",
                "biomarkerId": "B0001D9",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": "Pre 2010",
                "region": [
                    "Japan"
                ],
                "research": {
                    "methods": [
                        "We analyzed the genomic region spanning wild-type R132 of IDH1 by direct sequencing (PCR) in 125 glial tumors. The Mann\u2013Whitney test was used to compare data acquired in each group for the patient age. The overall survival was defined as the time between the first surgery and death. Survival distributions were estimated by Kaplan\u2013Meier analysis and compared among patient subsets using log\u2010rank tests."
                    ],
                    "results": [
                        "A total of 39 IDH1 mutations were observed. Mutations of the IDH2 gene, homologous to IDH1, were often detected in gliomas without IDH1 mutations. In the present study, R172 mutation of the IDH2 gene was detected in one anaplastic astrocytoma. IDH1 or IDH2 mutations were frequently in oligodendrogliomas (67%), anaplastic astrocytomas (62%), anaplastic oligoastrocytomas (75%), anaplastic oligodendrogliomas (50%), secondary glioblastomas (67%), gangliogliomas (38%), and anaplastic gangliogliomas (60%). Primary glioblastomas were characterized by a low frequency of mutations (5%) at amino acid position 132 of IDH1. Mutations of the IDH1 or IDH2 genes were significantly associated with improved outcome in patients with anaplastic astrocytomas. Our data suggest that IDH1 or IDH2 mutation plays a role in early tumor progression of several types of glioma and might arise from a common glial precursor."
                    ],
                    "conclusions": [
                        "The infrequency of IDH1 mutation in primary glioblastomas revealed that these subtypes are genetically distinct entities from other glial tumors."
                    ]
                },
                "application": {
                    "validated": "Yes",
                    "diagnosis": "Potential",
                    "prognosis": "YES",
                    "predictive": "YES",
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": "Testing for IDH1 mutations is a current clinical backbone for GBM patient stratification. ",
                    "implication": null,
                    "treatment": null
                },
                "comments": "Potential",
                "curator": "Erik Samelsson"
            },
            {
                "_id": "V0001DA",
                "pmid": "19755387",
                "biomarkerId": "B0001DA",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": 59.5,
                    "sd": 13.9,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": "Pre 2010",
                "region": [
                    "Switzerland"
                ],
                "research": {
                    "methods": [
                        "We screened glioblastomas from a population-based study for IDH1 mutations and correlated them with clinical data and other genetic alterations. Single-strand conformational polymorphism (SSCP) analysis and direct DNA sequencing for IDH1 and IDH2 mutations."
                    ],
                    "results": [
                        "IDH1 mutations were detected in 36 of 407 glioblastomas (8.8%). Glioblastoma patients with IDH1 mutations were younger (mean, 47.9 years) than those with EGFR amplification (60.9 years) and were associated with significantly longer survival (mean, 27.1 versus 11.3 months",
                        "P < 0.0001). IDH1 mutations were frequent in glioblastomas diagnosed as secondary (22 of 30",
                        "73%), but rare in primary glioblastomas (14 of 377",
                        "3.7%: P < 0.0001). IDH1 mutations as genetic marker of secondary glioblastoma corresponded to the respective clinical diagnosis in 95% of cases. Glioblastomas with IDH1 mutation diagnosed as primary had clinical and genetic profiles similar to those of secondary glioblastomas, suggesting that they may have rapidly progressed from a less malignant precursor lesion that escaped clinical diagnosis and were thus misclassified as primary. Conversely, glioblastomas without IDH1 mutations clinically diagnosed as secondary typically developed from anaplastic rather than low-grade gliomas, suggesting that at least some were actually primary glioblastomas, that may have been misclassified, possibly due to histologic sampling error."
                    ],
                    "conclusions": [
                        "IDH1 mutations are a strong predictor of a more favorable prognosis and a highly selective molecular marker of secondary glioblastomas that complements clinical criteria for distinguishing them from primary glioblastomas."
                    ]
                },
                "application": {
                    "validated": "Yes",
                    "diagnosis": "Potential",
                    "prognosis": "YES",
                    "predictive": "YES",
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": "Testing for IDH1 mutations is a current clinical backbone for GBM patient stratification. ",
                    "implication": null,
                    "treatment": null
                },
                "comments": "Potential",
                "curator": "Erik Samelsson"
            },
            {
                "_id": "V0001DB",
                "pmid": "19331209",
                "biomarkerId": "B0001DB",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": 55.0,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": "Pre 2010",
                "region": [
                    "Japan"
                ],
                "research": {
                    "methods": [
                        "The pattern of subcellular localization of p27 expression was examined immunohistochemically in 49 patients with high-grade astrocytoma who were over 20 years of age. The relationship between p27 localization and the prognosis was statistically examined."
                    ],
                    "results": [
                        "Kaplan-Meier survival analysis showed that cytoplasmic p27 expression was statistically associated with a worse prognosis (p = 0.0203), while nuclear p27 expression showed some tendency towards a better prognosis (p = 0.1180). Cox multiple regression analysis showed the combination of high nuclear and low cytoplasmic p27 expression associated with a significantly better prognosis in high-grade astrocytoma."
                    ],
                    "conclusions": [
                        "A combination of low cytoplasmic and high nuclear expression of p27 predicts a better prognosis in high-grade astrocytomas and thus the subcellular localization of p27 expression is useful for predicting the prognosis for these patients."
                    ]
                },
                "application": {
                    "validated": "Potential",
                    "diagnosis": null,
                    "prognosis": "Potential",
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": "CDKN1B is a biomarker of considerable interest for cancer in general.",
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Erik Samelsson"
            },
            {
                "_id": "V0001DC",
                "pmid": "19264916",
                "biomarkerId": "B0001DC",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": 45.0,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "I",
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": "Pre 2010",
                "region": [
                    "China"
                ],
                "research": {
                    "methods": [
                        "Immunostaining and flow cytometric analysis indicate that B7-H1 was expressed primarily by Ki67-negative tumor cells."
                    ],
                    "results": [
                        "In vitro, tumors cultured under medium favoring the growth of neural stem cells were able to form spheres, along with expression of neural stem/progenitor cell markers. These cells were able to differentiate into different neural lineages when cultured in differentiation medium, indicating that these cells have TSC characteristics. We also found that B7-H1 was expressed, but not exclusively on CD133-positive stem cells. Interestingly, we found that CD133-negative tumor cells also had the capacity to form brain tumors."
                    ],
                    "conclusions": [
                        "Our data establish a correlation between the expression of the negative costimulatory molecule B7-H1 and the malignancy grade of human gliomas, suggesting that B7-H1 may be a novel tumor marker and target for therapy, although it is not expressed exclusively on brain TSCs."
                    ]
                },
                "application": {
                    "validated": "Potential",
                    "diagnosis": "Potential",
                    "prognosis": "Potential",
                    "predictive": null,
                    "therapeutic": "Potential"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": "Potential",
                "curator": "Erik Samelsson"
            },
            {
                "_id": "V0001DD",
                "pmid": "19141386",
                "biomarkerId": "B0001DD",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": 59.5,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": "Pre 2010",
                "region": [
                    "Spain"
                ],
                "research": {
                    "methods": [
                        "In this study, we analyzed relevant molecular and clinical variables in 194 primary GBMs and tested them for survival analysis. (FISH and Immunohistochemical Analysis on Tissue Microarrays, Mutations in exons 5 to 8 of the p53 gene were screened by direct sequencing in an ABI PRISM 310 DNA Analyzer, Univariate and multivariate Cox regression analyses were performed to identify the clinical and molecular variables related to survival. Hazard ratios (HRs) and their associated 95% confidence intervals were computed for selected variables using standard options for the Cox regression analysis. Kaplan-Meier survival curves and Pearson correlation coefficients were also calculated. )"
                    ],
                    "results": [
                        "Although most of the tumors showed a mutually exclusive pattern, concurrent alterations of EGFR and p53 were detected. Survival analysis of CDK4 amplification revealed a highly significant association with a worse clinical outcome (P = .01), whereas MDM2, CDK6, PTEN, and p21 were not associated with patient survival. Multivariate analysis including the significant clinical and molecular variables revealed CDK4 amplification, age, and radiotherapy to be markers with independent prognostic value. In addition, the primary GBM tumors showing simultaneous EGFR and p53 alterations were significantly associated with worse survival (P < .01)."
                    ],
                    "conclusions": [
                        "These results highlight the prognostic value of CDK4 amplification and of simultaneous EGFR-p53 alterations in the clinical outcome of patients with primary GBM."
                    ]
                },
                "application": {
                    "validated": "Potential",
                    "diagnosis": null,
                    "prognosis": "Potential",
                    "predictive": "Potential",
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Erik Samelsson"
            },
            {
                "_id": "V0001DE",
                "pmid": "18991494",
                "biomarkerId": "B0001DE",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": 59.0,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": "Pre 2010",
                "region": [
                    "The Netherlands"
                ],
                "research": {
                    "methods": [
                        "The tumor tissue used was obtained in adult patients who underwent neurosurgical debulking. Microvessel density was assessed by morphometric analysis. Double immunostaining for Ki 67/CD34 and cleaved caspase-3/CD34 was used to investigate the proliferation and apoptotic fraction of both endothelial and tumor cells. The expression of VEGFs (A-D) was evaluated on immunohistochemistry. To measure tumor vascular stabilization, the ANGPT1/ANGPT2 mRNA balance was determined using real-time reverse transcriptase polymerase chain reaction."
                    ],
                    "results": [
                        "Within the hypoxic perinecrotic tumor area, the apoptotic fraction of endothelial cells was positively correlated with VEGFA expression (p < 0.001). Higher levels of VEGFA correlated with greater proliferation of endothelial cells in the intermediate tumor area (p = 0.031). Vascular endothelial growth factor D was significantly more highly expressed within the perinecrotic tumor area compared with the intermediate tumor area (p < 0.001). Multivariate analysis showed a significant association between the ANGPT1/ANGPT2 balance and the survival time of patients with GBMs (p = 0.035)."
                    ],
                    "conclusions": [
                        "The results of the present study suggest that the ANGPT1/ANGPT2 balance has prognostic value in patients with primary GBMs. The authors' findings support the need for further studies of the feasibility of antiangiogenic therapy in primary GBMs, with a special focus on the normalization of tumor vasculature."
                    ]
                },
                "application": {
                    "validated": "Potential",
                    "diagnosis": null,
                    "prognosis": "Potential",
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Erik Samelsson"
            },
            {
                "_id": "V0001DF",
                "pmid": "18953492",
                "biomarkerId": "B0001DF",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": 59.0,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": "Pre 2010",
                "region": [
                    "Japan"
                ],
                "research": {
                    "methods": [
                        "Tissue specimens were obtained from 66 patients with glioblastoma treated with radiotherapy. Survivin expression was detected by an immunohistochemical method. Nuclear and cytoplasm survivin scores were defined by using the cell positivity and staining intensity. The scores were defined as follows, 0 (no staining), 1 (less than 50% of cell positivity and any staining), 2 (more than 50% of cell positivity and weak to moderate intensity) and 3 (more than 50% of cell positivity and strong intensity). The correlation between survivin scores and the overall survival rate was evaluated."
                    ],
                    "results": [
                        "Nuclear and cytoplasm survivin staining were noted in 47 and 58 patients, respectively. The number of patients with nuclear survivin score of 0, 1, 2 and 3, were 19 (28.8%), 26 (39.4%), 9 (13.6%) and 12 (18.2%), respectively. The 3-year overall survival rate of the nuclear survivin score 3 was 0%, significantly lower than the 11.6% of the nuclear survivin score </=2 (P = 0.0003). Cytoplasm survivin score did not correlate with the prognosis."
                    ],
                    "conclusions": [
                        "Nuclear survivin expression may be a useful biomarker for predicting prognosis in patients with glioblastoma."
                    ]
                },
                "application": {
                    "validated": "Potential",
                    "diagnosis": null,
                    "prognosis": "Potential",
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Erik Samelsson"
            },
            {
                "_id": "V0001E0",
                "pmid": "18552083",
                "biomarkerId": "B0001E0",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": "Pre 2010",
                "region": [
                    "Japan"
                ],
                "research": {
                    "methods": [
                        "Tumors were immunohistochemically studied for the expression of Olig2 as well as other markers including epithelial membrane antigen (EMA) and CD99.  Comparisons between two groups were conducted by the Mann-Whitney U-test, while those among three or more groups were conducted by the ANOVA post-hoc test (Scheffe\u2019s F). A p value of less than 0.05 was considered significant."
                    ],
                    "results": [
                        "In general, the Olig2-positive nuclei were only sparsely distributed in ependymomas",
                        "in contrast, they were very numerous in astrocytomas and oligodendrogliomas. Particularly in cases of glioblastoma or pilocytic astrocytoma that histologically mimicked ependymoma, the Olig2-positive nuclei were numerous as in conventional astrocytomas, which helped to differentiate them from ependymomas. The EMA-positive structures were helpful for the diagnosis of ependymoma, however, they were occasionally very modest and sparse on immunostained sections. A quantitative study showed that the Olig2-positive nuclei were much fewer in ependymomas than in astrocytomas and oligodendrogliomas. CD99 is a cell surface antigen expressed in some tumors, most notably in Ewing's sarcomas. In our preliminary experiment, we noted the absence of CD99-immunoreactivity in a fraction of brain tumors with clear cell morphology, including oligodendroglioma, clear cell ependymoma, and pilocytic astrocytoma (the oligodendroglioma-like component). Thus, we investigated the expression of CD99 in an additional series of brain tumors with clear cell morphology, including oligoastrocytoma (7 cases), central neurocytoma (6), and dysembryoplastic neuroepithelial tumor (9)."
                    ],
                    "conclusions": [
                        "These results indicate that the Olig2-immunohistochemistry is useful and potentially more reliable than the EMA-immunohistochemistry for the diagnosis ofependymoma. We found that the absence of CD99-immunoreactivity was dependent on clear cell morphology rather than on tumor entities. The CD99-immunohistochemistry is unique in that it is helpful for the diagnosis of clear cell brain tumors through the visualization of CD99-negative clear cells."
                    ]
                },
                "application": {
                    "validated": "Potential",
                    "diagnosis": "Potential",
                    "prognosis": null,
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": "Both biomarkers are objects of GBM research.",
                    "implication": "Potential Immunk",
                    "treatment": null
                },
                "comments": "Potential",
                "curator": "Erik Samelsson"
            },
            {
                "_id": "V0001E1",
                "pmid": "18493866",
                "biomarkerId": "B0001E1",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "I",
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": null,
                "region": [
                    "Croatia"
                ],
                "research": {
                    "methods": [
                        "Immunohistochemistry",
                        ""
                    ],
                    "results": [
                        "In normal brain tissue some glial and neuronal cells showed weak cytoplasmic staining, while interstitium was negative",
                        "Astrocytomas were heterogeneous regarding the OPN expression",
                        "High cytoplasmic OPN expression in GBMs was associated with poor patients' survival",
                        "The association of interstitial OPN expression and angiogenesis, i.e. the number of newly formed blood vessels was higher in tumors showing high interstitial OPN expression"
                    ],
                    "conclusions": [
                        "Results indicate the overexpression of OPN protein in astrocytoma cells and suggest the role of OPN in astrocytoma progression and angiogenesis"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": null,
                    "prognosis": null,
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "BP"
            },
            {
                "_id": "V0001E2",
                "pmid": "17571214",
                "biomarkerId": "B0001E2",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "III",
                    "IV"
                ],
                "whoclass": "2007",
                "region": [
                    "France"
                ],
                "research": {
                    "methods": [
                        "Immunohistochemistry",
                        "Kaplan Meier curves",
                        "Univariate analysis",
                        "Log-rank test"
                    ],
                    "results": [
                        "All GBM expressing highly HER2 (2+ and 3+) were de novo GBM",
                        "All secondary GBM expressed HER2 with low intensity (0+ and 1+)",
                        "Survival time was significantly longer when HER2 expression was low",
                        "The patterns of HER2 expression were similar between grade III gliomas and secondary GBM"
                    ],
                    "conclusions": [
                        "Showed for the first time a significant association between HER2 expression and the type of GBM, with subsequent influence on survival rate",
                        "GBM with low-HER2 expression are more likely to be secondary GBM, carrying a better prognosis than de novo GBM"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": null,
                    "prognosis": "Potential",
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "BP"
            },
            {
                "_id": "V0001E3",
                "pmid": "17415524",
                "biomarkerId": "B0001E3",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": null,
                "region": [
                    "France"
                ],
                "research": {
                    "methods": null,
                    "results": [
                        "FABP7, found in 91 out of 123 samples, showed a pure cytoplasmic expression in 69 cases, and cytoplasmic+nuclear expression in 22 cases",
                        "FABP7 expression was associated with pure GBM histology and shorter survival (15.7 months versus 21.5 months)",
                        "Nuclear expression of FABP7 was more specifically related to EGFR amplification and more invasive tumors"
                    ],
                    "conclusions": [
                        "The data support the relation between FABP7, astrocytic features, invasion and poor prognosis and suggests that EGFR amplification is associated with nuclear translocation of FABP7"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": null,
                    "prognosis": "YES",
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "BP"
            },
            {
                "_id": "V0001E4",
                "pmid": "17219056",
                "biomarkerId": "B0001E4",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": null,
                "region": [
                    "France"
                ],
                "research": {
                    "methods": null,
                    "results": [
                        "MGMT methylation had no impact on survival for the whole group, but showed a significant advantage (17.1 months vs. 13.1) for patients treated with RT+ adjuvant chemotherapy (relative risk of death (RR) = 0.53",
                        "P = 0.041), particularly when patients received CT during the course of RT (MS = 19.9 months vs. 12.5 months",
                        "RR = 0.227, P = 0.001)",
                        "MGMT methylation was not correlated with the main molecular alterations, such as 10q loss and p53 expression"
                    ],
                    "conclusions": [
                        "The prognostic impact of MGMT methylation is dependent on therapeutic modalities and schedules"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": null,
                    "prognosis": "YES",
                    "predictive": "YES",
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "BP"
            },
            {
                "_id": "V0001E5",
                "pmid": "17048097",
                "biomarkerId": "B0001E5",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": "2000",
                "region": [
                    "Germany"
                ],
                "research": {
                    "methods": [
                        "Methylation specific PCR",
                        ""
                    ],
                    "results": [
                        "The overall TMS1/ASC methylation rate in the 57 analyzed tumors was 21.05 percent",
                        "Hypermethylation of TMS1/ASC was significantly more frequent in LTS GBM (57.1 percent vs. 16 percent, P=0.029, Fisher's exact test)",
                        "DAPK promoter hypermethylation was only observed in the LTS subset (14.3 percent) whereas TIMP2 and TIMP3 were unmethylated in both GBM collectives"
                    ],
                    "conclusions": [
                        "Results strongly suggest that, compared to classic GBM, LTS GBM display distinct epigenetic characteristics which might provide additional prognostic biomarkers for the assessment of this malignancy"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": null,
                    "prognosis": null,
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "BP"
            },
            {
                "_id": "V0001E6",
                "pmid": "16849758",
                "biomarkerId": "B0001E6",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": 3.0,
                        "under": 21.0,
                        "over": 76.0
                    }
                },
                "gender": {
                    "male": 76.0,
                    "female": 76.0,
                    "other": -1
                },
                "stage": [
                    "III",
                    "IV"
                ],
                "whoclass": "2000",
                "region": [
                    "USA"
                ],
                "research": {
                    "methods": [
                        "Alkylator-based chemotherapy",
                        "Immunohistochemical analysis",
                        "Log-rank test",
                        "Fischer's exact test"
                    ],
                    "results": [
                        "12 of the 109 samples demonstrated overexpression of MGMT compared with normal brain",
                        "Five-year progression-free survival was 42.1% \u00b1 5% in the 97 patients whose tumors had low levels of MGMT expression versus 8.3% \u00b1 8% in the 12 patients whose tumors overexpressed MGMT",
                        "The association between MGMT overexpression and adverse outcome remained significant after stratifying for institutional histologic diagnosis (eg, anaplastic astrocytoma or glioblastoma multiforme), as well as age, amount of residual tumor, and tumor location"
                    ],
                    "conclusions": [
                        "Overexpression of MGMT in childhood malignant gliomas is strongly associated with an adverse outcome in children treated with alkylator-based chemotherapy, independently of a variety of clinical prognostic factors"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": null,
                    "prognosis": null,
                    "predictive": "YES",
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "BP"
            },
            {
                "_id": "V0001E7",
                "pmid": "16550604",
                "biomarkerId": "B0001E7",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": 54.4,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": "2000",
                "region": [
                    "Northern Ireland"
                ],
                "research": {
                    "methods": [
                        "ELISA",
                        "Immunohistochemistry",
                        "Dual-labelled immunofluorescence",
                        "Kaplan-Meier method",
                        "Cox model"
                    ],
                    "results": [
                        "ELISA revealed minimal expression of CatS in normal brain homogenates",
                        "CatS expression was increased in grade IV tumours whereas astrocytoma grades I\u2013III exhibited lower values",
                        "High\u2010CatS immunohistochemical scores in glioblastomas were associated with significantly shorter survival",
                        "CatS score was found to be an independent predictor of survival"
                    ],
                    "conclusions": [
                        "CatS expression in astrocytomas is associated with tumour progression and poor outcome in glioblastomas",
                        "CatS may serve as a useful prognostic indicator and potential target for anti\u2010invasive therapy"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": null,
                    "prognosis": "Potential",
                    "predictive": null,
                    "therapeutic": "Potential"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "BP"
            },
            {
                "_id": "V0001E8",
                "pmid": "16320026",
                "biomarkerId": "B0001E8",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": "2000",
                "region": [
                    "Japan"
                ],
                "research": {
                    "methods": [
                        "Immunohistochemistry",
                        "cDNA microarray",
                        "Semi quantitaive RT-PCR"
                    ],
                    "results": [
                        "Identified 54 gene with increased expression and 45 with reduced expression in GBMs",
                        "Semi-quantitative RT-PCR experiments with 6 of those genes confirmed higher expression of DNCH2, ARHGEF6, NPM1 and SRI and lower expression of NRGN and TM4SF2 in GBM tumors",
                        "Immunohistochemical staining for 3 of the respective gene products, dynein (product of DNCH2), alpha-PIX (product of ARHGEF6), and sorcin (product of SRI) indicated that this technique might be useful for histological grading of glial tumors"
                    ],
                    "conclusions": [
                        "These findings indicated that levels of these three proteins might serve as histological markers for malignant glioma classification."
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": "Potential",
                    "prognosis": null,
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": "Potential",
                "curator": "BP"
            },
            {
                "_id": "V0001E9",
                "pmid": "12582944",
                "biomarkerId": "B0001E9",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo sapiens"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "IV"
                ],
                "whoclass": "Pre 2007",
                "region": [
                    "Germany"
                ],
                "research": {
                    "methods": [
                        "Immunochemistry"
                    ],
                    "results": [
                        "P53 protein expression was significantly decreasing with advanced age whereas EGFR and Mdm2 expression was increasing. Msh2 protein expression as a significant predictor of prolonged survival"
                    ],
                    "conclusions": [
                        "p53, Mdm2 and EGFR expression is related with the age. Msh2 might be an pronostic indicator"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": null,
                    "prognosis": "Potential",
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Cristian"
            },
            {
                "_id": "V0001EA",
                "pmid": "29991124",
                "biomarkerId": "B0001EA",
                "sourceIds": [
                    "Tissue"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens",
                    "Mus musculus"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": null,
                "whoclass": null,
                "region": [
                    "China"
                ],
                "research": {
                    "methods": null,
                    "results": [
                        "In both datasets, GBM tissues exhibited increased mRNA expression of GBP1 gene, its expression level was co-related to PETN deletion and EGFR amplification, and was associated with prognosis of GBM patients",
                        "GBP1 overexpression can enhance migration and invasion ability of tumor cells in vitro, and in vivo studies showed that GBP1 can promote tumor proliferation, decrease survival in tumor-bearing mice",
                        "GSEA analysis predicted that GBP1 may play its biological roles via toll-like receptor pathway"
                    ],
                    "conclusions": [
                        "This study provides new insights and evidences that high level expression of GBP1 is significantly correlated with progression and prognosis in GBMs",
                        "Transfection of GBP1 revealed its regulation on migration and invasiveness of glioma cells, decreasing sensitivity of chemotherapeutic agent, shortening survival of tumor-bearing animals",
                        "Data demonstrate that GBP1 may serve as a novel prognostic biomarker and a potential therapeutic target for gliomas"
                    ]
                },
                "application": {
                    "validated": null,
                    "diagnosis": null,
                    "prognosis": null,
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "Erik Samuelsson"
            },
            {
                "_id": "V0001EB",
                "pmid": "26515590",
                "biomarkerId": "B0001EB",
                "sourceIds": [
                    "Tissue",
                    "Cell line"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens",
                    "Mus musculus"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": 45.0,
                        "under": 80.0,
                        "over": 66.0
                    }
                },
                "gender": {
                    "male": 66.0,
                    "female": 66.0,
                    "other": -1
                },
                "stage": [
                    "I",
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": "2007",
                "region": [
                    "China"
                ],
                "research": {
                    "methods": [
                        "Immunohistochemistry",
                        "Western blot",
                        "Murine orthotopic glioma model",
                        "Survival curves",
                        "Cox model"
                    ],
                    "results": [
                        "GMF-\u03b2 was more frequently found in tumor cells in high-grade gliomas than in low-grade ones",
                        "Higher expression of GMF-\u03b2 is associated with poorer prognosis of glioma patients",
                        "GMF-\u03b2 is involved in neovasculogenesis in human glioblastoma",
                        "GMF-\u03b2 knockdown inhibits the proliferation and tubulogenesis of U87 cells in vitro",
                        "GMF-\u03b2 knockdown represses the formation of human CD31-positive microvessels in murine orthotopic glioma model"
                    ],
                    "conclusions": [
                        "Innovatively found the specific expression pattern of GMF-\u03b2 in glioma cells and TECs, and evaluated their correlation with tumor grade, MVD, and clinical prognosis",
                        "findings may offer a prognostic biomarker as well as a cell type-specific target for anti-vasculogenic therapy in glioma"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": "NO",
                    "prognosis": "Potential",
                    "predictive": "NO",
                    "therapeutic": "Potential"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": "NO",
                "curator": "BP"
            },
            {
                "_id": "V0001EC",
                "pmid": "25669971",
                "biomarkerId": "B0001EC",
                "sourceIds": [
                    "Tissue",
                    "Cell lines"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens",
                    "Mus musculus"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": -1,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": 60.0,
                        "under": 173.0,
                        "over": 36.0
                    }
                },
                "gender": {
                    "male": 36.0,
                    "female": 36.0,
                    "other": -1
                },
                "stage": [
                    "I",
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": "2007",
                "region": [
                    "China"
                ],
                "research": {
                    "methods": [
                        "Immunohistochemisrty",
                        "quantitative real time PCR",
                        "Lentivirus production and transduction",
                        "Subcutaneous xenograft model",
                        "Co-immunoprecipitatio",
                        "Western blot",
                        "Cox model",
                        "Kaplan Meier curves"
                    ],
                    "results": [
                        "Transcriptional or protein levels of NMI expression were significantly increased according to tumor grade in all three cohorts",
                        "High expression of NMI predicted significantly unfavorable clinical outcome for GBM patients, which was further determined as an independent prognostic factor",
                        "Expression and prognostic value of NMI were associated with molecular features of GBM including PTEN deletion and EGFR amplification in TCGA cohort",
                        "Overexpression or depletion of NMI revealed its regulation on G1/S progression and cell proliferation (both in vitro and in vivo), and this effect was partially dependent on STAT1, which interacted with and was regulated by NMI"
                    ],
                    "conclusions": [
                        "Data demonstrate that NMI may serve as a novel prognostic biomarker and a potential therapeutic target for glioblastoma"
                    ]
                },
                "application": {
                    "validated": "Yes",
                    "diagnosis": null,
                    "prognosis": "Potential",
                    "predictive": null,
                    "therapeutic": "Potential"
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": "BP"
            },
            {
                "_id": "V0001ED",
                "pmid": "22287159",
                "biomarkerId": "B0001ED",
                "sourceIds": [
                    "Tissue",
                    "Cell line"
                ],
                "samples": "TODO",
                "species": [
                    "Homo Sapiens",
                    "Mus musculus"
                ],
                "age": {
                    "min": -1,
                    "max": -1,
                    "med": 59.5,
                    "avg": -1,
                    "sd": -1,
                    "range": {
                        "cutoff": -1,
                        "under": -1,
                        "over": -1
                    }
                },
                "gender": {
                    "male": -1,
                    "female": -1,
                    "other": -1
                },
                "stage": [
                    "II",
                    "III",
                    "IV"
                ],
                "whoclass": "2000",
                "region": [
                    "Slovenia"
                ],
                "research": {
                    "methods": [
                        "Xenograft model",
                        "Quantitative real-time PCR",
                        "ELISA tests",
                        "Immunohistochemical statining",
                        "Survival probabilities"
                    ],
                    "results": [
                        "In human GBM samples, all cathepsins were elevated at the tumor periphery compared to brain parenchyma",
                        "CatB was also typically associated with angiogenic endothelia and necrotic areas",
                        "StefB was mainly detected in the tumor core, whereas CysC and StefA were evenly distributed, reflecting the observations in the xenografts",
                        "At the mRNA level, no differences in cathepsins and cystatins were observed between the tumor center and the periphery in both human biopsies and xenografts",
                        "In human tumors, cathepsin and stefin transcript levels correlated with CD68 and CXCR4 levels, but not with epidermal growth factor receptor (EGFR)",
                        "An elevated StefA mRNA level is a highly significant prognostic was revelaed for the first time as a factor for patient survival in GBM"
                    ],
                    "conclusions": [
                        "A report of an altered balance between cysteine cathepsins and cystatins at the periphery vs. central parts of human GBMs and U87\u2010MG xenografts",
                        "The imbalance is in part due to differential translocation and secretion of cathepsins at the tumor border",
                        "Data suggest that post\u2010translational events lead to higher cathepsin activity in the peripheral regions of human GBMs",
                        "A further novel finding is the peripheral localization of the inhibitor StefA transcript in U87\u2010MG xenografts and its association with poor GBM prognosis"
                    ]
                },
                "application": {
                    "validated": "No",
                    "diagnosis": null,
                    "prognosis": "Potential",
                    "predictive": null,
                    "therapeutic": null
                },
                "clinical": {
                    "relevance": null,
                    "implication": null,
                    "treatment": null
                },
                "comments": null,
                "curator": null
            }
        ]
    }
]